
<html lang="en"     class="pb-page"  data-request-id="14f6c1af-a29f-4d35-b5ec-e94f0bb76e8d"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.9b01226;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-5"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="The Immunoproteasome: An Emerging Target in Cancer and Autoimmune and Neurological Disorders" /></meta><meta name="dc.Creator" content="Breanna L.  Zerfas" /></meta><meta name="dc.Creator" content="Marianne E.  Maresh" /></meta><meta name="dc.Creator" content="Darci J.  Trader" /></meta><meta name="dc.Description" content="The immunoproteasome (iCP) is an isoform of the 20S proteasome that is expressed when cells are stressed or receive an inflammatory signal. The primary role of the iCP is to hydrolyze proteins into..." /></meta><meta name="Description" content="The immunoproteasome (iCP) is an isoform of the 20S proteasome that is expressed when cells are stressed or receive an inflammatory signal. The primary role of the iCP is to hydrolyze proteins into..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 31, 2019" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01226" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright Â© 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01226" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01226" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01226" /></link>
        
    
    

<title>The Immunoproteasome: An Emerging Target in Cancer and Autoimmune and Neurological Disorders | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01226" /></meta><meta property="og:title" content="The Immunoproteasome: An Emerging Target in Cancer and Autoimmune and Neurological Disorders" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0016.jpeg" /></meta><meta property="og:description" content="The immunoproteasome (iCP) is an isoform of the 20S proteasome that is expressed when cells are stressed or receive an inflammatory signal. The primary role of the iCP is to hydrolyze proteins into peptides that are compatible with being loaded into a MHC-I complex. When the activity of the iCP is dysregulated or highly expressed, it can lead to unwanted cell death. Some cancer types express the iCP rather than the standard proteasome, and selective inhibitors have been developed to exploit this difference. Here, we describe diseases known to be influenced by iCP activity and the current status for targeting the iCP to elicit a therapeutic response. We also describe a variety of chemical tools that have been developed to monitor the activity of the iCP in cells. Finally, we present the future outlook for targeting the iCP in a variety of disease types and with mechanisms besides inhibition." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01226"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01226">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01226&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01226&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01226&amp;href=/doi/10.1021/acs.jmedchem.9b01226" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 1841-1858</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00797" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.9b01279" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">The Immunoproteasome: An Emerging Target in Cancer and Autoimmune and Neurological Disorders</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Breanna L. Zerfas</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Breanna L. Zerfas</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 575 West Stadium Avenue, West Lafayette, Indiana 47907, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Breanna+L.++Zerfas">Breanna L. Zerfas</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Marianne E. Maresh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marianne E. Maresh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 575 West Stadium Avenue, West Lafayette, Indiana 47907, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marianne+E.++Maresh">Marianne E. Maresh</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Darci J. Trader</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Darci J. Trader</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 575 West Stadium Avenue, West Lafayette, Indiana 47907, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#492d3d3b282d2c3b09393c3b2d3c2c672c2d3c"><span class="__cf_email__" data-cfemail="3357474152575641734346415746561d565746">[emailÂ protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Darci+J.++Trader">Darci J. Trader</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0607-1243" title="Orcid link">http://orcid.org/0000-0002-0607-1243</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01226&amp;href=/doi/10.1021%2Facs.jmedchem.9b01226" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 1841â1858</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 31, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>29 July 2019</li><li><span class="item_label"><b>Published</b> online</span>31 October 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 March 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01226" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01226</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1841%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DBreanna%2BL.%2BZerfas%252C%2BMarianne%2BE.%2BMaresh%252C%2BDarci%2BJ.%2BTrader%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D5%26contentID%3Dacs.jmedchem.9b01226%26title%3DThe%2BImmunoproteasome%253A%2BAn%2BEmerging%2BTarget%2Bin%2BCancer%2Band%2BAutoimmune%2Band%2BNeurological%2BDisorders%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1858%26publicationDate%3DMarch%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01226"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2206</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">8</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01226" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;The Immunoproteasome: An Emerging Target in Cancer and Autoimmune and Neurological Disorders&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Breanna&quot;,&quot;last_name&quot;:&quot;L. Zerfas&quot;},{&quot;first_name&quot;:&quot;Marianne&quot;,&quot;last_name&quot;:&quot;E. Maresh&quot;},{&quot;first_name&quot;:&quot;Darci&quot;,&quot;last_name&quot;:&quot;J. Trader&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;31&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;1841-1858&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01226&quot;},&quot;abstract&quot;:&quot;The immunoproteasome (iCP) is an isoform of the 20S proteasome that is expressed when cells are stressed or receive an inflammatory signal. The primary role of the iCP is to hydrolyze proteins into peptides that are compatible with being loaded into a MHC-I complex. When the activity of the iCP is dysregulated or highly expressed, it can lead to unwanted cell death. Some cancer types express the iCP rather than the standard proteasome, and selective inhibitors have been developed to exploit this difference. Here, we describe diseases known to be influenced by iCP activity and the current status for targeting the iCP to elicit a therapeutic response. We also describe a variety of chemical tools that have been developed to monitor the activity of the iCP in cells. Finally, we present the future outlook for targeting the iCP in a variety of disease types and with mechanisms besides inhibition.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01226&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01226" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01226&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01226" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01226&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01226" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01226&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01226&amp;href=/doi/10.1021/acs.jmedchem.9b01226" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01226" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01226" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01226%26sid%3Dliteratum%253Aachs%26pmid%3D31670954%26genre%3Darticle%26aulast%3DZerfas%26date%3D2020%26atitle%3DThe%2BImmunoproteasome%253A%2BAn%2BEmerging%2BTarget%2Bin%2BCancer%2Band%2BAutoimmune%2Band%2BNeurological%2BDisorders%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D5%26spage%3D1841%26epage%3D1858%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292601" title="Probes">Probes</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/jmcmar.2020.63.issue-5/20200312/jmcmar.2020.63.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The immunoproteasome (iCP) is an isoform of the 20S proteasome that is expressed when cells are stressed or receive an inflammatory signal. The primary role of the iCP is to hydrolyze proteins into peptides that are compatible with being loaded into a MHC-I complex. When the activity of the iCP is dysregulated or highly expressed, it can lead to unwanted cell death. Some cancer types express the iCP rather than the standard proteasome, and selective inhibitors have been developed to exploit this difference. Here, we describe diseases known to be influenced by iCP activity and the current status for targeting the iCP to elicit a therapeutic response. We also describe a variety of chemical tools that have been developed to monitor the activity of the iCP in cells. Finally, we present the future outlook for targeting the iCP in a variety of disease types and with mechanisms besides inhibition.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar/63/5"><issue-title>Women in Medicinal Chemistry</issue-title></a> special issue.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14780" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14780" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The proteasome, a multiprotein, multicatalytic complex, is part of the ubiquitin-proteasome system (UPS) that is responsible for degrading damaged or misfolded proteins tagged with ubiquitin. The UPS is responsible for degrading up to 90% of proteins in a cell, making its proper function critical to viability.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The proteasome consists of two parts, a 19S regulatory particle (19S RP) and a 20S catalytic core particle (sCP).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The 19S RP is responsible for recognizing and removing ubiquitin tags, unfolding proteins, and shuttling them into the sCP.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The sCP is composed of four heptameric rings consisting of Î± subunits or Î² subunits.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> While the Î± subunits act as a gate to allow unfolded proteins into the sCP, the Î² rings contain three subunits with specific protease-like activities. Short peptide sequences are produced after the sCP has cleaved a protein, and these peptides can then be recycled in newly synthesized proteins or used to carry out other functions in the cell.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The sCP can also cleave small or disordered proteins that are not tagged with ubiquitin in the absence of the 19S RP.<a onclick="showRef(event, 'ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5">(3â5)</a> In fact, â¼80% of the sCPs in the cell are not capped with the 19S RP.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">Several isoforms of the sCP exist, including the immunoproteasome (iCP). Primarily expressed in immune cells,<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7â9)</a> the iCP is also expressed in response to a viral infection or after stimulation by interferon Î³ (IFN-Î³) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref9 ref10 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12 ref13">(9â13)</a> The iCP is formed by incorporating immuno-subunits into newly assembled proteasomes. It has been observed that incorporation of Î²5i is required for preproteasomes to efficiently mature, which then leads to more proteasomes containing Î²1i and Î²2i.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> The iCP is more capable of degrading proteins into antigenic peptides that can be loaded into major histocompatibility complexes type I (MHC-I) than the sCP. Specifically, the iCP produces more peptides with hydrophobic C-termini, a necessary characteristic for antigenic peptides to be loaded into a MHC-I.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The difference in peptide products is attributed to how the protein substrate fits into the catalytic channel.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Additionally, Î²1i has chymotrypsin-like activity, differentiating it from its standard Î²1, which has caspase-like activity.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> This change in cleavage preference may contribute to the increase in MHC-I compatible peptides. However, it is currently unclear if the hydrolysis rates of the iCP and the sCP also play a role in generating different products.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. SCP is a barrel-shaped catalytic protein complex that is responsible for degrading proteins in the cell into short peptide sequences. Upon stimulation by IFN-Î³, new catalytic subunits replace the subunits of the sCP to form the iCP. The iCP is more efficient at producing peptides that can be incorporated into MHC-I complexes. The iCP is generally expressed in cells that are virally infected or immune cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition to its role in generating antigenic peptides, the iCP can also degrade misfolded and or damaged proteins, similar to the sCP, to limit the accumulation of unwanted proteins.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> It has long been hypothesized that the purpose of the iCP is to degrade defective ribosomal products or DRIPS.<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16â18)</a> This is a logical hypothesis because, when cells are stressed or infected by a virus, proteins are more likely to become oxidatively damaged. There are conflicting reports about whether the iCP is actually faster at degrading these misfolded or oxidized proteins and whether it preferentially degrades ubiquitinated proteins.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a></div><div class="NLM_p">Recent research has also revealed the role of the iCP in differentiation and proliferation in several types of tissues.<a onclick="showRef(event, 'ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23">(21â23)</a> This is highlighted by a recent study that showed knockout of iCP subunits leads to substantial changes in the abundance of several transcription factors, such as IRF3, IRF7, STAT1, STAT3, and STAT6, which all regulate genes involved in the immune response and cell division.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> iCP expression has also been shown to affect proliferation of T-cells in response to mitogenic stimulation.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> When both Î²2i expression and Î²5i expression were knocked out in mice, isolated T-cells were shown to have higher rates of proliferation in response to mitogenic stimulation and demonstrated more cell divisions and an accelerated cell cycle progression compared to those of wild type cells. Similarly, it was shown that cells deficient in both iCP subunits had an impaired ability to undergo activation-induced death. All of this evidence taken together strongly suggests that the iCP has several functions outside of producing antigenic peptides as there is a robust correlation between cell proliferation and differentiation with iCP expression.</div><div class="NLM_p last">Although the iCP has a very low level of expression in non-immune cells, the detection of immuno-subunits in certain cancers,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> autoimmune disorders,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and neurodegenerative diseases<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> suggests it plays an important role in modulating several different disease states. As a result, significant research has focused on elucidating the role of the iCP in a variety of diseases to evaluate its potential as a therapeutic target. This low level of expression in normal cells also makes the iCP a target of interest for these diseases as it can provide a basis for discriminating between diseased and normal cells. Utilizing iCP stimulators and inhibitors to modulate the activity of the iCP represents the use of novel classes of drugs for diseases that currently have limited treatment options.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Tools for Analyzing the Composition and Activity of the iCP</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70472" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70472" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A crucial aspect of understanding any protein or protein complex is elucidating what activities it has and which pathways it may participate in. Given its important roles in cell cycle and disease, this has been an important research avenue in the case of proteasome isoforms. Shortly after the discovery of the proteasome, fluorogenic probes that mimic peptide substrates were developed to monitor its activity.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> These probes are composed of three or four amino acids with a fluorophore on the C-terminus, with the most common fluorophore being 7-amino-4-methylcoumarin (AMC). Upon recognition of the peptide by a specific active site of the proteasome, the amide bond is cleaved, and AMC is released to yield a fluorescent signal. Via modulation of the peptide sequence, different probes specific for each of the Î² subunit activities have been developed and made commercially available. These AMC probes are commonly used to characterize new proteasome inhibitors by determining the Î² subunit(s) with which they interact. More recently, this has been expanded to probes that can distinguish between the sCP and the iCP,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and Î²5i- and Î²1i-specific probes have become commercially available through various sources (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A,B). These AMC probes have seen the most use in biochemical-based assays, including with cell lysates, and have been used for testing of inhibitors.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Data collected to compare the signal of the cell lysate versus that of intact cells with the most popular AMC-based probe, Suc-LLVY-AMC, are shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C; while a good change in signal is observed in the lysate, no significant change in fluorescence is seen with intact cells.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. AMC-based substrate probes selective for (A) Î²5i and (B) Î²1i have recently become commercially available through Boston Biochem. (C) A549 cells (5000 cells/well) were either lysed with a nondenaturing buffer (blue) or left intact (red) and incubated with Suc-LLVY-AMC (63 Î¼M), a common sCP probe. These data demonstrate these types of probes are not effective for use in whole cells. Data collected by the authors, previously unpublished.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As iCP-selective inhibitors were discovered, they provided new scaffolds for the development of activity-based probes (ABPs). Previously, several probes had been developed by attaching a fluorophore to covalent inhibitors of the Î² subunits.<a onclick="showRef(event, 'ref31 ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33 ref34">(31â34)</a> While this set of probes was an improvement from the AMC-based substrates because their improved cell permeability allows for their use with intact cells, they could interact with standard subunits and immuno-subunits, requiring the use of sodium dodecyl sulfateâpolyacrylamide gel electrophoresis (SDSâPAGE) to distinguish between them. Unfortunately, it can be difficult to resolve the two Î²5 isoforms and the two Î²1 isoforms, leaving some ambiguity in the cell sample analysis. For this reason, the Overkleeft group sought to discover a set of probes that would separate each immuno-subunit from its standard counterpart as a way to evaluate the selectivity of different inhibitors.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Using three subunit-selective inhibitors, the authors synthesized Cy5-NC-001 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A) for Î²1 labeling, BODIPY(FL)-LU-112 for Î²2 labeling (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B), and BODIPY(TMR)-NC-005-VS for Î²5 labeling (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C). Using this cocktail in cell lysates, the IFN-Î³-dependent change from sCP to iCP expression could be monitored in a fluorescent SDSâPAGE experiment. Furthermore, the probes were able to provide useful information about proteasome inhibitor selectivity in various cell lines and patient-derived samples. This analysis also provided important information about iCP expression in patient samples of various hematological cancers. Using activity-based protein profiling (ABPP), this cocktail of probes also offered a way to screen for new proteasome inhibitors while simultaneously providing information about selectivity.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Fluorescent probes based on inhibitors selective for (A) Î²1, (B) Î²2, and (C) Î²5 are used in ABPP to examine the expression levels of each subunit and selectivity profiles of new inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As mentioned above, several intermediate proteasomes have been observed in various cell types, but little is known about their function or the composition of intact complexes. Due to the proximity of the different catalytically active Î² subunits in each ring (28 Ã between Î²1 and Î²2 and 64 Ã between Î²5 and both Î²1 and Î²2),<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> FÃ¶rster resonance energy transfer (FRET) is an attractive strategy for examining the composition of intermediate proteasomes. This was first demonstrated by the Kim lab, using inhibitor-based probes similar to those discussed above.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The authors conjugated Cy3 or Cy5 to three inhibitors selective for either Î²1/Î²1i (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A), Î²2/Î²2i (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B), or Î²5/Î²5i (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). Using the pairs of probes with complementary fluorophores, FRET was observed in solutions of the cell lysate that could be decreased by treating samples with unlabeled inhibitors. Unfortunately, it was observed that using a FRET pair for Î²1 and Î²2 did not have a high efficiency of FRET, likely due to the subunits being directly adjacent to each other. Although this system has potential, until it includes inhibitors selective for the respective standard subunits or immuno-subunits, there is not much that can be learned about the proteasome composition.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Kim lab developed selective inhibitors targeting (A) Î²1/Î²1i, (B) Î²2/Î²2i, and (C) Î²5/Î²5i as FRET pairs to look at proteasome composition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The Overkleeft group also used FRET to further develop their ABPP cocktail to provide useful information about the composition of proteasomes in cells.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> To be able to begin making this distinction between pure and mixed proteasome isoforms, de Bruin and co-workers used a suite of subunit-selective probes in FRET pairs and analyzed cell lysate samples by native-PAGE and SDSâPAGE. Using native-PAGE, they were able to determine which subunits were closely associated in the intact proteasomes, while SDSâPAGE allowed for fluorescence quantification of the total levels of each subunit. Overall, this provided a method for examining the makeup of mixed proteasomes, which is especially useful as the immuno-subunits begin to be incorporated after IFN-Î³ exposure.</div><div class="NLM_p">Finally, a suite of inhibitor-based probes have also been developed, which does not rely on fluorescence-based assays. For this, the Kim lab synthesized bifunctional structures by linking two epoxy-ketone inhibitors selective for different subunits (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> These probes can then covalently cross-link the two subunits, and Western blot analysis with specific antibodies can determine which subunit types composed mixed proteasomes. The authors demonstrated the utility of this system in both purified proteasomes and cell lysate samples, with the appearance of bands in the range of 45â50 kDa after probe treatments. Furthermore, they confirmed the cross-linking can be diminished by pretreating cells with corresponding inhibitors selective for one of the immuno-subunits. Overall, this provided a more streamlined analysis of the mixed proteasome compositions of cell samples.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Example of the probes developed by the Kim lab to covalently link two Î²2 subunits. Shown are selective inhibitors for Î²1/Î²1i (red) and Î²5/Î²5i (blue) with a C<sub>6</sub> linker (black).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although all of the work mentioned above has led to great strides in understanding the different activities of the iCP and how those are affected by various inhibitors, there are still several key characteristics that are limiting the types of assays for which these probes can be used. In the case of the AMC-based substrate probes, they are limited to biochemical assays due to poor cell permeability at the necessary assay concentrations as well as their poor selectivity for the proteasome over other proteases in cells. For the inhibitor-based probes, as their binding to the Î² subunits is irreversible, they cannot be used to continuously monitor activity but are better suited for looking at overall expression of various subunits under different conditions. Recently, our group designed a new probe for the iCP to overcome some of these issues.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> To accomplish this, we discovered a short peptide selectively cleaved by the iCP compared to the sCP using a one-bead, one-compound (OBOC) library. This sequence was then conjugated to a rhodamine-110 (Rh110) molecule (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Rh110 offers increased sensitivity and stability compared to AMC, allowing us to use a lower probe concentration. To overcome the poor cell permeability of the other substrate probes, we also conjugated a short peptoid on the opposite side of the Rh110 molecule, as they have been shown to have improved solubility and cell permeability compared to those of peptides.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> With our probe, named TBZ1, we were able to monitor the activity of the iCP in live cells using both a microplate assay and confocal microscopy. Furthermore, we demonstrated the selectivity of the probe for the iCP over not only the sCP but also other proteases by dosing with ONX-0914, an iCP-selective inhibitor. We expect TBZ1 will prove to be very useful in the discovery of molecules to perturb the activity of the iCP as well as for monitoring changes in iCP activity caused by various environmental factors.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Our group recently developed a new iCP-selective activity probe that can be used in live cells. Attached to a rhodamine-110 molecule (green) are an iCP recognition peptide (blue) that provides the probeâs selectivity and a short peptoid (orange) that assists in cell permeability.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">With these varied probes and assays available to examine iCP activity, especially how it is distinguished from that of the sCP, its roles in both healthy and diseased cells are becoming better understood. For example, until the use of selective inhibitor-based ABPs with primary cells, the relative abundance of the iCP to the sCP in hematological cancers was not well characterized.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> This new finding suggests greater roles for the iCP in these types of diseases, as well as a more significant role in the mechanism of action of various proteasome inhibitors. As the body of evidence for the iCP as a new therapeutic target continues to grow, the number of ABPs will also continue to expand.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">3.  The Immunoproteasome and Cancer</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18812" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18812" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">It is well established that the proteasome plays an important role in cancer cell survival and cell cycle progression.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Several transcription factors are degraded by the proteasome, giving it an important role in regulating the cell cycle, as well.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Additionally, mutations in the cancer cell genome lead to abhorrent protein production and proteotoxic stress, making the removal of accumulating proteins critical to cell survival; an increased level of protein production must be matched by enhanced protein degradation to maintain proteostasis.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> As a result, cancer cells often overexpress subunits of the proteasome. Because some cancer types rely more heavily on proteasome activity than normal cells, it has emerged as a target for small molecule therapeutics.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Inhibition of the proteasome can lead to cancer cell death, and several small molecule proteasome inhibitors have been developed as a result of this research. While the role of the sCP in cell cycle progression and its implication in cancer cells has been well characterized, current research also suggests an important role of the iCP in cancer progression; several forms of cancer overexpress the iCP, including multiple myeloma (MM),<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> prostate cancer,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> and some forms of breast cancer,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> and its overexpression has also been linked to resistance of certain cancers to proteasome inhibitor therapeutics.<a onclick="showRef(event, 'ref9 ref47'); return false;" href="javascript:void(0);" class="ref ref9 ref47">(9,47)</a> As a result, several research groups have focused on elucidating the role of the iCP in cancer and its potential as a therapeutic target (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. sCP inhibitors such as bortezomib have been developed to kill MM cells. However, cells eventually confer resistance to the drug. Current research is focused on developing iCP inhibitors to overcome drug resistance in MM and determine if the iCP is a good therapeutic target for some forms of cancer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">3.1.  Role of the Immunoproteasome and the Proteasome in Cancer</h3><div class="NLM_p">Many cancers overexpress the iCP for a variety of reasons to enhance their ability to survive.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The tumor microenvironment is vastly different from those of healthy tissues, partly due to an influx of tumor-infiltrating lymphocytes.<a onclick="showRef(event, 'ref25 ref49'); return false;" href="javascript:void(0);" class="ref ref25 ref49">(25,49)</a> These lymphocytes release copious amounts of IFN-Î³, which in turn trigger cancer cells to begin producing the iCP.<a onclick="showRef(event, 'ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25">(23â25)</a> This phenomenon is most often observed in solid tumors, such as breast cancer and colorectal cancer, as these types of cancer are subjected to tumor-infiltrating lymphocytes.<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50,51)</a> Interestingly, upon examination of gene expression data across patients, a high level of expression of the iCP was associated with better prognosis and improved survival in breast cancer.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div class="NLM_p last">While infiltration of lymphocytes accounts for overexpression of the iCP in solid tumors, there are several types of hematological malignancies that also overexpress the iCP but do not form tumors recognized by lymphocytes.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> In these cases, iCP overexpression is the result of IFN-Î³-independent pathways. Previous research shows that the iCP is expressed in hematopoietic cells in the absence of IFN-Î³.<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52,53)</a> Additionally, levels of iCP production in the spleen of mice lacking IFN-Î³ signaling were shown to be the same as those of wild type mice.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Similar evidence of iCP overexpression independent of IFN-Î³ stimulation in hematological cancers, such as acute myeloid leukemia (AML), has also been observed.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Analysis of overexpressed genes in AML cells revealed iCP subunit expression, but this did not correlate to activation of genes stimulated by IFN-Î³ secretion or the presence of tumor-infiltrating lymphocytes. When breast cancer cell lines grown in the absence of tumor-infiltrating lymphocytes and leukemia cell lines were compared for iCP subunit expression, it was found that leukemia cell lines produce higher levels of iCP subunits, highlighting the necessity of lymphocytes in solid tumors for iCP production. While several forms of cancer overexpress the iCP compared to their normal tissue counterparts, it is important to note that the iCP increases the pool of MHC-I compatible peptides and this may leave cancer cells more vulnerable to detection by the immune system.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> As a result, the expression of the iCP varies between types of cancer and therapies targeting the iCP must be carefully tailored to each specific form.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">3.2.  sCP and iCP Inhibitors as Chemotherapy Agents for Hematological Cancers</h3><div class="NLM_p">Research has established that hematological cells, namely B-cells, require complex regulation of proteasome activity during differentiation and secretion of antibodies.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> After encountering an antigen, B-cells differentiate and produce antibodies in an effort to control and eliminate an infection.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> A recent study demonstrated that the level of proteasome expression and activity significantly decrease during differentiation of B-cells.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> This was met with an increase in polyubiquitinated proteins, suggesting that a decreased level of expression of the proteasome leads to insufficient protein degradation and proteotoxic stress. To further explore this model, apoptosis of a B-cell lymphoma cell line was monitored over several days of treatment with lipopolysaccharide (LPS), an antigen known to cause B-cell differentiation, and treatment of varying doses of the proteasome inhibitor MG-132. It was found that B-cells that had been exposed to LPS over several days were more susceptible to MG-132-induced cell death than undosed cells, further indicating that sensitivity to proteasome inhibitors is enhanced in B-cells. Similarly, in a follow-up study examining proteasome activity of several B-cell lymphoma cell lines with varying sensitivity to bortezomib, it was discovered that cell lines with increased sensitivity showed less proteasome activity than the less sensitive counterparts.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Taken together, these data suggest that B-cells may be more sensitive to proteasome inhibitors than other cell types because a decrease in the level of proteasome expression during differentiation leads to an increased workload and proteotoxic stress. Therefore, targeting the proteasome as a treatment option for hematological cancers became a focal point of research.</div><div class="NLM_p">The use of small molecule proteasome inhibitors as a chemotherapy agent has been extensively studied in hematological cancers such as MM. This led to the development of bortezomib, a first-generation proteasome inhibitor that reversibly binds the Î²5c subunit of the standard proteasome (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Bortezomib is a dipeptide containing a boronic acid moiety that facilitates binding of the Î²5c subunit by interacting with the catalytic threonine residue.<a onclick="showRef(event, 'ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref59 ref60">(59,60)</a> This small molecule inhibitor was approved by the Food and Drug Administration (FDA) in 2003 as a treatment for refractory MM. Additionally, it has been shown to bind the Î²5i subunit of the iCP. While the full mechanism of bortezomib-induced apoptosis in cancer cells remains unclear, it is currently believed that inhibition of the sCP prevents degradation of key cycle regulators, such as p53, and represses activation of the NF-ÎºB pathway.<a onclick="showRef(event, 'ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref61 ref62">(61,62)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Bortezomib was the first proteasome inhibitor approved by the Food and Drug Administration as a chemotherapeutic agent for MM. The boronic acid moiety binds the threonine amino acid residue in the active site of the Î²5c subunit. (B) Structure of MG-132, a proteasome inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Despite promising initial results in the clinic, treatment with bortezomib is accompanied by several undesirable side effects.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Many patients suffer from severe gastrointestinal discomfort (nausea, vomiting, and diarrhea) and as a result must discontinue its use.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Additionally, peripheral neuropathy is another undesired side effect of bortezomib and also warrants discontinuation of its use. Unfortunately, it is also common that MM patients eventually confer resistance to bortezomib, rendering the drug ineffective.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> The molecular mechanisms underlying bortezomib resistance remain to be fully elucidated, but current research suggests mutations in genes encoding proteasome subunits are not the main driving force.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Despite several studies utilizing various cell models of hematological cancers that reveal mutations in PSMB5, the gene encoding the Î²5 subunit,<a onclick="showRef(event, 'ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref65 ref66">(65,66)</a> single-nucleotide polymorphism analysis from patient tumor samples shows these mutations are not relevant in the clinic and do not contribute to bortezomib resistance.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> While variations in PSMB5 were noted, there was no significant difference in the occurrence of these mutations before and after bortezomib treatment, indicating they do not contribute to bortezomib resistance. Improved cell models are required to fully understand the mechanism of bortezomib resistance.</div><div class="NLM_p last">Because the case of patients conferring resistance to bortezomib is inevitable, current research is focused on discovering novel proteasome inhibitors, and this has led to the development of several second-generation proteasome inhibitors such as carfilzomib.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Additionally, attention has been turned to the iCP. It is hypothesized that inhibition of the iCP may overcome drug resistance to bortezomib and open doors to a novel class of hematological cancer therapeutics. Significant effort in establishing the iCP as a target for therapeutic intervention has yielded several new iCP-specific inhibitors (IPSIs).</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">3.3.  PR-924</h3><div class="NLM_p">One of several newly developed iCP inhibitors is PR-924, an epoxyketone tripeptide that binds the Î²5i subunit of the iCP with 130-fold selectivity over the Î²5c (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> At low concentrations (10â100 nM), PR-924 inhibits only Î²5i activity, but at higher concentrations (1â10 Î¼M), the compound also begins to inhibit activity of both the Î²5c subunit of the sCP and the Î²1i subunit of the iCP.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> This compound has been studied to determine its ability to inhibit growth of several hematological cancers and has been found to induce apoptosis in several leukemia cell lines known to express the iCP. Excitingly, PR-924 was also able to trigger apoptosis in bortezomib-resistant cell lines, although not to an extent as great as that of nonresistant parental cell lines. However, concentrations of PR-924 that triggered apoptosis in leukemia cell lines were high, leading to inhibition of the Î²5i and Î²5c subunits. This indicates that inhibiting only one subunit of the iCP alone may not be enough to trigger apoptosis in cancer cells and/or overcome bortezomib resistance. Interestingly, resistance of cells to PR-924 has been observed and appears to be the result of mutations occurring in the <i>PSMB5</i> gene that encodes the Î²5c subunit, not Î²5i. This was also met with resistance to bortezomib and ONX-0914, another established IPSI.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. PR-924 is an epoxyketone tripeptide that specifically binds that Î²5i iCP subunit. At high concentrations, this compound can bind and inhibit the activity of the Î²5c and Î²1i subunits.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Similar research has been conducted to study the effects of PR-924 in MM cells.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Comparable to data obtained from the leukemia cell lines, PR-924 was observed to inhibit growth and trigger apoptosis in several MM cell lines, including those resistant to bortezomib, with an IC<sub>50</sub> range of 3â7 Î¼M. It has also been demonstrated that PR-924 triggers apoptosis in a variety of patient MM cells, while normal cells are unaffected. The antitumor effect of PR-924 was also observed in mouse models; mice with MM that had been treated with PR-924 exhibited decreases in tumor growth and prolonged survival compared to untreated mice. Excitingly, PR-924 did not appear to have significant side effects as no changes in weight of the mice were observed, a common measure of general toxicity.</div><div class="NLM_p last">Despite these promising results, further research is required to determine whether PR-924 is a good candidate for continued development. Although PR-924 caused apoptosis in leukemia cells, it is unclear whether this is due to iCP inhibition alone because apoptosis was observed only at concentrations at which both Î²5i and Î²5c subunits were inhibited.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">3.4.  UK-101</h3><div class="NLM_p">UK-101 was the first reported iCP-specific inhibitor that covalently binds the Î²1i subunit.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> This tripeptide epoxyketone bears a linear hydrophobic region that is critical to its ability to selectively bind the Î²1i subunit (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).<a onclick="showRef(event, 'ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref72 ref73">(72,73)</a> UK-101 was discovered by modifying the structure of a previously reported inhibitor that was shown to exhibit iCP specificity, dihydroeponemycin. Addition of the <i>tert</i>-butyldimethyl silyl (TBDMS) group to the structure conferred higher specificity to the Î²1i subunit than the molecule with the free hydroxyl group.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Molecular modeling and dynamic simulation studies of UK-101 binding the iCP suggest binding is facilitated through interaction of the leucine side chain of UK-101 with the hydrophobic pocket of the Î²1i subunit and insertion of the TBDMS group in the active site.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> When exposed to the EL4 cell lysate, a cell line known to express large amounts of both iCP and sCP, as little as 1 Î¼M UK-101 was required to covalently modify all Î²1i subunits, without noticeable binding to other catalytic subunits of the iCP or sCP.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Shifts in the molecular weight of the Î²1i subunit were observed by Western blot analysis when EL4 cells were allowed to preincubate with the inhibitor molecule, helping to confirm that it was a covalent, irreversible inhibitor. The shifts in the Î²1i band correlated with the molecular weight of UK-101 and were not observed for other iCP or sCP subunits.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. UK-101 was the first reported inhibitor of the Î²1i subunit of the iCP. It is thought that the leucine side chain binds the hydrophobic pocket of the Î²1i subunit and facilitates insertion of the TBDMS group into the active site to inhibit the subunitâs activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To confirm its specificity for the iCP, UK-101 was tested for its ability to inhibit angiogenic growth of endothelial cells, a process that significantly relies on the activity of the sCP, but not the iCP.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> It was hypothesized that UK-101 would not inhibit growth, while other nonspecific proteasome inhibitors would prevent growth. As expected, it was observed that UK-101 did not inhibit angiogenic growth of endothelial cells, while other proteasome inhibitors did, further suggesting that UK-101 specifically targets iCP subunits and iCP inhibitors may prove to be a novel class of drugs that limit off-target effects observed by other proteasome inhibitors.</div><div class="NLM_p">Because UK-101 was unable to inhibit angiogenic growth of endothelial cells, it was hypothesized that it could slow proliferation or trigger apoptosis in cell lines that overexpress the iCP.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> When tested against a variety of prostate cancer cell lines that overexpress the iCP, it was observed that UK-101 slowed the growth of those known to overexpress the iCP, compared to cell lines that did not. All cell lines were equally sensitive to nonspecific proteasome inhibitors, suggesting that UK-101 specifically targets the iCP and can inhibit proliferation of cells that overexpress the iCP. When prostate cancer cells were dosed with UK-101, stable conjugates of the Î²1i subunit and the inhibitor were detected 48 h after treatment.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Additionally, proteasomes from prostate cancer cell lysates showed a significant reduction in chymotrypsin-like activity. Because the Î²1i subunit of the iCP can exhibit chymotrypsin-like activity,<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> this is likely due to the binding with UK-101. This was also confirmed by the observation of accumulated ubiquitinated proteins in prostate cancer cells after treatment with UK-101, suggesting that the inhibitor binding to the Î²1i subunit reduces the activity of the iCP in cancer cells.</div><div class="NLM_p last">Finally, to determine the effects of UK-101 <i>in vivo</i>, mice with prostate cancer xeongrafts were treated with UK-101 over several days and tumor size and mass were evaluated.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> Treatment with UK-101 showed a significant reduction in tumor volume and tumor growth. Excitingly, mice appeared to better tolerate UK-101 treatment compared to other standard prostate cancer drugs, as the mice did not lose weight throughout the course of treatment.</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">3.5.  Future Work toward the Development of an iCP Inhibitor To Treat Cancer</h3><div class="NLM_p">Significant effort has been put forth toward the discovery of novel iCP inhibitors to be used as cancer therapeutic agents. Several forms of cancer, particularly hematological cancers, are characterized by overexpression of the iCP, making it an attractive target for therapeutic intervention.<a onclick="showRef(event, 'ref47 ref69'); return false;" href="javascript:void(0);" class="ref ref47 ref69">(47,69)</a> Recent research has yielded several new iCP inhibitors that have proven to reduce the level of proliferation and induce apoptosis in several leukemia,<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> MM,<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> and prostate cancer cell lines.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> One of several iCP inhibitors, PR-924, specifically binds the Î²5i subunit and was shown to trigger apoptosis in many forms of MM, including those resistant to bortezomib.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Similarly, UK-101, an iCP inhibitor that binds the Î²1i subunit, was shown to reduce the level of proliferation of prostate cancer cells and prevent tumor growth in mice.<a onclick="showRef(event, 'ref48 ref73'); return false;" href="javascript:void(0);" class="ref ref48 ref73">(48,73)</a> Excitingly, both PR-924 and UK-101 appeared to present lower toxicities compared to those of other cancer therapeutics and were better tolerated by mouse models.<a onclick="showRef(event, 'ref48 ref70'); return false;" href="javascript:void(0);" class="ref ref48 ref70">(48,70)</a> Recently, a new highly selective iCP inhibitor, M3258, has been discovered and shows >500-fold greater specificity to the Î²5i subunit than other sCP and iCP subunits.<a onclick="showRef(event, 'ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref76 ref77">(76,77)</a> This small molecule was optimized by examining co-crystallization of a series of compounds containing an Î±-aminoboronic acid scaffold with the iCP. Differences in the properties of the P1 and P3 pockets of the iCP compared to the sCP were also utilized to optimize the structure and specificity of M3258. M3258 represents a unique class of iCP inhibitors not only because of its high specificity but also because of its oral bioavailability. Dosage of this inhibitor in MM xenograft rat models showed strong antitumor effects, with some rats showing complete elimination of tumors. Moreover, only the lymphatic and hematopoietic systems were impacted by the inhibitor, and overall, less toxicity was observed than for other sCP and iCP inhibitors. Preclinical studies with these inhibitors show great promise that they could be developed into novel cancer therapeutics.</div><div class="NLM_p last">Although initial data are encouraging, much remains unknown about off-target effects and development of resistance. While PR-924 produced very promising results in triggering apoptosis in leukemia, the concentration at which apoptosis was induced was high enough that the Î²5c and the Î²5i subunits were inhibited,<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> suggesting inhibition of both isoforms is required. Similarly, there is controversy over whether inhibiting the iCP alone is sufficient to induce apoptosis, as some research suggests it is not, while others show induction of apoptosis as a result of iCP inhibition alone.<a onclick="showRef(event, 'ref48 ref68 ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref48 ref68 ref69 ref70">(48,68â70)</a> Further investigation is required to determine if the iCP is a good target for cancer therapeutics as a result. Similarly, the extent of off-target effects of iCP inhibitors and side effects of using these as drugs remains largely unknown and will require careful study to ensure they are safe and effective. Finally, the development of resistance to iCP inhibitors has not been thoroughly examined, which may present a challenge when inhibitors undergo a transition into clinical applications. As observed with acquired resistance to proteasome inhibitors such as bortezomib, it is possible results obtained from resistance studies in cell models for iCP inhibitors may not match clinically relevant mechanisms. As a result, a careful study of patient tumors must be conducted if iCP inhibitors are to be approved as cancer therapeutics. Interestingly, it is possible iCP inhibitors could be used in conjunction with other proteasome inhibitors to treat cancer. It has been demonstrated that treatment of MM cells with a sCP inhibitor prior to treatment with an iCP inhibitor made the cells significantly more sensitive to iCP inhibition.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> This result reveals great promise that both sCP and iCP inhibitors could be used together to treat MM and potentially other drug-resistant forms of cancer. Despite the need for more studies analyzing the potential of iCP inhibitors as cancer therapeutics, exciting preclinical data show promising results. iCP inhibitors represent a novel class of cancer therapeutics and have potential to reduce undesirable side effects and overcome challenges faced with traditional proteasome inhibitors.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">4.  The iCP in Autoimmune Disorders</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61885" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61885" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In addition to cancer, as described above, the iCP plays a critical role in various autoimmune disorders and inhibitors of its activity have begun to show promise in their treatment.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> The overarching commonality in autoimmune disorders is the immune system attack of seemingly healthy cells. This results in symptoms such as chronic inflammation and premature death of cells. Given that this can occur as a result of a miscommunication between antigen-presenting cells and T-cells, there has been a putative connection between autoimmune disorders and the dysregulation of antigen production by the iCP. In various diseases, including but not limited to those discussed below, research has been performed to uncover this connection and to manipulate the iCPâs role in each disease to investigate possible treatments.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">4.1.  Rheumatoid Arthritis</h3><div class="NLM_p">As a subset of arthritis, patients with rheumatoid arthritis (RA) experience joint inflammation and pain, typically with the occurrence of antibodies to citrullinated proteins (ACPAs) and/or rheumatoid factors (RF). RA is a disease categorized by phenotypic symptoms, with several different environmental and genetic risk factors.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Thus far, the most common environmental factor has been exposure to smoke and other inhaled irritants, such as silica.<a onclick="showRef(event, 'ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref81 ref82">(81,82)</a> On the other side, the most prevalent genetic risk factor is found in the gene for HLA-DR, a member of the MHC class II cluster, which may contribute to â¤40% of genetic influence in RA patients.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Upon examination in greater depth, a proposed susceptibility epitope found in four variants of the DRÎ² was observed in >90% of RA patients.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Ultimately, crystallographic studies performed by Scally et al. revealed that the described epitope allows for preferred binding of citrullinated antigens over their arginine counterparts,<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> which also offers a connection between these genetic epitopes and the presence of ACPAs in RA patients.</div><div class="NLM_p">In the joints of patients with RA is an environment of steady activation of the immune system. This environment includes the presence of pro-inflammatory cytokines, specifically tumor necrosis factor Î± (TNF-Î±) and interleukin six (IL-6), both proposed targets for treatment; both cytokines were validated for targeting with biologics in RA, and TNF-Î± biologics have since expanded to several other autoimmune diseases.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Unfortunately, very few patients experience long-term relief from symptoms, and use of biologics is not without various potential side effects. For this reason, there is still a need for the validation and development of other targets.</div><div class="NLM_p">As previously mentioned, the exposure of cells to TNF-Î± results in the expression of all three immunosubunits of the proteasome.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> With the understanding that TNF-Î± is prevalent enough in the local joint environments of RA patients and the connection between the iCP and antigen processing, targeting the iCP appeared to be a candidate to investigate in RA. Additionally, it has been shown that nonspecific inhibition of the proteasome can reduce the levels of both TNF-Î± and IL-6 along with various other cytokines.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> With no direct data to determine if these effects were a result of sCP or iCP inhibition, Muchamuel and co-workers sought to find inhibitors with improved selectivity for specific catalytic Î² subunits. In this endeavor, they successfully discovered an inhibitor with 20-fold selectivity for the Î²5i over Î²5c, termed PR-957 [later renamed ONX-0914 (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>A)].<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> After fully characterizing the selectivity and toxicity of PR-957, the investigators examined the moleculeâs biological effects <i>in vitro</i>. They found that the level of production of IL-23 was decreased by >90% with TNF-Î± and IL-6 both being decreased by â¼50% in peripheral blood mononuclear cells (PBMCs) in a Î²5i-dependent manner; this result was repeated in cells taken from patients with active RA. Being able to decrease the levels of these cytokines would be expected to lower the level of chronic inflammation, therefore relieving the disease symptoms. Having such promising results, the authors investigated the effect of PR-957 on two separate mouse models of arthritis <i>in vivo</i>. Their findings suggested that Î²5i inhibition alone was capable of stopping disease progression in a dose-dependent manner, with observation of disease regression as soon as 24 h after the first dose. Most notably, this regression was observed much more quickly than the anti-TNF-Î± therapy, etanercept, and at concentrations that were 10% of the maximum tolerated dose (MTD) for these mice.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) PR-957, also known as ONX-0914, is one of the first inhibitors with high selectivity for the Î²5i subunit, allowing for the probing of independent iCP activities. It has been investigated in several autoimmune disorders. (B) Carfilzomib is an FDA-approved second-generation proteasome inhibitor for the treatment of MM. (C) PR-893 is a Î²5c-selective inhibitor, discovered in the same endeavor as ONX-0914. Its improved selectivity compared to those of bortezomib and carfilzomib has allowed us to distinguish between the sCP and iCP effects of inhibition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">4.2.  Multiple Sclerosis</h3><div class="NLM_p">Multiple sclerosis (MS) is an autoimmune disorder that effects the central nervous system. Inflammation, myelin damage, and axonal degeneration result in the hallmark neurological symptoms, including numbness or tingling in different parts of the body, vision problems, muscle weakness, and changes in cognitive functions. Similar to RA, there have been various environmental and genetic factors associated with the onset of MS. Genetic factors have been found in both MHC class I and class II, with the autoantigen most commonly believed to stem from myelin, the insulating material surrounding nerve cell axons that serves to accelerate action potentials. Overall, these factors result in the active inflammation state that is responsible for the damage seen in MS patients.</div><div class="NLM_p">Given that the iCP is expressed under inflammatory conditions and the role of CD8<sup>+</sup> T-cells in MS, a role for the iCP can likely be assumed in the central nervous system (CNS) of MS patients. The presence of Î²1i and Î²5i was confirmed by Mishto and colleagues in brain cell types of MS patients but not found in healthy brains.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Furthermore, Î²1i was found to be concentrated in MS plaques. Mishto was also able to demonstrate the ability of the iCP to degrade a peptide from myelin basic protein (MBP<sub>102â129</sub>) to produce a myelin antigen of interest in MS (MBP<sub>111â119</sub>). It is noteworthy that this study also confirmed the presence of the iCP in oligodendrocytes, the main producer of myelin. Overall, these data may suggest a role of the iCP in the onset of MS, particularly in the production of myelin-based autoantigens.</div><div class="NLM_p">A study comparing brains of MS patients to healthy controls sought to determine why an accumulation of carbonylated proteins was observed in the brains of MS patients.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Their results showed a decrease in all three protease-like activities for both gray and white matter, without any significant decrease in the protein levels of each catalytic subunit. Overall, this suggested an inhibited level of protein degradation in brains of MS patients.</div><div class="NLM_p">Experimental autoimmune encephalomyelitis (EAE) is a commonly used animal model for MS, induced in mice by introducing synthetic autoantigens. Many of the events in the pathogenesis of MS have been confirmed in EAE, and it has thus served as a system for testing and validating MS drugs.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> With EAE being an inducible disease state, early stages of the disease can be studied to look at initial symptoms as well as possible targets for early intervention, which is not possible in patients with MS as the autoantigens and methods for early diagnosis are not known. Having an available and effective model, Basler and co-workers sought to investigate the role of the iCP in the onset and progression of MS.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Following the same groupâs promising results in RA, they used ONX-0914 to determine if selective Î²5i inhibition could result in the decreased occurrence of EAE when beginning treatment on the day of immunization. The results showed â¼4-fold reduction in disease incidence when compared to mice treated with vehicle. This decreased incidence was attributed to a reduction in the level of invasion of CD4<sup>+</sup> T-helper cells, activated lymphocytes, and activated myeloid cells into the brain and spinal cord, as well as an overall reduction in signs of inflammation in these localized areas. Furthermore, as had been shown in the original study toward RA, ONX-0914 was found to significantly reduce the level of expression of critical cytokines for disease progression, as shown through reduced levels of the corresponding mRNA.</div><div class="NLM_p last">Basler and colleagues also looked at the effects of iCP inhibition on the progression of EAE.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Beginning treatment at the point that clinical symptoms were observed, ONX-0914 prevented progression to a severe disease state. This is likely a result of a reduced level of cellular infiltration to the spinal cord and a reduced level of expression of inflammatory cytokines.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">4.3.  Lupus</h3><div class="NLM_p">Systemic lupus erythematosus (SLE) covers a vast set of diseases associated on the basis of a common systemic autoimmune phenotype. It is understood that the onset of SLE is broadly caused by sustained autoantibody production in a patient, which results in a range of symptoms and severities. These autoantibodies are known to be targeted toward nucleic acids, and in SLE, it is believed that enhanced access to nuclear antigens is triggered by a discrepancy in apoptotic cell production and disposal of this cell material.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> The unusual presence of nuclear antigens leads to an immune response via nucleic acid recognition receptor activation, and further SLE-associated dysregulation of downfield pathways has been connected to vulnerability to the disease.</div><div class="NLM_p">As noted with the other diseases discussed in this section, SLE has many different environmental and genetic factors associated with development of the disease. One unique factor, however, is the contribution of hormones to SLE, as 90% of patients are female. In addition to ultraviolet light, other environmental factors include Epstein-Barr and cytomegalovirus infections, although these are not the only systemic infections with a correlative effect to SLE. Also, a strong heritability has been observed in SLE, based on information gathered on occurrence rates in identical versus fraternal twins and siblings, suggesting a genetic connection.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> As such, several genomewide association studies have been performed, and many of these are summarized in a review,<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> in which the authors highlight more than 40 loci with literature suggesting association with SLE.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Perhaps unsurprisingly as similar observations have been made in other autoimmune disorders, mutations in the MHC-II cluster appear to be the most strongly causative of SLE.</div><div class="NLM_p">The most common treatment options for patients with SLE include various immunosuppressants, including corticosteroids. These serve to decrease the overall effects of inflammation, such as the increased levels of cytokines. For example, IFN-Î±, a type I IFN affected by the upregulation of TNF, has been observed at elevated levels in SLE patients, which in turn upregulates B-cell activating factor (BAFF).<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Targeting of BAFF was considered an interesting mechanism for therapeutics, as it would be expected to decrease the level of production of autoantibodies, and such research resulted in the first biologic drug approved for SLE, belimumab.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a></div><div class="NLM_p">Although great strides have been made toward the treatment of lupus, a 60% decrease in all-cause death rates was achieved by comparing 1970 to 2001,<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> and there is still much room for improvement. After its approval for the treatment of MM, Neubert and co-workers investigated the potential use of bortezomib in a mouse model of SLE, proposing that depletion of plasma cells (PC), including B cells, would decrease the level of cytokine and autoantibody production.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> In this study, the authors were able to demonstrate a decrease in both short- and long-lived PCs, resulting in a decrease in autoantibodies against double-stranded DNA as well as the cells known to secrete these antibodies. Ultimately, this decrease gave rise to longer survival of mice treated with bortezomib. However, mice undergoing treatment were less capable of producing antibodies when challenged with a specific antigen, suggesting they may not be able to combat an infection. Additionally, the high percentage of patients treated with bortezomib that experience neuropathy would hinder it from the long-term use typically necessary for autoimmune diseases.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a></div><div class="NLM_p">Given these promising results with bortezomib as well as the data showing the selective inhibition of the iCP is responsible for the decreased level of cytokine expression,<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Ichikawa and co-workers sought to explore the use of other proteasome inhibitors, namely, carfilzomib (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>B) and ONX-0914, in the treatment of a mouse model of SLE.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> In this study, the authors found that both carfilzomib and ONX-0914 were able to prevent the progression of lupus-associated nephritis to a degree similar to that of bortezomib. This was complemented by a decrease in serum concentrations of anti-dsDNA antibody levels. Notably, the same degree of long-term effects in antibody reduction was not observed for carfilzomib as the other two inhibitors, which was presumed to be a result of its lower tolerable dose limiting the concentration used. As observed in the original work with bortezomib, a decrease in PC cells with treatment of carfilzomib or ONX-0914 was observed, with a preference for those that produce autoantibodies. With its known role in the pathogenesis of lupus, Ichikawa and colleagues investigated whether treatment with the proteasome inhibitors could prevent the production of IFN-Î±. Via treatment with either ONX-0914 (Î²5i-selective) or PR-893 (Î²5c-selective) (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>C), the authors found selective Î²5i inhibition reduced the level of production of IFN-Î±. Furthermore, they observed that this occurred through multiple TLR ligands, a novel mechanism for the inhibition of iCP. Overall, they concluded that dual inhibition of the production of autoantibodies and IFN-Î± via iCP inhibition could be a beneficial treatment for SLE.</div><div class="NLM_p">ONX-0914 has been thoroughly characterized as a selective inhibitor of Î²5i. This was especially supported by co-crystal structure data demonstrating that a steric hindrance between the inhibitor and Phe31 of Î²1i prevents favorable binding. Therefore, it was thought that selective inhibition of Î²5i was the mechanism by which ONX-0914 was able to limit the progression of SLE. Toward this end, efforts were made to develop more selective and potent inhibitors. In one study published by Basler and colleagues, one such inhibitor was presented, named PRN1126 (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>A).<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> This structure was able to improve upon both potency and selectivity for Î²5i through the addition of a reversible covalent interaction with Cys48, which is a unique residue found near the substrate binding pocket S2. Through various biochemical assays, the authors demonstrated the selectivity of PRN1126 for Î²5i over both the sCP and the other immuno-subunits. However, when looking for effects of the inhibitor on mouse models of colitis and EAE, they did not observe the same benefits that were observed with ONX-0914. Through further analysis of the binding characteristics of ONX-0914 in mouse lymphocytes, it was found that both Î²5i and Î²1i were covalently modified upon incubation with ONX-0194 for extended periods of time. For this reason, they hypothesized inhibition of both subunits is required to achieve anti-inflammatory effects. To investigate this hypothesis, the authors compared the effects of treatment with PRN1126 and Î²1i-selective inhibitors ML604440 and LU-001i or co-treatment with PRN1126 and one of these Î²1i inhibitors to those of ONX-0914. Co-treatment of PRN1126 with either Î²1i inhibitor achieved similar anti-inflammatory responses to ONX-0914, including a reduction in the level of IL-6 production. Dual inhibition through co-treatment of these inhibitors was also able to demonstrate an <i>in vivo</i> efficacy similar to that of ONX-0914 in the two mouse models of interest. Ultimately, this work demonstrated that dual inhibition of Î²5i and Î²1i is likely required to achieve effective treatments for autoimmune disorders.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. (A) PRN1126, a selective inhibitor of Î²5i, gains selectivity by reversibly, covalently binding to Cys48. (B) KRZ-504 is a selective inhibitor of Î²1i. Compound <b>8</b> is (C) a Î²5i-selective inhibitor, and compound <b>10</b> (D) is a Î²2i-selective inhibitor developed. (E) KRZ-616, a pan-iCP inhibitor currently in clinical trials for SLE.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Considering the promise for the treatment of autoimmune disorders with ONX-0914, inhibitors of Î²1i also began to be investigated for their potential effects on similar models. Researchers from Onyx Pharmaceuticals and Kezar Life Sciences first sought to synthesize second-generation inhibitors of Î²1i, seeking to improve upon the selectivity observed with UK-101, az-NC-001, and LU-001i.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> In a screening campaign against a library of peptide epoxyketones, the authors identified an inhibitor with an order of magnitude more potent binding to Î²1i than to Î²5i. The structural basis for this selectivity was investigated using modeling of the inhibitor, compound <b>10</b>, with the crystal structure of mouse iCP. Specifically, compound <b>10</b> was overlaid with ONX-0914, which indicated selectivity was driven by differences in how the two inhibitors fit into the S3 pocket of Î²1i. Unfortunately, when compound <b>10</b> was tested <i>in vivo</i> in mice, it was found to have poor stability, resulting in an only minor inhibition of Î²1i activity. For this reason, the authors designed KRZ-504 (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>B) by exchanging the <i>p</i>-methoxyphenylalanine residue in compound <b>10</b> with a serine. This resulted in improved solubility as well as improved selectivity over Î²5i as it weakened a hydrophobic interaction occurring between residue C48 and compound <b>10</b>. Despite the improved profile of KRZ-504, there was little effect observed on cytokine production, especially compared to ONX-0914. Overall, this suggested that inhibition of Î²1i would not be a viable approach to treating autoimmune disorders, but KRZ-504 can instead serve as a potential tool to better understand the various biological effects of iCP expression and inhibition.</div><div class="NLM_p">To further investigate their finding about the effects of individual and combined inhibition of the three immuno-subunits, Johnson and colleagues sought to design selective inhibitors for each.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> The authors designed these inhibitors using the same homology model as they had with KRZ-504<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> and synthesized compound <b>8</b> [Î²5i-selective (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>C)] and compound <b>10</b> [Î²2i-selective (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>D)]. As expected, inhibition of the individual subunits did not have the same effect on cytokine secretion as ONX-0914. Furthermore, upon investigation of the different pairs of inhibitors, it was observed that dual inhibition of Î²1i and Î²2i also did not elicit the desired reduction in cytokines. Considering all of these data, the authors concluded that inhibition of Î²5i is required but not sufficient for the anti-inflammatory responses necessary for effectiveness against autoimmune disease mouse models. Despite its success in these mouse models, ONX-0914 is not a viable clinical candidate due to its poor solubility. For this reason, the authors sought to design a more soluble epoxyketone inhibitor with an inhibition profile similar to that of ONX-0914. This was accomplished by first substituting the P1 phenylalanine side chain of ONX-0914 with a cyclopentene, which increased solubility while maintaining favorable selectivity for Î²5i. The second alteration was made at the Î² position of the P2 methyltyrosine by adding a hydroxyl. This yielded a compound, namely KRZ-616 (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>E), with a solubility more than 4 orders of magnitude higher than that of ONX-0914. KRZ-616, at half the dosage, displayed an efficacy similar to that of ONX-0914 when used in the anti-collagen antibody-induced arthritis model and is currently in Phase 1b/2 clinical trials for SLE<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> with plans to expand further to other autoimmune diseases.</div><div class="NLM_p">Recently, investigators from Genetech, Inc., published their work on developing selective iCP inhibitors expected to affect antibody production and cytokine secretion through inducing apoptosis in various immune cells.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> For this, they started with an Î±-aminoboronic acid with moderate selectivity for the iCP subunits over their corresponding sCP subunits developed by Roche.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Using this inhibitor, they obtained a co-crystal X-ray structure with the human iCP, which they note to be the first reported iCP crystal structure not obtained from engineering of yeast. Determining this co-crystal structure provided the authors with means to perform a structureâactivity-based study, yielding both a more selective dual inhibitor of Î²5i and Î²1i (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>A) as well as a more selective inhibitor of Î²5i (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>B). They found that none of their inhibitors had any potent effects on the viability of PBMCs, pDCs or PBs, while the less selective Roche compound did. Ultimately, they determined that, upon inhibition of the iCP, these immune cells upregulate the expression of sCP subunits to compensate and that any loss of viability with the other inhibitors was possible only at concentrations at which the sCP is also inhibited. The authors supported this further through CRISPR/Cas-9-mediated knockouts of either Î²5i or Î²5c. Upon treatment with the iCP-selective inhibitor, only the Î²5c knockout was observed to have any loss of viability. Ultimately, the authors conclude that iCP inhibition would not be a viable strategy for autoimmune disorders that would require the depletion of immune cells for a clinical response.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Inhibitors of (A) Î²5i and Î²1i and (B) Î²5i developed by Genentech, Inc.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">4.4.  Type I Diabetes</h3><div class="NLM_p">Type I diabetes (T1D) is a chronic autoimmune disease in which pancreatic Î²-islet cells are destroyed, preventing the production of insulin in affected patients. Without the proper levels of insulin, patients cannot effectively regulate glucose levels, leading to a wide range of health issues. The onset of the disease is most often observed at age five up to the beginning of puberty,<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> although in recent years, age is no longer a defining factor for diagnosis of the disease, with onset in adult years being recognized.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> The greatest genetic linkages are found to occur in the HLA gene clusters and associated proteins, including Î²5i and Î²1i.<a onclick="showRef(event, 'ref111 ref112 ref113'); return false;" href="javascript:void(0);" class="ref ref111 ref112 ref113">(111â113)</a></div><div class="NLM_p">With the pathogenesis of T1D being tied to the destruction of the insulin-producing cells, autoantibodies have a putative role in the disease. As a result, much research has been done to determine the autoantigens involved; confirmed antigens have included those derived from insulin, glutamic acid decarboxylase 65, insulinoma antigen-2, heat shock protein, and more recently Î²-cell-specific zinc transporter-8, islet amyloid polypeptide, chromogranin A, and pancreatic duodenal homeobox factor 1. Thus far, detection of such autoantibodies has been used for diagnosis, specifically as a way to distinguish between type 1 and type 2 forms of diabetes.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a></div><div class="NLM_p">The ubiquitous treatment for T1D is insulin replacement, but this requires the patientâs stringent monitoring of blood glucose levels and direct injection of sufficient insulin. In recent years, the progression of medical device technology has simplified this process with the invention of continuous glucose monitoring systems, which have been shown to decrease rates of hypoglycemia.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> With the addition of insulin pumps, further decreases in incidences of hypoglycemia as well as increased patient compliance have been observed.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> Since then, closed-loop systems integrating the two technologies have been shown to be safe and efficacious,<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> leading to its approval by the FDA. Unfortunately, insulin-dependent diabetes mellitus, including T1D, is associated with many long-term complications, most often renal failure, visual impairment/blindness, and heart attack.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> As such, additional therapeutic options for T1D are necessary to decrease the occurrence of these complications.</div><div class="NLM_p">It has long been proposed that the immune response to Î² cells is due in part to a hyperexpression of MHC-I proteins on the cell surface of these insulin-producing cells.<a onclick="showRef(event, 'ref119 ref120 ref121'); return false;" href="javascript:void(0);" class="ref ref119 ref120 ref121">(119â121)</a> The authors were able to study the most comprehensive set of data examining HLA expression in pancreatic cells, concluding MHC-I hyperexpression is an important pathological feature of T1D.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> Because data have been published demonstrating the ability of iCP inhibition to decrease the level of MHC-I expression,<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> treatment with an iCP inhibitor may preserve the viability of insulin-producing cells in T1D. Additionally, because IFN-Î³ has been associated with the hyperexpression of MHC-I<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> and the fact that inhibition of the iCP has been shown to reduce levels of IFN-Î± in other autoimmune disorders,<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> it is possible that treatment of T1D with iCP inhibitors could be beneficial for the survival of Î² cells.</div><div class="NLM_p">Overall, inhibitors of the iCP show great potential as treatments for autoimmune disorders (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). Inhibition of the iCP has been shown to decrease the level of local inflammation in many of the disorders mentioned above, characterized by a decrease in inflammatory cytokines. Additionally, inhibiting the activity of the iCP is expected to decrease the production of autoantigens. As unnatural expression of autoantigens in MHC-Iâs at the cell surface is known to be a mechanism by which apoptosis is triggered in autoimmune disorders, this would serve as a beneficial therapeutic effect overall.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. When cells are exposed to inflammatory cytokines (i.e., IFN-Î³ and TNF-Î±), the iCP is expressed. In autoimmune disorders, the presence of autoantigens activates T-cells and leads to apoptosis. If dosed with an iCP inhibitor, production of cytokines, such as IL-6 and TNF-Î±, is reduced, therefore decreasing the localized inflammation and allowing the cells to evade triggering of the immune system.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">5.  The iCP and Neurodegenerative Diseases</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56137" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56137" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">While the importance of the iCP in autoimmune diseases and cancer has been well studied, its implication in other diseases remains relatively unknown. Expression of iCP subunits has been observed in several neurological diseases such as Alzheimerâs disease (AD),<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> Huntingtonâs disease (HD),<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> and amyotrophic lateral sclerosis (ALS).<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> Often, these diseases are characterized by the buildup of protein aggregates that are difficult for the proteasome to degrade. Overall, reducing activity of the proteasome does not represent a feasible strategy for treating neurodegenerative diseases, as this is part of their pathology. However, the implications of iCP expression in neurodegeneration are less studied and could provide new clues about the onset, progression, and treatment of these diseases. Neuroinflammation is a hallmark of neurodegenerative disease and stimulates the release of cytokines such as IFN-Î³ and TNF-Î± in the brain and spinal cord.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> Similarly, low levels of neuroinflammation are typical in the brains of healthy older humans and mouse models, but the impact of this inflammation on cognitive function remains unknown. Significantly, in rat models, enhanced iCP expression can last several days upon induction of inflammation in the brain, suggesting it plays an important role in regulating protein degradation in the brain.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> It has been established that induction of neuroinflammation significantly alters the UPS, leading to the accumulation of ubiquitinated proteins and increased the level of expression of the iCP. The exact implications of iCP expression and activity as a result of neuroinflammation and neurodegenerative diseases remain to be further studied, but preliminary data suggest the iCP may be a potential target for therapeutic intervention (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>). Because expression of the iCP exacerbates inflammation by degrading proteins into peptides that can be incorporated into MHC-I molecules and displayed on the surface of cells, it is possible that reducing its activity through the use of small molecule inhibitors could reduce the pool of MHC-I compatible peptides, resulting in repressed neural inflammation and slowing the progression of multiple neurodegenerative diseases.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Expression of the iCP has been implicated in aging and several neurodegenerative diseases. Recent research has focused on determining the role of the iCP in neurodegenerative diseases. Although controversial, altering the extent of iCP activity could potentially help reverse damage from aging and neurodegenerative diseases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">5.1.  The iCP and AD</h3><div class="NLM_p">AD is the leading cause of dementia in the United States and is characterized by progressive loss of memory, cognitive skills, and functional ability.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> The pathogenesis of AD remains to be fully elucidated but is marked by the formation of amyloid-Î² (AÎ²) aggregates in extracellular spaces and formation of intracellular tau fibrils.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Despite significant progress toward understanding the pathogenesis of this disease, few FDA-approved therapies are available, and they treat only the symptoms of AD progression, not the underlying cause.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> As a result, current research is underway to discover new targets for therapeutic intervention in an effort to better treat AD. Recently, it has been established that the iCP is expressed at low levels in several regions of the brain.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> In patients with AD, an increase in the level of expression of the iCP is observed in regions of the brain typically affected by the disease, such as the hippocampus, but not in other regions, such as the cerebellum.<a onclick="showRef(event, 'ref124 ref129'); return false;" href="javascript:void(0);" class="ref ref124 ref129">(124,129)</a> Similarly, astrocytes and glial cells in the proximity of extracellular AÎ² plaques also show increased levels of iCP expression compared to those of cells from healthy tissue.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> This has also been demonstrated in AD mouse models in which enhanced gene expression of iCP subunits and a subsequent increase in the level of iCP protein expression were observed in mice with AÎ² pathology compared to control mice.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> The mechanism behind increased iCP expression remains unclear, but it is hypothesized that endoplasmic reticulum stress that results from the buildup of misfolded proteins is at least partially responsible for promotion of iCP subunit expression.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Research has also indicated that enhanced expression of the iCP during AD progression is associated with changes in the release of cytokines from microglial cells.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> A study with AD mouse models knocked out for Î²5i expression revealed that release of pro-inflammatory cytokines such as TNF-Î± and IL-6 was significantly attenuated in mice lacking Î²5i compared to control littermates. This was accompanied by an increased level of release of anti-inflammatory cytokines IL-4 and IL-10. AD mice lacking iCP expression also demonstrated improved cognitive function, as they performed better in maze tests, a measure of spatial memory, than iCP-expressing AD mice. Excitingly, the performance of iCP deficient mice was almost identical to that of non-AD control mice, suggesting the iCP plays an important role in the pathogenesis of AD and potentially symptom onset. Taken together, these data suggest that enhanced expression of the iCP in AD leads to an increased level of pro-inflammatory cytokine release and cognitive decline in mice models. Removal of iCP expression by knocking out Î²5i in AD mice led to suppression of pro-inflammatory cytokine release and improved cognitive function, suggesting alterations in expression and function of the iCP may represent a novel mechanism for slowing or reversing AD progression.</div><div class="NLM_p last">AD is also characterized by neural inflammation and an increased level of cytokine release in the brain, which may contribute to activation of iCP expression. Interestingly, the level of iCP expression appears to significantly increase with progression of AD, as evidenced by the observation that gene expression of the Î²1i and Î²5i is enhanced in mouse models and brain samples from patients with advanced-stage AD. The exact effect of protein aggregates on sCP and iCP activity remains unclear, as conflicting evidence has been reported; while some research groups show aggregates slow the rate of chymotrypsin- and caspase-like activity in homogenized patient brain tissue, it remains unclear if the impact is greater on the sCP or iCP.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> Similarly, several mouse models showed impaired sCP activity in response to aggregate formation,<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> but the role of the iCP in this process requires more thorough investigation. Conflicting evidence also suggests no change in the activity of the sCP in response to protein aggregation in AD.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> As such, significant work is required to fully understand the role of the iCP in AD and its potential as a therapeutic target. It is possible that manipulating the activity of the iCP could either slow the progression of AD or reverse its effects on the brain, but this cannot be determined on the basis of the current data.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">5.2.  The iCP and HD</h3><div class="NLM_p last">HD is a neurodegenerative disease that results from a mutation in the huntingtin protein, which leads to aggregation within neurons.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Patients with HD suffer from impaired cognitive, psychological, and motor abilities and eventually succumb to the disease. The impact of protein aggregation on sCP and iCP activity in neurons is not fully established, and current research has produced conflicting results. It has been demonstrated that ubiquitin and sCP subunits are sequestered in intraneuronal aggregates, suggesting the sCP is involved in attempting to clear the built-up protein.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> However, there is conflicting evidence about how the activity of the sCP is influenced by aggregates and the role of the iCP in this process, as some groups have reported inhibition<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> and others have reported enhanced activity of certain subunits.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Interestingly, the increased activity of chymotrypsin- and trypsin-like subunits has been correlated with an increased level of expression of Î²1i and Î²5i, indicating the increased level of expression of the iCP in the brains of HD mouse models. This observation was seen only in the brain regions impacted by HD, such as the cortex and striatum, but not others, like the cerebellum. Immunofluorescence studies of brain tissue also revealed a subset of intraneuronal aggregates sequestering iCP subunits, further suggesting the iCP is expressed in HD. This phenomenon was observed in not only mice but also brain tissues from human patients with HD. The mechanism of induction of iCP expression remains unclear, but it is possible that inhibition of the sCP triggers iCP expression to compensate for a decreased level of protein degradation, as it has been demonstrated that mutant huntingtin protein expression alone is not sufficient to stimulate expression of iCP subunits <i>in vivo</i>.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> As previously mentioned, neuroinflammation is a hallmark of neurodegenerative diseases, and a synergistic relationship between mutant huntingtin protein expression and IFN-Î³ stimulation on inducing expression of the Î²1i subunit in primary neuron cultures from HD mouse models has been observed. This result indicates that the combination of cytokines released as a result of neuroinflammation and the mutant huntingtin protein may be required to upregulate iCP expression in HD. Results from studies attempting to elucidate the function of both the sCP and the iCP in HD are also difficult to interpret because several different techniques are employed to monitor sCP and iCP activity.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> A lack of standardized techniques, cell models, and mouse models further complicates evaluation of the impact of the iCP on HD. However, preliminary studies suggest it may be important in disease progression, and careful study is required to fully understand the iCP as a therapeutic target in HD.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">5.3.  The iCP and ALS</h3><div class="NLM_p">ALS is neurodegenerative disease in which motor neurons in the spinal cord and brain stem die, resulting in paralysis and eventual death.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> With no effective treatments available to reverse ALS or slow its progression, significant effort is being dedicated to further understanding this disease and discovering new therapeutic targets. ALS is characterized by mutations in the gene encoding the superoxide dismutase (SOD1) protein. Mutant SOD1 has been shown to form insoluble protein aggregates in motor neurons, thus potentially implicating dysregulation of the UPS as one of the reasons for disease progression. Interestingly, it has been established that the activity of the sCP catalytic subunits is not reduced in spinal cords from ALS mouse models, but accumulation of ubiquitinated proteins is evident.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> In addition, a significant reduction in the level of expression of sCP subunits was observed, while iCP subunits were strongly expressed in spinal cord tissue from ALS mouse models; this phenomenon was not observed in healthy control mice. An increased level of iCP subunit expression may explain the lack of change in the activity of the catalytic subunits, despite a decrease in the level of sCP subunit expression. Similarly, it was also shown that the level of mRNA expression of the gene encoding the Î²5i subunit increased significantly as the disease progressed in ALS mouse models.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> In agreement with these data, it has been shown that treatment of ALS rat models with pyrrolidine dithiobarbamate (PDTC), a NF-kB inhibitor, decreases the rate of survival and is also correlated with weakened induction of iCP expression.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> After treatment of ALS rats with PDTC, the onset of paralysis and subsequent death were shown to occur significantly earlier than in control rats not dosed with the compound. PDTC treatment of ALS rats was also shown to significantly impair sCP activity. Similarly, a high level of expression of the iCP was observed prior to PDTC treatment; however, it was completely abolished after treatment. PDTC appeared to have no effect on sCP expression, potentially indicating that the iCP plays an important role in ALS. Similar to results obtained from other studies, it was also found that the level of Î²5i subunit expression was increased throughout disease progression.</div><div class="NLM_p last">Although outstanding progress has been made in understanding the implications of iCP and sCP expression in neurodegenerative disease, more work is required to fully evaluate the iCP as a therapeutic target. Unfortunately, a lack of consistency in cell models, mouse models, and analytical techniques to study sCP and iCP activity are likely to be at least partially responsible for conflicting data. Similarly, the immunobiology of the brain and spinal cord is different from that of other body tissues and not completely understood, making identifying the roles of the UPS in neurodegenerative diseases more complicated. Although a large degree of progress is still required, exciting preliminary data may suggest the iCP is a novel target for neuroinflammation and neurodegenerative diseases that, as of right now, do not have many treatment options. Future study of the iCP as well as a better understanding of the brain and spinal cord will hopefully facilitate development of new therapeutics for these devastating diseases.</div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">6.  Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62803" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62803" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Significant progress has been made in recent years toward understanding the iCP and the critical roles it plays in various diseases. This has largely been helped by being able to apply the ample tools and research from the sCP to the iCP, changing for specificity. However, there is still much left unknown or misunderstood due to the lack in standardized, convenient probes and assay techniques that will further distinguish between the two isoforms and their activity levels in cells of interest. With work done in the past couple of years by our lab and others,<a onclick="showRef(event, 'ref35 ref41'); return false;" href="javascript:void(0);" class="ref ref35 ref41">(35,41)</a> we are getting closer to filling in these gaps, in addition to having a set of tools that could provide reproducible and comparable results across cell lines and experiments.</div><div class="NLM_p">Current research has thus far demonstrated that iCP inhibition is not an effective mechanism for cancer therapeutics. Treatment of autoimmune disorders with iCP-specific inhibitors, however, has great potential, and the data gained from the KZR-616 (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B) clinical trials for SLE (ID: NCT03393013) will inform on the broad applicability of this therapeutic mechanism. Beyond inhibition, stimulation of the sCP is now becoming in interesting avenue in various protein accumulation diseases,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> suggesting iCP stimulation is also worth exploring. As mentioned above, there is much unknown about the role of the iCP in different neurological diseases. Therefore, it is not known if potential treatments for these disease could include either inhibition or stimulation of the iCP. As the role of the iCP in these diseases is further studied, it may be useful to consider one or both of these mechanisms.</div><div class="NLM_p">In addition to the diseases in which the level of iCP expression or activity is higher than normal, there are also different diseases in which the iCP is hindered, which may benefit from stimulation of the iCP activity. One possible class of diseases that could benefit from iCP stimulation is viral infections. Several types of viruses, including HIV,<a onclick="showRef(event, 'ref138 ref139'); return false;" href="javascript:void(0);" class="ref ref138 ref139">(138,139)</a> Kaposiâs sarcoma-associated herpes virus (KSHV),<a onclick="showRef(event, 'ref140 ref141'); return false;" href="javascript:void(0);" class="ref ref140 ref141">(140,141)</a> and various other herpes viruses,<a onclick="showRef(event, 'ref142 ref143 ref144'); return false;" href="javascript:void(0);" class="ref ref142 ref143 ref144">(142â144)</a> have been shown to interfere with different stages of MHC-I expression. Notably, HIV Tat protein has also been shown to bind to various Î± and Î² subunits of the iCP as a way to prevent production of viral antigens.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> Overall, these different mechanisms serve to prevent recognition of virally infected cells by the hostâs immune system.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> An interesting way to restore MHC-I expression of viral antigens would then be to stimulate the iCP, therefore increasing the size of the overall pool of viral antigens to be expressed on the cell surface.</div><div class="NLM_p last">In conclusion, the iCP is becoming a validated target in several different disease types, but there is still much left to be understood about its activity and its roles in these and other diseases. We expect that, as the recently published tools for distinguishing between the sCP and the iCP are used for further studies, targeting the iCP through either inhibition or stimulation will offer important research tools as well as inform upon its use in therapeutic strategies.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01226" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03832" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03832" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Darci J. Trader</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry
and Molecular Pharmacology, Purdue University, 575 West Stadium Avenue, West Lafayette, Indiana 47907, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0607-1243" title="Orcid link">http://orcid.org/0000-0002-0607-1243</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#84e0f0f6e5e0e1f6c4f4f1f6e0f1e1aae1e0f1"><span class="__cf_email__" data-cfemail="7511010714111007350500071100105b101100">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Breanna L. Zerfas</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry
and Molecular Pharmacology, Purdue University, 575 West Stadium Avenue, West Lafayette, Indiana 47907, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marianne E. Maresh</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry
and Molecular Pharmacology, Purdue University, 575 West Stadium Avenue, West Lafayette, Indiana 47907, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50543" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50543" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Breanna L. Zerfas</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=BIO-d7e1092-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Breanna L. Zerfas</b> received her Ph.D. in chemistry from Boston College in 2017. While she was there, her research focused on synthesizing unnatural analogues of the antimicrobial peptide gramicidin A to improve its selectivity for bacteria. Since then, she has been a postdoc in the Trader lab at Purdue University, where her research focuses on selectively harnessing the activity of the immunoproteasome.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Marianne E. Maresh</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=BIO-d7e1097-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Marianne E. Maresh</b> received her B.S. in biology from Wayne State University in 2016. After completion of this degree, she moved to Purdue University where she was admitted to the Interdisciplinary Life Sciences Program. She joined Prof. Traderâs lab where she focuses on the discovery of small molecule binders for oncoproteins and impacts of proteasome stimulators on aging.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Darci J. Trader</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=BIO-d7e1102-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Darci J. Trader</b> received her Ph.D. in 2013 under the direction of Prof. Erin Carlson while at Indiana University. She began her independent career at Purdue University in the Department of Medicinal Chemistry and Molecular Pharmacology in 2016. Her lab is focused on discovering new molecules to monitor and perturb a variety of isoforms of the proteasome.</p></figure></div><div class="ack" id="ACK-d7e1110-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78655" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78655" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported through a start-up package from the Purdue University School of Pharmacy, Purdue University Center for Cancer Research National Institutes of Health (NIH) Grant P30 CA023168, American Cancer Society Institutional Research Grant IRG-14-190-56 to the Purdue University Center for Cancer Research, and NIH Grant R21GM131206. M.E.M. is currently supported through a graduate fellowship from the Purdue University Center for Cancer Research. B.L.Z. is currently partially supported by a Showalter Research Trust Grant.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">iCP</td><td class="NLM_def"><p class="first last">noncapped isoform of the immunoproteasome</p></td></tr><tr><td class="NLM_term">sCP</td><td class="NLM_def"><p class="first last">noncapped isoform of the standard proteasome</p></td></tr><tr><td class="NLM_term">UPS</td><td class="NLM_def"><p class="first last">ubiquitin-dependent proteasome system</p></td></tr><tr><td class="NLM_term">19S RP</td><td class="NLM_def"><p class="first last">19S regulatory particle of the sCP, which indicates the sCP is capped to perform ubiquitin-dependent degradation</p></td></tr><tr><td class="NLM_term">IFN-Î³</td><td class="NLM_def"><p class="first last">interferon Î³, a cytokine that is required to turn on the genes that produce the iCP subunits</p></td></tr><tr><td class="NLM_term">MHC-I</td><td class="NLM_def"><p class="first last">major histocompatibility complexes type I</p></td></tr><tr><td class="NLM_term">MM</td><td class="NLM_def"><p class="first last">multiple myeloma</p></td></tr><tr><td class="NLM_term">SLE</td><td class="NLM_def"><p class="first last">systemic lupus erythematosus</p></td></tr><tr><td class="NLM_term">EAE</td><td class="NLM_def"><p class="first last">experimental autoimmune encephalomyelitis</p></td></tr><tr><td class="NLM_term">T1D</td><td class="NLM_def"><p class="first last">type 1 diabetes</p></td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimerâs disease</p></td></tr><tr><td class="NLM_term">HD</td><td class="NLM_def"><p class="first last">Huntingtonâs disease</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37187" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37187" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 145 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span> <span> </span><span class="NLM_article-title">An Atomic Structure of the Human 26S Proteasome</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">778</span>â <span class="NLM_lpage">785</span>, <span class="refDoi">Â DOI: 10.1038/nsmb.3273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fnsmb.3273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=27428775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1KmurnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=778-785&issue=9&author=X.+Huangauthor=B.+Luanauthor=J.+Wuauthor=Y.+Shi&title=An+Atomic+Structure+of+the+Human+26S+Proteasome&doi=10.1038%2Fnsmb.3273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">An atomic structure of the human 26S proteasome</span></div><div class="casAuthors">Huang, Xiuliang; Luan, Bai; Wu, Jianping; Shi, Yigong</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">778-785</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We report the cryo-EM structure of the human 26S proteasome at an av. resoln. of 3.5 Ã, allowing at. modeling of 28 subunits in the core particle (CP) and 18 subunits in the regulatory particle (RP).  The C-terminal residues of Rpt3 and Rpt5 subunits in the RP can be seen inserted into surface pockets formed between adjacent Î± subunits in the CP.  Each of the six Rpt subunits contains a bound nucleotide, and the central gate of the CP Î±-ring is closed despite RP assocn.  The six pore 1 loops in the Rpt ring are arranged similarly to a spiral staircase along the axial channel of substrate transport, which is constricted by the pore 2 loops.  We also detd. the cryo-EM structure of the human proteasome bound to the deubiquitinating enzyme USP14 at 4.35-Ã resoln.  Together, our structures provide a framework for mechanistic understanding of eukaryotic proteasome function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7cgdtPPda8bVg90H21EOLACvtfcHk0lj1MWNKCJtVqA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1KmurnN&md5=4b341b3da5cb3560cf048c87c279393a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.3273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.3273%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DLuan%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DAn%2520Atomic%2520Structure%2520of%2520the%2520Human%252026S%2520Proteasome%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2016%26volume%3D23%26issue%3D9%26spage%3D778%26epage%3D785%26doi%3D10.1038%2Fnsmb.3273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coux, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, A. L.</span></span> <span> </span><span class="NLM_article-title">Structure and Functions of the 20S and 26S Proteasomes</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">801</span>â <span class="NLM_lpage">847</span>, <span class="refDoi">Â DOI: 10.1146/annurev.bi.65.070196.004101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1146%2Fannurev.bi.65.070196.004101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=8811196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADyaK28XktFamurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1996&pages=801-847&author=O.+Couxauthor=K.+Tanakaauthor=A.+L.+Goldberg&title=Structure+and+Functions+of+the+20S+and+26S+Proteasomes&doi=10.1146%2Fannurev.bi.65.070196.004101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and functions of the 20S and 26S proteasomes</span></div><div class="casAuthors">Coux, Olivier; Tanaka, Keiji; Goldberg, Alfred L.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">801-847</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review with 287 refs., of recent progress with respect to biochem. mechanisms and intracellular functions of the 20 S and 26 S proteasomes (multicatalytic proteinases).  The proteasome is an essential component of the ATP-dependent proteolytic pathway in eukaryotic cells and is responsible for the degrdn. of most cellular proteins.  The 20 S (700-kDa) proteasome contains multiple peptidase activities that function through a new type of proteolytic mechanism involving a threonine active site.  The 26 S (2000-kDa) complex, which degrades ubiquitinated proteins, contains in addn. to the 20 S proteasome a 19 S regulatory complex composed of multiple ATPases and components necessary for binding protein substrates.  The proteasome has been highly conserved during eukaryotic evolution, and simpler forms are even found in archaebacteria and eubacteria.  Major advances have been achieved recently in the knowledge about the mol. organization of the 20 S and 19 S particles, their subunits, the proteasome's role in MHC-class 1 antigen presentation, and regulators of its activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCV4euIYQJHLVg90H21EOLACvtfcHk0lj1MWNKCJtVqA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XktFamurc%253D&md5=546ea9ad61ac1cf74667da7e5075484c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1146%2Fannurev.bi.65.070196.004101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.bi.65.070196.004101%26sid%3Dliteratum%253Aachs%26aulast%3DCoux%26aufirst%3DO.%26aulast%3DTanaka%26aufirst%3DK.%26aulast%3DGoldberg%26aufirst%3DA.%2BL.%26atitle%3DStructure%2520and%2520Functions%2520of%2520the%252020S%2520and%252026S%2520Proteasomes%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D1996%26volume%3D65%26spage%3D801%26epage%3D847%26doi%3D10.1146%2Fannurev.bi.65.070196.004101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabre, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambour, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delobel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amalric, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monsarrat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlet-Schiltz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bousquet-Dubouch, M.-P.</span></span> <span> </span><span class="NLM_article-title">Subcellular Distribution and Dynamics of Active Proteasome Complexes Unraveled by a Workflow Combining in Vivo Complex Cross-Linking and Quantitative Proteomics</span>. <i>Mol. Cell. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">687</span>â <span class="NLM_lpage">699</span>, <span class="refDoi">Â DOI: 10.1074/mcp.M112.023317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1074%2Fmcp.M112.023317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=23242550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtlOitL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=687-699&issue=3&author=B.+Fabreauthor=T.+Lambourauthor=J.+Delobelauthor=F.+Amalricauthor=B.+Monsarratauthor=O.+Burlet-Schiltzauthor=M.-P.+Bousquet-Dubouch&title=Subcellular+Distribution+and+Dynamics+of+Active+Proteasome+Complexes+Unraveled+by+a+Workflow+Combining+in+Vivo+Complex+Cross-Linking+and+Quantitative+Proteomics&doi=10.1074%2Fmcp.M112.023317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Subcellular Distribution and Dynamics of Active Proteasome Complexes Unraveled by a Workflow Combining in Vivo Complex Cross-Linking and Quantitative Proteomics</span></div><div class="casAuthors">Fabre, Bertrand; Lambour, Thomas; Delobel, Julien; Amalric, Francois; Monsarrat, Bernard; Burlet-Schiltz, Odile; Bousquet-Dubouch, Marie-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Molecular & Cellular Proteomics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">687-699</span>CODEN:
                <span class="NLM_cas:coden">MCPOBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-9484</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Through protein degrdn., the proteasome plays fundamental roles in different cell compartments.  Although the compn. of the 20S catalytic core particle (CP) has been well documented, little is known about the compn. and dynamics of the regulatory complexes that play a crucial role in its activity, or about how they assoc. with the CP in different cell compartments, different cell lines, and in response to external stimuli.  Because of difficulties performing acceptable cell fractionation while maintaining complex integrity, it has been challenging to characterize proteasome complexes by proteomic approaches.  Here, we report an integrated protocol, combining a crosslinking procedure on intact cells with cell fractionation, proteasome immuno-purifn., and robust label-free quant. proteomic anal. by mass spectrometry to det. the distribution and dynamics of cellular proteasome complexes in leukemic cells.  Activity profiles of proteasomes were correlated fully with the compn. of protein complexes and stoichiometry.  Moreover, our results suggest that, at the subcellular level, proteasome function is regulated by dynamic interactions between the 20S CP and its regulatory proteins-which modulate proteasome activity, stability, localization, or substrate uptake-rather than by profound changes in 20S CP compn.  Proteasome plasticity was obsd. both in the 20S CP and in its network of interactions following IFNÎ³ stimulation.  The fractionation protocol also revealed specific proteolytic activities and structural features of low-abundance microsomal proteasomes from U937 and KG1a cells.  These could be linked to their important roles in the endoplasmic reticulum assocd. degrdn. pathway in leukemic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopH0HunTPDfLVg90H21EOLACvtfcHk0lj1MWNKCJtVqA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtlOitL4%253D&md5=93d90b61268072123e712a8861bde7c8</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1074%2Fmcp.M112.023317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fmcp.M112.023317%26sid%3Dliteratum%253Aachs%26aulast%3DFabre%26aufirst%3DB.%26aulast%3DLambour%26aufirst%3DT.%26aulast%3DDelobel%26aufirst%3DJ.%26aulast%3DAmalric%26aufirst%3DF.%26aulast%3DMonsarrat%26aufirst%3DB.%26aulast%3DBurlet-Schiltz%26aufirst%3DO.%26aulast%3DBousquet-Dubouch%26aufirst%3DM.-P.%26atitle%3DSubcellular%2520Distribution%2520and%2520Dynamics%2520of%2520Active%2520Proteasome%2520Complexes%2520Unraveled%2520by%2520a%2520Workflow%2520Combining%2520in%2520Vivo%2520Complex%2520Cross-Linking%2520and%2520Quantitative%2520Proteomics%26jtitle%3DMol.%2520Cell.%2520Proteomics%26date%3D2013%26volume%3D12%26issue%3D3%26spage%3D687%26epage%3D699%26doi%3D10.1074%2Fmcp.M112.023317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trader, D. J.</span></span> <span> </span><span class="NLM_article-title">All About the Core: A Therapeutic Strategy to Prevent Protein Accumulation with Proteasome Core Particle Stimulators</span>. <i>ACS Pharmacol. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">140</span>â <span class="NLM_lpage">142</span>, <span class="refDoi">Â DOI: 10.1021/acsptsci.8b00042</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsptsci.8b00042" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFeitr7N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2018&pages=140-142&issue=2&author=R.+A.+Colemanauthor=D.+J.+Trader&title=All+About+the+Core%3A+A+Therapeutic+Strategy+to+Prevent+Protein+Accumulation+with+Proteasome+Core+Particle+Stimulators&doi=10.1021%2Facsptsci.8b00042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">All About the Core: A Therapeutic Strategy to Prevent Protein Accumulation with Proteasome Core Particle Stimulators</span></div><div class="casAuthors">Coleman, Rachel A.; Trader, Darci J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Pharmacology & Translational Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-142</span>CODEN:
                <span class="NLM_cas:coden">APTSFN</span>;
        ISSN:<span class="NLM_cas:issn">2575-9108</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The proteasome is an essential enzyme complex in cells whose main responsibility is to degrade proteins.  Proteins can be degraded through either a ubiquitin-dependent or -independent mechanism by the proteasome.  A variety of small mols. have been discovered that can increase the rate of protein degrdn. through either mechanism.  However, stimulation of the ubiquitin-independent system is likely to be the most therapeutically impactful for protein-accumulation diseases.  Preliminary evidence has demonstrated efficacy of this approach for reducing proteins assocd. with disease.  To advance the field forward, validation of this mechanism in a disease model as well as more detailed studies on how much stimulation is required to achieve a therapeutic effect must be performed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSbvH2uuL6GLVg90H21EOLACvtfcHk0ljuzVbi3RlAgQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFeitr7N&md5=5b356c5fb7c7a7a6c9793f4eebe55940</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Facsptsci.8b00042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsptsci.8b00042%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DR.%2BA.%26aulast%3DTrader%26aufirst%3DD.%2BJ.%26atitle%3DAll%2520About%2520the%2520Core%253A%2520A%2520Therapeutic%2520Strategy%2520to%2520Prevent%2520Protein%2520Accumulation%2520with%2520Proteasome%2520Core%2520Particle%2520Stimulators%26jtitle%3DACS%2520Pharmacol.%2520Transl.%2520Sci.%26date%3D2018%26volume%3D1%26issue%3D2%26spage%3D140%26epage%3D142%26doi%3D10.1021%2Facsptsci.8b00042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Opoku-Nsiah, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gestwicki, J. E.</span></span> <span> </span><span class="NLM_article-title">Aim for the Core: Suitability of the Ubiquitin-Independent 20S Proteasome as a Drug Target in Neurodegeneration</span>. <i>Transl. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>198</i></span>,  <span class="NLM_fpage">48</span>â <span class="NLM_lpage">57</span>, <span class="refDoi">Â DOI: 10.1016/j.trsl.2018.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.trsl.2018.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=30244692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht12mu73K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2018&pages=48-57&author=K.+A.+Opoku-Nsiahauthor=J.+E.+Gestwicki&title=Aim+for+the+Core%3A+Suitability+of+the+Ubiquitin-Independent+20S+Proteasome+as+a+Drug+Target+in+Neurodegeneration&doi=10.1016%2Fj.trsl.2018.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Aim for the core: suitability of the ubiquitin-independent 20S proteasome as a drug target in neurodegeneration</span></div><div class="casAuthors">Opoku-Nsiah, Kwadwo A.; Gestwicki, Jason E.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">198</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">48-57</span>CODEN:
                <span class="NLM_cas:coden">TRRECL</span>;
        ISSN:<span class="NLM_cas:issn">1878-1810</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Neurodegenerative diseases are a class of age-assocd. proteopathies characterized by the accumulation of misfolded and/or aggregation-prone proteins.  This imbalance has been attributed, in part, to an age-dependent decay in the capacity of protein turnover.  Most proteins are degraded by the ubiquitin-proteasome system (UPS), which is composed of ubiquitin ligases and regulatory particles, such as the 19S, that deliver cargo to the proteolytically active 20S proteasome (20S) core.  However, a subset of clients, esp. intrinsically disordered proteins (IDPs), are also removed by the action of the ubiquitin-independent proteasome system (UIPS).  What are the specific contributions of the UPS and UIPS in the context of neurodegeneration.  Here, we explore how age-assocd. changes in the relative contribution of the UPS and UIPS, combined with the IDP-like structure of many neurodegenerative disease-assocd. proteins, might contribute.  Strikingly, the 20S has been shown to predominate in older neurons and to preferentially act on relevant substrates, such as synuclein and tau.  Moreover, pharmacol. activation of the 20S has been shown to accelerate removal of aggregation-prone proteins in some models.  Together, these recent studies are turning attention to the 20S and the UIPS as potential therapeutic targets in neurodegeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1GEmdqyg24bVg90H21EOLACvtfcHk0ljuzVbi3RlAgQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht12mu73K&md5=f5e957eb4d08fb227f130b8446ee763c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.trsl.2018.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trsl.2018.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DOpoku-Nsiah%26aufirst%3DK.%2BA.%26aulast%3DGestwicki%26aufirst%3DJ.%2BE.%26atitle%3DAim%2520for%2520the%2520Core%253A%2520Suitability%2520of%2520the%2520Ubiquitin-Independent%252020S%2520Proteasome%2520as%2520a%2520Drug%2520Target%2520in%2520Neurodegeneration%26jtitle%3DTransl.%2520Res.%26date%3D2018%26volume%3D198%26spage%3D48%26epage%3D57%26doi%3D10.1016%2Fj.trsl.2018.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Nissan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharon, M.</span></span> <span> </span><span class="NLM_article-title">Regulating the 20S Proteasome Ubiquitin-Independent Degradation Pathway</span>. <i>Biomolecules</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">862</span>â <span class="NLM_lpage">884</span>, <span class="refDoi">Â DOI: 10.3390/biom4030862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.3390%2Fbiom4030862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=25250704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12hsLrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=862-884&issue=3&author=G.+Ben-Nissanauthor=M.+Sharon&title=Regulating+the+20S+Proteasome+Ubiquitin-Independent+Degradation+Pathway&doi=10.3390%2Fbiom4030862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Regulating the 20S proteasome ubiquitin-independent degradation pathway</span></div><div class="casAuthors">Ben-Nissan, Gili; Sharon, Michal</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">862-884, 23 pp.</span>CODEN:
                <span class="NLM_cas:coden">BIOMHC</span>;
        ISSN:<span class="NLM_cas:issn">2218-273X</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">For many years, the ubiquitin-26S proteasome degrdn. pathway was considered the primary route for proteasomal degrdn.  However, it is now becoming clear that proteins can also be targeted for degrdn. by the core 20S proteasome itself.  Degrdn. by the 20S proteasome does not require ubiquitin tagging or the presence of the 19S regulatory particle; rather, it relies on the inherent structural disorder of the protein being degraded.  Thus, proteins that contain unstructured regions due to oxidn., mutation, or aging, as well as naturally, intrinsically unfolded proteins, are susceptible to 20S degrdn.  Unlike the extensive knowledge acquired over the years concerning degrdn. by the 26S proteasome, relatively little is known about the means by which 20S-mediated proteolysis is controlled.  Here, we describe our current understanding of the regulatory mechanisms that coordinate 20S proteasome-mediated degrdn., and highlight the gaps in knowledge that remain to be bridged.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIDvYhAH_verVg90H21EOLACvtfcHk0ljuzVbi3RlAgQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12hsLrL&md5=b079f6d24dcd96070d8fbc3da2c49dcb</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3390%2Fbiom4030862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fbiom4030862%26sid%3Dliteratum%253Aachs%26aulast%3DBen-Nissan%26aufirst%3DG.%26aulast%3DSharon%26aufirst%3DM.%26atitle%3DRegulating%2520the%252020S%2520Proteasome%2520Ubiquitin-Independent%2520Degradation%2520Pathway%26jtitle%3DBiomolecules%26date%3D2014%26volume%3D4%26issue%3D3%26spage%3D862%26epage%3D884%26doi%3D10.3390%2Fbiom4030862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, K.</span></span> <span> </span><span class="NLM_article-title">Role of Proteasomes Modified by Interferon-Gamma in Antigen Processing</span>. <i>J. Leukocyte Biol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">571</span>â <span class="NLM_lpage">575</span>, <span class="refDoi">Â DOI: 10.1002/jlb.56.5.571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1002%2Fjlb.56.5.571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=7964165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADyaK2cXmvFymtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1994&pages=571-575&issue=5&author=K.+Tanaka&title=Role+of+Proteasomes+Modified+by+Interferon-Gamma+in+Antigen+Processing&doi=10.1002%2Fjlb.56.5.571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Role of proteasomes modified by interferon-Î³ in antigen processing</span></div><div class="casAuthors">Tanaka, Keiji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">571-5</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">A review with 31 refs. of the possible function of proteasomes in antigen processing with special ref. to the influence of interferon-Î³ on their function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI--bWlvkbibVg90H21EOLACvtfcHk0ljzlZRk97UrFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvFymtbg%253D&md5=4b225932ff9e7fb1fb67ebd9b8cf7444</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fjlb.56.5.571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlb.56.5.571%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DK.%26atitle%3DRole%2520of%2520Proteasomes%2520Modified%2520by%2520Interferon-Gamma%2520in%2520Antigen%2520Processing%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D1994%26volume%3D56%26issue%3D5%26spage%3D571%26epage%3D575%26doi%3D10.1002%2Fjlb.56.5.571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eskandari, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seelen, M. a. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzi, J. R.</span></span> <span> </span><span class="NLM_article-title">The Immunoproteasome: An Old Player with a Novel and Emerging Role in Alloimmunity</span>. <i>Am. J. Transplant.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3033</span>â <span class="NLM_lpage">3039</span>, <span class="refDoi">Â DOI: 10.1111/ajt.14435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1111%2Fajt.14435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=28719024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BC1cjoslSjsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=3033-3039&issue=12&author=S.+K.+Eskandariauthor=M.+a.+J.+Seelenauthor=G.+Linauthor=J.+R.+Azzi&title=The+Immunoproteasome%3A+An+Old+Player+with+a+Novel+and+Emerging+Role+in+Alloimmunity&doi=10.1111%2Fajt.14435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The immunoproteasome: An old player with a novel and emerging role in alloimmunity</span></div><div class="casAuthors">Eskandari S K; Azzi J R; Eskandari S K; Seelen M A J; Lin G</div><div class="citationInfo"><span class="NLM_cas:title">American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3033-3039</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Modern treatment strategies for the maintenance of allograft acceptance frequently target ubiquitously-expressed pathways, leading to significant side-effects and poor long-term allograft outcomes.  Constitutive proteasome inhibitors, which have recently been introduced for the treatment of antibody-mediated rejection, target the ubiquitously-expressed proteasome.  To limit off-target effects and serious mechanism-based toxicity, however, these inhibitors are administered intermittently and suboptimally.  Immunoproteasomes, which are an inducible subset of proteasomes enriched in immune cells, replace constitutive proteasomes after cell exposure to proinflammatory cytokines such as interferon-Î³.  While immunoproteasomes were first described as processors of antigen for presentation by major histocompatibility complex molecules, recent findings point to its broader biological roles.  These vary from activating different subsets of the immune system, by controlling transcriptional activators and downstream cytokines, to affecting their differentiation and survival.  These emerging roles of the immunoproteasome in activated immune cells have made it a rational candidate for the targeted treatment of immune-mediated diseases.  Preclinical studies have established its role in maintaining allograft acceptance without significant short- or long-term toxicity.  This review provides a brief background of the immunoproteasome and outlines its role in immunological pathways and its potential in alloimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSEMLlHyBytPZHZzFRCXxVKfW6udTcc2eZ69KxhxwWT2rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjoslSjsg%253D%253D&md5=8ae1e2258dcad625a497d4a190b9a876</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fajt.14435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fajt.14435%26sid%3Dliteratum%253Aachs%26aulast%3DEskandari%26aufirst%3DS.%2BK.%26aulast%3DSeelen%26aufirst%3DM.%2Ba.%2BJ.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DAzzi%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520Immunoproteasome%253A%2520An%2520Old%2520Player%2520with%2520a%2520Novel%2520and%2520Emerging%2520Role%2520in%2520Alloimmunity%26jtitle%3DAm.%2520J.%2520Transplant.%26date%3D2017%26volume%3D17%26issue%3D12%26spage%3D3033%26epage%3D3039%26doi%3D10.1111%2Fajt.14435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span></span> <span> </span><span class="NLM_article-title">Proteasomes in Immune Cells: More than Peptide Producers?</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">73</span>â <span class="NLM_lpage">78</span>, <span class="refDoi">Â DOI: 10.1038/nri2687</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fnri2687" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=20010787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFChtbnI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=73-78&issue=1&author=M.+Groettrupauthor=C.+J.+Kirkauthor=M.+Basler&title=Proteasomes+in+Immune+Cells%3A+More+than+Peptide+Producers%3F&doi=10.1038%2Fnri2687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasomes in immune cells: more than peptide producers?</span></div><div class="casAuthors">Groettrup, Marcus; Kirk, Christopher J.; Basler, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-78</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  When cells are stimulated with pro-inflammatory cytokines, most of their constitutively expressed proteasomes are replaced with immunoproteasomes, which increase the prodn. of peptides for presentation on MHC class I mols.  In addn., cortical thymic epithelial cells selectively express a type of proteasome known as the thymoproteasome that is required for the pos. selection of thymocytes.  Here, we discuss how these specialized types of proteasome shape the T cell receptor repertoire of cytotoxic T lymphocytes and propose that immunoproteasomes have functions, in addn. to antigen processing, that influence cytokine prodn. and T cell differentiation, survival and function.  We also discuss how inhibitors of immunoproteasomes can suppress undesired T cell responses in autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomQzel5QNbpbVg90H21EOLACvtfcHk0ljzlZRk97UrFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFChtbnI&md5=e11dedb3a06970299bc4c69b92edaf8a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnri2687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2687%26sid%3Dliteratum%253Aachs%26aulast%3DGroettrup%26aufirst%3DM.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DBasler%26aufirst%3DM.%26atitle%3DProteasomes%2520in%2520Immune%2520Cells%253A%2520More%2520than%2520Peptide%2520Producers%253F%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2010%26volume%3D10%26issue%3D1%26spage%3D73%26epage%3D78%26doi%3D10.1038%2Fnri2687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimbara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takashina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kagawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanahashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, A.</span></span> <span> </span><span class="NLM_article-title">Interferon-Gamma Induces Different Subunit Organizations and Functional Diversity of Proteasomes</span>. <i>J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>115</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">257</span>â <span class="NLM_lpage">269</span>, <span class="refDoi">Â DOI: 10.1093/oxfordjournals.jbchem.a124327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1093%2Foxfordjournals.jbchem.a124327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=8206875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADyaK2cXhs1WgsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=1994&pages=257-269&issue=2&author=M.+Akiauthor=N.+Shimbaraauthor=M.+Takashinaauthor=K.+Akiyamaauthor=S.+Kagawaauthor=T.+Tamuraauthor=N.+Tanahashiauthor=T.+Yoshimuraauthor=K.+Tanakaauthor=A.+Ichihara&title=Interferon-Gamma+Induces+Different+Subunit+Organizations+and+Functional+Diversity+of+Proteasomes&doi=10.1093%2Foxfordjournals.jbchem.a124327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Interferon-Î³ induces different subunit organizations and functional diversity of proteasomes</span></div><div class="casAuthors">Aki, Masashi; Shimbara, Naoki; Takashina, Makoto; Akiyama, Kinya; Kagawa, Susumu; Tamura, Tomohiro; Tanahashi, Nobuyuki; Yoshimura, Tetsuro; Tanaka, Keiji; Ichihara, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biochemistry </span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-69</span>CODEN:
                <span class="NLM_cas:coden">JOBIAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-924X</span>.
    </div><div class="casAbstract">To obtain information on the role of proteasomes in the immune system, the authors examd. the effect of a major immunomodulatory cytokine, gamma interferon (IFN-Î³), on the expressions, structures, and functions of proteasomes,.  IFN-Î³ greatly increased the levels of the mRNAs encoding LMP2 and LMP7, putative immuno-proteasome subunits encoded by genes within the class II MHC region, and these two subunits synthesized were assembled completely into the proteasomal multi-subunit complex in various types of human cells.  The subunit organization of the proteasome changed in response to IFN-Î³ stimulation, due to assembly of newly synthesized subunits through up- and down-expressions of at least 6 proteasome genes including LMP2/LMP7 without change in the structure of pre-existing proteasomes.  Interestingly, IFN-Î³ dramatically stimulated the trypsin-like and chymotrypsin-like activities of the multifunctional proteasome and depressed the peptidylglutamyl-peptide-hydrolyzing activity, without affecting the activity for ATP-, ubiquitin-dependent proteolysis.  These results indicate that IFN-Î³ modifies not only the structural organization of the proteasome, but also its functions.  Based on these findings, the authors discuss the role in the antigen processing/presentation pathway of proteasomes with functional diversity acquired through alteration of their subunit assembly in response to IFN-Î³ stimulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjnsqNQStGLLVg90H21EOLACvtfcHk0ljzlZRk97UrFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhs1WgsbY%253D&md5=68702387a6ac451dbe67180e99072afc</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1093%2Foxfordjournals.jbchem.a124327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Foxfordjournals.jbchem.a124327%26sid%3Dliteratum%253Aachs%26aulast%3DAki%26aufirst%3DM.%26aulast%3DShimbara%26aufirst%3DN.%26aulast%3DTakashina%26aufirst%3DM.%26aulast%3DAkiyama%26aufirst%3DK.%26aulast%3DKagawa%26aufirst%3DS.%26aulast%3DTamura%26aufirst%3DT.%26aulast%3DTanahashi%26aufirst%3DN.%26aulast%3DYoshimura%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DK.%26aulast%3DIchihara%26aufirst%3DA.%26atitle%3DInterferon-Gamma%2520Induces%2520Different%2520Subunit%2520Organizations%2520and%2520Functional%2520Diversity%2520of%2520Proteasomes%26jtitle%3DJ.%2520Biochem.%26date%3D1994%26volume%3D115%26issue%3D2%26spage%3D257%26epage%3D269%26doi%3D10.1093%2Foxfordjournals.jbchem.a124327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hengel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruppert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multhaup, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koszinowski, U. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kloetzel, P. M.</span></span> <span> </span><span class="NLM_article-title">Interferon Gamma Stimulation Modulates the Proteolytic Activity and Cleavage Site Preference of 20S Mouse Proteasomes</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>179</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">901</span>â <span class="NLM_lpage">909</span>, <span class="refDoi">Â DOI: 10.1084/jem.179.3.901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1084%2Fjem.179.3.901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=8113682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADyaK2cXhvV2gu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=1994&pages=901-909&issue=3&author=B.+Boesauthor=H.+Hengelauthor=T.+Ruppertauthor=G.+Multhaupauthor=U.+H.+Koszinowskiauthor=P.+M.+Kloetzel&title=Interferon+Gamma+Stimulation+Modulates+the+Proteolytic+Activity+and+Cleavage+Site+Preference+of+20S+Mouse+Proteasomes&doi=10.1084%2Fjem.179.3.901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Interferon Î³ stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes</span></div><div class="casAuthors">Boes, Bettina; Hengel, Hartmut; Ruppert, Thomas; Multhaup, Gerd; Koszinowski, Ulrich H.; Kloetzel, Peter-M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">901-9</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    </div><div class="casAbstract">The proteasome is a 700 kDa multisubunit enzyme complex with several proteolytically active sites.  The enzyme complex is involved in both ubiquitin-dependent and -independent protein degrdn. and may contribute to the processing of antigens presented by major histocompatibility complex (MHC) class I mols.  Here the authors demonstrate that treatment of mouse fibroblast cells with 20 U interferon Î³ (IFN-Î³) for 3 days induces a change in the proteasome subunit compn. and that the Î²-type subunit LMP2, which is encoded in the MHC class II region, is incorporated into the enzyme complex.  This is paralleled by redn. of the homologous Î´-subunit.  IFN-Î³ stimulation results in a downregulation of the chymotrypsin-like Suc-LLVY-MCA peptide hydrolyzing activity of 20S proteasomes whereas the trypsin-like activity remains unaffected.  When tested as a substrate a synthetic 25-mer polypeptide whose sequence covers the antigenic nonapeptide YPHFMPTNL of the murine cytomegalovirus pp89, 20S proteasomes of IFN-Î³-induced cells exhibit altered chymotrypsin-like cleavage site preferences.  In the absence of IFN-Î³ induction, the naturally processed nonamer peptide that is presented by MHC class I mols. appears as a minor cleavage product.  IFN-Î³ activation does not result in an increase of the final peptide but results in a different set of peptides.  The authors hypothesize that these peptides represent precursor peptides that can be trimmed to final peptide size.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6HQn9BlCdubVg90H21EOLACvtfcHk0ljbC3iBEnGdAQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhvV2gu7k%253D&md5=fbf65e3e729be9828100829306b9b5f0</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1084%2Fjem.179.3.901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.179.3.901%26sid%3Dliteratum%253Aachs%26aulast%3DBoes%26aufirst%3DB.%26aulast%3DHengel%26aufirst%3DH.%26aulast%3DRuppert%26aufirst%3DT.%26aulast%3DMulthaup%26aufirst%3DG.%26aulast%3DKoszinowski%26aufirst%3DU.%2BH.%26aulast%3DKloetzel%26aufirst%3DP.%2BM.%26atitle%3DInterferon%2520Gamma%2520Stimulation%2520Modulates%2520the%2520Proteolytic%2520Activity%2520and%2520Cleavage%2520Site%2520Preference%2520of%252020S%2520Mouse%2520Proteasomes%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1994%26volume%3D179%26issue%3D3%26spage%3D901%26epage%3D909%26doi%3D10.1084%2Fjem.179.3.901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nandi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monaco, J. J.</span></span> <span> </span><span class="NLM_article-title">Identification of MECL-1 (LMP-10) as the Third IFN-Gamma-Inducible Proteasome Subunit</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>156</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2361</span>â <span class="NLM_lpage">2364</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=8786291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADyaK28XhvVGlsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=1996&pages=2361-2364&issue=7&author=D.+Nandiauthor=H.+Jiangauthor=J.+J.+Monaco&title=Identification+of+MECL-1+%28LMP-10%29+as+the+Third+IFN-Gamma-Inducible+Proteasome+Subunit"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of MECL-1 (LMP-10) as the third IFN-Î³-inducible proteasome subunit</span></div><div class="casAuthors">Nandi, Dipankar; Jiang, Haibo; Monaco, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2361-4</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">We show that six proteasome-assocd. proteins are induced by IFN-Î³, corresponding to three proteasome Î²-type subunits and their precursors: the MHC-linked subunits (LMP-2 and LMP-7) and LMP-10.  Concurrently, incorporation of LMP-9, LMP-17, and LMP-19 into proteasomes is reduced.  LMP-10 appears to be the product of a previously cloned proteasome subunit gene, MECL-1.  MECL-1 transcription is increased in the presence of IFN-Î³, whereas the transcription of two other proteasome genes, Lmp-15 and Lmp-3, is not affected.  The three IFN-Î³-inducible subunits and their constitutively expressed counterparts contain most or all of the catalytic sites of the proteasome.  Independent assortment of LMP-2, LMP-7, and LMP-10 into different proteasome complexes may thus generate up to 36 unique proteasome subsets.  This may increase the repertoire of potentially antigenic peptides for presentation by MHC class I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJyRmDfKN_XbVg90H21EOLACvtfcHk0ljbC3iBEnGdAQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhvVGlsbo%253D&md5=27d55e7ac9a848e7910e37d5b4d53fc1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNandi%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DMonaco%26aufirst%3DJ.%2BJ.%26atitle%3DIdentification%2520of%2520MECL-1%2520%2528LMP-10%2529%2520as%2520the%2520Third%2520IFN-Gamma-Inducible%2520Proteasome%2520Subunit%26jtitle%3DJ.%2520Immunol.%26date%3D1996%26volume%3D156%26issue%3D7%26spage%3D2361%26epage%3D2364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caturegli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span> <span> </span><span class="NLM_article-title">New Insights into the Function of the Immunoproteasome in Immune and Nonimmune Cells</span>. <i>J. Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">8</span>, <span class="refDoi">Â DOI: 10.1155/2015/541984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1155%2F2015%2F541984" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=1-8&author=H.+Kimuraauthor=P.+Caturegliauthor=M.+Takahashiauthor=K.+Suzuki&title=New+Insights+into+the+Function+of+the+Immunoproteasome+in+Immune+and+Nonimmune+Cells&doi=10.1155%2F2015%2F541984"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1155%2F2015%2F541984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F541984%26sid%3Dliteratum%253Aachs%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DCaturegli%26aufirst%3DP.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DK.%26atitle%3DNew%2520Insights%2520into%2520the%2520Function%2520of%2520the%2520Immunoproteasome%2520in%2520Immune%2520and%2520Nonimmune%2520Cells%26jtitle%3DJ.%2520Immunol.%2520Res.%26date%3D2015%26volume%3D2015%26spage%3D1%26epage%3D8%26doi%3D10.1155%2F2015%2F541984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nandi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehling, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaer, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monaco, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colbert, R. A.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasome Assembly: Cooperative Incorporation of Interferon Î³ (IFN-Î³)âInducible Subunits</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>187</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">97</span>â <span class="NLM_lpage">104</span>, <span class="refDoi">Â DOI: 10.1084/jem.187.1.97</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1084%2Fjem.187.1.97" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=9419215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADyaK1cXjtV2nuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=1998&pages=97-104&issue=1&author=T.+A.+Griffinauthor=D.+Nandiauthor=M.+Cruzauthor=H.+J.+Fehlingauthor=L.+V.+Kaerauthor=J.+J.+Monacoauthor=R.+A.+Colbert&title=Immunoproteasome+Assembly%3A+Cooperative+Incorporation+of+Interferon+%CE%B3+%28IFN-%CE%B3%29%E2%80%93Inducible+Subunits&doi=10.1084%2Fjem.187.1.97"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoproteasome assembly: cooperative incorporation of interferon Î³ (IFN-Î³)-inducible subunits</span></div><div class="casAuthors">Griffin, Thomas A.; Nandi, Dipankar; Cruz, Miguel; Fehling, Hans Jorg; Van Kaer, Luc; Monaco, John J.; Colbert, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-104</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">LMP2, LMP7, and MECL are interferon Î³-inducible catalytic subunits of vertebrate 20S proteasomes, which can replace constitutive catalytic subunits (delta, X, and Z, resp.) during proteasome biogenesis.  We demonstrate that MECL requires LMP2 for efficient incorporation into preproteasomes, and preproteasomes contg. LMP2 and MECL require LMP7 for efficient maturation.  The latter effect depends on the presequence of LMP7, but not on LMP7 catalytic activity.  This cooperative mechanism favors the assembly of homogeneous "immunoproteasomes" contg. all three inducible subunits, suggesting that these subunits act in concert to enhance proteasomal generation of major histocompatibility complex class I-binding peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7_OY37rmBw7Vg90H21EOLACvtfcHk0ljbC3iBEnGdAQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtV2nuw%253D%253D&md5=fbef51a79cab7dea3c81d59a8f2bce23</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1084%2Fjem.187.1.97&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.187.1.97%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DT.%2BA.%26aulast%3DNandi%26aufirst%3DD.%26aulast%3DCruz%26aufirst%3DM.%26aulast%3DFehling%26aufirst%3DH.%2BJ.%26aulast%3DKaer%26aufirst%3DL.%2BV.%26aulast%3DMonaco%26aufirst%3DJ.%2BJ.%26aulast%3DColbert%26aufirst%3DR.%2BA.%26atitle%3DImmunoproteasome%2520Assembly%253A%2520Cooperative%2520Incorporation%2520of%2520Interferon%2520%25CE%25B3%2520%2528IFN-%25CE%25B3%2529%25E2%2580%2593Inducible%2520Subunits%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1998%26volume%3D187%26issue%3D1%26spage%3D97%26epage%3D104%26doi%3D10.1084%2Fjem.187.1.97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rock, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, A. L.</span></span> <span> </span><span class="NLM_article-title">Degradation of Cell Proteins and the Generation of MHC Class I-Presented Peptides</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">739</span>â <span class="NLM_lpage">779</span>, <span class="refDoi">Â DOI: 10.1146/annurev.immunol.17.1.739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1146%2Fannurev.immunol.17.1.739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10358773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADyaK1MXjtVWmtLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=739-779&author=K.+L.+Rockauthor=A.+L.+Goldberg&title=Degradation+of+Cell+Proteins+and+the+Generation+of+MHC+Class+I-Presented+Peptides&doi=10.1146%2Fannurev.immunol.17.1.739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Degradation of cell proteins and the generation of MHC class I-presented peptides</span></div><div class="casAuthors">Rock, Kenneth L.; Goldberg, Alfred L.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">739-779</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with 211 refs.  Major histocompatibility complex (MHC) class I mols. display on the cell surface 8- to 10-residue peptides derived from the spectrum of proteins expressed in the cells.  By screening for non-self MHC-bound peptides, the immune system identifies and then can eliminate cells that are producing viral or mutant proteins.  These antigenic peptides are generated as side products in the continual turnover of intracellular proteins, which occurs primarily by the ubiquitin-proteasome pathway.  Most of the oligopeptides generated by the proteasome are further degraded by distinct endopeptidases and aminopeptidases into amino acids, which are used for new protein synthesis or energy prodn.  However, a fraction of these peptides escape complete destruction and after transport into the endoplasmic reticulum are bound by MHC class I mols. and delivered to the cell surface.  Herein we review recent discoveries about the proteolytic systems that degrade cell proteins, how the ubiquitin-proteasome pathway generates the peptides presented on MHC-class I mols., and how this process is stimulated by immune modifiers to enhance antigen presentation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLgUzwitMedLVg90H21EOLACvtfcHk0ljUr1GZD2kWRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjtVWmtLY%253D&md5=ad0c421306a313b77d901d7c76c161d5</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.17.1.739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.17.1.739%26sid%3Dliteratum%253Aachs%26aulast%3DRock%26aufirst%3DK.%2BL.%26aulast%3DGoldberg%26aufirst%3DA.%2BL.%26atitle%3DDegradation%2520of%2520Cell%2520Proteins%2520and%2520the%2520Generation%2520of%2520MHC%2520Class%2520I-Presented%2520Peptides%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D1999%26volume%3D17%26spage%3D739%26epage%3D779%26doi%3D10.1146%2Fannurev.immunol.17.1.739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrington, D. A.</span>; <span class="NLM_string-name">Gregerson, D. S.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasomes</span>. In  <i>Progress in Molecular Biology and Translational Science</i>; The Proteasomal System in Aging and Disease; <span class="NLM_publisher-name">Elsevier</span>, <span class="NLM_year">2012</span>; Vol.  <span class="NLM_volume">109</span>, pp  <span class="NLM_fpage">75</span>â <span class="NLM_lpage">112</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2FB978-0-12-397863-9.00003-1" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=75-112&author=D.+A.+Ferrington&author=D.+S.+Gregerson&title=Progress+in+Molecular+Biology+and+Translational+Science"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-397863-9.00003-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-397863-9.00003-1%26sid%3Dliteratum%253Aachs%26aulast%3DFerrington%26aufirst%3DD.%2BA.%26atitle%3DImmunoproteasomes%26btitle%3DProgress%2520in%2520Molecular%2520Biology%2520and%2520Translational%2520Science%26pub%3DElsevier%26date%3D2012%26volume%3D109%26spage%3D75%26epage%3D112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husom, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, L. V.</span></span> <span> </span><span class="NLM_article-title">Altered Proteasome Structure, Function, and Oxidation in Aged Muscle</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">644</span>â <span class="NLM_lpage">646</span>, <span class="refDoi">Â DOI: 10.1096/fj.04-2578fje</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1096%2Ffj.04-2578fje" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=15677694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFaksLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=644-646&issue=6&author=D.+A.+Ferringtonauthor=A.+D.+Husomauthor=L.+V.+Thompson&title=Altered+Proteasome+Structure%2C+Function%2C+and+Oxidation+in+Aged+Muscle&doi=10.1096%2Ffj.04-2578fje"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Altered proteasome structure, function, and oxidation in aged muscle</span></div><div class="casAuthors">Ferrington, Deborah A.; Husom, Aimee D.; Thompson, LaDora V.</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">644-646, 10.1096/fj.04-2578fje</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">The proteasome is the main protease for degrading oxidized proteins.  We asked whether altered proteasome function contributes to the accumulation of oxidized muscle proteins with aging.  Proteasome structure, function, and oxidn. state were compared in young and aged F344BN rat fast-twitch skeletal muscle.  In proteasome-enriched homogenates from aged muscle, we obsd. a two- to threefold increase in content of the 20S proteasome that was due to a corresponding increase in immunoproteasome.  Content of the regulatory proteins, PA700 and PA28, relative to the 20S were reduced 75% with aging.  Upon addn. of exogenous PA700, there was a twofold increase in peptide hydrolysis in aged muscle, suggesting the endogenous content of PA700 is inadequate for complete activation of the 20S.  Measures of catalytic activity showed a 50% redn. in specific activity for proteasome-enriched homogenates with aging.  With purifn. of the 20S, proteasome specific activity was equiv. between ages, indicating that endogenous regulators inhibit proteasome in aged muscle.  Significantly less degrdn. of oxidized calmodulin by the 20S from aged muscle was obsd.  Partial rescue of activity for aged 20S by DTT implies oxidn. of functionally significant cysteines.  These results demonstrate significant age-related changes in proteasome structure, function, and oxidn. state that could inhibit removal of oxidized proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqlrtfBvUVAbVg90H21EOLACvtfcHk0ljUr1GZD2kWRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFaksLo%253D&md5=abfbafaebec98c7e5bdc019997c92aaf</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1096%2Ffj.04-2578fje&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.04-2578fje%26sid%3Dliteratum%253Aachs%26aulast%3DFerrington%26aufirst%3DD.%2BA.%26aulast%3DHusom%26aufirst%3DA.%2BD.%26aulast%3DThompson%26aufirst%3DL.%2BV.%26atitle%3DAltered%2520Proteasome%2520Structure%252C%2520Function%252C%2520and%2520Oxidation%2520in%2520Aged%2520Muscle%26jtitle%3DFASEB%2520J.%26date%3D2005%26volume%3D19%26issue%3D6%26spage%3D644%26epage%3D646%26doi%3D10.1096%2Ffj.04-2578fje" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, J. B.</span></span> <span> </span><span class="NLM_article-title">The Immunoproteasome and Viral Infection: A Complex Regulator of Inflammation</span>. <i>Front. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">21</span>, <span class="refDoi">Â DOI: 10.3389/fmicb.2015.00021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.3389%2Ffmicb.2015.00021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=25688236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BC2Mrmt1Ohtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=21&author=M.+K.+McCarthyauthor=J.+B.+Weinberg&title=The+Immunoproteasome+and+Viral+Infection%3A+A+Complex+Regulator+of+Inflammation&doi=10.3389%2Ffmicb.2015.00021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The immunoproteasome and viral infection: a complex regulator of inflammation</span></div><div class="casAuthors">McCarthy Mary K; Weinberg Jason B</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in microbiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21</span>
        ISSN:<span class="NLM_cas:issn">1664-302X</span>.
    </div><div class="casAbstract">During viral infection, proper regulation of immune responses is necessary to ensure successful viral clearance with minimal host tissue damage.  Proteasomes play a crucial role in the generation of antigenic peptides for presentation on MHC class I molecules, and thus activation of CD8 T cells, as well as activation of the NF-ÎºB pathway.  A specialized type of proteasome called the immunoproteasome is constitutively expressed in hematopoietic cells and induced in non-immune cells during viral infection by interferon signaling.  The immunoproteasome regulates CD8 T cell responses to many viral epitopes during infection.  Accumulating evidence suggests that the immunoproteasome may also contribute to regulation of proinflammatory cytokine production, activation of the NF-ÎºB pathway, and management of oxidative stress.  Many viruses have mechanisms of interfering with immunoproteasome function, including prevention of transcriptional upregulation of immunoproteasome components as well as direct interaction of viral proteins with immunoproteasome subunits.  A better understanding of the role of the immunoproteasome in different cell types, tissues, and hosts has the potential to improve vaccine design and facilitate the development of effective treatment strategies for viral infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnTotxTDCg9YhLSh9fo81bfW6udTcc2ebjVCtqaKIgJbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mrmt1Ohtw%253D%253D&md5=dd375485b121e26a3a30afb4fa099640</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.3389%2Ffmicb.2015.00021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmicb.2015.00021%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarthy%26aufirst%3DM.%2BK.%26aulast%3DWeinberg%26aufirst%3DJ.%2BB.%26atitle%3DThe%2520Immunoproteasome%2520and%2520Viral%2520Infection%253A%2520A%2520Complex%2520Regulator%2520of%2520Inflammation%26jtitle%3DFront.%2520Microbiol.%26date%3D2015%26volume%3D6%26spage%3D21%26doi%3D10.3389%2Ffmicb.2015.00021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinnenhirn, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidtke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, A. L.</span></span> <span> </span><span class="NLM_article-title">Immuno- and Constitutive Proteasomes Do Not Differ in Their Abilities to Degrade Ubiquitinated Proteins</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>152</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1184</span>â <span class="NLM_lpage">1194</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2013.01.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.cell.2013.01.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=23452861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFCjs74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2013&pages=1184-1194&issue=5&author=J.+A.+Nathanauthor=V.+Spinnenhirnauthor=G.+Schmidtkeauthor=M.+Baslerauthor=M.+Groettrupauthor=A.+L.+Goldberg&title=Immuno-+and+Constitutive+Proteasomes+Do+Not+Differ+in+Their+Abilities+to+Degrade+Ubiquitinated+Proteins&doi=10.1016%2Fj.cell.2013.01.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Immuno- and Constitutive Proteasomes Do Not Differ in Their Abilities to Degrade Ubiquitinated Proteins</span></div><div class="casAuthors">Nathan, James A.; Spinnenhirn, Valentina; Schmidtke, Gunter; Basler, Michael; Groettrup, Marcus; Goldberg, Alfred L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1184-1194</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Immunoproteasomes are alternative forms of proteasomes that have an enhanced ability to generate antigenic peptides.  Recently, Seifert and colleagues reported surprising observations concerning the functions of immunoproteasomes and cellular responses to interferon-Î³: (1) that immunoproteasomes degrade ubiquitinated proteins faster than the constitutive proteasomes, (2) that polyubiquitin conjugates accumulate after interferon-Î³ treatment but then are preferentially degraded by immunoproteasomes, and (3) that immunoproteasome deficiency causes the formation of inclusions and more severe exptl. autoimmune encephalomyelitis (EAE).  In contrast, we find that polyubiquitin conjugates do not transiently accumulate following IFNÎ³-treatment and that immunoproteasomes do not prevent the formation of intracellular inclusions or protect against EAE.  Furthermore, purified 26S constitutive and immunoproteasomes bind ubiquitin conjugates similarly and degrade them at similar rates.  We conclude that, although immunoproteasomes can increase the generation of peptides appropriate for MHC class I presentation, they do not degrade ubiquitinated proteins more efficiently than constitutive particles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_g-gcOxyf8bVg90H21EOLACvtfcHk0lgY4DoY8TNehw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFCjs74%253D&md5=2608171cbeae8ccdaaa665b6938245da</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2013.01.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2013.01.037%26sid%3Dliteratum%253Aachs%26aulast%3DNathan%26aufirst%3DJ.%2BA.%26aulast%3DSpinnenhirn%26aufirst%3DV.%26aulast%3DSchmidtke%26aufirst%3DG.%26aulast%3DBasler%26aufirst%3DM.%26aulast%3DGroettrup%26aufirst%3DM.%26aulast%3DGoldberg%26aufirst%3DA.%2BL.%26atitle%3DImmuno-%2520and%2520Constitutive%2520Proteasomes%2520Do%2520Not%2520Differ%2520in%2520Their%2520Abilities%2520to%2520Degrade%2520Ubiquitinated%2520Proteins%26jtitle%3DCell%26date%3D2013%26volume%3D152%26issue%3D5%26spage%3D1184%26epage%3D1194%26doi%3D10.1016%2Fj.cell.2013.01.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bialy, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebstein, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bech-Otschir, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voigt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchrÃ¶ter, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prozorovski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuckelkorn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aktas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kloetzel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, E.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasomes Preserve Protein Homeostasis upon Interferon-Induced Oxidative Stress</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>142</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">613</span>â <span class="NLM_lpage">624</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2010.07.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.cell.2010.07.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=20723761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVKhurzK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2010&pages=613-624&issue=4&author=U.+Seifertauthor=L.+P.+Bialyauthor=F.+Ebsteinauthor=D.+Bech-Otschirauthor=A.+Voigtauthor=F.+Schr%C3%B6terauthor=T.+Prozorovskiauthor=N.+Langeauthor=J.+Steffenauthor=M.+Riegerauthor=U.+Kuckelkornauthor=O.+Aktasauthor=P.+Kloetzelauthor=E.+Kruger&title=Immunoproteasomes+Preserve+Protein+Homeostasis+upon+Interferon-Induced+Oxidative+Stress&doi=10.1016%2Fj.cell.2010.07.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoproteasomes Preserve Protein Homeostasis upon Interferon-Induced Oxidative Stress</span></div><div class="casAuthors">Seifert, Ulrike; Bialy, Lukasz P.; Ebstein, Frederic; Bech-Otschir, Dawadschargal; Voigt, Antje; Schroeter, Friederike; Prozorovski, Timour; Lange, Nicole; Steffen, Janos; Rieger, Melanie; Kuckelkorn, Ulrike; Aktas, Orhan; Kloetzel, Peter-M.; Krueger, Elke</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">613-624</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Interferon (IFN)-induced immunoproteasomes (i-proteasomes) have been assocd. with improved processing of major histocompatibility complex (MHC) class I antigens.  Here, we show that i-proteasomes function to protect cell viability under conditions of IFN-induced oxidative stress.  IFNs trigger the prodn. of reactive oxygen species, which induce protein oxidn. and the formation of nascent, oxidant-damaged proteins.  We find that the ubiquitylation machinery is concomitantly upregulated in response to IFNs, functioning to target defective ribosomal products (DRiPs) for degrdn. by i-proteasomes.  I-proteasome-deficiency in cells and in murine inflammation models results in the formation of aggresome-like induced structures and increased sensitivity to apoptosis.  Efficient clearance of these aggregates by the enhanced proteolytic activity of the i-proteasome is important for the preservation of cell viability upon IFN-induced oxidative stress.  Our findings suggest that rather than having a specific role in the prodn. of class I antigens, i-proteasomes increase the peptide supply for antigen presentation as part of a more general role in the maintenance of protein homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrke2GhhFrNT7Vg90H21EOLACvtfcHk0lgY4DoY8TNehw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVKhurzK&md5=62106a7fef1d42e8f50dc55f5938a097</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.07.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.07.036%26sid%3Dliteratum%253Aachs%26aulast%3DSeifert%26aufirst%3DU.%26aulast%3DBialy%26aufirst%3DL.%2BP.%26aulast%3DEbstein%26aufirst%3DF.%26aulast%3DBech-Otschir%26aufirst%3DD.%26aulast%3DVoigt%26aufirst%3DA.%26aulast%3DSchr%25C3%25B6ter%26aufirst%3DF.%26aulast%3DProzorovski%26aufirst%3DT.%26aulast%3DLange%26aufirst%3DN.%26aulast%3DSteffen%26aufirst%3DJ.%26aulast%3DRieger%26aufirst%3DM.%26aulast%3DKuckelkorn%26aufirst%3DU.%26aulast%3DAktas%26aufirst%3DO.%26aulast%3DKloetzel%26aufirst%3DP.%26aulast%3DKruger%26aufirst%3DE.%26atitle%3DImmunoproteasomes%2520Preserve%2520Protein%2520Homeostasis%2520upon%2520Interferon-Induced%2520Oxidative%2520Stress%26jtitle%3DCell%26date%3D2010%26volume%3D142%26issue%3D4%26spage%3D613%26epage%3D624%26doi%3D10.1016%2Fj.cell.2010.07.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caudill, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayarapu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elenich, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monaco, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colbert, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, T. A.</span></span> <span> </span><span class="NLM_article-title">T Cells Lacking Immunoproteasome Subunits MECL-1 and LMP7 Hyperproliferate in Response to Polyclonal Mitogens</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>176</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">4075</span>â <span class="NLM_lpage">4082</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.176.7.4075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.4049%2Fjimmunol.176.7.4075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=16547243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD28Xis1erurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2006&pages=4075-4082&issue=7&author=C.+M.+Caudillauthor=K.+Jayarapuauthor=L.+Elenichauthor=J.+J.+Monacoauthor=R.+A.+Colbertauthor=T.+A.+Griffin&title=T+Cells+Lacking+Immunoproteasome+Subunits+MECL-1+and+LMP7+Hyperproliferate+in+Response+to+Polyclonal+Mitogens&doi=10.4049%2Fjimmunol.176.7.4075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">T Cells Lacking Immunoproteasome Subunits MECL-1 and LMP7 Hyperproliferate in Response to Polyclonal Mitogens</span></div><div class="casAuthors">Caudill, Christy M.; Jayarapu, Krupakar; Elenich, Laura; Monaco, John J.; Colbert, Robert A.; Griffin, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4075-4082</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Immunoproteasomes comprise a specialized subset of proteasomes that is defined by the presence of three catalytic immunosubunits: LMP2, MECL-1 (LMP10), and LMP7.  Proteasomes in general serve many cellular functions through protein degrdn., whereas the specific function of immunoproteasomes has been thought to be largely, if not exclusively, optimization of MHC class I Ag processing.  In this report, the authors demonstrate that T cells from double knockout mice lacking two of the immunosubunits, MECL-1 and LMP7, hyperproliferate in vitro in response to various polyclonal mitogens.  The authors observe hyperproliferation of both CD4+ and CD8+ T cell subsets and demonstrate accelerated cell cycling.  The authors do not observe hyperproliferation of T cells lacking only one of these subunits, and thus hyperproliferation is independent of either reduced MHC class I expression in LMP7-/- mice or reduced CD8+ T cell nos. in MECL-1-/- mice.  The authors observe both of these latter two phenotypes in MECL-1/LMP7-/- mice, which indicates that they also are independent of each other.  Finally, the authors provide evidence of in vivo T cell dysfunction by demonstrating increased nos. of central memory phenotype CD8+ T cells in MECL-1/LMP7-/- mice.  In summary, this novel phenotype of hyperproliferation of T cells lacking both MECL-1 and LMP7 implicates a specific role for immunoproteasomes in T cell proliferation that is not obviously connected to MHC class I Ag processing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIbRrSmPrddLVg90H21EOLACvtfcHk0lgY4DoY8TNehw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xis1erurg%253D&md5=71b5862b4630518f2594021c74593516</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.176.7.4075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.176.7.4075%26sid%3Dliteratum%253Aachs%26aulast%3DCaudill%26aufirst%3DC.%2BM.%26aulast%3DJayarapu%26aufirst%3DK.%26aulast%3DElenich%26aufirst%3DL.%26aulast%3DMonaco%26aufirst%3DJ.%2BJ.%26aulast%3DColbert%26aufirst%3DR.%2BA.%26aulast%3DGriffin%26aufirst%3DT.%2BA.%26atitle%3DT%2520Cells%2520Lacking%2520Immunoproteasome%2520Subunits%2520MECL-1%2520and%2520LMP7%2520Hyperproliferate%2520in%2520Response%2520to%2520Polyclonal%2520Mitogens%26jtitle%3DJ.%2520Immunol.%26date%3D2006%26volume%3D176%26issue%3D7%26spage%3D4075%26epage%3D4082%26doi%3D10.4049%2Fjimmunol.176.7.4075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, A. V.</span></span> <span> </span><span class="NLM_article-title">Identification of the Immunoproteasome as a Novel Regulator of Skeletal Muscle Differentiation</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">96</span>â <span class="NLM_lpage">109</span>, <span class="refDoi">Â DOI: 10.1128/MCB.00622-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1128%2FMCB.00622-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=24164898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtV2ntrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=96-109&issue=1&author=Z.+Cuiauthor=S.+M.+Hwangauthor=A.+V.+Gomes&title=Identification+of+the+Immunoproteasome+as+a+Novel+Regulator+of+Skeletal+Muscle+Differentiation&doi=10.1128%2FMCB.00622-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the immunoproteasome as a novel regulator of skeletal muscle differentiation</span></div><div class="casAuthors">Cui, Ziyou; Hwang, Soyun Michelle; Gomes, Aldrin V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">96-109, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">While many of the mol. details of myogenesis have been investigated extensively, the function of immunoproteasomes (i-proteasomes) in myogenic differentiation remains unknown.  We show here that the mRNA of i-proteasome subunits, the protein levels of constitutive and inducible proteasome subunits, and the proteolytic activities of the 20S and 26S proteasomes were significantly upregulated during differentiation of skeletal muscle C2C12 cells.  Knockdown of the i-proteasome catalytic subunit PSMB9 by short hairpin RNA (shRNA) decreased the expression of both PSMB9 and PSMB8 without affecting other catalytic subunits of the proteasome.  PSMB9 knockdown and the use of i-proteasome-specific inhibitors both decreased 26S proteasome activities and prevented C2C12 differentiation.  Inhibition of the i-proteasome also impaired human skeletal myoblast differentiation.  Suppression of the i-proteasome increased protein oxidn., and these oxidized proteins were found to be more susceptible to degrdn. by exogenous i-proteasomes.  Downregulation of the i-proteasome also increased proapoptotic proteins, including Bax, as well as cleaved caspase 3, cleaved caspase 9, and cleaved poly(ADP-ribose) polymerase (PARP), suggesting that impaired differentiation is likely to occur because of significantly increased apoptosis.  These results demonstrate for the first time that i-proteasomes, independent of constitutive proteasomes, are crit. for skeletal muscle differentiation of mouse C2C12 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph-e4EV27lx7Vg90H21EOLACvtfcHk0ljFJAfREeKZkA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtV2ntrk%253D&md5=30769ba401a971758ee7e3a0a3b39a3c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1128%2FMCB.00622-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00622-13%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DZ.%26aulast%3DHwang%26aufirst%3DS.%2BM.%26aulast%3DGomes%26aufirst%3DA.%2BV.%26atitle%3DIdentification%2520of%2520the%2520Immunoproteasome%2520as%2520a%2520Novel%2520Regulator%2520of%2520Skeletal%2520Muscle%2520Differentiation%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2014%26volume%3D34%26issue%3D1%26spage%3D96%26epage%3D109%26doi%3D10.1128%2FMCB.00622-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedja, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox-Talbot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrielson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Kaer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z. P.</span></span> <span> </span><span class="NLM_article-title">Evidence for a Role of Immunoproteasomes in Regulating Cardiac Muscle Mass in Diabetic Mice</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">5</span>â <span class="NLM_lpage">15</span>, <span class="refDoi">Â DOI: 10.1016/j.yjmcc.2010.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.yjmcc.2010.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=20153750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmslCntb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=5-15&issue=1&author=L.+Zuauthor=D.+Bedjaauthor=K.+Fox-Talbotauthor=K.+L.+Gabrielsonauthor=L.+Van+Kaerauthor=L.+C.+Beckerauthor=Z.+P.+Cai&title=Evidence+for+a+Role+of+Immunoproteasomes+in+Regulating+Cardiac+Muscle+Mass+in+Diabetic+Mice&doi=10.1016%2Fj.yjmcc.2010.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for a role of immunoproteasomes in regulating cardiac muscle mass in diabetic mice</span></div><div class="casAuthors">Zu, Lingyun; Bedja, Djahida; Fox-Talbot, Karen; Gabrielson, Kathleen L.; Van Kaer, Luc; Becker, Lewis C.; Cai, Zheqing P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-15</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The ubiquitin-proteasome system plays an important role in regulating muscle mass.  Inducible immunoproteasome subunits LMP-2 and LMP-7 are constitutively expressed in the heart; however, their regulation and functions are poorly understood.  We here investigated the hypothesis that immunoproteasomes regulate cardiac muscle mass in diabetic mice.  Type 1 diabetes was induced in wildtype mice by streptozotocin.  After hyperglycemia developed, insulin and the proteasome inhibitor epoxomicin were used to treat diabetic mice for 6 wk.  Isolated mouse hearts were perfused with control or high glucose soln.  Catalytic proteasome Î²-subunits and proteolytic activities were analyzed in the heart by immunoblotting and fluorogenic peptide degrdn. assays, resp.  Insulin and epoxomicin blocked loss of heart wt. and improved cardiac function in diabetic mice.  LMP-7 and its corresponding chymotryptic-like proteasome activity were increased in diabetic hearts and high glucose-treated hearts.  Myosin heavy chain protein was decreased in diabetic hearts, which was largely reversed by epoxomicin.  High glucose decreased LMP-2 protein levels in perfused hearts.  In diabetic hearts, LMP-2 expression was downregulated whereas expression of the phosphatase and tensin homolog deleted on chromosome ten (PTEN) and the muscle atrophy F-box were upregulated.  Moreover, mice with muscle-specific knockout of PTEN gene demonstrated increased cardiac muscle mass, while mice with LMP-2 deficiency demonstrated PTEN accumulation, muscle mass loss, and contractile impairment in the heart.  Therefore, we concluded that high glucose regulates immunoproteasome subunits and modifies proteasome activities in the heart, and that dysregulated immunoproteasome subunits may mediate loss of cardiac muscle mass in exptl. diabetic mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbPwnq9tvvI7Vg90H21EOLACvtfcHk0ljFJAfREeKZkA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmslCntb4%253D&md5=7437db478efd1dea873068a80a3ceb40</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2010.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2010.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DZu%26aufirst%3DL.%26aulast%3DBedja%26aufirst%3DD.%26aulast%3DFox-Talbot%26aufirst%3DK.%26aulast%3DGabrielson%26aufirst%3DK.%2BL.%26aulast%3DVan%2BKaer%26aufirst%3DL.%26aulast%3DBecker%26aufirst%3DL.%2BC.%26aulast%3DCai%26aufirst%3DZ.%2BP.%26atitle%3DEvidence%2520for%2520a%2520Role%2520of%2520Immunoproteasomes%2520in%2520Regulating%2520Cardiac%2520Muscle%2520Mass%2520in%2520Diabetic%2520Mice%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2010%26volume%3D49%26issue%3D1%26spage%3D5%26epage%3D15%26doi%3D10.1016%2Fj.yjmcc.2010.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Verteuil, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouette, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, M.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LavallÃ©e, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trofimov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaucher, Ã.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perreault, C.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasomes Shape the Transcriptome and Regulate the Function of Dendritic Cells</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>193</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1121</span>â <span class="NLM_lpage">1132</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.1400871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.4049%2Fjimmunol.1400871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=24958905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyqs77E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2014&pages=1121-1132&issue=3&author=D.+A.+de%0AVerteuilauthor=A.+Rouetteauthor=M.-P.+Hardyauthor=S.+Lavall%C3%A9eauthor=A.+Trofimovauthor=%C3%89.+Gaucherauthor=C.+Perreault&title=Immunoproteasomes+Shape+the+Transcriptome+and+Regulate+the+Function+of+Dendritic+Cells&doi=10.4049%2Fjimmunol.1400871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoproteasomes Shape the Transcriptome and Regulate the Function of Dendritic Cells</span></div><div class="casAuthors">de Verteuil, Danielle A.; Rouette, Alexandre; Hardy, Marie-Pierre; Lavallee, Stephanie; Trofimov, Assya; Gaucher, Etienne; Perreault, Claude</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1121-1132</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">By regulating protein degrdn., constitutive proteasomes (CPs) control practically all cellular functions.  In addn. to CPs, vertebrates express immunoproteasomes (IPs).  The major nonredundant role ascribed to IPs is their enhanced ability to generate antigenic peptides.  We report that CPs and IPs differentially regulate the expression of >8000 transcripts in maturing mouse dendritic cells (DCs) via regulation of signaling pathways such as IFN regulatory factors, STATs, and NF-ÎºB.  IPs regulate the transcription of many mRNAs and maturation of a few of them.  Moreover, even when engineered to present optimal amts. of antigenic peptide, IP-deficient DCs are inefficient for in vivo T cell priming.  Our study shows that the role of IPs in DCs is not limited to Ag processing and reveals a major nonredundant role for IPs in transcription regulation.  The dramatic effect of IPs on the transcriptional landscape could explain the various immune and nonimmune phenotypes obsd. in vertebrates with IP deficiency or mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquYPmj1pi-trVg90H21EOLACvtfcHk0ljFJAfREeKZkA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyqs77E&md5=8a3ffd577e1bcafdc4a5f54dd0a27a5c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1400871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1400871%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BVerteuil%26aufirst%3DD.%2BA.%26aulast%3DRouette%26aufirst%3DA.%26aulast%3DHardy%26aufirst%3DM.-P.%26aulast%3DLavall%25C3%25A9e%26aufirst%3DS.%26aulast%3DTrofimov%26aufirst%3DA.%26aulast%3DGaucher%26aufirst%3D%25C3%2589.%26aulast%3DPerreault%26aufirst%3DC.%26atitle%3DImmunoproteasomes%2520Shape%2520the%2520Transcriptome%2520and%2520Regulate%2520the%2520Function%2520of%2520Dendritic%2520Cells%26jtitle%3DJ.%2520Immunol.%26date%3D2014%26volume%3D193%26issue%3D3%26spage%3D1121%26epage%3D1132%26doi%3D10.4049%2Fjimmunol.1400871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rouette, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trofimov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LavallÃ©e, V.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâAngelo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HÃ©bert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauvageau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perreault, C.</span></span> <span> </span><span class="NLM_article-title">Expression of Immunoproteasome Genes Is Regulated by Cell-Intrinsic and -Extrinsic Factors in Human Cancers</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">34019</span>, <span class="refDoi">Â DOI: 10.1038/srep34019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fsrep34019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=27659694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFOnurvP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=34019&author=A.+Rouetteauthor=A.+Trofimovauthor=D.+Haberlauthor=G.+Boucherauthor=V.-P.+Lavall%C3%A9eauthor=G.+D%E2%80%99Angeloauthor=J.+H%C3%A9bertauthor=G.+Sauvageauauthor=S.+Lemieuxauthor=C.+Perreault&title=Expression+of+Immunoproteasome+Genes+Is+Regulated+by+Cell-Intrinsic+and+-Extrinsic+Factors+in+Human+Cancers&doi=10.1038%2Fsrep34019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of immunoproteasome genes is regulated by cell-intrinsic and -extrinsic factors in human cancers</span></div><div class="casAuthors">Rouette, Alexandre; Trofimov, Assya; Haberl, David; Boucher, Genevieve; Lavallee, Vincent-Philippe; D'Angelo, Giovanni; Hebert, Josee; Sauvageau, Guy; Lemieux, Sebastien; Perreault, Claude</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34019</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Based on transcriptomic analyses of thousands of samples from The Cancer Genome Atlas, we report that expression of constitutive proteasome (CP) genes (PSMB5, PSMB6, PSMB7) and immunoproteasome (IP) genes (PSMB8, PSMB9, PSMB10) is increased in most cancer types.  In breast cancer, expression of IP genes was detd. by the abundance of tumor infiltrating lymphocytes and high expression of IP genes was assocd. with longer survival.  In contrast, IP upregulation in acute myeloid leukemia (AML) was a cell-intrinsic feature that was not assocd. with longer survival.  Expression of IP genes in AML was IFN-independent, correlated with the methylation status of IP genes, and was particularly high in AML with an M5 phenotype and/or MLL rearrangement.  Notably, PSMB8 inhibition led to accumulation of polyubiquitinated proteins and cell death in IPhigh but not IPlow AML cells.  Co-clustering anal. revealed that genes correlated with IP subunits in non-M5 AMLs were primarily implicated in immune processes.  However, in M5 AML, IP genes were primarily co-regulated with genes involved in cell metab. and proliferation, mitochondrial activity and stress responses.  We conclude that M5 AML cells can upregulate IP genes in a cell-intrinsic manner in order to resist cell stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnIk53mYYeT7Vg90H21EOLACvtfcHk0lgNFZlj_KNQ3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFOnurvP&md5=bf5b5134793a46808c7f66d9be97e8bb</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fsrep34019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep34019%26sid%3Dliteratum%253Aachs%26aulast%3DRouette%26aufirst%3DA.%26aulast%3DTrofimov%26aufirst%3DA.%26aulast%3DHaberl%26aufirst%3DD.%26aulast%3DBoucher%26aufirst%3DG.%26aulast%3DLavall%25C3%25A9e%26aufirst%3DV.-P.%26aulast%3DD%25E2%2580%2599Angelo%26aufirst%3DG.%26aulast%3DH%25C3%25A9bert%26aufirst%3DJ.%26aulast%3DSauvageau%26aufirst%3DG.%26aulast%3DLemieux%26aufirst%3DS.%26aulast%3DPerreault%26aufirst%3DC.%26atitle%3DExpression%2520of%2520Immunoproteasome%2520Genes%2520Is%2520Regulated%2520by%2520Cell-Intrinsic%2520and%2520-Extrinsic%2520Factors%2520in%2520Human%2520Cancers%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D34019%26doi%3D10.1038%2Fsrep34019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span> <span> </span><span class="NLM_article-title">The Immunoproteasome: A Novel Drug Target for Autoimmune Diseases</span>. <i>Clin. Exp. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">S74</span>â <span class="NLM_lpage">S79</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=26458097" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=S74-S79&author=M.+Baslerauthor=S.+Mundtauthor=A.+Bitzerauthor=C.+Schmidtauthor=M.+Groettrup&title=The+Immunoproteasome%3A+A+Novel+Drug+Target+for+Autoimmune+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBasler%26aufirst%3DM.%26aulast%3DMundt%26aufirst%3DS.%26aulast%3DBitzer%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DC.%26aulast%3DGroettrup%26aufirst%3DM.%26atitle%3DThe%2520Immunoproteasome%253A%2520A%2520Novel%2520Drug%2520Target%2520for%2520Autoimmune%2520Diseases%26jtitle%3DClin.%2520Exp.%2520Rheumatol.%26date%3D2015%26volume%3D33%26spage%3DS74%26epage%3DS79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnston-Carey, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomatto, L. C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, K. J. A.</span></span> <span> </span><span class="NLM_article-title">The Immunoproteasome in Oxidative Stress, Aging, and Disease</span>. <i>Crit. Rev. Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">268</span>â <span class="NLM_lpage">281</span>, <span class="refDoi">Â DOI: 10.3109/10409238.2016.1172554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.3109%2F10409238.2016.1172554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFyktb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2016&pages=268-281&issue=4&author=H.+K.+Johnston-Careyauthor=L.+C.+D.+Pomattoauthor=K.+J.+A.+Davies&title=The+Immunoproteasome+in+Oxidative+Stress%2C+Aging%2C+and+Disease&doi=10.3109%2F10409238.2016.1172554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The Immunoproteasome in oxidative stress, aging, and disease</span></div><div class="casAuthors">Johnston-Carey, Helen K.; Pomatto, Laura C. D.; Davies, Kelvin J. A.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">268-281</span>CODEN:
                <span class="NLM_cas:coden">CRBBEJ</span>;
        ISSN:<span class="NLM_cas:issn">1040-9238</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The Immunoproteasome has traditionally been viewed primarily for its role in peptide prodn. for antigen presentation by the major histocompatibility complex, which is crit. for immunity.  However, recent research has shown that the Immunoproteasome is also very important for the clearance of oxidatively damaged proteins in homeostasis, and esp. during stress and disease.  The importance of the Immunoproteasome in protein degrdn. has become more evident as diseases characterized by protein aggregates have also been linked to deficiencies of the Immunoproteasome.  Addnl., there are now diseases defined by mutations or polymorphisms within Immunoproteasome-specific subunit genes, further suggesting its crucial role in cytokine signaling and protein homeostasis (or "proteostasis").  The purpose of this review is to highlight our growing understanding of the importance of the Immunoproteasome in the management of protein quality control, and the detrimental impact of its dysregulation during disease and aging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJWYBMP5NXIbVg90H21EOLACvtfcHk0lgNFZlj_KNQ3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFyktb4%253D&md5=a529c3034e4284776f5f57e5c8af5360</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.3109%2F10409238.2016.1172554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10409238.2016.1172554%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston-Carey%26aufirst%3DH.%2BK.%26aulast%3DPomatto%26aufirst%3DL.%2BC.%2BD.%26aulast%3DDavies%26aufirst%3DK.%2BJ.%2BA.%26atitle%3DThe%2520Immunoproteasome%2520in%2520Oxidative%2520Stress%252C%2520Aging%252C%2520and%2520Disease%26jtitle%3DCrit.%2520Rev.%2520Biochem.%2520Mol.%2520Biol.%26date%3D2016%26volume%3D51%26issue%3D4%26spage%3D268%26epage%3D281%26doi%3D10.3109%2F10409238.2016.1172554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kisselev, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, A. L.</span></span> <span> </span><span class="NLM_article-title">Monitoring Activity and Inhibition of 26S Proteasomes with Fluorogenic Peptide Substrates</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>398</i></span>,  <span class="NLM_fpage">364</span>â <span class="NLM_lpage">378</span>, <span class="refDoi">Â DOI: 10.1016/S0076-6879(05)98030-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2FS0076-6879%2805%2998030-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=16275343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD28Xot1ajs7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=398&publication_year=2005&pages=364-378&author=A.+F.+Kisselevauthor=A.+L.+Goldberg&title=Monitoring+Activity+and+Inhibition+of+26S+Proteasomes+with+Fluorogenic+Peptide+Substrates&doi=10.1016%2FS0076-6879%2805%2998030-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates</span></div><div class="casAuthors">Kisselev, Alexei F.; Goldberg, Alfred L.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">398</span>
        (<span class="NLM_cas:issue">Ubiquitin and Protein Degradation, Part A</span>),
    <span class="NLM_cas:pages">364-378</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Eukaryotic proteasomes have three different types of active sites: two chymotrypsin-like, two trypsin-like, and two caspase-like (also termed PGPH) sites that differ in their specificity toward model fluorogenic pep-tide substrates.  The chymotrypsin-like site is often considered the most important in protein breakdown, and the only one whose activity has to be assayed in order to assess the capacity of proteasomes to degrade proteins.  However, recent results indicate that either trypsin-like or caspase-like sites also have to be inhibited in order to reduce breakdown of most proteins by 50%.  Thus, the activities of all three types of active sites have to be assayed in order to evaluate the state of the proteasome inside cells or the potency of inhibitors.  This chapter describes assays of purified 26S proteasomes with fluorogenic peptide substrates, including new substrates of the caspase- and trypsin-like sites.  A novel assay of proteasome activity in crude cell exts. that allows rapid evaluation of the state of the proteasomes in cells treated with inhibitors is also described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMjuxD75BZIrVg90H21EOLACvtfcHk0lgNFZlj_KNQ3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xot1ajs7g%253D&md5=bd4655e6fe62a90bcd847af5cb80b1d6</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2805%2998030-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252805%252998030-0%26sid%3Dliteratum%253Aachs%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26aulast%3DGoldberg%26aufirst%3DA.%2BL.%26atitle%3DMonitoring%2520Activity%2520and%2520Inhibition%2520of%252026S%2520Proteasomes%2520with%2520Fluorogenic%2520Peptide%2520Substrates%26jtitle%3DMethods%2520Enzymol.%26date%3D2005%26volume%3D398%26spage%3D364%26epage%3D378%26doi%3D10.1016%2FS0076-6879%2805%2998030-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Greca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arastu-Kapur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caiazza, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cimermancic, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchholz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderl, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravalin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDonoghue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craik, C.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasome Functions Explained by Divergence in Cleavage Specificity and Regulation</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">e27364</span>, <span class="refDoi">Â DOI: 10.7554/eLife.27364</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.7554%2FeLife.27364" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=29182146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitl2ktLvO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=e27364&author=M.+B.+Winterauthor=F.+La+Grecaauthor=S.+Arastu-Kapurauthor=F.+Caiazzaauthor=P.+Cimermancicauthor=T.+J.+Buchholzauthor=J.+L.+Anderlauthor=M.+Ravalinauthor=M.+F.+Bohnauthor=A.+Saliauthor=A.+O%E2%80%99Donoghueauthor=C.+Craik&title=Immunoproteasome+Functions+Explained+by+Divergence+in+Cleavage+Specificity+and+Regulation&doi=10.7554%2FeLife.27364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoproteasome functions explained by divergence in cleavage specificity and regulation</span></div><div class="casAuthors">Winter, Michael B.; La Greca, Florencia; Arastu-Kapur, Shirin; Caiazza, Francesco; Cimermancic, Peter; Buchholz, Tonia J.; Anderl, Janet L.; Ravalin, Matthew; Bohn, Markus F.; Sali, Andrej; O'Donoghue, Anthony J.; Craik, Charles S.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e27364/1-e27364/23</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">The immunoproteasome (iP) has been proposed to perform specialized roles in MHC class I antigen presentation, cytokine modulation, and T cell differentiation and has emerged as a promising therapeutic target for autoimmune disorders and cancer.  However, divergence in function between the iP and the constitutive proteasome (cP) has been unclear.  A global peptide library-based screening strategy revealed that the proteasomes have overlapping but distinct substrate specificities.  Differing iP specificity alters the quantity of prodn. of certain MHC I epitopes but does not appear to be preferentially suited for antigen presentation.  Furthermore, iP specificity was found to have likely arisen through genetic drift from the ancestral cP.  Specificity differences were exploited to develop isoform-selective substrates.  Cellular profiling using these substrates revealed that divergence in regulation of the iP balances its relative contribution to proteasome capacity in immune cells, resulting in selective recovery from inhibition.  These findings have implications for iP-targeted therapeutic development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoArGjvv0tV5rVg90H21EOLACvtfcHk0lj9mWUn5PFziA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitl2ktLvO&md5=b0a8704ed4b007e14514769d134b5bab</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.7554%2FeLife.27364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.27364%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DM.%2BB.%26aulast%3DLa%2BGreca%26aufirst%3DF.%26aulast%3DArastu-Kapur%26aufirst%3DS.%26aulast%3DCaiazza%26aufirst%3DF.%26aulast%3DCimermancic%26aufirst%3DP.%26aulast%3DBuchholz%26aufirst%3DT.%2BJ.%26aulast%3DAnderl%26aufirst%3DJ.%2BL.%26aulast%3DRavalin%26aufirst%3DM.%26aulast%3DBohn%26aufirst%3DM.%2BF.%26aulast%3DSali%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Donoghue%26aufirst%3DA.%26aulast%3DCraik%26aufirst%3DC.%26atitle%3DImmunoproteasome%2520Functions%2520Explained%2520by%2520Divergence%2520in%2520Cleavage%2520Specificity%2520and%2520Regulation%26jtitle%3DeLife%26date%3D2017%26volume%3D6%26spage%3De27364%26doi%3D10.7554%2FeLife.27364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattarai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">H727 Cells Are Inherently Resistant to the Proteasome Inhibitor Carfilzomib, yet Require Proteasome Activity for Cell Survival and Growth</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">4089</span>, <span class="refDoi">Â DOI: 10.1038/s41598-019-40635-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fs41598-019-40635-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=30858500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BB3cbivVGktw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=4089&issue=1&author=M.+J.+Leeauthor=Z.+Millerauthor=J.+E.+Parkauthor=D.+Bhattaraiauthor=W.+Leeauthor=K.+B.+Kim&title=H727+Cells+Are+Inherently+Resistant+to+the+Proteasome+Inhibitor+Carfilzomib%2C+yet+Require+Proteasome+Activity+for+Cell+Survival+and+Growth&doi=10.1038%2Fs41598-019-40635-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth</span></div><div class="casAuthors">Lee Min Jae; Miller Zachary; Bhattarai Deepak; Kim Kyung Bo; Park Ji Eun; Lee Wooin</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4089</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The second-in-class proteasome inhibitor (PI) carfilzomib (Kyprolis, Cfz) has contributed to a substantial advancement in multiple myeloma treatment by improving patient survival and quality of life.  A considerable portion of patients however display intrinsic resistance to Cfz.  Our mechanistic understanding of intrinsic Cfz resistance is limited due to a lack of suitable cell-based models.  We report that H727 human bronchial carcinoid cells are inherently resistant to Cfz, yet susceptible to other PIs and inhibitors targeting upstream components of the ubiquitin-proteasome system (UPS).  These results indicate that H727 cells remain dependent on the UPS for cell survival and growth despite harboring intrinsic resistance to Cfz.  Alterations in the composition of proteasome catalytic subunits via interferon-Î³ treatment or siRNA knockdown results in sensitization of H727 cells to Cfz.  We postulate that a potential link may exist between the composition of proteasome catalytic subunits and the cellular response to Cfz.  Overall, H727 cells may serve as a useful cell-based model for de novo Cfz resistance and our results suggest previously unexplored mechanisms of de novo PI resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHLlRY4-lmF3T4ugvCDgnZfW6udTcc2eb_i5FZTnsIyrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbivVGktw%253D%253D&md5=2eac99d394dd7fa2e1fe2922cd32b87f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-40635-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-40635-1%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%2BJ.%26aulast%3DMiller%26aufirst%3DZ.%26aulast%3DPark%26aufirst%3DJ.%2BE.%26aulast%3DBhattarai%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DH727%2520Cells%2520Are%2520Inherently%2520Resistant%2520to%2520the%2520Proteasome%2520Inhibitor%2520Carfilzomib%252C%2520yet%2520Require%2520Proteasome%2520Activity%2520for%2520Cell%2520Survival%2520and%2520Growth%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26issue%3D1%26spage%3D4089%26doi%3D10.1038%2Fs41598-019-40635-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berkers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdoes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiebiger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploegh, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galardy, P. J.</span></span> <span> </span><span class="NLM_article-title">Activity Probe for in Vivo Profiling of the Specificity of Proteasome Inhibitor Bortezomib</span>. <i>Nat. Methods</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">357</span>, <span class="refDoi">Â DOI: 10.1038/nmeth759</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fnmeth759" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=15846363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsVyls70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=357&issue=5&author=C.+R.+Berkersauthor=M.+Verdoesauthor=E.+Lichtmanauthor=E.+Fiebigerauthor=B.+M.+Kesslerauthor=K.+C.+Andersonauthor=H.+L.+Ploeghauthor=H.+Ovaaauthor=P.+J.+Galardy&title=Activity+Probe+for+in+Vivo+Profiling+of+the+Specificity+of+Proteasome+Inhibitor+Bortezomib&doi=10.1038%2Fnmeth759"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib</span></div><div class="casAuthors">Berkers, Celia R.; Verdoes, Martijn; Lichtman, Eben; Fiebiger, Edda; Kessler, Benedikt M.; Anderson, Kenneth C.; Ploegh, Hidde L.; Ovaa, Huib; Galardy, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Methods</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">357-362</span>CODEN:
                <span class="NLM_cas:coden">NMAEA3</span>;
        ISSN:<span class="NLM_cas:issn">1548-7091</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Proteasome inhibitors, such as the dipeptide boronic acid bortezomib, are emerging as important tools in the treatment of the fatal hematol. malignancy multiple myeloma.  Despite the recent US Food and Drug Administration approval of bortezomib (PS341, Velcade) for the treatment of refractory multiple myeloma, many of the basic pharmacol. parameters of bortezomib and its mode of action on myeloma cells remain to be detd.  We describe the synthesis and use of a cell-permeant active site-directed probe, which allows profiling of proteasomal activities in living cells.  When we compared proteasome activity patterns in cultured cells and crude cell exts. with this probe, we obsd. substantial differences, stressing the importance for bioassays compatible with live cells to ensure accuracy of such measurements.  Using this probe, we investigated the in vivo subunit specificities of bortezomib and another inhibitor, MG132.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomPqiElUEWtLVg90H21EOLACvtfcHk0lgy9fZ9SonwGg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsVyls70%253D&md5=5055e0a80ecfd5ea8272e6b38f0c73bc</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnmeth759&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmeth759%26sid%3Dliteratum%253Aachs%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3DVerdoes%26aufirst%3DM.%26aulast%3DLichtman%26aufirst%3DE.%26aulast%3DFiebiger%26aufirst%3DE.%26aulast%3DKessler%26aufirst%3DB.%2BM.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DPloegh%26aufirst%3DH.%2BL.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DGalardy%26aufirst%3DP.%2BJ.%26atitle%3DActivity%2520Probe%2520for%2520in%2520Vivo%2520Profiling%2520of%2520the%2520Specificity%2520of%2520Proteasome%2520Inhibitor%2520Bortezomib%26jtitle%3DNat.%2520Methods%26date%3D2005%26volume%3D2%26issue%3D5%26spage%3D357%26doi%3D10.1038%2Fnmeth759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verdoes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florea, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menendez-Benito, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynard, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Linden, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Nieuwendijk, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Leeuwen, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groothuis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeuwenburgh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neefjes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Marel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dantuma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H.</span></span> <span> </span><span class="NLM_article-title">A Fluorescent Broad-Spectrum Proteasome Inhibitor for Labeling Proteasomes In Vitro and In Vivo</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1217</span>â <span class="NLM_lpage">1226</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2006.09.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.chembiol.2006.09.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=17114003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Cis7fN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=1217-1226&issue=11&author=M.+Verdoesauthor=B.+I.+Floreaauthor=V.+Menendez-Benitoauthor=C.+J.+Maynardauthor=M.+D.+Witteauthor=W.+A.+van+der+Lindenauthor=A.+M.+van+den+Nieuwendijkauthor=T.+Hofmannauthor=C.+R.+Berkersauthor=F.+W.+van+Leeuwenauthor=T.+Groothuisauthor=M.+Leeuwenburghauthor=H.+Ovaaauthor=J.+Neefjesauthor=D.+Filippovauthor=G.+van+der+Marelauthor=N.+Dantumaauthor=H.+Overkleeft&title=A+Fluorescent+Broad-Spectrum+Proteasome+Inhibitor+for+Labeling+Proteasomes+In+Vitro+and+In+Vivo&doi=10.1016%2Fj.chembiol.2006.09.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">A Fluorescent Broad-Spectrum Proteasome Inhibitor for Labeling Proteasomes In Vitro and In Vivo</span></div><div class="casAuthors">Verdoes, Martijn; Florea, Bogdan I.; Menendez-Benito, Victoria; Maynard, Christa J.; Witte, Martin D.; van der Linden, Wouter A.; van den Nieuwendijk, Adrianus M. C. H.; Hofmann, Tanja; Berkers, Celia R.; van Leeuwen, Fijs W. B.; Groothuis, Tom A.; Leeuwenburgh, Michiel A.; Ovaa, Huib; Neefjes, Jacques J.; Filippov, Dmitri V.; van der Marel, Gijs A.; Dantuma, Nico P.; Overkleeft, Herman S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1217-1226</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The proteasome is an essential evolutionary conserved protease involved in many regulatory systems.  Here, the authors describe the synthesis and characterization of the activity-based, fluorescent, and cell-permeable inhibitor Bodipy TMR-Ahx3L3VS (MV151), which specifically targets all active subunits of the proteasome and immunoproteasome in living cells, allowing for rapid and sensitive in-gel detection.  The inhibition profile of a panel of commonly used proteasome inhibitors could be readily detd. by MV151 labeling.  Administration of MV151 to mice allowed for in vivo labeling of proteasomes, which correlated with inhibition of proteasomal degrdn. in the affected tissues.  This probe can be used for many applications ranging from clin. profiling of proteasome activity, to biochem. anal. of subunit specificity of inhibitors, and to cell biol. anal. of the proteasome function and dynamics in living cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMZq52j_0-wLVg90H21EOLACvtfcHk0lgy9fZ9SonwGg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Cis7fN&md5=95b57d47d477020254a0fb2bd24fef87</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2006.09.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2006.09.013%26sid%3Dliteratum%253Aachs%26aulast%3DVerdoes%26aufirst%3DM.%26aulast%3DFlorea%26aufirst%3DB.%2BI.%26aulast%3DMenendez-Benito%26aufirst%3DV.%26aulast%3DMaynard%26aufirst%3DC.%2BJ.%26aulast%3DWitte%26aufirst%3DM.%2BD.%26aulast%3Dvan%2Bder%2BLinden%26aufirst%3DW.%2BA.%26aulast%3Dvan%2Bden%2BNieuwendijk%26aufirst%3DA.%2BM.%26aulast%3DHofmann%26aufirst%3DT.%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3Dvan%2BLeeuwen%26aufirst%3DF.%2BW.%26aulast%3DGroothuis%26aufirst%3DT.%26aulast%3DLeeuwenburgh%26aufirst%3DM.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DNeefjes%26aufirst%3DJ.%26aulast%3DFilippov%26aufirst%3DD.%26aulast%3Dvan%2Bder%2BMarel%26aufirst%3DG.%26aulast%3DDantuma%26aufirst%3DN.%26aulast%3DOverkleeft%26aufirst%3DH.%26atitle%3DA%2520Fluorescent%2520Broad-Spectrum%2520Proteasome%2520Inhibitor%2520for%2520Labeling%2520Proteasomes%2520In%2520Vitro%2520and%2520In%2520Vivo%26jtitle%3DChem.%2520Biol.%26date%3D2006%26volume%3D13%26issue%3D11%26spage%3D1217%26epage%3D1226%26doi%3D10.1016%2Fj.chembiol.2006.09.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berkers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Leeuwen, F. W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groothuis, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peperzak, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Tilburg, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borst, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neefjes, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span> <span> </span><span class="NLM_article-title">Profiling Proteasome Activity in Tissue with Fluorescent Probes</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">739</span>â <span class="NLM_lpage">748</span>, <span class="refDoi">Â DOI: 10.1021/mp0700256</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp0700256" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpt1GisbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=739-748&issue=5&author=C.+R.+Berkersauthor=F.+W.+B.+van+Leeuwenauthor=T.+A.+Groothuisauthor=V.+Peperzakauthor=E.+W.+van+Tilburgauthor=J.+Borstauthor=J.+J.+Neefjesauthor=H.+Ovaa&title=Profiling+Proteasome+Activity+in+Tissue+with+Fluorescent+Probes&doi=10.1021%2Fmp0700256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Profiling Proteasome Activity in Tissue with Fluorescent Probes</span></div><div class="casAuthors">Berkers, Celia R.; van Leeuwen, Fijs W. B.; Groothuis, Tom A.; Peperzak, Victor; van Tilburg, Erica W.; Borst, Jannie; Neefjes, Jacques J.; Ovaa, Huib</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">739-748</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">With proteasome inhibitors in use in the clinic for the treatment of multiple myeloma and with clin. trials in progress investigating the treatment of a variety of hematol. and solid malignancies, accurate methods that allow profiling of proteasome inhibitor specificity and efficacy in patients are in demand.  Here, we describe the development, full biochem. validation, and comparison of fluorescent proteasome activity reporters that can be used to profile proteasome activities in living cells with high sensitivity.  Seven of the synthesized probes tested label proteasomes in lysates, although the fluorescent dye used affects their specificity.  Two differentially labeled probes tested are suitable for studying proteasome activity in living cells by gel-based assays, by confocal laser scanning microscopy, and by flow cytometry.  We established methods using these fluorescent reporters to profile proteasome activity in different mouse tissues, carefully avoiding postlysis artifacts, and we show that proteasome subunit activity is regulated in an organ-specific manner.  The techniques described here could be used to study in vivo pharmacol. properties of proteasome inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdW9Lx7lRHTbVg90H21EOLACvtfcHk0lgy9fZ9SonwGg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpt1GisbY%253D&md5=78b8f398f2060e995e6382ce1ff7caca</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fmp0700256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp0700256%26sid%3Dliteratum%253Aachs%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3Dvan%2BLeeuwen%26aufirst%3DF.%2BW.%2BB.%26aulast%3DGroothuis%26aufirst%3DT.%2BA.%26aulast%3DPeperzak%26aufirst%3DV.%26aulast%3Dvan%2BTilburg%26aufirst%3DE.%2BW.%26aulast%3DBorst%26aufirst%3DJ.%26aulast%3DNeefjes%26aufirst%3DJ.%2BJ.%26aulast%3DOvaa%26aufirst%3DH.%26atitle%3DProfiling%2520Proteasome%2520Activity%2520in%2520Tissue%2520with%2520Fluorescent%2520Probes%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2007%26volume%3D4%26issue%3D5%26spage%3D739%26epage%3D748%26doi%3D10.1021%2Fmp0700256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verdoes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Linden, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duivenvoorden, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Marel, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florea, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisselev, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span> <span> </span><span class="NLM_article-title">A Panel of Subunit-Selective Activity-Based Proteasome Probes</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2719</span>â <span class="NLM_lpage">2727</span>, <span class="refDoi">Â DOI: 10.1039/c001036g</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1039%2Fc001036g" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=20449511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmvVWkt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=2719-2727&issue=12&author=M.+Verdoesauthor=L.+I.+Willemsauthor=W.+A.+van+der+Lindenauthor=B.+A.+Duivenvoordenauthor=G.+A.+van+der+Marelauthor=B.+I.+Floreaauthor=A.+F.+Kisselevauthor=H.+S.+Overkleeft&title=A+Panel+of+Subunit-Selective+Activity-Based+Proteasome+Probes&doi=10.1039%2Fc001036g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A panel of subunit-selective activity-based proteasome probes</span></div><div class="casAuthors">Verdoes, Martijn; Willems, Lianne I.; van der Linden, Wouter A.; Duivenvoorden, Boudewijn A.; van der Marel, Gijsbert A.; Florea, Bogdan I.; Kisselev, Alexei F.; Overkleeft, Herman S.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2719-2727</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Mammals express seven different catalytically active proteasome subunits.  To det. the roles of the different proteolytically active subunits in antigen presentation and other cellular processes, highly specific inhibitors and activity-based probes that selectively target specific active sites are needed.  We present the development of fluorescent activity-based probes that selectively target the Î²1 and Î²5 sites of the constitutive proteasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopSK6QWooDJ7Vg90H21EOLACvtfcHk0lid2ykXUBDd3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmvVWkt7g%253D&md5=6d645dd55647f6b25f290fd5c112e482</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1039%2Fc001036g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc001036g%26sid%3Dliteratum%253Aachs%26aulast%3DVerdoes%26aufirst%3DM.%26aulast%3DWillems%26aufirst%3DL.%2BI.%26aulast%3Dvan%2Bder%2BLinden%26aufirst%3DW.%2BA.%26aulast%3DDuivenvoorden%26aufirst%3DB.%2BA.%26aulast%3Dvan%2Bder%2BMarel%26aufirst%3DG.%2BA.%26aulast%3DFlorea%26aufirst%3DB.%2BI.%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26atitle%3DA%2520Panel%2520of%2520Subunit-Selective%2520Activity-Based%2520Proteasome%2520Probes%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2010%26volume%3D8%26issue%3D12%26spage%3D2719%26epage%3D2727%26doi%3D10.1039%2Fc001036g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Bruin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Stelt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Marel, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisselev, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florea, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span> <span> </span><span class="NLM_article-title">A Set of Activity-Based Probes to Visualize Human (Immuno)Proteasome Activities</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">4199</span>â <span class="NLM_lpage">4203</span>, <span class="refDoi">Â DOI: 10.1002/anie.201509092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1002%2Fanie.201509092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslCntLbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=4199-4203&issue=13&author=G.+de%0ABruinauthor=B.+T.+Xinauthor=M.+Krausauthor=M.+van+der%0ASteltauthor=G.+A.+van+der+Marelauthor=A.+F.+Kisselevauthor=C.+Driessenauthor=B.+I.+Floreaauthor=H.+S.+Overkleeft&title=A+Set+of+Activity-Based+Probes+to+Visualize+Human+%28Immuno%29Proteasome+Activities&doi=10.1002%2Fanie.201509092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A set of activity-based probes to visualize human (immuno)proteasome activities</span></div><div class="casAuthors">de Bruin, Gerjan; Xin, Bo Tao; Kraus, Marianne; van der Stelt, Mario; van der Marel, Gijsbert A.; Kisselev, Alexei F.; Driessen, Christoph; Florea, Bogdan I.; Overkleeft, Herman S.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4199-4203</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Proteasomes are therapeutic targets for various cancers and autoimmune diseases.  Constitutively expressed proteasomes have three active sites, Î²1c, Î²2c, and Î²5c.  Lymphoid tissues also express the immunoproteasome subunits Î²1i, Î²2i, and Î²5i.  Rapid and simultaneous measurement of the activity of these catalytic subunits would assist in the discovery of new inhibitors, improve anal. of proteasome inhibitors in clin. trials, and simplify anal. of subunit expression.  In this work, we present a cocktail of activity-based probes that enables simultaneous gel-based detection of all six catalytic human proteasome subunits.  We used this cocktail to develop specific inhibitors for Î²1c, Î²2c, Î²5c, and Î²2i, to compare the active-site specificity of clin. proteasome inhibitors, and to demonstrate that many hematol. malignancies predominantly express immunoproteasomes.  Furthermore, we show that selective and complete inhibition of Î²5i and Î²1i is cytotoxic to primary cells from acute lymphocytic leukemia (ALL) patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrebn-jSmyOmLVg90H21EOLACvtfcHk0lid2ykXUBDd3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslCntLbJ&md5=b04c6ea92827f327395fc313444e5126</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fanie.201509092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201509092%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBruin%26aufirst%3DG.%26aulast%3DXin%26aufirst%3DB.%2BT.%26aulast%3DKraus%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BStelt%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BMarel%26aufirst%3DG.%2BA.%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26aulast%3DDriessen%26aufirst%3DC.%26aulast%3DFlorea%26aufirst%3DB.%2BI.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26atitle%3DA%2520Set%2520of%2520Activity-Based%2520Probes%2520to%2520Visualize%2520Human%2520%2528Immuno%2529Proteasome%2520Activities%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26issue%3D13%26spage%3D4199%26epage%3D4203%26doi%3D10.1002%2Fanie.201509092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borissenko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span> <span> </span><span class="NLM_article-title">20S Proteasome and Its Inhibitors: Crystallographic Knowledge for Drug Development</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>107</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">687</span>â <span class="NLM_lpage">717</span>, <span class="refDoi">Â DOI: 10.1021/cr0502504</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr0502504" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvF2kuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2007&pages=687-717&issue=3&author=L.+Borissenkoauthor=M.+Groll&title=20S+Proteasome+and+Its+Inhibitors%3A+Crystallographic+Knowledge+for+Drug+Development&doi=10.1021%2Fcr0502504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">20S Proteasome and Its Inhibitors: Crystallographic Knowledge for Drug Development</span></div><div class="casAuthors">Borissenko, Ljudmila; Groll, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">687-717</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The aim of this review is to discuss the latest insights on the structure and function of the proteasome, highlighting the structural features that det. its activity and specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwElwBj8JBKrVg90H21EOLACvtfcHk0lid2ykXUBDd3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvF2kuro%253D&md5=af2e998e5443f598a46ffef71118a119</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fcr0502504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0502504%26sid%3Dliteratum%253Aachs%26aulast%3DBorissenko%26aufirst%3DL.%26aulast%3DGroll%26aufirst%3DM.%26atitle%3D20S%2520Proteasome%2520and%2520Its%2520Inhibitors%253A%2520Crystallographic%2520Knowledge%2520for%2520Drug%2520Development%26jtitle%3DChem.%2520Rev.%26date%3D2007%26volume%3D107%26issue%3D3%26spage%3D687%26epage%3D717%26doi%3D10.1021%2Fcr0502504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinemeyer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">JÃ¤ger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bochtler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, R.</span></span> <span> </span><span class="NLM_article-title">The Catalytic Sites of 20S Proteasomes and Their Role in Subunit Maturation: A Mutational and Crystallographic Study</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">10976</span>â <span class="NLM_lpage">10983</span>, <span class="refDoi">Â DOI: 10.1073/pnas.96.20.10976</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1073%2Fpnas.96.20.10976" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10500111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADyaK1MXmvVCnt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=10976-10983&issue=20&author=M.+Grollauthor=W.+Heinemeyerauthor=S.+J%C3%A4gerauthor=T.+Ullrichauthor=M.+Bochtlerauthor=D.+H.+Wolfauthor=R.+Huber&title=The+Catalytic+Sites+of+20S+Proteasomes+and+Their+Role+in+Subunit+Maturation%3A+A+Mutational+and+Crystallographic+Study&doi=10.1073%2Fpnas.96.20.10976"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study</span></div><div class="casAuthors">Groll, Michael; Heinemeyer, Wolfgang; Jager, Sibylle; Ullrich, Tobias; Bochtler, Mathias; Wolf, Dieter H.; Huber, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">10976-10983</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We present a biochem. and crystallog. characterization of active site mutants of the yeast 20S proteasome with the aim to characterize substrate cleavage specificity, subunit intermediate processing, and maturation.  Î²1(Pre3), Î²2(Pup1), and Î²5(Pre2) are responsible for the postacidic, tryptic, and chymotryptic activity, resp.  The maturation of active subunits is independent of the presence of other active subunits and occurs by intrasubunit autolysis.  The propeptides of Î²6(Pre7) and Î²7(Pre4) are intermediately processed to their final forms by Î²2(Pup1) in the wild-type enzyme and by Î²5(Pre2) and Î²1(Pre3) in the Î²2(Pup1) inactive mutants.  A role of the propeptide of Î²1(Pre3) is to prevent acetylation and thereby inactivation.  A gallery of proteasome mutants that contain active site residues in the context of the inactive subunits Î²3(Pup3), Î²6(Pre7), and Î²7(Pre4) show that the presence of Gly1, Thr1, Asp17, Lys33, Ser129, Asp166, and Ser169 is not sufficient to generate activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqATmrU0JPzvrVg90H21EOLACvtfcHk0lid2ykXUBDd3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmvVCnt7c%253D&md5=5f4948819bf38d5364c61ffd16167a00</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.20.10976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.20.10976%26sid%3Dliteratum%253Aachs%26aulast%3DGroll%26aufirst%3DM.%26aulast%3DHeinemeyer%26aufirst%3DW.%26aulast%3DJ%25C3%25A4ger%26aufirst%3DS.%26aulast%3DUllrich%26aufirst%3DT.%26aulast%3DBochtler%26aufirst%3DM.%26aulast%3DWolf%26aufirst%3DD.%2BH.%26aulast%3DHuber%26aufirst%3DR.%26atitle%3DThe%2520Catalytic%2520Sites%2520of%252020S%2520Proteasomes%2520and%2520Their%2520Role%2520in%2520Subunit%2520Maturation%253A%2520A%2520Mutational%2520and%2520Crystallographic%2520Study%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26issue%3D20%26spage%3D10976%26epage%3D10983%26doi%3D10.1073%2Fpnas.96.20.10976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmony, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.-B.</span></span> <span> </span><span class="NLM_article-title">A FRET-Based Approach for Identification of Proteasome Catalytic Subunit Composition</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">196</span>â <span class="NLM_lpage">200</span>, <span class="refDoi">Â DOI: 10.1039/C3MB70471H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1039%2FC3MB70471H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=24301521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvF2kt7fN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=196-200&issue=2&author=J.+E.+Parkauthor=Y.+Wuauthor=K.+C.+Carmonyauthor=Z.+Millerauthor=L.+K.+Sharmaauthor=D.-M.+Leeauthor=D.-Y.+Kimauthor=W.+Leeauthor=K.-B.+Kim&title=A+FRET-Based+Approach+for+Identification+of+Proteasome+Catalytic+Subunit+Composition&doi=10.1039%2FC3MB70471H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A FRET-based approach for identification of proteasome catalytic subunit composition</span></div><div class="casAuthors">Park, Ji Eun; Wu, Ying; Carmony, Kimberly Cornish; Miller, Zachary; Sharma, Lalit Kumar; Lee, Do-Min; Kim, Doo-Young; Lee, Wooin; Kim, Kyung-Bo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">196-200</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-2051</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Mammalian cells have two main types of proteasomes, the constitutive proteasome and the immunoproteasome, each contg. a distinct set of three catalytic subunits.  Recently, addnl. proteasome subtypes contg. a non-std. mixt. of catalytic subunits have gained increasing attention, esp. due to their presence in cancer settings.  However, practical methods for identifying proteasome subtypes have been lacking.  Here, we report the development of the first fluorescence resonance energy transfer (FRET)-based strategy that can be utilized to identify different proteasome subtypes present within cells.  We have developed FRET donor- and acceptor-probes that are based on previously reported peptide epoxyketones and selectively target individual proteasome catalytic subunits.  Using the purified proteasome and cancer cell lysates, we demonstrate the feasibility of a FRET-based approach for detg. the catalytic subunit compn. of individual 20S proteasome subtypes.  Ultimately, this approach may be utilized to study the functions of individual proteasome subtypes in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhgLKcZOP5H7Vg90H21EOLACvtfcHk0ljl1KHn4Oj6rA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvF2kt7fN&md5=c0fc15b0a6dac620b689ab5b26d3e38c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1039%2FC3MB70471H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC3MB70471H%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BE.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DCarmony%26aufirst%3DK.%2BC.%26aulast%3DMiller%26aufirst%3DZ.%26aulast%3DSharma%26aufirst%3DL.%2BK.%26aulast%3DLee%26aufirst%3DD.-M.%26aulast%3DKim%26aufirst%3DD.-Y.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DK.-B.%26atitle%3DA%2520FRET-Based%2520Approach%2520for%2520Identification%2520of%2520Proteasome%2520Catalytic%2520Subunit%2520Composition%26jtitle%3DMol.%2520BioSyst.%26date%3D2014%26volume%3D10%26issue%3D2%26spage%3D196%26epage%3D200%26doi%3D10.1039%2FC3MB70471H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Bruin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, B.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florea, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span> <span> </span><span class="NLM_article-title">Proteasome Subunit Selective Activity-Based Probes Report on Proteasome Core Particle Composition in a Native Polyacrylamide Gel Electrophoresis Fluorescence-Resonance Energy Transfer Assay</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>138</i></span> (<span class="NLM_issue">31</span>),  <span class="NLM_fpage">9874</span>â <span class="NLM_lpage">9880</span>, <span class="refDoi">Â DOI: 10.1021/jacs.6b04207</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.6b04207" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFyitLrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=9874-9880&issue=31&author=G.+de%0ABruinauthor=B.-T.+Xinauthor=B.+I.+Floreaauthor=H.+S.+Overkleeft&title=Proteasome+Subunit+Selective+Activity-Based+Probes+Report+on+Proteasome+Core+Particle+Composition+in+a+Native+Polyacrylamide+Gel+Electrophoresis+Fluorescence-Resonance+Energy+Transfer+Assay&doi=10.1021%2Fjacs.6b04207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome Subunit Selective Activity-Based Probes Report on Proteasome Core Particle Composition in a Native Polyacrylamide Gel Electrophoresis Fluorescence-Resonance Energy Transfer Assay</span></div><div class="casAuthors">de Bruin, Gerjan; Xin, Bo-Tao; Florea, Bogdan I.; Overkleeft, Herman S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">9874-9880</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Most mammalian tissues contain a single proteasome species: constitutive proteasomes.  Tissues able to express, next to the constitutive proteasome catalytic activities (Î²1c, Î²2c, Î²5c), the three homologous activities, Î²1i, Î²2i and Î²5i, may contain numerous distinct proteasome particles: immunoproteasomes (composed of Î²1i, Î²2i and Î²5i) and mixed proteasomes contg. a mix of these activities.  This work describes the development of new subunit-selective activity-based probes and their use in an activity-based protein profiling assay that allows the detection of various proteasome particles.  Tissue exts. are treated with subunit-specific probes bearing distinct fluorophores and subunit-specific inhibitors.  The samples are resolved by native PAGE, after which fluorescence-resonance energy transfer (FRET) reports on the nature of proteasomes present.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLNYVRgN-5w7Vg90H21EOLACvtfcHk0ljl1KHn4Oj6rA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFyitLrI&md5=4d9a6aa332499943d9a3952ce9b9cef5</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjacs.6b04207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.6b04207%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBruin%26aufirst%3DG.%26aulast%3DXin%26aufirst%3DB.-T.%26aulast%3DFlorea%26aufirst%3DB.%2BI.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26atitle%3DProteasome%2520Subunit%2520Selective%2520Activity-Based%2520Probes%2520Report%2520on%2520Proteasome%2520Core%2520Particle%2520Composition%2520in%2520a%2520Native%2520Polyacrylamide%2520Gel%2520Electrophoresis%2520Fluorescence-Resonance%2520Energy%2520Transfer%2520Assay%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2016%26volume%3D138%26issue%3D31%26spage%3D9874%26epage%3D9880%26doi%3D10.1021%2Fjacs.6b04207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cornish
Carmony, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.-B.</span></span> <span> </span><span class="NLM_article-title">Elucidating the Catalytic Subunit Composition of Distinct Proteasome Subtypes: A Crosslinking Approach Employing Bifunctional Activity-Based Probes</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">284</span>â <span class="NLM_lpage">292</span>, <span class="refDoi">Â DOI: 10.1002/cbic.201402491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1002%2Fcbic.201402491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=25477005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVaksbnI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=284-292&issue=2&author=K.+Cornish%0ACarmonyauthor=L.+K.+Sharmaauthor=D.-M.+Leeauthor=J.+E.+Parkauthor=W.+Leeauthor=K.-B.+Kim&title=Elucidating+the+Catalytic+Subunit+Composition+of+Distinct+Proteasome+Subtypes%3A+A+Crosslinking+Approach+Employing+Bifunctional+Activity-Based+Probes&doi=10.1002%2Fcbic.201402491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Elucidating the Catalytic Subunit Composition of Distinct Proteasome Subtypes: A Crosslinking Approach Employing Bifunctional Activity-Based Probes</span></div><div class="casAuthors">Cornish Carmony, Kimberly; Sharma, Lalit Kumar; Lee, Do-Min; Park, Ji Eun; Lee, Wooin; Kim, Kyung-Bo</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">284-292</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">In addn. to two well-recognized proteasome subtypes-constitutive proteasomes and immunoproteasomes-mounting evidence also suggests the existence of intermediate proteasome subtypes contg. unconventional mixts. of catalytic subunits.  Although they appear to play unique biol. roles, the lack of practical methods for detecting distinct proteasome subtypes has limited functional investigations.  Here, we report the development of activity-based probes that crosslink two catalytic subunits within intact proteasome complexes.  Identification of the crosslinked subunit pairs provides direct evidence of the catalytic subunit compn. of proteasomes.  Using these probes, we found that U266 multiple myeloma cells contain intermediate proteasomes comprising both Î²1i and Î²2, but not Î²1 and Î²2i, consistent with previous findings with other cell types.  Our bifunctional probes can be utilized in functional investigations of distinct proteasome subtypes in various biol. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkAqXgBr4VX7Vg90H21EOLACvtfcHk0ljl1KHn4Oj6rA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVaksbnI&md5=639cbfaeb83cf6e3811b696af9971c1b</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201402491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201402491%26sid%3Dliteratum%253Aachs%26aulast%3DCornish%2BCarmony%26aufirst%3DK.%26aulast%3DSharma%26aufirst%3DL.%2BK.%26aulast%3DLee%26aufirst%3DD.-M.%26aulast%3DPark%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DK.-B.%26atitle%3DElucidating%2520the%2520Catalytic%2520Subunit%2520Composition%2520of%2520Distinct%2520Proteasome%2520Subtypes%253A%2520A%2520Crosslinking%2520Approach%2520Employing%2520Bifunctional%2520Activity-Based%2520Probes%26jtitle%3DChemBioChem%26date%3D2015%26volume%3D16%26issue%3D2%26spage%3D284%26epage%3D292%26doi%3D10.1002%2Fcbic.201402491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zerfas, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trader, D. J.</span></span> <span> </span><span class="NLM_article-title">Monitoring the Immunoproteasome in Live Cells Using an Activity-Based PeptideâPeptoid Hybrid Probe</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">5252</span>â <span class="NLM_lpage">5260</span>, <span class="refDoi">Â DOI: 10.1021/jacs.8b12873</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b12873" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVSmsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=5252-5260&issue=13&author=B.+L.+Zerfasauthor=D.+J.+Trader&title=Monitoring+the+Immunoproteasome+in+Live+Cells+Using+an+Activity-Based+Peptide%E2%80%93Peptoid+Hybrid+Probe&doi=10.1021%2Fjacs.8b12873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Monitoring the immunoproteasome in live cells using an activity-based peptide-peptoid hybrid probe</span></div><div class="casAuthors">Zerfas, Breanna L.; Trader, Darci J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5252-5260</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Activity-based probes have greatly improved our understanding of the intrinsic roles and expression levels of various proteins within cells.  To be useful in live cells, probes must be cell permeable and provide a read-out that can be measured without disrupting the cells or the activity of the target.  Unfortunately, probes for the various forms of the proteasome that can be utilized in intact cells are limited; com. available probes are most effectively used with purified protein or cell lysate.  The proteasome, both the 26S and various isoforms of the 20S CP, is an important target with reported roles in cancer, autoimmune disorders, and neurodegenerative diseases.  Here, we present the development of a selective probe for the immunoproteasome, a specialized isoform of the 20S proteasome, that becomes expressed in cells that encounter an inflammatory signal.  Using a one-bead, one-compd. library of small peptides, we discovered a trimer sequence efficiently cleaved by the immunoproteasome with significant selectivity over the std. proteasome.  Upon conjugating this sequence to rhodamine 110 and a peptoid, we generated a probe with a considerable improvement in sensitivity compared to that of current aminomethylcoumarin-based proteasome probes.  Importantly, our probe was capable of labeling immunoproteasome-expressing cells while maintaining its selectivity over other cellular proteases in live cell cultures.  We anticipate this probe to find wide utility for those that wish to study the immunoproteasome's activity in a variety of cell lines and to be used as a reporter to discover small mols. that can perturb the activity of this proteasome isoform.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGottEI8PGqCE7Vg90H21EOLACvtfcHk0lhsyhnq9562mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVSmsLo%253D&md5=a475e510aaccc86edb1ca80e21eb7d5c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b12873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b12873%26sid%3Dliteratum%253Aachs%26aulast%3DZerfas%26aufirst%3DB.%2BL.%26aulast%3DTrader%26aufirst%3DD.%2BJ.%26atitle%3DMonitoring%2520the%2520Immunoproteasome%2520in%2520Live%2520Cells%2520Using%2520an%2520Activity-Based%2520Peptide%25E2%2580%2593Peptoid%2520Hybrid%2520Probe%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D141%26issue%3D13%26spage%3D5252%26epage%3D5260%26doi%3D10.1021%2Fjacs.8b12873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henninot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuss, J. M.</span></span> <span> </span><span class="NLM_article-title">The Current State of Peptide Drug Discovery: Back to the Future?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1382</span>â <span class="NLM_lpage">1414</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00318</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00318" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1ansLbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1382-1414&issue=4&author=A.+Henninotauthor=J.+C.+Collinsauthor=J.+M.+Nuss&title=The+Current+State+of+Peptide+Drug+Discovery%3A+Back+to+the+Future%3F&doi=10.1021%2Facs.jmedchem.7b00318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">The Current State of Peptide Drug Discovery: Back to the Future?</span></div><div class="casAuthors">Henninot, Antoine; Collins, James C.; Nuss, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1382-1414</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Over the last decade, peptide drug discovery has experienced a revival of interest and scientific momentum, as the pharmaceutical industry has come to appreciate the role that peptide therapeutics can play in addressing unmet medical needs, and how this class of compds. can be an excellent complement or even preferable alternative to small mol. and biol. therapeutics.  In this perspective we give a concise description of the recent progress in peptide drug discovery in a holistic manner, highlighting enabling technol. advances affecting nearly every aspect of this field: from lead discovery, to synthesis and optimization, to peptide drug delivery.  An emphasis is placed on describing research efforts to overcome the inherent weaknesses of peptide drugs, in particular their poor pharmacokinetic properties, and how these efforts have been crit. to the discovery, design and subsequent development of novel therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosOkeBHqLwj7Vg90H21EOLACvtfcHk0lhsyhnq9562mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1ansLbM&md5=825f15ed57fceaa1226f57be696c639e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00318%26sid%3Dliteratum%253Aachs%26aulast%3DHenninot%26aufirst%3DA.%26aulast%3DCollins%26aufirst%3DJ.%2BC.%26aulast%3DNuss%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520Current%2520State%2520of%2520Peptide%2520Drug%2520Discovery%253A%2520Back%2520to%2520the%2520Future%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D4%26spage%3D1382%26epage%3D1414%26doi%3D10.1021%2Facs.jmedchem.7b00318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fosgerau, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, T.</span></span> <span> </span><span class="NLM_article-title">Peptide Therapeutics: Current Status and Future Directions</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">122</span>â <span class="NLM_lpage">128</span>, <span class="refDoi">Â DOI: 10.1016/j.drudis.2014.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.drudis.2014.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=25450771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsl2ksLnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=122-128&issue=1&author=K.+Fosgerauauthor=T.+Hoffmann&title=Peptide+Therapeutics%3A+Current+Status+and+Future+Directions&doi=10.1016%2Fj.drudis.2014.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide therapeutics: current status and future directions</span></div><div class="casAuthors">Fosgerau, Keld; Hoffmann, Torsten</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">122-128</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Peptides are recognized for being highly selective and efficacious and, at the same time, relatively safe and well tolerated.  Consequently, there is an increased interest in peptides in pharmaceutical research and development (R&D), and approx. 140 peptide therapeutics are currently being evaluated in clin. trials.  Given that the low-hanging fruits in the form of obvious peptide targets have already been picked, it has now become necessary to explore new routes beyond traditional peptide design.  Examples of such approaches are multifunctional and cell penetrating peptides, as well as peptide drug conjugates.  Here, we discuss the current status, strengths, and weaknesses of peptides as medicines and the emerging new opportunities in peptide drug design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmhpp8GnJ6JLVg90H21EOLACvtfcHk0lhsyhnq9562mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsl2ksLnM&md5=f6b74aaa4e3fdb317b091b0450f3618a</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DFosgerau%26aufirst%3DK.%26aulast%3DHoffmann%26aufirst%3DT.%26atitle%3DPeptide%2520Therapeutics%253A%2520Current%2520Status%2520and%2520Future%2520Directions%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26issue%3D1%26spage%3D122%26epage%3D128%26doi%3D10.1016%2Fj.drudis.2014.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span> <span> </span><span class="NLM_article-title">Proteasome Dysregulation in Human Cancer: Implications for Clinical Therapies</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">703</span>â <span class="NLM_lpage">716</span>, <span class="refDoi">Â DOI: 10.1007/s10555-017-9704-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1007%2Fs10555-017-9704-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=29039081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1KgsLnE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2017&pages=703-716&issue=4&author=Y.+Chenauthor=Y.+Zhangauthor=X.+Guo&title=Proteasome+Dysregulation+in+Human+Cancer%3A+Implications+for+Clinical+Therapies&doi=10.1007%2Fs10555-017-9704-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome dysregulation in human cancer: implications for clinical therapies</span></div><div class="casAuthors">Chen, Yulin; Zhang, Yanan; Guo, Xing</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">703-716</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Cancer cells show heightened dependency on the proteasome for their survival, growth, and spread.  Proteasome dysregulation is therefore commonly selected in favor of the development of many types of cancer.  The vast abnormalities in a cancer cell, on top of the complexity of the proteasome itself, have enabled a plethora of mechanisms gearing the proteasome to the oncogenic process.  Here, we use selected examples to highlight some general mechanisms underlying proteasome dysregulation in cancer, including copy no. variations, transcriptional control, epigenetic regulation, and post-translational modifications.  Research in this field has greatly advanced our understanding of proteasome regulation and will shed new light on proteasome-based combination therapies for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGPLufCMjdrLVg90H21EOLACvtfcHk0lg0KmIhRbiZZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1KgsLnE&md5=5666e31291740ebd904f5da56b5a13a1</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs10555-017-9704-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-017-9704-y%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DX.%26atitle%3DProteasome%2520Dysregulation%2520in%2520Human%2520Cancer%253A%2520Implications%2520for%2520Clinical%2520Therapies%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2017%26volume%3D36%26issue%3D4%26spage%3D703%26epage%3D716%26doi%3D10.1007%2Fs10555-017-9704-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Almond, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, G. M.</span></span> <span> </span><span class="NLM_article-title">The Proteasome: A Novel Target for Cancer Chemotherapy</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">433</span>â <span class="NLM_lpage">443</span>, <span class="refDoi">Â DOI: 10.1038/sj.leu.2402417</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fsj.leu.2402417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=11960320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvFGnur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2002&pages=433-443&issue=4&author=J.+B.+Almondauthor=G.+M.+Cohen&title=The+Proteasome%3A+A+Novel+Target+for+Cancer+Chemotherapy&doi=10.1038%2Fsj.leu.2402417"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome: A novel target for cancer chemotherapy</span></div><div class="casAuthors">Almond, J. B.; Cohen, G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">433-443</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The ubiquitin-proteasome system is an important regulator of cell growth and apoptosis.  The potential of specific proteasome inhibitors to act as novel anti-cancer agents is currently under intensive investigation.  Several proteasome inhibitors exert anti-tumor activity in vivo and potently induce apoptosis in tumor cells in vitro, including those resistant to conventional chemotherapeutic agents.  By inhibiting NF-ÎºB transcriptional activity, proteasome inhibitors may also prevent angiogenesis and metastasis in vivo and further increase the sensitivity of cancer cells to apoptosis.  Proteasome inhibitors also exhibit some level of selective cytotoxicity to cancer cells by preferentially inducing apoptosis in proliferating or transformed cells or by overcoming deficiencies in growth-inhibitory or proapoptotic mols.  High expression of oncogene products like c-Myc also makes cancer cells more susceptible to proteasome inhibitor-induced apoptosis.  The induction of apoptosis by proteasome inhibitors varies between cell types but often occurs following an initial accumulation of short-lived proteins such as p53, p27, pro-apoptotic Bcl-2 family members or activation of the stress kinase JNK.  These initial events often result in a perturbation of mitochondria with concomitant release of cytochrome c and activation of the Apaf-1 contg. apoptosome complex.  This results in activation of the apical caspase-9 followed by activation of effector caspases-3 and -7, which are responsible for the biochem. and morphol. changes assocd. with apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohX4u2GEzGOLVg90H21EOLACvtfcHk0lg0KmIhRbiZZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvFGnur8%253D&md5=1ebb4d9573591c2076bf56f5c75547e8</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2402417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2402417%26sid%3Dliteratum%253Aachs%26aulast%3DAlmond%26aufirst%3DJ.%2BB.%26aulast%3DCohen%26aufirst%3DG.%2BM.%26atitle%3DThe%2520Proteasome%253A%2520A%2520Novel%2520Target%2520for%2520Cancer%2520Chemotherapy%26jtitle%3DLeukemia%26date%3D2002%26volume%3D16%26issue%3D4%26spage%3D433%26epage%3D443%26doi%3D10.1038%2Fsj.leu.2402417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freije, J. M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraile, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LÃ³pez-OtÃ­n, C.</span></span> <span> </span><span class="NLM_article-title">Protease Addiction and Synthetic Lethality in Cancer</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">25</span>, <span class="refDoi">Â DOI: 10.3389/fonc.2011.00025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.3389%2Ffonc.2011.00025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=22655236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BC38notFWgsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=25&author=J.+M.+P.+Freijeauthor=J.+M.+Fraileauthor=C.+L%C3%B3pez-Ot%C3%ADn&title=Protease+Addiction+and+Synthetic+Lethality+in+Cancer&doi=10.3389%2Ffonc.2011.00025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Protease addiction and synthetic lethality in cancer</span></div><div class="casAuthors">Freije Jose M P; Fraile Julia M; Lopez-Otin Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">25</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The "oncogene addiction" concept refers to the dependence of cancer cells on the function of the oncogenes responsible for their transformed phenotype, while the term "non-oncogene addiction" has been introduced to define the exacerbated necessity of the normal function of non-mutated genes.  In this Perspective, we focus on the importance of proteolytic enzymes to maintain the viability of cancer cells and hypothesize that most, if not all, tumors present "addiction" to a number of proteolytic activities, which in turn may represent valuable targets of anti-cancer therapies, even without being mutated or over-expressed by the malignant cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQGOjJJch7csyCEBeYuoi7AfW6udTcc2eYwyMtgqMkDzLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38notFWgsQ%253D%253D&md5=c7638722f1588919cde3972f6ae4b48f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2011.00025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2011.00025%26sid%3Dliteratum%253Aachs%26aulast%3DFreije%26aufirst%3DJ.%2BM.%2BP.%26aulast%3DFraile%26aufirst%3DJ.%2BM.%26aulast%3DL%25C3%25B3pez-Ot%25C3%25ADn%26aufirst%3DC.%26atitle%3DProtease%2520Addiction%2520and%2520Synthetic%2520Lethality%2520in%2520Cancer%26jtitle%3DFront.%2520Oncol.%26date%3D2011%26volume%3D1%26spage%3D25%26doi%3D10.3389%2Ffonc.2011.00025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunsucker, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorhees, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, R. Z.</span></span> <span> </span><span class="NLM_article-title">Targeted Inhibition of the Immunoproteasome Is a Potent Strategy against Models of Multiple Myeloma That Overcomes Resistance to Conventional Drugs and Nonspecific Proteasome Inhibitors</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">4667</span>â <span class="NLM_lpage">4676</span>, <span class="refDoi">Â DOI: 10.1182/blood-2008-07-171637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1182%2Fblood-2008-07-171637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=19050304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvVyqurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=4667-4676&issue=19&author=D.+J.+Kuhnauthor=S.+A.+Hunsuckerauthor=Q.+Chenauthor=P.+M.+Voorheesauthor=M.+Orlowskiauthor=R.+Z.+Orlowski&title=Targeted+Inhibition+of+the+Immunoproteasome+Is+a+Potent+Strategy+against+Models+of+Multiple+Myeloma+That+Overcomes+Resistance+to+Conventional+Drugs+and+Nonspecific+Proteasome+Inhibitors&doi=10.1182%2Fblood-2008-07-171637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors</span></div><div class="casAuthors">Kuhn, Deborah J.; Hunsucker, Sally A.; Chen, Qing; Voorhees, Peter M.; Orlowski, Marian; Orlowski, Robert Z.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4667-4676</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Proteasome inhibition is a validated strategy for therapy of multiple myeloma, but this disease remains challenging as relapses are common, and often assocd. with increasing chemoresistance.  Moreover, nonspecific proteasome inhibitors such as bortezomib can induce peripheral neuropathy and other toxicities that may compromise the ability to deliver therapy at full doses, thereby decreasing efficacy.  One novel approach may be to target the immunoproteasome, a proteasomal variant found predominantly in cells of hematopoietic origin that differs from the constitutive proteasome found in most other cell types.  Using purified prepns. of constitutive and immunoproteasomes, we screened a rationally designed series of peptidyl-aldehydes and identified several with relative specificity for the immunoproteasome.  The most potent immunoproteasome-specific inhibitor, IPSI-001, preferentially targeted the Î²1i subunit of the immunoproteasome in vitro and in cellulo in a dose-dependent manner.  This agent induced accumulation of ubiquitin-protein conjugates, proapoptotic proteins, and activated caspase-mediated apoptosis.  IPSI-001 potently inhibited proliferation in myeloma patient samples and other hematol. malignancies.  Importantly, IPSI-001 was able to overcome conventional and novel drug resistance, including resistance to bortezomib.  These findings provide a rationale for the translation of IPSIs to the clinic, where they may provide antimyeloma activity with greater specificity and less toxicity than current inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyFUysXTzcsrVg90H21EOLACvtfcHk0lg0KmIhRbiZZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvVyqurk%253D&md5=6753f40ae6057eeadbbde2f6650828fc</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-07-171637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-07-171637%26sid%3Dliteratum%253Aachs%26aulast%3DKuhn%26aufirst%3DD.%2BJ.%26aulast%3DHunsucker%26aufirst%3DS.%2BA.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DVoorhees%26aufirst%3DP.%2BM.%26aulast%3DOrlowski%26aufirst%3DM.%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26atitle%3DTargeted%2520Inhibition%2520of%2520the%2520Immunoproteasome%2520Is%2520a%2520Potent%2520Strategy%2520against%2520Models%2520of%2520Multiple%2520Myeloma%2520That%2520Overcomes%2520Resistance%2520to%2520Conventional%2520Drugs%2520and%2520Nonspecific%2520Proteasome%2520Inhibitors%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26issue%3D19%26spage%3D4667%26epage%3D4676%26doi%3D10.1182%2Fblood-2008-07-171637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wehenkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ban, J.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, Y.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmony, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">A Selective Inhibitor of the Immunoproteasome Subunit LMP2 Induces Apoptosis in PC-3 Cells and Suppresses Tumour Growth in Nude Mice</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>107</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">53</span>â <span class="NLM_lpage">62</span>, <span class="refDoi">Â DOI: 10.1038/bjc.2012.243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fbjc.2012.243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=22677907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC38Xptl2isbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2012&pages=53-62&issue=1&author=M.+Wehenkelauthor=J.-O.+Banauthor=Y.-K.+Hoauthor=K.+C.+Carmonyauthor=J.+T.+Hongauthor=K.+B.+Kim&title=A+Selective+Inhibitor+of+the+Immunoproteasome+Subunit+LMP2+Induces+Apoptosis+in+PC-3+Cells+and+Suppresses+Tumour+Growth+in+Nude+Mice&doi=10.1038%2Fbjc.2012.243"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice</span></div><div class="casAuthors">Wehenkel, M.; Ban, J.-O.; Ho, Y.-K.; Carmony, K. C.; Hong, J. T.; Kim, K. B.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-62</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Although the proteasome is a validated anticancer target, the clin. application of its inhibitors has been limited because of inherent systemic toxicity.  To broaden clin. utility of proteasome inhibitors as anticancer agents, it is crit. to develop strategies to selectively target proteasomes in cancer cells.  The immunoproteasome is an alternative form of the constitutive proteasome that is expressed at high levels in cancer tissues, but not in most normal cells in the body.  Methods: To validate the immunoproteasome as a chemotherapeutic target, an immunoproteasome catalytic subunit LMP2-targeting inhibitor and siRNA were used.  The sensitivity of PC-3 prostate cancer cells to these reagents was investigated using viability assays.  Further, a xenograft model of prostate cancer was studied to test the in vivo effects of LMP2 inhibition.  Results: A small mol. inhibitor of the immunoproteasome subunit LMP2, UK-101, induced apoptosis of PC-3 cells and resulted in significant inhibition (â¼50-60%) of tumor growth in vivo.  Interestingly, UK-101 did not block degrdn. of IÎºBÎ± in PC-3 cells treated with TNF-Î±, suggesting that its mode of action may be different from that of general proteasome inhibitors, such as bortezomib, which block IÎºBÎ± degrdn.  Conclusion: These results strongly suggest that the immunoproteasome has important roles in cancer cell growth and thus provide a rationale for targeting the immunoproteasome in the treatment of prostate cancer.  British Journal of Cancer (2012) 107, 53-62. doi:10.1038/bjc.2012.243 www.bjcancer.com published online 7 June 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrLJQKXNlNKrVg90H21EOLACvtfcHk0lhpEiT9qaPZRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xptl2isbk%253D&md5=59390ce6295216a78e584049754b2c03</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2012.243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2012.243%26sid%3Dliteratum%253Aachs%26aulast%3DWehenkel%26aufirst%3DM.%26aulast%3DBan%26aufirst%3DJ.-O.%26aulast%3DHo%26aufirst%3DY.-K.%26aulast%3DCarmony%26aufirst%3DK.%2BC.%26aulast%3DHong%26aufirst%3DJ.%2BT.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DA%2520Selective%2520Inhibitor%2520of%2520the%2520Immunoproteasome%2520Subunit%2520LMP2%2520Induces%2520Apoptosis%2520in%2520PC-3%2520Cells%2520and%2520Suppresses%2520Tumour%2520Growth%2520in%2520Nude%2520Mice%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2012%26volume%3D107%26issue%3D1%26spage%3D53%26epage%3D62%26doi%3D10.1038%2Fbjc.2012.243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mlecnik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bindea, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirilovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angell, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obenauf, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Church, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maby, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasaturo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredriksen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speicher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pages, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valge-Archer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galon, J.</span></span> <span> </span><span class="NLM_article-title">The Tumor Microenvironment and Immunoscore Are Critical Determinants of Dissemination to Distant Metastasis</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">327</span>),  <span class="NLM_fpage">327ra26</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.aad6352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1126%2Fscitranslmed.aad6352" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=26912905" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=327ra26&issue=327&author=B.+Mlecnikauthor=G.+Bindeaauthor=A.+Kirilovskyauthor=H.+K.+Angellauthor=A.+C.+Obenaufauthor=M.+Tosoliniauthor=S.+E.+Churchauthor=P.+Mabyauthor=A.+Vasaturoauthor=M.+Angelovaauthor=T.+Fredriksenauthor=S.+Maugerauthor=M.+Waldnerauthor=A.+Bergerauthor=M.+Speicherauthor=F.+Pagesauthor=V.+Valge-Archerauthor=J.+Galon&title=The+Tumor+Microenvironment+and+Immunoscore+Are+Critical+Determinants+of+Dissemination+to+Distant+Metastasis&doi=10.1126%2Fscitranslmed.aad6352"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aad6352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aad6352%26sid%3Dliteratum%253Aachs%26aulast%3DMlecnik%26aufirst%3DB.%26aulast%3DBindea%26aufirst%3DG.%26aulast%3DKirilovsky%26aufirst%3DA.%26aulast%3DAngell%26aufirst%3DH.%2BK.%26aulast%3DObenauf%26aufirst%3DA.%2BC.%26aulast%3DTosolini%26aufirst%3DM.%26aulast%3DChurch%26aufirst%3DS.%2BE.%26aulast%3DMaby%26aufirst%3DP.%26aulast%3DVasaturo%26aufirst%3DA.%26aulast%3DAngelova%26aufirst%3DM.%26aulast%3DFredriksen%26aufirst%3DT.%26aulast%3DMauger%26aufirst%3DS.%26aulast%3DWaldner%26aufirst%3DM.%26aulast%3DBerger%26aufirst%3DA.%26aulast%3DSpeicher%26aufirst%3DM.%26aulast%3DPages%26aufirst%3DF.%26aulast%3DValge-Archer%26aufirst%3DV.%26aulast%3DGalon%26aufirst%3DJ.%26atitle%3DThe%2520Tumor%2520Microenvironment%2520and%2520Immunoscore%2520Are%2520Critical%2520Determinants%2520of%2520Dissemination%2520to%2520Distant%2520Metastasis%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2016%26volume%3D8%26issue%3D327%26spage%3D327ra26%26doi%3D10.1126%2Fscitranslmed.aad6352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heo, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span> <span> </span><span class="NLM_article-title">Expression of Immunoproteasome Subunit LMP7 in Breast Cancer and Its Association with Immune-Related Markers</span>. <i>Cancer Res. Treat. Off. J. Korean Cancer Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">80</span>â <span class="NLM_lpage">89</span>, <span class="refDoi">Â DOI: 10.4143/crt.2017.500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.4143%2Fcrt.2017.500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=29510614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BC1Mrot1yhsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2019&pages=80-89&issue=1&author=M.+Leeauthor=I.+H.+Songauthor=S.-H.+Heoauthor=Y.-A.+Kimauthor=I.+A.+Parkauthor=W.+S.+Bangauthor=H.+S.+Parkauthor=G.+Gongauthor=H.+J.+Lee&title=Expression+of+Immunoproteasome+Subunit+LMP7+in+Breast+Cancer+and+Its+Association+with+Immune-Related+Markers&doi=10.4143%2Fcrt.2017.500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of Immunoproteasome Subunit LMP7 in Breast Cancer and Its Association with Immune-Related Markers</span></div><div class="casAuthors">Lee Miseon; Song In Hye; Heo Sun-Hee; Kim Young-Ae; Park In Ah; Bang Won Seon; Park Hye Seon; Gong Gyungyub; Lee Hee Jin; Heo Sun-Hee; Kim Young-Ae; Bang Won Seon; Park Hye Seon</div><div class="citationInfo"><span class="NLM_cas:title">Cancer research and treatment : official journal of Korean Cancer Association</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80-89</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  In the presence of interferon, proteasome subunits are replaced by their inducible counterparts to form an immunoproteasome (IP) plays a key role in generation of antigenic peptides presented by MHC class I molecules, leading to elicitation of a T cell-mediated immune response.  Although the roles of IP in other cancers, and inflammatory diseases have been extensively studied, its significance in breast cancer is unclear.  Materials and Methods:  We investigated the expression of LMP7, an IP subunit, and its relationship with immune system components in two breast cancer cohorts.  RESULTS:  In 668 consecutive breast cancer cohort, 40% of tumors showed high level of LMP7 expression, and tumors with high expression of LMP7 had more tumor-infiltrating lymphocytes (TILs) in each subtype of breast cancer.  In another cohort of 681 triple-negative breast cancer patients cohort, the expression of LMP7 in tumor cells was significantly correlated with the amount of TILs and the expression of interferon-associated molecules (MxA [p < 0.001] and PKR [p < 0.001]), endoplasmic reticulum stress-associated molecules (PERK [p=0.012], p-eIF2a [p=0.001], and XBP1 [p < 0.001]), and damage-associated molecular patterns (HMGN1 [p < 0.001] and HMGB1 [p < 0.001]).  Patients with higher LMP7 expression had better disease-free survival outcomes than those with no or low expression in the positive lymph node metastasis group (p=0.041).  CONCLUSION:  Close association between the TIL levels and LMP7 expression in breast cancer indicates that better antigen presentation through greater LMP7 expression might be associated with more TILs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_FuCjjUju10h5eUSa2oe_fW6udTcc2ebnsbBwCSATTLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mrot1yhsw%253D%253D&md5=06caad90faf567c04c36a9faab4366c5</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.4143%2Fcrt.2017.500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4143%252Fcrt.2017.500%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%26aulast%3DSong%26aufirst%3DI.%2BH.%26aulast%3DHeo%26aufirst%3DS.-H.%26aulast%3DKim%26aufirst%3DY.-A.%26aulast%3DPark%26aufirst%3DI.%2BA.%26aulast%3DBang%26aufirst%3DW.%2BS.%26aulast%3DPark%26aufirst%3DH.%2BS.%26aulast%3DGong%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26atitle%3DExpression%2520of%2520Immunoproteasome%2520Subunit%2520LMP7%2520in%2520Breast%2520Cancer%2520and%2520Its%2520Association%2520with%2520Immune-Related%2520Markers%26jtitle%3DCancer%2520Res.%2520Treat.%2520Off.%2520J.%2520Korean%2520Cancer%2520Assoc.%26date%3D2019%26volume%3D51%26issue%3D1%26spage%3D80%26epage%3D89%26doi%3D10.4143%2Fcrt.2017.500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koerner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition and Deficiency of the Immunoproteasome Subunit LMP7 Suppress the Development and Progression of Colorectal Carcinoma in Mice</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">31</span>),  <span class="NLM_fpage">50873</span>â <span class="NLM_lpage">50888</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.15141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.18632%2Foncotarget.15141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=28881611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BC1cbls1Onug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=50873-50888&issue=31&author=J.+Koernerauthor=T.+Brunnerauthor=M.+Groettrup&title=Inhibition+and+Deficiency+of+the+Immunoproteasome+Subunit+LMP7+Suppress+the+Development+and+Progression+of+Colorectal+Carcinoma+in+Mice&doi=10.18632%2Foncotarget.15141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition and deficiency of the immunoproteasome subunit LMP7 suppress the development and progression of colorectal carcinoma in mice</span></div><div class="casAuthors">Koerner Julia; Groettrup Marcus; Koerner Julia; Brunner Thomas; Groettrup Marcus; Brunner Thomas; Groettrup Marcus</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">50873-50888</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">New treatment options and drug targets for colorectal carcinoma are a pressing medical need.  Inflammation and pro-inflammatory cytokines produced by Th1 and Th17 cells like IL-6, TNF, IL-17 and IL-23 promote the development and growth of colorectal cancer (CRC).  The immunoproteasome is a proteasome subtype highly expressed in immune cells but also in the intestine.  Since the immunoproteasome promotes Th1 and Th17 differentiation and pro-inflammatory cytokine production, we investigated here whether deficiency or inhibition of the immunoproteasome subunit LMP7 would interfere with CRC development and exacerbation in preventive and therapeutic mouse models.  Treatment with the LMP7 inhibitor ONX 0914 blocked tumor initiation and progression in either chemically-induced (AOM/DSS) or transgenic mouse models (Apc(Min/+)) of colon carcinogenesis.  ONX 0914 treatment strongly reduced tumor numbers and CRC-associated loss of body weight while the survival rates were significantly enhanced.  Moreover, genetic LMP7 deficiency markedly reduced the tumor burden in AOM/DSS induced wild type and Apc(Min/+) mice.  In conclusion, we show that the immunoproteasome is involved in CRC development and progression and we identify LMP7 as a new potential drug target for the treatment of CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR4ra5hF3i41sjl5L8hwNX0fW6udTcc2eZjWtdsHM1WW7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbls1Onug%253D%253D&md5=957c97b288946ec6953a305f0b743e8f</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.15141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.15141%26sid%3Dliteratum%253Aachs%26aulast%3DKoerner%26aufirst%3DJ.%26aulast%3DBrunner%26aufirst%3DT.%26aulast%3DGroettrup%26aufirst%3DM.%26atitle%3DInhibition%2520and%2520Deficiency%2520of%2520the%2520Immunoproteasome%2520Subunit%2520LMP7%2520Suppress%2520the%2520Development%2520and%2520Progression%2520of%2520Colorectal%2520Carcinoma%2520in%2520Mice%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D31%26spage%3D50873%26epage%3D50888%26doi%3D10.18632%2Foncotarget.15141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frisan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitsky, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masucci, M. G.</span></span> <span> </span><span class="NLM_article-title">Variations in Proteasome Subunit Composition and Enzymatic Activity in B-Lymphoma Lines and Normal B Cells</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>88</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">881</span>â <span class="NLM_lpage">888</span>, <span class="refDoi">Â DOI: 10.1002/1097-0215(20001215)88:6<881::AID-IJC7>3.0.CO;2-D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1002%2F1097-0215%2820001215%2988%3A6%3C881%3A%3AAID-IJC7%3E3.0.CO%3B2-D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=11093809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovVGht7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2000&pages=881-888&issue=6&author=T.+Frisanauthor=V.+Levitskyauthor=M.+G.+Masucci&title=Variations+in+Proteasome+Subunit+Composition+and+Enzymatic+Activity+in+B-Lymphoma+Lines+and+Normal+B+Cells&doi=10.1002%2F1097-0215%2820001215%2988%3A6%3C881%3A%3AAID-IJC7%3E3.0.CO%3B2-D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Variations in proteasome subunit composition and enzymatic activity in B-lymphoma lines and normal B cells</span></div><div class="casAuthors">Frisan, Teresa; Levitsky, Victor; Masucci, Maria G.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">881-888</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">We investigated the expression of interferon gamma (IFN-Î³)-regulated subunits and the enzymic activity of proteasomes purified from tumor-derived and normal B lymphocytes representing different stages of B-cell activation/differentiation.  The catalytic Î² subunits (Lmp2 and Lmp7) and the regulatory subunits (PA28Î± and PA28Î²) were expressed at equally high levels in Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCLs), freshly isolated B-chronic lymphocytic leukemia (B-CLL) cells and normal CD23- B lymphocytes.  Lmp2 and Lmp7 were selectively down-regulated in germinal center cell-derived Burkitt's lymphoma (BL) and Hodgkin's lymphoma (HD) cell lines.  There was a direct correlation between the expression of Lmp2/7 and the chymotrypsin and trypsin-like activities in proteasomes purified from LCLs, BLs and CLL cells, whereas 5 HD cell lines expressing B or T-cell markers exhibited a variable pattern of subunit expression and enzymic activity.  Poor hydrolysis of the fluorogenic substrates by proteasomes from BL cells correlated with a distinct pattern of cleavage of a ref. 50mer peptide, prodn. of different sets of degrdn. products and significantly reduced recovery of a known cytotoxic T-lymphocyte (CTL) target epitope.  The enzymic activity of proteasomes from normal CD23- "resting" B lymphocytes resembled that of BL cells in spite of high Lmp2/7 expression.  This pattern was not reversed by treatment with the B-cell mitogen, lipopolysaccharide (LPS).  The results suggest that different stages of B-cell activation/differentiation are assocd. with distinct profiles of IFN-Î³-regulated subunit compn. and enzymic activity of the proteasome.  This may have important implications for the anal. and manipulation of tumor-specific immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGwFbnkq8wvLVg90H21EOLACvtfcHk0lhFuNDjXiaAOQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovVGht7Y%253D&md5=47dc9992bd69e33e2da06bc8af2cd31c</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1002%2F1097-0215%2820001215%2988%3A6%3C881%3A%3AAID-IJC7%3E3.0.CO%3B2-D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1097-0215%252820001215%252988%253A6%253C881%253A%253AAID-IJC7%253E3.0.CO%253B2-D%26sid%3Dliteratum%253Aachs%26aulast%3DFrisan%26aufirst%3DT.%26aulast%3DLevitsky%26aufirst%3DV.%26aulast%3DMasucci%26aufirst%3DM.%2BG.%26atitle%3DVariations%2520in%2520Proteasome%2520Subunit%2520Composition%2520and%2520Enzymatic%2520Activity%2520in%2520B-Lymphoma%2520Lines%2520and%2520Normal%2520B%2520Cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2000%26volume%3D88%26issue%3D6%26spage%3D881%26epage%3D888%26doi%3D10.1002%2F1097-0215%2820001215%2988%3A6%3C881%3A%3AAID-IJC7%3E3.0.CO%3B2-D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ebstein, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kloetzel, P.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KrÃ¼ger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, U.</span></span> <span> </span><span class="NLM_article-title">Emerging Roles of Immunoproteasomes beyond MHC Class I Antigen Processing</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">2543</span>â <span class="NLM_lpage">2558</span>, <span class="refDoi">Â DOI: 10.1007/s00018-012-0938-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1007%2Fs00018-012-0938-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=22382925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVansbbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=2543-2558&issue=15&author=F.+Ebsteinauthor=P.-M.+Kloetzelauthor=E.+Kr%C3%BCgerauthor=U.+Seifert&title=Emerging+Roles+of+Immunoproteasomes+beyond+MHC+Class+I+Antigen+Processing&doi=10.1007%2Fs00018-012-0938-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging roles of immunoproteasomes beyond MHC class I antigen processing</span></div><div class="casAuthors">Ebstein, Frederic; Kloetzel, Peter-Michael; Krueger, Elke; Seifert, Ulrike</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2543-2558</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">A review.  The proteasome is a multi-catalytic protein complex whose primary function is the degrdn. of abnormal or foreign proteins.  Upon exposure of cells to interferons (IFNs), the Î²1i/LMP2, Î²2i/MECL-1, and Î²5i/LMP7 subunits are induced and incorporated into newly synthesized immunoproteasomes (IP), which are thought to function solely as crit. players in the optimization of the CD8+ T-cell response.  However, the observation that IP are present in several non-immune tissues under normal conditions and/or following pathol. events militates against the view that its role is limited to MHC class I presentation.  In support of this concept, the recent use of genetic models deficient for Î²1i/LMP2, Î²2i/MECL-1, or Î²5i/LMP7 has uncovered unanticipated functions for IP in innate immunity and non-immune processes.  Herein, we review recent data in an attempt to clarify the role of IP beyond MHC class I epitope presentation with emphasis on its involvement in the regulation of protein homeostasis, cell proliferation, and cytokine gene expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNZw6RsOpMoLVg90H21EOLACvtfcHk0lhFuNDjXiaAOQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVansbbJ&md5=6f1603c2657b5fea21a5e7e3ad19cdf5</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1007%2Fs00018-012-0938-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-012-0938-0%26sid%3Dliteratum%253Aachs%26aulast%3DEbstein%26aufirst%3DF.%26aulast%3DKloetzel%26aufirst%3DP.-M.%26aulast%3DKr%25C3%25BCger%26aufirst%3DE.%26aulast%3DSeifert%26aufirst%3DU.%26atitle%3DEmerging%2520Roles%2520of%2520Immunoproteasomes%2520beyond%2520MHC%2520Class%2520I%2520Antigen%2520Processing%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2012%26volume%3D69%26issue%3D15%26spage%3D2543%26epage%3D2558%26doi%3D10.1007%2Fs00018-012-0938-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barton, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rangwala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deepe, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monaco, J. J.</span></span> <span> </span><span class="NLM_article-title">Regulation of Immunoproteasome Subunit Expression In Vivo Following Pathogenic Fungal Infection</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>169</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">3046</span>â <span class="NLM_lpage">3052</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.169.6.3046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.4049%2Fjimmunol.169.6.3046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=12218120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD38XntFahtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2002&pages=3046-3052&issue=6&author=L.+F.+Bartonauthor=M.+Cruzauthor=R.+Rangwalaauthor=G.+S.+Deepeauthor=J.+J.+Monaco&title=Regulation+of+Immunoproteasome+Subunit+Expression+In+Vivo+Following+Pathogenic+Fungal+Infection&doi=10.4049%2Fjimmunol.169.6.3046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of immunoproteasome subunit expression in vivo following pathogenic fungal infection</span></div><div class="casAuthors">Barton, Lance F.; Cruz, Miguel; Rangwala, Reshma; Deepe, George S., Jr.; Monaco, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3046-3052</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The proteasome catalytic Î² subunits LMP2, LMP7, and MECL-1 and two proteasome activator proteins, PA28 Î± and Î², are induced following exposure to IFN-Î³ in vitro.  Induction of these immunosubunits and the PA28 Î±/Î² hetero-oligomer alters proteasome catalytic functions and specificity and enhances prodn. of certain MHC class I epitopes.  We sought to det. whether and to what extent proteasome subunit compn. is regulated in vivo and to elucidate the mechanisms of such regulation.  We analyzed basal expression levels of these inducible genes in normal, IFN-Î³-deficient, and Stat-1-deficient mice.  Mice of all three genotypes display constitutive expression of the immunosubunits and PA28, demonstrating that basal expression in vivo is independent of endogenous IFN-Î³ prodn.  However, basal expression levels are reduced in Stat-1-/- mice, demonstrating a role for Stat-1 independent of IFN-Î³ signaling.  To demonstrate that IFN-Î³ can induce these genes in vivo, mice were infected with Histoplasma capsulatum.  Elevated expression of these genes followed the same time course as IFN-Î³ expression in infected mice.  IFN-Î³-deficient mice did not display elevated protein expression following infection, suggesting that other inflammatory cytokines produced in infected mice are unable to influence proteasome expression.  Cytokines other than IFN-Î³ also failed to influence proteasome gene expression in vitro in cell lines that had no basal expression of LMP2, LMP7, or MECL-1.  Thus, both in vitro and in vivo data demonstrate that IFN-Î³ is essential for up-regulation, but not constitutive expression, of immunoproteasome subunits in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEbd92vE7SFLVg90H21EOLACvtfcHk0lgK_Tz79IGzXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntFahtbg%253D&md5=b8fbef6b077d36d233fac5b382c19328</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.169.6.3046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.169.6.3046%26sid%3Dliteratum%253Aachs%26aulast%3DBarton%26aufirst%3DL.%2BF.%26aulast%3DCruz%26aufirst%3DM.%26aulast%3DRangwala%26aufirst%3DR.%26aulast%3DDeepe%26aufirst%3DG.%2BS.%26aulast%3DMonaco%26aufirst%3DJ.%2BJ.%26atitle%3DRegulation%2520of%2520Immunoproteasome%2520Subunit%2520Expression%2520In%2520Vivo%2520Following%2520Pathogenic%2520Fungal%2520Infection%26jtitle%3DJ.%2520Immunol.%26date%3D2002%26volume%3D169%26issue%3D6%26spage%3D3046%26epage%3D3052%26doi%3D10.4049%2Fjimmunol.169.6.3046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seliger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeurer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrone, S.</span></span> <span> </span><span class="NLM_article-title">Antigen-Processing Machinery Breakdown and Tumor Growth</span>. <i>Immunol. Today</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">455</span>â <span class="NLM_lpage">464</span>, <span class="refDoi">Â DOI: 10.1016/S0167-5699(00)01692-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2FS0167-5699%2800%2901692-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10953098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtVCmsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2000&pages=455-464&issue=9&author=B.+Seligerauthor=M.+J.+Maeurerauthor=S.+Ferrone&title=Antigen-Processing+Machinery+Breakdown+and+Tumor+Growth&doi=10.1016%2FS0167-5699%2800%2901692-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Antigen-processing machinery breakdown and tumor growth</span></div><div class="casAuthors">Seliger, B.; Maeurer, M. J.; Ferrone, S.</div><div class="citationInfo"><span class="NLM_cas:title">Immunology Today</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">455-464</span>CODEN:
                <span class="NLM_cas:coden">IMTOD8</span>;
        ISSN:<span class="NLM_cas:issn">0167-4919</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 96 refs.  Defects in the major histocompatibility complex (MHC) class I antigen-processing machinery (APM) have been described in tumors of different histol.  Murine data suggest that defects in the MHC class II APM might also be assocd. with malignant transformation of human cells.  This article describes the pathophysiol. of the MHC class I and II APM, reviews APM abnormalities in tumor cells and discusses their role in the escape of tumor cells from in vitro recognition by T cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0G2-lKQUf2bVg90H21EOLACvtfcHk0lgK_Tz79IGzXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtVCmsr0%253D&md5=37a986d69d3b6d49850c56d6429d1b40</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2FS0167-5699%2800%2901692-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0167-5699%252800%252901692-3%26sid%3Dliteratum%253Aachs%26aulast%3DSeliger%26aufirst%3DB.%26aulast%3DMaeurer%26aufirst%3DM.%2BJ.%26aulast%3DFerrone%26aufirst%3DS.%26atitle%3DAntigen-Processing%2520Machinery%2520Breakdown%2520and%2520Tumor%2520Growth%26jtitle%3DImmunol.%2520Today%26date%3D2000%26volume%3D21%26issue%3D9%26spage%3D455%26epage%3D464%26doi%3D10.1016%2FS0167-5699%2800%2901692-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cenci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezghrani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerruti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelouard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masciarelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattioli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasqualetto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruffato, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagliavacca, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitia, R.</span></span> <span> </span><span class="NLM_article-title">Progressively Impaired Proteasomal Capacity during Terminal Plasma Cell Differentiation</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1104</span>â <span class="NLM_lpage">1113</span>, <span class="refDoi">Â DOI: 10.1038/sj.emboj.7601009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fsj.emboj.7601009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=16498407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD28XitVyisrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=1104-1113&issue=5&author=S.+Cenciauthor=A.+Mezghraniauthor=P.+Cascioauthor=G.+Bianchiauthor=F.+Cerrutiauthor=A.+Fraauthor=H.+Lelouardauthor=S.+Masciarelliauthor=L.+Mattioliauthor=L.+Olivaauthor=A.+Orsiauthor=E.+Pasqualettoauthor=P.+Pierreauthor=E.+Ruffatoauthor=L.+Tagliavaccaauthor=R.+Sitia&title=Progressively+Impaired+Proteasomal+Capacity+during+Terminal+Plasma+Cell+Differentiation&doi=10.1038%2Fsj.emboj.7601009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Progressively impaired proteasomal capacity during terminal plasma cell differentiation</span></div><div class="casAuthors">Cenci, Simone; Mezghrani, Alexandre; Cascio, Paolo; Bianchi, Giada; Cerruti, Fulvia; Fra, Anna; Lelouard, Hugues; Masciarelli, Silvia; Mattioli, Laura; Oliva, Laura; Orsi, Andrea; Pasqualetto, Elena; Pierre, Philippe; Ruffato, Elena; Tagliavacca, Luigina; Sitia, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1104-1113</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">After few days of intense Ig secretion, most plasma cells undergo apoptosis, thus ending the humoral immune response.  The authors asked whether intrinsic factors link plasma cell lifespan to Ig secretion.  Here the authors show that in the late phases of plasmacytic differentiation, when antibody prodn. becomes maximal, proteasomal activity decreases.  The excessive load for the reduced proteolytic capacity correlates with accumulation of polyubiquitinated proteins, stabilization of endogenous proteasomal substrates (including Xbp1s, IÎºBÎ±, and Bax), onset of apoptosis, and sensitization to proteasome inhibitors (PI).  These events can be reproduced by expressing Ig-Î¼ chain in nonlymphoid cells.  The authors' results suggest that a developmental program links plasma cell death to protein prodn., and help explaining the peculiar sensitivity of normal and malignant plasma cells to PI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriiTN9EGlsB7Vg90H21EOLACvtfcHk0lgK_Tz79IGzXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitVyisrc%253D&md5=73c65465fd831fb4560d67e9740c6b21</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7601009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7601009%26sid%3Dliteratum%253Aachs%26aulast%3DCenci%26aufirst%3DS.%26aulast%3DMezghrani%26aufirst%3DA.%26aulast%3DCascio%26aufirst%3DP.%26aulast%3DBianchi%26aufirst%3DG.%26aulast%3DCerruti%26aufirst%3DF.%26aulast%3DFra%26aufirst%3DA.%26aulast%3DLelouard%26aufirst%3DH.%26aulast%3DMasciarelli%26aufirst%3DS.%26aulast%3DMattioli%26aufirst%3DL.%26aulast%3DOliva%26aufirst%3DL.%26aulast%3DOrsi%26aufirst%3DA.%26aulast%3DPasqualetto%26aufirst%3DE.%26aulast%3DPierre%26aufirst%3DP.%26aulast%3DRuffato%26aufirst%3DE.%26aulast%3DTagliavacca%26aufirst%3DL.%26aulast%3DSitia%26aufirst%3DR.%26atitle%3DProgressively%2520Impaired%2520Proteasomal%2520Capacity%2520during%2520Terminal%2520Plasma%2520Cell%2520Differentiation%26jtitle%3DEMBO%2520J.%26date%3D2006%26volume%3D25%26issue%3D5%26spage%3D1104%26epage%3D1113%26doi%3D10.1038%2Fsj.emboj.7601009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakkis, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, G.</span></span> <span> </span><span class="NLM_article-title">B Cells, Antibodies, and More</span>. <i>Clin. J. Am. Soc. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">137</span>â <span class="NLM_lpage">154</span>, <span class="refDoi">Â DOI: 10.2215/CJN.09430915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.2215%2FCJN.09430915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=26700440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC28XntFWjsLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=137-154&issue=1&author=W.+Hoffmanauthor=F.+G.+Lakkisauthor=G.+Chalasani&title=B+Cells%2C+Antibodies%2C+and+More&doi=10.2215%2FCJN.09430915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">B Cells, antibodies, and more</span></div><div class="casAuthors">Hoffman, William; Lakkis, Fadi G.; Chalasani, Geetha</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">137-154</span>CODEN:
                <span class="NLM_cas:coden">CJASC7</span>;
        ISSN:<span class="NLM_cas:issn">1555-9041</span>.
    
            (<span class="NLM_cas:orgname">American Society of Nephrology</span>)
        </div><div class="casAbstract">B cells play a central role in the immunopathogenesis of glomerulonephritides and transplant rejection.  B cells secrete antibodies that contribute to tissue injury via multiple mechanisms.  In addn., B cells contribute to disease pathogenesis in autoimmunity and alloimmunity by presenting antigens as well as providing costimulation and cytokines to T cells.  B cells also play an immunomodulatory role in regulating the immune response by secreting cytokines that inhibit disease onset and/or progression.  B cell-targeted approaches for treating immune diseases of the kidney and other organs have gained significant momentum.  However, much remains to be understood about B-cell biol. in order to det. the timing, duration, and context of optimal therapeutic response to B cell-targeted approaches.  In this review, we discuss the multifaceted roles of B cells as enhancers and regulators of immunity with relevance to kidney disease and transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0W5E5D9x6FbVg90H21EOLACvtfcHk0ljYJig0_j3IDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntFWjsLg%253D&md5=71b5c946dea4849cd1386104add29d58</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.2215%2FCJN.09430915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2215%252FCJN.09430915%26sid%3Dliteratum%253Aachs%26aulast%3DHoffman%26aufirst%3DW.%26aulast%3DLakkis%26aufirst%3DF.%2BG.%26aulast%3DChalasani%26aufirst%3DG.%26atitle%3DB%2520Cells%252C%2520Antibodies%252C%2520and%2520More%26jtitle%3DClin.%2520J.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2016%26volume%3D11%26issue%3D1%26spage%3D137%26epage%3D154%26doi%3D10.2215%2FCJN.09430915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pengo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerruti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasqualetto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezghrani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calbi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palladini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cenci, S.</span></span> <span> </span><span class="NLM_article-title">The Proteasome Load versus Capacity Balance Determines Apoptotic Sensitivity of Multiple Myeloma Cells to Proteasome Inhibition</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3040</span>â <span class="NLM_lpage">3049</span>, <span class="refDoi">Â DOI: 10.1182/blood-2008-08-172734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1182%2Fblood-2008-08-172734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=19164601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFWntrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=3040-3049&issue=13&author=G.+Bianchiauthor=L.+Olivaauthor=P.+Cascioauthor=N.+Pengoauthor=F.+Fontanaauthor=F.+Cerrutiauthor=A.+Orsiauthor=E.+Pasqualettoauthor=A.+Mezghraniauthor=V.+Calbiauthor=G.+Palladiniauthor=N.+Giulianiauthor=K.+Andersonauthor=R.+Sitiaauthor=S.+Cenci&title=The+Proteasome+Load+versus+Capacity+Balance+Determines+Apoptotic+Sensitivity+of+Multiple+Myeloma+Cells+to+Proteasome+Inhibition&doi=10.1182%2Fblood-2008-08-172734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition</span></div><div class="casAuthors">Bianchi, Giada; Oliva, Laura; Cascio, Paolo; Pengo, Niccolo; Fontana, Francesca; Cerruti, Fulvia; Orsi, Andrea; Pasqualetto, Elena; Mezghrani, Alexandre; Calbi, Valeria; Palladini, Giovanni; Giuliani, Nicola; Anderson, Kenneth C.; Sitia, Roberto; Cenci, Simone</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3040-3049</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Proteasome inhibitors (PIs) are effective against multiple myeloma (MM), but the mechanisms of action and bases of individual susceptibility remain unclear.  Recent work linked PI sensitivity to protein synthesis and proteasome activity, raising the question whether different levels of proteasome expression and workload underlie PI sensitivity in MM cells (MMCs).  Exploiting human MM lines characterized by differential PI sensitivity, we report that highly sensitive MMCs express lower proteasome levels and higher proteasomal workload than relatively PI-resistant MMCs, resulting in the accumulation of polyubiquitinated proteins at the expense of free ubiquitin (proteasome stress).  Manipulating proteasome expression or workload alters apoptotic sensitivity to PI, demonstrating a cause-effect relationship between proteasome stress and apoptotic responses in MMCs.  Intracellular immunostaining in primary, patient-derived MMCs reveals that polyubiquitinated proteins hallmark neoplastic plasma cells, in pos. correlation with Ig content, both intra- and interpatient.  Moreover, overall proteasome activity of primary MMCs inversely correlates with apoptotic sensitivity to PI.  Altogether, our data indicate that the balance between proteasome workload and degradative capacity represents a crit. determinant of apoptotic sensitivity of MMCs to PI, potentially providing a framework for identifying indicators of responsiveness and designing novel combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojZB8ZrWDyLbVg90H21EOLACvtfcHk0ljYJig0_j3IDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFWntrs%253D&md5=dd9f98f07f06ba2d312a54228d96ceef</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-08-172734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-08-172734%26sid%3Dliteratum%253Aachs%26aulast%3DBianchi%26aufirst%3DG.%26aulast%3DOliva%26aufirst%3DL.%26aulast%3DCascio%26aufirst%3DP.%26aulast%3DPengo%26aufirst%3DN.%26aulast%3DFontana%26aufirst%3DF.%26aulast%3DCerruti%26aufirst%3DF.%26aulast%3DOrsi%26aufirst%3DA.%26aulast%3DPasqualetto%26aufirst%3DE.%26aulast%3DMezghrani%26aufirst%3DA.%26aulast%3DCalbi%26aufirst%3DV.%26aulast%3DPalladini%26aufirst%3DG.%26aulast%3DGiuliani%26aufirst%3DN.%26aulast%3DAnderson%26aufirst%3DK.%26aulast%3DSitia%26aufirst%3DR.%26aulast%3DCenci%26aufirst%3DS.%26atitle%3DThe%2520Proteasome%2520Load%2520versus%2520Capacity%2520Balance%2520Determines%2520Apoptotic%2520Sensitivity%2520of%2520Multiple%2520Myeloma%2520Cells%2520to%2520Proteasome%2520Inhibition%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26issue%3D13%26spage%3D3040%26epage%3D3049%26doi%3D10.1182%2Fblood-2008-08-172734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frezza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanwar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, Q. P.</span></span> <span> </span><span class="NLM_article-title">Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">239</span>â <span class="NLM_lpage">253</span>, <span class="refDoi">Â DOI: 10.2174/156800911794519752</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.2174%2F156800911794519752" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=21247388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjt1agtbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=239-253&issue=3&author=D.+Chenauthor=M.+Frezzaauthor=S.+Schmittauthor=J.+Kanwarauthor=Q.+P.+Dou&title=Bortezomib+as+the+First+Proteasome+Inhibitor+Anticancer+Drug%3A+Current+Status+and+Future+Perspectives&doi=10.2174%2F156800911794519752"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives</span></div><div class="casAuthors">Chen, D.; Frezza, M.; Schmitt, S.; Kanwar, J.; Dou, Q. P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-253</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Targeting the ubiquitin-proteasome pathway has emerged as a rational approach in the treatment of human cancer.  Based on pos. preclin. and clin. studies, bortezomib was subsequently approved for the clin. use as a front-line treatment for newly diagnosed multiple myeloma patients and for the treatment of relapsed/refractory multiple myeloma and mantle cell lymphoma, for which this drug has become the staple of treatment.  The approval of bortezomib by the US Food and Drug Administration (FDA) represented a significant milestone as the first proteasome inhibitor to be implemented in the treatment of malignant disease.  Bortezomib has shown a pos. clin. benefit either alone or as a part of combination therapy to induce chemo-/radio-sensitization or overcome drug resistance.  One of the major mechanisms of bortezomib assocd. with its anticancer activity is through upregulation of NOXA, which is a proapoptotic protein, and NOXA may interact with the anti-apoptotic proteins of Bcl-2 subfamily Bcl-XL and Bcl-2, and result in apoptotic cell death in malignant cells.  Another important mechanism of bortezomib is through suppression of the NF-ÎºB signaling pathway resulting in the down-regulation of its anti-apoptotic target genes.  Although the majority of success achieved with bortezomib has been in hematol. malignancies, its effect toward solid tumors has been less than encouraging.  Addnl., the widespread clin. use of bortezomib continues to be hampered by the appearance of dose-limiting toxicities, drug-resistance and interference by some natural compds.  These findings could help guide physicians in refining the clin. use of bortezomib, and encourage basic scientists to generate next generation proteasome inhibitors that broaden the spectrum of efficacy and produce a more durable clin. response in cancer patients.  Other desirable applications for the use of proteasome inhibitors include the development of inhibitors against specific E3 ligases, which act at an early step in the ubiquitin-proteasome pathway, and the discovery of less toxic and novel proteasome inhibitors from natural products and traditional medicines, which may provide more viable drug candidates for cancer chemoprevention and the treatment of cancer patients in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP4QCk3nP8BLVg90H21EOLACvtfcHk0ljYJig0_j3IDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjt1agtbs%253D&md5=15becbceb98ec3e244fc066315815dd2</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.2174%2F156800911794519752&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156800911794519752%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DD.%26aulast%3DFrezza%26aufirst%3DM.%26aulast%3DSchmitt%26aufirst%3DS.%26aulast%3DKanwar%26aufirst%3DJ.%26aulast%3DDou%26aufirst%3DQ.%2BP.%26atitle%3DBortezomib%2520as%2520the%2520First%2520Proteasome%2520Inhibitor%2520Anticancer%2520Drug%253A%2520Current%2520Status%2520and%2520Future%2520Perspectives%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2011%26volume%3D11%26issue%3D3%26spage%3D239%26epage%3D253%26doi%3D10.2174%2F156800911794519752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kane, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bross, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">VelcadeÂ®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">508</span>â <span class="NLM_lpage">513</span>, <span class="refDoi">Â DOI: 10.1634/theoncologist.8-6-508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1634%2Ftheoncologist.8-6-508" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=14657528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BD3srnslGhtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=508-513&issue=6&author=R.+C.+Kaneauthor=P.+F.+Brossauthor=A.+T.+Farrellauthor=R.+Pazdur&title=Velcade%C2%AE%3A+U.S.+FDA+Approval+for+the+Treatment+of+Multiple+Myeloma+Progressing+on+Prior+Therapy&doi=10.1634%2Ftheoncologist.8-6-508"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy</span></div><div class="casAuthors">Kane Robert C; Bross Peter F; Farrell Ann T; Pazdur Richard</div><div class="citationInfo"><span class="NLM_cas:title">The oncologist</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">508-13</span>
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    </div><div class="casAbstract">Bortezomib (formerly PS-341), a promising new drug for the treatment of multiple myeloma, recently received accelerated approval from the U.S.  Food and Drug Administration (FDA) for the therapy of patients with progressive myeloma after previous treatment.  Two phase II studies of bortezomib used the same schedule of twice-weekly i.v. dosing for the first 2 weeks of each 3-week cycle.  In a randomized study of 54 patients, two doses were compared (1.0 and 1.3 mg/m2) and objective responses occurred at both dose levels (23% versus 35%), including one complete response in each arm.  In the other phase II study, 202 heavily pretreated patients (median of six prior therapies) all received the same schedule at 1.3 mg/m2.  Of 188 evaluable patients, complete responses occurred in five (3%) and partial responses occurred in 47 (25%).  The median duration of response was 365 days.  The most clinically relevant adverse events were asthenic conditions, nausea, vomiting, diarrhea, thrombocytopenia, and a peripheral neuropathy that often was painful.  This report highlights the FDA analysis supporting the accelerated approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTS_wiRSzN1ZNy3lHz94U-GfW6udTcc2ebXqoQ_qdJ5zbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3srnslGhtQ%253D%253D&md5=e5420a8677aa046abed3f232889d194c</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.8-6-508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.8-6-508%26sid%3Dliteratum%253Aachs%26aulast%3DKane%26aufirst%3DR.%2BC.%26aulast%3DBross%26aufirst%3DP.%2BF.%26aulast%3DFarrell%26aufirst%3DA.%2BT.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DVelcade%25C2%25AE%253A%2520U.S.%2520FDA%2520Approval%2520for%2520the%2520Treatment%2520of%2520Multiple%2520Myeloma%2520Progressing%2520on%2520Prior%2520Therapy%26jtitle%3DOncologist%26date%3D2003%26volume%3D8%26issue%3D6%26spage%3D508%26epage%3D513%26doi%3D10.1634%2Ftheoncologist.8-6-508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manyak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altamirano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borad, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frantzen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neeser, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjak-Shie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vescio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berenson, J.</span></span> <span> </span><span class="NLM_article-title">The Proteasome Inhibitor PS-341 Markedly Enhances Sensitivity of Multiple Myeloma Tumor Cells to Chemotherapeutic Agents</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1136</span>â <span class="NLM_lpage">1144</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=12631619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvFKitbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=1136-1144&issue=3&author=M.+H.+Maauthor=H.+H.+Yangauthor=K.+Parkerauthor=S.+Manyakauthor=J.+M.+Friedmanauthor=C.+Altamiranoauthor=Z.+Wuauthor=M.+J.+Boradauthor=M.+Frantzenauthor=E.+Roussosauthor=J.+Neeserauthor=A.+Mikaliauthor=J.+Adamsauthor=N.+Sjak-Shieauthor=R.+Vescioauthor=J.+Berenson&title=The+Proteasome+Inhibitor+PS-341+Markedly+Enhances+Sensitivity+of+Multiple+Myeloma+Tumor+Cells+to+Chemotherapeutic+Agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">The Proteasome Inhibitor PS-341 Markedly Enhances Sensitivity of Multiple Myeloma Tumor Cells to Chemotherapeutic Agents</span></div><div class="casAuthors">Ma, Mark H.; Yang, Hank H.; Parker, Kimberly; Manyak, Steven; Friedman, Jeffrey M.; Altamirano, Cibby; Wu, Zhi-qun; Borad, Mitesh J.; Frantzen, Malka; Roussos, Evanthia; Neeser, Jason; Mikail, Amy; Adams, Julian; Sjak-Shie, Nelida; Vescio, Robert A.; Berenson, James R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1136-1144</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Increased nuclear factor ÎºB (NF-ÎºB) activity is assocd. with increased tumor cell survival in multiple myeloma.  The function of NF-ÎºB is inhibited through binding to its inhibitor, IÎºB.  Release of activated NF-B follows proteasome-mediated degrdn. of IB resulting from phosphorylation of the inhibitor and, finally, conjugation with ubiquitin.  We report that myeloma cells have enhanced IÎºBÎ± phosphorylation and increased NF-ÎºB activity compared with normal hematopoietic cells.  The proteasome inhibitor PS-341 blocked nuclear translocation of NF-ÎºB, blocked NF-ÎºB DNA binding, and demonstrated consistent antitumor activity against chemoresistant and chemosensitive myeloma cells.  The sensitivity of chemoresistant myeloma cells to chemotherapeutic agents was markedly increased (100,000-1,000,000-fold) when combined with a noncytotoxic dose of PS-341 without affecting normal hematopoietic cells.  Similar effects were obsd. using a dominant neg. super-repressor for IÎºBÎ±.  Thus, these results suggest that inhibition of NF-ÎºB with PS-341 may overcome chemoresistance and allow doses of chemotherapeutic agents to be markedly reduced with antitumor effects without significant toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIyqYjYivBfrVg90H21EOLACvtfcHk0li9rw4WcQLI7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvFKitbo%253D&md5=4c8ec85cedfe85c29a297d687091b5cf</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DM.%2BH.%26aulast%3DYang%26aufirst%3DH.%2BH.%26aulast%3DParker%26aufirst%3DK.%26aulast%3DManyak%26aufirst%3DS.%26aulast%3DFriedman%26aufirst%3DJ.%2BM.%26aulast%3DAltamirano%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DBorad%26aufirst%3DM.%2BJ.%26aulast%3DFrantzen%26aufirst%3DM.%26aulast%3DRoussos%26aufirst%3DE.%26aulast%3DNeeser%26aufirst%3DJ.%26aulast%3DMikali%26aufirst%3DA.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DSjak-Shie%26aufirst%3DN.%26aulast%3DVescio%26aufirst%3DR.%26aulast%3DBerenson%26aufirst%3DJ.%26atitle%3DThe%2520Proteasome%2520Inhibitor%2520PS-341%2520Markedly%2520Enhances%2520Sensitivity%2520of%2520Multiple%2520Myeloma%2520Tumor%2520Cells%2520to%2520Chemotherapeutic%2520Agents%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2003%26volume%3D9%26issue%3D3%26spage%3D1136%26epage%3D1144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">An, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagosklonny, M. V.</span></span> <span> </span><span class="NLM_article-title">Protease Inhibitor-Induced Apoptosis: Accumulation of Wt P53, P21WAF1/CIP1, and Induction of Apoptosis Are Independent Markers of Proteasome Inhibition</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1276</span>â <span class="NLM_lpage">1283</span>, <span class="refDoi">Â DOI: 10.1038/sj.leu.2401812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fsj.leu.2401812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10914553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD3cXls1Oitbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2000&pages=1276-1283&issue=7&author=W.+G.+Anauthor=S.+G.+Hwangauthor=J.+B.+Trepelauthor=M.+V.+Blagosklonny&title=Protease+Inhibitor-Induced+Apoptosis%3A+Accumulation+of+Wt+P53%2C+P21WAF1%2FCIP1%2C+and+Induction+of+Apoptosis+Are+Independent+Markers+of+Proteasome+Inhibition&doi=10.1038%2Fsj.leu.2401812"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Protease inhibitor-induced apoptosis: Accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition</span></div><div class="casAuthors">An, W. G.; Hwang, S. -G.; Trepel, J. B.; Blagosklonny, M. V.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1276-1283</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibitors of proteases are currently emerging as a potential anti-cancer modality.  Nonselective protease inhibitors are cytotoxic to leukemia and cancer cell lines and we found that this cytotoxicity is correlated with their potency as inhibitors of the proteasome but not as inhibitors of calpain and cathepsin.  Highly selective inhibitors of the proteasome were more cytotoxic and fast-acting than less selective inhibitors (PS341Â»ALLNÂ»ALLM).  Induction of wt p53 correlated with inhibition of the proteasome and antiproliferative effect in MCF-7, a breast cancer cell line, which was resistant to apoptosis caused by proteasome inhibitors.  In contrast, inhibitors of the proteasome induced apoptosis in four leukemia cell lines lacking wt p53.  The order of sensitivity of leukemia cells was: Jurkat>HL60âªU937Â»K562.  The highly selective proteasome inhibitor PS-341 induced cell death with an IC50 as low as 5 nM in apoptosis-prone leukemia cells.  Cell death was preceded by p21WAF1/CIP1 accumulation, an alternative marker of proteasome inhibition, and by cleavage of PARP and Rb proteins and nuclear fragmentation.  Inhibition of caspases abrogated PARP cleavage and nuclear fragmentation and delayed, but did not completely prevent cell death caused by PS-341.  Re-introduction of wt p53 into p53-null PC3 prostate carcinoma cells did not increase their sensitivity to proteasome inhibitors.  Likewise, comparison of parental and p21-deficient cells demonstrated that p21WAF1/CIP1 was dispensable for proteasome inhibitor-induced cytotoxicity.  We conclude that accumulation of wt p53 and induction of apoptosis are independent markers of proteasome inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1tvPyuwzZzLVg90H21EOLACvtfcHk0li9rw4WcQLI7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXls1Oitbg%253D&md5=be2c8a1811cef52258092b592d405ac8</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2401812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2401812%26sid%3Dliteratum%253Aachs%26aulast%3DAn%26aufirst%3DW.%2BG.%26aulast%3DHwang%26aufirst%3DS.%2BG.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26aulast%3DBlagosklonny%26aufirst%3DM.%2BV.%26atitle%3DProtease%2520Inhibitor-Induced%2520Apoptosis%253A%2520Accumulation%2520of%2520Wt%2520P53%252C%2520P21WAF1%252FCIP1%252C%2520and%2520Induction%2520of%2520Apoptosis%2520Are%2520Independent%2520Markers%2520of%2520Proteasome%2520Inhibition%26jtitle%3DLeukemia%26date%3D2000%26volume%3D14%26issue%3D7%26spage%3D1276%26epage%3D1283%26doi%3D10.1038%2Fsj.leu.2401812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonneveld, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irwin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmauer, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harousseau, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Yehuda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldschmidt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reece, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San-Miguel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blade, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boccadoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavenagh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boral, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esseltine, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenkein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span> <span> </span><span class="NLM_article-title">Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">2487</span>â <span class="NLM_lpage">2498</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa043445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1056%2FNEJMoa043445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=15958804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlaksLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=2487-2498&issue=24&author=P.+G.+Richardsonauthor=P.+Sonneveldauthor=M.+W.+Schusterauthor=D.+Irwinauthor=E.+A.+Stadtmauerauthor=T.+Faconauthor=J.-L.+Harousseauauthor=D.+Ben-Yehudaauthor=S.+Lonialauthor=H.+Goldschmidtauthor=D.+Reeceauthor=J.+San-Miguelauthor=J.+Bladeauthor=M.+Boccadoroauthor=J.+Cavenaghauthor=W.+Daltonauthor=A.+Boralauthor=D.+Esseltineauthor=J.+Porterauthor=D.+Schenkeinauthor=K.+Anderson&title=Bortezomib+or+High-Dose+Dexamethasone+for+Relapsed+Multiple+Myeloma&doi=10.1056%2FNEJMoa043445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Bortezomib or high-dose dexamethasone for relapsed multiple myeloma</span></div><div class="casAuthors">Richardson, Paul G.; Sonneveld, Pieter; Schuster, Michael W.; Irwin, David; Stadtmauer, Edward A.; Facon, Thierry; Harousseau, Jean-Luc; Ben-Yehuda, Dina; Lonial, Sagar; Goldschmidt, Hartmut; Reece, Donna; San-Miguel, Jesus F.; Blade, Joan; Boccadoro, Mario; Cavenaugh, Jamie; Dalton, William S.; Boral, Anthony L.; Esseltine, Dixie L.; Porter, Jane B.; Schenkein, David; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2487-2498</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">This study compared bortezomib with high-dose dexamethasone in patients with re- lapsed multiple myeloma who had received one to three previous therapies.  We randomly assigned 669 patients with relapsed myeloma to receive either an i.v. bolus of bortezomib (1.3 mg per square meter of body-surface area) on days 1, 4, 8, and 11 for eight three-week cycles, followed by treatment on days 1, 8, 15, and 22 for three five-week cycles, or high-dose dexamethasone (40 mg orally) on days 1 through 4, 9 through 12, and 17 through' 20 for four five-week cycles, followed by treatment on days 1 through 4 for five four-week cycles.  Patients who were assigned to receive dexamethasone were permitted to cross over to receive bortezomib in a companion study after disease progression.  Patients treated with bortezomib had higher response rates, a longer time to progression (the primary end point), and a longer survival than patients treated with dexamethasone.  The combined complete and partial response rates were 38 % for bortezomib and 18 % for dexamethasone (P < 0.001), and the complete response rates were 6 % and less than 1 %, resp. (P < 0.001).  Median times to progression in the bortezomib and dexamethasone groups were 6.22 mo (189 days) and 3.49 mo (106 days), resp. (hazard ratio, 0.55; P < 0.001).  The one-year survival rate was 80 % among patients taking bortezomib and 66 % among patients taking dexamethasone (P = 0.003), and the hazard ratio for overall survival with bortezomib was 0.57 (P = 0.001).  Grade 3 or 4 adverse events were reported in 75 % of patients treated with bortezomib and in 60 % of those treated with dexamethasone.  Bortezomib is superior to high-dose dexamethasone for the treatment of patients with multiple myeloma who have had a relapse after one to three previous therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlMw95MftsqLVg90H21EOLACvtfcHk0lh2fwBw22J53Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlaksLc%253D&md5=d277c662178e725f9f88aa6a7e1187f2</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa043445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa043445%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DSonneveld%26aufirst%3DP.%26aulast%3DSchuster%26aufirst%3DM.%2BW.%26aulast%3DIrwin%26aufirst%3DD.%26aulast%3DStadtmauer%26aufirst%3DE.%2BA.%26aulast%3DFacon%26aufirst%3DT.%26aulast%3DHarousseau%26aufirst%3DJ.-L.%26aulast%3DBen-Yehuda%26aufirst%3DD.%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DGoldschmidt%26aufirst%3DH.%26aulast%3DReece%26aufirst%3DD.%26aulast%3DSan-Miguel%26aufirst%3DJ.%26aulast%3DBlade%26aufirst%3DJ.%26aulast%3DBoccadoro%26aufirst%3DM.%26aulast%3DCavenagh%26aufirst%3DJ.%26aulast%3DDalton%26aufirst%3DW.%26aulast%3DBoral%26aufirst%3DA.%26aulast%3DEsseltine%26aufirst%3DD.%26aulast%3DPorter%26aufirst%3DJ.%26aulast%3DSchenkein%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DK.%26atitle%3DBortezomib%2520or%2520High-Dose%2520Dexamethasone%2520for%2520Relapsed%2520Multiple%2520Myeloma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26issue%3D24%26spage%3D2487%26epage%3D2498%26doi%3D10.1056%2FNEJMoa043445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lichter, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danaee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickard, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tayber, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavenagh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BladÃ©, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FaÃ§on, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niesvizky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonneveld, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Velde, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esseltine, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepicchio, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span> <span> </span><span class="NLM_article-title">Sequence Analysis of Î²-Subunit Genes of the 20S Proteasome in Patients with Relapsed Multiple Myeloma Treated with Bortezomib or Dexamethasone</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>120</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">4513</span>â <span class="NLM_lpage">4516</span>, <span class="refDoi">Â DOI: 10.1182/blood-2012-05-426924</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1182%2Fblood-2012-05-426924" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=23018640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVWgtb%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2012&pages=4513-4516&issue=23&author=D.+I.+Lichterauthor=H.+Danaeeauthor=M.+D.+Pickardauthor=O.+Tayberauthor=M.+Sintchakauthor=H.+Shiauthor=P.+G.+Richardsonauthor=J.+Cavenaghauthor=J.+Blad%C3%A9author=T.+Fa%C3%A7onauthor=R.+Niesvizkyauthor=M.+Alsinaauthor=W.+Daltonauthor=P.+Sonneveldauthor=S.+Lonialauthor=H.+van+de+Veldeauthor=D.+Ricciauthor=D.+Esseltineauthor=W.+Trepicchioauthor=G.+Mulliganauthor=K.+Anderson&title=Sequence+Analysis+of+%CE%B2-Subunit+Genes+of+the+20S+Proteasome+in+Patients+with+Relapsed+Multiple+Myeloma+Treated+with+Bortezomib+or+Dexamethasone&doi=10.1182%2Fblood-2012-05-426924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Sequence analysis of Î²-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone</span></div><div class="casAuthors">Lichter, David I.; Danaee, Hadi; Pickard, Michael D.; Tayber, Olga; Sintchak, Michael; Shi, Hongliang; Richardson, Paul G.; Cavenagh, Jamie; Blade, Joan; Facon, Thierry; Niesvizky, Ruben; Alsina, Melissa; Dalton, William; Sonneveld, Pieter; Lonial, Sagar; van de Velde, Helgi; Ricci, Deborah; Esseltine, Dixie-Lee; Trepicchio, William L.; Mulligan, George; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4513-4516</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Variations within proteasome Î² (PSMB) genes, which encode the Î² subunits of the 20S proteasome, may affect proteasome function, assembly, and/or binding of proteasome inhibitors.  To investigate the potential assocn. between PSMB gene variants and treatment-emergent resistance to bortezomib and/or long-term outcomes, in the present study, PSMB gene sequence variation was characterized in tumor DNA samples from patients who participated in the phase 3 Assessment of Proteasome Inhibition for Extending Remissions (APEX) study of bortezomib vs. high-dose dexamethasone for treatment of relapsed multiple myeloma.  Twelve new PSMB variants were identified.  No assocns. were found between PSMB single nucleotide polymorphism genotype frequency and clin. response to bortezomib or dexamethasone treatment or between PSMB single nucleotide polymorphism allelic frequency and pooled overall survival or time to progression.  Although specific PSMB5 variants have been identified previously in preclin. models of bortezomib resistance, these variants were not detected in patient tumor samples collected after clin. relapse from bortezomib, which suggests that alternative mechanisms underlie bortezomib insensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX89b8LFEdJrVg90H21EOLACvtfcHk0lh2fwBw22J53Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVWgtb%252FJ&md5=a2b26bfdf114d54db88202a929c4734f</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1182%2Fblood-2012-05-426924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2012-05-426924%26sid%3Dliteratum%253Aachs%26aulast%3DLichter%26aufirst%3DD.%2BI.%26aulast%3DDanaee%26aufirst%3DH.%26aulast%3DPickard%26aufirst%3DM.%2BD.%26aulast%3DTayber%26aufirst%3DO.%26aulast%3DSintchak%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DCavenagh%26aufirst%3DJ.%26aulast%3DBlad%25C3%25A9%26aufirst%3DJ.%26aulast%3DFa%25C3%25A7on%26aufirst%3DT.%26aulast%3DNiesvizky%26aufirst%3DR.%26aulast%3DAlsina%26aufirst%3DM.%26aulast%3DDalton%26aufirst%3DW.%26aulast%3DSonneveld%26aufirst%3DP.%26aulast%3DLonial%26aufirst%3DS.%26aulast%3Dvan%2Bde%2BVelde%26aufirst%3DH.%26aulast%3DRicci%26aufirst%3DD.%26aulast%3DEsseltine%26aufirst%3DD.%26aulast%3DTrepicchio%26aufirst%3DW.%26aulast%3DMulligan%26aufirst%3DG.%26aulast%3DAnderson%26aufirst%3DK.%26atitle%3DSequence%2520Analysis%2520of%2520%25CE%25B2-Subunit%2520Genes%2520of%2520the%252020S%2520Proteasome%2520in%2520Patients%2520with%2520Relapsed%2520Multiple%2520Myeloma%2520Treated%2520with%2520Bortezomib%2520or%2520Dexamethasone%26jtitle%3DBlood%26date%3D2012%26volume%3D120%26issue%3D23%26spage%3D4513%26epage%3D4516%26doi%3D10.1182%2Fblood-2012-05-426924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LÃ¼, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Different Mutants of PSMB5 Confer Varying Bortezomib Resistance in T Lymphoblastic Lymphoma/Leukemia Cells Derived from the Jurkat Cell Line</span>. <i>Exp. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">831</span>â <span class="NLM_lpage">837</span>, <span class="refDoi">Â DOI: 10.1016/j.exphem.2009.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.exphem.2009.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=19426847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFSjtb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=831-837&issue=7&author=S.+L%C3%BCauthor=J.+Yangauthor=Z.+Chenauthor=S.+Gongauthor=H.+Zhouauthor=X.+Xuauthor=J.+Wang&title=Different+Mutants+of+PSMB5+Confer+Varying+Bortezomib+Resistance+in+T+Lymphoblastic+Lymphoma%2FLeukemia+Cells+Derived+from+the+Jurkat+Cell+Line&doi=10.1016%2Fj.exphem.2009.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line</span></div><div class="casAuthors">Lue, Shuqing; Yang, Jianmin; Chen, Zhilong; Gong, Shenglan; Zhou, Hong; Xu, Xiaoqian; Wang, Jianmin</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Hematology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">831-837</span>CODEN:
                <span class="NLM_cas:coden">EXHMA6</span>;
        ISSN:<span class="NLM_cas:issn">0301-472X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Objective: To investigate the relationship between bortezomib resistance and mutations in the proteasome Î²5 subunit (PSMB5) gene.  Materials and Methods: Various bortezomib-resistant lymphoblastic lymphoma/leukemia lines were established by repeated cycles of bortezomib selection.  Mutations were detected by sequencing the complementary DNA of the PSMB5 gene.  Mutated clones were selected by limited diln. and cultured without bortezomib.  MRNA expression levels of PSMB5 in these mutated clones were measured by quant. reverse transcription polymerase chain reaction.  The degree of resistance was detd. by cytotoxicity at various bortezomib concns.  The chymotrypsin-like activities were assayed by measuring the release of the fluorescent 7-amido-4-methylcoumarin from the substrate N-succinyl-Leu-Leu-Val-Tyr - 7-amido-4-methylcoumarin.  Results: In addn. to the previously reported PSMB5 G322A mutant (Ala49Thr), a C323T mutant (Ala49Val), and G322A, C326T conjoined mutant (Ala49Thr and Ala50Val) were selected and clones contg. these mutations (JurkatB-G322A, JurkatB-C323T, and JurkatB-G322A/C326T) were obtained.  After being cultured without bortezomib for >2 mo, no significant difference in PSMB5 mRNA levels was detected between these JurkatB cells and parental Jurkat cells.  JurkatB-G322A, JurkatB-C323T, and JurkatB-G322A/C326T clones displayed 22.0-fold, 39.4-fold, and 66.7-fold resistance, resp., to bortezomib compared to Jurkat cells.  There were no significant differences between the chymotrypsin-like activities of these mutants and Jurkat cells.  The inhibitory effect of bortezomib on chymotrypsin-like activity was the weakest in JurkatB-G322A/C326T cells, and the strongest in JurkatB-G322A cells, with JurkatB-C323T cells falling in between.  Conclusion: Mutations of the PSMB5 gene resulting in substitutions of Ala49 and Ala50 of PSMB5 protein can confer varying bortezomib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbRv5fdeYb57Vg90H21EOLACvtfcHk0lgljcN1fn31ZA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFSjtb4%253D&md5=35b9303e3b0393f867a67a197c688c10</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.exphem.2009.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exphem.2009.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25BC%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DGong%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DDifferent%2520Mutants%2520of%2520PSMB5%2520Confer%2520Varying%2520Bortezomib%2520Resistance%2520in%2520T%2520Lymphoblastic%2520Lymphoma%252FLeukemia%2520Cells%2520Derived%2520from%2520the%2520Jurkat%2520Cell%2520Line%26jtitle%3DExp.%2520Hematol.%26date%3D2009%26volume%3D37%26issue%3D7%26spage%3D831%26epage%3D837%26doi%3D10.1016%2Fj.exphem.2009.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oerlemans, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franke, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaraf, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Zantwijk, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffer, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debipersad, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vojtekova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Heijden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ylstra, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaspers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dijkmans, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheper, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, G.</span></span> <span> </span><span class="NLM_article-title">Molecular Basis of Bortezomib Resistance: Proteasome Subunit Beta5 (PSMB5) Gene Mutation and Overexpression of PSMB5 Protein</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>112</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2489</span>â <span class="NLM_lpage">2499</span>, <span class="refDoi">Â DOI: 10.1182/blood-2007-08-104950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1182%2Fblood-2007-08-104950" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=18565852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFCru7zO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2008&pages=2489-2499&issue=6&author=R.+Oerlemansauthor=N.+E.+Frankeauthor=Y.+G.+Assarafauthor=J.+Cloosauthor=I.+van+Zantwijkauthor=C.+R.+Berkersauthor=G.+L.+Schefferauthor=K.+Debipersadauthor=K.+Vojtekovaauthor=C.+Lemosauthor=J.+van+der%0AHeijdenauthor=B.+Ylstraauthor=G.+Petersauthor=G.+Kaspersauthor=B.+Dijkmansauthor=R.+Scheperauthor=G.+Jansen&title=Molecular+Basis+of+Bortezomib+Resistance%3A+Proteasome+Subunit+Beta5+%28PSMB5%29+Gene+Mutation+and+Overexpression+of+PSMB5+Protein&doi=10.1182%2Fblood-2007-08-104950"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis of bortezomib resistance: proteasome subunit Î²5 (PSMB5) gene mutation and overexpression of PSMB5 protein</span></div><div class="casAuthors">Oerlemans, Ruud; Franke, Niels E.; Assaraf, Yehuda G.; Cloos, Jacqueline; van Zantwijk, Ina; Berkers, Celia R.; Scheffer, George L.; Debipersad, Kabir; Vojtekova, Katharina; Lemos, Clara; van der Heijden, Joost W.; Ylstra, Bauke; Peters, Godefridus J.; Kaspers, Gertjan L.; Dijkmans, Ben A. C.; Scheper, Rik J.; Jansen, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2489-2499</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The proteasome inhibitor bortezomib is a novel anticancer drug that has shown promise in the treatment of refractory multiple myeloma.  However, its clin. efficacy has been hampered by the emergence of drug-resistance phenomena, the mol. basis of which remains elusive.  Toward this end, we here developed high levels (45- to 129-fold) of acquired resistance to bortezomib in human myelomonocytic THP1 cells by exposure to stepwise increasing (2.5-200 nM) concns. of bortezomib.  Study of the mol. mechanism of bortezomib resistance in these cells revealed (1) an Ala49Thr mutation residing in a highly conserved bortezomib-binding pocket in the proteasome Î²5-subunit (PSMB5) protein, (2) a dramatic overexpression (up to 60-fold) of PSMB5 protein but not of other proteasome subunits including PSMB6, PSMB7, and PSMA7, (3) high levels of cross-resistance to Î²5 subunit-targeted cytotoxic peptides 4A6, MG132, MG262, and ALLN, but not to a broad spectrum of chemotherapeutic drugs, (4) no marked changes in chymotrypsin-like proteasome activity, and (5) restoration of bortezomib sensitivity in bortezomib-resistant cells by siRNA-mediated silencing of PSMB5 gene expression.  Collectively, these findings establish a novel mechanism of bortezomib resistance assocd. with the selective overexpression of a mutant PSMB5 protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtSyGb53RI9rVg90H21EOLACvtfcHk0lgljcN1fn31ZA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFCru7zO&md5=48981ee986f506ff7c36107cfd606d43</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-08-104950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-08-104950%26sid%3Dliteratum%253Aachs%26aulast%3DOerlemans%26aufirst%3DR.%26aulast%3DFranke%26aufirst%3DN.%2BE.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3DCloos%26aufirst%3DJ.%26aulast%3Dvan%2BZantwijk%26aufirst%3DI.%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3DScheffer%26aufirst%3DG.%2BL.%26aulast%3DDebipersad%26aufirst%3DK.%26aulast%3DVojtekova%26aufirst%3DK.%26aulast%3DLemos%26aufirst%3DC.%26aulast%3Dvan%2Bder%2BHeijden%26aufirst%3DJ.%26aulast%3DYlstra%26aufirst%3DB.%26aulast%3DPeters%26aufirst%3DG.%26aulast%3DKaspers%26aufirst%3DG.%26aulast%3DDijkmans%26aufirst%3DB.%26aulast%3DScheper%26aufirst%3DR.%26aulast%3DJansen%26aufirst%3DG.%26atitle%3DMolecular%2520Basis%2520of%2520Bortezomib%2520Resistance%253A%2520Proteasome%2520Subunit%2520Beta5%2520%2528PSMB5%2529%2520Gene%2520Mutation%2520and%2520Overexpression%2520of%2520PSMB5%2520Protein%26jtitle%3DBlood%26date%3D2008%26volume%3D112%26issue%3D6%26spage%3D2489%26epage%3D2499%26doi%3D10.1182%2Fblood-2007-08-104950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reece, D. E.</span></span> <span> </span><span class="NLM_article-title">Carfilzomib in Multiple Myeloma: Gold, Silver, or Bronze?</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>120</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2776</span>â <span class="NLM_lpage">2777</span>, <span class="refDoi">Â DOI: 10.1182/blood-2012-08-446534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1182%2Fblood-2012-08-446534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=23043023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFaksLnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2012&pages=2776-2777&issue=14&author=D.+E.+Reece&title=Carfilzomib+in+Multiple+Myeloma%3A+Gold%2C+Silver%2C+or+Bronze%3F&doi=10.1182%2Fblood-2012-08-446534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Carfilzomib in multiple myeloma: gold, silver, or bronze?</span></div><div class="casAuthors">Reece, Donna E.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2776-2777</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  In this issue of Blood, Siegel and colleagues report that the next-generation proteasome inhibitor carfilzomib, when administered as a single agent, can produce meaningful disease control in heavily pretreated patients with relapsed/refractory multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS7nBQyV3bI7Vg90H21EOLACvtfcHk0lgEkYY1Sp--sA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFaksLnM&md5=cb0f5c40fdb7b12609b4c1c60dbaf8e5</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1182%2Fblood-2012-08-446534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2012-08-446534%26sid%3Dliteratum%253Aachs%26aulast%3DReece%26aufirst%3DD.%2BE.%26atitle%3DCarfilzomib%2520in%2520Multiple%2520Myeloma%253A%2520Gold%252C%2520Silver%252C%2520or%2520Bronze%253F%26jtitle%3DBlood%26date%3D2012%26volume%3D120%26issue%3D14%26spage%3D2776%26epage%3D2777%26doi%3D10.1182%2Fblood-2012-08-446534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parlati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aujay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitsky, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorens, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Micklem, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruurs, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylvain, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M.</span></span> <span> </span><span class="NLM_article-title">Carfilzomib Can Induce Tumor Cell Death through Selective Inhibition of the Chymotrypsin-like Activity of the Proteasome</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">3439</span>â <span class="NLM_lpage">3447</span>, <span class="refDoi">Â DOI: 10.1182/blood-2009-05-223677</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1182%2Fblood-2009-05-223677" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=19671918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlensb7L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=3439-3447&issue=16&author=F.+Parlatiauthor=S.+J.+Leeauthor=M.+Aujayauthor=E.+Suzukiauthor=K.+Levitskyauthor=J.+B.+Lorensauthor=D.+R.+Micklemauthor=P.+Ruursauthor=C.+Sylvainauthor=Y.+Luauthor=K.+Shenkauthor=M.+Bennett&title=Carfilzomib+Can+Induce+Tumor+Cell+Death+through+Selective+Inhibition+of+the+Chymotrypsin-like+Activity+of+the+Proteasome&doi=10.1182%2Fblood-2009-05-223677"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome</span></div><div class="casAuthors">Parlati, Francesco; Lee, Susan J.; Aujay, Monette; Suzuki, Erika; Levitsky, Konstantin; Lorens, James B.; Micklem, David R.; Ruurs, Paulina; Sylvain, Catherine; Lu, Yan; Shenk, Kevin D.; Bennett, Mark K.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3439-3447</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Carfilzomib is a proteasome inhibitor in clin. development that primarily targets the chymotrypsin-like (CT-L) subunits in both the constitutive proteasome (c20S) and the immunoproteasome (i20S).  To investigate the impact of inhibiting the CT-L activity with carfilzomib, we set out to quantitate the levels of CT-L subunits Î²5 from the c20S and LMP7 from the i20S in normal and malignant hematopoietic cells.  We found that the i20S is a major form of the proteasome expressed in cells of hematopoietic origin, including multiple myeloma (MM) CD138+ tumor cells.  Although specific inhibition of either LMP7 or Î²5 alone was insufficient to produce an antitumor response, inhibition of all proteasome subunits was cytotoxic to both hematol. tumor cells and peripheral blood mononuclear cells.  However, selective inhibition of both Î²5 and LMP7 was sufficient to induce an antitumor effect in MM, non-Hodgkin lymphoma, and leukemia cells while minimizing the toxicity toward nontransformed cells.  In MM tumor cells, CT-L inhibition alone was sufficient to induce proapoptotic sequelae, including proteasome substrate accumulation, Noxa and caspase 3/7 induction, and phospho-eIF2Î± suppression.  These data support a hypothesis that hematol. tumor cells are uniquely sensitive to CT-L inhibition and provide a mechanistic understanding of the clin. safety profile and antitumor activity of proteasome inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqao7Quh7ueurVg90H21EOLACvtfcHk0lgEkYY1Sp--sA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlensb7L&md5=8f430741ad461693fc89907fff97f731</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-05-223677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-05-223677%26sid%3Dliteratum%253Aachs%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DAujay%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DE.%26aulast%3DLevitsky%26aufirst%3DK.%26aulast%3DLorens%26aufirst%3DJ.%2BB.%26aulast%3DMicklem%26aufirst%3DD.%2BR.%26aulast%3DRuurs%26aufirst%3DP.%26aulast%3DSylvain%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DShenk%26aufirst%3DK.%26aulast%3DBennett%26aufirst%3DM.%26atitle%3DCarfilzomib%2520Can%2520Induce%2520Tumor%2520Cell%2520Death%2520through%2520Selective%2520Inhibition%2520of%2520the%2520Chymotrypsin-like%2520Activity%2520of%2520the%2520Proteasome%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26issue%3D16%26spage%3D3439%26epage%3D3447%26doi%3D10.1182%2Fblood-2009-05-223677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niewerth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Meerloo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaraf, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickx, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderl, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zweegman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaspers, G. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloos, J.</span></span> <span> </span><span class="NLM_article-title">Anti-Leukemic Activity and Mechanisms Underlying Resistance to the Novel Immunoproteasome Inhibitor PR-924</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>89</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">43</span>â <span class="NLM_lpage">51</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2014.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.bcp.2014.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=24552657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjsF2htLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2014&pages=43-51&issue=1&author=D.+Niewerthauthor=J.+van+Meerlooauthor=G.+Jansenauthor=Y.+G.+Assarafauthor=T.+C.+Hendrickxauthor=C.+J.+Kirkauthor=J.+L.+Anderlauthor=S.+Zweegmanauthor=G.+J.+L.+Kaspersauthor=J.+Cloos&title=Anti-Leukemic+Activity+and+Mechanisms+Underlying+Resistance+to+the+Novel+Immunoproteasome+Inhibitor+PR-924&doi=10.1016%2Fj.bcp.2014.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924</span></div><div class="casAuthors">Niewerth, Denise; van Meerloo, Johan; Jansen, Gerrit; Assaraf, Yehuda G.; Hendrickx, Tessa C.; Kirk, Christopher J.; Anderl, Janet L.; Zweegman, Sonja; Kaspers, Gertjan J. L.; Cloos, Jacqueline</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-51</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">PR-924 is a novel prototypic immunoproteasome inhibitor bearing markedly enhanced specificity for the Î²5i immunoproteasome subunit, compared to the classical proteasome inhibitor bortezomib.  Here, we assessed the growth inhibitory potential of PR-924 in three human hematol. malignancy cell lines (CCRF-CEM, THP1, and 8226) and their bortezomib-resistant sublines.  Parental cells displayed equal sensitivity to PR-924 (IC50: 1.5-2.8 Î¼M), whereas their bortezomib-resistant tumor lines displayed a 10-12 fold cross-resistance to PR-924.  However, PR-924 cross-resistance factors for bortezomib-resistant sublines were markedly lower compared to the resistance factors to bortezomib.  Proteasome inhibition expts. confirmed that PR-924 specifically inhibited Î²5i activity, even far below concns. that exerted anti-proliferative activity.  We further detd. whether PR-924 activity might be compromised by acquisition of drug resistance phenomena.  Indeed, CEM cells rendered stepwise resistant to 20 Î¼M PR-924 (CEM/PR20) displayed 13-fold PR-924-resistance and 10-fold cross-resistance to bortezomib.  CEM/PR20 cells were devoid of mutations in the PSMB8 gene (encoding Î²5i), but acquired Met45Ile mutation in the PSMB5 gene (encoding constitutive Î²5), consistent with Î²5 mutations obsd. in bortezomib-resistant cells.  Furthermore, compared to parental CEM cells, CEM/PR20 cells exhibited 2.5-fold upregulation of constitutive proteasome subunit expression, whereas immunoproteasome subunit expression was 2-fold decreased.  In conclusion, PR-924 displayed potent anti-leukemic activity including toward bortezomib-resistant leukemia cells.  Despite the specificity of PR-924 to the Î²5i immunoproteasome subunit, its anti-leukemic effect required concns. that blocked both Î²5 and Î²5i subunits.  This is underscored by the emergence of mutations in PSMB5 rather than in PSMB8.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs3uUbQ67XibVg90H21EOLACvtfcHk0lg_of7fnhSAHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjsF2htLk%253D&md5=4bb4db2af8ae1a1676d7e126b49c2b26</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2014.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2014.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DNiewerth%26aufirst%3DD.%26aulast%3Dvan%2BMeerloo%26aufirst%3DJ.%26aulast%3DJansen%26aufirst%3DG.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3DHendrickx%26aufirst%3DT.%2BC.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DAnderl%26aufirst%3DJ.%2BL.%26aulast%3DZweegman%26aufirst%3DS.%26aulast%3DKaspers%26aufirst%3DG.%2BJ.%2BL.%26aulast%3DCloos%26aufirst%3DJ.%26atitle%3DAnti-Leukemic%2520Activity%2520and%2520Mechanisms%2520Underlying%2520Resistance%2520to%2520the%2520Novel%2520Immunoproteasome%2520Inhibitor%2520PR-924%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2014%26volume%3D89%26issue%3D1%26spage%3D43%26epage%3D51%26doi%3D10.1016%2Fj.bcp.2014.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aujay, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hark, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raje, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">PR-924, a Selective Inhibitor of the Immunoproteasome Subunit LMP-7, Blocks Multiple Myeloma Cell Growth Both in Vitro and in Vivo</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>152</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">155</span>â <span class="NLM_lpage">163</span>, <span class="refDoi">Â DOI: 10.1111/j.1365-2141.2010.08491.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1111%2Fj.1365-2141.2010.08491.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=21114484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVGjtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2011&pages=155-163&issue=2&author=A.+V.+Singhauthor=M.+Bandiauthor=M.+A.+Aujayauthor=C.+J.+Kirkauthor=D.+E.+Harkauthor=N.+Rajeauthor=D.+Chauhanauthor=K.+C.+Anderson&title=PR-924%2C+a+Selective+Inhibitor+of+the+Immunoproteasome+Subunit+LMP-7%2C+Blocks+Multiple+Myeloma+Cell+Growth+Both+in+Vitro+and+in+Vivo&doi=10.1111%2Fj.1365-2141.2010.08491.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo</span></div><div class="casAuthors">Singh, Ajita V.; Bandi, Madhavi; Aujay, Monette A.; Kirk, Christopher J.; Hark, David E.; Raje, Noopur; Chauhan, Dharminder; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">155-163</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">PR-924 is an LMP-7-selective tripeptide epoxyketone proteasome inhibitor that covalently modifies proteasomal N-terminal threonine active sites.  In the present study, we show that PR-924 inhibits growth and triggers apoptosis in multiple myeloma (MM) cell lines and primary patient MM cells, without significantly affecting normal peripheral blood mononuclear cells.  PR-924-induced apoptosis in MM cells is assocd. with activation of caspase-3, caspase-8, caspase-9, BID, PARP and cytochrome-c release.  In vivo administration of PR-924 inhibits tumor growth in human plasmacytoma xenografts.  Results from SCID-hu model show a significant redn. in the shIL-6R levels in mice treated with PR-924 vs. vehicle-control.  PR-924 treatment was well tolerated as evidenced by the lack of wt. loss.  Importantly, treatment of tumor-bearing mice with PR-924, but not vehicle alone, prolonged survival.  Our preclin. findings therefore validate immunoproteasome LMP-7 subunit as a novel therapeutic target in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU0KS8376dorVg90H21EOLACvtfcHk0lg_of7fnhSAHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVGjtrs%253D&md5=c33893786317e38b96c2fe6817925e85</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2010.08491.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2010.08491.x%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DA.%2BV.%26aulast%3DBandi%26aufirst%3DM.%26aulast%3DAujay%26aufirst%3DM.%2BA.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DHark%26aufirst%3DD.%2BE.%26aulast%3DRaje%26aufirst%3DN.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DPR-924%252C%2520a%2520Selective%2520Inhibitor%2520of%2520the%2520Immunoproteasome%2520Subunit%2520LMP-7%252C%2520Blocks%2520Multiple%2520Myeloma%2520Cell%2520Growth%2520Both%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2011%26volume%3D152%26issue%3D2%26spage%3D155%26epage%3D163%26doi%3D10.1111%2Fj.1365-2141.2010.08491.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bo Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the Immunoproteasome: Current Status and Future Directions</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">4140</span>â <span class="NLM_lpage">4151</span>, <span class="refDoi">Â DOI: 10.2174/1381612811319220018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.2174%2F1381612811319220018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=23181576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslyrtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=4140-4151&issue=22&author=Z.+Millerauthor=L.+Aoauthor=K.+Bo+Kimauthor=W.+Lee&title=Inhibitors+of+the+Immunoproteasome%3A+Current+Status+and+Future+Directions&doi=10.2174%2F1381612811319220018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of the immunoproteasome: current status and future directions</span></div><div class="casAuthors">Miller, Zachary; Ao, Lin; Kim, Kyung Bo; Lee, Wooin</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4140-4151</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The ubiquitin-proteasome system (UPS) plays a vital role in maintaining protein homeostasis and regulating numerous cellular processes.  The proteasome, a multi-protease complex, is the key component of the UPS and has been validated as a therapeutic target by the FDA's approval of bortezomib and carfilzomib.  These proteasome inhibitor drugs have substantially improved outcomes in patients with hematol. malignancies and are currently being investigated for other types of cancer as well as several other diseases.  These approved proteasome inhibitors target the catalytic activity of both the constitutive proteasome and the immunoproteasome indiscriminately, and their inhibitory effects on the constitutive proteasome in normal cells are believed to contribute to unwanted side effects.  In addn., selective immunoproteasome inhibition has been proposed to have unique effects on other diseases, including those involving aberrant immune function.  Initially recognized for its role in the adaptive immune response, the immunoproteasome is often upregulated in disease states such as inflammatory diseases and cancer, suggesting functions beyond antigen presentation.  In an effort to explore the immunoproteasome as a potential therapeutic target in these diseases, the development of immunoproteasome-specific inhibitors has become the focus of recent studies.  Owing to considerable efforts by both academic and industry groups, immunoproteasome-selective inhibitors have now been identified and tested against several disease models.  These inhibitors also provide a valuable set of chem. tools for investigating the biol. function of the immunoproteasome.  In this review, we will focus on the recent efforts towards the development of immunoproteasome-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiaZ1chVK_KrVg90H21EOLACvtfcHk0liFvUvx29NJ_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslyrtrc%253D&md5=597fa7cdfee60647d64bad55a2bb0672</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.2174%2F1381612811319220018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612811319220018%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DZ.%26aulast%3DAo%26aufirst%3DL.%26aulast%3DBo%2BKim%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DW.%26atitle%3DInhibitors%2520of%2520the%2520Immunoproteasome%253A%2520Current%2520Status%2520and%2520Future%2520Directions%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2013%26volume%3D19%26issue%3D22%26spage%3D4140%26epage%3D4151%26doi%3D10.2174%2F1381612811319220018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Proteasome Inhibition by the Natural Products Epoxomicin and Dihydroeponemycin: Insights into Specificity and Potency</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">3335</span>â <span class="NLM_lpage">3340</span>, <span class="refDoi">Â DOI: 10.1016/S0960-894X(99)00612-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2FS0960-894X%2899%2900612-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10612595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADyaK1MXotFSrsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1999&pages=3335-3340&issue=23&author=K.+B.+Kimauthor=J.+Myungauthor=N.+Sinauthor=C.+M.+Crews&title=Proteasome+Inhibition+by+the+Natural+Products+Epoxomicin+and+Dihydroeponemycin%3A+Insights+into+Specificity+and+Potency&doi=10.1016%2FS0960-894X%2899%2900612-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency</span></div><div class="casAuthors">Kim, Kyung Bo; Myung, Jayhyuk; Sin, Ny; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3335-3340</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">While two structurally related epoxyketone-contg. antitumor natural products, epoxomicin and eponemycin, share the proteasome as a common intracellular target, they differ in their antiproliferative activity, proteasome subunit binding specificity, and rates of proteasome inhibition.  As a first step towards understanding such differences and developing novel proteasome subunit-specific inhibitors, the authors report here the synthesis and characterization of epoxomicin/dihydroeponemycin chimerae.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdGLgLcWtf2bVg90H21EOLACvtfcHk0liurfjFZdGTvQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXotFSrsLw%253D&md5=22d279a74a2c4051ee980f2f844be12b</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2899%2900612-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252899%252900612-5%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DMyung%26aufirst%3DJ.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DProteasome%2520Inhibition%2520by%2520the%2520Natural%2520Products%2520Epoxomicin%2520and%2520Dihydroeponemycin%253A%2520Insights%2520into%2520Specificity%2520and%2520Potency%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1999%26volume%3D9%26issue%3D23%26spage%3D3335%26epage%3D3340%26doi%3D10.1016%2FS0960-894X%2899%2900612-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargagna-Mohan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehenkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.-B.</span></span> <span> </span><span class="NLM_article-title">LMP2-Specific Inhibitors: Chemical Genetic Tools for Proteasome Biology</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">419</span>â <span class="NLM_lpage">430</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2007.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.chembiol.2007.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=17462577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkslaitbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=419-430&issue=4&author=Y.+K.+Hoauthor=P.+Bargagna-Mohanauthor=M.+Wehenkelauthor=R.+Mohanauthor=K.-B.+Kim&title=LMP2-Specific+Inhibitors%3A+Chemical+Genetic+Tools+for+Proteasome+Biology&doi=10.1016%2Fj.chembiol.2007.03.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">LMP2-Specific Inhibitors: Chemical Genetic Tools for Proteasome Biology</span></div><div class="casAuthors">Ho, Yik Khuan; Bargagna-Mohan, Paola; Wehenkel, Marie; Mohan, Royce; Kim, Kyung-Bo</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">419-430</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The immunoproteasome, having been linked to neurodegenerative diseases and hematol. cancers, has been shown to play an important role in MHC class I antigen presentation.  However, its other pathophysiol. functions are still not very well understood.  This can be attributed mainly to a lack of appropriate mol. probes that can selectively modulate the immunoproteasome catalytic subunits.  Herein, the authors report the development of mol. probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome.  The authors show that these compds. irreversibly modify the LMP2 subunit with high specificity.  Importantly, LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of malignant tumors that highly express LMP2.  Thus, the development of the immunoproteasome catalytic subunit LMP2-specific inhibitors may not only hold great potential as a therapeutic agent for certain diseases but can also provide a valuable chem. genetic probe to investigate immunoproteasome biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDvEUufIJ3K7Vg90H21EOLACvtfcHk0liurfjFZdGTvQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkslaitbY%253D&md5=d12fa5065f6bdd4aee8ad12491a1c072</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2007.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2007.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DY.%2BK.%26aulast%3DBargagna-Mohan%26aufirst%3DP.%26aulast%3DWehenkel%26aufirst%3DM.%26aulast%3DMohan%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DK.-B.%26atitle%3DLMP2-Specific%2520Inhibitors%253A%2520Chemical%2520Genetic%2520Tools%2520for%2520Proteasome%2520Biology%26jtitle%3DChem.%2520Biol.%26date%3D2007%26volume%3D14%26issue%3D4%26spage%3D419%26epage%3D430%26doi%3D10.1016%2Fj.chembiol.2007.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul Hameed, M. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehenkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzyka, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, C.-G.</span></span> <span> </span><span class="NLM_article-title">Molecular Basis of the Selectivity of the Immunoproteasome Catalytic Subunit LMP2-Specific Inhibitor Revealed by Molecular Modeling and Dynamics Simulations</span>. <i>J. Phys. Chem. B</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">38</span>),  <span class="NLM_fpage">12333</span>â <span class="NLM_lpage">12339</span>, <span class="refDoi">Â DOI: 10.1021/jp1058098</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp1058098" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFSlsrvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2010&pages=12333-12339&issue=38&author=B.+Leiauthor=M.+D.+M.+Abdul+Hameedauthor=A.+Hamzaauthor=M.+Wehenkelauthor=J.+L.+Muzykaauthor=X.-J.+Yaoauthor=K.-B.+Kimauthor=C.-G.+Zhan&title=Molecular+Basis+of+the+Selectivity+of+the+Immunoproteasome+Catalytic+Subunit+LMP2-Specific+Inhibitor+Revealed+by+Molecular+Modeling+and+Dynamics+Simulations&doi=10.1021%2Fjp1058098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Basis of the Selectivity of the Immunoproteasome Catalytic Subunit LMP2-Specific Inhibitor Revealed by Molecular Modeling and Dynamics Simulations</span></div><div class="casAuthors">Lei, Beilei; Abdul Hameed, Mohamed Diwan M.; Hamza, Adel; Wehenkel, Marie; Muzyka, Jennifer L.; Yao, Xiao-Jun; Kim, Kyung-Bo; Zhan, Chang-Guo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry B</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">12333-12339</span>CODEN:
                <span class="NLM_cas:coden">JPCBFK</span>;
        ISSN:<span class="NLM_cas:issn">1520-6106</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Given that immunoproteasome inhibitors are currently being developed for a variety of potent therapeutic purposes, the unique specificity of an Î±',Î²'-epoxyketone peptide (UK101) toward the LMP2 subunit of the immunoproteasome (analogous to Î²5 subunit of the constitutive proteasome) has been investigated in this study for the first time by employing homol. modeling, mol. docking, mol. dynamics simulation, and mol. mechanics Poisson-Boltzmann surface area (MM-PBSA) binding free energy calcns.  On the basis of the simulated binding structures, the calcd. binding free energies are in qual. agreement with the corresponding exptl. data, and the selectivity of UK101 is explained reasonably.  The obsd. selectivity of UK101 for the LMP2 subunit is rationalized by the requirement for both a linear hydrocarbon chain at the N terminus and a bulky group at the C terminus of the inhibitor, because the LMP2 subunit has a much more favorable hydrophobic pocket interacting with the linear hydrocarbon chain, and the bulky group at the C terminus has a steric clash with the Tyr 169 in Î²5 subunit.  Finally, our results help to clarify why UK101 is specific to the LMP2 subunit of immunoproteasome, and this investigation should be valuable for rational design of more potent LMP2-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIzcYhY1bQYLVg90H21EOLACvtfcHk0lhfjZXlRCakIg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFSlsrvE&md5=a0cdc03651c648729405d1a9a6f5c12e</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fjp1058098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp1058098%26sid%3Dliteratum%253Aachs%26aulast%3DLei%26aufirst%3DB.%26aulast%3DAbdul%2BHameed%26aufirst%3DM.%2BD.%2BM.%26aulast%3DHamza%26aufirst%3DA.%26aulast%3DWehenkel%26aufirst%3DM.%26aulast%3DMuzyka%26aufirst%3DJ.%2BL.%26aulast%3DYao%26aufirst%3DX.-J.%26aulast%3DKim%26aufirst%3DK.-B.%26aulast%3DZhan%26aufirst%3DC.-G.%26atitle%3DMolecular%2520Basis%2520of%2520the%2520Selectivity%2520of%2520the%2520Immunoproteasome%2520Catalytic%2520Subunit%2520LMP2-Specific%2520Inhibitor%2520Revealed%2520by%2520Molecular%2520Modeling%2520and%2520Dynamics%2520Simulations%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D2010%26volume%3D114%26issue%3D38%26spage%3D12333%26epage%3D12339%26doi%3D10.1021%2Fjp1058098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wehenkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ban, J.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, Y.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmony, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">A Selective Inhibitor of the Immunoproteasome Subunit LMP2 Induces Apoptosis in PC-3 Cells and Suppresses Tumour Growth in Nude Mice</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>107</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">53</span>â <span class="NLM_lpage">62</span>, <span class="refDoi">Â DOI: 10.1038/bjc.2012.243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fbjc.2012.243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=22677907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC38Xptl2isbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2012&pages=53-62&issue=1&author=M.+Wehenkelauthor=J.-O.+Banauthor=Y.-K.+Hoauthor=K.+C.+Carmonyauthor=J.+T.+Hongauthor=K.+B.+Kim&title=A+Selective+Inhibitor+of+the+Immunoproteasome+Subunit+LMP2+Induces+Apoptosis+in+PC-3+Cells+and+Suppresses+Tumour+Growth+in+Nude+Mice&doi=10.1038%2Fbjc.2012.243"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice</span></div><div class="casAuthors">Wehenkel, M.; Ban, J.-O.; Ho, Y.-K.; Carmony, K. C.; Hong, J. T.; Kim, K. B.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-62</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Although the proteasome is a validated anticancer target, the clin. application of its inhibitors has been limited because of inherent systemic toxicity.  To broaden clin. utility of proteasome inhibitors as anticancer agents, it is crit. to develop strategies to selectively target proteasomes in cancer cells.  The immunoproteasome is an alternative form of the constitutive proteasome that is expressed at high levels in cancer tissues, but not in most normal cells in the body.  Methods: To validate the immunoproteasome as a chemotherapeutic target, an immunoproteasome catalytic subunit LMP2-targeting inhibitor and siRNA were used.  The sensitivity of PC-3 prostate cancer cells to these reagents was investigated using viability assays.  Further, a xenograft model of prostate cancer was studied to test the in vivo effects of LMP2 inhibition.  Results: A small mol. inhibitor of the immunoproteasome subunit LMP2, UK-101, induced apoptosis of PC-3 cells and resulted in significant inhibition (â¼50-60%) of tumor growth in vivo.  Interestingly, UK-101 did not block degrdn. of IÎºBÎ± in PC-3 cells treated with TNF-Î±, suggesting that its mode of action may be different from that of general proteasome inhibitors, such as bortezomib, which block IÎºBÎ± degrdn.  Conclusion: These results strongly suggest that the immunoproteasome has important roles in cancer cell growth and thus provide a rationale for targeting the immunoproteasome in the treatment of prostate cancer.  British Journal of Cancer (2012) 107, 53-62. doi:10.1038/bjc.2012.243 www.bjcancer.com published online 7 June 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrLJQKXNlNKrVg90H21EOLACvtfcHk0lhfjZXlRCakIg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xptl2isbk%253D&md5=59390ce6295216a78e584049754b2c03</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2012.243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2012.243%26sid%3Dliteratum%253Aachs%26aulast%3DWehenkel%26aufirst%3DM.%26aulast%3DBan%26aufirst%3DJ.-O.%26aulast%3DHo%26aufirst%3DY.-K.%26aulast%3DCarmony%26aufirst%3DK.%2BC.%26aulast%3DHong%26aufirst%3DJ.%2BT.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DA%2520Selective%2520Inhibitor%2520of%2520the%2520Immunoproteasome%2520Subunit%2520LMP2%2520Induces%2520Apoptosis%2520in%2520PC-3%2520Cells%2520and%2520Suppresses%2520Tumour%2520Growth%2520in%2520Nude%2520Mice%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2012%26volume%3D107%26issue%3D1%26spage%3D53%26epage%3D62%26doi%3D10.1038%2Fbjc.2012.243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esdar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friese-Hamim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musil, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohdich, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanelli, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span> <span> </span><span class="NLM_article-title">Abstract LB-054: Discovery and Profiling of M3258, a Potent and Selective LMP7 Inhibitor Demonstrating High Efficacy in Multiple Myeloma Models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">LB-054</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.AM2019-LB-054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1158%2F1538-7445.AM2019-LB-054" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=LB-054&author=M.+Kleinauthor=M.+Buschauthor=C.+Esdarauthor=M.+Friese-Hamimauthor=M.+Krierauthor=D.+Musilauthor=F.+Rohdichauthor=M.+Sandersonauthor=G.+Walterauthor=O.+Schadtauthor=U.+Zanelliauthor=J.+Ma&title=Abstract+LB-054%3A+Discovery+and+Profiling+of+M3258%2C+a+Potent+and+Selective+LMP7+Inhibitor+Demonstrating+High+Efficacy+in+Multiple+Myeloma+Models&doi=10.1158%2F1538-7445.AM2019-LB-054"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-LB-054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-LB-054%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%26aufirst%3DM.%26aulast%3DBusch%26aufirst%3DM.%26aulast%3DEsdar%26aufirst%3DC.%26aulast%3DFriese-Hamim%26aufirst%3DM.%26aulast%3DKrier%26aufirst%3DM.%26aulast%3DMusil%26aufirst%3DD.%26aulast%3DRohdich%26aufirst%3DF.%26aulast%3DSanderson%26aufirst%3DM.%26aulast%3DWalter%26aufirst%3DG.%26aulast%3DSchadt%26aufirst%3DO.%26aulast%3DZanelli%26aufirst%3DU.%26aulast%3DMa%26aufirst%3DJ.%26atitle%3DAbstract%2520LB-054%253A%2520Discovery%2520and%2520Profiling%2520of%2520M3258%252C%2520a%2520Potent%2520and%2520Selective%2520LMP7%2520Inhibitor%2520Demonstrating%2520High%2520Efficacy%2520in%2520Multiple%2520Myeloma%2520Models%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3DLB-054%26doi%3D10.1158%2F1538-7445.AM2019-LB-054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esdar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friese-Hamim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musil, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohdich, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sloot, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanelli, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, M.</span></span> <span> </span><span class="NLM_article-title">Abstract DDT02â01: First-Time Disclosure of M3258: A Selective Inhibitor of the Immunoproteasome Subunit LMP7 with Potential for Improved Therapeutic Utility in Multiple Myeloma Compared to Pan-Proteasome Inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">DDT02-01</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.AM2019-DDT02-01</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1158%2F1538-7445.AM2019-DDT02-01" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=DDT02-01&author=M.+Sandersonauthor=M.+Buschauthor=C.+Esdarauthor=M.+Friese-Hamimauthor=M.+Krierauthor=J.+Maauthor=D.+Musilauthor=F.+Rohdichauthor=W.+Slootauthor=G.+Walterauthor=U.+Zanelliauthor=O.+Schadtauthor=M.+Klein&title=Abstract+DDT02%E2%80%9301%3A+First-Time+Disclosure+of+M3258%3A+A+Selective+Inhibitor+of+the+Immunoproteasome+Subunit+LMP7+with+Potential+for+Improved+Therapeutic+Utility+in+Multiple+Myeloma+Compared+to+Pan-Proteasome+Inhibitors&doi=10.1158%2F1538-7445.AM2019-DDT02-01"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-DDT02-01&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-DDT02-01%26sid%3Dliteratum%253Aachs%26aulast%3DSanderson%26aufirst%3DM.%26aulast%3DBusch%26aufirst%3DM.%26aulast%3DEsdar%26aufirst%3DC.%26aulast%3DFriese-Hamim%26aufirst%3DM.%26aulast%3DKrier%26aufirst%3DM.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DMusil%26aufirst%3DD.%26aulast%3DRohdich%26aufirst%3DF.%26aulast%3DSloot%26aufirst%3DW.%26aulast%3DWalter%26aufirst%3DG.%26aulast%3DZanelli%26aufirst%3DU.%26aulast%3DSchadt%26aufirst%3DO.%26aulast%3DKlein%26aufirst%3DM.%26atitle%3DAbstract%2520DDT02%25E2%2580%259301%253A%2520First-Time%2520Disclosure%2520of%2520M3258%253A%2520A%2520Selective%2520Inhibitor%2520of%2520the%2520Immunoproteasome%2520Subunit%2520LMP7%2520with%2520Potential%2520for%2520Improved%2520Therapeutic%2520Utility%2520in%2520Multiple%2520Myeloma%2520Compared%2520to%2520Pan-Proteasome%2520Inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3DDDT02-01%26doi%3D10.1158%2F1538-7445.AM2019-DDT02-01" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Downey-Kopyscinski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daily, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florea, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisselev, A. F.</span></span> <span> </span><span class="NLM_article-title">An Inhibitor of Proteasome B2 Sites Sensitizes Myeloma Cells to Immunoproteasome Inhibitors</span>. <i>Blood Adv.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">2443</span>â <span class="NLM_lpage">2451</span>, <span class="refDoi">Â DOI: 10.1182/bloodadvances.2018016360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1182%2Fbloodadvances.2018016360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=30266819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFWhtL7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2018&pages=2443-2451&issue=19&author=S.+Downey-Kopyscinskiauthor=E.+W.+Dailyauthor=M.+Gautierauthor=A.+Bhattauthor=B.+I.+Floreaauthor=C.+S.+Mitsiadesauthor=P.+G.+Richardsonauthor=C.+Driessenauthor=H.+S.+Overkleeftauthor=A.+F.+Kisselev&title=An+Inhibitor+of+Proteasome+B2+Sites+Sensitizes+Myeloma+Cells+to+Immunoproteasome+Inhibitors&doi=10.1182%2Fbloodadvances.2018016360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">An inhibitor of proteasome Î²2 sites sensitizes myeloma cells to immunoproteasome inhibitors</span></div><div class="casAuthors">Downey-Kopyscinski, Sondra; Daily, Ellen W.; Gautier, Marc; Bhatt, Ananta; Florea, Bogdan I.; Mitsiades, Constantine S.; Richardson, Paul G.; Driessen, Christoph; Overkleeft, Herman S.; Kisselev, Alexei F.</div><div class="citationInfo"><span class="NLM_cas:title">Blood Advances</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2443-2451</span>CODEN:
                <span class="NLM_cas:coden">BALDBA</span>;
        ISSN:<span class="NLM_cas:issn">2473-9537</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Proteasome inhibitors bortezomib, carfilzomib and ixazomib (approved by the US Food and Drug Administration [FDA]) induce remissions in patients with multiple myeloma (MM), but most patients eventually become resistant.  MM and other hematol. malignancies express ubiquitous constitutive proteasomes and lymphoid tissue-specific immunoproteasomes; immunoproteasome expression is increased in resistant patients.  Immunoproteasomes contain 3 distinct pairs of active sites, Î²5i, Î²1i, and Î²2i, which are different from their constitutive Î²5c, Î²1c, and Î²2c counterparts.  Bortezomib and carfilzomib block Î²5c and Î²5i sites.  We report here that pharmacol. relevant concns. of Î²5i-specific inhibitor ONX-0914 show cytotoxicity in MM cell lines similar to that of carfilzomib and bortezomib.  In addn., increasing immunoproteasome expression by interferon-Î³ increases sensitivity to ONX-0914 but not to carfilzomib.  LU-102, an inhibitor of Î²2 sites, dramatically sensitizes MM cell lines and primary cells to ONX-0914.  ONX-0914 synergizes with all FDA-approved proteasome inhibitors in MM in vitro and in vivo.  Thus, immunoproteasome inhibitors, currently in clin. trials for the treatment of autoimmune diseases, should also be considered for the treatment of MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwFqWlmqq7yrVg90H21EOLACvtfcHk0liGAtoKig4Jhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFWhtL7O&md5=cf4301160cd5251989f7cde1ecff4a89</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1182%2Fbloodadvances.2018016360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fbloodadvances.2018016360%26sid%3Dliteratum%253Aachs%26aulast%3DDowney-Kopyscinski%26aufirst%3DS.%26aulast%3DDaily%26aufirst%3DE.%2BW.%26aulast%3DGautier%26aufirst%3DM.%26aulast%3DBhatt%26aufirst%3DA.%26aulast%3DFlorea%26aufirst%3DB.%2BI.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DDriessen%26aufirst%3DC.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26atitle%3DAn%2520Inhibitor%2520of%2520Proteasome%2520B2%2520Sites%2520Sensitizes%2520Myeloma%2520Cells%2520to%2520Immunoproteasome%2520Inhibitors%26jtitle%3DBlood%2520Adv.%26date%3D2018%26volume%3D2%26issue%3D19%26spage%3D2443%26epage%3D2451%26doi%3D10.1182%2Fbloodadvances.2018016360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, H. W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderl, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moebius, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMinn, D. L.</span></span> <span> </span><span class="NLM_article-title">Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 <i>S</i>, 3 <i>R</i>)- <i>N</i> -((<i>S</i>)-3-(Cyclopent-1-En-1-Yl)-1-((<i>R</i>)-2-Methyloxiran-2-Yl)-1-Oxopropan-2-Yl)-3-Hydroxy-3-(4-Methoxyphenyl)-2-((<i>S</i>)-2-(2-Morpholinoacetamido)Propanamido)Propenamide)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">11127</span>â <span class="NLM_lpage">11143</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b01201</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01201" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVKltLfF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=11127-11143&issue=24&author=H.+W.+B.+Johnsonauthor=E.+Loweauthor=J.+L.+Anderlauthor=A.+Fanauthor=T.+Muchamuelauthor=S.+Bowersauthor=D.+C.+Moebiusauthor=C.+Kirkauthor=D.+L.+McMinn&title=Required+Immunoproteasome+Subunit+Inhibition+Profile+for+Anti-Inflammatory+Efficacy+and+Clinical+Candidate+KZR-616+%28%282+S%2C+3+R%29-+N+-%28%28S%29-3-%28Cyclopent-1-En-1-Yl%29-1-%28%28R%29-2-Methyloxiran-2-Yl%29-1-Oxopropan-2-Yl%29-3-Hydroxy-3-%284-Methoxyphenyl%29-2-%28%28S%29-2-%282-Morpholinoacetamido%29Propanamido%29Propenamide%29&doi=10.1021%2Facs.jmedchem.8b01201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2S,3R)-N-((S)-3-(Cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenamide)</span></div><div class="casAuthors">Johnson, Henry W. B.; Lowe, Eric; Anderl, Janet L.; Fan, Andrea; Muchamuel, Tony; Bowers, Simeon; Moebius, David C.; Kirk, Christopher; McMinn, Dustin L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11127-11143</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selective immunoproteasome inhibition is a promising approach for treating autoimmune disorders, but optimal proteolytic active site subunit inhibition profiles remain unknown.  We reveal here our design of peptide epoxyketone-based selective low mol. mass polypeptide-7 (LMP7) and multicatalytic endopeptidase complex subunit-1 (MECL-1) subunit inhibitors.  Utilizing these and our previously disclosed low mol. mass polypeptide-2 (LMP2) inhibitor, we demonstrate a requirement of dual LMP7/LMP2 or LMP7/MECL-1 subunit inhibition profiles for potent cytokine expression inhibition and in vivo efficacy in an inflammatory disease model.  These and addnl. findings toward optimized soly. led the design and selection of KZR-616 disclosed here and presently in clin. trials for treatment of rheumatic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNq1pg3kpVXrVg90H21EOLACvtfcHk0lgOVviRLxbu8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVKltLfF&md5=70170b636fbb858edda5f571af45ca7f</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01201%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DH.%2BW.%2BB.%26aulast%3DLowe%26aufirst%3DE.%26aulast%3DAnderl%26aufirst%3DJ.%2BL.%26aulast%3DFan%26aufirst%3DA.%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DBowers%26aufirst%3DS.%26aulast%3DMoebius%26aufirst%3DD.%2BC.%26aulast%3DKirk%26aufirst%3DC.%26aulast%3DMcMinn%26aufirst%3DD.%2BL.%26atitle%3DRequired%2520Immunoproteasome%2520Subunit%2520Inhibition%2520Profile%2520for%2520Anti-Inflammatory%2520Efficacy%2520and%2520Clinical%2520Candidate%2520KZR-616%2520%2528%25282%2520S%252C%25203%2520R%2529-%2520N%2520-%2528%2528S%2529-3-%2528Cyclopent-1-En-1-Yl%2529-1-%2528%2528R%2529-2-Methyloxiran-2-Yl%2529-1-Oxopropan-2-Yl%2529-3-Hydroxy-3-%25284-Methoxyphenyl%2529-2-%2528%2528S%2529-2-%25282-Morpholinoacetamido%2529Propanamido%2529Propenamide%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D24%26spage%3D11127%26epage%3D11143%26doi%3D10.1021%2Facs.jmedchem.8b01201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Firestein, G. S.</span></span> <span> </span><span class="NLM_article-title">The Disease Formerly Known as Rheumatoid Arthritis</span>. <i>Arthritis Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">114</span>, <span class="refDoi">Â DOI: 10.1186/ar4593</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1186%2Far4593" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=25167330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252Fls1SqtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=114&issue=3&author=G.+S.+Firestein&title=The+Disease+Formerly+Known+as+Rheumatoid+Arthritis&doi=10.1186%2Far4593"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">The disease formerly known as rheumatoid arthritis</span></div><div class="casAuthors">Firestein Gary S</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis research & therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">114</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Rheumatoid arthritis is a complex disease where predetermined and stochastic factors conspire to confer disease susceptibility.  In light of the diverse responses to targeted therapies, rheumatoid arthritis might represent a final common clinical phenotype that reflects many pathogenic pathways.  Therefore, it might be appropriate to begin thinking about rheumatoid arthritis as a syndrome rather than a disease.  Use of genetics, epigenetics, microbiomics,and other unbiased technologies will probably permit stratification of patients based on mechanisms of disease rather than by clinical phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcruvwZJ_w7gWRJ3OJdH_qfW6udTcc2eZKnE96mBrBvLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252Fls1SqtQ%253D%253D&md5=55e32e410846b2185c1d928fea511f66</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1186%2Far4593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Far4593%26sid%3Dliteratum%253Aachs%26aulast%3DFirestein%26aufirst%3DG.%2BS.%26atitle%3DThe%2520Disease%2520Formerly%2520Known%2520as%2520Rheumatoid%2520Arthritis%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2014%26volume%3D16%26issue%3D3%26spage%3D114%26doi%3D10.1186%2Far4593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Catrina, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ytterberg, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynisdottir, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MalmstrÃ¶m, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klareskog, L.</span></span> <span> </span><span class="NLM_article-title">Lungs, Joints and Immunity against Citrullinated Proteins in Rheumatoid Arthritis</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">645</span>â <span class="NLM_lpage">653</span>, <span class="refDoi">Â DOI: 10.1038/nrrheum.2014.115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fnrrheum.2014.115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=25072264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1GksLrF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=645-653&issue=11&author=A.+I.+Catrinaauthor=A.+J.+Ytterbergauthor=G.+Reynisdottirauthor=V.+Malmstr%C3%B6mauthor=L.+Klareskog&title=Lungs%2C+Joints+and+Immunity+against+Citrullinated+Proteins+in+Rheumatoid+Arthritis&doi=10.1038%2Fnrrheum.2014.115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Lungs, joints and immunity against citrullinated proteins in rheumatoid arthritis</span></div><div class="casAuthors">Catrina, Anca I.; Ytterberg, A. Jimmy; Reynisdottir, Gudrun; Malmstroem, Vivianne; Klareskog, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Rheumatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">645-653</span>CODEN:
                <span class="NLM_cas:coden">NRRACB</span>;
        ISSN:<span class="NLM_cas:issn">1759-4790</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Rheumatoid arthritis (RA) is a prototype for a criterion-defined inflammatory disease, for which the etiol. and initial mol. pathogenesis has been elusive for a long time.  We describe in this Review how studies on the interplay between specific immunity, alongside genetic and environmental predisposing factors, provide new tools to understand the mol. basis of distinct subsets of the disease.  A particular emphasis is on the possibility that pathogenic immune reactions might be initiated at other sites than the joints, and that the lungs could harbor such sites.  New data strengthen this concept, showing that local immunity towards citrullinated proteins and accompanying inflammation might be present in the lungs early during disease development.  This progress makes RA an interesting case for the future development of therapies that might be directed against disease-inducing immunity even before inflammation and destruction of joints has begun.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbs3opo4mVm7Vg90H21EOLACvtfcHk0ljpwKbA5g6HZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1GksLrF&md5=5034084a9f9a6163e6c2db19db69f2f1</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2014.115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2014.115%26sid%3Dliteratum%253Aachs%26aulast%3DCatrina%26aufirst%3DA.%2BI.%26aulast%3DYtterberg%26aufirst%3DA.%2BJ.%26aulast%3DReynisdottir%26aufirst%3DG.%26aulast%3DMalmstr%25C3%25B6m%26aufirst%3DV.%26aulast%3DKlareskog%26aufirst%3DL.%26atitle%3DLungs%252C%2520Joints%2520and%2520Immunity%2520against%2520Citrullinated%2520Proteins%2520in%2520Rheumatoid%2520Arthritis%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2014%26volume%3D10%26issue%3D11%26spage%3D645%26epage%3D653%26doi%3D10.1038%2Fnrrheum.2014.115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Catrina, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshua, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klareskog, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MalmstrÃ¶m, V.</span></span> <span> </span><span class="NLM_article-title">Mechanisms Involved in Triggering Rheumatoid Arthritis</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>269</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">162</span>â <span class="NLM_lpage">174</span>, <span class="refDoi">Â DOI: 10.1111/imr.12379</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1111%2Fimr.12379" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=26683152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVeqtrzN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=2016&pages=162-174&issue=1&author=A.+I.+Catrinaauthor=V.+Joshuaauthor=L.+Klareskogauthor=V.+Malmstr%C3%B6m&title=Mechanisms+Involved+in+Triggering+Rheumatoid+Arthritis&doi=10.1111%2Fimr.12379"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms involved in triggering rheumatoid arthritis</span></div><div class="casAuthors">Catrina, Anca I.; Joshua, Vijay; Klareskog, Lars; Malmstroem, Vivianne</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">162-174</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Rheumatoid arthritis (RA) is a chronic inflammatory syndrome with a strong autoimmune component.  The autoantigens in RA are neither tissue nor organ-specific, but comprise a broad collection of post-translational modified proteins, such as citrullinated proteins.  These modifications are likely to be triggered by innate stimuli.  In genetically susceptible hosts, they can lead to a more substantiated secondary autoimmune reaction targeting the joints and pptg. the clin. onset of RA.  Both innate and adaptive mechanisms will then closely interplay to promote chronic joint inflammation in the several absence of appropriate treatment.  This scenario, is shared with other autoimmune diseases where potentially pathogenic immune responses are present already before disease onset.  Better understanding of these processes will allow both earlier diagnosis of RA and identification of those healthy individuals that are at risk of developing disease, opening possibilities for disease prevention.  In this review, we discuss the iterative processes of innate and adaptive immunity responsible for the (longitudinal) development of immune reactions that may contribute to the development of RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfWw33Fo2zLLVg90H21EOLACvtfcHk0ljpwKbA5g6HZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVeqtrzN&md5=9dfcd32551a9119e1476b922f121cee4</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1111%2Fimr.12379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fimr.12379%26sid%3Dliteratum%253Aachs%26aulast%3DCatrina%26aufirst%3DA.%2BI.%26aulast%3DJoshua%26aufirst%3DV.%26aulast%3DKlareskog%26aufirst%3DL.%26aulast%3DMalmstr%25C3%25B6m%26aufirst%3DV.%26atitle%3DMechanisms%2520Involved%2520in%2520Triggering%2520Rheumatoid%2520Arthritis%26jtitle%3DImmunol.%2520Rev.%26date%3D2016%26volume%3D269%26issue%3D1%26spage%3D162%26epage%3D174%26doi%3D10.1111%2Fimr.12379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Firestein, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I. B.</span></span> <span> </span><span class="NLM_article-title">Immunopathogenesis of Rheumatoid Arthritis</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">183</span>â <span class="NLM_lpage">196</span>, <span class="refDoi">Â DOI: 10.1016/j.immuni.2017.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.immuni.2017.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=28228278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtlerur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2017&pages=183-196&issue=2&author=G.+S.+Firesteinauthor=I.+B.+McInnes&title=Immunopathogenesis+of+Rheumatoid+Arthritis&doi=10.1016%2Fj.immuni.2017.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Immunopathogenesis of Rheumatoid Arthritis</span></div><div class="casAuthors">Firestein, Gary S.; McInnes, Iain B.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">183-196</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Rheumatoid arthritis (RA) is the most common inflammatory arthropathy.  The majority of evidence, derived from genetics, tissue analyses, models, and clin. studies, points to an immune-mediated etiol. assocd. with stromal tissue dysregulation that together propagate chronic inflammation and articular destruction.  A pre-RA phase lasting months to years may be characterized by the presence of circulating autoantibodies, increasing concn. and range of inflammatory cytokines and chemokines, and altered metab.  Clin. disease onset comprises synovitis and systemic comorbidities affecting the vasculature, metab., and bone.  Targeted immune therapeutics and aggressive treatment strategies have substantially improved clin. outcomes and informed pathogenetic understanding, but no cure as yet exists.  Herein we review recent data that support intriguing models of disease pathogenesis.  They allude to the possibility of restoration of immunol. homeostasis and thus a state of tolerance assocd. with drug-free remission.  This target represents a bold vision for the future of RA therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCIKsD764_-bVg90H21EOLACvtfcHk0ljpwKbA5g6HZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtlerur8%253D&md5=dc7e6fe1fb3a5c9470718f1b2699f9e0</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2017.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2017.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DFirestein%26aufirst%3DG.%2BS.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26atitle%3DImmunopathogenesis%2520of%2520Rheumatoid%2520Arthritis%26jtitle%3DImmunity%26date%3D2017%26volume%3D46%26issue%3D2%26spage%3D183%26epage%3D196%26doi%3D10.1016%2Fj.immuni.2017.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weyand, C. M.</span></span> <span> </span><span class="NLM_article-title">The Influence of HLA-DRB1 Genes on Disease Severity in Rheumatoid Arthritis</span>. <i>Ann. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>117</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">801</span>, <span class="refDoi">Â DOI: 10.7326/0003-4819-117-10-801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.7326%2F0003-4819-117-10-801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1416553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADyaK3s%252Fjs12htQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=1992&pages=801&issue=10&author=C.+M.+Weyand&title=The+Influence+of+HLA-DRB1+Genes+on+Disease+Severity+in+Rheumatoid+Arthritis&doi=10.7326%2F0003-4819-117-10-801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis</span></div><div class="casAuthors">Weyand C M; Hicok K C; Conn D L; Goronzy J J</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">801-6</span>
        ISSN:<span class="NLM_cas:issn">0003-4819</span>.
    </div><div class="casAbstract">OBJECTIVE:  To explore the role of HLA-DRB1 genes in determining disease severity in rheumatoid arthritis.  DESIGN:  Case series of patients with seropositive rheumatoid arthritis.  SETTING:  The outpatient clinic of the Division of Rheumatology, Mayo Clinic.  PATIENTS:  One hundred and two patients with seropositive, erosive rheumatoid arthritis and a minimum disease duration of 3 years.  MEASUREMENTS:  Patients were genotyped for both HLA-DRB1 alleles and were categorized according to the expression of one or two disease-linked HLA-DRB1 alleles.  Identification of HLA-DRB1 alleles was done by the polymerase chain reaction and subsequent oligonucleotide hybridization.  Homozygosity for allelic variants was confirmed by sequence analysis.  Immunogenetically defined patient subgroups were retrospectively evaluated for joint destruction and patterns of disease manifestation, including rheumatoid organ disease.  RESULTS:  Of 102 patients, 98 (96%) expressed the disease-linked sequence polymorphism.  Forty-seven patients (46%) carried a double dose of the relevant sequence stretch: Twenty-eight patients expressed HLA-DRB1*04 variants on both alleles, and 19 combined an HLA-DRB*04 variant with HLA-DRB1*0101 or DRB1*1402.  Nodular disease was present in 100% of patients typed as HLA-DRB1*04/04 and in 59% of patients typed as HLA-DRB1*04 and who had inherited only a single dose of the disease-linked sequence polymorphism (P < 0.0001).  Major organ systems were involved in 61% and 11% of these two patient groups, respectively (P < 0.0001); and joint surgery was required in 61% and 25% (P < 0.002), respectively.  Patients typed as HLA-DR*04/01 had intermediate clinical courses.  CONCLUSION:  Genotyping patients with rheumatoid arthritis for both HLA-DRB1 alleles identifies clinical subsets with distinct profiles of disease manifestations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS65dOdFeMH0xLDWw4HIq2sfW6udTcc2eafCxmTj9RLU7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s%252Fjs12htQ%253D%253D&md5=f6014e58e6e74c45590557d54260e0c5</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-117-10-801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-117-10-801%26sid%3Dliteratum%253Aachs%26aulast%3DWeyand%26aufirst%3DC.%2BM.%26atitle%3DThe%2520Influence%2520of%2520HLA-DRB1%2520Genes%2520on%2520Disease%2520Severity%2520in%2520Rheumatoid%2520Arthritis%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D1992%26volume%3D117%26issue%3D10%26spage%3D801%26doi%3D10.7326%2F0003-4819-117-10-801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scally, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nel, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijeyewickrema, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckle, S. B.G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van
Heemst, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCluskey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toes, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Gruta, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcell, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossjohn, J.</span></span> <span> </span><span class="NLM_article-title">A Molecular Basis for the Association of the HLA-DRB1 Locus, Citrullination, and Rheumatoid Arthritis</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>210</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2569</span>â <span class="NLM_lpage">2582</span>, <span class="refDoi">Â DOI: 10.1084/jem.20131241</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1084%2Fjem.20131241" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=24190431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKjsbfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2013&pages=2569-2582&issue=12&author=S.+W.+Scallyauthor=J.+Petersenauthor=S.+C.+Lawauthor=N.+L.+Dudekauthor=H.+J.+Nelauthor=K.+L.+Lohauthor=L.+C.+Wijeyewickremaauthor=S.+B.G.+Eckleauthor=J.+van%0AHeemstauthor=R.+N.+Pikeauthor=J.+McCluskeyauthor=R.+E.+Toesauthor=N.+L.+La+Grutaauthor=A.+W.+Purcellauthor=H.+H.+Reidauthor=R.+Thomasauthor=J.+Rossjohn&title=A+Molecular+Basis+for+the+Association+of+the+HLA-DRB1+Locus%2C+Citrullination%2C+and+Rheumatoid+Arthritis&doi=10.1084%2Fjem.20131241"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis</span></div><div class="casAuthors">Scally, Stephen W.; Petersen, Jan; Law, Soi Cheng; Dudek, Nadine L.; Nel, Hendrik J.; Loh, Khai Lee; Wijeyewickrema, Lakshmi C.; Eckle, Sidonia B. G.; van Heemst, Jurgen; Pike, Robert N.; McCluskey, James; Toes, Rene E.; La Gruta, Nicole L.; Purcell, Anthony W.; Reid, Hugh H.; Thomas, Ranjeny; Rossjohn, Jamie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2569-2582</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Rheumatoid arthritis (RA) is strongly assocd. with the human leukocyte antigen (HLA)-DRB1 locus that possesses the shared susceptibility epitope (SE) and the citrullination of self-antigens.  We show how citrullinated aggrecan and vimentin epitopes bind to HLA-DRB1*04:01/04.  Citrulline was accommodated within the electropos. P4 pocket of HLA-DRB1*04:01/04, whereas the electroneg. P4 pocket of the RA-resistant HLA-DRB1*04:02 allomorph interacted with arginine or citrulline-contg. epitopes.  Peptide elution studies revealed P4 arginine-contg. peptides from HLA-DRB1*04:02, but not from HLA-DRB1*04:01/04.  Citrullination altered protease susceptibility of vimentin, thereby generating self-epitopes that are presented to T cells in HLA-DRB1*04:01+ individuals.  Using HLA-II tetramers, we obsd. citrullinated vimentin- and aggrecan-specific CD4+ T cells in the peripheral blood of HLA-DRB1*04:01+ RA-affected and healthy individuals.  In RA patients, autoreactive T cell nos. correlated with disease activity and were deficient in regulatory T cells relative to healthy individuals.  These findings reshape our understanding of the assocn. between citrullination, the HLA-DRB1 locus, and T cell autoreactivity in RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaneyo6yni2rVg90H21EOLACvtfcHk0lhmSpKZ_mlA8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKjsbfN&md5=a4b53a2a1ca25c49c00265a776b3f048</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1084%2Fjem.20131241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20131241%26sid%3Dliteratum%253Aachs%26aulast%3DScally%26aufirst%3DS.%2BW.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DLaw%26aufirst%3DS.%2BC.%26aulast%3DDudek%26aufirst%3DN.%2BL.%26aulast%3DNel%26aufirst%3DH.%2BJ.%26aulast%3DLoh%26aufirst%3DK.%2BL.%26aulast%3DWijeyewickrema%26aufirst%3DL.%2BC.%26aulast%3DEckle%26aufirst%3DS.%2BB.G.%26aulast%3Dvan%2BHeemst%26aufirst%3DJ.%26aulast%3DPike%26aufirst%3DR.%2BN.%26aulast%3DMcCluskey%26aufirst%3DJ.%26aulast%3DToes%26aufirst%3DR.%2BE.%26aulast%3DLa%2BGruta%26aufirst%3DN.%2BL.%26aulast%3DPurcell%26aufirst%3DA.%2BW.%26aulast%3DReid%26aufirst%3DH.%2BH.%26aulast%3DThomas%26aufirst%3DR.%26aulast%3DRossjohn%26aufirst%3DJ.%26atitle%3DA%2520Molecular%2520Basis%2520for%2520the%2520Association%2520of%2520the%2520HLA-DRB1%2520Locus%252C%2520Citrullination%252C%2520and%2520Rheumatoid%2520Arthritis%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2013%26volume%3D210%26issue%3D12%26spage%3D2569%26epage%3D2582%26doi%3D10.1084%2Fjem.20131241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Semerano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minichiello, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bessis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boissier, M.-C.</span></span> <span> </span><span class="NLM_article-title">Novel Immunotherapeutic Avenues for Rheumatoid Arthritis</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">214</span>â <span class="NLM_lpage">229</span>, <span class="refDoi">Â DOI: 10.1016/j.molmed.2016.01.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.molmed.2016.01.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=26875450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFSku7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=214-229&issue=3&author=L.+Semeranoauthor=E.+Minichielloauthor=N.+Bessisauthor=M.-C.+Boissier&title=Novel+Immunotherapeutic+Avenues+for+Rheumatoid+Arthritis&doi=10.1016%2Fj.molmed.2016.01.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Immunotherapeutic Avenues for Rheumatoid Arthritis</span></div><div class="casAuthors">Semerano, Luca; Minichiello, Emeline; Bessis, Natacha; Boissier, Marie-Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">214-229</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Rheumatoid arthritis (RA) is the most common inflammatory rheumatic disease.  It leads to irreversible joint damage, phys. handicap, and reduced life expectancy.  The past two decades have seen considerable therapeutic advances with the development of biol. treatments to block proinflammatory cytokines or modulate lymphocyte function, followed by the development of small mols. to target intracellular signaling.  Nevertheless, only a minority of patients can achieve disease remission, esp. long term, warranting further investigation into newer therapeutic options.  Targeting single proinflammatory pathways may not be sufficient, as suggested by variable results with T helper (Th)-17-related cytokine blockade.  Multilevel information from 'omics' techniques along with data from mechanistic studies might facilitate the identification of pivotal checkpoints in RA disease pathogenesis and the subsequent development of new effective treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaylgOPcQjrbVg90H21EOLACvtfcHk0lh5HmMTxZtOqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFSku7k%253D&md5=57c882580d93a5c290184995061a41df</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2016.01.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2016.01.005%26sid%3Dliteratum%253Aachs%26aulast%3DSemerano%26aufirst%3DL.%26aulast%3DMinichiello%26aufirst%3DE.%26aulast%3DBessis%26aufirst%3DN.%26aulast%3DBoissier%26aufirst%3DM.-C.%26atitle%3DNovel%2520Immunotherapeutic%2520Avenues%2520for%2520Rheumatoid%2520Arthritis%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2016%26volume%3D22%26issue%3D3%26spage%3D214%26epage%3D229%26doi%3D10.1016%2Fj.molmed.2016.01.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hallermalm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivoltini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiessling, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitskaya, J.</span></span> <span> </span><span class="NLM_article-title">Tumor Necrosis Factor-Î± Induces Coordinated Changes in Major Histocompatibility Class I Presentation Pathway, Resulting in Increased Stability of Class I Complexes at the Cell Surface</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>98</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1108</span>â <span class="NLM_lpage">1115</span>, <span class="refDoi">Â DOI: 10.1182/blood.V98.4.1108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1182%2Fblood.V98.4.1108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=11493458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmtFeisbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=1108-1115&issue=4&author=K.+Hallermalmauthor=K.+Sekiauthor=C.+Weiauthor=C.+Castelliauthor=L.+Rivoltiniauthor=R.+Kiesslingauthor=J.+Levitskaya&title=Tumor+Necrosis+Factor-%CE%B1+Induces+Coordinated+Changes+in+Major+Histocompatibility+Class+I+Presentation+Pathway%2C+Resulting+in+Increased+Stability+of+Class+I+Complexes+at+the+Cell+Surface&doi=10.1182%2Fblood.V98.4.1108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor necrosis factor-Î± induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface</span></div><div class="casAuthors">Hallermalm, Kristian; Seki, Katzutake; Wei, Chenhong; Castelli, Chiara; Rivoltini, Licia; Kiessling, Rolf; Levitskaya, Jelena</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1108-1115</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">It is demonstrated that similar to interferon Î³ (IFN-Î³), tumor necrosis factor-Î± (TNF-Î±) induces coordinated changes at different steps of the major histocompatibility complex (MHC) class I processing and presentation pathway in nonprofessional antigen-presenting cells (APCs).  TNF-Î± up-regulates the expression of 3 catalytic immunoproteasome subunits-LMP2, LMP7, and MECL-1-the immunomodulatory proteasome activator PA28Î±, the TAP1/TAP2 heterodimer, and the total pool of MHC class I heavy chain.  It was also found that in TNF-Î±-treated cells, MHC class I mols. reconstitute more rapidly and have an increased av. half-life at the cell surface.  Biochem. changes induced by TNF-Î± in the MHC class I pathway were translated into increased sensitivity of TNF-Î±-treated targets to lysis by CD8+ cytotoxic T cells, demonstrating improved presentation of at least certain endogenously processed MHC class I-restricted peptide epitopes.  Significantly, it was demonstrated that the effects of TNF-Î± obsd. in this exptl. system were not mediated through the induction of IFN-Î³.  It appears to be likely that TNF-Î±-mediated effects on MHC class I processing and presentation do not involve any intermediate messengers.  Collectively, these data demonstrate the existence of yet another biol. activity exerted by TNF-Î±, namely its capacity to act as a coordinated multi-step modulator of the MHC class I pathway of antigen processing and presentation.  These results suggest that TNF-Î± may be useful when a concerted up-regulation of the MHC class I presentation machinery is required but cannot be achieved by IFN-Î³.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNs_fYNnbk67Vg90H21EOLACvtfcHk0lh5HmMTxZtOqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmtFeisbo%253D&md5=d7ed804b083677777a5f9c3635d8e2fa</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1182%2Fblood.V98.4.1108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V98.4.1108%26sid%3Dliteratum%253Aachs%26aulast%3DHallermalm%26aufirst%3DK.%26aulast%3DSeki%26aufirst%3DK.%26aulast%3DWei%26aufirst%3DC.%26aulast%3DCastelli%26aufirst%3DC.%26aulast%3DRivoltini%26aufirst%3DL.%26aulast%3DKiessling%26aufirst%3DR.%26aulast%3DLevitskaya%26aufirst%3DJ.%26atitle%3DTumor%2520Necrosis%2520Factor-%25CE%25B1%2520Induces%2520Coordinated%2520Changes%2520in%2520Major%2520Histocompatibility%2520Class%2520I%2520Presentation%2520Pathway%252C%2520Resulting%2520in%2520Increased%2520Stability%2520of%2520Class%2520I%2520Complexes%2520at%2520the%2520Cell%2520Surface%26jtitle%3DBlood%26date%3D2001%26volume%3D98%26issue%3D4%26spage%3D1108%26epage%3D1115%26doi%3D10.1182%2Fblood.V98.4.1108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qureshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perera, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenschat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Splitter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, S. N.</span></span> <span> </span><span class="NLM_article-title">The Proteasome as a Lipopolysaccharide-Binding Protein in Macrophages: Differential Effects of Proteasome Inhibition on Lipopolysaccharide-Induced Signaling Events</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>171</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1515</span>â <span class="NLM_lpage">1525</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.171.3.1515</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.4049%2Fjimmunol.171.3.1515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=12874245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlsFyltbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2003&pages=1515-1525&issue=3&author=N.+Qureshiauthor=P.-Y.+Pereraauthor=J.+Shenauthor=G.+Zhangauthor=A.+Lenschatauthor=G.+Splitterauthor=D.+C.+Morrisonauthor=S.+N.+Vogel&title=The+Proteasome+as+a+Lipopolysaccharide-Binding+Protein+in+Macrophages%3A+Differential+Effects+of+Proteasome+Inhibition+on+Lipopolysaccharide-Induced+Signaling+Events&doi=10.4049%2Fjimmunol.171.3.1515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">The Proteasome as a Lipopolysaccharide-Binding Protein in Macrophages: Differential Effects of Proteasome Inhibition on Lipopolysaccharide-Induced Signaling Events</span></div><div class="casAuthors">Qureshi, Nilofer; Perera, Pin-Yu; Shen, Jing; Zhang, Guochi; Lenschat, Arnd; Splitter, Gary; Morrison, David C.; Vogel, Stefanie N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1515-1525</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The authors have developed a novel LPS probe using a highly purified and homogeneous prepn. of [3H] Escherichia coli LPS from the deep rough mutant, which contains a covalently linked, photoactivable 4-p-(azidosalicylamido)-butylamine group.  This cross-linker was used to identify the LPS-binding proteins in membranes of the murine-macrophage-like cell line RAW 264.7.  The Î±-subunit (PSMA1 C2, 29.5 kDa) and the Î²-subunit (PSMB4 N3, 24.36 kDa) of the 20S proteasome complex were identified as LPS-binding proteins.  This is the first report demonstrating LPS binding to enzymes such as the proteasome subunits.  Functionally, LPS enhanced the chymotrypsin-like activity of the proteasome to degrade synthetic peptides in vitro and, conversely, the proteasome inhibitor lactacystin completely blocked the LPS-induced proteasome's chymotrypsin activity as well as macrophage TNF-Î± secretion and the expression of multiple inflammatory mediator genes.  Lactacystin also completely blocked the LPS-induced expression of Toll-like receptor 2 mRNA.  In addn., lactacystin dysregulated mitogen-activated protein kinase phosphorylation in LPS-stimulated macrophages, but failed to inhibit IL-1 receptor-assocd. kinase-1 activity.  Importantly, lactacystin also prevented LPS-induced shock in mice.  These data strongly suggest that the proteasome complex regulates the LPS-induced signal transduction and that it may be an important therapeutic target in Gram-neg. sepsis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoICoGVmBiUsrVg90H21EOLACvtfcHk0ljZwh66dYBUPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlsFyltbY%253D&md5=a36e0928159357968b2201b606d6ee3e</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.171.3.1515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.171.3.1515%26sid%3Dliteratum%253Aachs%26aulast%3DQureshi%26aufirst%3DN.%26aulast%3DPerera%26aufirst%3DP.-Y.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DLenschat%26aufirst%3DA.%26aulast%3DSplitter%26aufirst%3DG.%26aulast%3DMorrison%26aufirst%3DD.%2BC.%26aulast%3DVogel%26aufirst%3DS.%2BN.%26atitle%3DThe%2520Proteasome%2520as%2520a%2520Lipopolysaccharide-Binding%2520Protein%2520in%2520Macrophages%253A%2520Differential%2520Effects%2520of%2520Proteasome%2520Inhibition%2520on%2520Lipopolysaccharide-Induced%2520Signaling%2520Events%26jtitle%3DJ.%2520Immunol.%26date%3D2003%26volume%3D171%26issue%3D3%26spage%3D1515%26epage%3D1525%26doi%3D10.4049%2Fjimmunol.171.3.1515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aujay, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalim, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylvain, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ring, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shields, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shwonek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parlati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span> <span> </span><span class="NLM_article-title">A Selective Inhibitor of the Immunoproteasome Subunit LMP7 Blocks Cytokine Production and Attenuates Progression of Experimental Arthritis</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">781</span>â <span class="NLM_lpage">787</span>, <span class="refDoi">Â DOI: 10.1038/nm.1978</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fnm.1978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=19525961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1ShtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=781-787&issue=7&author=T.+Muchamuelauthor=M.+Baslerauthor=M.+A.+Aujayauthor=E.+Suzukiauthor=K.+W.+Kalimauthor=C.+Lauerauthor=C.+Sylvainauthor=E.+R.+Ringauthor=J.+Shieldsauthor=J.+Jiangauthor=P.+Shwonekauthor=F.+Parlatiauthor=S.+Demoauthor=M.+Bennettauthor=C.+Kirkauthor=M.+Groettrup&title=A+Selective+Inhibitor+of+the+Immunoproteasome+Subunit+LMP7+Blocks+Cytokine+Production+and+Attenuates+Progression+of+Experimental+Arthritis&doi=10.1038%2Fnm.1978"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis</span></div><div class="casAuthors">Muchamuel, Tony; Basler, Michael; Aujay, Monette A.; Suzuki, Erika; Kalim, Khalid W.; Lauer, Christoph; Sylvain, Catherine; Ring, Eileen R.; Shields, Jamie; Jiang, Jing; Shwonek, Peter; Parlati, Francesco; Demo, Susan D.; Bennett, Mark K.; Kirk, Christopher J.; Groettrup, Marcus</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">781-787</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The immunoproteasome, a distinct class of proteasome found predominantly in monocytes and lymphocytes, is known to shape the antigenic repertoire presented on class I major histocompatibility complexes (MHC-I).  However, a specific role for the immunoproteasome in regulating other facets of immune responses has not been established.  The authors describe here the characterization of PR-957, a selective inhibitor of low-mol. mass polypeptide-7 (LMP7, encoded by Psmb8), the chymotrypsin-like subunit of the immunoproteasome.  PR-957 blocked presentation of LMP7-specific, MHC-I-restricted antigens in vitro and in vivo.  Selective inhibition of LMP7 by PR-957 blocked prodn. of interleukin-23 (IL-23) by activated monocytes and interferon-Î³ and IL-2 by T cells.  In mouse models of rheumatoid arthritis, PR-957 treatment reversed signs of disease and resulted in redns. in cellular infiltration, cytokine prodn. and autoantibody levels.  These studies reveal a unique role for LMP7 in controlling pathogenic immune responses and provide a therapeutic rationale for targeting LMP7 in autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJsuXHN4oyBbVg90H21EOLACvtfcHk0ljZwh66dYBUPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1ShtLs%253D&md5=3961ba1ec6786d0318bfa2b64e5e7cfa</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fnm.1978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.1978%26sid%3Dliteratum%253Aachs%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DBasler%26aufirst%3DM.%26aulast%3DAujay%26aufirst%3DM.%2BA.%26aulast%3DSuzuki%26aufirst%3DE.%26aulast%3DKalim%26aufirst%3DK.%2BW.%26aulast%3DLauer%26aufirst%3DC.%26aulast%3DSylvain%26aufirst%3DC.%26aulast%3DRing%26aufirst%3DE.%2BR.%26aulast%3DShields%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DShwonek%26aufirst%3DP.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DDemo%26aufirst%3DS.%26aulast%3DBennett%26aufirst%3DM.%26aulast%3DKirk%26aufirst%3DC.%26aulast%3DGroettrup%26aufirst%3DM.%26atitle%3DA%2520Selective%2520Inhibitor%2520of%2520the%2520Immunoproteasome%2520Subunit%2520LMP7%2520Blocks%2520Cytokine%2520Production%2520and%2520Attenuates%2520Progression%2520of%2520Experimental%2520Arthritis%26jtitle%3DNat.%2520Med.%26date%3D2009%26volume%3D15%26issue%3D7%26spage%3D781%26epage%3D787%26doi%3D10.1038%2Fnm.1978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mishto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellavista, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligorio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Textoris-Taube, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâAlfonso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ListÃ¬, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacmias, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cellini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimaldi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenoglio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposito, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli-Boneschi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galimberti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foschini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kloetzel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceschi, C.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasome LMP2 60HH Variant Alters MBP Epitope Generation and Reduces the Risk to Develop Multiple Sclerosis in Italian Female Population</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">e9287</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0009287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1371%2Fjournal.pone.0009287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=20174631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BC3c7itlKqtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=e9287&issue=2&author=M.+Mishtoauthor=E.+Bellavistaauthor=C.+Ligorioauthor=K.+Textoris-Taubeauthor=A.+Santoroauthor=M.+Giordanoauthor=S.+D%E2%80%99Alfonsoauthor=F.+List%C3%ACauthor=B.+Nacmiasauthor=E.+Celliniauthor=M.+Leoneauthor=L.+Grimaldiauthor=C.+Fenoglioauthor=F.+Espositoauthor=F.+Martinelli-Boneschiauthor=D.+Galimbertiauthor=E.+Scarpiniauthor=U.+Seifertauthor=M.+Amatoauthor=C.+Carusoauthor=M.+Foschiniauthor=P.+Kloetzelauthor=C.+Franceschi&title=Immunoproteasome+LMP2+60HH+Variant+Alters+MBP+Epitope+Generation+and+Reduces+the+Risk+to+Develop+Multiple+Sclerosis+in+Italian+Female+Population&doi=10.1371%2Fjournal.pone.0009287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoproteasome LMP2 60HH variant alters MBP epitope generation and reduces the risk to develop multiple sclerosis in Italian female population</span></div><div class="casAuthors">Mishto Michele; Bellavista Elena; Ligorio Claudia; Textoris-Taube Kathrin; Santoro Aurelia; Giordano Mara; D'Alfonso Sandra; Listi Florinda; Nacmias Benedetta; Cellini Elena; Leone Maurizio; Grimaldi Luigi M E; Fenoglio Chiara; Esposito Federica; Martinelli-Boneschi Filippo; Galimberti Daniela; Scarpini Elio; Seifert Ulrike; Amato Maria Pia; Caruso Calogero; Foschini Maria P; Kloetzel Peter M; Franceschi Claudio</div><div class="citationInfo"><span class="NLM_cas:title">PloS one</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e9287</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Albeit several studies pointed out the pivotal role that CD4+T cells have in Multiple Sclerosis, the CD8+ T cells involvement in the pathology is still in its early phases of investigation.  Proteasome degradation is the key step in the production of MHC class I-restricted epitopes and therefore its activity could be an important element in the activation and regulation of autoreactive CD8+ T cells in Multiple Sclerosis.  METHODOLOGY/PRINCIPAL FINDINGS:  Immunoproteasomes and PA28-alphabeta regulator are present in MS affected brain area and accumulated in plaques.  They are expressed in cell types supposed to be involved in MS development such as neurons, endothelial cells, oligodendrocytes, macrophages/macroglia and lymphocytes.  Furthermore, in a genetic study on 1262 Italian MS cases and 845 controls we observed that HLA-A*02+ female subjects carrying the immunoproteasome LMP2 codon 60HH variant have a reduced risk to develop MS.  Accordingly, immunoproteasomes carrying the LMP2 60H allele produce in vitro a lower amount of the HLA-A*0201 restricted immunodominant epitope MBP(111-119).  CONCLUSION/SIGNIFICANCE:  The immunoproteasome LMP2 60HH variant reduces the risk to develop MS amongst Italian HLA-A*02+ females.  We propose that such an effect is mediated by the altered proteasome-dependent production of a specific MBP epitope presented on the MHC class I.  Our observations thereby support the hypothesis of an involvement of immunoproteasome in the MS pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRqeMCB9jJ7CkPI-fCgwosgfW6udTcc2ebX3RUIjkki-Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7itlKqtw%253D%253D&md5=6cd094e954c051702c322c26392e22ac</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0009287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0009287%26sid%3Dliteratum%253Aachs%26aulast%3DMishto%26aufirst%3DM.%26aulast%3DBellavista%26aufirst%3DE.%26aulast%3DLigorio%26aufirst%3DC.%26aulast%3DTextoris-Taube%26aufirst%3DK.%26aulast%3DSantoro%26aufirst%3DA.%26aulast%3DGiordano%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Alfonso%26aufirst%3DS.%26aulast%3DList%25C3%25AC%26aufirst%3DF.%26aulast%3DNacmias%26aufirst%3DB.%26aulast%3DCellini%26aufirst%3DE.%26aulast%3DLeone%26aufirst%3DM.%26aulast%3DGrimaldi%26aufirst%3DL.%26aulast%3DFenoglio%26aufirst%3DC.%26aulast%3DEsposito%26aufirst%3DF.%26aulast%3DMartinelli-Boneschi%26aufirst%3DF.%26aulast%3DGalimberti%26aufirst%3DD.%26aulast%3DScarpini%26aufirst%3DE.%26aulast%3DSeifert%26aufirst%3DU.%26aulast%3DAmato%26aufirst%3DM.%26aulast%3DCaruso%26aufirst%3DC.%26aulast%3DFoschini%26aufirst%3DM.%26aulast%3DKloetzel%26aufirst%3DP.%26aulast%3DFranceschi%26aufirst%3DC.%26atitle%3DImmunoproteasome%2520LMP2%252060HH%2520Variant%2520Alters%2520MBP%2520Epitope%2520Generation%2520and%2520Reduces%2520the%2520Risk%2520to%2520Develop%2520Multiple%2520Sclerosis%2520in%2520Italian%2520Female%2520Population%26jtitle%3DPLoS%2520One%26date%3D2010%26volume%3D5%26issue%3D2%26spage%3De9287%26doi%3D10.1371%2Fjournal.pone.0009287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bizzozero, O. A.</span></span> <span> </span><span class="NLM_article-title">Decreased Activity of the 20S Proteasome in the Brain White Matter and Gray Matter of Patients with Multiple Sclerosis</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>117</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">143</span>â <span class="NLM_lpage">153</span>, <span class="refDoi">Â DOI: 10.1111/j.1471-4159.2011.07182.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1111%2Fj.1471-4159.2011.07182.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=21235577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFalsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=143-153&issue=1&author=J.+Zhengauthor=O.+A.+Bizzozero&title=Decreased+Activity+of+the+20S+Proteasome+in+the+Brain+White+Matter+and+Gray+Matter+of+Patients+with+Multiple+Sclerosis&doi=10.1111%2Fj.1471-4159.2011.07182.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Decreased activity of the 20S proteasome in the brain white matter and gray matter of patients with multiple sclerosis</span></div><div class="casAuthors">Zheng, Jianzheng; Bizzozero, Oscar A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">143-153</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Carbonylated (oxidized) proteins are known to accumulate in the cerebral white matter (WM) and gray matter (GM) of patients with multiple sclerosis (MS).  Although oxidative stress is necessary for carbonyl generation, it is the failure of the degrdn. systems that ultimately leads to the buildup of carbonylated proteins within tissues.  In this study, we measured the activity of the 20S proteasome and other proteolytic systems in the cerebral WM and GM of 13 MS patients and 13 controls.  We report that the activities of the 3 peptidases of the 20S proteasome (i.e. chymotrypsin-like, caspase-like and trypsin-like) in both MS-WM and MS-GM are greatly reduced.  Interestingly, neither the amt. of proteasome nor the levels of the catalytic subunits (Î²1, Î²2, and Î²5) are diminished in this disease.  Proteins contg. Lys-48 poly-ubiquitin also accumulate in MS tissues, indicating failure of the 26S proteasome as well.  Levels of the regulatory caps 11S Î± and 19S are also lower in MS than in controls, suggesting that the activity of the more complex proteasomes may be reduced further.  Finally, the activities of other proteases that might also remove oxidized proteins (calpain, cathepsin B, mitochondrial LonP) are not lessened in MS.  Together, these studies suggest that direct inactivation of proteolytic centers in the 20S particle and/or the presence of specific inhibitors is the underlying cause of proteasomal dysfunction in MS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCkGx4gyYzg7Vg90H21EOLACvtfcHk0ljZ1Q71V_Fpcw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFalsbY%253D&md5=356908c0754d91ad183f78b4815dd974</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2011.07182.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2011.07182.x%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DBizzozero%26aufirst%3DO.%2BA.%26atitle%3DDecreased%2520Activity%2520of%2520the%252020S%2520Proteasome%2520in%2520the%2520Brain%2520White%2520Matter%2520and%2520Gray%2520Matter%2520of%2520Patients%2520with%2520Multiple%2520Sclerosis%26jtitle%3DJ.%2520Neurochem.%26date%3D2011%26volume%3D117%26issue%3D1%26spage%3D143%26epage%3D153%26doi%3D10.1111%2Fj.1471-4159.2011.07182.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Constantinescu, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farooqi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâBrien, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gran, B.</span></span> <span> </span><span class="NLM_article-title">Experimental Autoimmune Encephalomyelitis (EAE) as a Model for Multiple Sclerosis (MS)</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>164</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1079</span>â <span class="NLM_lpage">1106</span>, <span class="refDoi">Â DOI: 10.1111/j.1476-5381.2011.01302.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1111%2Fj.1476-5381.2011.01302.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=21371012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlShtrjK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2011&pages=1079-1106&issue=4&author=C.+S.+Constantinescuauthor=N.+Farooqiauthor=K.+O%E2%80%99Brienauthor=B.+Gran&title=Experimental+Autoimmune+Encephalomyelitis+%28EAE%29+as+a+Model+for+Multiple+Sclerosis+%28MS%29&doi=10.1111%2Fj.1476-5381.2011.01302.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)</span></div><div class="casAuthors">Constantinescu, Cris S.; Farooqi, Nasr; O'Brien, Kate; Gran, Bruno</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1079-1106</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Exptl. autoimmune encephalomyelitis (EAE) is the most commonly used exptl. model for the human inflammatory demyelinating disease, multiple sclerosis (MS).  EAE is a complex condition in which the interaction between a variety of immunopathol. and neuropathol. mechanisms leads to an approxn. of the key pathol. features of MS: inflammation, demyelination, axonal loss and gliosis.  The counter-regulatory mechanisms of resoln. of inflammation and remyelination also occur in EAE, which, therefore can also serve as a model for these processes.  Moreover, EAE is often used as a model of cell-mediated organ-specific autoimmune conditions in general.  EAE has a complex neuropharmacol., and many of the drugs that are in current or imminent use in MS have been developed, tested or validated on the basis of EAE studies.  There is great heterogeneity in the susceptibility to the induction, the method of induction and the response to various immunol. or neuropharmacol. interventions, many of which are reviewed here.  This makes EAE a very versatile system to use in translational neuro- and immunopharmacol., but the model needs to be tailored to the scientific question being asked.  While creating difficulties and underscoring the inherent weaknesses of this model of MS in straightforward translation from EAE to the human disease, this variability also creates an opportunity to explore multiple facets of the immune and neural mechanisms of immune-mediated neuroinflammation and demyelination as well as intrinsic protective mechanisms.  This allows the eventual development and preclin. testing of a wide range of potential therapeutic interventions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNSPtAegOyxbVg90H21EOLACvtfcHk0lh3HREs_Ud9Kw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlShtrjK&md5=3ded21438fbedc8ce73c659424fdf5de</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01302.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01302.x%26sid%3Dliteratum%253Aachs%26aulast%3DConstantinescu%26aufirst%3DC.%2BS.%26aulast%3DFarooqi%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DK.%26aulast%3DGran%26aufirst%3DB.%26atitle%3DExperimental%2520Autoimmune%2520Encephalomyelitis%2520%2528EAE%2529%2520as%2520a%2520Model%2520for%2520Multiple%2520Sclerosis%2520%2528MS%2529%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D164%26issue%3D4%26spage%3D1079%26epage%3D1106%26doi%3D10.1111%2Fj.1476-5381.2011.01302.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moll, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the Immunoproteasome Ameliorates Experimental Autoimmune Encephalomyelitis</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">226</span>â <span class="NLM_lpage">238</span>, <span class="refDoi">Â DOI: 10.1002/emmm.201303543</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1002%2Femmm.201303543" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=24399752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWkur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=226-238&issue=2&author=M.+Baslerauthor=S.+Mundtauthor=T.+Muchamuelauthor=C.+Mollauthor=J.+Jiangauthor=M.+Groettrupauthor=C.+J.+Kirk&title=Inhibition+of+the+Immunoproteasome+Ameliorates+Experimental+Autoimmune+Encephalomyelitis&doi=10.1002%2Femmm.201303543"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis</span></div><div class="casAuthors">Basler, Michael; Mundt, Sarah; Muchamuel, Tony; Moll, Carlo; Jiang, Jing; Groettrup, Marcus; Kirk, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">226-238</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Multiple sclerosis (MS) is a chronic demyelinating immune mediated disease of the central nervous system.  The immunoproteasome is a distinct class of proteasomes found predominantly in monocytes and lymphocytes.  Recently, we demonstrated a novel function of immunoproteasomes in cytokine prodn. and T cell differentiation.  In this study, we investigated the therapeutic efficacy of an inhibitor of the immunoproteasome (ONX 0914) in two different mouse models of MS.  ONX 0914 attenuated disease progression after active and passive induction of exptl. autoimmune encephalomyelitis (EAE), both in MOG35-55 and PLP139-151-induced EAE.  Isolation of lymphocytes from the brain or spinal cord revealed a strong redn. of cytokine-producing CD4+ cells in ONX 0914 treated mice.  Addnl., ONX 0914 treatment prevented disease exacerbation in a relapsing-remitting model.  An anal. of draining lymph nodes after induction of EAE revealed that the differentiation to Th17 or Th1 cells was strongly impaired in ONX 0914 treated mice.  These results implicate the immunoproteasome in the development of EAE and suggest that immunoproteasome inhibitors are promising drugs for the treatment of MS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7NZVATJbqxLVg90H21EOLACvtfcHk0lh3HREs_Ud9Kw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWkur4%253D&md5=b092b6f79d66e9bcc23c4477cce19a67</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1002%2Femmm.201303543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.201303543%26sid%3Dliteratum%253Aachs%26aulast%3DBasler%26aufirst%3DM.%26aulast%3DMundt%26aufirst%3DS.%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DMoll%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DGroettrup%26aufirst%3DM.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26atitle%3DInhibition%2520of%2520the%2520Immunoproteasome%2520Ameliorates%2520Experimental%2520Autoimmune%2520Encephalomyelitis%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2014%26volume%3D6%26issue%3D2%26spage%3D226%26epage%3D238%26doi%3D10.1002%2Femmm.201303543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsokos, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, K. E.</span></span> <span> </span><span class="NLM_article-title">New Insights into the Immunopathogenesis of Systemic Lupus Erythematosus</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">716</span>â <span class="NLM_lpage">730</span>, <span class="refDoi">Â DOI: 10.1038/nrrheum.2016.186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fnrrheum.2016.186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=27872476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFGgsbfF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=716-730&issue=12&author=G.+C.+Tsokosauthor=M.+S.+Loauthor=P.+C.+Reisauthor=K.+E.+Sullivan&title=New+Insights+into+the+Immunopathogenesis+of+Systemic+Lupus+Erythematosus&doi=10.1038%2Fnrrheum.2016.186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into the immunopathogenesis of systemic lupus erythematosus</span></div><div class="casAuthors">Tsokos, George C.; Lo, Mindy S.; Reis, Patricia Costa; Sullivan, Kathleen E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Rheumatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">716-730</span>CODEN:
                <span class="NLM_cas:coden">NRRACB</span>;
        ISSN:<span class="NLM_cas:issn">1759-4790</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The etiol. of systemic lupus erythematosus (SLE) is multifactorial, and includes contributions from the environment, stochastic factors, and genetic susceptibility.  Great gains have been made in understanding SLE through the use of genetic variant identification, mouse models, gene expression studies, and epigenetic analyses.  Collectively, these studies support the concept that defective clearance of immune complexes and biol. waste (such as apoptotic cells), neutrophil extracellular traps, nucleic acid sensing, lymphocyte signalling, and interferon prodn. pathways are all central to loss of tolerance and tissue damage.  Increased understanding of the pathogenesis of SLE is driving a renewed interest in targeted therapy, and researchers are now on the verge of developing targeted immunotherapy directed at treating either specific organ system involvement or specific subsets of patients with SLE.  Accordingly, this Review places these insights within the context of our current understanding of the pathogenesis of SLE and highlights pathways that are ripe for therapeutic targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzf0_wLOx_aLVg90H21EOLACvtfcHk0ljpC0yn1-T1dQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFGgsbfF&md5=58b91fc499fbcd3628cd67c400798d00</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2016.186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2016.186%26sid%3Dliteratum%253Aachs%26aulast%3DTsokos%26aufirst%3DG.%2BC.%26aulast%3DLo%26aufirst%3DM.%2BS.%26aulast%3DReis%26aufirst%3DP.%2BC.%26aulast%3DSullivan%26aufirst%3DK.%2BE.%26atitle%3DNew%2520Insights%2520into%2520the%2520Immunopathogenesis%2520of%2520Systemic%2520Lupus%2520Erythematosus%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2016%26volume%3D12%26issue%3D12%26spage%3D716%26epage%3D730%26doi%3D10.1038%2Fnrrheum.2016.186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">AlarcÃ³n-Segovia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AlarcÃ³n-Riquelme, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardiel, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caeiro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pons-Estel, B. A.</span></span> <span> </span><span class="NLM_article-title">Familial Aggregation of Systemic Lupus Erythematosus, Rheumatoid Arthritis, and Other Autoimmune Diseases in 1,177 Lupus Patients from the GLADEL Cohort</span>. <i>Arthritis Rheum.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1138</span>â <span class="NLM_lpage">1147</span>, <span class="refDoi">Â DOI: 10.1002/art.20999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1002%2Fart.20999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=15818688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BD2M7ptlWnsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2005&pages=1138-1147&issue=4&author=D.+Alarc%C3%B3n-Segoviaauthor=M.+E.+Alarc%C3%B3n-Riquelmeauthor=M.+H.+Cardielauthor=F.+Caeiroauthor=L.+Massardoauthor=A.+R.+Villaauthor=B.+A.+Pons-Estel&title=Familial+Aggregation+of+Systemic+Lupus+Erythematosus%2C+Rheumatoid+Arthritis%2C+and+Other+Autoimmune+Diseases+in+1%2C177+Lupus+Patients+from+the+GLADEL+Cohort&doi=10.1002%2Fart.20999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort</span></div><div class="casAuthors">Alarcon-Segovia Donato; Alarcon-Riquelme Marta E; Cardiel Mario H; Caeiro Francisco; Massardo Loreto; Villa Antonio R; Pons-Estel Bernardo A</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis and rheumatism</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1138-47</span>
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    </div><div class="casAbstract">OBJECTIVE:  To determine whether there is familial aggregation of systemic lupus erythematosus (SLE) and/or other autoimmune diseases in SLE patients and to identify clinical differences between patients with and those without familial autoimmunity.  METHODS:  We interviewed members of the Grupo Latinoamericano de Estudio del Lupus Eritematoso (GLADEL) inception cohort of 1,214 SLE patients to ascertain whether they had relatives with SLE and/or other autoimmune diseases.  Identified relatives were studied.  Familial aggregation was tested using reported highest and intermediate population prevalence data for SLE, rheumatoid arthritis (RA), or all autoimmune diseases, and studies were performed to identify the genetic model applicable for SLE.  RESULTS:  We identified 116 first-, second-, or third-degree relatives with SLE, 79 with RA, 23 with autoimmune thyroiditis, 3 with scleroderma, 1 with polymyositis, and 16 with other autoimmune diseases, related to 166 of the 1,177 SLE patients in the GLADEL cohort who agreed to participate.  Forty-two SLE patients had 2 or more relatives with an autoimmune disease.  We found a lambda(sibling) of 5.8 and 29.0 for SLE and of 3.2-5.3 for RA, when comparing with their reported high or intermediate population prevalence, respectively.  We also found familial aggregation for autoimmune disease in general (lambda(sibling) = 1.5) and determined that for SLE, a polygenic additive genetic model, rather than a multiplicative one, is applicable.  CONCLUSION:  In SLE there is familial aggregation of SLE, RA, and autoimmune disease in general.  A polygenic additive model applies for SLE.  American Indian-white Mestizo SLE patients and those with higher socioeconomic level were more likely to have familial autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSroVkpgDFNoGyYR5VtavbzfW6udTcc2eby6HnOS3zhkrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7ptlWnsA%253D%253D&md5=d37934a9cef4ff883e07dcda67fd9487</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1002%2Fart.20999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.20999%26sid%3Dliteratum%253Aachs%26aulast%3DAlarc%25C3%25B3n-Segovia%26aufirst%3DD.%26aulast%3DAlarc%25C3%25B3n-Riquelme%26aufirst%3DM.%2BE.%26aulast%3DCardiel%26aufirst%3DM.%2BH.%26aulast%3DCaeiro%26aufirst%3DF.%26aulast%3DMassardo%26aufirst%3DL.%26aulast%3DVilla%26aufirst%3DA.%2BR.%26aulast%3DPons-Estel%26aufirst%3DB.%2BA.%26atitle%3DFamilial%2520Aggregation%2520of%2520Systemic%2520Lupus%2520Erythematosus%252C%2520Rheumatoid%2520Arthritis%252C%2520and%2520Other%2520Autoimmune%2520Diseases%2520in%25201%252C177%2520Lupus%2520Patients%2520from%2520the%2520GLADEL%2520Cohort%26jtitle%3DArthritis%2520Rheum.%26date%3D2005%26volume%3D52%26issue%3D4%26spage%3D1138%26epage%3D1147%26doi%3D10.1002%2Fart.20999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">Genetic Susceptibility to SLE: Recent Progress from GWAS</span>. <i>J. Autoimmun.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">25</span>â <span class="NLM_lpage">33</span>, <span class="refDoi">Â DOI: 10.1016/j.jaut.2013.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.jaut.2013.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=23395425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Khtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=25-33&author=Y.+Cuiauthor=Y.+Shengauthor=X.+Zhang&title=Genetic+Susceptibility+to+SLE%3A+Recent+Progress+from+GWAS&doi=10.1016%2Fj.jaut.2013.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic susceptibility to SLE: Recent progress from GWAS</span></div><div class="casAuthors">Cui, Yong; Sheng, Yujun; Zhang, Xuejun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Autoimmunity</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">25-33</span>CODEN:
                <span class="NLM_cas:coden">JOAUEP</span>;
        ISSN:<span class="NLM_cas:issn">0896-8411</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Systemic lupus erythematosus (SLE) is a prototype autoimmune disease with a strong genetic component, characterized by hyperactive T and B cells, autoantibody prodn., immune complex deposition and multi-organ damage.  It affects predominantly women of child-bearing age and has population differences in both disease prevalence and severity.  Genetic factors are known to play key roles in the disease through the use of assocn. and family studies.  Previously, SLE susceptibility genes were mainly revealed through linkage anal. and candidate gene studies.  Since 2008, our understanding of the genetic basis of SLE has been rapidly advanced through genome-wide assocn. studies (GWASs).  More than 40 robust susceptibility loci have been identified and conformed to be assocd. with SLE using this technique.  Most of these assocd. genes productions participate in important pathways involved in the pathogenesis of SLE, such as immune complex processing, toll-like receptor signaling, type I interferon prodn., and so on.  A no. of susceptibility loci with unknown functions in the pathogenesis of SLE have also been identified, indicating that addnl. mol. mechanisms contribute to the risk of developing SLE.  It is noteworthy that susceptibility loci of SLE are shared by other immune-related diseases.  Thus, common mol. pathways may be involved in the pathogenesis of these diseases.  In this review, we summarize the key loci, achieving genome-wide significance, which have been shown to predispose to SLE.  Anal. of relevant mol. pathways suggests new etiol. clues to SLE development.  These genetic loci may help building the foundation for genetic diagnosis and personalized treatment for patients with SLE in the near future.  However, substantial addnl. studies, including functional and gene-targeted studies, are required to confirm the causality of the genetic variants and their biol. relevance in SLE development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfMjUpspSKirVg90H21EOLACvtfcHk0lhYX9apn_MNBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Khtrs%253D&md5=87d587e3dde2ed3bffa0eed22426d546</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.jaut.2013.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaut.2013.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DGenetic%2520Susceptibility%2520to%2520SLE%253A%2520Recent%2520Progress%2520from%2520GWAS%26jtitle%3DJ.%2520Autoimmun.%26date%3D2013%26volume%3D41%26spage%3D25%26epage%3D33%26doi%3D10.1016%2Fj.jaut.2013.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span> <span> </span><span class="NLM_article-title">IFNÎ± Inducible Models of Murine SLE</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">306</span>, <span class="refDoi">Â DOI: 10.3389/fimmu.2013.00306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.3389%2Ffimmu.2013.00306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=24106491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BC2cfltlWmsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=306&author=A.+Davidsonauthor=Z.+Liu&title=IFN%CE%B1+Inducible+Models+of+Murine+SLE&doi=10.3389%2Ffimmu.2013.00306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">IFNÎ± Inducible Models of Murine SLE</span></div><div class="casAuthors">Liu Zheng; Davidson Anne</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">306</span>
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    </div><div class="casAbstract">The role of type I interferons (IFNs) in SLE pathogenesis has been a subject of intense investigation in the last decade.  The strong link between type I IFNs and SLE was initially provided by ex vivo studies showing that exposure of peripheral blood mononuclear cells to immune complexes from SLE patients elicits a signature of IFN inducible genes and was then further highlighted by human genetic studies.  The mechanisms by which type I IFNs, especially IFN alpha (IFNÎ±), modulate the immune system and exacerbate SLE have been largely elucidated through studies in mouse lupus models.  In this review, we discuss the characteristics of several such models in which disease is accelerated by ectopically expressed IFNÎ±.  We also summarize several studies which tested therapeutic interventions in these models and discuss the advantages and disadvantages of using IFNÎ± accelerated models to study experimental treatments for lupus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0YQxum6hoa669lAbTj9rGfW6udTcc2eaA3fKUxfWKibntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfltlWmsQ%253D%253D&md5=71900c110682f12925125e6d40dbef26</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2013.00306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2013.00306%26sid%3Dliteratum%253Aachs%26aulast%3DDavidson%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DZ.%26atitle%3DIFN%25CE%25B1%2520Inducible%2520Models%2520of%2520Murine%2520SLE%26jtitle%3DFront.%2520Immunol.%26date%3D2013%26volume%3D4%26spage%3D306%26doi%3D10.3389%2Ffimmu.2013.00306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ledford, H.</span></span> <span> </span><span class="NLM_article-title">After Half-Centuryâs Wait, Approval Paves Path for New Lupus Drugs</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">400</span>, <span class="refDoi">Â DOI: 10.1038/nm0411-400a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fnm0411-400a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=21475219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksVCqs7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=400&issue=4&author=H.+Ledford&title=After+Half-Century%E2%80%99s+Wait%2C+Approval+Paves+Path+for+New+Lupus+Drugs&doi=10.1038%2Fnm0411-400a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Pooled trials drowning in conflict-of-interest oversights</span></div><div class="casAuthors">Ledford, Heidi</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">400-401</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTpW99kq1e27Vg90H21EOLACvtfcHk0lhY4VwOaPIaDA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksVCqs7k%253D&md5=a9939df17ee82e5d0781cdade3ead335</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1038%2Fnm0411-400a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0411-400a%26sid%3Dliteratum%253Aachs%26aulast%3DLedford%26aufirst%3DH.%26atitle%3DAfter%2520Half-Century%25E2%2580%2599s%2520Wait%252C%2520Approval%2520Paves%2520Path%2520for%2520New%2520Lupus%2520Drugs%26jtitle%3DNat.%2520Med.%26date%3D2011%26volume%3D17%26issue%3D4%26spage%3D400%26doi%3D10.1038%2Fnm0411-400a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernatsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boivin, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginzler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladman, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urowitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isenberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dooley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nived, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturfelt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinsson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alarcon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senecal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zummer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ensworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pope, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edworthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Gabalawy, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Pierre, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey-Goldman, R.</span></span> <span> </span><span class="NLM_article-title">Mortality in Systemic Lupus Erythematosus</span>. <i>Arthritis Rheum.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2550</span>â <span class="NLM_lpage">2557</span>, <span class="refDoi">Â DOI: 10.1002/art.21955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1002%2Fart.21955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=16868977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BD28rgvFOrtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2006&pages=2550-2557&issue=8&author=S.+Bernatskyauthor=J.-F.+Boivinauthor=L.+Josephauthor=S.+Manziauthor=E.+Ginzlerauthor=D.+D.+Gladmanauthor=M.+Urowitzauthor=P.+R.+Fortinauthor=M.+Petriauthor=S.+Barrauthor=C.+Gordonauthor=S.+Baeauthor=D.+Isenbergauthor=A.+Zomaauthor=C.+Aranowauthor=M.+Dooleyauthor=O.+Nivedauthor=G.+Sturfeltauthor=K.+Steinssonauthor=G.+Alarconauthor=J.+Senecalauthor=M.+Zummerauthor=J.+Hanlyauthor=S.+Ensworthauthor=J.+Popeauthor=S.+Edworthyauthor=A.+Rahmanauthor=J.+Sibleyauthor=H.+El-Gabalawyauthor=T.+McCarthyauthor=Y.+St.+Pierreauthor=A.+Clarkeauthor=R.+Ramsey-Goldman&title=Mortality+in+Systemic+Lupus+Erythematosus&doi=10.1002%2Fart.21955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Mortality in systemic lupus erythematosus</span></div><div class="casAuthors">Bernatsky S; Boivin J-F; Joseph L; Manzi S; Ginzler E; Gladman D D; Urowitz M; Fortin P R; Petri M; Barr S; Gordon C; Bae S-C; Isenberg D; Zoma A; Aranow C; Dooley M-A; Nived O; Sturfelt G; Steinsson K; Alarcon G; Senecal J-L; Zummer M; Hanly J; Ensworth S; Pope J; Edworthy S; Rahman A; Sibley J; El-Gabalawy H; McCarthy T; St Pierre Y; Clarke A; Ramsey-Goldman R</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis and rheumatism</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2550-7</span>
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    </div><div class="casAbstract">OBJECTIVE:  To examine mortality rates in the largest systemic lupus erythematosus (SLE) cohort ever assembled.  METHODS:  Our sample was a multisite international SLE cohort (23 centers, 9,547 patients).  Deaths were ascertained by vital statistics registry linkage.  Standardized mortality ratio (SMR; ratio of deaths observed to deaths expected) estimates were calculated for all deaths and by cause.  The effects of sex, age, SLE duration, race, and calendar-year periods were determined.  RESULTS:  The overall SMR was 2.4 (95% confidence interval 2.3-2.5).  Particularly high mortality was seen for circulatory disease, infections, renal disease, non-Hodgkin's lymphoma, and lung cancer.  The highest SMR estimates were seen in patient groups characterized by female sex, younger age, SLE duration <1 year, or black/African American race.  There was a dramatic decrease in total SMR estimates across calendar-year periods, which was demonstrable for specific causes including death due to infections and death due to renal disorders.  However, the SMR due to circulatory diseases tended to increase slightly from the 1970s to the year 2001.  CONCLUSION:  Our data from a very large multicenter international cohort emphasize what has been demonstrated previously in smaller samples.  These results highlight the increased mortality rate in SLE patients compared with the general population, and they suggest particular risk associated with female sex, younger age, shorter SLE duration, and black/African American race.  The risk for certain types of deaths, primarily related to lupus activity (such as renal disease), has decreased over time, while the risk for deaths due to circulatory disease does not appear to have diminished.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbwHSFM5QIVY3yKPtYViAGfW6udTcc2eY_0S4Gv160VLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rgvFOrtw%253D%253D&md5=c2eed8393fc4f4598a46bbbebe8c87d7</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1002%2Fart.21955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.21955%26sid%3Dliteratum%253Aachs%26aulast%3DBernatsky%26aufirst%3DS.%26aulast%3DBoivin%26aufirst%3DJ.-F.%26aulast%3DJoseph%26aufirst%3DL.%26aulast%3DManzi%26aufirst%3DS.%26aulast%3DGinzler%26aufirst%3DE.%26aulast%3DGladman%26aufirst%3DD.%2BD.%26aulast%3DUrowitz%26aufirst%3DM.%26aulast%3DFortin%26aufirst%3DP.%2BR.%26aulast%3DPetri%26aufirst%3DM.%26aulast%3DBarr%26aufirst%3DS.%26aulast%3DGordon%26aufirst%3DC.%26aulast%3DBae%26aufirst%3DS.%26aulast%3DIsenberg%26aufirst%3DD.%26aulast%3DZoma%26aufirst%3DA.%26aulast%3DAranow%26aufirst%3DC.%26aulast%3DDooley%26aufirst%3DM.%26aulast%3DNived%26aufirst%3DO.%26aulast%3DSturfelt%26aufirst%3DG.%26aulast%3DSteinsson%26aufirst%3DK.%26aulast%3DAlarcon%26aufirst%3DG.%26aulast%3DSenecal%26aufirst%3DJ.%26aulast%3DZummer%26aufirst%3DM.%26aulast%3DHanly%26aufirst%3DJ.%26aulast%3DEnsworth%26aufirst%3DS.%26aulast%3DPope%26aufirst%3DJ.%26aulast%3DEdworthy%26aufirst%3DS.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DSibley%26aufirst%3DJ.%26aulast%3DEl-Gabalawy%26aufirst%3DH.%26aulast%3DMcCarthy%26aufirst%3DT.%26aulast%3DSt.%2BPierre%26aufirst%3DY.%26aulast%3DClarke%26aufirst%3DA.%26aulast%3DRamsey-Goldman%26aufirst%3DR.%26atitle%3DMortality%2520in%2520Systemic%2520Lupus%2520Erythematosus%26jtitle%3DArthritis%2520Rheum.%26date%3D2006%26volume%3D54%26issue%3D8%26spage%3D2550%26epage%3D2557%26doi%3D10.1002%2Fart.21955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neubert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maseda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiethe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalden, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manz, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voll, R.</span></span> <span> </span><span class="NLM_article-title">The Proteasome Inhibitor Bortezomib Depletes Plasma Cells and Protects Mice with Lupus-like Disease from Nephritis</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">748</span>â <span class="NLM_lpage">755</span>, <span class="refDoi">Â DOI: 10.1038/nm1763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fnm1763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=18542049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotF2lurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=748-755&issue=7&author=K.+Neubertauthor=S.+Meisterauthor=K.+Moserauthor=F.+Weiselauthor=D.+Masedaauthor=K.+Amannauthor=C.+Wietheauthor=T.+H.+Winklerauthor=J.+R.+Kaldenauthor=R.+A.+Manzauthor=R.+Voll&title=The+Proteasome+Inhibitor+Bortezomib+Depletes+Plasma+Cells+and+Protects+Mice+with+Lupus-like+Disease+from+Nephritis&doi=10.1038%2Fnm1763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis</span></div><div class="casAuthors">Neubert, Kirsten; Meister, Silke; Moser, Katrin; Weisel, Florian; Maseda, Damian; Amann, Kerstin; Wiethe, Carsten; Winkler, Thomas H.; Kalden, Joachim R.; Manz, Rudolf A.; Voll, Reinhard E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">748-755</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bortezomib, a drug useful for the treatment of multiple myeloma, reduces kidney damage in animal models of lupus.  Autoantibody-mediated diseases like myasthenia gravis, autoimmune hemolytic anemia and systemic lupus erythematosus represent a therapeutic challenge.  In particular, long-lived plasma cells producing autoantibodies resist current therapeutic and exptl. approaches.  Recently, we showed that the sensitivity of myeloma cells toward proteasome inhibitors directly correlates with their Ig synthesis rates.  Therefore, we hypothesized that normal plasma cells are also hypersensitive to proteasome inhibition owing to their extremely high amt. of protein biosynthesis.  Here we show that the proteasome inhibitor bortezomib, which is approved for the treatment of multiple myeloma, eliminates both short- and long-lived plasma cells by activation of the terminal unfolded protein response.  Treatment with bortezomib depleted plasma cells producing antibodies to double-stranded DNA, eliminated autoantibody prodn., ameliorated glomerulonephritis and prolonged survival of two mouse strains with lupus-like disease, NZB/W F1 and MRL/lpr mice.  Hence, the elimination of autoreactive plasma cells by proteasome inhibitors might represent a new treatment strategy for antibody-mediated diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZtv5EvAwSRLVg90H21EOLACvtfcHk0liKRoG3HGKsIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotF2lurw%253D&md5=a53d9cfc5690c95b1454a50b40a0bdb7</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1038%2Fnm1763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1763%26sid%3Dliteratum%253Aachs%26aulast%3DNeubert%26aufirst%3DK.%26aulast%3DMeister%26aufirst%3DS.%26aulast%3DMoser%26aufirst%3DK.%26aulast%3DWeisel%26aufirst%3DF.%26aulast%3DMaseda%26aufirst%3DD.%26aulast%3DAmann%26aufirst%3DK.%26aulast%3DWiethe%26aufirst%3DC.%26aulast%3DWinkler%26aufirst%3DT.%2BH.%26aulast%3DKalden%26aufirst%3DJ.%2BR.%26aulast%3DManz%26aufirst%3DR.%2BA.%26aulast%3DVoll%26aufirst%3DR.%26atitle%3DThe%2520Proteasome%2520Inhibitor%2520Bortezomib%2520Depletes%2520Plasma%2520Cells%2520and%2520Protects%2520Mice%2520with%2520Lupus-like%2520Disease%2520from%2520Nephritis%26jtitle%3DNat.%2520Med.%26date%3D2008%26volume%3D14%26issue%3D7%26spage%3D748%26epage%3D755%26doi%3D10.1038%2Fnm1763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Badros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goloubeva, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalal, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Can, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapoport, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akpek, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenton, R. G.</span></span> <span> </span><span class="NLM_article-title">Neurotoxicity of Bortezomib Therapy in Multiple Myeloma: A Single-Center Experience and Review of the Literature</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>110</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1042</span>â <span class="NLM_lpage">1049</span>, <span class="refDoi">Â DOI: 10.1002/cncr.22921</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1002%2Fcncr.22921" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=17654660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVChs7fP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=1042-1049&issue=5&author=A.+Badrosauthor=O.+Goloubevaauthor=J.+S.+Dalalauthor=I.+Canauthor=J.+Thompsonauthor=A.+P.+Rapoportauthor=M.+Heymanauthor=G.+Akpekauthor=R.+G.+Fenton&title=Neurotoxicity+of+Bortezomib+Therapy+in+Multiple+Myeloma%3A+A+Single-Center+Experience+and+Review+of+the+Literature&doi=10.1002%2Fcncr.22921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature</span></div><div class="casAuthors">Badros, Ashraf; Goloubeva, Olga; Dalal, Jay S.; Can, Ilyas; Thompson, Jennifer; Rapoport, Aaron P.; Heyman, Meyer; Akpek, Gorgon; Fenton, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1042-1049</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">BACKGROUND: Bortezomib is active in heavily pretreated multiple myeloma patients; the dose-limiting toxicity is peripheral neuropathy (PN).  METHODS: The authors retrospectively reviewed the incidence, severity, and risk factors for PN in 78 patients who received bortezomib.  The median age was 57 years (range, 33-80 years), 62% of patients were men, and 37% of patients were African Americans.  Seventeen patients (22%) had diabetes mellitus (DM), and 66 patients (85%) had received thalidomide.  Before bortezomib treatment, 37% of the patients reported subjective, grade 1 or 2 PN.  Patients received bortezomib alone (n - 10 patients) plus dexamethasone (n - 36 patients) and thalidomide (n = 20 patients) or chemotherapy (n = 12 patients).  PN affected 52% of patients, including grade 3 and 4 PN in 15% and 7% resp.  RESULTS: Twelve patients stopped bortezomib because of side effects that included PN (n = 9 patients), diarrhea (n = 2 patients) and cytomegalovirus pneumonia (n = 1 patient); 11 patients had dose redns. because of PN.  Grade 4 PN affected 6 patients (sensory, n = 4 patients; motor/sensory, n - 2 patients).  The onset of grade 4 PN was sudden rather than cumulative.  Factors that were predictive of PN grade were baseline PN (P = .002), prior thalidomide use (P = .03), and the presence of DM (P = .03).  Multiple myeloma responses included complete, near complete, and partial responses in 5% of patients, 10% of patients, and 27% of patients, resp.  Responses were independent of PN and of whether bortezomib was combined with chemotherapy or thalidomide.  Patients remained on therapy longer for a median of 5 cycles (range, 2-36 cycles) when they received bortezomib plus thalidomide vs. 3 cycles (range, 1-19 cycles) for the other combinations.  PN therapy was mostly supportive.  It was noteworthy that 6 of 9 patients with PN who received lenalidomide as salvage therapy after bortezomib had significant improvement in their symptoms.  CONCLUSIONS: The risk of bortezomib-related PN was greater in patients who had PN and DM at baseline.  The authors concluded that an unexpected, symptomatic improvement of PN on lenalidomide is worth further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPiBBwv4BrjLVg90H21EOLACvtfcHk0liKRoG3HGKsIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVChs7fP&md5=a6237838ddb35e2984b4b79e84001fd3</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1002%2Fcncr.22921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.22921%26sid%3Dliteratum%253Aachs%26aulast%3DBadros%26aufirst%3DA.%26aulast%3DGoloubeva%26aufirst%3DO.%26aulast%3DDalal%26aufirst%3DJ.%2BS.%26aulast%3DCan%26aufirst%3DI.%26aulast%3DThompson%26aufirst%3DJ.%26aulast%3DRapoport%26aufirst%3DA.%2BP.%26aulast%3DHeyman%26aufirst%3DM.%26aulast%3DAkpek%26aufirst%3DG.%26aulast%3DFenton%26aufirst%3DR.%2BG.%26atitle%3DNeurotoxicity%2520of%2520Bortezomib%2520Therapy%2520in%2520Multiple%2520Myeloma%253A%2520A%2520Single-Center%2520Experience%2520and%2520Review%2520of%2520the%2520Literature%26jtitle%3DCancer%26date%3D2007%26volume%3D110%26issue%3D5%26spage%3D1042%26epage%3D1049%26doi%3D10.1002%2Fcncr.22921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conley, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevarez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Looney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anolik, J.</span></span> <span> </span><span class="NLM_article-title">Novel Proteasome Inhibitors Have a Beneficial Effect in Murine Lupus via the Dual Inhibition of Type I Interferon and Autoantibody Secreting Cells</span>. <i>Arthritis Rheum.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>64</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">493</span>â <span class="NLM_lpage">503</span>, <span class="refDoi">Â DOI: 10.1002/art.33333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1002%2Fart.33333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=21905015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yrurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=493-503&issue=2&author=H.+T.+Ichikawaauthor=T.+Conleyauthor=T.+Muchamuelauthor=J.+Jiangauthor=S.+Leeauthor=T.+Owenauthor=J.+Barnardauthor=S.+Nevarezauthor=B.+I.+Goldmanauthor=C.+J.+Kirkauthor=R.+Looneyauthor=J.+Anolik&title=Novel+Proteasome+Inhibitors+Have+a+Beneficial+Effect+in+Murine+Lupus+via+the+Dual+Inhibition+of+Type+I+Interferon+and+Autoantibody+Secreting+Cells&doi=10.1002%2Fart.33333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells</span></div><div class="casAuthors">Ichikawa, H. Travis; Conley, Thomas; Muchamuel, Tony; Jiang, Jing; Lee, Susan; Owen, Teresa; Barnard, Jennifer; Nevarez, Sarah; Goldman, Bruce I.; Kirk, Christopher J.; Looney, R. John; Anolik, Jennifer H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">493-503</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : To investigate the hypothesis that proteasome inhibition may have potential in the treatment of SLE, by targeting plasmacytoid dendritic cells (PDCs) and plasma cells, both of which are crit. in disease pathogenesis.  Methods : Lupus-prone mice were treated with the nonselective proteasome inhibitors carfilzomib and bortezomib, the immunoproteasome inhibitor ONX 0914, or vehicle control.  Tissue was harvested and analyzed by flow cytometry using std. markers.  Nephritis was monitored by evaluation for proteinuria and by histol. anal. of kidneys.  Serum anti-double-stranded DNA (anti-dsDNA) levels were measured by ELISA (ELISA), and total IgG and dsDNA antibody-secreting cells (ASCs) by enzyme-linked immunospot assay.  Human peripheral blood mononuclear cells or mouse bone marrow cells were incubated with Toll-like receptor (TLR) agonists and proteasome inhibitors, and interferon-Î± (IFNÎ±) levels were measured by ELISA and flow cytometry.  Results : Early treatment of lupus-prone mice with the dual-targeting proteasome inhibitors carfilzomib or bortezomib or the immunoproteasome-specific inhibitor ONX 0914 prevented disease progression, and treatment of mice with established disease dramatically abrogated nephritis.  Treatment had profound effects on plasma cells, with greater redns. in autoreactive than in total IgG ASCs, an effect that became more pronounced with prolonged treatment and was reflected in decreasing serum autoantibody levels.  Notably, proteasome inhibition efficiently suppressed prodn. of IFNÎ± by TLR-activated PDCs in vitro and in vivo, an effect mediated by inhibition of both PDC survival and PDC function.  Conclusion : Inhibition of the immunoproteasome is equally efficacious as dual targeting agents in preventing lupus disease progression by targeting 2 crit. pathways in disease pathogenesis, type I IFN activation and autoantibody prodn. by plasma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgx8A-mW0b_bVg90H21EOLACvtfcHk0ljOn2z4qqT1CA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yrurk%253D&md5=1055201f4931e5c09ae292b07e26c0cc</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1002%2Fart.33333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.33333%26sid%3Dliteratum%253Aachs%26aulast%3DIchikawa%26aufirst%3DH.%2BT.%26aulast%3DConley%26aufirst%3DT.%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DOwen%26aufirst%3DT.%26aulast%3DBarnard%26aufirst%3DJ.%26aulast%3DNevarez%26aufirst%3DS.%26aulast%3DGoldman%26aufirst%3DB.%2BI.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DLooney%26aufirst%3DR.%26aulast%3DAnolik%26aufirst%3DJ.%26atitle%3DNovel%2520Proteasome%2520Inhibitors%2520Have%2520a%2520Beneficial%2520Effect%2520in%2520Murine%2520Lupus%2520via%2520the%2520Dual%2520Inhibition%2520of%2520Type%2520I%2520Interferon%2520and%2520Autoantibody%2520Secreting%2520Cells%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26issue%3D2%26spage%3D493%26epage%3D503%26doi%3D10.1002%2Fart.33333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaStant, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurits, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langrish, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span> <span> </span><span class="NLM_article-title">Co-Inhibition of Immunoproteasome Subunits LMP2 and LMP7 Is Required to Block Autoimmunity</span>. <i>EMBO Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">e46521</span>, <span class="refDoi">Â DOI: 10.15252/embr.201846512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.15252%2Fembr.201846512" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=e46521&issue=12&author=M.+Baslerauthor=M.+M.+Lindstromauthor=J.+J.+LaStantauthor=J.+M.+Bradshawauthor=T.+D.+Owensauthor=C.+Schmidtauthor=E.+Mauritsauthor=C.+Tsuauthor=H.+S.+Overkleeftauthor=C.+J.+Kirkauthor=C.+Langrishauthor=M.+Groettrup&title=Co-Inhibition+of+Immunoproteasome+Subunits+LMP2+and+LMP7+Is+Required+to+Block+Autoimmunity&doi=10.15252%2Fembr.201846512"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.15252%2Fembr.201846512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Fembr.201846512%26sid%3Dliteratum%253Aachs%26aulast%3DBasler%26aufirst%3DM.%26aulast%3DLindstrom%26aufirst%3DM.%2BM.%26aulast%3DLaStant%26aufirst%3DJ.%2BJ.%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DSchmidt%26aufirst%3DC.%26aulast%3DMaurits%26aufirst%3DE.%26aulast%3DTsu%26aufirst%3DC.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DLangrish%26aufirst%3DC.%26aulast%3DGroettrup%26aufirst%3DM.%26atitle%3DCo-Inhibition%2520of%2520Immunoproteasome%2520Subunits%2520LMP2%2520and%2520LMP7%2520Is%2520Required%2520to%2520Block%2520Autoimmunity%26jtitle%3DEMBO%2520Rep.%26date%3D2018%26volume%3D19%26issue%3D12%26spage%3De46521%26doi%3D10.15252%2Fembr.201846512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, H. W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderl, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arastu-Kapur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moebius, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMinn, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">413</span>â <span class="NLM_lpage">417</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.6b00496</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00496" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktVahtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=413-417&issue=4&author=H.+W.+B.+Johnsonauthor=J.+L.+Anderlauthor=E.+K.+Bradleyauthor=J.+Buiauthor=J.+Jonesauthor=S.+Arastu-Kapurauthor=L.+M.+Kellyauthor=E.+Loweauthor=D.+C.+Moebiusauthor=T.+Muchamuelauthor=C.+Kirkauthor=Z.+Wangauthor=D.+McMinn&title=Discovery+of+Highly+Selective+Inhibitors+of+the+Immunoproteasome+Low+Molecular+Mass+Polypeptide+2+%28LMP2%29+Subunit&doi=10.1021%2Facsmedchemlett.6b00496"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit</span></div><div class="casAuthors">Johnson, Henry W. B.; Anderl, Janet L.; Bradley, Erin K.; Bui, John; Jones, Jeffrey; Arastu-Kapur, Shirin; Kelly, Lisa M.; Lowe, Eric; Moebius, David C.; Muchamuel, Tony; Kirk, Christopher; Wang, Zhengping; McMinn, Dustin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">413-417</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Building upon the success of bortezomib (VELCADE) and carfilzomib (KYPROLIS), the design of a next generation of inhibitors targeting specific subunits within the immunoproteasome is of interest for the treatment of autoimmune disease.  There are three catalytic subunits within the immunoproteasome (low mol. mass polypeptide-7, -2, and multicatalytic endopeptidase complex subunit-1; LMP7, LMP2, and MECL-1), and a campaign was undertaken to design a potent and selective LMP2 inhibitor with sufficient properties to allow for sustained inhibition in vivo.  Screening a focused library of epoxyketones revealed a series of potent dipeptides that were optimized to provide the highly selective inhibitor KZR-504 (12).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL-9Mx7yA1VLVg90H21EOLACvtfcHk0ljOn2z4qqT1CA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktVahtLs%253D&md5=5abf3912c1dbcc6f77d271235c75b17c</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00496%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DH.%2BW.%2BB.%26aulast%3DAnderl%26aufirst%3DJ.%2BL.%26aulast%3DBradley%26aufirst%3DE.%2BK.%26aulast%3DBui%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DJ.%26aulast%3DArastu-Kapur%26aufirst%3DS.%26aulast%3DKelly%26aufirst%3DL.%2BM.%26aulast%3DLowe%26aufirst%3DE.%26aulast%3DMoebius%26aufirst%3DD.%2BC.%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DKirk%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DMcMinn%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520Highly%2520Selective%2520Inhibitors%2520of%2520the%2520Immunoproteasome%2520Low%2520Molecular%2520Mass%2520Polypeptide%25202%2520%2528LMP2%2529%2520Subunit%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D4%26spage%3D413%26epage%3D417%26doi%3D10.1021%2Facsmedchemlett.6b00496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, H. W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderl, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moebius, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMinn, D. L.</span></span> <span> </span><span class="NLM_article-title">Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 <i>S</i>, 3 <i>R</i>)- <i>N</i> -((<i>S</i>)-3-(Cyclopent-1-En-1-Yl)-1-((<i>R</i>)-2-Methyloxiran-2-Yl)-1-Oxopropan-2-Yl)-3-Hydroxy-3-(4-Methoxyphenyl)-2-((<i>S</i>)-2-(2-Morpholinoacetamido)Propanamido)Propenamide</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">11127</span>â <span class="NLM_lpage">11143</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b01201</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01201" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVKltLfF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=11127-11143&issue=24&author=H.+W.+B.+Johnsonauthor=E.+Loweauthor=J.+L.+Anderlauthor=A.+Fanauthor=T.+Muchamuelauthor=S.+Bowersauthor=D.+C.+Moebiusauthor=C.+Kirkauthor=D.+L.+McMinn&title=Required+Immunoproteasome+Subunit+Inhibition+Profile+for+Anti-Inflammatory+Efficacy+and+Clinical+Candidate+KZR-616+%28%282+S%2C+3+R%29-+N+-%28%28S%29-3-%28Cyclopent-1-En-1-Yl%29-1-%28%28R%29-2-Methyloxiran-2-Yl%29-1-Oxopropan-2-Yl%29-3-Hydroxy-3-%284-Methoxyphenyl%29-2-%28%28S%29-2-%282-Morpholinoacetamido%29Propanamido%29Propenamide&doi=10.1021%2Facs.jmedchem.8b01201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2S,3R)-N-((S)-3-(Cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenamide)</span></div><div class="casAuthors">Johnson, Henry W. B.; Lowe, Eric; Anderl, Janet L.; Fan, Andrea; Muchamuel, Tony; Bowers, Simeon; Moebius, David C.; Kirk, Christopher; McMinn, Dustin L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11127-11143</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selective immunoproteasome inhibition is a promising approach for treating autoimmune disorders, but optimal proteolytic active site subunit inhibition profiles remain unknown.  We reveal here our design of peptide epoxyketone-based selective low mol. mass polypeptide-7 (LMP7) and multicatalytic endopeptidase complex subunit-1 (MECL-1) subunit inhibitors.  Utilizing these and our previously disclosed low mol. mass polypeptide-2 (LMP2) inhibitor, we demonstrate a requirement of dual LMP7/LMP2 or LMP7/MECL-1 subunit inhibition profiles for potent cytokine expression inhibition and in vivo efficacy in an inflammatory disease model.  These and addnl. findings toward optimized soly. led the design and selection of KZR-616 disclosed here and presently in clin. trials for treatment of rheumatic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNq1pg3kpVXrVg90H21EOLACvtfcHk0liVPTMLNCF5NQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVKltLfF&md5=70170b636fbb858edda5f571af45ca7f</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01201%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DH.%2BW.%2BB.%26aulast%3DLowe%26aufirst%3DE.%26aulast%3DAnderl%26aufirst%3DJ.%2BL.%26aulast%3DFan%26aufirst%3DA.%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DBowers%26aufirst%3DS.%26aulast%3DMoebius%26aufirst%3DD.%2BC.%26aulast%3DKirk%26aufirst%3DC.%26aulast%3DMcMinn%26aufirst%3DD.%2BL.%26atitle%3DRequired%2520Immunoproteasome%2520Subunit%2520Inhibition%2520Profile%2520for%2520Anti-Inflammatory%2520Efficacy%2520and%2520Clinical%2520Candidate%2520KZR-616%2520%2528%25282%2520S%252C%25203%2520R%2529-%2520N%2520-%2528%2528S%2529-3-%2528Cyclopent-1-En-1-Yl%2529-1-%2528%2528R%2529-2-Methyloxiran-2-Yl%2529-1-Oxopropan-2-Yl%2529-3-Hydroxy-3-%25284-Methoxyphenyl%2529-2-%2528%2528S%2529-2-%25282-Morpholinoacetamido%2529Propanamido%2529Propenamide%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D24%26spage%3D11127%26epage%3D11143%26doi%3D10.1021%2Facs.jmedchem.8b01201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span> </span><span class="NLM_article-title">A Study of KZR-616 in Patients With Systemic
Lupus Erythematosus
With and Without Nephritis</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT03393013" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03393013</a> (accessed June 20, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study+of+KZR-616+in+Patients+With+Systemic%0ALupus+Erythematosus%0AWith+and+Without+Nephritis.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03393013+%28accessed+June+20%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520Study%2520of%2520KZR-616%2520in%2520Patients%2520With%2520Systemic%250ALupus%2520Erythematosus%250AWith%2520and%2520Without%2520Nephritis" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ladi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stivala, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durk, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huestis, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaesse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidenschenk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, M.</span></span> <span> </span><span class="NLM_article-title">Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">7032</span>â <span class="NLM_lpage">7041</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b00509</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00509" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlamsbnO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7032-7041&issue=15&author=E.+Ladiauthor=C.+Everettauthor=C.+E.+Stivalaauthor=B.+E.+Danielsauthor=M.+R.+Durkauthor=S.+F.+Harrisauthor=M.+P.+Huestisauthor=H.+E.+Purkeyauthor=S.+T.+Stabenauthor=M.+Augustinauthor=M.+Blaesseauthor=S.+Steinbacherauthor=C.+Eidenschenkauthor=R.+Pappuauthor=M.+Siu&title=Design+and+Evaluation+of+Highly+Selective+Human+Immunoproteasome+Inhibitors+Reveal+a+Compensatory+Process+That+Preserves+Immune+Cell+Viability&doi=10.1021%2Facs.jmedchem.9b00509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability</span></div><div class="casAuthors">Ladi, Ena; Everett, Christine; Stivala, Craig E.; Daniels, Blake E.; Durk, Matthew R.; Harris, Seth F.; Huestis, Malcolm P.; Purkey, Hans E.; Staben, Steven T.; Augustin, Martin; Blaesse, Michael; Steinbacher, Stefan; Eidenschenk, Celine; Pappu, Rajita; Siu, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7032-7041</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pan-proteasome inhibitor bortezomib demonstrated clin. efficacy in off-label trials of Systemic Lupus Erythematosus.  One potential mechanism of this clin. benefit is from the depletion of pathogenic immune cells (plasmablasts and plasmacytoid dendritic cells).  However, bortezomib is cytotoxic against non-immune cells which limits its use for autoimmune diseases.  An attractive alternative is to selectively inhibit the immune cell-specific immunoproteasome to deplete pathogenic immune cells and spare non-hematopoietic cells.  Here we disclose the development of highly subunit-selective immunoproteasome inhibitors using insights obtained from the first bona fide human immunoproteasome co-crystal structures.  Evaluation of these inhibitors revealed that immunoproteasome-specific inhibition does not lead to immune cell death as anticipated and that targeting viability requires inhibition of both immuno- and constitutive proteasomes.  CRISPR/Cas9-mediated knock-out expts. confirmed upregulation of the constitutive proteasome upon disruption of the immunoproteasome, protecting cells from death.  Thus, immunoproteasome inhibition alone is not a suitable approach to deplete immune cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBtaasYDyZZ7Vg90H21EOLACvtfcHk0ljC7hyqO0BBDA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlamsbnO&md5=21b810621134c447794d5fb88337dbd2</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00509%26sid%3Dliteratum%253Aachs%26aulast%3DLadi%26aufirst%3DE.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DStivala%26aufirst%3DC.%2BE.%26aulast%3DDaniels%26aufirst%3DB.%2BE.%26aulast%3DDurk%26aufirst%3DM.%2BR.%26aulast%3DHarris%26aufirst%3DS.%2BF.%26aulast%3DHuestis%26aufirst%3DM.%2BP.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DAugustin%26aufirst%3DM.%26aulast%3DBlaesse%26aufirst%3DM.%26aulast%3DSteinbacher%26aufirst%3DS.%26aulast%3DEidenschenk%26aufirst%3DC.%26aulast%3DPappu%26aufirst%3DR.%26aulast%3DSiu%26aufirst%3DM.%26atitle%3DDesign%2520and%2520Evaluation%2520of%2520Highly%2520Selective%2520Human%2520Immunoproteasome%2520Inhibitors%2520Reveal%2520a%2520Compensatory%2520Process%2520That%2520Preserves%2520Immune%2520Cell%2520Viability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D15%26spage%3D7032%26epage%3D7041%26doi%3D10.1021%2Facs.jmedchem.9b00509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, S. M.</span>; <span class="NLM_string-name">Neidhart, W.</span>; <span class="NLM_string-name">Plancher, J.-M.</span>; <span class="NLM_string-name">Schulz-Gasch, T.</span></span> <span> </span><span class="NLM_article-title">Substituted Triazole Boronic Acid Compounds</span>. <span class="NLM_patent">EP2925765A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=S.+M.+Lynch&author=W.+Neidhart&author=J.-M.+Plancher&author=T.+Schulz-Gasch&title=Substituted+Triazole+Boronic+Acid+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DS.%2BM.%26atitle%3DSubstituted%2520Triazole%2520Boronic%2520Acid%2520Compounds%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harjutsalo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SjÃ¶berg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuomilehto, J.</span></span> <span> </span><span class="NLM_article-title">Time Trends in the Incidence of Type 1 Diabetes in Finnish Children: A Cohort Study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>371</i></span> (<span class="NLM_issue">9626</span>),  <span class="NLM_fpage">1777</span>â <span class="NLM_lpage">1782</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(08)60765-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2FS0140-6736%2808%2960765-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=18502302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BD1czjvFKmtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2008&pages=1777-1782&issue=9626&author=V.+Harjutsaloauthor=L.+Sj%C3%B6bergauthor=J.+Tuomilehto&title=Time+Trends+in+the+Incidence+of+Type+1+Diabetes+in+Finnish+Children%3A+A+Cohort+Study&doi=10.1016%2FS0140-6736%2808%2960765-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study</span></div><div class="casAuthors">Harjutsalo Valma; Sjoberg Lena; Tuomilehto Jaakko</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">9626</span>),
    <span class="NLM_cas:pages">1777-82</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Finland has the highest incidence of type 1 diabetes worldwide, reaching 40 per 100,000 people per year in the 1990s.  Our aim was to assess the temporal trend in type 1 diabetes incidence since 2000 in Finnish children aged younger than 15 years and to predict the number of cases of type 1 diabetes in the future.  METHODS:  Children with newly diagnosed type 1 diabetes in Finland who were listed on the National Public Health Institute diabetes register, Central Drug Register, and Hospital Discharge Register in 1980-2005 were included in a cohort study.  We excluded patients with type 2 diabetes and diabetes occurring secondary to other conditions, such as steroid use, Down's syndrome, and congenital malformations of pancreas.  FINDINGS:  10,737 children-5816 boys and 4921 girls-were diagnosed with type 1 diabetes before 15 years of age during 1980-2005.  The average age-standardised incidence was 42.9 per 100,000 per year (95% CI 42.6-44.3) during this period, increasing from 31.4 per 100,000 per year in 1980 to 64.2 per 100,000 per year in 2005.  The age-specific rates per 100,000 per year were 31.0, 50.5, and 50.6 at ages 0-4 years, 5-9 years, and 10-14-years, respectively.  We noted a significant non-linear component to the time trend (p<0.0003).  In children aged 0-4 years, the increase was largest, at 4.7% more affected every year.  The overall boy-to-girl ratio of incidence was 1.1; at the age of 13 years, it was 1.7 (1.4-2.0).  The predicted cumulative number of new cases with type 1 diabetes before 15 years of age between 2006 and 2020 was about 10 800.  INTERPRETATION:  The incidence of type 1 diabetes in Finnish children is increasing even faster than before.  The number of new cases diagnosed at or before 14 years of age will double in the next 15 years and the age of onset will be younger (0-4 years).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQy9T5zwrdRZu3MPKNEWB5RfW6udTcc2ebuBIjOpEYt1Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czjvFKmtQ%253D%253D&md5=c17ff8ede34255155db2d1fd6f8e22d0</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2808%2960765-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252808%252960765-5%26sid%3Dliteratum%253Aachs%26aulast%3DHarjutsalo%26aufirst%3DV.%26aulast%3DSj%25C3%25B6berg%26aufirst%3DL.%26aulast%3DTuomilehto%26aufirst%3DJ.%26atitle%3DTime%2520Trends%2520in%2520the%2520Incidence%2520of%2520Type%25201%2520Diabetes%2520in%2520Finnish%2520Children%253A%2520A%2520Cohort%2520Study%26jtitle%3DLancet%26date%3D2008%26volume%3D371%26issue%3D9626%26spage%3D1777%26epage%3D1782%26doi%3D10.1016%2FS0140-6736%2808%2960765-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, R. D.</span></span> <span> </span><span class="NLM_article-title">Predicting Adult-Onset Autoimmune Diabetes</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">330</span>â <span class="NLM_lpage">331</span>, <span class="refDoi">Â DOI: 10.2337/db09-1620</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.2337%2Fdb09-1620" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=20103711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvVyrur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2010&pages=330-331&issue=2&author=R.+D.+Leslie&title=Predicting+Adult-Onset+Autoimmune+Diabetes&doi=10.2337%2Fdb09-1620"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting adult-onset autoimmune diabetes: clarity from complexity</span></div><div class="casAuthors">Leslie, R. David</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">330-331</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">A review of findings by V. Lundgren et al. (ibid.) that presence of autoantibodies to glutamic acid decarboxylase predicts development of autoimmune diabetes in adult humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBsX99XvCTM7Vg90H21EOLACvtfcHk0lhAmgDHmFn_BA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvVyrur8%253D&md5=a1b6e9f64d45501825e99199b7ea1e96</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.2337%2Fdb09-1620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb09-1620%26sid%3Dliteratum%253Aachs%26aulast%3DLeslie%26aufirst%3DR.%2BD.%26atitle%3DPredicting%2520Adult-Onset%2520Autoimmune%2520Diabetes%26jtitle%3DDiabetes%26date%3D2010%26volume%3D59%26issue%3D2%26spage%3D330%26epage%3D331%26doi%3D10.2337%2Fdb09-1620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenbarth, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, A. W.</span></span> <span> </span><span class="NLM_article-title">Type 1 Diabetes</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>383</i></span> (<span class="NLM_issue">9911</span>),  <span class="NLM_fpage">69</span>â <span class="NLM_lpage">82</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(13)60591-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2FS0140-6736%2813%2960591-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=23890997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BC3sfksFaqtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2014&pages=69-82&issue=9911&author=M.+A.+Atkinsonauthor=G.+S.+Eisenbarthauthor=A.+W.+Michels&title=Type+1+Diabetes&doi=10.1016%2FS0140-6736%2813%2960591-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Type 1 diabetes</span></div><div class="casAuthors">Atkinson Mark A; Eisenbarth George S; Michels Aaron W</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue">9911</span>),
    <span class="NLM_cas:pages">69-82</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Over the past decade, knowledge of the pathogenesis and natural history of type 1 diabetes has grown substantially, particularly with regard to disease prediction and heterogeneity, pancreatic pathology, and epidemiology.  Technological improvements in insulin pumps and continuous glucose monitors help patients with type 1 diabetes manage the challenge of lifelong insulin administration.  Agents that show promise for averting debilitating disease-associated complications have also been identified.  However, despite broad organisational, intellectual, and fiscal investments, no means for preventing or curing type 1 diabetes exists, and, globally, the quality of diabetes management remains uneven.  This Seminar discusses current progress in epidemiology, pathology, diagnosis, and treatment of type 1 diabetes, and prospects for an improved future for individuals with this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgANOcimHnecuCWE5mhx1RfW6udTcc2eZJNwD_ZoIyfLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfksFaqtw%253D%253D&md5=09e0deffd2247e7ea14627ffd147dee8</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2813%2960591-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252813%252960591-7%26sid%3Dliteratum%253Aachs%26aulast%3DAtkinson%26aufirst%3DM.%2BA.%26aulast%3DEisenbarth%26aufirst%3DG.%2BS.%26aulast%3DMichels%26aufirst%3DA.%2BW.%26atitle%3DType%25201%2520Diabetes%26jtitle%3DLancet%26date%3D2014%26volume%3D383%26issue%3D9911%26spage%3D69%26epage%3D82%26doi%3D10.1016%2FS0140-6736%2813%2960591-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brorsson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tue Hansen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergholdt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pociot, F.</span></span> <span> </span><span class="NLM_article-title">The Type 1 Diabetes - HLA Susceptibility Interactome - Identification of HLA Genotype-Specific Disease Genes for Type 1 Diabetes</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">e9576</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0009576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1371%2Fjournal.pone.0009576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=20221424" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=e9576&issue=3&author=C.+Brorssonauthor=N.+Tue+Hansenauthor=R.+Bergholdtauthor=S.+Brunakauthor=F.+Pociot&title=The+Type+1+Diabetes+-+HLA+Susceptibility+Interactome+-+Identification+of+HLA+Genotype-Specific+Disease+Genes+for+Type+1+Diabetes&doi=10.1371%2Fjournal.pone.0009576"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0009576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0009576%26sid%3Dliteratum%253Aachs%26aulast%3DBrorsson%26aufirst%3DC.%26aulast%3DTue%2BHansen%26aufirst%3DN.%26aulast%3DBergholdt%26aufirst%3DR.%26aulast%3DBrunak%26aufirst%3DS.%26aulast%3DPociot%26aufirst%3DF.%26atitle%3DThe%2520Type%25201%2520Diabetes%2520-%2520HLA%2520Susceptibility%2520Interactome%2520-%2520Identification%2520of%2520HLA%2520Genotype-Specific%2520Disease%2520Genes%2520for%2520Type%25201%2520Diabetes%26jtitle%3DPLoS%2520One%26date%3D2010%26volume%3D5%26issue%3D3%26spage%3De9576%26doi%3D10.1371%2Fjournal.pone.0009576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noble, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdes, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varney, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moonsamy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fear, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavant, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Concannon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mychaleckyj, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlich, H.</span></span> <span> </span><span class="NLM_article-title">HLA Class I and Genetic Susceptibility to Type 1 Diabetes: Results from the Type 1 Diabetes Genetics Consortium</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2972</span>â <span class="NLM_lpage">2979</span>, <span class="refDoi">Â DOI: 10.2337/db10-0699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.2337%2Fdb10-0699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=20798335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsV2nsb3P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2010&pages=2972-2979&issue=11&author=J.+A.+Nobleauthor=A.+M.+Valdesauthor=M.+D.+Varneyauthor=J.+A.+Carlsonauthor=P.+Moonsamyauthor=A.+L.+Fearauthor=J.+A.+Laneauthor=E.+Lavantauthor=R.+Rappnerauthor=A.+Loueyauthor=P.+Concannonauthor=J.+Mychaleckyjauthor=H.+Erlich&title=HLA+Class+I+and+Genetic+Susceptibility+to+Type+1+Diabetes%3A+Results+from+the+Type+1+Diabetes+Genetics+Consortium&doi=10.2337%2Fdb10-0699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">HLA class I and genetic susceptibility to type 1 diabetes: results from the type 1 diabetes genetics consortium</span></div><div class="casAuthors">Noble, Janelle A.; Valdes, Ana Maria; Varney, Michael D.; Carlson, Joyce A.; Moonsamy, Priscilla; Fear, Anna Lisa; Lane, Julie A.; Lavant, Eva; Rappner, Rebecca; Louey, Anthony; Concannon, Patrick; Mychaleckyj, Josyf C.; Erlich, Henry A.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2972-2979</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">We report here genotyping data and type 1 diabetes assocn. analyses for HLA class I loci (A, B, and C) on 1,753 multiplex pedigrees from the Type 1 Diabetes Genetics Consortium (T1DGC), a large international collaborative study.  Complete eight-locus HLA genotyping data were generated.  Expected patient class I (HLA-A, -B, and -C) allele frequencies were calcd., based on linkage disequil. (LD) patterns with obsd. HLA class II DRB1-DQA1-DQB1 haplotype frequencies.  Expected frequencies were compared to obsd. allele frequencies in patients.  Significant type 1 diabetes assocns. were obsd. at all class I HLA loci.  After accounting for LD with HLA class II, the most significantly type 1 diabetes-assocd. alleles were B*5701 (odds ratio 0.19; P = 4 Ã 10-11) and B*3906 (10.31; P = 4 Ã 10-10).  Other significantly type 1 diabetes-assocd. alleles included A*2402, A*0201, B*1801, and C*0501 (predisposing) and A*1101, A*3201, A*6601, B*0702, B*4403, B*3502, C*1601, and C*0401 (protective).  Some alleles, notably B*3906, appear to modulate the risk of all DRB1-DQA1-DQB1 haplotypes on which they reside, suggesting a class I effect that is independent of class II.  Other class I type 1 diabetes assocns. appear to be specific to individual class II haplotypes.  Some apparent assocns. (e.g., C*1601) could be attributed to strong LD to another class I susceptibility locus (B*4403).  These data indicate that HLA class I alleles, in addn. to and independently from HLA class II alleles, are assocd. with type 1 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1KvYg-D1Sl7Vg90H21EOLACvtfcHk0lhAmgDHmFn_BA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsV2nsb3P&md5=85ed308ca1b23e522f49f6e89c44c4e8</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.2337%2Fdb10-0699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb10-0699%26sid%3Dliteratum%253Aachs%26aulast%3DNoble%26aufirst%3DJ.%2BA.%26aulast%3DValdes%26aufirst%3DA.%2BM.%26aulast%3DVarney%26aufirst%3DM.%2BD.%26aulast%3DCarlson%26aufirst%3DJ.%2BA.%26aulast%3DMoonsamy%26aufirst%3DP.%26aulast%3DFear%26aufirst%3DA.%2BL.%26aulast%3DLane%26aufirst%3DJ.%2BA.%26aulast%3DLavant%26aufirst%3DE.%26aulast%3DRappner%26aufirst%3DR.%26aulast%3DLouey%26aufirst%3DA.%26aulast%3DConcannon%26aufirst%3DP.%26aulast%3DMychaleckyj%26aufirst%3DJ.%26aulast%3DErlich%26aufirst%3DH.%26atitle%3DHLA%2520Class%2520I%2520and%2520Genetic%2520Susceptibility%2520to%2520Type%25201%2520Diabetes%253A%2520Results%2520from%2520the%2520Type%25201%2520Diabetes%2520Genetics%2520Consortium%26jtitle%3DDiabetes%26date%3D2010%26volume%3D59%26issue%3D11%26spage%3D2972%26epage%3D2979%26doi%3D10.2337%2Fdb10-0699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, D. A.</span></span> <span> </span><span class="NLM_article-title">Autoimmune Markers in Diabetes</span>. <i>Clin. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">168</span>â <span class="NLM_lpage">175</span>, <span class="refDoi">Â DOI: 10.1373/clinchem.2010.148205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1373%2Fclinchem.2010.148205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=21127152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3MXislajurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2011&pages=168-175&issue=2&author=W.+E.+Winterauthor=D.+A.+Schatz&title=Autoimmune+Markers+in+Diabetes&doi=10.1373%2Fclinchem.2010.148205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Autoimmune markers in diabetes</span></div><div class="casAuthors">Winter, William E.; Schatz, Desmond A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Chemistry (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">168-175</span>CODEN:
                <span class="NLM_cas:coden">CLCHAU</span>;
        ISSN:<span class="NLM_cas:issn">0009-9147</span>.
    
            (<span class="NLM_cas:orgname">American Association for Clinical Chemistry</span>)
        </div><div class="casAbstract">A review.  BACKGROUND: Type 1 diabetes (T1DM) results from cell-mediated autoimmune destruction of the Î² cells of the islets of Langerhans.  Autoantibodies directed against the islets are useful clin. tools that allow the recognition and confirmation of Î²-cell autoimmunity.  CONTENT: In this review we define the term "islet autoantibody," describe the pathogenesis of autoantibody generation, and explain the uses of islet autoantibodies in clin. medicine and in research studies that concern the interruption or prevention of T1DM.  We also discuss the biol. of islet autoantibodies and their rates of appearance at the time of onset of T1DM and their appearance before the development of T1DM.  SUMMARY: The presence of islet autoantibodies in persons with diabetes confirms an autoimmune etiol.  In nondiabetic individuals, islet autoantibodies are strong predictors of the later development of T1DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGxqY9V4OXeLVg90H21EOLACvtfcHk0liT00hEguNNtg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXislajurc%253D&md5=17af37daeaa33ce068c44a60ff2a1cc0</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1373%2Fclinchem.2010.148205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1373%252Fclinchem.2010.148205%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DW.%2BE.%26aulast%3DSchatz%26aufirst%3DD.%2BA.%26atitle%3DAutoimmune%2520Markers%2520in%2520Diabetes%26jtitle%3DClin.%2520Chem.%26date%3D2011%26volume%3D57%26issue%3D2%26spage%3D168%26epage%3D175%26doi%3D10.1373%2Fclinchem.2010.148205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Juvenile Diabetes Research Foundation Continuous
Glucose Monitoring
Study Group</span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamborlane, W. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckingham, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chase, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiallo-Scharer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliam, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laffel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauras, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâGrady, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruedy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tansey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsalikian, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinzimer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolpert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wysocki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, D.</span></span> <span> </span><span class="NLM_article-title">Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>359</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">1464</span>â <span class="NLM_lpage">1476</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa0805017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1056%2FNEJMoa0805017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=18779236" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2008&pages=1464-1476&issue=14&author=Juvenile+Diabetes+Research+Foundation+Continuous%0AGlucose+Monitoring%0AStudy+Groupauthor=W.+V.+Tamborlaneauthor=R.+W.+Beckauthor=B.+W.+Bodeauthor=B.+Buckinghamauthor=H.+P.+Chaseauthor=R.+Clemonsauthor=R.+Fiallo-Scharerauthor=L.+A.+Foxauthor=L.+K.+Gilliamauthor=I.+Hirschauthor=E.+Huangauthor=C.+Kollmanauthor=A.+Kowalskiauthor=J.+Laffelauthor=J.+Leeauthor=N.+Maurasauthor=M.+O%E2%80%99Gradyauthor=K.+Ruedyauthor=M.+Tanseyauthor=E.+Tsalikianauthor=S.+Weinzimerauthor=D.+Wilsonauthor=H.+Wolpertauthor=T.+Wysockiauthor=D.+Xing&title=Continuous+Glucose+Monitoring+and+Intensive+Treatment+of+Type+1+Diabetes&doi=10.1056%2FNEJMoa0805017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0805017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0805017%26sid%3Dliteratum%253Aachs%26aulast%3D%26aulast%3DTamborlane%26aufirst%3DW.%2BV.%26aulast%3DBeck%26aufirst%3DR.%2BW.%26aulast%3DBode%26aufirst%3DB.%2BW.%26aulast%3DBuckingham%26aufirst%3DB.%26aulast%3DChase%26aufirst%3DH.%2BP.%26aulast%3DClemons%26aufirst%3DR.%26aulast%3DFiallo-Scharer%26aufirst%3DR.%26aulast%3DFox%26aufirst%3DL.%2BA.%26aulast%3DGilliam%26aufirst%3DL.%2BK.%26aulast%3DHirsch%26aufirst%3DI.%26aulast%3DHuang%26aufirst%3DE.%26aulast%3DKollman%26aufirst%3DC.%26aulast%3DKowalski%26aufirst%3DA.%26aulast%3DLaffel%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DMauras%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Grady%26aufirst%3DM.%26aulast%3DRuedy%26aufirst%3DK.%26aulast%3DTansey%26aufirst%3DM.%26aulast%3DTsalikian%26aufirst%3DE.%26aulast%3DWeinzimer%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DD.%26aulast%3DWolpert%26aufirst%3DH.%26aulast%3DWysocki%26aufirst%3DT.%26aulast%3DXing%26aufirst%3DD.%26atitle%3DContinuous%2520Glucose%2520Monitoring%2520and%2520Intensive%2520Treatment%2520of%2520Type%25201%2520Diabetes%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D359%26issue%3D14%26spage%3D1464%26epage%3D1476%26doi%3D10.1056%2FNEJMoa0805017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergenstal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamborlane, W. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buse, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dailey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peoples, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsh, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span> <span> </span><span class="NLM_article-title">Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">311</span>â <span class="NLM_lpage">320</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1002853</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1056%2FNEJMoa1002853" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=20587585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptFajtLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=311-320&issue=4&author=R.+M.+Bergenstalauthor=W.+V.+Tamborlaneauthor=A.+Ahmannauthor=J.+B.+Buseauthor=G.+Daileyauthor=S.+N.+Davisauthor=C.+Joyceauthor=T.+Peoplesauthor=B.+A.+Perkinsauthor=J.+B.+Welshauthor=S.+Williauthor=M.+Wood&title=Effectiveness+of+Sensor-Augmented+Insulin-Pump+Therapy+in+Type+1+Diabetes&doi=10.1056%2FNEJMoa1002853"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes</span></div><div class="casAuthors">Bergenstal, Richard M.; Tamborlane, William V.; Ahmann, Andrew; Buse, John B.; Dailey, George; Davis, Stephen N.; Joyce, Carol; Peoples, Tim; Perkins, Bruce A.; Welsh, John B.; Willi, Steven M.; Wood, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">311-320</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Recently developed technologies for the treatment of type 1 diabetes mellitus include a variety of pumps and pumps with glucose sensors.  METHODS: In this 1-yr, multicenter, randomized, controlled trial, we compared the efficacy of sensor-augmented pump therapy (pump therapy) with that of a regimen of multiple daily insulin injections (injection therapy) in 485 patients (329 adults and 156 children) with inadequately controlled type 1 diabetes.  Patients received recombinant insulin analogs and were supervised by expert clin. teams.  The primary end point was the change from the baseline glycated Hb level.  RESULTS: At 1 yr, the baseline mean glycated Hb level (8.3% in the two study groups) had decreased to 7.5% in the pump-therapy group, as compared with 8.1% in the injection-therapy group (P < 0.001).  The proportion of patients who reached the glycated Hb target ( < 7%) was greater in the pump-therapy group than in the injection-therapy group.  The rate of severe hypoglycemia in the pump-therapy group (13.31 cases per 100 person-years) did not differ significantly from that in the injection-therapy group (13.48 per 100 person-years, P = 0.58).  There was no significant wt. gain in either group.  CONCLUSIONS: In both adults and children with inadequately controlled type 1 diabetes, sensor-augmented pump therapy resulted in significant improvement in glycated Hb levels, as compared with injection therapy.  A significantly greater proportion of both adults and children in the pump-therapy group than in the injection-therapy group reached the target glycated Hb level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpashlH1Eh19LVg90H21EOLACvtfcHk0liT00hEguNNtg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptFajtLw%253D&md5=ae39e3228636b53dfdbc259459097c3a</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002853%26sid%3Dliteratum%253Aachs%26aulast%3DBergenstal%26aufirst%3DR.%2BM.%26aulast%3DTamborlane%26aufirst%3DW.%2BV.%26aulast%3DAhmann%26aufirst%3DA.%26aulast%3DBuse%26aufirst%3DJ.%2BB.%26aulast%3DDailey%26aufirst%3DG.%26aulast%3DDavis%26aufirst%3DS.%2BN.%26aulast%3DJoyce%26aufirst%3DC.%26aulast%3DPeoples%26aufirst%3DT.%26aulast%3DPerkins%26aufirst%3DB.%2BA.%26aulast%3DWelsh%26aufirst%3DJ.%2BB.%26aulast%3DWilli%26aufirst%3DS.%26aulast%3DWood%26aufirst%3DM.%26atitle%3DEffectiveness%2520of%2520Sensor-Augmented%2520Insulin-Pump%2520Therapy%2520in%2520Type%25201%2520Diabetes%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26issue%3D4%26spage%3D311%26epage%3D320%26doi%3D10.1056%2FNEJMoa1002853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergenstal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinzimer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckingham, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamborlane, W. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, F. R.</span></span> <span> </span><span class="NLM_article-title">Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>316</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1407</span>, <span class="refDoi">Â DOI: 10.1001/jama.2016.11708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1001%2Fjama.2016.11708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=27629148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BC2svgsFWrsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2016&pages=1407&issue=13&author=R.+M.+Bergenstalauthor=S.+Gargauthor=S.+A.+Weinzimerauthor=B.+A.+Buckinghamauthor=B.+W.+Bodeauthor=W.+V.+Tamborlaneauthor=F.+R.+Kaufman&title=Safety+of+a+Hybrid+Closed-Loop+Insulin+Delivery+System+in+Patients+With+Type+1+Diabetes&doi=10.1001%2Fjama.2016.11708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes</span></div><div class="casAuthors">Bergenstal Richard M; Garg Satish; Weinzimer Stuart A; Tamborlane William V; Buckingham Bruce A; Bode Bruce W; Kaufman Francine R</div><div class="citationInfo"><span class="NLM_cas:title">JAMA</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1407-1408</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ91Ck_h9aCvdbHMBt0mMIXfW6udTcc2ebH4pUuP6_CCbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svgsFWrsQ%253D%253D&md5=7f6c1e7117ea124854dee9b2baa80271</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1001%2Fjama.2016.11708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2016.11708%26sid%3Dliteratum%253Aachs%26aulast%3DBergenstal%26aufirst%3DR.%2BM.%26aulast%3DGarg%26aufirst%3DS.%26aulast%3DWeinzimer%26aufirst%3DS.%2BA.%26aulast%3DBuckingham%26aufirst%3DB.%2BA.%26aulast%3DBode%26aufirst%3DB.%2BW.%26aulast%3DTamborlane%26aufirst%3DW.%2BV.%26aulast%3DKaufman%26aufirst%3DF.%2BR.%26atitle%3DSafety%2520of%2520a%2520Hybrid%2520Closed-Loop%2520Insulin%2520Delivery%2520System%2520in%2520Patients%2520With%2520Type%25201%2520Diabetes%26jtitle%3DJAMA%26date%3D2016%26volume%3D316%26issue%3D13%26spage%3D1407%26doi%3D10.1001%2Fjama.2016.11708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, D. M.</span></span> <span> </span><span class="NLM_article-title">Long-Term Complications of Diabetes Mellitus</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>328</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">1676</span>â <span class="NLM_lpage">1685</span>, <span class="refDoi">Â DOI: 10.1056/NEJM199306103282306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1056%2FNEJM199306103282306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=8487827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADyaK3s3lsVGgsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=328&publication_year=1993&pages=1676-1685&issue=23&author=D.+M.+Nathan&title=Long-Term+Complications+of+Diabetes+Mellitus&doi=10.1056%2FNEJM199306103282306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term complications of diabetes mellitus</span></div><div class="casAuthors">Nathan D M</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">328</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">1676-85</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQeI2Wva4wSrWlSCSgBhwJFfW6udTcc2ebH4pUuP6_CCbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s3lsVGgsA%253D%253D&md5=2a29d58d4dec1bf483f668b439055709</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1056%2FNEJM199306103282306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199306103282306%26sid%3Dliteratum%253Aachs%26aulast%3DNathan%26aufirst%3DD.%2BM.%26atitle%3DLong-Term%2520Complications%2520of%2520Diabetes%2520Mellitus%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1993%26volume%3D328%26issue%3D23%26spage%3D1676%26epage%3D1685%26doi%3D10.1056%2FNEJM199306103282306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foulis, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farquharson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardman, R.</span></span> <span> </span><span class="NLM_article-title">Aberrant Expression of Class II Major Histocompatibility Complex Molecules by B Cells and Hyperexpression of Class I Major Histocompatibility Complex Molecules by Insulin Containing Islets in Type 1 (Insulin-Dependent) Diabetes Mellitus</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">333</span>â <span class="NLM_lpage">343</span>, <span class="refDoi">Â DOI: 10.1007/BF00299027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1007%2FBF00299027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=3301484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADyaL2s3nslSisg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1987&pages=333-343&issue=5&author=A.+K.+Foulisauthor=M.+A.+Farquharsonauthor=R.+Hardman&title=Aberrant+Expression+of+Class+II+Major+Histocompatibility+Complex+Molecules+by+B+Cells+and+Hyperexpression+of+Class+I+Major+Histocompatibility+Complex+Molecules+by+Insulin+Containing+Islets+in+Type+1+%28Insulin-Dependent%29+Diabetes+Mellitus&doi=10.1007%2FBF00299027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Aberrant expression of class II major histocompatibility complex molecules by B cells and hyperexpression of class I major histocompatibility complex molecules by insulin containing islets in type 1 (insulin-dependent) diabetes mellitus</span></div><div class="casAuthors">Foulis A K; Farquharson M A; Hardman R</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">333-43</span>
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    </div><div class="casAbstract">Twenty-three patients with recent onset Type 1 (insulin-dependent) diabetes in whom residual insulin secreting B cells were present and 12 patients with disease of more prolonged duration (maximum 9 years), 8 of whom had residual B cells, were studied.  Aberrant expression of Class II major histocompatibility complex molecules was demonstrated immunohistochemically on insulin secreting B cells in 21 out of 23 patients with recent onset disease and 6 of the patients with more prolonged disease.  No such expression was seen on glucagon secreting A cells or somatostatin secreting D cells.  Islets where there was marked hyperexpression of Class I major histocompatibility complex molecules on islet endocrine cells were seen in all cases in which residual B cells were present.  Ninety-two per cent of insulin containing islets but only 1% of insulin deficient islets exhibited this phenomenon (p less than 0.001, Chi-squared test).  There was evidence to suggest that both these abnormalities of major histocompatibility complex expression preceded insulitis within a given islet.  They also appeared to be unique to Type 1 diabetes, being absent in pancreases of patients with Type 2 (non-insulin-dependent) diabetes, chronic pancreatitis, cystic fibrosis, graft-versus-host disease and Coxsackie B viral pancreatitis.  The development of autoimmunity to B cells in Type 1 diabetes may be a "multistep" process in which abnormalities of major histocompatibility complex expression on islet endocrine cells are crucial events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSSZHEhX5gIXUH3Rlp_k91zfW6udTcc2ebH4pUuP6_CCbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2s3nslSisg%253D%253D&md5=841f370771c5eeddcc3e375d6365396e</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1007%2FBF00299027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00299027%26sid%3Dliteratum%253Aachs%26aulast%3DFoulis%26aufirst%3DA.%2BK.%26aulast%3DFarquharson%26aufirst%3DM.%2BA.%26aulast%3DHardman%26aufirst%3DR.%26atitle%3DAberrant%2520Expression%2520of%2520Class%2520II%2520Major%2520Histocompatibility%2520Complex%2520Molecules%2520by%2520B%2520Cells%2520and%2520Hyperexpression%2520of%2520Class%2520I%2520Major%2520Histocompatibility%2520Complex%2520Molecules%2520by%2520Insulin%2520Containing%2520Islets%2520in%2520Type%25201%2520%2528Insulin-Dependent%2529%2520Diabetes%2520Mellitus%26jtitle%3DDiabetologia%26date%3D1987%26volume%3D30%26issue%3D5%26spage%3D333%26epage%3D343%26doi%3D10.1007%2FBF00299027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bottazzo, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNally, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKay, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swift, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamble, D. R.</span></span> <span> </span><span class="NLM_article-title">In Situ Characterization of Autoimmune Phenomena and Expression of HLA Molecules in the Pancreas in Diabetic Insulitis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>313</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">353</span>â <span class="NLM_lpage">360</span>, <span class="refDoi">Â DOI: 10.1056/NEJM198508083130604</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1056%2FNEJM198508083130604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=3159965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADyaL2M3ktVCqsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=1985&pages=353-360&issue=6&author=G.+F.+Bottazzoauthor=B.+M.+Deanauthor=J.+M.+McNallyauthor=E.+H.+MacKayauthor=P.+G.+Swiftauthor=D.+R.+Gamble&title=In+Situ+Characterization+of+Autoimmune+Phenomena+and+Expression+of+HLA+Molecules+in+the+Pancreas+in+Diabetic+Insulitis&doi=10.1056%2FNEJM198508083130604"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis</span></div><div class="casAuthors">Bottazzo G F; Dean B M; McNally J M; MacKay E H; Swift P G; Gamble D R</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">313</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">353-60</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">After the death of a 12-year old girl with newly discovered insulin-dependent diabetes mellitus, we used monoclonal antibodies in an effort to identify the cells invading the pancreas.  The majority of infiltrating lymphocytes were of the T cytotoxic/suppressor phenotype, but other T-cell subpopulations were present.  Some of the T cells were "activated" (positive for HLA-DR antigen, and the interleukin-2 receptor).  Immunocytes bearing IgG were scattered in the gland, and complement-fixing IgG antibodies were deposited in some islets.  Increased expression of Class I (HLA-A, B, and C) molecules was observed in the affected islet cells, and in damaged islets showing scant lymphocytic infiltration, some beta cells (still producing insulin), but not glucagon or somatostatin cells, were HLA-DR positive.  The capillary endothelium was markedly dilated and strongly HLA-DR positive.  These findings may contribute to an understanding of the sequence of events leading to the destruction of beta cells in classic Type I diabetes mellitus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTHZ86wpEiL0yCEBeYuoi7AfW6udTcc2ebLmE5vYabCfrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2M3ktVCqsQ%253D%253D&md5=2bf422c4fcabc121ef52fb4c684898e2</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1056%2FNEJM198508083130604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM198508083130604%26sid%3Dliteratum%253Aachs%26aulast%3DBottazzo%26aufirst%3DG.%2BF.%26aulast%3DDean%26aufirst%3DB.%2BM.%26aulast%3DMcNally%26aufirst%3DJ.%2BM.%26aulast%3DMacKay%26aufirst%3DE.%2BH.%26aulast%3DSwift%26aufirst%3DP.%2BG.%26aulast%3DGamble%26aufirst%3DD.%2BR.%26atitle%3DIn%2520Situ%2520Characterization%2520of%2520Autoimmune%2520Phenomena%2520and%2520Expression%2520of%2520HLA%2520Molecules%2520in%2520the%2520Pancreas%2520in%2520Diabetic%2520Insulitis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1985%26volume%3D313%26issue%3D6%26spage%3D353%26epage%3D360%26doi%3D10.1056%2FNEJM198508083130604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pujol-Borrell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doshi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottazzo, G. F.</span></span> <span> </span><span class="NLM_article-title">Differential Expression and Regulation of MHC Products in the Endocrine and Exocrine Cells of the Human Pancreas</span>. <i>Clin. Exp. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">128</span>â <span class="NLM_lpage">139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=3098471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADyaL2s%252FnvV2ksw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1986&pages=128-139&issue=1&author=R.+Pujol-Borrellauthor=I.+Toddauthor=M.+Doshiauthor=D.+Grayauthor=M.+Feldmannauthor=G.+F.+Bottazzo&title=Differential+Expression+and+Regulation+of+MHC+Products+in+the+Endocrine+and+Exocrine+Cells+of+the+Human+Pancreas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Differential expression and regulation of MHC products in the endocrine and exocrine cells of the human pancreas</span></div><div class="casAuthors">Pujol-Borrell R; Todd I; Doshi M; Gray D; Feldmann M; Bottazzo G F</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and experimental immunology</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-39</span>
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    </div><div class="casAbstract">Inappropriate expression of HLA Class II (D/DR) molecules has been detected in the target cells of most autoimmune diseases including Type I (insulin-dependent) diabetes.  The possibility that this phenomenon is due to the action of lymphocytes or some of their products has been investigated by analysing in vitro the modulation of HLA products in Beta cells.  Monolayer cultures from 25 human pancreatic glands were supplemented with alpha-interferon (IFN), beta-IFN or gamma-IFN, interleukin 2 (IL-2) and supernatants from activated lymphocytes.  In addition, lectins and a variety of other hormones, biological products and chemicals were tested.  Major histocompatibility complex (MHC) expression was assessed by double immunofluorescence technique using monoclonal antibodies to non-polymorphic determinants of Class I and Class II molecules and the pancreatic cells were identified by antibodies to islet hormones and other cytoplasmic antigens. gamma-IFN and lectins produced a parallel enhancement of HLA-A,B,C expression in islet, exocrine/ductal cells and fibroblasts.  HLA-D/DR was inducible in all pancreatic cell types, except endocrine islet cells which did not produce Class II molecules in response to any of the stimuli including supernatants from activated lymphocytes.  Exocrine/ductal cells from glands of patients with chronic pancreatitis spontaneously expressed Class II products, but islet cells were devoid of any detectable D/DR.  These data are consistent with recent observations which have indicated that in the 'diabetic' pancreas inappropriate Class II expression in the Beta cells occurs independently of the presence of lymphocytes infiltrating the islets, and make it necessary to postulate that other factors are responsible for the Class II induction in Beta cells in human Type I diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLAwTKyoIkO5otVjB3IRIyfW6udTcc2ebLmE5vYabCfrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2s%252FnvV2ksw%253D%253D&md5=c23b5691b1ca79e81eb7041acf427883</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPujol-Borrell%26aufirst%3DR.%26aulast%3DTodd%26aufirst%3DI.%26aulast%3DDoshi%26aufirst%3DM.%26aulast%3DGray%26aufirst%3DD.%26aulast%3DFeldmann%26aufirst%3DM.%26aulast%3DBottazzo%26aufirst%3DG.%2BF.%26atitle%3DDifferential%2520Expression%2520and%2520Regulation%2520of%2520MHC%2520Products%2520in%2520the%2520Endocrine%2520and%2520Exocrine%2520Cells%2520of%2520the%2520Human%2520Pancreas%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D1986%26volume%3D65%26issue%3D1%26spage%3D128%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Calvo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerling, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaddis, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeissler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leete, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogvold, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahl-JÃ¸rgensen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Herrath, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugliese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, N. G.</span></span> <span> </span><span class="NLM_article-title">Islet Cell Hyperexpression of HLA Class I Antigens: A Defining Feature in Type 1 Diabetes</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2448</span>â <span class="NLM_lpage">2458</span>, <span class="refDoi">Â DOI: 10.1007/s00125-016-4067-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1007%2Fs00125-016-4067-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=27506584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtleqsLbK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2448-2458&issue=11&author=S.+J.+Richardsonauthor=T.+Rodriguez-Calvoauthor=I.+C.+Gerlingauthor=C.+E.+Mathewsauthor=J.+S.+Kaddisauthor=M.+A.+Russellauthor=M.+Zeisslerauthor=P.+Leeteauthor=L.+Krogvoldauthor=K.+Dahl-J%C3%B8rgensenauthor=M.+von+Herrathauthor=A.+Puglieseauthor=M.+A.+Atkinsonauthor=N.+G.+Morgan&title=Islet+Cell+Hyperexpression+of+HLA+Class+I+Antigens%3A+A+Defining+Feature+in+Type+1+Diabetes&doi=10.1007%2Fs00125-016-4067-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes</span></div><div class="casAuthors">Richardson, Sarah J.; Rodriguez-Calvo, Teresa; Gerling, Ivan C.; Mathews, Clayton E.; Kaddis, John S.; Russell, Mark A.; Zeissler, Marie; Leete, Pia; Krogvold, Lars; Dahl-Joergensen, Knut; von Herrath, Matthias; Pugliese, Alberto; Atkinson, Mark A.; Morgan, Noel G.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2448-2458</span>CODEN:
                <span class="NLM_cas:coden">DBTGAJ</span>;
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Aims/hypothesis: Human pancreatic beta cells may be complicit in their own demise in type 1 diabetes, but how this occurs remains unclear.  One potentially contributing factor is hyperexpression of HLA class I antigens.  This was first described approx. 30 years ago, but has never been fully characterised and was recently challenged as artifactual.  Therefore, we investigated HLA class I expression at the protein and RNA levels in pancreases from three cohorts of patients with type 1 diabetes.  The principal aims were to consider whether HLA class I hyperexpression is artifactual and, if not, to det. the factors driving it.  Methods: Pancreas samples from type 1 diabetes patients with residual insulin-contg. islets (n = 26) from the Network for Pancreatic Organ donors with Diabetes (nPOD), Diabetes Virus Detection study (DiViD) and UK recent-onset type 1 diabetes collections were immunostained for HLA class I isoforms, signal transducer and activator of transcription 1 (STAT1), NLR family CARD domain contg. 5 (NLRC5) and islet hormones.  RNA was extd. from islets isolated by laser-capture microdissection from nPOD and DiViD samples and analyzed using gene-expression arrays.  Results: Hyperexpression of HLA class I was obsd. in the insulin-contg. islets of type 1 diabetes patients from all three tissue collections, and was confirmed at both the RNA and protein levels.  The expression of Î²2-microglobulin (a second component required for the generation of functional HLA class I complexes) was also elevated.  Both 'classical' HLA class I isoforms (i.e. HLA-ABC) as well as a 'non-classical' HLA mol., HLA-F, were hyperexpressed in insulin-contg. islets.  This hyperexpression did not correlate with detectable upregulation of the transcriptional regulator NLRC5.  However, it was strongly assocd. with increased STAT1 expression in all three cohorts.  Islet hyperexpression of HLA class I mols. occurred in the insulin-contg. islets of patients with recent-onset type 1 diabetes and was also detectable in many patients with disease duration of up to 11 years, declining thereafter.  Conclusions/interpretation: Islet cell HLA class I hyperexpression is not an artifact, but is a hallmark in the immunopathogenesis of type 1 diabetes.  The response is closely assocd. with elevated expression of STAT1 and, together, these occur uniquely in patients with type 1 diabetes, thereby contributing to their selective susceptibility to autoimmune-mediated destruction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVeRphwEO_-LVg90H21EOLACvtfcHk0lgvUBCoidubqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtleqsLbK&md5=cc5d7964a3a4607d447cc35d91e7cdb8</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1007%2Fs00125-016-4067-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-016-4067-4%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DS.%2BJ.%26aulast%3DRodriguez-Calvo%26aufirst%3DT.%26aulast%3DGerling%26aufirst%3DI.%2BC.%26aulast%3DMathews%26aufirst%3DC.%2BE.%26aulast%3DKaddis%26aufirst%3DJ.%2BS.%26aulast%3DRussell%26aufirst%3DM.%2BA.%26aulast%3DZeissler%26aufirst%3DM.%26aulast%3DLeete%26aufirst%3DP.%26aulast%3DKrogvold%26aufirst%3DL.%26aulast%3DDahl-J%25C3%25B8rgensen%26aufirst%3DK.%26aulast%3Dvon%2BHerrath%26aufirst%3DM.%26aulast%3DPugliese%26aufirst%3DA.%26aulast%3DAtkinson%26aufirst%3DM.%2BA.%26aulast%3DMorgan%26aufirst%3DN.%2BG.%26atitle%3DIslet%2520Cell%2520Hyperexpression%2520of%2520HLA%2520Class%2520I%2520Antigens%253A%2520A%2520Defining%2520Feature%2520in%2520Type%25201%2520Diabetes%26jtitle%3DDiabetologia%26date%3D2016%26volume%3D59%26issue%3D11%26spage%3D2448%26epage%3D2458%26doi%3D10.1007%2Fs00125-016-4067-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foulis, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farquharson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meager, A.</span></span> <span> </span><span class="NLM_article-title">Immunoreactive Alpha-Interferon in Insulin-Secreting Beta Cells in Type 1 Diabetes Mellitus</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>330</i></span> (<span class="NLM_issue">8573</span>),  <span class="NLM_fpage">1423</span>â <span class="NLM_lpage">1427</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(87)91128-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2FS0140-6736%2887%2991128-7" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=1987&pages=1423-1427&issue=8573&author=A.+K.+Foulisauthor=M.+A.+Farquharsonauthor=A.+Meager&title=Immunoreactive+Alpha-Interferon+in+Insulin-Secreting+Beta+Cells+in+Type+1+Diabetes+Mellitus&doi=10.1016%2FS0140-6736%2887%2991128-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2887%2991128-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252887%252991128-7%26sid%3Dliteratum%253Aachs%26aulast%3DFoulis%26aufirst%3DA.%2BK.%26aulast%3DFarquharson%26aufirst%3DM.%2BA.%26aulast%3DMeager%26aufirst%3DA.%26atitle%3DImmunoreactive%2520Alpha-Interferon%2520in%2520Insulin-Secreting%2520Beta%2520Cells%2520in%2520Type%25201%2520Diabetes%2520Mellitus%26jtitle%3DLancet%26date%3D1987%26volume%3D330%26issue%3D8573%26spage%3D1423%26epage%3D1427%26doi%3D10.1016%2FS0140-6736%2887%2991128-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mishto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellavista, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolzing, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligorio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacmias, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spazzafumo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiappelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licastro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorbi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pession, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grune, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceschi, C.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasome and LMP2 Polymorphism in Aged and Alzheimerâs Disease Brains</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">54</span>â <span class="NLM_lpage">66</span>, <span class="refDoi">Â DOI: 10.1016/j.neurobiolaging.2004.12.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.neurobiolaging.2004.12.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=16298241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1egsr3E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=54-66&issue=1&author=M.+Mishtoauthor=E.+Bellavistaauthor=A.+Santoroauthor=A.+Stolzingauthor=C.+Ligorioauthor=B.+Nacmiasauthor=L.+Spazzafumoauthor=M.+Chiappelliauthor=F.+Licastroauthor=S.+Sorbiauthor=A.+Pessionauthor=T.+Ohmauthor=T.+Gruneauthor=C.+Franceschi&title=Immunoproteasome+and+LMP2+Polymorphism+in+Aged+and+Alzheimer%E2%80%99s+Disease+Brains&doi=10.1016%2Fj.neurobiolaging.2004.12.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains</span></div><div class="casAuthors">Mishto, Michele; Bellavista, Elena; Santoro, Aurelia; Stolzing, Alexandra; Ligorio, Claudia; Nacmias, Benedetta; Spazzafumo, Liana; Chiappelli, Martina; Licastro, Federico; Sorbi, Sandro; Pession, Annalisa; Ohm, Thomas; Grune, Tilman; Franceschi, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-66</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In this study, we investigated the presence and role of immunoproteasome and its LMP2 subunit polymorphism at codon 60 in Alzheimer's disease (AD).  Immunoproteasome was present in brain areas such as hippocampus and cerebellum and localized in neurons, astrocytes and endothelial cells.  A higher expression of immunoproteasome was found in brain of AD patients than in brain of non-demented elderly, being its expression in young brain negligible or absent.  Furthermore, AD affected regions showed a partial decrease in proteasome trypsin-like activity.  The study of LMP2 polymorphism (R/H) showed that it does not influence LMP2 expression (neither the mRNA nor mature protein) in brain tissue.  However, control brain areas of AD patients carrying the RR genotype showed an increased proteasome activity in comparison with RH carriers.  To test whether this effect of the genotype might be related to AD onset we performed a genetic study, which allowed us to exclude an assocn. of LMP2 codon 60 polymorphism with AD onset, despite its influence on the proteasome activity in human brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBR5TJqY4-frVg90H21EOLACvtfcHk0ljRgputh1YLHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1egsr3E&md5=cb7aeff396023f3fcfd6664e775b2c06</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2004.12.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2004.12.004%26sid%3Dliteratum%253Aachs%26aulast%3DMishto%26aufirst%3DM.%26aulast%3DBellavista%26aufirst%3DE.%26aulast%3DSantoro%26aufirst%3DA.%26aulast%3DStolzing%26aufirst%3DA.%26aulast%3DLigorio%26aufirst%3DC.%26aulast%3DNacmias%26aufirst%3DB.%26aulast%3DSpazzafumo%26aufirst%3DL.%26aulast%3DChiappelli%26aufirst%3DM.%26aulast%3DLicastro%26aufirst%3DF.%26aulast%3DSorbi%26aufirst%3DS.%26aulast%3DPession%26aufirst%3DA.%26aulast%3DOhm%26aufirst%3DT.%26aulast%3DGrune%26aufirst%3DT.%26aulast%3DFranceschi%26aufirst%3DC.%26atitle%3DImmunoproteasome%2520and%2520LMP2%2520Polymorphism%2520in%2520Aged%2520and%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Brains%26jtitle%3DNeurobiol.%2520Aging%26date%3D2006%26volume%3D27%26issue%3D1%26spage%3D54%26epage%3D66%26doi%3D10.1016%2Fj.neurobiolaging.2004.12.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DÃ­az-HernÃ¡ndez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HernÃ¡ndez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MartÃ­n-Aparicio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GÃ³mez-Ramos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MorÃ¡n, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">CastaÃ±o, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, J. J.</span></span> <span> </span><span class="NLM_article-title">Neuronal Induction of the Immunoproteasome in Huntingtonâs Disease</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">37</span>),  <span class="NLM_fpage">11653</span>â <span class="NLM_lpage">11661</span>, <span class="refDoi">Â DOI: 10.1523/JNEUROSCI.23-37-11653.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1523%2FJNEUROSCI.23-37-11653.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=14684867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFyntA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=11653-11661&issue=37&author=M.+D%C3%ADaz-Hern%C3%A1ndezauthor=F.+Hern%C3%A1ndezauthor=E.+Mart%C3%ADn-Aparicioauthor=P.+G%C3%B3mez-Ramosauthor=M.+A.+Mor%C3%A1nauthor=J.+G.+Casta%C3%B1oauthor=I.+Ferrerauthor=J.+Avilaauthor=J.+J.+Lucas&title=Neuronal+Induction+of+the+Immunoproteasome+in+Huntington%E2%80%99s+Disease&doi=10.1523%2FJNEUROSCI.23-37-11653.2003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Neuronal induction of the immunoproteasome in Huntington's disease</span></div><div class="casAuthors">Diaz-hernandez, Miguel; Hernandez, Felix; Martin-aparicio, Ester; Gomez-ramos, Pilar; Moran, Maria A.; Castano, Jose G.; Ferrer, Isidro; Avila, Jesus; Lucas, Jose J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">11653-11661</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Huntington's disease (HD) inclusions are stained with anti-ubiquitin and anti-proteasome antibodies.  This, together with proteasome activity studies on transfected cells, suggest that an impairment of the ubiquitin-proteasome system (UPS) may be key in HD pathogenesis.  To test whether proteasome activity is impaired in vivo, we performed enzymic assays for the three peptidase activities of the proteasome in brain exts. from the HD94 conditional mouse model of HD.  We found no inhibition of any of the activities, suggesting that if UPS impairment happens in vivo, it is not at the level of the proteasome catalytic core.  Intriguingly, the chymotrypsin- and trypsin-like activities increased selectively in the affected and aggregate-contg. regions: cortex and striatum.  Western blot anal. revealed no difference in total proteasome content whereas an increase in the interferon-inducible subunits of the immunoproteasome, LMP2 and LMP7, was obsd.  These subunits confer to the proteasome catalytic properties that are optimal for MHC-I peptide presentation.  Immunohistochem. in control mouse brain revealed LMP2 and LMP7 mainly in neurons.  Accordingly, their increase in HD94 mice predominantly took place in neurons, and 5% of the ubiquitin-pos. cortical aggregates were also LMP2-pos.  Ultrastructural anal. of neurons with high level of immunoproteasome subunits revealed signs of neurodegeneration like nuclear indentation or fragmentation and dark cell appearance.  The neuronal induction of LMP2 and LMP7 and the assocd. signs of neurodegeneration were also found in HD postmortem brains.  Our results indicate that LMP2 and LMP7 participate in normal neuronal physiol. and suggest a role in HD neurodegeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUuKczRgYbE7Vg90H21EOLACvtfcHk0ljRgputh1YLHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFyntA%253D%253D&md5=b862bc3c6d5b8e4f1c0ea213878d8da3</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.23-37-11653.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.23-37-11653.2003%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25ADaz-Hern%25C3%25A1ndez%26aufirst%3DM.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DF.%26aulast%3DMart%25C3%25ADn-Aparicio%26aufirst%3DE.%26aulast%3DG%25C3%25B3mez-Ramos%26aufirst%3DP.%26aulast%3DMor%25C3%25A1n%26aufirst%3DM.%2BA.%26aulast%3DCasta%25C3%25B1o%26aufirst%3DJ.%2BG.%26aulast%3DFerrer%26aufirst%3DI.%26aulast%3DAvila%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DJ.%2BJ.%26atitle%3DNeuronal%2520Induction%2520of%2520the%2520Immunoproteasome%2520in%2520Huntington%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Neurosci.%26date%3D2003%26volume%3D23%26issue%3D37%26spage%3D11653%26epage%3D11661%26doi%3D10.1523%2FJNEUROSCI.23-37-11653.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheroni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peviani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debiasi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendotti, C.</span></span> <span> </span><span class="NLM_article-title">Accumulation of Human SOD1 and Ubiquitinated Deposits in the Spinal Cord of SOD1G93A Mice during Motor Neuron Disease Progression Correlates with a Decrease of Proteasome</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">509</span>â <span class="NLM_lpage">522</span>, <span class="refDoi">Â DOI: 10.1016/j.nbd.2004.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.nbd.2004.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=15755678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhvFyns7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=509-522&issue=3&author=C.+Cheroniauthor=M.+Pevianiauthor=P.+Cascioauthor=S.+Debiasiauthor=C.+Montiauthor=C.+Bendotti&title=Accumulation+of+Human+SOD1+and+Ubiquitinated+Deposits+in+the+Spinal+Cord+of+SOD1G93A+Mice+during+Motor+Neuron+Disease+Progression+Correlates+with+a+Decrease+of+Proteasome&doi=10.1016%2Fj.nbd.2004.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Accumulation of human SOD1 and ubiquitinated deposits in the spinal cord of SOD1G93A mice during motor neuron disease progression correlates with a decrease of proteasome</span></div><div class="casAuthors">Cheroni, C.; Peviani, M.; Cascio, P.; DeBiasi, S.; Monti, C.; Bendotti, C.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">509-522</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Mutations in SOD1 cause selective motor neuron degeneration in familial amyotrophic lateral sclerosis patients and transgenic mice overexpressing the mutant enzyme.  Formation and accumulation of ubiquitinated aggregates in motor neurons are thought to be involved in the toxic gain of function of mutant SOD1.  The present study shows that the accumulation of sol. and detergent-insol. mutant SOD1 in spinal cord of symptomatic SOD1G93A transgenic mice is due to impaired degrdn. of mutant SOD1 rather than to increased transcript levels.  This effect was accompanied by a decrease of constitutive proteasome levels and a concomitant increase of immunoproteasome in the spinal cord homogenate which resulted in overall unchanged proteasome activity.  A decrease of constitutive proteasome occurred in the motor neurons of SOD1G93A mice at the presymptomatic stage and became remarkable with the progression of the disease.  This provides further evidence for an involvement of proteasome impairment in the toxicity of mutant SOD1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5IdE87NeAPrVg90H21EOLACvtfcHk0ljRgputh1YLHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhvFyns7s%253D&md5=f96f6999700cd639253f8b875eb33068</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2004.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2004.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DCheroni%26aufirst%3DC.%26aulast%3DPeviani%26aufirst%3DM.%26aulast%3DCascio%26aufirst%3DP.%26aulast%3DDebiasi%26aufirst%3DS.%26aulast%3DMonti%26aufirst%3DC.%26aulast%3DBendotti%26aufirst%3DC.%26atitle%3DAccumulation%2520of%2520Human%2520SOD1%2520and%2520Ubiquitinated%2520Deposits%2520in%2520the%2520Spinal%2520Cord%2520of%2520SOD1G93A%2520Mice%2520during%2520Motor%2520Neuron%2520Disease%2520Progression%2520Correlates%2520with%2520a%2520Decrease%2520of%2520Proteasome%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2005%26volume%3D18%26issue%3D3%26spage%3D509%26epage%3D522%26doi%3D10.1016%2Fj.nbd.2004.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pintado, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GavilÃ¡n, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GavilÃ¡n, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GarcÃ­a-Cuervo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GutiÃ©rrez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitorica, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">CastaÃ±o, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RÃ­os, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruano, D.</span></span> <span> </span><span class="NLM_article-title">Lipopolysaccharide-Induced Neuroinflammation Leads to the Accumulation of Ubiquitinated Proteins and Increases Susceptibility to Neurodegeneration Induced by Proteasome Inhibition in Rat Hippocampus</span>. <i>J. Neuroinflammation</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">87</span>, <span class="refDoi">Â DOI: 10.1186/1742-2094-9-87</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1186%2F1742-2094-9-87" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=22559833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsVChsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=87&issue=1&author=C.+Pintadoauthor=M.+P.+Gavil%C3%A1nauthor=E.+Gavil%C3%A1nauthor=L.+Garc%C3%ADa-Cuervoauthor=A.+Guti%C3%A9rrezauthor=J.+Vitoricaauthor=A.+Casta%C3%B1oauthor=R.+M.+R%C3%ADosauthor=D.+Ruano&title=Lipopolysaccharide-Induced+Neuroinflammation+Leads+to+the+Accumulation+of+Ubiquitinated+Proteins+and+Increases+Susceptibility+to+Neurodegeneration+Induced+by+Proteasome+Inhibition+in+Rat+Hippocampus&doi=10.1186%2F1742-2094-9-87"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Lipopolysaccharide-induced neuroinflammation leads to the accumulation of ubiquitinated proteins and increases susceptibility to neurodegeneration induced by proteasome inhibition in rat hippocampus</span></div><div class="casAuthors">Pintado, Cristina; Gavilan, Maria P.; Gavilan, Elena; Garcia-Cuervo, Luisa; Gutierrez, Antonia; Vitorica, Javier; Castano, Angelica; Rios, Rosa M.; Ruano, Diego</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroinflammation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">87</span>CODEN:
                <span class="NLM_cas:coden">JNOEB3</span>;
        ISSN:<span class="NLM_cas:issn">1742-2094</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Neuroinflammation and protein accumulation are characteristic hallmarks of both normal aging and age-related neurodegenerative diseases.  However, the relationship between these factors in neurodegenerative processes is poorly understood.  We have previously shown that proteasome inhibition produced higher neurodegeneration in aged than in young rats, suggesting that other addnl. age-related events could be involved in neurodegeneration.  We evaluated the role of lipopolysaccharide (LPS)-induced neuroinflammation as a potential synergic risk factor for hippocampal neurodegeneration induced by proteasome inhibition.  Methods: Young male Wistar rats were injected with 1 Î¼L of saline or LPS (5 mg/mL) into the hippocampus to evaluate the effect of LPS-induced neuroinflammation on protein homeostasis.  The synergic effect of LPS and proteasome inhibition was analyzed in young rats that first received 1 Î¼L of LPS and 24 h later 1 Î¼L (5 mg/mL) of the proteasome inhibitor lactacystin.  Animals were sacrificed at different times post-injection and hippocampi isolated and processed for gene expression anal. by real-time polymerase chain reaction; protein expression anal. by western blots; proteasome activity by fluorescence spectroscopy; immunofluorescence anal. by confocal microscopy; and degeneration assay by Fluoro-Jade B staining.  Results: LPS injection produced the accumulation of ubiquitinated proteins in hippocampal neurons, increased expression of the E2 ubiquitin-conjugating enzyme UB2L6, decreased proteasome activity and increased immunoproteasome content.  However, LPS injection was not sufficient to produce neurodegeneration.  The combination of neuroinflammation and proteasome inhibition leads to higher neuronal accumulation of ubiquitinated proteins, predominant expression of pro-apoptotic markers and increased neurodegeneration, when compared with LPS or lactacystin (LT) injection alone.  Conclusions: Our results identify neuroinflammation as a risk factor that increases susceptibility to neurodegeneration induced by proteasome inhibition.  These results highlight the modulation of neuroinflammation as a mechanism for neuronal protection that could be relevant in situations where both factors are present, such as aging and neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1-VCUFdZox7Vg90H21EOLACvtfcHk0lhipnbZEQgfog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsVChsw%253D%253D&md5=4d3af7ab4628c7a1af1a4c9dd6411ac8</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1186%2F1742-2094-9-87&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-2094-9-87%26sid%3Dliteratum%253Aachs%26aulast%3DPintado%26aufirst%3DC.%26aulast%3DGavil%25C3%25A1n%26aufirst%3DM.%2BP.%26aulast%3DGavil%25C3%25A1n%26aufirst%3DE.%26aulast%3DGarc%25C3%25ADa-Cuervo%26aufirst%3DL.%26aulast%3DGuti%25C3%25A9rrez%26aufirst%3DA.%26aulast%3DVitorica%26aufirst%3DJ.%26aulast%3DCasta%25C3%25B1o%26aufirst%3DA.%26aulast%3DR%25C3%25ADos%26aufirst%3DR.%2BM.%26aulast%3DRuano%26aufirst%3DD.%26atitle%3DLipopolysaccharide-Induced%2520Neuroinflammation%2520Leads%2520to%2520the%2520Accumulation%2520of%2520Ubiquitinated%2520Proteins%2520and%2520Increases%2520Susceptibility%2520to%2520Neurodegeneration%2520Induced%2520by%2520Proteasome%2520Inhibition%2520in%2520Rat%2520Hippocampus%26jtitle%3DJ.%2520Neuroinflammation%26date%3D2012%26volume%3D9%26issue%3D1%26spage%3D87%26doi%3D10.1186%2F1742-2094-9-87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alzheimerâs Association</span></span> <span> </span><span class="NLM_article-title">2017 Alzheimerâs Disease Facts and Figures</span>. <i>Alzheimer's Dementia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">325</span>â <span class="NLM_lpage">373</span>, <span class="refDoi">Â DOI: 10.1016/j.jalz.2017.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.jalz.2017.02.001" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=325-373&issue=4&author=+Alzheimer%E2%80%99s+Association&title=2017+Alzheimer%E2%80%99s+Disease+Facts+and+Figures&doi=10.1016%2Fj.jalz.2017.02.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.jalz.2017.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jalz.2017.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DAlzheimer%25E2%2580%2599s%2BAssociation%26atitle%3D2017%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Facts%2520and%2520Figures%26jtitle%3DAlzheimer%2527s%2520Dementia%26date%3D2017%26volume%3D13%26issue%3D4%26spage%3D325%26epage%3D373%26doi%3D10.1016%2Fj.jalz.2017.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nijholt, D. a. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Graaf, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Haastert, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoozemans, J. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheper, W.</span></span> <span> </span><span class="NLM_article-title">Endoplasmic Reticulum Stress Activates Autophagy but Not the Proteasome in Neuronal Cells: Implications for Alzheimerâs Disease</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1071</span>â <span class="NLM_lpage">1081</span>, <span class="refDoi">Â DOI: 10.1038/cdd.2010.176</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fcdd.2010.176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=21252911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvFCrurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=1071-1081&issue=6&author=D.+a.+T.+Nijholtauthor=T.+R.+de+Graafauthor=E.+S.+van+Haastertauthor=A.+O.+Oliveiraauthor=C.+R.+Berkersauthor=R.+Zwartauthor=H.+Ovaaauthor=F.+Baasauthor=J.+J.+M.+Hoozemansauthor=W.+Scheper&title=Endoplasmic+Reticulum+Stress+Activates+Autophagy+but+Not+the+Proteasome+in+Neuronal+Cells%3A+Implications+for+Alzheimer%E2%80%99s+Disease&doi=10.1038%2Fcdd.2010.176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Endoplasmic reticulum stress activates autophagy but not the proteasome in neuronal cells: implications for Alzheimer's disease</span></div><div class="casAuthors">Nijholt, D. A. T.; de Graaf, T. R.; van Haastert, E. S.; Oliveira, A. Osorio; Berkers, C. R.; Zwart, R.; Ovaa, H.; Baas, F.; Hoozemans, J. J. M.; Scheper, W.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1071-1081</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein folding stress in the endoplasmic reticulum (ER) may lead to activation of the unfolded protein response (UPR), aimed to restore cellular homeostasis via transcriptional and post-transcriptional mechanisms.  ER stress is also reported to activate the ER overload response (EOR), which activates transcription via NF-ÎºB.  We previously demonstrated that UPR activation is an early event in pre-tangle neurons in Alzheimer's disease (AD) brain.  Misfolded and unfolded proteins are degraded via the ubiquitin proteasome system (UPS) or autophagy.  UPR activation is found in AD neurons displaying both early UPS pathol. and autophagic pathol.  Here we investigate whether activation of the UPR and/or EOR is employed to enhance the proteolytic capacity of neuronal cells.  Expression of the immunoproteasome subunits Î²2i and Î²5i is increased in AD brain.  However, expression of the proteasome subunits is not increased by the UPR or EOR.  UPR activation does not relocalize the proteasome or increase overall proteasome activity.  Therefore proteasomal degrdn. is not increased by ER stress.  In contrast, UPR activation enhances autophagy and LC3 levels are increased in neurons displaying UPR activation in AD brain.  Our data suggest that autophagy is the major degradational pathway following UPR activation in neuronal cells and indicate a connection between UPR activation and autophagic pathol. in AD brain.  Cell Death and Differentiation (2011) 18, 1071-1081; doi:10.1038/cdd.2010.176; published online 21 Jan. 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTEqki0ep4NLVg90H21EOLACvtfcHk0lhipnbZEQgfog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvFCrurw%253D&md5=48b285e857833fc14871b5ccd170a0ed</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2010.176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2010.176%26sid%3Dliteratum%253Aachs%26aulast%3DNijholt%26aufirst%3DD.%2Ba.%2BT.%26aulast%3Dde%2BGraaf%26aufirst%3DT.%2BR.%26aulast%3Dvan%2BHaastert%26aufirst%3DE.%2BS.%26aulast%3DOliveira%26aufirst%3DA.%2BO.%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3DZwart%26aufirst%3DR.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DBaas%26aufirst%3DF.%26aulast%3DHoozemans%26aufirst%3DJ.%2BJ.%2BM.%26aulast%3DScheper%26aufirst%3DW.%26atitle%3DEndoplasmic%2520Reticulum%2520Stress%2520Activates%2520Autophagy%2520but%2520Not%2520the%2520Proteasome%2520in%2520Neuronal%2520Cells%253A%2520Implications%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2011%26volume%3D18%26issue%3D6%26spage%3D1071%26epage%3D1081%26doi%3D10.1038%2Fcdd.2010.176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekavali</span></span> <span> </span><span class="NLM_article-title">A Review on Alzheimerâs Disease Pathophysiology and Its Management: An Update</span>. <i>Pharmacol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">195</span>â <span class="NLM_lpage">203</span>, <span class="refDoi">Â DOI: 10.1016/j.pharep.2014.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.pharep.2014.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=25712639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmt1Shu7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=195-203&issue=2&author=A.+Kumarauthor=A.+Singhauthor=+Ekavali&title=A+Review+on+Alzheimer%E2%80%99s+Disease+Pathophysiology+and+Its+Management%3A+An+Update&doi=10.1016%2Fj.pharep.2014.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">A review on Alzheimer's disease pathophysiology and its management: an update</span></div><div class="casAuthors">Kumar, Anil; Singh, Arti; Ekavali</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-203</span>CODEN:
                <span class="NLM_cas:coden">PRHEDU</span>;
        ISSN:<span class="NLM_cas:issn">2299-5684</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Alzheimer's disease acknowledged as progressive multifarious neurodegenerative disorder, is the leading cause of dementia in late adult life.  Pathol. it is characterized by intracellular neurofibrillary tangles and extracellular amyloidal protein deposits contributing to senile plaques.  Over the last two decades, advances in the field of pathogenesis have inspired the researchers for the investigation of novel pharmacol. therapeutics centered more towards the pathophysiol. events of the disease.  Currently available treatments i.e. acetylcholinesterase inhibitors (rivastigmine, galantamine, donepezil) and N-Me d-aspartate receptor antagonist (memantine) contribute minimal impact on the disease and target late aspects of the disease.  These drugs decelerate the progression of the disease, provide symptomatic relief but fail to achieve a definite cure.  While the neuropathol. features of Alzheimer's disease are recognized but the intricacies of the mechanism have not been clearly defined.  This lack of understanding regarding the pathogenic process may be the likely reason for the non-availability of effective treatment which can prevent onset and progression of the disease.  Owing to the important progress in the field of pathophysiol. in the last couple of years, new therapeutic targets are available that should render the underlying disease process to be tackled directly.  In this review, authors will discusses the different aspects of pathophysiol. mechanisms behind Alzheimer's disease and its management through conventional drug therapy, including modern investigational therapeutic strategies, recently completed and ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb19P5Zhq4u7Vg90H21EOLACvtfcHk0lhipnbZEQgfog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmt1Shu7o%253D&md5=34c2453a693877d1c787687bf978b775</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.pharep.2014.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharep.2014.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DEkavali%26atitle%3DA%2520Review%2520on%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Pathophysiology%2520and%2520Its%2520Management%253A%2520An%2520Update%26jtitle%3DPharmacol.%2520Rep.%26date%3D2015%26volume%3D67%26issue%3D2%26spage%3D195%26epage%3D203%26doi%3D10.1016%2Fj.pharep.2014.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamphuis, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dooves, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kooijman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimayuga Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hol, E.</span></span> <span> </span><span class="NLM_article-title">Reactive Glia Show Increased Immunoproteasome Activity in Alzheimerâs Disease</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">1415</span>â <span class="NLM_lpage">1431</span>, <span class="refDoi">Â DOI: 10.1093/brain/awt083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1093%2Fbrain%2Fawt083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=23604491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BC3srmvFaisg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2013&pages=1415-1431&author=M.+Orreauthor=W.+Kamphuisauthor=S.+Doovesauthor=L.+Kooijmanauthor=E.+T.+Chanauthor=C.+J.+Kirkauthor=V.+Dimayuga+Smithauthor=S.+Kootauthor=C.+Mamberauthor=A.+H.+Jansenauthor=H.+Ovaaauthor=E.+Hol&title=Reactive+Glia+Show+Increased+Immunoproteasome+Activity+in+Alzheimer%E2%80%99s+Disease&doi=10.1093%2Fbrain%2Fawt083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive glia show increased immunoproteasome activity in Alzheimer's disease</span></div><div class="casAuthors">Orre Marie; Kamphuis Willem; Dooves Stephanie; Kooijman Lieneke; Chan Elena T; Kirk Christopher J; Dimayuga Smith Vanessa; Koot Sanne; Mamber Carlyn; Jansen Anne H; Ovaa Huib; Hol Elly M</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">Pt 5</span>),
    <span class="NLM_cas:pages">1415-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The proteasome is the major protein degradation system within the cell, comprised of different proteolytic subunits; amyloid-Î² is thought to impair its activity in Alzheimer's disease.  Neuroinflammation is a prominent hallmark of Alzheimer's disease, which may implicate an activation of the immunoproteasome, a specific proteasome variant induced by immune signalling that holds slightly different proteolytic properties than the constitutive proteasome.  Using a novel cell-permeable proteasome activity probe, we found that amyloid-Î² enhances proteasome activity in glial and neuronal cultures.  Additionally, using a subunit-specific proteasome activity assay we showed that in the cortex of the APPswePS1dE9 plaque pathology mouse model, immunoproteasome activities were strongly increased together with increased messenger RNA and protein expression in reactive glia surrounding plaques.  Importantly, this elevated activity was confirmed in human post-mortem tissue from donors with Alzheimer's disease.  These findings are in contrast with earlier studies, which reported impairment of proteasome activity in human Alzheimer's disease tissue and mouse models.  Targeting the increased immunoproteasome activity with a specific inhibitor resulted in a decreased expression of inflammatory markers in ex vivo microglia.  This may serve as a potential novel approach to modulate sustained neuroinflammation and glial dysfunction associated with Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRtUv1o7ovLKYYPsCkJIw00fW6udTcc2eZjgh7jlQALUbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srmvFaisg%253D%253D&md5=8ae273c3ca26fd107d41a141afa4e0ef</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawt083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawt083%26sid%3Dliteratum%253Aachs%26aulast%3DOrre%26aufirst%3DM.%26aulast%3DKamphuis%26aufirst%3DW.%26aulast%3DDooves%26aufirst%3DS.%26aulast%3DKooijman%26aufirst%3DL.%26aulast%3DChan%26aufirst%3DE.%2BT.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DDimayuga%2BSmith%26aufirst%3DV.%26aulast%3DKoot%26aufirst%3DS.%26aulast%3DMamber%26aufirst%3DC.%26aulast%3DJansen%26aufirst%3DA.%2BH.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DHol%26aufirst%3DE.%26atitle%3DReactive%2520Glia%2520Show%2520Increased%2520Immunoproteasome%2520Activity%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DBrain%26date%3D2013%26volume%3D136%26spage%3D1415%26epage%3D1431%26doi%3D10.1093%2Fbrain%2Fawt083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilling, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schormann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kloetzel, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppner, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KrÃ¼ger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prokop, S.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasome Deficiency Alters Microglial Cytokine Response and Improves Cognitive Deficits in Alzheimerâs Disease-like APPPS1Mice</span>. <i>Acta Neuropathol. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">52</span>, <span class="refDoi">Â DOI: 10.1186/s40478-017-0453-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1186%2Fs40478-017-0453-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=28646899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvF2qt7vI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=52&issue=1&author=L.+K.+Wagnerauthor=K.+E.+Gillingauthor=E.+Schormannauthor=P.+M.+Kloetzelauthor=F.+L.+Heppnerauthor=E.+Kr%C3%BCgerauthor=S.+Prokop&title=Immunoproteasome+Deficiency+Alters+Microglial+Cytokine+Response+and+Improves+Cognitive+Deficits+in+Alzheimer%E2%80%99s+Disease-like+APPPS1Mice&doi=10.1186%2Fs40478-017-0453-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoproteasome deficiency alters microglial cytokine response and improves cognitive deficits in Alzheimer's disease-like APPPS1 mice</span></div><div class="casAuthors">Wagner, Lisa K.; Gilling, Kate E.; Schormann, Eileen; Kloetzel, Peter M.; Heppner, Frank L.; Krueger, Elke; Prokop, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Acta Neuropathologica Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">52/1-52/16</span>CODEN:
                <span class="NLM_cas:coden">ANCCC9</span>;
        ISSN:<span class="NLM_cas:issn">2051-5960</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The immunoproteasome (iP) represents a specialized type of proteasomes, which plays an important role in the clearance of oxidant-damaged proteins under inflammatory and pathol. conditions detg. the outcome of various diseases.  In Alzheimer's disease (AD)-like APPPS1 mice AÎ²-deposition is paralleled by iP upregulation,most likely mediated through type I interferon induction.  To define the impact of increased iP expression we crossed APPPS1 mice with mice deficient in the iP subunit LMP7 resulting in impaired iP function.  While LMP7 deficient APPPS1 mice showed no major change in cerebral AÎ²-pathol., we obsd. an altered cytokine response in microglia isolated from LMP7 deficient APPPS1 mice compared to LMP7 expressing APPPS1 control mice.  The altered microglial cytokine profile upon iP deficiency in the presence of extracellular AÎ²-pathol. was assocd. with an improvement of AÎ²-assocd. cognitive deficits typically present in APPPS1 mice.  Our findings suggest a role for iP in the regulation of the innate immune response towards extracellular AÎ²-pathol. and indicate that inhibition of iP function can modulate the cognitive phenotype upon overexpression of AÎ².</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9-Es2yxPY3LVg90H21EOLACvtfcHk0ljBY520SBCTuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvF2qt7vI&md5=4de0d34ef2bf87269cf1c26d6ec11052</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1186%2Fs40478-017-0453-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40478-017-0453-5%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DL.%2BK.%26aulast%3DGilling%26aufirst%3DK.%2BE.%26aulast%3DSchormann%26aufirst%3DE.%26aulast%3DKloetzel%26aufirst%3DP.%2BM.%26aulast%3DHeppner%26aufirst%3DF.%2BL.%26aulast%3DKr%25C3%25BCger%26aufirst%3DE.%26aulast%3DProkop%26aufirst%3DS.%26atitle%3DImmunoproteasome%2520Deficiency%2520Alters%2520Microglial%2520Cytokine%2520Response%2520and%2520Improves%2520Cognitive%2520Deficits%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease-like%2520APPPS1Mice%26jtitle%3DActa%2520Neuropathol.%2520Commun.%26date%3D2017%26volume%3D5%26issue%3D1%26spage%3D52%26doi%3D10.1186%2Fs40478-017-0453-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blurton-Jones, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFerla, F. M.</span></span> <span> </span><span class="NLM_article-title">AÎ² Inhibits the Proteasome and Enhances Amyloid and Tau Accumulation</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1607</span>â <span class="NLM_lpage">1618</span>, <span class="refDoi">Â DOI: 10.1016/j.neurobiolaging.2007.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.neurobiolaging.2007.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=17544172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFCksLzN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=1607-1618&issue=11&author=B.+P.+Tsengauthor=K.+N.+Greenauthor=J.+L.+Chanauthor=M.+Blurton-Jonesauthor=F.+M.+LaFerla&title=A%CE%B2+Inhibits+the+Proteasome+and+Enhances+Amyloid+and+Tau+Accumulation&doi=10.1016%2Fj.neurobiolaging.2007.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">AÎ² inhibits the proteasome and enhances amyloid and tau accumulation</span></div><div class="casAuthors">Tseng, Bertrand P.; Green, Kim N.; Chan, Julie L.; Blurton-Jones, Mathew; LaFerla, Frank M.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1607-1618</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The accumulation of misfolded protein aggregates is a common feature of numerous neurodegenerative disorders including Alzheimer disease (AD).  Here, we examd. the effects of different assembly states of amyloid beta (AÎ²) on proteasome function.  We find that AÎ² oligomers, but not monomers, inhibit the proteasome in vitro.  In young 3xTg-AD mice, we obsd. impaired proteasome activity that correlates with the detection of intraneuronal AÎ² oligomers.  Blocking proteasome function in pre-pathol. 3xTg-AD mice with specific inhibitors causes a marked increase in AÎ² and tau accumulation, highlighting the adverse consequences of impaired proteasome activity for AD.  Lastly, we show that AÎ² immunotherapy in the 3xTg-AD mice reduces AÎ² oligomers and reverses the deficits in proteasome activity.  Taken together, our results indicate that AÎ² oligomers impair proteasome activity, contributing to the age-related pathol. accumulation of AÎ² and tau.  These findings provide further evidence that the proteasome represents a viable target for therapeutic intervention in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpttqgvGJaDL7Vg90H21EOLACvtfcHk0ljBY520SBCTuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFCksLzN&md5=a89d83f96442fad61c84cb9b3d9b6df8</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2007.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2007.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DTseng%26aufirst%3DB.%2BP.%26aulast%3DGreen%26aufirst%3DK.%2BN.%26aulast%3DChan%26aufirst%3DJ.%2BL.%26aulast%3DBlurton-Jones%26aufirst%3DM.%26aulast%3DLaFerla%26aufirst%3DF.%2BM.%26atitle%3DA%25CE%25B2%2520Inhibits%2520the%2520Proteasome%2520and%2520Enhances%2520Amyloid%2520and%2520Tau%2520Accumulation%26jtitle%3DNeurobiol.%2520Aging%26date%3D2008%26volume%3D29%26issue%3D11%26spage%3D1607%26epage%3D1618%26doi%3D10.1016%2Fj.neurobiolaging.2007.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dasgupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahallati, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tashima, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferro, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricker, L. D.</span></span> <span> </span><span class="NLM_article-title">Reduced Levels of Proteasome Products in a Mouse Striatal Cell Model of Huntingtonâs Disease</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">e0145333</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0145333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1371%2Fjournal.pone.0145333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=26691307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC28Xms1arsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0145333&issue=12&author=S.+Dasguptaauthor=M.+A.+Fishmanauthor=H.+Mahallatiauthor=L.+M.+Castroauthor=A.+K.+Tashimaauthor=E.+S.+Ferroauthor=L.+D.+Fricker&title=Reduced+Levels+of+Proteasome+Products+in+a+Mouse+Striatal+Cell+Model+of+Huntington%E2%80%99s+Disease&doi=10.1371%2Fjournal.pone.0145333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Reduced levels of proteasome products in a mouse striatal cell model of Huntington's disease</span></div><div class="casAuthors">Dasgupta, Sayani; Fishman, Michael A.; Mahallati, Hana; Castro, Leandro M.; Tashima, Alexandre K.; Ferro, Emer S.; Fricker, Lloyd D.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e0145333/1-e0145333/20</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Huntington's disease is the result of a long polyglutamine tract in the gene encoding huntingtin protein, which in turn causes a large no. of cellular changes and ultimately results in neurodegeneration of striatal neurons.  Although many theories have been proposed, the precise mechanism by which the polyglutamine expansion causes cellular changes is not certain.  Some evidence supports the hypothesis that the long polyglutamine tract inhibits the proteasome, a multiprotein complex involved in protein degrdn.  However, other studies report normal proteasome function in cells expressing long polyglutamine tracts.  The controversy may be due to the methods used to examine proteasome activity in each of the previous studies.  In the present study, we measured proteasome function by examg. levels of endogenous peptides that are products of proteasome cleavage.  Peptide levels were compared among mouse striatal cell lines expressing either 7 glutamines (STHdhQ7/Q7) or 111 glutamines in the huntingtin protein, either heterozygous (STHdhQ7/Q111) or homozygous (STHdhQ111/Q111).  Both of the cell lines expressing huntingtin with 111 glutamines showed a large redn. in nearly all of the peptides detected in the cells, relative to levels of these peptides in cells homozygous for 7 glutamines.  Treatment of STHdhQ7/Q7 cells with proteasome inhibitors epoxomicin or bortezomib also caused a large redn. in most of these peptides, suggesting that they are products of proteasome-mediated cleavage of cellular proteins.  Taken together, these results support the hypothesis that proteasome function is impaired by the expression of huntingtin protein contg. long polyglutamine tracts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0Zm6uS3iyBLVg90H21EOLACvtfcHk0lgrKcrbhkgUTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xms1arsr0%253D&md5=31dae2383c38a024d901fd37dfc969e8</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0145333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0145333%26sid%3Dliteratum%253Aachs%26aulast%3DDasgupta%26aufirst%3DS.%26aulast%3DFishman%26aufirst%3DM.%2BA.%26aulast%3DMahallati%26aufirst%3DH.%26aulast%3DCastro%26aufirst%3DL.%2BM.%26aulast%3DTashima%26aufirst%3DA.%2BK.%26aulast%3DFerro%26aufirst%3DE.%2BS.%26aulast%3DFricker%26aufirst%3DL.%2BD.%26atitle%3DReduced%2520Levels%2520of%2520Proteasome%2520Products%2520in%2520a%2520Mouse%2520Striatal%2520Cell%2520Model%2520of%2520Huntington%25E2%2580%2599s%2520Disease%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26issue%3D12%26spage%3De0145333%26doi%3D10.1371%2Fjournal.pone.0145333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DÃ­az-HernÃ¡ndez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MartÃ­n-Aparicio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HernÃ¡ndez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, J. J.</span></span> <span> </span><span class="NLM_article-title">Enhaced Induction of the Immunoproteasome by Interferon Gamma in Neurons Expressing Mutant Huntingtin</span>. <i>Neurotoxic. Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">463</span>â <span class="NLM_lpage">468</span>, <span class="refDoi">Â DOI: 10.1007/BF03033282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1007%2FBF03033282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=15658001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BD2M%252FjtVyrsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=463-468&issue=6&author=M.+D%C3%ADaz-Hern%C3%A1ndezauthor=E.+Mart%C3%ADn-Aparicioauthor=J.+Avilaauthor=F.+Hern%C3%A1ndezauthor=J.+J.+Lucas&title=Enhaced+Induction+of+the+Immunoproteasome+by+Interferon+Gamma+in+Neurons+Expressing+Mutant+Huntingtin&doi=10.1007%2FBF03033282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced induction of the immunoproteasome by interferon gamma in neurons expressing mutant Huntingtin</span></div><div class="casAuthors">Diaz-Hernandez Miguel; Martin-Aparicio Ester; Avila Jesus; Hernandez Felix; Lucas Jose J</div><div class="citationInfo"><span class="NLM_cas:title">Neurotoxicity research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">463-8</span>
        ISSN:<span class="NLM_cas:issn">1029-8428</span>.
    </div><div class="casAbstract">Huntington disease (HD) inclusions are stained with anti-ubiquitin and anti-proteasome antibodies.  This, together with proteasome activity studies on transfected cell, suggested that alterations in the ubiquitin-proteasome system (UPS) might contribute to HD pathogenesis.  In previous work we reported that in a conditional mouse model of Huntington's disease (HD94 mice), the chymiotrypsin- and trypsin-"like" activities of the proteasome are increased selectivity in the affected and aggregate-containing brain regions: striatum, and cortex.  Moreover, in these areas a neuronal increase in the interferon-inducible subunits of the immunoproteasome LMP2 and LPM7 was observed.  In order to test if the expression of N-terminal mutant huntingtin (htt) by itself is sufficient to induce the change in proteasome catalytic activities as well as in LMP2 subunit expression, we performed activities of the proteasome and western blot experiments in striatal cultured neurons from HD94 mice free of glial contamination.  We found no changes in any of the activities in these cells.  Furthermore, western blot analysis performed with specific antibody against LMP2 subunits, revealed no difference in levels of this subunit in striatal neurons from HD94 compared to control cultures were treated with interferon-gamma (IFN-gamma) during 72 hours, a clear increase in LMP2 levels was observed in control neuronal cultures.  Interestingly, this increase was much more pronounced (95% higher) in HD94 striatal cultures.  These results indicate that although expression of mutant htt is not sufficient to induce the changes in proteasome catalytic core observed in HD, it synergizes the changes induced by IFN-gamma.  Furthermore, immunocytochemical studies revealed that HD94 striatal neuron expressing high levels of LMP2 subunit showed a pre-apoptotic appearance.  These results suggest that the correlation between neuronal induction of the immunoproteasome and neurodegeneration found in HD brains is secondary to inflammatory processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfl0yIS-3DfoHWj6b1v8uTfW6udTcc2eYoObTILiGPN7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M%252FjtVyrsg%253D%253D&md5=ce24f9933f7fedcee1d94e602cf8894a</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1007%2FBF03033282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF03033282%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25ADaz-Hern%25C3%25A1ndez%26aufirst%3DM.%26aulast%3DMart%25C3%25ADn-Aparicio%26aufirst%3DE.%26aulast%3DAvila%26aufirst%3DJ.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DF.%26aulast%3DLucas%26aufirst%3DJ.%2BJ.%26atitle%3DEnhaced%2520Induction%2520of%2520the%2520Immunoproteasome%2520by%2520Interferon%2520Gamma%2520in%2520Neurons%2520Expressing%2520Mutant%2520Huntingtin%26jtitle%3DNeurotoxic.%2520Res.%26date%3D2004%26volume%3D6%26issue%3D6%26spage%3D463%26epage%3D468%26doi%3D10.1007%2FBF03033282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheroni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tortarolo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veglianese, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Biasi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccarello, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynard, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dantuma, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendotti, C.</span></span> <span> </span><span class="NLM_article-title">Functional Alterations of the Ubiquitin-Proteasome System in Motor Neurons of a Mouse Model of Familial Amyotrophic Lateral Sclerosis</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">82</span>â <span class="NLM_lpage">96</span>, <span class="refDoi">Â DOI: 10.1093/hmg/ddn319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1093%2Fhmg%2Fddn319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=18826962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsV2lurrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=82-96&issue=1&author=C.+Cheroniauthor=M.+Marinoauthor=M.+Tortaroloauthor=P.+Veglianeseauthor=S.+De+Biasiauthor=E.+Fontanaauthor=L.+V.+Zuccarelloauthor=C.+J.+Maynardauthor=N.+P.+Dantumaauthor=C.+Bendotti&title=Functional+Alterations+of+the+Ubiquitin-Proteasome+System+in+Motor+Neurons+of+a+Mouse+Model+of+Familial+Amyotrophic+Lateral+Sclerosis&doi=10.1093%2Fhmg%2Fddn319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Functional alterations of the ubiquitin-proteasome system in motor neurons of a mouse model of familial amyotrophic lateral sclerosis</span></div><div class="casAuthors">Cheroni, Cristina; Marino, Marianna; Tortarolo, Massimo; Veglianese, Pietro; De Biasi, Silvia; Fontana, Elena; Zuccarello, Laura Vitellaro; Maynard, Christa J.; Dantuma, Nico P.; Bendotti, Caterina</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">82-96</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">In familial and sporadic amyotrophic lateral sclerosis (ALS) and in rodent models of the disease, alterations in the ubiquitin-proteasome system (UPS) may be responsible for the accumulation of potentially harmful ubiquitinated proteins, leading to motor neuron death.  In the spinal cord of transgenic mice expressing the familial ALS superoxide dismutase 1 (SOD1) gene mutation G93A (SOD1G93A), we found a decrease in constitutive proteasome subunits during disease progression, as assessed by real-time PCR and immunohistochem.  In parallel, an increased immunoproteasome expression was obsd., which correlated with a local inflammatory response due to glial activation.  These findings support the existence of proteasome modifications in ALS vulnerable tissues.  To functionally investigate the UPS in ALS motor neurons in vivo, we crossed SOD1G93A mice with transgenic mice that express a fluorescently tagged reporter substrate of the UPS.  In double-transgenic UbG76V-GFP /SOD1G93A mice an increase in UbG76V-GFP reporter, indicative of UPS impairment, was detectable in a few spinal motor neurons and not in reactive astrocytes or microglia, at symptomatic stage but not before symptoms onset.  The levels of reporter transcript were unaltered, suggesting that the accumulation of UbG76V-GFP was due to deficient reporter degrdn.  In some motor neurons the increase of UbG76V-GFP was accompanied by the accumulation of ubiquitin and phosphorylated neurofilaments, both markers of ALS pathol.  These data suggest that UPS impairment occurs in motor neurons of mutant SOD1-linked ALS mice and may play a role in the disease progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm-JWqfmORsbVg90H21EOLACvtfcHk0lgrKcrbhkgUTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsV2lurrL&md5=ac070204ef2793217df6b1828053a428</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddn319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddn319%26sid%3Dliteratum%253Aachs%26aulast%3DCheroni%26aufirst%3DC.%26aulast%3DMarino%26aufirst%3DM.%26aulast%3DTortarolo%26aufirst%3DM.%26aulast%3DVeglianese%26aufirst%3DP.%26aulast%3DDe%2BBiasi%26aufirst%3DS.%26aulast%3DFontana%26aufirst%3DE.%26aulast%3DZuccarello%26aufirst%3DL.%2BV.%26aulast%3DMaynard%26aufirst%3DC.%2BJ.%26aulast%3DDantuma%26aufirst%3DN.%2BP.%26aulast%3DBendotti%26aufirst%3DC.%26atitle%3DFunctional%2520Alterations%2520of%2520the%2520Ubiquitin-Proteasome%2520System%2520in%2520Motor%2520Neurons%2520of%2520a%2520Mouse%2520Model%2520of%2520Familial%2520Amyotrophic%2520Lateral%2520Sclerosis%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2009%26volume%3D18%26issue%3D1%26spage%3D82%26epage%3D96%26doi%3D10.1093%2Fhmg%2Fddn319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahtoniemi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsteins, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keksa-Goldsteine, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanninen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salminen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koistinaho, J.</span></span> <span> </span><span class="NLM_article-title">Pyrrolidine Dithiocarbamate Inhibits Induction of Immunoproteasome and Decreases Survival in a Rat Model of Amyotrophic Lateral Sclerosis</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>71</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">30</span>â <span class="NLM_lpage">37</span>, <span class="refDoi">Â DOI: 10.1124/mol.106.028415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1124%2Fmol.106.028415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=17008387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1GktA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2007&pages=30-37&issue=1&author=T.+Ahtoniemiauthor=G.+Goldsteinsauthor=V.+Keksa-Goldsteineauthor=T.+Malmauthor=K.+Kanninenauthor=A.+Salminenauthor=J.+Koistinaho&title=Pyrrolidine+Dithiocarbamate+Inhibits+Induction+of+Immunoproteasome+and+Decreases+Survival+in+a+Rat+Model+of+Amyotrophic+Lateral+Sclerosis&doi=10.1124%2Fmol.106.028415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrrolidine dithiocarbamate inhibits induction of immunoproteasome and decreases survival in a rat model of amyotrophic lateral sclerosis</span></div><div class="casAuthors">Ahtoniemi, Toni; Goldsteins, Gundars; Keksa-Goldsteine, Velta; Malm, Tarja; Kanninen, Katja; Salminen, Antero; Koistinaho, Jari</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-37</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Pyrrolidine dithiocarbamate (PDTC), an inhibitor of nuclear transcription factor Îº-B (NF-ÎºB) and an antioxidant, has beneficial effects in animal models of various diseases, including arthritis, brain ischemia, spinal cord injury, Alzheimer's disease, and Duchenne muscular dystrophy.  Because inflammation and oxidative damage are also hallmarks of amyotrophic lateral sclerosis (ALS), we studied the effect of oral PDTC treatment on G93A-superoxide dismutase 1 (SOD1) transgenic (TG) rat model of human ALS and obsd. that PDTC treatment significantly decreases the survival.  PDTC treatment evoked the end stage of the disease at 121Â±21 days, whereas untreated TG animals reached the end stage at 141Â±13 days (p < 0.01).  The DNA binding activity of NF-ÎºB was not altered in G93A-SOD1 TG rats by PDTC treatment.  The copper concn. in the spinal cord was increased after PDTC treatment both in G93A-SOD1 TG and wild-type rats, suggesting that increased copper may enhance the neurotoxicity of mutant SOD1.  The amt. of ubiquitinated proteins were significantly higher and proteasomal activity was decreased in the spinal cords of PDTC-treated TG rats compared with other groups, suggesting that PDTC treatment decreases proteasome function.  Immunoblotting and immunocytochem. showed that the level of immunoproteasome but not constitutive proteasome was increased in glia of G93A-SOD1 TG rats along with disease development.  PDTC treatment completely blocked the induction of immunoproteasome expression without affecting constitutive proteasome.  These results suggest that PDTC acts as an immunoproteasome inhibitor in mutant SOD1 rats and that immunoproteasome may help the nervous system to cope with deleterious effects of SOD1-G93A mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDufLbSaKmK7Vg90H21EOLACvtfcHk0lhYP44OY3PL6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1GktA%253D%253D&md5=e20bfe3e7e735ddb9df9aa6ae3509347</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1124%2Fmol.106.028415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.106.028415%26sid%3Dliteratum%253Aachs%26aulast%3DAhtoniemi%26aufirst%3DT.%26aulast%3DGoldsteins%26aufirst%3DG.%26aulast%3DKeksa-Goldsteine%26aufirst%3DV.%26aulast%3DMalm%26aufirst%3DT.%26aulast%3DKanninen%26aufirst%3DK.%26aulast%3DSalminen%26aufirst%3DA.%26aulast%3DKoistinaho%26aufirst%3DJ.%26atitle%3DPyrrolidine%2520Dithiocarbamate%2520Inhibits%2520Induction%2520of%2520Immunoproteasome%2520and%2520Decreases%2520Survival%2520in%2520a%2520Rat%2520Model%2520of%2520Amyotrophic%2520Lateral%2520Sclerosis%26jtitle%3DMol.%2520Pharmacol.%26date%3D2007%26volume%3D71%26issue%3D1%26spage%3D30%26epage%3D37%26doi%3D10.1124%2Fmol.106.028415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desrosiers, R. C.</span></span> <span> </span><span class="NLM_article-title">Viral Persistence: HIVâs Strategies of Immune System Evasion</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">499</span>â <span class="NLM_lpage">518</span>, <span class="refDoi">Â DOI: 10.1146/annurev.med.53.082901.104053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1146%2Fannurev.med.53.082901.104053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=11818487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD38Xitl2mt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2002&pages=499-518&issue=1&author=W.+E.+Johnsonauthor=R.+C.+Desrosiers&title=Viral+Persistence%3A+HIV%E2%80%99s+Strategies+of+Immune+System+Evasion&doi=10.1146%2Fannurev.med.53.082901.104053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Viral Persistence: HIV's strategies of immune system evasion</span></div><div class="casAuthors">Johnson, Welkin E.; Desrosiers, Ronald C.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">499-518</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  In contrast to most animal viruses, infection with the human and simian immunodeficiency viruses results in prolonged, continuous viral replication in the infected host.  Remarkably, viral persistence is not thwarted by the presence of apparently vigorous, virus-specific immune responses.  Several factors are thought to contribute to persistent viral replication, most notably the destruction of virus-specific T helper cells, the emergence of antigenic escape variants, and the expression of an envelope complex that structurally minimizes antibody access to conserved epitopes.  Not as well understood, though potentially important, is the ability of at least one viral encoded protein (Nef) to prevent presentation of viral antigens in the context of major histocompatibility complex.  The future success of antiviral therapies and vaccination strategies may depend largely on understanding how and to what degree each of these factors (and presumably others) contributes to immune evasion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobcjc-d9AagrVg90H21EOLACvtfcHk0lhYP44OY3PL6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xitl2mt7c%253D&md5=0bdd07b0423098e52c8d154cce5be92b</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1146%2Fannurev.med.53.082901.104053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.med.53.082901.104053%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DW.%2BE.%26aulast%3DDesrosiers%26aufirst%3DR.%2BC.%26atitle%3DViral%2520Persistence%253A%2520HIV%25E2%2580%2599s%2520Strategies%2520of%2520Immune%2520System%2520Evasion%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2002%26volume%3D53%26issue%3D1%26spage%3D499%26epage%3D518%26doi%3D10.1146%2Fannurev.med.53.082901.104053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arora, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredericksen, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, J. V.</span></span> <span> </span><span class="NLM_article-title">Nef: Agent of Cell Subversion</span>. <i>Microbes Infect.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">189</span>â <span class="NLM_lpage">199</span>, <span class="refDoi">Â DOI: 10.1016/S1286-4579(01)01527-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2FS1286-4579%2801%2901527-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=11880052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD38XhslWguro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2002&pages=189-199&issue=2&author=V.+K.+Aroraauthor=B.+L.+Fredericksenauthor=J.+V.+Garcia&title=Nef%3A+Agent+of+Cell+Subversion&doi=10.1016%2FS1286-4579%2801%2901527-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Nef: agent of cell subversion</span></div><div class="casAuthors">Arora, Vivek K.; Fredericksen, Brenda L.; Garcia, J. Victor</div><div class="citationInfo"><span class="NLM_cas:title">Microbes and Infection</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">189-199</span>CODEN:
                <span class="NLM_cas:coden">MCINFS</span>;
        ISSN:<span class="NLM_cas:issn">1286-4579</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">A review.  Primate lentiviruses encode a small protein designated Nef that has been shown to be a major determinant of virus pathogenicity.  Nef regulates multiple host factors in order to optimize the cellular environment for virus replication.  The mechanisms by which this small protein modulates distinct host cell properties provide intriguing insight into the intricate interaction between virus and host.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgKXFZoc2_xbVg90H21EOLACvtfcHk0lhYP44OY3PL6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhslWguro%253D&md5=d49e2de63907bc285cbb94437bb40cff</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2FS1286-4579%2801%2901527-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1286-4579%252801%252901527-1%26sid%3Dliteratum%253Aachs%26aulast%3DArora%26aufirst%3DV.%2BK.%26aulast%3DFredericksen%26aufirst%3DB.%2BL.%26aulast%3DGarcia%26aufirst%3DJ.%2BV.%26atitle%3DNef%253A%2520Agent%2520of%2520Cell%2520Subversion%26jtitle%3DMicrobes%2520Infect.%26date%3D2002%26volume%3D4%26issue%3D2%26spage%3D189%26epage%3D199%26doi%3D10.1016%2FS1286-4579%2801%2901527-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishido, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, J. U.</span></span> <span> </span><span class="NLM_article-title">Downregulation of Major Histocompatibility Complex Class I Molecules by Kaposiâs Sarcoma-Associated Herpesvirus K3 and K5 Proteins</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">5300</span>â <span class="NLM_lpage">5309</span>, <span class="refDoi">Â DOI: 10.1128/JVI.74.11.5300-5309.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1128%2FJVI.74.11.5300-5309.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10799607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjsVKns7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2000&pages=5300-5309&issue=11&author=S.+Ishidoauthor=C.+Wangauthor=B.-S.+Leeauthor=G.+B.+Cohenauthor=J.+U.+Jung&title=Downregulation+of+Major+Histocompatibility+Complex+Class+I+Molecules+by+Kaposi%E2%80%99s+Sarcoma-Associated+Herpesvirus+K3+and+K5+Proteins&doi=10.1128%2FJVI.74.11.5300-5309.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins</span></div><div class="casAuthors">Ishido, Satoshi; Wang, Chunyang; Lee, Bok-Soo; Cohen, George B.; Jung, J. U.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5300-5309</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The T-cell-mediated immune response plays a central role in the defense against intracellular pathogens.  To avoid this immune response, viruses have evolved elaborate mechanisms that target and modulate many different aspects of the host's immune system.  A target common to many of these viruses is the major histocompatibility complex (MHC) class I mols.  Kaposi's sarcoma-assocd. herpesvirus (KSHV) encodes K3 and K5 zinc finger membrane proteins which remove MHC class I mols. from the cell surface.  K3 and K5 exhibit 40% amino acid identity to each other and localize primarily near the plasma membrane.  While K3 and K5 dramatically downregulated class I mols., they displayed different specificities in downregulation of HLA allotypes.  K5 significantly downregulated HLA-A and -B and downregulated HLA-C only weakly, but not HLA-E, whereas K3 downregulated all four HLA allotypes.  This selective downregulation of HLA allotypes by K5 was partly due to differences in amino acid sequences in their transmembrane regions.  Biochem. analyses demonstrated that while K3 and K5 did not affect expression and intracellular transport of class I mols., their expression induced rapid endocytosis of the mols.  These results demonstrate that KSHV has evolved a novel immune evasion mechanism by harboring similar but distinct genes, K3 and K5, which target MHC class I mols. in different ways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3lJ48LzDuV7Vg90H21EOLACvtfcHk0licYjxDn72vHg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjsVKns7o%253D&md5=f9b5a3f99a0468212958730b848b8fe4</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1128%2FJVI.74.11.5300-5309.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.74.11.5300-5309.2000%26sid%3Dliteratum%253Aachs%26aulast%3DIshido%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DB.-S.%26aulast%3DCohen%26aufirst%3DG.%2BB.%26aulast%3DJung%26aufirst%3DJ.%2BU.%26atitle%3DDownregulation%2520of%2520Major%2520Histocompatibility%2520Complex%2520Class%2520I%2520Molecules%2520by%2520Kaposi%25E2%2580%2599s%2520Sarcoma-Associated%2520Herpesvirus%2520K3%2520and%2520K5%2520Proteins%26jtitle%3DJ.%2520Virol.%26date%3D2000%26volume%3D74%26issue%3D11%26spage%3D5300%26epage%3D5309%26doi%3D10.1128%2FJVI.74.11.5300-5309.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coscoy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganem, D.</span></span> <span> </span><span class="NLM_article-title">Kaposiâs Sarcoma-Associated Herpesvirus Encodes Two Proteins That Block Cell Surface Display of MHC Class I Chains by Enhancing Their Endocytosis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>97</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">8051</span>â <span class="NLM_lpage">8056</span>, <span class="refDoi">Â DOI: 10.1073/pnas.140129797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1073%2Fpnas.140129797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10859362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkvFCmsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=8051-8056&issue=14&author=L.+Coscoyauthor=D.+Ganem&title=Kaposi%E2%80%99s+Sarcoma-Associated+Herpesvirus+Encodes+Two+Proteins+That+Block+Cell+Surface+Display+of+MHC+Class+I+Chains+by+Enhancing+Their+Endocytosis&doi=10.1073%2Fpnas.140129797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis</span></div><div class="casAuthors">Coscoy, Laurent; Ganem, Don</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">8051-8056</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Down-regulation of the cell surface display of class I MHC proteins is an important mechanism of immune evasion by human and animal viruses.  Herpesviruses in particular encode a variety of proteins that function to lower MHC I display by several mechanisms.  These include binding and retention of MHC I chains in the endoplasmic reticulum, dislocation of class I chains from the ER, inhibition of the peptide transporter (TAP) involved in antigen presentation, and shunting of newly assembled chains to lysosomes.  Kaposi's sarcoma (KS)-assocd. herpesvirus (KSHV) is a human herpesvirus strongly linked to the development of KS and to certain AIDS-assocd. lymphoproliferative disorders.  Here the authors show that KSHV encodes 2 distinctive gene products that function to dramatically reduce cell surface MHC I expression.  These viral proteins are localized predominantly to the ER.  However, unlike previously described MHC I inhibitors, they do not interfere with the synthesis, translocation, or assembly of class I chains, nor do they retain them in the ER.  Rather, they act to enhance endocytosis of MHC I from the cell surface; internalized class I chains are delivered to endolysosomal vesicles, where they undergo degrdn.  These KSHV proteins define a mechanism of class I down-regulation distinct from the mechanisms of other herpesviruses and are likely to contribute importantly to immune evasion during viral infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdQbe-2HOQQLVg90H21EOLACvtfcHk0licYjxDn72vHg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkvFCmsrc%253D&md5=1a794c029769a193d0b83aa8cee210ff</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1073%2Fpnas.140129797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.140129797%26sid%3Dliteratum%253Aachs%26aulast%3DCoscoy%26aufirst%3DL.%26aulast%3DGanem%26aufirst%3DD.%26atitle%3DKaposi%25E2%2580%2599s%2520Sarcoma-Associated%2520Herpesvirus%2520Encodes%2520Two%2520Proteins%2520That%2520Block%2520Cell%2520Surface%2520Display%2520of%2520MHC%2520Class%2520I%2520Chains%2520by%2520Enhancing%2520Their%2520Endocytosis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2000%26volume%3D97%26issue%3D14%26spage%3D8051%26epage%3D8056%26doi%3D10.1073%2Fpnas.140129797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tortorella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gewurz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schust, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploegh, H. L.</span></span> <span> </span><span class="NLM_article-title">Viral Subversion of the Immune System</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">861</span>â <span class="NLM_lpage">926</span>, <span class="refDoi">Â DOI: 10.1146/annurev.immunol.18.1.861</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1146%2Fannurev.immunol.18.1.861" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10837078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjs1Gmt78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2000&pages=861-926&issue=1&author=D.+Tortorellaauthor=B.+E.+Gewurzauthor=M.+H.+Furmanauthor=D.+J.+Schustauthor=H.+L.+Ploegh&title=Viral+Subversion+of+the+Immune+System&doi=10.1146%2Fannurev.immunol.18.1.861"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Viral subversion of the immune system</span></div><div class="casAuthors">Tortorella, Domenico; Gewurz, Benjamin E.; Furman, Margo H.; Schust, Danny J.; Ploegh, Hidde L.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">861-926</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review, with 418 refs., describing the diverse array of pathways and mol. targets that are used by viruses to elude immune detection and destruction.  These include targeting of pathways for major histocompatibility complex-restricted antigen presentation, apoptosis, cytokine-mediated signaling, and humoral immune responses.  The continuous interactions between host and pathogens during their coevolution have shaped the immune system, but also the counter measures used by pathogens.  Further study of their interactions should improve the authors' ability to manipulate and exploit the various pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKostmJ51-27Vg90H21EOLACvtfcHk0liZjLErGpeIBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjs1Gmt78%253D&md5=5c88fc8e2f439d29024c7b1e041c37ca</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.18.1.861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.18.1.861%26sid%3Dliteratum%253Aachs%26aulast%3DTortorella%26aufirst%3DD.%26aulast%3DGewurz%26aufirst%3DB.%2BE.%26aulast%3DFurman%26aufirst%3DM.%2BH.%26aulast%3DSchust%26aufirst%3DD.%2BJ.%26aulast%3DPloegh%26aufirst%3DH.%2BL.%26atitle%3DViral%2520Subversion%2520of%2520the%2520Immune%2520System%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2000%26volume%3D18%26issue%3D1%26spage%3D861%26epage%3D926%26doi%3D10.1146%2Fannurev.immunol.18.1.861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tortorella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploegh, H. L.</span></span> <span> </span><span class="NLM_article-title">The Human Cytomegalovirus US10 Gene Product Delays Trafficking of Major Histocompatibility Complex Class I Molecules</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">11753</span>â <span class="NLM_lpage">11756</span>, <span class="refDoi">Â DOI: 10.1128/JVI.76.22.11753-11756.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1128%2FJVI.76.22.11753-11756.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=12388737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD38XoslKjtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2002&pages=11753-11756&issue=22&author=M.+H.+Furmanauthor=N.+Deyauthor=D.+Tortorellaauthor=H.+L.+Ploegh&title=The+Human+Cytomegalovirus+US10+Gene+Product+Delays+Trafficking+of+Major+Histocompatibility+Complex+Class+I+Molecules&doi=10.1128%2FJVI.76.22.11753-11756.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">The human cytomegalovirus US10 gene product delays trafficking of major histocompatibility complex class I molecules</span></div><div class="casAuthors">Furman, Margo H.; Dey, Neelendu; Tortorella, Domenico; Ploegh, Hidde L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">11753-11756</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Human cytomegalovirus (HCMV) US10 encodes a glycoprotein that binds to major histocompatibility complex (MHC) class I heavy chains.  While expression of US10 delays the normal trafficking of MHC class I mols. out of the endoplasmic reticulum, US10 does not obviously facilitate or inhibit the action of two other HCMV-encoded MHC class I binding proteins, US2 and US11.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh3EaY3wmaELVg90H21EOLACvtfcHk0liZjLErGpeIBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XoslKjtLg%253D&md5=a2d4e5a578897e30435bd9653ea25c7a</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1128%2FJVI.76.22.11753-11756.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.76.22.11753-11756.2002%26sid%3Dliteratum%253Aachs%26aulast%3DFurman%26aufirst%3DM.%2BH.%26aulast%3DDey%26aufirst%3DN.%26aulast%3DTortorella%26aufirst%3DD.%26aulast%3DPloegh%26aufirst%3DH.%2BL.%26atitle%3DThe%2520Human%2520Cytomegalovirus%2520US10%2520Gene%2520Product%2520Delays%2520Trafficking%2520of%2520Major%2520Histocompatibility%2520Complex%2520Class%2520I%2520Molecules%26jtitle%3DJ.%2520Virol.%26date%3D2002%26volume%3D76%26issue%3D22%26spage%3D11753%26epage%3D11756%26doi%3D10.1128%2FJVI.76.22.11753-11756.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, E. W.</span></span> <span> </span><span class="NLM_article-title">The MHC Class I Antigen Presentation Pathway: Strategies for Viral Immune Evasion</span>. <i>Immunology</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>110</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">163</span>â <span class="NLM_lpage">169</span>, <span class="refDoi">Â DOI: 10.1046/j.1365-2567.2003.01738.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1046%2Fj.1365-2567.2003.01738.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=14511229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotFSmtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2003&pages=163-169&issue=2&author=E.+W.+Hewitt&title=The+MHC+Class+I+Antigen+Presentation+Pathway%3A+Strategies+for+Viral+Immune+Evasion&doi=10.1046%2Fj.1365-2567.2003.01738.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">The MHC class I antigen presentation pathway: Strategies for viral immune evasion</span></div><div class="casAuthors">Hewitt, Eric W.</div><div class="citationInfo"><span class="NLM_cas:title">Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-169</span>CODEN:
                <span class="NLM_cas:coden">IMMUAM</span>;
        ISSN:<span class="NLM_cas:issn">0019-2805</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Presumably because of the selective pressure exerted by the immune system, many viruses have evolved proteins that interfere with antigen presentation by major histocompatibility complex (MHC) class I mols.  These viruses utilize a whole variety of ingenious strategies to inhibit the MHC class I pathway.  Viral proteins have been characterized that exploit bottlenecks in the MHC class I pathway, such as peptide translocation by the transporter assocd. with antigen processing.  Alternatively, viral proteins can cause the degrdn. or mislocalization of MHC class I mols.  This is often achieved by the subversion of the host cell's own protein degrdn. and trafficking pathways.  As a consequence elucidation of how these viral proteins act to subvert host cell function will continue to give important insights not only into virus-host interactions but also the function and mechanism of cellular pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjcMhRExiK2rVg90H21EOLACvtfcHk0liZjLErGpeIBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFSmtbk%253D&md5=c669b243791ce0c2a3e6e6dad5665c12</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2567.2003.01738.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2567.2003.01738.x%26sid%3Dliteratum%253Aachs%26aulast%3DHewitt%26aufirst%3DE.%2BW.%26atitle%3DThe%2520MHC%2520Class%2520I%2520Antigen%2520Presentation%2520Pathway%253A%2520Strategies%2520for%2520Viral%2520Immune%2520Evasion%26jtitle%3DImmunology%26date%3D2003%26volume%3D110%26issue%3D2%26spage%3D163%26epage%3D169%26doi%3D10.1046%2Fj.1365-2567.2003.01738.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Apcher, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heink, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zantopf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kloetzel, P.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, H.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KrÃ¼ger, E.</span></span> <span> </span><span class="NLM_article-title">Human Immunodeficiency Virus-1 Tat Protein Interacts with Distinct Proteasomal Î± and Î² Subunits</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>553</i></span> (<span class="NLM_issue">1â2</span>),  <span class="NLM_fpage">200</span>â <span class="NLM_lpage">204</span>, <span class="refDoi">Â DOI: 10.1016/S0014-5793(03)01025-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2FS0014-5793%2803%2901025-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=14550573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvFWhtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=553&publication_year=2003&pages=200-204&issue=1%E2%80%932&author=G.+S.+Apcherauthor=S.+Heinkauthor=D.+Zantopfauthor=P.-M.+Kloetzelauthor=H.-P.+Schmidauthor=R.+J.+Mayerauthor=E.+Kr%C3%BCger&title=Human+Immunodeficiency+Virus-1+Tat+Protein+Interacts+with+Distinct+Proteasomal+%CE%B1+and+%CE%B2+Subunits&doi=10.1016%2FS0014-5793%2803%2901025-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Human immunodeficiency virus-1 Tat protein interacts with distinct proteasomal Î± and Î² subunits</span></div><div class="casAuthors">Apcher, G. Sebastien; Heink, Sylvia; Zantopf, Daniela; Kloetzel, Peter-M.; Schmid, Hans-P.; Mayer, R. John; Kruger, Elke</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">553</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">200-204</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The human immunodeficiency virus-1 (HIV-1) Tat protein was previously reported to compete the assocn. of PA28 regulator with the Î± rings of the 20S proteasome and to inhibit its peptidase activity.  However, the distinct interaction sites within the proteasome complex remained to be detd.  Here the authors show that HIV-1 Tat binds to Î±4 and Î±7, six Î² subunits of the constitutive 20S proteasome and the interferon-Î³-inducible subunits Î²2i and Î²5i.  A Tat-proteasome interaction can also be demonstrated in vivo and leads to inhibition of proteasomal activity.  This indicates that Tat can modulate or interfere with cellular proteasome function by specific interaction with distinct proteasomal subunits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOWMBmk7NxXbVg90H21EOLACvtfcHk0lj6o6LTpkkO-g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvFWhtrc%253D&md5=f17e506eec7b159b3f1979ac535a9e19</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2FS0014-5793%2803%2901025-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-5793%252803%252901025-1%26sid%3Dliteratum%253Aachs%26aulast%3DApcher%26aufirst%3DG.%2BS.%26aulast%3DHeink%26aufirst%3DS.%26aulast%3DZantopf%26aufirst%3DD.%26aulast%3DKloetzel%26aufirst%3DP.-M.%26aulast%3DSchmid%26aufirst%3DH.-P.%26aulast%3DMayer%26aufirst%3DR.%2BJ.%26aulast%3DKr%25C3%25BCger%26aufirst%3DE.%26atitle%3DHuman%2520Immunodeficiency%2520Virus-1%2520Tat%2520Protein%2520Interacts%2520with%2520Distinct%2520Proteasomal%2520%25CE%25B1%2520and%2520%25CE%25B2%2520Subunits%26jtitle%3DFEBS%2520Lett.%26date%3D2003%26volume%3D553%26issue%3D1%25E2%2580%25932%26spage%3D200%26epage%3D204%26doi%3D10.1016%2FS0014-5793%2803%2901025-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 8 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eva M.  Huber</span>, <span class="hlFld-ContribAuthor ">Michael  Groll</span>. </span><span class="cited-content_cbyCitation_article-title">A Nut for Every Bolt: Subunit-Selective Inhibitors of the Immunoproteasome and Their Therapeutic Potential. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2021,</strong> <em>10 </em>
                                    (8)
                                     , 1929. <a href="https://doi.org/10.3390/cells10081929" title="DOI URL">https://doi.org/10.3390/cells10081929</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells10081929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells10081929%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DA%252BNut%252Bfor%252BEvery%252BBolt%25253A%252BSubunit-Selective%252BInhibitors%252Bof%252Bthe%252BImmunoproteasome%252Band%252BTheir%252BTherapeutic%252BPotential%26aulast%3DHuber%26aufirst%3DEva%2BM.%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D8%26spage%3D1929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Levente  KollÃ¡r</span>, <span class="hlFld-ContribAuthor ">Martina  Gobec</span>, <span class="hlFld-ContribAuthor ">Bence  SzilÃ¡gyi</span>, <span class="hlFld-ContribAuthor ">Matic  Proj</span>, <span class="hlFld-ContribAuthor ">Damijan  Knez</span>, <span class="hlFld-ContribAuthor ">PÃ©ter  ÃbrÃ¡nyi-Balogh</span>, <span class="hlFld-ContribAuthor ">LÃ¡szlÃ³  Petri</span>, <span class="hlFld-ContribAuthor ">TÃ­mea  Imre</span>, <span class="hlFld-ContribAuthor ">DÃ¡vid  Bajusz</span>, <span class="hlFld-ContribAuthor ">GyÃ¶rgy G.  Ferenczy</span>, <span class="hlFld-ContribAuthor ">Stanislav  Gobec</span>, <span class="hlFld-ContribAuthor ">GyÃ¶rgy M.  KeserÅ±</span>, <span class="hlFld-ContribAuthor ">Izidor  SosiÄ</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of selective fragment-sized immunoproteasome inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>219 </em>, 113455. <a href="https://doi.org/10.1016/j.ejmech.2021.113455" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113455</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113455%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bselective%252Bfragment-sized%252Bimmunoproteasome%252Binhibitors%26aulast%3DKoll%25C3%25A1r%26aufirst%3DLevente%26date%3D2021%26volume%3D219%26spage%3D113455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fulya  TÃ¼rker</span>, <span class="hlFld-ContribAuthor ">Emily K.  Cook</span>, <span class="hlFld-ContribAuthor ">Seth S.  Margolis</span>. </span><span class="cited-content_cbyCitation_article-title">The proteasome and its role in the nervous system. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2021,</strong> <em>28 </em>
                                    (7)
                                     , 903-917. <a href="https://doi.org/10.1016/j.chembiol.2021.04.003" title="DOI URL">https://doi.org/10.1016/j.chembiol.2021.04.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2021.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2021.04.003%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DThe%252Bproteasome%252Band%252Bits%252Brole%252Bin%252Bthe%252Bnervous%252Bsystem%26aulast%3DT%25C3%25BCrker%26aufirst%3DFulya%26date%3D2021%26volume%3D28%26issue%3D7%26spage%3D903%26epage%3D917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sara  Sarroca</span>, <span class="hlFld-ContribAuthor ">AlaÃ³  Gatius</span>, <span class="hlFld-ContribAuthor ">Eduard  RodrÃ­guez-FarrÃ©</span>, <span class="hlFld-ContribAuthor ">David  Vilchez</span>, <span class="hlFld-ContribAuthor ">MercÃ¨  PallÃ s</span>, <span class="hlFld-ContribAuthor ">Christian  GriÃ±Ã¡n-FerrÃ©</span>, <span class="hlFld-ContribAuthor ">Coral  Sanfeliu</span>, <span class="hlFld-ContribAuthor ">RubÃ©n  Corpas</span>. </span><span class="cited-content_cbyCitation_article-title">Resveratrol confers neuroprotection against high-fat diet in a mouse model of Alzheimer's disease via modulation of proteolytic mechanisms. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Nutritional Biochemistry</span><span> <strong>2021,</strong> <em>89 </em>, 108569. <a href="https://doi.org/10.1016/j.jnutbio.2020.108569" title="DOI URL">https://doi.org/10.1016/j.jnutbio.2020.108569</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jnutbio.2020.108569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jnutbio.2020.108569%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Nutritional%2520Biochemistry%26atitle%3DResveratrol%252Bconfers%252Bneuroprotection%252Bagainst%252Bhigh-fat%252Bdiet%252Bin%252Ba%252Bmouse%252Bmodel%252Bof%252BAlzheimer%252527s%252Bdisease%252Bvia%252Bmodulation%252Bof%252Bproteolytic%252Bmechanisms%26aulast%3DSarroca%26aufirst%3DSara%26date%3D2021%26volume%3D89%26spage%3D108569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wioletta  Breczko</span>, <span class="hlFld-ContribAuthor ">Dorota  Lemancewicz</span>, <span class="hlFld-ContribAuthor ">Janusz  DziÄcioÅ</span>, <span class="hlFld-ContribAuthor ">Janusz  KÅoczko</span>, <span class="hlFld-ContribAuthor ">Åukasz  BoÅkun</span>. </span><span class="cited-content_cbyCitation_article-title">High immunoproteasome concentration in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of longer OS. </span><span class="cited-content_cbyCitation_journal-name">Advances in Medical Sciences</span><span> <strong>2021,</strong> <em>66 </em>
                                    (1)
                                     , 21-27. <a href="https://doi.org/10.1016/j.advms.2020.11.003" title="DOI URL">https://doi.org/10.1016/j.advms.2020.11.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.advms.2020.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.advms.2020.11.003%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvances%2520in%2520Medical%2520Sciences%26atitle%3DHigh%252Bimmunoproteasome%252Bconcentration%252Bin%252Bthe%252Bplasma%252Bof%252Bpatients%252Bwith%252Bnewly%252Bdiagnosed%252Bmultiple%252Bmyeloma%252Btreated%252Bwith%252Bbortezomib%252Bis%252Bpredictive%252Bof%252Blonger%252BOS%26aulast%3DBreczko%26aufirst%3DWioletta%26date%3D2021%26volume%3D66%26issue%3D1%26spage%3D21%26epage%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paolo  Cascio</span>. </span><span class="cited-content_cbyCitation_article-title">PA28Î³: New Insights on an Ancient Proteasome Activator. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2021,</strong> <em>11 </em>
                                    (2)
                                     , 228. <a href="https://doi.org/10.3390/biom11020228" title="DOI URL">https://doi.org/10.3390/biom11020228</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom11020228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom11020228%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DPA28%2525CE%2525B3%25253A%252BNew%252BInsights%252Bon%252Ban%252BAncient%252BProteasome%252BActivator%26aulast%3DCascio%26aufirst%3DPaolo%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D2%26spage%3D228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marianne E  Maresh</span>, <span class="hlFld-ContribAuthor ">Andres F  Salazar-Chaparro</span>, <span class="hlFld-ContribAuthor ">Darci J  Trader</span>. </span><span class="cited-content_cbyCitation_article-title">Methods for the discovery of small molecules to monitor and perturb the activity of the human proteasome. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2021,</strong> <em>13 </em>
                                    (2)
                                     , 99-116. <a href="https://doi.org/10.4155/fmc-2020-0288" title="DOI URL">https://doi.org/10.4155/fmc-2020-0288</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2020-0288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2020-0288%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DMethods%252Bfor%252Bthe%252Bdiscovery%252Bof%252Bsmall%252Bmolecules%252Bto%252Bmonitor%252Band%252Bperturb%252Bthe%252Bactivity%252Bof%252Bthe%252Bhuman%252Bproteasome%26aulast%3DMaresh%26aufirst%3DMarianne%2BE%26date%3D2021%26volume%3D13%26issue%3D2%26spage%3D99%26epage%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elmer  Maurits</span>, <span class="hlFld-ContribAuthor ">Christian G.  Degeling</span>, <span class="hlFld-ContribAuthor ">Alexei F.  Kisselev</span>, <span class="hlFld-ContribAuthor ">Bogdan I.  Florea</span>, <span class="hlFld-ContribAuthor ">Herman S.  Overkleeft</span>. </span><span class="cited-content_cbyCitation_article-title">StructureâBased Design of Fluorogenic Substrates Selective for Human Proteasome Subunits. </span><span class="cited-content_cbyCitation_journal-name">ChemBioChem</span><span> <strong>2020,</strong> <em>21 </em>
                                    (22)
                                     , 3220-3224. <a href="https://doi.org/10.1002/cbic.202000375" title="DOI URL">https://doi.org/10.1002/cbic.202000375</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbic.202000375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbic.202000375%26sid%3Dliteratum%253Aachs%26jtitle%3DChemBioChem%26atitle%3DStructure%2525E2%252580%252590Based%252BDesign%252Bof%252BFluorogenic%252BSubstrates%252BSelective%252Bfor%252BHuman%252BProteasome%252BSubunits%26aulast%3DMaurits%26aufirst%3DElmer%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D22%26spage%3D3220%26epage%3D3224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. SCP is a barrel-shaped catalytic protein complex that is responsible for degrading proteins in the cell into short peptide sequences. Upon stimulation by IFN-Î³, new catalytic subunits replace the subunits of the sCP to form the iCP. The iCP is more efficient at producing peptides that can be incorporated into MHC-I complexes. The iCP is generally expressed in cells that are virally infected or immune cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. AMC-based substrate probes selective for (A) Î²5i and (B) Î²1i have recently become commercially available through Boston Biochem. (C) A549 cells (5000 cells/well) were either lysed with a nondenaturing buffer (blue) or left intact (red) and incubated with Suc-LLVY-AMC (63 Î¼M), a common sCP probe. These data demonstrate these types of probes are not effective for use in whole cells. Data collected by the authors, previously unpublished.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Fluorescent probes based on inhibitors selective for (A) Î²1, (B) Î²2, and (C) Î²5 are used in ABPP to examine the expression levels of each subunit and selectivity profiles of new inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Kim lab developed selective inhibitors targeting (A) Î²1/Î²1i, (B) Î²2/Î²2i, and (C) Î²5/Î²5i as FRET pairs to look at proteasome composition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Example of the probes developed by the Kim lab to covalently link two Î²2 subunits. Shown are selective inhibitors for Î²1/Î²1i (red) and Î²5/Î²5i (blue) with a C<sub>6</sub> linker (black).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Our group recently developed a new iCP-selective activity probe that can be used in live cells. Attached to a rhodamine-110 molecule (green) are an iCP recognition peptide (blue) that provides the probeâs selectivity and a short peptoid (orange) that assists in cell permeability.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. sCP inhibitors such as bortezomib have been developed to kill MM cells. However, cells eventually confer resistance to the drug. Current research is focused on developing iCP inhibitors to overcome drug resistance in MM and determine if the iCP is a good therapeutic target for some forms of cancer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Bortezomib was the first proteasome inhibitor approved by the Food and Drug Administration as a chemotherapeutic agent for MM. The boronic acid moiety binds the threonine amino acid residue in the active site of the Î²5c subunit. (B) Structure of MG-132, a proteasome inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. PR-924 is an epoxyketone tripeptide that specifically binds that Î²5i iCP subunit. At high concentrations, this compound can bind and inhibit the activity of the Î²5c and Î²1i subunits.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. UK-101 was the first reported inhibitor of the Î²1i subunit of the iCP. It is thought that the leucine side chain binds the hydrophobic pocket of the Î²1i subunit and facilitates insertion of the TBDMS group into the active site to inhibit the subunitâs activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) PR-957, also known as ONX-0914, is one of the first inhibitors with high selectivity for the Î²5i subunit, allowing for the probing of independent iCP activities. It has been investigated in several autoimmune disorders. (B) Carfilzomib is an FDA-approved second-generation proteasome inhibitor for the treatment of MM. (C) PR-893 is a Î²5c-selective inhibitor, discovered in the same endeavor as ONX-0914. Its improved selectivity compared to those of bortezomib and carfilzomib has allowed us to distinguish between the sCP and iCP effects of inhibition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. (A) PRN1126, a selective inhibitor of Î²5i, gains selectivity by reversibly, covalently binding to Cys48. (B) KRZ-504 is a selective inhibitor of Î²1i. Compound <b>8</b> is (C) a Î²5i-selective inhibitor, and compound <b>10</b> (D) is a Î²2i-selective inhibitor developed. (E) KRZ-616, a pan-iCP inhibitor currently in clinical trials for SLE.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Inhibitors of (A) Î²5i and Î²1i and (B) Î²5i developed by Genentech, Inc.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. When cells are exposed to inflammatory cytokines (i.e., IFN-Î³ and TNF-Î±), the iCP is expressed. In autoimmune disorders, the presence of autoantigens activates T-cells and leads to apoptosis. If dosed with an iCP inhibitor, production of cytokines, such as IL-6 and TNF-Î±, is reduced, therefore decreasing the localized inflammation and allowing the cells to evade triggering of the immune system.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/medium/jm9b01226_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Expression of the iCP has been implicated in aging and several neurodegenerative diseases. Recent research has focused on determining the role of the iCP in neurodegenerative diseases. Although controversial, altering the extent of iCP activity could potentially help reverse damage from aging and neurodegenerative diseases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01226/20200306/images/large/jm9b01226_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01226&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i25">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78056" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78056" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 145 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span> <span> </span><span class="NLM_article-title">An Atomic Structure of the Human 26S Proteasome</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">778</span>â <span class="NLM_lpage">785</span>, <span class="refDoi">Â DOI: 10.1038/nsmb.3273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fnsmb.3273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=27428775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1KmurnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=778-785&issue=9&author=X.+Huangauthor=B.+Luanauthor=J.+Wuauthor=Y.+Shi&title=An+Atomic+Structure+of+the+Human+26S+Proteasome&doi=10.1038%2Fnsmb.3273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">An atomic structure of the human 26S proteasome</span></div><div class="casAuthors">Huang, Xiuliang; Luan, Bai; Wu, Jianping; Shi, Yigong</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">778-785</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We report the cryo-EM structure of the human 26S proteasome at an av. resoln. of 3.5 Ã, allowing at. modeling of 28 subunits in the core particle (CP) and 18 subunits in the regulatory particle (RP).  The C-terminal residues of Rpt3 and Rpt5 subunits in the RP can be seen inserted into surface pockets formed between adjacent Î± subunits in the CP.  Each of the six Rpt subunits contains a bound nucleotide, and the central gate of the CP Î±-ring is closed despite RP assocn.  The six pore 1 loops in the Rpt ring are arranged similarly to a spiral staircase along the axial channel of substrate transport, which is constricted by the pore 2 loops.  We also detd. the cryo-EM structure of the human proteasome bound to the deubiquitinating enzyme USP14 at 4.35-Ã resoln.  Together, our structures provide a framework for mechanistic understanding of eukaryotic proteasome function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7cgdtPPda8bVg90H21EOLACvtfcHk0lhcWeCEn55_ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1KmurnN&md5=4b341b3da5cb3560cf048c87c279393a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.3273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.3273%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DLuan%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DAn%2520Atomic%2520Structure%2520of%2520the%2520Human%252026S%2520Proteasome%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2016%26volume%3D23%26issue%3D9%26spage%3D778%26epage%3D785%26doi%3D10.1038%2Fnsmb.3273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coux, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, A. L.</span></span> <span> </span><span class="NLM_article-title">Structure and Functions of the 20S and 26S Proteasomes</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">801</span>â <span class="NLM_lpage">847</span>, <span class="refDoi">Â DOI: 10.1146/annurev.bi.65.070196.004101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1146%2Fannurev.bi.65.070196.004101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=8811196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADyaK28XktFamurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1996&pages=801-847&author=O.+Couxauthor=K.+Tanakaauthor=A.+L.+Goldberg&title=Structure+and+Functions+of+the+20S+and+26S+Proteasomes&doi=10.1146%2Fannurev.bi.65.070196.004101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and functions of the 20S and 26S proteasomes</span></div><div class="casAuthors">Coux, Olivier; Tanaka, Keiji; Goldberg, Alfred L.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">801-847</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review with 287 refs., of recent progress with respect to biochem. mechanisms and intracellular functions of the 20 S and 26 S proteasomes (multicatalytic proteinases).  The proteasome is an essential component of the ATP-dependent proteolytic pathway in eukaryotic cells and is responsible for the degrdn. of most cellular proteins.  The 20 S (700-kDa) proteasome contains multiple peptidase activities that function through a new type of proteolytic mechanism involving a threonine active site.  The 26 S (2000-kDa) complex, which degrades ubiquitinated proteins, contains in addn. to the 20 S proteasome a 19 S regulatory complex composed of multiple ATPases and components necessary for binding protein substrates.  The proteasome has been highly conserved during eukaryotic evolution, and simpler forms are even found in archaebacteria and eubacteria.  Major advances have been achieved recently in the knowledge about the mol. organization of the 20 S and 19 S particles, their subunits, the proteasome's role in MHC-class 1 antigen presentation, and regulators of its activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCV4euIYQJHLVg90H21EOLACvtfcHk0lhcWeCEn55_ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XktFamurc%253D&md5=546ea9ad61ac1cf74667da7e5075484c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1146%2Fannurev.bi.65.070196.004101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.bi.65.070196.004101%26sid%3Dliteratum%253Aachs%26aulast%3DCoux%26aufirst%3DO.%26aulast%3DTanaka%26aufirst%3DK.%26aulast%3DGoldberg%26aufirst%3DA.%2BL.%26atitle%3DStructure%2520and%2520Functions%2520of%2520the%252020S%2520and%252026S%2520Proteasomes%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D1996%26volume%3D65%26spage%3D801%26epage%3D847%26doi%3D10.1146%2Fannurev.bi.65.070196.004101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabre, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambour, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delobel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amalric, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monsarrat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlet-Schiltz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bousquet-Dubouch, M.-P.</span></span> <span> </span><span class="NLM_article-title">Subcellular Distribution and Dynamics of Active Proteasome Complexes Unraveled by a Workflow Combining in Vivo Complex Cross-Linking and Quantitative Proteomics</span>. <i>Mol. Cell. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">687</span>â <span class="NLM_lpage">699</span>, <span class="refDoi">Â DOI: 10.1074/mcp.M112.023317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1074%2Fmcp.M112.023317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=23242550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtlOitL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=687-699&issue=3&author=B.+Fabreauthor=T.+Lambourauthor=J.+Delobelauthor=F.+Amalricauthor=B.+Monsarratauthor=O.+Burlet-Schiltzauthor=M.-P.+Bousquet-Dubouch&title=Subcellular+Distribution+and+Dynamics+of+Active+Proteasome+Complexes+Unraveled+by+a+Workflow+Combining+in+Vivo+Complex+Cross-Linking+and+Quantitative+Proteomics&doi=10.1074%2Fmcp.M112.023317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Subcellular Distribution and Dynamics of Active Proteasome Complexes Unraveled by a Workflow Combining in Vivo Complex Cross-Linking and Quantitative Proteomics</span></div><div class="casAuthors">Fabre, Bertrand; Lambour, Thomas; Delobel, Julien; Amalric, Francois; Monsarrat, Bernard; Burlet-Schiltz, Odile; Bousquet-Dubouch, Marie-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Molecular & Cellular Proteomics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">687-699</span>CODEN:
                <span class="NLM_cas:coden">MCPOBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-9484</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Through protein degrdn., the proteasome plays fundamental roles in different cell compartments.  Although the compn. of the 20S catalytic core particle (CP) has been well documented, little is known about the compn. and dynamics of the regulatory complexes that play a crucial role in its activity, or about how they assoc. with the CP in different cell compartments, different cell lines, and in response to external stimuli.  Because of difficulties performing acceptable cell fractionation while maintaining complex integrity, it has been challenging to characterize proteasome complexes by proteomic approaches.  Here, we report an integrated protocol, combining a crosslinking procedure on intact cells with cell fractionation, proteasome immuno-purifn., and robust label-free quant. proteomic anal. by mass spectrometry to det. the distribution and dynamics of cellular proteasome complexes in leukemic cells.  Activity profiles of proteasomes were correlated fully with the compn. of protein complexes and stoichiometry.  Moreover, our results suggest that, at the subcellular level, proteasome function is regulated by dynamic interactions between the 20S CP and its regulatory proteins-which modulate proteasome activity, stability, localization, or substrate uptake-rather than by profound changes in 20S CP compn.  Proteasome plasticity was obsd. both in the 20S CP and in its network of interactions following IFNÎ³ stimulation.  The fractionation protocol also revealed specific proteolytic activities and structural features of low-abundance microsomal proteasomes from U937 and KG1a cells.  These could be linked to their important roles in the endoplasmic reticulum assocd. degrdn. pathway in leukemic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopH0HunTPDfLVg90H21EOLACvtfcHk0li7QLlC8MTeEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtlOitL4%253D&md5=93d90b61268072123e712a8861bde7c8</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1074%2Fmcp.M112.023317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fmcp.M112.023317%26sid%3Dliteratum%253Aachs%26aulast%3DFabre%26aufirst%3DB.%26aulast%3DLambour%26aufirst%3DT.%26aulast%3DDelobel%26aufirst%3DJ.%26aulast%3DAmalric%26aufirst%3DF.%26aulast%3DMonsarrat%26aufirst%3DB.%26aulast%3DBurlet-Schiltz%26aufirst%3DO.%26aulast%3DBousquet-Dubouch%26aufirst%3DM.-P.%26atitle%3DSubcellular%2520Distribution%2520and%2520Dynamics%2520of%2520Active%2520Proteasome%2520Complexes%2520Unraveled%2520by%2520a%2520Workflow%2520Combining%2520in%2520Vivo%2520Complex%2520Cross-Linking%2520and%2520Quantitative%2520Proteomics%26jtitle%3DMol.%2520Cell.%2520Proteomics%26date%3D2013%26volume%3D12%26issue%3D3%26spage%3D687%26epage%3D699%26doi%3D10.1074%2Fmcp.M112.023317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trader, D. J.</span></span> <span> </span><span class="NLM_article-title">All About the Core: A Therapeutic Strategy to Prevent Protein Accumulation with Proteasome Core Particle Stimulators</span>. <i>ACS Pharmacol. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">140</span>â <span class="NLM_lpage">142</span>, <span class="refDoi">Â DOI: 10.1021/acsptsci.8b00042</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsptsci.8b00042" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFeitr7N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2018&pages=140-142&issue=2&author=R.+A.+Colemanauthor=D.+J.+Trader&title=All+About+the+Core%3A+A+Therapeutic+Strategy+to+Prevent+Protein+Accumulation+with+Proteasome+Core+Particle+Stimulators&doi=10.1021%2Facsptsci.8b00042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">All About the Core: A Therapeutic Strategy to Prevent Protein Accumulation with Proteasome Core Particle Stimulators</span></div><div class="casAuthors">Coleman, Rachel A.; Trader, Darci J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Pharmacology & Translational Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-142</span>CODEN:
                <span class="NLM_cas:coden">APTSFN</span>;
        ISSN:<span class="NLM_cas:issn">2575-9108</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The proteasome is an essential enzyme complex in cells whose main responsibility is to degrade proteins.  Proteins can be degraded through either a ubiquitin-dependent or -independent mechanism by the proteasome.  A variety of small mols. have been discovered that can increase the rate of protein degrdn. through either mechanism.  However, stimulation of the ubiquitin-independent system is likely to be the most therapeutically impactful for protein-accumulation diseases.  Preliminary evidence has demonstrated efficacy of this approach for reducing proteins assocd. with disease.  To advance the field forward, validation of this mechanism in a disease model as well as more detailed studies on how much stimulation is required to achieve a therapeutic effect must be performed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSbvH2uuL6GLVg90H21EOLACvtfcHk0li7QLlC8MTeEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFeitr7N&md5=5b356c5fb7c7a7a6c9793f4eebe55940</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Facsptsci.8b00042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsptsci.8b00042%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DR.%2BA.%26aulast%3DTrader%26aufirst%3DD.%2BJ.%26atitle%3DAll%2520About%2520the%2520Core%253A%2520A%2520Therapeutic%2520Strategy%2520to%2520Prevent%2520Protein%2520Accumulation%2520with%2520Proteasome%2520Core%2520Particle%2520Stimulators%26jtitle%3DACS%2520Pharmacol.%2520Transl.%2520Sci.%26date%3D2018%26volume%3D1%26issue%3D2%26spage%3D140%26epage%3D142%26doi%3D10.1021%2Facsptsci.8b00042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Opoku-Nsiah, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gestwicki, J. E.</span></span> <span> </span><span class="NLM_article-title">Aim for the Core: Suitability of the Ubiquitin-Independent 20S Proteasome as a Drug Target in Neurodegeneration</span>. <i>Transl. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>198</i></span>,  <span class="NLM_fpage">48</span>â <span class="NLM_lpage">57</span>, <span class="refDoi">Â DOI: 10.1016/j.trsl.2018.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.trsl.2018.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=30244692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht12mu73K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2018&pages=48-57&author=K.+A.+Opoku-Nsiahauthor=J.+E.+Gestwicki&title=Aim+for+the+Core%3A+Suitability+of+the+Ubiquitin-Independent+20S+Proteasome+as+a+Drug+Target+in+Neurodegeneration&doi=10.1016%2Fj.trsl.2018.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Aim for the core: suitability of the ubiquitin-independent 20S proteasome as a drug target in neurodegeneration</span></div><div class="casAuthors">Opoku-Nsiah, Kwadwo A.; Gestwicki, Jason E.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">198</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">48-57</span>CODEN:
                <span class="NLM_cas:coden">TRRECL</span>;
        ISSN:<span class="NLM_cas:issn">1878-1810</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Neurodegenerative diseases are a class of age-assocd. proteopathies characterized by the accumulation of misfolded and/or aggregation-prone proteins.  This imbalance has been attributed, in part, to an age-dependent decay in the capacity of protein turnover.  Most proteins are degraded by the ubiquitin-proteasome system (UPS), which is composed of ubiquitin ligases and regulatory particles, such as the 19S, that deliver cargo to the proteolytically active 20S proteasome (20S) core.  However, a subset of clients, esp. intrinsically disordered proteins (IDPs), are also removed by the action of the ubiquitin-independent proteasome system (UIPS).  What are the specific contributions of the UPS and UIPS in the context of neurodegeneration.  Here, we explore how age-assocd. changes in the relative contribution of the UPS and UIPS, combined with the IDP-like structure of many neurodegenerative disease-assocd. proteins, might contribute.  Strikingly, the 20S has been shown to predominate in older neurons and to preferentially act on relevant substrates, such as synuclein and tau.  Moreover, pharmacol. activation of the 20S has been shown to accelerate removal of aggregation-prone proteins in some models.  Together, these recent studies are turning attention to the 20S and the UIPS as potential therapeutic targets in neurodegeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1GEmdqyg24bVg90H21EOLACvtfcHk0li7QLlC8MTeEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht12mu73K&md5=f5e957eb4d08fb227f130b8446ee763c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.trsl.2018.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trsl.2018.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DOpoku-Nsiah%26aufirst%3DK.%2BA.%26aulast%3DGestwicki%26aufirst%3DJ.%2BE.%26atitle%3DAim%2520for%2520the%2520Core%253A%2520Suitability%2520of%2520the%2520Ubiquitin-Independent%252020S%2520Proteasome%2520as%2520a%2520Drug%2520Target%2520in%2520Neurodegeneration%26jtitle%3DTransl.%2520Res.%26date%3D2018%26volume%3D198%26spage%3D48%26epage%3D57%26doi%3D10.1016%2Fj.trsl.2018.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Nissan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharon, M.</span></span> <span> </span><span class="NLM_article-title">Regulating the 20S Proteasome Ubiquitin-Independent Degradation Pathway</span>. <i>Biomolecules</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">862</span>â <span class="NLM_lpage">884</span>, <span class="refDoi">Â DOI: 10.3390/biom4030862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.3390%2Fbiom4030862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=25250704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12hsLrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=862-884&issue=3&author=G.+Ben-Nissanauthor=M.+Sharon&title=Regulating+the+20S+Proteasome+Ubiquitin-Independent+Degradation+Pathway&doi=10.3390%2Fbiom4030862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Regulating the 20S proteasome ubiquitin-independent degradation pathway</span></div><div class="casAuthors">Ben-Nissan, Gili; Sharon, Michal</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">862-884, 23 pp.</span>CODEN:
                <span class="NLM_cas:coden">BIOMHC</span>;
        ISSN:<span class="NLM_cas:issn">2218-273X</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">For many years, the ubiquitin-26S proteasome degrdn. pathway was considered the primary route for proteasomal degrdn.  However, it is now becoming clear that proteins can also be targeted for degrdn. by the core 20S proteasome itself.  Degrdn. by the 20S proteasome does not require ubiquitin tagging or the presence of the 19S regulatory particle; rather, it relies on the inherent structural disorder of the protein being degraded.  Thus, proteins that contain unstructured regions due to oxidn., mutation, or aging, as well as naturally, intrinsically unfolded proteins, are susceptible to 20S degrdn.  Unlike the extensive knowledge acquired over the years concerning degrdn. by the 26S proteasome, relatively little is known about the means by which 20S-mediated proteolysis is controlled.  Here, we describe our current understanding of the regulatory mechanisms that coordinate 20S proteasome-mediated degrdn., and highlight the gaps in knowledge that remain to be bridged.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIDvYhAH_verVg90H21EOLACvtfcHk0li7QLlC8MTeEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12hsLrL&md5=b079f6d24dcd96070d8fbc3da2c49dcb</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3390%2Fbiom4030862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fbiom4030862%26sid%3Dliteratum%253Aachs%26aulast%3DBen-Nissan%26aufirst%3DG.%26aulast%3DSharon%26aufirst%3DM.%26atitle%3DRegulating%2520the%252020S%2520Proteasome%2520Ubiquitin-Independent%2520Degradation%2520Pathway%26jtitle%3DBiomolecules%26date%3D2014%26volume%3D4%26issue%3D3%26spage%3D862%26epage%3D884%26doi%3D10.3390%2Fbiom4030862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, K.</span></span> <span> </span><span class="NLM_article-title">Role of Proteasomes Modified by Interferon-Gamma in Antigen Processing</span>. <i>J. Leukocyte Biol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">571</span>â <span class="NLM_lpage">575</span>, <span class="refDoi">Â DOI: 10.1002/jlb.56.5.571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1002%2Fjlb.56.5.571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=7964165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADyaK2cXmvFymtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1994&pages=571-575&issue=5&author=K.+Tanaka&title=Role+of+Proteasomes+Modified+by+Interferon-Gamma+in+Antigen+Processing&doi=10.1002%2Fjlb.56.5.571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Role of proteasomes modified by interferon-Î³ in antigen processing</span></div><div class="casAuthors">Tanaka, Keiji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">571-5</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">A review with 31 refs. of the possible function of proteasomes in antigen processing with special ref. to the influence of interferon-Î³ on their function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI--bWlvkbibVg90H21EOLACvtfcHk0lg3ksVfgKq4aQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvFymtbg%253D&md5=4b225932ff9e7fb1fb67ebd9b8cf7444</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fjlb.56.5.571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlb.56.5.571%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DK.%26atitle%3DRole%2520of%2520Proteasomes%2520Modified%2520by%2520Interferon-Gamma%2520in%2520Antigen%2520Processing%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D1994%26volume%3D56%26issue%3D5%26spage%3D571%26epage%3D575%26doi%3D10.1002%2Fjlb.56.5.571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eskandari, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seelen, M. a. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzi, J. R.</span></span> <span> </span><span class="NLM_article-title">The Immunoproteasome: An Old Player with a Novel and Emerging Role in Alloimmunity</span>. <i>Am. J. Transplant.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3033</span>â <span class="NLM_lpage">3039</span>, <span class="refDoi">Â DOI: 10.1111/ajt.14435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1111%2Fajt.14435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=28719024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BC1cjoslSjsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=3033-3039&issue=12&author=S.+K.+Eskandariauthor=M.+a.+J.+Seelenauthor=G.+Linauthor=J.+R.+Azzi&title=The+Immunoproteasome%3A+An+Old+Player+with+a+Novel+and+Emerging+Role+in+Alloimmunity&doi=10.1111%2Fajt.14435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The immunoproteasome: An old player with a novel and emerging role in alloimmunity</span></div><div class="casAuthors">Eskandari S K; Azzi J R; Eskandari S K; Seelen M A J; Lin G</div><div class="citationInfo"><span class="NLM_cas:title">American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3033-3039</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Modern treatment strategies for the maintenance of allograft acceptance frequently target ubiquitously-expressed pathways, leading to significant side-effects and poor long-term allograft outcomes.  Constitutive proteasome inhibitors, which have recently been introduced for the treatment of antibody-mediated rejection, target the ubiquitously-expressed proteasome.  To limit off-target effects and serious mechanism-based toxicity, however, these inhibitors are administered intermittently and suboptimally.  Immunoproteasomes, which are an inducible subset of proteasomes enriched in immune cells, replace constitutive proteasomes after cell exposure to proinflammatory cytokines such as interferon-Î³.  While immunoproteasomes were first described as processors of antigen for presentation by major histocompatibility complex molecules, recent findings point to its broader biological roles.  These vary from activating different subsets of the immune system, by controlling transcriptional activators and downstream cytokines, to affecting their differentiation and survival.  These emerging roles of the immunoproteasome in activated immune cells have made it a rational candidate for the targeted treatment of immune-mediated diseases.  Preclinical studies have established its role in maintaining allograft acceptance without significant short- or long-term toxicity.  This review provides a brief background of the immunoproteasome and outlines its role in immunological pathways and its potential in alloimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSEMLlHyBytPZHZzFRCXxVKfW6udTcc2eYeQhH3cjyd87ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjoslSjsg%253D%253D&md5=8ae1e2258dcad625a497d4a190b9a876</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fajt.14435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fajt.14435%26sid%3Dliteratum%253Aachs%26aulast%3DEskandari%26aufirst%3DS.%2BK.%26aulast%3DSeelen%26aufirst%3DM.%2Ba.%2BJ.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DAzzi%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520Immunoproteasome%253A%2520An%2520Old%2520Player%2520with%2520a%2520Novel%2520and%2520Emerging%2520Role%2520in%2520Alloimmunity%26jtitle%3DAm.%2520J.%2520Transplant.%26date%3D2017%26volume%3D17%26issue%3D12%26spage%3D3033%26epage%3D3039%26doi%3D10.1111%2Fajt.14435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span></span> <span> </span><span class="NLM_article-title">Proteasomes in Immune Cells: More than Peptide Producers?</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">73</span>â <span class="NLM_lpage">78</span>, <span class="refDoi">Â DOI: 10.1038/nri2687</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fnri2687" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=20010787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFChtbnI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=73-78&issue=1&author=M.+Groettrupauthor=C.+J.+Kirkauthor=M.+Basler&title=Proteasomes+in+Immune+Cells%3A+More+than+Peptide+Producers%3F&doi=10.1038%2Fnri2687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasomes in immune cells: more than peptide producers?</span></div><div class="casAuthors">Groettrup, Marcus; Kirk, Christopher J.; Basler, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-78</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  When cells are stimulated with pro-inflammatory cytokines, most of their constitutively expressed proteasomes are replaced with immunoproteasomes, which increase the prodn. of peptides for presentation on MHC class I mols.  In addn., cortical thymic epithelial cells selectively express a type of proteasome known as the thymoproteasome that is required for the pos. selection of thymocytes.  Here, we discuss how these specialized types of proteasome shape the T cell receptor repertoire of cytotoxic T lymphocytes and propose that immunoproteasomes have functions, in addn. to antigen processing, that influence cytokine prodn. and T cell differentiation, survival and function.  We also discuss how inhibitors of immunoproteasomes can suppress undesired T cell responses in autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomQzel5QNbpbVg90H21EOLACvtfcHk0lg3ksVfgKq4aQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFChtbnI&md5=e11dedb3a06970299bc4c69b92edaf8a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnri2687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2687%26sid%3Dliteratum%253Aachs%26aulast%3DGroettrup%26aufirst%3DM.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DBasler%26aufirst%3DM.%26atitle%3DProteasomes%2520in%2520Immune%2520Cells%253A%2520More%2520than%2520Peptide%2520Producers%253F%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2010%26volume%3D10%26issue%3D1%26spage%3D73%26epage%3D78%26doi%3D10.1038%2Fnri2687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimbara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takashina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kagawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanahashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, A.</span></span> <span> </span><span class="NLM_article-title">Interferon-Gamma Induces Different Subunit Organizations and Functional Diversity of Proteasomes</span>. <i>J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>115</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">257</span>â <span class="NLM_lpage">269</span>, <span class="refDoi">Â DOI: 10.1093/oxfordjournals.jbchem.a124327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1093%2Foxfordjournals.jbchem.a124327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=8206875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADyaK2cXhs1WgsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=1994&pages=257-269&issue=2&author=M.+Akiauthor=N.+Shimbaraauthor=M.+Takashinaauthor=K.+Akiyamaauthor=S.+Kagawaauthor=T.+Tamuraauthor=N.+Tanahashiauthor=T.+Yoshimuraauthor=K.+Tanakaauthor=A.+Ichihara&title=Interferon-Gamma+Induces+Different+Subunit+Organizations+and+Functional+Diversity+of+Proteasomes&doi=10.1093%2Foxfordjournals.jbchem.a124327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Interferon-Î³ induces different subunit organizations and functional diversity of proteasomes</span></div><div class="casAuthors">Aki, Masashi; Shimbara, Naoki; Takashina, Makoto; Akiyama, Kinya; Kagawa, Susumu; Tamura, Tomohiro; Tanahashi, Nobuyuki; Yoshimura, Tetsuro; Tanaka, Keiji; Ichihara, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biochemistry </span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-69</span>CODEN:
                <span class="NLM_cas:coden">JOBIAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-924X</span>.
    </div><div class="casAbstract">To obtain information on the role of proteasomes in the immune system, the authors examd. the effect of a major immunomodulatory cytokine, gamma interferon (IFN-Î³), on the expressions, structures, and functions of proteasomes,.  IFN-Î³ greatly increased the levels of the mRNAs encoding LMP2 and LMP7, putative immuno-proteasome subunits encoded by genes within the class II MHC region, and these two subunits synthesized were assembled completely into the proteasomal multi-subunit complex in various types of human cells.  The subunit organization of the proteasome changed in response to IFN-Î³ stimulation, due to assembly of newly synthesized subunits through up- and down-expressions of at least 6 proteasome genes including LMP2/LMP7 without change in the structure of pre-existing proteasomes.  Interestingly, IFN-Î³ dramatically stimulated the trypsin-like and chymotrypsin-like activities of the multifunctional proteasome and depressed the peptidylglutamyl-peptide-hydrolyzing activity, without affecting the activity for ATP-, ubiquitin-dependent proteolysis.  These results indicate that IFN-Î³ modifies not only the structural organization of the proteasome, but also its functions.  Based on these findings, the authors discuss the role in the antigen processing/presentation pathway of proteasomes with functional diversity acquired through alteration of their subunit assembly in response to IFN-Î³ stimulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjnsqNQStGLLVg90H21EOLACvtfcHk0lhCJZkRPR67Wg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhs1WgsbY%253D&md5=68702387a6ac451dbe67180e99072afc</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1093%2Foxfordjournals.jbchem.a124327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Foxfordjournals.jbchem.a124327%26sid%3Dliteratum%253Aachs%26aulast%3DAki%26aufirst%3DM.%26aulast%3DShimbara%26aufirst%3DN.%26aulast%3DTakashina%26aufirst%3DM.%26aulast%3DAkiyama%26aufirst%3DK.%26aulast%3DKagawa%26aufirst%3DS.%26aulast%3DTamura%26aufirst%3DT.%26aulast%3DTanahashi%26aufirst%3DN.%26aulast%3DYoshimura%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DK.%26aulast%3DIchihara%26aufirst%3DA.%26atitle%3DInterferon-Gamma%2520Induces%2520Different%2520Subunit%2520Organizations%2520and%2520Functional%2520Diversity%2520of%2520Proteasomes%26jtitle%3DJ.%2520Biochem.%26date%3D1994%26volume%3D115%26issue%3D2%26spage%3D257%26epage%3D269%26doi%3D10.1093%2Foxfordjournals.jbchem.a124327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hengel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruppert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multhaup, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koszinowski, U. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kloetzel, P. M.</span></span> <span> </span><span class="NLM_article-title">Interferon Gamma Stimulation Modulates the Proteolytic Activity and Cleavage Site Preference of 20S Mouse Proteasomes</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>179</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">901</span>â <span class="NLM_lpage">909</span>, <span class="refDoi">Â DOI: 10.1084/jem.179.3.901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1084%2Fjem.179.3.901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=8113682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADyaK2cXhvV2gu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=1994&pages=901-909&issue=3&author=B.+Boesauthor=H.+Hengelauthor=T.+Ruppertauthor=G.+Multhaupauthor=U.+H.+Koszinowskiauthor=P.+M.+Kloetzel&title=Interferon+Gamma+Stimulation+Modulates+the+Proteolytic+Activity+and+Cleavage+Site+Preference+of+20S+Mouse+Proteasomes&doi=10.1084%2Fjem.179.3.901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Interferon Î³ stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes</span></div><div class="casAuthors">Boes, Bettina; Hengel, Hartmut; Ruppert, Thomas; Multhaup, Gerd; Koszinowski, Ulrich H.; Kloetzel, Peter-M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">901-9</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    </div><div class="casAbstract">The proteasome is a 700 kDa multisubunit enzyme complex with several proteolytically active sites.  The enzyme complex is involved in both ubiquitin-dependent and -independent protein degrdn. and may contribute to the processing of antigens presented by major histocompatibility complex (MHC) class I mols.  Here the authors demonstrate that treatment of mouse fibroblast cells with 20 U interferon Î³ (IFN-Î³) for 3 days induces a change in the proteasome subunit compn. and that the Î²-type subunit LMP2, which is encoded in the MHC class II region, is incorporated into the enzyme complex.  This is paralleled by redn. of the homologous Î´-subunit.  IFN-Î³ stimulation results in a downregulation of the chymotrypsin-like Suc-LLVY-MCA peptide hydrolyzing activity of 20S proteasomes whereas the trypsin-like activity remains unaffected.  When tested as a substrate a synthetic 25-mer polypeptide whose sequence covers the antigenic nonapeptide YPHFMPTNL of the murine cytomegalovirus pp89, 20S proteasomes of IFN-Î³-induced cells exhibit altered chymotrypsin-like cleavage site preferences.  In the absence of IFN-Î³ induction, the naturally processed nonamer peptide that is presented by MHC class I mols. appears as a minor cleavage product.  IFN-Î³ activation does not result in an increase of the final peptide but results in a different set of peptides.  The authors hypothesize that these peptides represent precursor peptides that can be trimmed to final peptide size.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6HQn9BlCdubVg90H21EOLACvtfcHk0lhCJZkRPR67Wg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhvV2gu7k%253D&md5=fbf65e3e729be9828100829306b9b5f0</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1084%2Fjem.179.3.901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.179.3.901%26sid%3Dliteratum%253Aachs%26aulast%3DBoes%26aufirst%3DB.%26aulast%3DHengel%26aufirst%3DH.%26aulast%3DRuppert%26aufirst%3DT.%26aulast%3DMulthaup%26aufirst%3DG.%26aulast%3DKoszinowski%26aufirst%3DU.%2BH.%26aulast%3DKloetzel%26aufirst%3DP.%2BM.%26atitle%3DInterferon%2520Gamma%2520Stimulation%2520Modulates%2520the%2520Proteolytic%2520Activity%2520and%2520Cleavage%2520Site%2520Preference%2520of%252020S%2520Mouse%2520Proteasomes%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1994%26volume%3D179%26issue%3D3%26spage%3D901%26epage%3D909%26doi%3D10.1084%2Fjem.179.3.901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nandi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monaco, J. J.</span></span> <span> </span><span class="NLM_article-title">Identification of MECL-1 (LMP-10) as the Third IFN-Gamma-Inducible Proteasome Subunit</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>156</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2361</span>â <span class="NLM_lpage">2364</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=8786291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADyaK28XhvVGlsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=1996&pages=2361-2364&issue=7&author=D.+Nandiauthor=H.+Jiangauthor=J.+J.+Monaco&title=Identification+of+MECL-1+%28LMP-10%29+as+the+Third+IFN-Gamma-Inducible+Proteasome+Subunit"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of MECL-1 (LMP-10) as the third IFN-Î³-inducible proteasome subunit</span></div><div class="casAuthors">Nandi, Dipankar; Jiang, Haibo; Monaco, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2361-4</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">We show that six proteasome-assocd. proteins are induced by IFN-Î³, corresponding to three proteasome Î²-type subunits and their precursors: the MHC-linked subunits (LMP-2 and LMP-7) and LMP-10.  Concurrently, incorporation of LMP-9, LMP-17, and LMP-19 into proteasomes is reduced.  LMP-10 appears to be the product of a previously cloned proteasome subunit gene, MECL-1.  MECL-1 transcription is increased in the presence of IFN-Î³, whereas the transcription of two other proteasome genes, Lmp-15 and Lmp-3, is not affected.  The three IFN-Î³-inducible subunits and their constitutively expressed counterparts contain most or all of the catalytic sites of the proteasome.  Independent assortment of LMP-2, LMP-7, and LMP-10 into different proteasome complexes may thus generate up to 36 unique proteasome subsets.  This may increase the repertoire of potentially antigenic peptides for presentation by MHC class I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJyRmDfKN_XbVg90H21EOLACvtfcHk0lhCJZkRPR67Wg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhvVGlsbo%253D&md5=27d55e7ac9a848e7910e37d5b4d53fc1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNandi%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DMonaco%26aufirst%3DJ.%2BJ.%26atitle%3DIdentification%2520of%2520MECL-1%2520%2528LMP-10%2529%2520as%2520the%2520Third%2520IFN-Gamma-Inducible%2520Proteasome%2520Subunit%26jtitle%3DJ.%2520Immunol.%26date%3D1996%26volume%3D156%26issue%3D7%26spage%3D2361%26epage%3D2364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caturegli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span> <span> </span><span class="NLM_article-title">New Insights into the Function of the Immunoproteasome in Immune and Nonimmune Cells</span>. <i>J. Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">8</span>, <span class="refDoi">Â DOI: 10.1155/2015/541984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1155%2F2015%2F541984" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=1-8&author=H.+Kimuraauthor=P.+Caturegliauthor=M.+Takahashiauthor=K.+Suzuki&title=New+Insights+into+the+Function+of+the+Immunoproteasome+in+Immune+and+Nonimmune+Cells&doi=10.1155%2F2015%2F541984"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1155%2F2015%2F541984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F541984%26sid%3Dliteratum%253Aachs%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DCaturegli%26aufirst%3DP.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DK.%26atitle%3DNew%2520Insights%2520into%2520the%2520Function%2520of%2520the%2520Immunoproteasome%2520in%2520Immune%2520and%2520Nonimmune%2520Cells%26jtitle%3DJ.%2520Immunol.%2520Res.%26date%3D2015%26volume%3D2015%26spage%3D1%26epage%3D8%26doi%3D10.1155%2F2015%2F541984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nandi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehling, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaer, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monaco, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colbert, R. A.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasome Assembly: Cooperative Incorporation of Interferon Î³ (IFN-Î³)âInducible Subunits</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>187</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">97</span>â <span class="NLM_lpage">104</span>, <span class="refDoi">Â DOI: 10.1084/jem.187.1.97</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1084%2Fjem.187.1.97" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=9419215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADyaK1cXjtV2nuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=1998&pages=97-104&issue=1&author=T.+A.+Griffinauthor=D.+Nandiauthor=M.+Cruzauthor=H.+J.+Fehlingauthor=L.+V.+Kaerauthor=J.+J.+Monacoauthor=R.+A.+Colbert&title=Immunoproteasome+Assembly%3A+Cooperative+Incorporation+of+Interferon+%CE%B3+%28IFN-%CE%B3%29%E2%80%93Inducible+Subunits&doi=10.1084%2Fjem.187.1.97"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoproteasome assembly: cooperative incorporation of interferon Î³ (IFN-Î³)-inducible subunits</span></div><div class="casAuthors">Griffin, Thomas A.; Nandi, Dipankar; Cruz, Miguel; Fehling, Hans Jorg; Van Kaer, Luc; Monaco, John J.; Colbert, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-104</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">LMP2, LMP7, and MECL are interferon Î³-inducible catalytic subunits of vertebrate 20S proteasomes, which can replace constitutive catalytic subunits (delta, X, and Z, resp.) during proteasome biogenesis.  We demonstrate that MECL requires LMP2 for efficient incorporation into preproteasomes, and preproteasomes contg. LMP2 and MECL require LMP7 for efficient maturation.  The latter effect depends on the presequence of LMP7, but not on LMP7 catalytic activity.  This cooperative mechanism favors the assembly of homogeneous "immunoproteasomes" contg. all three inducible subunits, suggesting that these subunits act in concert to enhance proteasomal generation of major histocompatibility complex class I-binding peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7_OY37rmBw7Vg90H21EOLACvtfcHk0lhc62iXs7DawQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtV2nuw%253D%253D&md5=fbef51a79cab7dea3c81d59a8f2bce23</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1084%2Fjem.187.1.97&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.187.1.97%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DT.%2BA.%26aulast%3DNandi%26aufirst%3DD.%26aulast%3DCruz%26aufirst%3DM.%26aulast%3DFehling%26aufirst%3DH.%2BJ.%26aulast%3DKaer%26aufirst%3DL.%2BV.%26aulast%3DMonaco%26aufirst%3DJ.%2BJ.%26aulast%3DColbert%26aufirst%3DR.%2BA.%26atitle%3DImmunoproteasome%2520Assembly%253A%2520Cooperative%2520Incorporation%2520of%2520Interferon%2520%25CE%25B3%2520%2528IFN-%25CE%25B3%2529%25E2%2580%2593Inducible%2520Subunits%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1998%26volume%3D187%26issue%3D1%26spage%3D97%26epage%3D104%26doi%3D10.1084%2Fjem.187.1.97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rock, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, A. L.</span></span> <span> </span><span class="NLM_article-title">Degradation of Cell Proteins and the Generation of MHC Class I-Presented Peptides</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">739</span>â <span class="NLM_lpage">779</span>, <span class="refDoi">Â DOI: 10.1146/annurev.immunol.17.1.739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1146%2Fannurev.immunol.17.1.739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10358773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADyaK1MXjtVWmtLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=739-779&author=K.+L.+Rockauthor=A.+L.+Goldberg&title=Degradation+of+Cell+Proteins+and+the+Generation+of+MHC+Class+I-Presented+Peptides&doi=10.1146%2Fannurev.immunol.17.1.739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Degradation of cell proteins and the generation of MHC class I-presented peptides</span></div><div class="casAuthors">Rock, Kenneth L.; Goldberg, Alfred L.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">739-779</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with 211 refs.  Major histocompatibility complex (MHC) class I mols. display on the cell surface 8- to 10-residue peptides derived from the spectrum of proteins expressed in the cells.  By screening for non-self MHC-bound peptides, the immune system identifies and then can eliminate cells that are producing viral or mutant proteins.  These antigenic peptides are generated as side products in the continual turnover of intracellular proteins, which occurs primarily by the ubiquitin-proteasome pathway.  Most of the oligopeptides generated by the proteasome are further degraded by distinct endopeptidases and aminopeptidases into amino acids, which are used for new protein synthesis or energy prodn.  However, a fraction of these peptides escape complete destruction and after transport into the endoplasmic reticulum are bound by MHC class I mols. and delivered to the cell surface.  Herein we review recent discoveries about the proteolytic systems that degrade cell proteins, how the ubiquitin-proteasome pathway generates the peptides presented on MHC-class I mols., and how this process is stimulated by immune modifiers to enhance antigen presentation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLgUzwitMedLVg90H21EOLACvtfcHk0lhc62iXs7DawQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjtVWmtLY%253D&md5=ad0c421306a313b77d901d7c76c161d5</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.17.1.739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.17.1.739%26sid%3Dliteratum%253Aachs%26aulast%3DRock%26aufirst%3DK.%2BL.%26aulast%3DGoldberg%26aufirst%3DA.%2BL.%26atitle%3DDegradation%2520of%2520Cell%2520Proteins%2520and%2520the%2520Generation%2520of%2520MHC%2520Class%2520I-Presented%2520Peptides%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D1999%26volume%3D17%26spage%3D739%26epage%3D779%26doi%3D10.1146%2Fannurev.immunol.17.1.739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrington, D. A.</span>; <span class="NLM_string-name">Gregerson, D. S.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasomes</span>. In  <i>Progress in Molecular Biology and Translational Science</i>; The Proteasomal System in Aging and Disease; <span class="NLM_publisher-name">Elsevier</span>, <span class="NLM_year">2012</span>; Vol.  <span class="NLM_volume">109</span>, pp  <span class="NLM_fpage">75</span>â <span class="NLM_lpage">112</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2FB978-0-12-397863-9.00003-1" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=75-112&author=D.+A.+Ferrington&author=D.+S.+Gregerson&title=Progress+in+Molecular+Biology+and+Translational+Science"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-397863-9.00003-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-397863-9.00003-1%26sid%3Dliteratum%253Aachs%26aulast%3DFerrington%26aufirst%3DD.%2BA.%26atitle%3DImmunoproteasomes%26btitle%3DProgress%2520in%2520Molecular%2520Biology%2520and%2520Translational%2520Science%26pub%3DElsevier%26date%3D2012%26volume%3D109%26spage%3D75%26epage%3D112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husom, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, L. V.</span></span> <span> </span><span class="NLM_article-title">Altered Proteasome Structure, Function, and Oxidation in Aged Muscle</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">644</span>â <span class="NLM_lpage">646</span>, <span class="refDoi">Â DOI: 10.1096/fj.04-2578fje</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1096%2Ffj.04-2578fje" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=15677694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFaksLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=644-646&issue=6&author=D.+A.+Ferringtonauthor=A.+D.+Husomauthor=L.+V.+Thompson&title=Altered+Proteasome+Structure%2C+Function%2C+and+Oxidation+in+Aged+Muscle&doi=10.1096%2Ffj.04-2578fje"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Altered proteasome structure, function, and oxidation in aged muscle</span></div><div class="casAuthors">Ferrington, Deborah A.; Husom, Aimee D.; Thompson, LaDora V.</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">644-646, 10.1096/fj.04-2578fje</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">The proteasome is the main protease for degrading oxidized proteins.  We asked whether altered proteasome function contributes to the accumulation of oxidized muscle proteins with aging.  Proteasome structure, function, and oxidn. state were compared in young and aged F344BN rat fast-twitch skeletal muscle.  In proteasome-enriched homogenates from aged muscle, we obsd. a two- to threefold increase in content of the 20S proteasome that was due to a corresponding increase in immunoproteasome.  Content of the regulatory proteins, PA700 and PA28, relative to the 20S were reduced 75% with aging.  Upon addn. of exogenous PA700, there was a twofold increase in peptide hydrolysis in aged muscle, suggesting the endogenous content of PA700 is inadequate for complete activation of the 20S.  Measures of catalytic activity showed a 50% redn. in specific activity for proteasome-enriched homogenates with aging.  With purifn. of the 20S, proteasome specific activity was equiv. between ages, indicating that endogenous regulators inhibit proteasome in aged muscle.  Significantly less degrdn. of oxidized calmodulin by the 20S from aged muscle was obsd.  Partial rescue of activity for aged 20S by DTT implies oxidn. of functionally significant cysteines.  These results demonstrate significant age-related changes in proteasome structure, function, and oxidn. state that could inhibit removal of oxidized proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqlrtfBvUVAbVg90H21EOLACvtfcHk0lhc62iXs7DawQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFaksLo%253D&md5=abfbafaebec98c7e5bdc019997c92aaf</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1096%2Ffj.04-2578fje&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.04-2578fje%26sid%3Dliteratum%253Aachs%26aulast%3DFerrington%26aufirst%3DD.%2BA.%26aulast%3DHusom%26aufirst%3DA.%2BD.%26aulast%3DThompson%26aufirst%3DL.%2BV.%26atitle%3DAltered%2520Proteasome%2520Structure%252C%2520Function%252C%2520and%2520Oxidation%2520in%2520Aged%2520Muscle%26jtitle%3DFASEB%2520J.%26date%3D2005%26volume%3D19%26issue%3D6%26spage%3D644%26epage%3D646%26doi%3D10.1096%2Ffj.04-2578fje" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, J. B.</span></span> <span> </span><span class="NLM_article-title">The Immunoproteasome and Viral Infection: A Complex Regulator of Inflammation</span>. <i>Front. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">21</span>, <span class="refDoi">Â DOI: 10.3389/fmicb.2015.00021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.3389%2Ffmicb.2015.00021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=25688236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BC2Mrmt1Ohtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=21&author=M.+K.+McCarthyauthor=J.+B.+Weinberg&title=The+Immunoproteasome+and+Viral+Infection%3A+A+Complex+Regulator+of+Inflammation&doi=10.3389%2Ffmicb.2015.00021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The immunoproteasome and viral infection: a complex regulator of inflammation</span></div><div class="casAuthors">McCarthy Mary K; Weinberg Jason B</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in microbiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21</span>
        ISSN:<span class="NLM_cas:issn">1664-302X</span>.
    </div><div class="casAbstract">During viral infection, proper regulation of immune responses is necessary to ensure successful viral clearance with minimal host tissue damage.  Proteasomes play a crucial role in the generation of antigenic peptides for presentation on MHC class I molecules, and thus activation of CD8 T cells, as well as activation of the NF-ÎºB pathway.  A specialized type of proteasome called the immunoproteasome is constitutively expressed in hematopoietic cells and induced in non-immune cells during viral infection by interferon signaling.  The immunoproteasome regulates CD8 T cell responses to many viral epitopes during infection.  Accumulating evidence suggests that the immunoproteasome may also contribute to regulation of proinflammatory cytokine production, activation of the NF-ÎºB pathway, and management of oxidative stress.  Many viruses have mechanisms of interfering with immunoproteasome function, including prevention of transcriptional upregulation of immunoproteasome components as well as direct interaction of viral proteins with immunoproteasome subunits.  A better understanding of the role of the immunoproteasome in different cell types, tissues, and hosts has the potential to improve vaccine design and facilitate the development of effective treatment strategies for viral infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnTotxTDCg9YhLSh9fo81bfW6udTcc2ebZQNqbNGIvArntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mrmt1Ohtw%253D%253D&md5=dd375485b121e26a3a30afb4fa099640</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.3389%2Ffmicb.2015.00021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmicb.2015.00021%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarthy%26aufirst%3DM.%2BK.%26aulast%3DWeinberg%26aufirst%3DJ.%2BB.%26atitle%3DThe%2520Immunoproteasome%2520and%2520Viral%2520Infection%253A%2520A%2520Complex%2520Regulator%2520of%2520Inflammation%26jtitle%3DFront.%2520Microbiol.%26date%3D2015%26volume%3D6%26spage%3D21%26doi%3D10.3389%2Ffmicb.2015.00021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinnenhirn, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidtke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, A. L.</span></span> <span> </span><span class="NLM_article-title">Immuno- and Constitutive Proteasomes Do Not Differ in Their Abilities to Degrade Ubiquitinated Proteins</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>152</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1184</span>â <span class="NLM_lpage">1194</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2013.01.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.cell.2013.01.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=23452861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFCjs74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2013&pages=1184-1194&issue=5&author=J.+A.+Nathanauthor=V.+Spinnenhirnauthor=G.+Schmidtkeauthor=M.+Baslerauthor=M.+Groettrupauthor=A.+L.+Goldberg&title=Immuno-+and+Constitutive+Proteasomes+Do+Not+Differ+in+Their+Abilities+to+Degrade+Ubiquitinated+Proteins&doi=10.1016%2Fj.cell.2013.01.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Immuno- and Constitutive Proteasomes Do Not Differ in Their Abilities to Degrade Ubiquitinated Proteins</span></div><div class="casAuthors">Nathan, James A.; Spinnenhirn, Valentina; Schmidtke, Gunter; Basler, Michael; Groettrup, Marcus; Goldberg, Alfred L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1184-1194</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Immunoproteasomes are alternative forms of proteasomes that have an enhanced ability to generate antigenic peptides.  Recently, Seifert and colleagues reported surprising observations concerning the functions of immunoproteasomes and cellular responses to interferon-Î³: (1) that immunoproteasomes degrade ubiquitinated proteins faster than the constitutive proteasomes, (2) that polyubiquitin conjugates accumulate after interferon-Î³ treatment but then are preferentially degraded by immunoproteasomes, and (3) that immunoproteasome deficiency causes the formation of inclusions and more severe exptl. autoimmune encephalomyelitis (EAE).  In contrast, we find that polyubiquitin conjugates do not transiently accumulate following IFNÎ³-treatment and that immunoproteasomes do not prevent the formation of intracellular inclusions or protect against EAE.  Furthermore, purified 26S constitutive and immunoproteasomes bind ubiquitin conjugates similarly and degrade them at similar rates.  We conclude that, although immunoproteasomes can increase the generation of peptides appropriate for MHC class I presentation, they do not degrade ubiquitinated proteins more efficiently than constitutive particles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_g-gcOxyf8bVg90H21EOLACvtfcHk0ljTF9_SZq1j_Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFCjs74%253D&md5=2608171cbeae8ccdaaa665b6938245da</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2013.01.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2013.01.037%26sid%3Dliteratum%253Aachs%26aulast%3DNathan%26aufirst%3DJ.%2BA.%26aulast%3DSpinnenhirn%26aufirst%3DV.%26aulast%3DSchmidtke%26aufirst%3DG.%26aulast%3DBasler%26aufirst%3DM.%26aulast%3DGroettrup%26aufirst%3DM.%26aulast%3DGoldberg%26aufirst%3DA.%2BL.%26atitle%3DImmuno-%2520and%2520Constitutive%2520Proteasomes%2520Do%2520Not%2520Differ%2520in%2520Their%2520Abilities%2520to%2520Degrade%2520Ubiquitinated%2520Proteins%26jtitle%3DCell%26date%3D2013%26volume%3D152%26issue%3D5%26spage%3D1184%26epage%3D1194%26doi%3D10.1016%2Fj.cell.2013.01.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bialy, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebstein, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bech-Otschir, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voigt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchrÃ¶ter, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prozorovski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuckelkorn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aktas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kloetzel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, E.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasomes Preserve Protein Homeostasis upon Interferon-Induced Oxidative Stress</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>142</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">613</span>â <span class="NLM_lpage">624</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2010.07.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.cell.2010.07.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=20723761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVKhurzK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2010&pages=613-624&issue=4&author=U.+Seifertauthor=L.+P.+Bialyauthor=F.+Ebsteinauthor=D.+Bech-Otschirauthor=A.+Voigtauthor=F.+Schr%C3%B6terauthor=T.+Prozorovskiauthor=N.+Langeauthor=J.+Steffenauthor=M.+Riegerauthor=U.+Kuckelkornauthor=O.+Aktasauthor=P.+Kloetzelauthor=E.+Kruger&title=Immunoproteasomes+Preserve+Protein+Homeostasis+upon+Interferon-Induced+Oxidative+Stress&doi=10.1016%2Fj.cell.2010.07.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoproteasomes Preserve Protein Homeostasis upon Interferon-Induced Oxidative Stress</span></div><div class="casAuthors">Seifert, Ulrike; Bialy, Lukasz P.; Ebstein, Frederic; Bech-Otschir, Dawadschargal; Voigt, Antje; Schroeter, Friederike; Prozorovski, Timour; Lange, Nicole; Steffen, Janos; Rieger, Melanie; Kuckelkorn, Ulrike; Aktas, Orhan; Kloetzel, Peter-M.; Krueger, Elke</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">613-624</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Interferon (IFN)-induced immunoproteasomes (i-proteasomes) have been assocd. with improved processing of major histocompatibility complex (MHC) class I antigens.  Here, we show that i-proteasomes function to protect cell viability under conditions of IFN-induced oxidative stress.  IFNs trigger the prodn. of reactive oxygen species, which induce protein oxidn. and the formation of nascent, oxidant-damaged proteins.  We find that the ubiquitylation machinery is concomitantly upregulated in response to IFNs, functioning to target defective ribosomal products (DRiPs) for degrdn. by i-proteasomes.  I-proteasome-deficiency in cells and in murine inflammation models results in the formation of aggresome-like induced structures and increased sensitivity to apoptosis.  Efficient clearance of these aggregates by the enhanced proteolytic activity of the i-proteasome is important for the preservation of cell viability upon IFN-induced oxidative stress.  Our findings suggest that rather than having a specific role in the prodn. of class I antigens, i-proteasomes increase the peptide supply for antigen presentation as part of a more general role in the maintenance of protein homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrke2GhhFrNT7Vg90H21EOLACvtfcHk0lia5P4x_dNL7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVKhurzK&md5=62106a7fef1d42e8f50dc55f5938a097</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.07.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.07.036%26sid%3Dliteratum%253Aachs%26aulast%3DSeifert%26aufirst%3DU.%26aulast%3DBialy%26aufirst%3DL.%2BP.%26aulast%3DEbstein%26aufirst%3DF.%26aulast%3DBech-Otschir%26aufirst%3DD.%26aulast%3DVoigt%26aufirst%3DA.%26aulast%3DSchr%25C3%25B6ter%26aufirst%3DF.%26aulast%3DProzorovski%26aufirst%3DT.%26aulast%3DLange%26aufirst%3DN.%26aulast%3DSteffen%26aufirst%3DJ.%26aulast%3DRieger%26aufirst%3DM.%26aulast%3DKuckelkorn%26aufirst%3DU.%26aulast%3DAktas%26aufirst%3DO.%26aulast%3DKloetzel%26aufirst%3DP.%26aulast%3DKruger%26aufirst%3DE.%26atitle%3DImmunoproteasomes%2520Preserve%2520Protein%2520Homeostasis%2520upon%2520Interferon-Induced%2520Oxidative%2520Stress%26jtitle%3DCell%26date%3D2010%26volume%3D142%26issue%3D4%26spage%3D613%26epage%3D624%26doi%3D10.1016%2Fj.cell.2010.07.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caudill, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayarapu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elenich, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monaco, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colbert, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, T. A.</span></span> <span> </span><span class="NLM_article-title">T Cells Lacking Immunoproteasome Subunits MECL-1 and LMP7 Hyperproliferate in Response to Polyclonal Mitogens</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>176</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">4075</span>â <span class="NLM_lpage">4082</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.176.7.4075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.4049%2Fjimmunol.176.7.4075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=16547243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD28Xis1erurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2006&pages=4075-4082&issue=7&author=C.+M.+Caudillauthor=K.+Jayarapuauthor=L.+Elenichauthor=J.+J.+Monacoauthor=R.+A.+Colbertauthor=T.+A.+Griffin&title=T+Cells+Lacking+Immunoproteasome+Subunits+MECL-1+and+LMP7+Hyperproliferate+in+Response+to+Polyclonal+Mitogens&doi=10.4049%2Fjimmunol.176.7.4075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">T Cells Lacking Immunoproteasome Subunits MECL-1 and LMP7 Hyperproliferate in Response to Polyclonal Mitogens</span></div><div class="casAuthors">Caudill, Christy M.; Jayarapu, Krupakar; Elenich, Laura; Monaco, John J.; Colbert, Robert A.; Griffin, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4075-4082</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Immunoproteasomes comprise a specialized subset of proteasomes that is defined by the presence of three catalytic immunosubunits: LMP2, MECL-1 (LMP10), and LMP7.  Proteasomes in general serve many cellular functions through protein degrdn., whereas the specific function of immunoproteasomes has been thought to be largely, if not exclusively, optimization of MHC class I Ag processing.  In this report, the authors demonstrate that T cells from double knockout mice lacking two of the immunosubunits, MECL-1 and LMP7, hyperproliferate in vitro in response to various polyclonal mitogens.  The authors observe hyperproliferation of both CD4+ and CD8+ T cell subsets and demonstrate accelerated cell cycling.  The authors do not observe hyperproliferation of T cells lacking only one of these subunits, and thus hyperproliferation is independent of either reduced MHC class I expression in LMP7-/- mice or reduced CD8+ T cell nos. in MECL-1-/- mice.  The authors observe both of these latter two phenotypes in MECL-1/LMP7-/- mice, which indicates that they also are independent of each other.  Finally, the authors provide evidence of in vivo T cell dysfunction by demonstrating increased nos. of central memory phenotype CD8+ T cells in MECL-1/LMP7-/- mice.  In summary, this novel phenotype of hyperproliferation of T cells lacking both MECL-1 and LMP7 implicates a specific role for immunoproteasomes in T cell proliferation that is not obviously connected to MHC class I Ag processing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIbRrSmPrddLVg90H21EOLACvtfcHk0lia5P4x_dNL7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xis1erurg%253D&md5=71b5862b4630518f2594021c74593516</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.176.7.4075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.176.7.4075%26sid%3Dliteratum%253Aachs%26aulast%3DCaudill%26aufirst%3DC.%2BM.%26aulast%3DJayarapu%26aufirst%3DK.%26aulast%3DElenich%26aufirst%3DL.%26aulast%3DMonaco%26aufirst%3DJ.%2BJ.%26aulast%3DColbert%26aufirst%3DR.%2BA.%26aulast%3DGriffin%26aufirst%3DT.%2BA.%26atitle%3DT%2520Cells%2520Lacking%2520Immunoproteasome%2520Subunits%2520MECL-1%2520and%2520LMP7%2520Hyperproliferate%2520in%2520Response%2520to%2520Polyclonal%2520Mitogens%26jtitle%3DJ.%2520Immunol.%26date%3D2006%26volume%3D176%26issue%3D7%26spage%3D4075%26epage%3D4082%26doi%3D10.4049%2Fjimmunol.176.7.4075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, A. V.</span></span> <span> </span><span class="NLM_article-title">Identification of the Immunoproteasome as a Novel Regulator of Skeletal Muscle Differentiation</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">96</span>â <span class="NLM_lpage">109</span>, <span class="refDoi">Â DOI: 10.1128/MCB.00622-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1128%2FMCB.00622-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=24164898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtV2ntrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=96-109&issue=1&author=Z.+Cuiauthor=S.+M.+Hwangauthor=A.+V.+Gomes&title=Identification+of+the+Immunoproteasome+as+a+Novel+Regulator+of+Skeletal+Muscle+Differentiation&doi=10.1128%2FMCB.00622-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the immunoproteasome as a novel regulator of skeletal muscle differentiation</span></div><div class="casAuthors">Cui, Ziyou; Hwang, Soyun Michelle; Gomes, Aldrin V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">96-109, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">While many of the mol. details of myogenesis have been investigated extensively, the function of immunoproteasomes (i-proteasomes) in myogenic differentiation remains unknown.  We show here that the mRNA of i-proteasome subunits, the protein levels of constitutive and inducible proteasome subunits, and the proteolytic activities of the 20S and 26S proteasomes were significantly upregulated during differentiation of skeletal muscle C2C12 cells.  Knockdown of the i-proteasome catalytic subunit PSMB9 by short hairpin RNA (shRNA) decreased the expression of both PSMB9 and PSMB8 without affecting other catalytic subunits of the proteasome.  PSMB9 knockdown and the use of i-proteasome-specific inhibitors both decreased 26S proteasome activities and prevented C2C12 differentiation.  Inhibition of the i-proteasome also impaired human skeletal myoblast differentiation.  Suppression of the i-proteasome increased protein oxidn., and these oxidized proteins were found to be more susceptible to degrdn. by exogenous i-proteasomes.  Downregulation of the i-proteasome also increased proapoptotic proteins, including Bax, as well as cleaved caspase 3, cleaved caspase 9, and cleaved poly(ADP-ribose) polymerase (PARP), suggesting that impaired differentiation is likely to occur because of significantly increased apoptosis.  These results demonstrate for the first time that i-proteasomes, independent of constitutive proteasomes, are crit. for skeletal muscle differentiation of mouse C2C12 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph-e4EV27lx7Vg90H21EOLACvtfcHk0lje_8Aqo8qsNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtV2ntrk%253D&md5=30769ba401a971758ee7e3a0a3b39a3c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1128%2FMCB.00622-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00622-13%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DZ.%26aulast%3DHwang%26aufirst%3DS.%2BM.%26aulast%3DGomes%26aufirst%3DA.%2BV.%26atitle%3DIdentification%2520of%2520the%2520Immunoproteasome%2520as%2520a%2520Novel%2520Regulator%2520of%2520Skeletal%2520Muscle%2520Differentiation%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2014%26volume%3D34%26issue%3D1%26spage%3D96%26epage%3D109%26doi%3D10.1128%2FMCB.00622-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedja, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox-Talbot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrielson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Kaer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z. P.</span></span> <span> </span><span class="NLM_article-title">Evidence for a Role of Immunoproteasomes in Regulating Cardiac Muscle Mass in Diabetic Mice</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">5</span>â <span class="NLM_lpage">15</span>, <span class="refDoi">Â DOI: 10.1016/j.yjmcc.2010.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.yjmcc.2010.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=20153750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmslCntb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=5-15&issue=1&author=L.+Zuauthor=D.+Bedjaauthor=K.+Fox-Talbotauthor=K.+L.+Gabrielsonauthor=L.+Van+Kaerauthor=L.+C.+Beckerauthor=Z.+P.+Cai&title=Evidence+for+a+Role+of+Immunoproteasomes+in+Regulating+Cardiac+Muscle+Mass+in+Diabetic+Mice&doi=10.1016%2Fj.yjmcc.2010.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for a role of immunoproteasomes in regulating cardiac muscle mass in diabetic mice</span></div><div class="casAuthors">Zu, Lingyun; Bedja, Djahida; Fox-Talbot, Karen; Gabrielson, Kathleen L.; Van Kaer, Luc; Becker, Lewis C.; Cai, Zheqing P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-15</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The ubiquitin-proteasome system plays an important role in regulating muscle mass.  Inducible immunoproteasome subunits LMP-2 and LMP-7 are constitutively expressed in the heart; however, their regulation and functions are poorly understood.  We here investigated the hypothesis that immunoproteasomes regulate cardiac muscle mass in diabetic mice.  Type 1 diabetes was induced in wildtype mice by streptozotocin.  After hyperglycemia developed, insulin and the proteasome inhibitor epoxomicin were used to treat diabetic mice for 6 wk.  Isolated mouse hearts were perfused with control or high glucose soln.  Catalytic proteasome Î²-subunits and proteolytic activities were analyzed in the heart by immunoblotting and fluorogenic peptide degrdn. assays, resp.  Insulin and epoxomicin blocked loss of heart wt. and improved cardiac function in diabetic mice.  LMP-7 and its corresponding chymotryptic-like proteasome activity were increased in diabetic hearts and high glucose-treated hearts.  Myosin heavy chain protein was decreased in diabetic hearts, which was largely reversed by epoxomicin.  High glucose decreased LMP-2 protein levels in perfused hearts.  In diabetic hearts, LMP-2 expression was downregulated whereas expression of the phosphatase and tensin homolog deleted on chromosome ten (PTEN) and the muscle atrophy F-box were upregulated.  Moreover, mice with muscle-specific knockout of PTEN gene demonstrated increased cardiac muscle mass, while mice with LMP-2 deficiency demonstrated PTEN accumulation, muscle mass loss, and contractile impairment in the heart.  Therefore, we concluded that high glucose regulates immunoproteasome subunits and modifies proteasome activities in the heart, and that dysregulated immunoproteasome subunits may mediate loss of cardiac muscle mass in exptl. diabetic mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbPwnq9tvvI7Vg90H21EOLACvtfcHk0lje_8Aqo8qsNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmslCntb4%253D&md5=7437db478efd1dea873068a80a3ceb40</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2010.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2010.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DZu%26aufirst%3DL.%26aulast%3DBedja%26aufirst%3DD.%26aulast%3DFox-Talbot%26aufirst%3DK.%26aulast%3DGabrielson%26aufirst%3DK.%2BL.%26aulast%3DVan%2BKaer%26aufirst%3DL.%26aulast%3DBecker%26aufirst%3DL.%2BC.%26aulast%3DCai%26aufirst%3DZ.%2BP.%26atitle%3DEvidence%2520for%2520a%2520Role%2520of%2520Immunoproteasomes%2520in%2520Regulating%2520Cardiac%2520Muscle%2520Mass%2520in%2520Diabetic%2520Mice%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2010%26volume%3D49%26issue%3D1%26spage%3D5%26epage%3D15%26doi%3D10.1016%2Fj.yjmcc.2010.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Verteuil, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouette, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, M.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LavallÃ©e, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trofimov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaucher, Ã.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perreault, C.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasomes Shape the Transcriptome and Regulate the Function of Dendritic Cells</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>193</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1121</span>â <span class="NLM_lpage">1132</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.1400871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.4049%2Fjimmunol.1400871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=24958905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyqs77E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2014&pages=1121-1132&issue=3&author=D.+A.+de%0AVerteuilauthor=A.+Rouetteauthor=M.-P.+Hardyauthor=S.+Lavall%C3%A9eauthor=A.+Trofimovauthor=%C3%89.+Gaucherauthor=C.+Perreault&title=Immunoproteasomes+Shape+the+Transcriptome+and+Regulate+the+Function+of+Dendritic+Cells&doi=10.4049%2Fjimmunol.1400871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoproteasomes Shape the Transcriptome and Regulate the Function of Dendritic Cells</span></div><div class="casAuthors">de Verteuil, Danielle A.; Rouette, Alexandre; Hardy, Marie-Pierre; Lavallee, Stephanie; Trofimov, Assya; Gaucher, Etienne; Perreault, Claude</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1121-1132</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">By regulating protein degrdn., constitutive proteasomes (CPs) control practically all cellular functions.  In addn. to CPs, vertebrates express immunoproteasomes (IPs).  The major nonredundant role ascribed to IPs is their enhanced ability to generate antigenic peptides.  We report that CPs and IPs differentially regulate the expression of >8000 transcripts in maturing mouse dendritic cells (DCs) via regulation of signaling pathways such as IFN regulatory factors, STATs, and NF-ÎºB.  IPs regulate the transcription of many mRNAs and maturation of a few of them.  Moreover, even when engineered to present optimal amts. of antigenic peptide, IP-deficient DCs are inefficient for in vivo T cell priming.  Our study shows that the role of IPs in DCs is not limited to Ag processing and reveals a major nonredundant role for IPs in transcription regulation.  The dramatic effect of IPs on the transcriptional landscape could explain the various immune and nonimmune phenotypes obsd. in vertebrates with IP deficiency or mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquYPmj1pi-trVg90H21EOLACvtfcHk0lje_8Aqo8qsNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyqs77E&md5=8a3ffd577e1bcafdc4a5f54dd0a27a5c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1400871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1400871%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BVerteuil%26aufirst%3DD.%2BA.%26aulast%3DRouette%26aufirst%3DA.%26aulast%3DHardy%26aufirst%3DM.-P.%26aulast%3DLavall%25C3%25A9e%26aufirst%3DS.%26aulast%3DTrofimov%26aufirst%3DA.%26aulast%3DGaucher%26aufirst%3D%25C3%2589.%26aulast%3DPerreault%26aufirst%3DC.%26atitle%3DImmunoproteasomes%2520Shape%2520the%2520Transcriptome%2520and%2520Regulate%2520the%2520Function%2520of%2520Dendritic%2520Cells%26jtitle%3DJ.%2520Immunol.%26date%3D2014%26volume%3D193%26issue%3D3%26spage%3D1121%26epage%3D1132%26doi%3D10.4049%2Fjimmunol.1400871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rouette, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trofimov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LavallÃ©e, V.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâAngelo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HÃ©bert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauvageau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perreault, C.</span></span> <span> </span><span class="NLM_article-title">Expression of Immunoproteasome Genes Is Regulated by Cell-Intrinsic and -Extrinsic Factors in Human Cancers</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">34019</span>, <span class="refDoi">Â DOI: 10.1038/srep34019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fsrep34019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=27659694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFOnurvP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=34019&author=A.+Rouetteauthor=A.+Trofimovauthor=D.+Haberlauthor=G.+Boucherauthor=V.-P.+Lavall%C3%A9eauthor=G.+D%E2%80%99Angeloauthor=J.+H%C3%A9bertauthor=G.+Sauvageauauthor=S.+Lemieuxauthor=C.+Perreault&title=Expression+of+Immunoproteasome+Genes+Is+Regulated+by+Cell-Intrinsic+and+-Extrinsic+Factors+in+Human+Cancers&doi=10.1038%2Fsrep34019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of immunoproteasome genes is regulated by cell-intrinsic and -extrinsic factors in human cancers</span></div><div class="casAuthors">Rouette, Alexandre; Trofimov, Assya; Haberl, David; Boucher, Genevieve; Lavallee, Vincent-Philippe; D'Angelo, Giovanni; Hebert, Josee; Sauvageau, Guy; Lemieux, Sebastien; Perreault, Claude</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34019</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Based on transcriptomic analyses of thousands of samples from The Cancer Genome Atlas, we report that expression of constitutive proteasome (CP) genes (PSMB5, PSMB6, PSMB7) and immunoproteasome (IP) genes (PSMB8, PSMB9, PSMB10) is increased in most cancer types.  In breast cancer, expression of IP genes was detd. by the abundance of tumor infiltrating lymphocytes and high expression of IP genes was assocd. with longer survival.  In contrast, IP upregulation in acute myeloid leukemia (AML) was a cell-intrinsic feature that was not assocd. with longer survival.  Expression of IP genes in AML was IFN-independent, correlated with the methylation status of IP genes, and was particularly high in AML with an M5 phenotype and/or MLL rearrangement.  Notably, PSMB8 inhibition led to accumulation of polyubiquitinated proteins and cell death in IPhigh but not IPlow AML cells.  Co-clustering anal. revealed that genes correlated with IP subunits in non-M5 AMLs were primarily implicated in immune processes.  However, in M5 AML, IP genes were primarily co-regulated with genes involved in cell metab. and proliferation, mitochondrial activity and stress responses.  We conclude that M5 AML cells can upregulate IP genes in a cell-intrinsic manner in order to resist cell stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnIk53mYYeT7Vg90H21EOLACvtfcHk0ljsvZBJKnSnpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFOnurvP&md5=bf5b5134793a46808c7f66d9be97e8bb</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fsrep34019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep34019%26sid%3Dliteratum%253Aachs%26aulast%3DRouette%26aufirst%3DA.%26aulast%3DTrofimov%26aufirst%3DA.%26aulast%3DHaberl%26aufirst%3DD.%26aulast%3DBoucher%26aufirst%3DG.%26aulast%3DLavall%25C3%25A9e%26aufirst%3DV.-P.%26aulast%3DD%25E2%2580%2599Angelo%26aufirst%3DG.%26aulast%3DH%25C3%25A9bert%26aufirst%3DJ.%26aulast%3DSauvageau%26aufirst%3DG.%26aulast%3DLemieux%26aufirst%3DS.%26aulast%3DPerreault%26aufirst%3DC.%26atitle%3DExpression%2520of%2520Immunoproteasome%2520Genes%2520Is%2520Regulated%2520by%2520Cell-Intrinsic%2520and%2520-Extrinsic%2520Factors%2520in%2520Human%2520Cancers%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D34019%26doi%3D10.1038%2Fsrep34019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span> <span> </span><span class="NLM_article-title">The Immunoproteasome: A Novel Drug Target for Autoimmune Diseases</span>. <i>Clin. Exp. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">S74</span>â <span class="NLM_lpage">S79</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=26458097" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=S74-S79&author=M.+Baslerauthor=S.+Mundtauthor=A.+Bitzerauthor=C.+Schmidtauthor=M.+Groettrup&title=The+Immunoproteasome%3A+A+Novel+Drug+Target+for+Autoimmune+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBasler%26aufirst%3DM.%26aulast%3DMundt%26aufirst%3DS.%26aulast%3DBitzer%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DC.%26aulast%3DGroettrup%26aufirst%3DM.%26atitle%3DThe%2520Immunoproteasome%253A%2520A%2520Novel%2520Drug%2520Target%2520for%2520Autoimmune%2520Diseases%26jtitle%3DClin.%2520Exp.%2520Rheumatol.%26date%3D2015%26volume%3D33%26spage%3DS74%26epage%3DS79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnston-Carey, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomatto, L. C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, K. J. A.</span></span> <span> </span><span class="NLM_article-title">The Immunoproteasome in Oxidative Stress, Aging, and Disease</span>. <i>Crit. Rev. Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">268</span>â <span class="NLM_lpage">281</span>, <span class="refDoi">Â DOI: 10.3109/10409238.2016.1172554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.3109%2F10409238.2016.1172554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFyktb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2016&pages=268-281&issue=4&author=H.+K.+Johnston-Careyauthor=L.+C.+D.+Pomattoauthor=K.+J.+A.+Davies&title=The+Immunoproteasome+in+Oxidative+Stress%2C+Aging%2C+and+Disease&doi=10.3109%2F10409238.2016.1172554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The Immunoproteasome in oxidative stress, aging, and disease</span></div><div class="casAuthors">Johnston-Carey, Helen K.; Pomatto, Laura C. D.; Davies, Kelvin J. A.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">268-281</span>CODEN:
                <span class="NLM_cas:coden">CRBBEJ</span>;
        ISSN:<span class="NLM_cas:issn">1040-9238</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The Immunoproteasome has traditionally been viewed primarily for its role in peptide prodn. for antigen presentation by the major histocompatibility complex, which is crit. for immunity.  However, recent research has shown that the Immunoproteasome is also very important for the clearance of oxidatively damaged proteins in homeostasis, and esp. during stress and disease.  The importance of the Immunoproteasome in protein degrdn. has become more evident as diseases characterized by protein aggregates have also been linked to deficiencies of the Immunoproteasome.  Addnl., there are now diseases defined by mutations or polymorphisms within Immunoproteasome-specific subunit genes, further suggesting its crucial role in cytokine signaling and protein homeostasis (or "proteostasis").  The purpose of this review is to highlight our growing understanding of the importance of the Immunoproteasome in the management of protein quality control, and the detrimental impact of its dysregulation during disease and aging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJWYBMP5NXIbVg90H21EOLACvtfcHk0ljsvZBJKnSnpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFyktb4%253D&md5=a529c3034e4284776f5f57e5c8af5360</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.3109%2F10409238.2016.1172554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10409238.2016.1172554%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston-Carey%26aufirst%3DH.%2BK.%26aulast%3DPomatto%26aufirst%3DL.%2BC.%2BD.%26aulast%3DDavies%26aufirst%3DK.%2BJ.%2BA.%26atitle%3DThe%2520Immunoproteasome%2520in%2520Oxidative%2520Stress%252C%2520Aging%252C%2520and%2520Disease%26jtitle%3DCrit.%2520Rev.%2520Biochem.%2520Mol.%2520Biol.%26date%3D2016%26volume%3D51%26issue%3D4%26spage%3D268%26epage%3D281%26doi%3D10.3109%2F10409238.2016.1172554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kisselev, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, A. L.</span></span> <span> </span><span class="NLM_article-title">Monitoring Activity and Inhibition of 26S Proteasomes with Fluorogenic Peptide Substrates</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>398</i></span>,  <span class="NLM_fpage">364</span>â <span class="NLM_lpage">378</span>, <span class="refDoi">Â DOI: 10.1016/S0076-6879(05)98030-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2FS0076-6879%2805%2998030-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=16275343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD28Xot1ajs7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=398&publication_year=2005&pages=364-378&author=A.+F.+Kisselevauthor=A.+L.+Goldberg&title=Monitoring+Activity+and+Inhibition+of+26S+Proteasomes+with+Fluorogenic+Peptide+Substrates&doi=10.1016%2FS0076-6879%2805%2998030-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates</span></div><div class="casAuthors">Kisselev, Alexei F.; Goldberg, Alfred L.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">398</span>
        (<span class="NLM_cas:issue">Ubiquitin and Protein Degradation, Part A</span>),
    <span class="NLM_cas:pages">364-378</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Eukaryotic proteasomes have three different types of active sites: two chymotrypsin-like, two trypsin-like, and two caspase-like (also termed PGPH) sites that differ in their specificity toward model fluorogenic pep-tide substrates.  The chymotrypsin-like site is often considered the most important in protein breakdown, and the only one whose activity has to be assayed in order to assess the capacity of proteasomes to degrade proteins.  However, recent results indicate that either trypsin-like or caspase-like sites also have to be inhibited in order to reduce breakdown of most proteins by 50%.  Thus, the activities of all three types of active sites have to be assayed in order to evaluate the state of the proteasome inside cells or the potency of inhibitors.  This chapter describes assays of purified 26S proteasomes with fluorogenic peptide substrates, including new substrates of the caspase- and trypsin-like sites.  A novel assay of proteasome activity in crude cell exts. that allows rapid evaluation of the state of the proteasomes in cells treated with inhibitors is also described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMjuxD75BZIrVg90H21EOLACvtfcHk0lhSxsS1Ocm-mQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xot1ajs7g%253D&md5=bd4655e6fe62a90bcd847af5cb80b1d6</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2805%2998030-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252805%252998030-0%26sid%3Dliteratum%253Aachs%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26aulast%3DGoldberg%26aufirst%3DA.%2BL.%26atitle%3DMonitoring%2520Activity%2520and%2520Inhibition%2520of%252026S%2520Proteasomes%2520with%2520Fluorogenic%2520Peptide%2520Substrates%26jtitle%3DMethods%2520Enzymol.%26date%3D2005%26volume%3D398%26spage%3D364%26epage%3D378%26doi%3D10.1016%2FS0076-6879%2805%2998030-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Greca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arastu-Kapur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caiazza, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cimermancic, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchholz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderl, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravalin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDonoghue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craik, C.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasome Functions Explained by Divergence in Cleavage Specificity and Regulation</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">e27364</span>, <span class="refDoi">Â DOI: 10.7554/eLife.27364</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.7554%2FeLife.27364" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=29182146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitl2ktLvO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=e27364&author=M.+B.+Winterauthor=F.+La+Grecaauthor=S.+Arastu-Kapurauthor=F.+Caiazzaauthor=P.+Cimermancicauthor=T.+J.+Buchholzauthor=J.+L.+Anderlauthor=M.+Ravalinauthor=M.+F.+Bohnauthor=A.+Saliauthor=A.+O%E2%80%99Donoghueauthor=C.+Craik&title=Immunoproteasome+Functions+Explained+by+Divergence+in+Cleavage+Specificity+and+Regulation&doi=10.7554%2FeLife.27364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoproteasome functions explained by divergence in cleavage specificity and regulation</span></div><div class="casAuthors">Winter, Michael B.; La Greca, Florencia; Arastu-Kapur, Shirin; Caiazza, Francesco; Cimermancic, Peter; Buchholz, Tonia J.; Anderl, Janet L.; Ravalin, Matthew; Bohn, Markus F.; Sali, Andrej; O'Donoghue, Anthony J.; Craik, Charles S.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e27364/1-e27364/23</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">The immunoproteasome (iP) has been proposed to perform specialized roles in MHC class I antigen presentation, cytokine modulation, and T cell differentiation and has emerged as a promising therapeutic target for autoimmune disorders and cancer.  However, divergence in function between the iP and the constitutive proteasome (cP) has been unclear.  A global peptide library-based screening strategy revealed that the proteasomes have overlapping but distinct substrate specificities.  Differing iP specificity alters the quantity of prodn. of certain MHC I epitopes but does not appear to be preferentially suited for antigen presentation.  Furthermore, iP specificity was found to have likely arisen through genetic drift from the ancestral cP.  Specificity differences were exploited to develop isoform-selective substrates.  Cellular profiling using these substrates revealed that divergence in regulation of the iP balances its relative contribution to proteasome capacity in immune cells, resulting in selective recovery from inhibition.  These findings have implications for iP-targeted therapeutic development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoArGjvv0tV5rVg90H21EOLACvtfcHk0lhSxsS1Ocm-mQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitl2ktLvO&md5=b0a8704ed4b007e14514769d134b5bab</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.7554%2FeLife.27364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.27364%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DM.%2BB.%26aulast%3DLa%2BGreca%26aufirst%3DF.%26aulast%3DArastu-Kapur%26aufirst%3DS.%26aulast%3DCaiazza%26aufirst%3DF.%26aulast%3DCimermancic%26aufirst%3DP.%26aulast%3DBuchholz%26aufirst%3DT.%2BJ.%26aulast%3DAnderl%26aufirst%3DJ.%2BL.%26aulast%3DRavalin%26aufirst%3DM.%26aulast%3DBohn%26aufirst%3DM.%2BF.%26aulast%3DSali%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Donoghue%26aufirst%3DA.%26aulast%3DCraik%26aufirst%3DC.%26atitle%3DImmunoproteasome%2520Functions%2520Explained%2520by%2520Divergence%2520in%2520Cleavage%2520Specificity%2520and%2520Regulation%26jtitle%3DeLife%26date%3D2017%26volume%3D6%26spage%3De27364%26doi%3D10.7554%2FeLife.27364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattarai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">H727 Cells Are Inherently Resistant to the Proteasome Inhibitor Carfilzomib, yet Require Proteasome Activity for Cell Survival and Growth</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">4089</span>, <span class="refDoi">Â DOI: 10.1038/s41598-019-40635-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fs41598-019-40635-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=30858500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BB3cbivVGktw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=4089&issue=1&author=M.+J.+Leeauthor=Z.+Millerauthor=J.+E.+Parkauthor=D.+Bhattaraiauthor=W.+Leeauthor=K.+B.+Kim&title=H727+Cells+Are+Inherently+Resistant+to+the+Proteasome+Inhibitor+Carfilzomib%2C+yet+Require+Proteasome+Activity+for+Cell+Survival+and+Growth&doi=10.1038%2Fs41598-019-40635-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth</span></div><div class="casAuthors">Lee Min Jae; Miller Zachary; Bhattarai Deepak; Kim Kyung Bo; Park Ji Eun; Lee Wooin</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4089</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The second-in-class proteasome inhibitor (PI) carfilzomib (Kyprolis, Cfz) has contributed to a substantial advancement in multiple myeloma treatment by improving patient survival and quality of life.  A considerable portion of patients however display intrinsic resistance to Cfz.  Our mechanistic understanding of intrinsic Cfz resistance is limited due to a lack of suitable cell-based models.  We report that H727 human bronchial carcinoid cells are inherently resistant to Cfz, yet susceptible to other PIs and inhibitors targeting upstream components of the ubiquitin-proteasome system (UPS).  These results indicate that H727 cells remain dependent on the UPS for cell survival and growth despite harboring intrinsic resistance to Cfz.  Alterations in the composition of proteasome catalytic subunits via interferon-Î³ treatment or siRNA knockdown results in sensitization of H727 cells to Cfz.  We postulate that a potential link may exist between the composition of proteasome catalytic subunits and the cellular response to Cfz.  Overall, H727 cells may serve as a useful cell-based model for de novo Cfz resistance and our results suggest previously unexplored mechanisms of de novo PI resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHLlRY4-lmF3T4ugvCDgnZfW6udTcc2eZDJX7XO1YSIrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbivVGktw%253D%253D&md5=2eac99d394dd7fa2e1fe2922cd32b87f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-40635-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-40635-1%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%2BJ.%26aulast%3DMiller%26aufirst%3DZ.%26aulast%3DPark%26aufirst%3DJ.%2BE.%26aulast%3DBhattarai%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DH727%2520Cells%2520Are%2520Inherently%2520Resistant%2520to%2520the%2520Proteasome%2520Inhibitor%2520Carfilzomib%252C%2520yet%2520Require%2520Proteasome%2520Activity%2520for%2520Cell%2520Survival%2520and%2520Growth%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26issue%3D1%26spage%3D4089%26doi%3D10.1038%2Fs41598-019-40635-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berkers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdoes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiebiger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploegh, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galardy, P. J.</span></span> <span> </span><span class="NLM_article-title">Activity Probe for in Vivo Profiling of the Specificity of Proteasome Inhibitor Bortezomib</span>. <i>Nat. Methods</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">357</span>, <span class="refDoi">Â DOI: 10.1038/nmeth759</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fnmeth759" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=15846363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsVyls70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=357&issue=5&author=C.+R.+Berkersauthor=M.+Verdoesauthor=E.+Lichtmanauthor=E.+Fiebigerauthor=B.+M.+Kesslerauthor=K.+C.+Andersonauthor=H.+L.+Ploeghauthor=H.+Ovaaauthor=P.+J.+Galardy&title=Activity+Probe+for+in+Vivo+Profiling+of+the+Specificity+of+Proteasome+Inhibitor+Bortezomib&doi=10.1038%2Fnmeth759"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib</span></div><div class="casAuthors">Berkers, Celia R.; Verdoes, Martijn; Lichtman, Eben; Fiebiger, Edda; Kessler, Benedikt M.; Anderson, Kenneth C.; Ploegh, Hidde L.; Ovaa, Huib; Galardy, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Methods</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">357-362</span>CODEN:
                <span class="NLM_cas:coden">NMAEA3</span>;
        ISSN:<span class="NLM_cas:issn">1548-7091</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Proteasome inhibitors, such as the dipeptide boronic acid bortezomib, are emerging as important tools in the treatment of the fatal hematol. malignancy multiple myeloma.  Despite the recent US Food and Drug Administration approval of bortezomib (PS341, Velcade) for the treatment of refractory multiple myeloma, many of the basic pharmacol. parameters of bortezomib and its mode of action on myeloma cells remain to be detd.  We describe the synthesis and use of a cell-permeant active site-directed probe, which allows profiling of proteasomal activities in living cells.  When we compared proteasome activity patterns in cultured cells and crude cell exts. with this probe, we obsd. substantial differences, stressing the importance for bioassays compatible with live cells to ensure accuracy of such measurements.  Using this probe, we investigated the in vivo subunit specificities of bortezomib and another inhibitor, MG132.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomPqiElUEWtLVg90H21EOLACvtfcHk0lh8R-GHz0_ncA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsVyls70%253D&md5=5055e0a80ecfd5ea8272e6b38f0c73bc</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnmeth759&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmeth759%26sid%3Dliteratum%253Aachs%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3DVerdoes%26aufirst%3DM.%26aulast%3DLichtman%26aufirst%3DE.%26aulast%3DFiebiger%26aufirst%3DE.%26aulast%3DKessler%26aufirst%3DB.%2BM.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DPloegh%26aufirst%3DH.%2BL.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DGalardy%26aufirst%3DP.%2BJ.%26atitle%3DActivity%2520Probe%2520for%2520in%2520Vivo%2520Profiling%2520of%2520the%2520Specificity%2520of%2520Proteasome%2520Inhibitor%2520Bortezomib%26jtitle%3DNat.%2520Methods%26date%3D2005%26volume%3D2%26issue%3D5%26spage%3D357%26doi%3D10.1038%2Fnmeth759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verdoes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florea, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menendez-Benito, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynard, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Linden, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Nieuwendijk, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Leeuwen, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groothuis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeuwenburgh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neefjes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Marel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dantuma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H.</span></span> <span> </span><span class="NLM_article-title">A Fluorescent Broad-Spectrum Proteasome Inhibitor for Labeling Proteasomes In Vitro and In Vivo</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1217</span>â <span class="NLM_lpage">1226</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2006.09.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.chembiol.2006.09.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=17114003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Cis7fN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=1217-1226&issue=11&author=M.+Verdoesauthor=B.+I.+Floreaauthor=V.+Menendez-Benitoauthor=C.+J.+Maynardauthor=M.+D.+Witteauthor=W.+A.+van+der+Lindenauthor=A.+M.+van+den+Nieuwendijkauthor=T.+Hofmannauthor=C.+R.+Berkersauthor=F.+W.+van+Leeuwenauthor=T.+Groothuisauthor=M.+Leeuwenburghauthor=H.+Ovaaauthor=J.+Neefjesauthor=D.+Filippovauthor=G.+van+der+Marelauthor=N.+Dantumaauthor=H.+Overkleeft&title=A+Fluorescent+Broad-Spectrum+Proteasome+Inhibitor+for+Labeling+Proteasomes+In+Vitro+and+In+Vivo&doi=10.1016%2Fj.chembiol.2006.09.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">A Fluorescent Broad-Spectrum Proteasome Inhibitor for Labeling Proteasomes In Vitro and In Vivo</span></div><div class="casAuthors">Verdoes, Martijn; Florea, Bogdan I.; Menendez-Benito, Victoria; Maynard, Christa J.; Witte, Martin D.; van der Linden, Wouter A.; van den Nieuwendijk, Adrianus M. C. H.; Hofmann, Tanja; Berkers, Celia R.; van Leeuwen, Fijs W. B.; Groothuis, Tom A.; Leeuwenburgh, Michiel A.; Ovaa, Huib; Neefjes, Jacques J.; Filippov, Dmitri V.; van der Marel, Gijs A.; Dantuma, Nico P.; Overkleeft, Herman S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1217-1226</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The proteasome is an essential evolutionary conserved protease involved in many regulatory systems.  Here, the authors describe the synthesis and characterization of the activity-based, fluorescent, and cell-permeable inhibitor Bodipy TMR-Ahx3L3VS (MV151), which specifically targets all active subunits of the proteasome and immunoproteasome in living cells, allowing for rapid and sensitive in-gel detection.  The inhibition profile of a panel of commonly used proteasome inhibitors could be readily detd. by MV151 labeling.  Administration of MV151 to mice allowed for in vivo labeling of proteasomes, which correlated with inhibition of proteasomal degrdn. in the affected tissues.  This probe can be used for many applications ranging from clin. profiling of proteasome activity, to biochem. anal. of subunit specificity of inhibitors, and to cell biol. anal. of the proteasome function and dynamics in living cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMZq52j_0-wLVg90H21EOLACvtfcHk0lh8R-GHz0_ncA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Cis7fN&md5=95b57d47d477020254a0fb2bd24fef87</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2006.09.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2006.09.013%26sid%3Dliteratum%253Aachs%26aulast%3DVerdoes%26aufirst%3DM.%26aulast%3DFlorea%26aufirst%3DB.%2BI.%26aulast%3DMenendez-Benito%26aufirst%3DV.%26aulast%3DMaynard%26aufirst%3DC.%2BJ.%26aulast%3DWitte%26aufirst%3DM.%2BD.%26aulast%3Dvan%2Bder%2BLinden%26aufirst%3DW.%2BA.%26aulast%3Dvan%2Bden%2BNieuwendijk%26aufirst%3DA.%2BM.%26aulast%3DHofmann%26aufirst%3DT.%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3Dvan%2BLeeuwen%26aufirst%3DF.%2BW.%26aulast%3DGroothuis%26aufirst%3DT.%26aulast%3DLeeuwenburgh%26aufirst%3DM.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DNeefjes%26aufirst%3DJ.%26aulast%3DFilippov%26aufirst%3DD.%26aulast%3Dvan%2Bder%2BMarel%26aufirst%3DG.%26aulast%3DDantuma%26aufirst%3DN.%26aulast%3DOverkleeft%26aufirst%3DH.%26atitle%3DA%2520Fluorescent%2520Broad-Spectrum%2520Proteasome%2520Inhibitor%2520for%2520Labeling%2520Proteasomes%2520In%2520Vitro%2520and%2520In%2520Vivo%26jtitle%3DChem.%2520Biol.%26date%3D2006%26volume%3D13%26issue%3D11%26spage%3D1217%26epage%3D1226%26doi%3D10.1016%2Fj.chembiol.2006.09.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berkers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Leeuwen, F. W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groothuis, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peperzak, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Tilburg, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borst, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neefjes, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span> <span> </span><span class="NLM_article-title">Profiling Proteasome Activity in Tissue with Fluorescent Probes</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">739</span>â <span class="NLM_lpage">748</span>, <span class="refDoi">Â DOI: 10.1021/mp0700256</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp0700256" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpt1GisbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=739-748&issue=5&author=C.+R.+Berkersauthor=F.+W.+B.+van+Leeuwenauthor=T.+A.+Groothuisauthor=V.+Peperzakauthor=E.+W.+van+Tilburgauthor=J.+Borstauthor=J.+J.+Neefjesauthor=H.+Ovaa&title=Profiling+Proteasome+Activity+in+Tissue+with+Fluorescent+Probes&doi=10.1021%2Fmp0700256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Profiling Proteasome Activity in Tissue with Fluorescent Probes</span></div><div class="casAuthors">Berkers, Celia R.; van Leeuwen, Fijs W. B.; Groothuis, Tom A.; Peperzak, Victor; van Tilburg, Erica W.; Borst, Jannie; Neefjes, Jacques J.; Ovaa, Huib</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">739-748</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">With proteasome inhibitors in use in the clinic for the treatment of multiple myeloma and with clin. trials in progress investigating the treatment of a variety of hematol. and solid malignancies, accurate methods that allow profiling of proteasome inhibitor specificity and efficacy in patients are in demand.  Here, we describe the development, full biochem. validation, and comparison of fluorescent proteasome activity reporters that can be used to profile proteasome activities in living cells with high sensitivity.  Seven of the synthesized probes tested label proteasomes in lysates, although the fluorescent dye used affects their specificity.  Two differentially labeled probes tested are suitable for studying proteasome activity in living cells by gel-based assays, by confocal laser scanning microscopy, and by flow cytometry.  We established methods using these fluorescent reporters to profile proteasome activity in different mouse tissues, carefully avoiding postlysis artifacts, and we show that proteasome subunit activity is regulated in an organ-specific manner.  The techniques described here could be used to study in vivo pharmacol. properties of proteasome inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdW9Lx7lRHTbVg90H21EOLACvtfcHk0lifEKdGBQ5oig"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpt1GisbY%253D&md5=78b8f398f2060e995e6382ce1ff7caca</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fmp0700256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp0700256%26sid%3Dliteratum%253Aachs%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3Dvan%2BLeeuwen%26aufirst%3DF.%2BW.%2BB.%26aulast%3DGroothuis%26aufirst%3DT.%2BA.%26aulast%3DPeperzak%26aufirst%3DV.%26aulast%3Dvan%2BTilburg%26aufirst%3DE.%2BW.%26aulast%3DBorst%26aufirst%3DJ.%26aulast%3DNeefjes%26aufirst%3DJ.%2BJ.%26aulast%3DOvaa%26aufirst%3DH.%26atitle%3DProfiling%2520Proteasome%2520Activity%2520in%2520Tissue%2520with%2520Fluorescent%2520Probes%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2007%26volume%3D4%26issue%3D5%26spage%3D739%26epage%3D748%26doi%3D10.1021%2Fmp0700256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verdoes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Linden, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duivenvoorden, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Marel, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florea, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisselev, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span> <span> </span><span class="NLM_article-title">A Panel of Subunit-Selective Activity-Based Proteasome Probes</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2719</span>â <span class="NLM_lpage">2727</span>, <span class="refDoi">Â DOI: 10.1039/c001036g</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1039%2Fc001036g" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=20449511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmvVWkt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=2719-2727&issue=12&author=M.+Verdoesauthor=L.+I.+Willemsauthor=W.+A.+van+der+Lindenauthor=B.+A.+Duivenvoordenauthor=G.+A.+van+der+Marelauthor=B.+I.+Floreaauthor=A.+F.+Kisselevauthor=H.+S.+Overkleeft&title=A+Panel+of+Subunit-Selective+Activity-Based+Proteasome+Probes&doi=10.1039%2Fc001036g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A panel of subunit-selective activity-based proteasome probes</span></div><div class="casAuthors">Verdoes, Martijn; Willems, Lianne I.; van der Linden, Wouter A.; Duivenvoorden, Boudewijn A.; van der Marel, Gijsbert A.; Florea, Bogdan I.; Kisselev, Alexei F.; Overkleeft, Herman S.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2719-2727</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Mammals express seven different catalytically active proteasome subunits.  To det. the roles of the different proteolytically active subunits in antigen presentation and other cellular processes, highly specific inhibitors and activity-based probes that selectively target specific active sites are needed.  We present the development of fluorescent activity-based probes that selectively target the Î²1 and Î²5 sites of the constitutive proteasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopSK6QWooDJ7Vg90H21EOLACvtfcHk0lifEKdGBQ5oig"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmvVWkt7g%253D&md5=6d645dd55647f6b25f290fd5c112e482</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1039%2Fc001036g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc001036g%26sid%3Dliteratum%253Aachs%26aulast%3DVerdoes%26aufirst%3DM.%26aulast%3DWillems%26aufirst%3DL.%2BI.%26aulast%3Dvan%2Bder%2BLinden%26aufirst%3DW.%2BA.%26aulast%3DDuivenvoorden%26aufirst%3DB.%2BA.%26aulast%3Dvan%2Bder%2BMarel%26aufirst%3DG.%2BA.%26aulast%3DFlorea%26aufirst%3DB.%2BI.%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26atitle%3DA%2520Panel%2520of%2520Subunit-Selective%2520Activity-Based%2520Proteasome%2520Probes%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2010%26volume%3D8%26issue%3D12%26spage%3D2719%26epage%3D2727%26doi%3D10.1039%2Fc001036g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Bruin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Stelt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Marel, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisselev, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florea, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span> <span> </span><span class="NLM_article-title">A Set of Activity-Based Probes to Visualize Human (Immuno)Proteasome Activities</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">4199</span>â <span class="NLM_lpage">4203</span>, <span class="refDoi">Â DOI: 10.1002/anie.201509092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1002%2Fanie.201509092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslCntLbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=4199-4203&issue=13&author=G.+de%0ABruinauthor=B.+T.+Xinauthor=M.+Krausauthor=M.+van+der%0ASteltauthor=G.+A.+van+der+Marelauthor=A.+F.+Kisselevauthor=C.+Driessenauthor=B.+I.+Floreaauthor=H.+S.+Overkleeft&title=A+Set+of+Activity-Based+Probes+to+Visualize+Human+%28Immuno%29Proteasome+Activities&doi=10.1002%2Fanie.201509092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A set of activity-based probes to visualize human (immuno)proteasome activities</span></div><div class="casAuthors">de Bruin, Gerjan; Xin, Bo Tao; Kraus, Marianne; van der Stelt, Mario; van der Marel, Gijsbert A.; Kisselev, Alexei F.; Driessen, Christoph; Florea, Bogdan I.; Overkleeft, Herman S.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4199-4203</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Proteasomes are therapeutic targets for various cancers and autoimmune diseases.  Constitutively expressed proteasomes have three active sites, Î²1c, Î²2c, and Î²5c.  Lymphoid tissues also express the immunoproteasome subunits Î²1i, Î²2i, and Î²5i.  Rapid and simultaneous measurement of the activity of these catalytic subunits would assist in the discovery of new inhibitors, improve anal. of proteasome inhibitors in clin. trials, and simplify anal. of subunit expression.  In this work, we present a cocktail of activity-based probes that enables simultaneous gel-based detection of all six catalytic human proteasome subunits.  We used this cocktail to develop specific inhibitors for Î²1c, Î²2c, Î²5c, and Î²2i, to compare the active-site specificity of clin. proteasome inhibitors, and to demonstrate that many hematol. malignancies predominantly express immunoproteasomes.  Furthermore, we show that selective and complete inhibition of Î²5i and Î²1i is cytotoxic to primary cells from acute lymphocytic leukemia (ALL) patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrebn-jSmyOmLVg90H21EOLACvtfcHk0lhb89nJdVld_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslCntLbJ&md5=b04c6ea92827f327395fc313444e5126</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fanie.201509092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201509092%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBruin%26aufirst%3DG.%26aulast%3DXin%26aufirst%3DB.%2BT.%26aulast%3DKraus%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BStelt%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BMarel%26aufirst%3DG.%2BA.%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26aulast%3DDriessen%26aufirst%3DC.%26aulast%3DFlorea%26aufirst%3DB.%2BI.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26atitle%3DA%2520Set%2520of%2520Activity-Based%2520Probes%2520to%2520Visualize%2520Human%2520%2528Immuno%2529Proteasome%2520Activities%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26issue%3D13%26spage%3D4199%26epage%3D4203%26doi%3D10.1002%2Fanie.201509092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borissenko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span> <span> </span><span class="NLM_article-title">20S Proteasome and Its Inhibitors: Crystallographic Knowledge for Drug Development</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>107</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">687</span>â <span class="NLM_lpage">717</span>, <span class="refDoi">Â DOI: 10.1021/cr0502504</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr0502504" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvF2kuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2007&pages=687-717&issue=3&author=L.+Borissenkoauthor=M.+Groll&title=20S+Proteasome+and+Its+Inhibitors%3A+Crystallographic+Knowledge+for+Drug+Development&doi=10.1021%2Fcr0502504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">20S Proteasome and Its Inhibitors: Crystallographic Knowledge for Drug Development</span></div><div class="casAuthors">Borissenko, Ljudmila; Groll, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">687-717</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The aim of this review is to discuss the latest insights on the structure and function of the proteasome, highlighting the structural features that det. its activity and specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwElwBj8JBKrVg90H21EOLACvtfcHk0lhb89nJdVld_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvF2kuro%253D&md5=af2e998e5443f598a46ffef71118a119</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fcr0502504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0502504%26sid%3Dliteratum%253Aachs%26aulast%3DBorissenko%26aufirst%3DL.%26aulast%3DGroll%26aufirst%3DM.%26atitle%3D20S%2520Proteasome%2520and%2520Its%2520Inhibitors%253A%2520Crystallographic%2520Knowledge%2520for%2520Drug%2520Development%26jtitle%3DChem.%2520Rev.%26date%3D2007%26volume%3D107%26issue%3D3%26spage%3D687%26epage%3D717%26doi%3D10.1021%2Fcr0502504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinemeyer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">JÃ¤ger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bochtler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, R.</span></span> <span> </span><span class="NLM_article-title">The Catalytic Sites of 20S Proteasomes and Their Role in Subunit Maturation: A Mutational and Crystallographic Study</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">10976</span>â <span class="NLM_lpage">10983</span>, <span class="refDoi">Â DOI: 10.1073/pnas.96.20.10976</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1073%2Fpnas.96.20.10976" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10500111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADyaK1MXmvVCnt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=10976-10983&issue=20&author=M.+Grollauthor=W.+Heinemeyerauthor=S.+J%C3%A4gerauthor=T.+Ullrichauthor=M.+Bochtlerauthor=D.+H.+Wolfauthor=R.+Huber&title=The+Catalytic+Sites+of+20S+Proteasomes+and+Their+Role+in+Subunit+Maturation%3A+A+Mutational+and+Crystallographic+Study&doi=10.1073%2Fpnas.96.20.10976"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study</span></div><div class="casAuthors">Groll, Michael; Heinemeyer, Wolfgang; Jager, Sibylle; Ullrich, Tobias; Bochtler, Mathias; Wolf, Dieter H.; Huber, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">10976-10983</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We present a biochem. and crystallog. characterization of active site mutants of the yeast 20S proteasome with the aim to characterize substrate cleavage specificity, subunit intermediate processing, and maturation.  Î²1(Pre3), Î²2(Pup1), and Î²5(Pre2) are responsible for the postacidic, tryptic, and chymotryptic activity, resp.  The maturation of active subunits is independent of the presence of other active subunits and occurs by intrasubunit autolysis.  The propeptides of Î²6(Pre7) and Î²7(Pre4) are intermediately processed to their final forms by Î²2(Pup1) in the wild-type enzyme and by Î²5(Pre2) and Î²1(Pre3) in the Î²2(Pup1) inactive mutants.  A role of the propeptide of Î²1(Pre3) is to prevent acetylation and thereby inactivation.  A gallery of proteasome mutants that contain active site residues in the context of the inactive subunits Î²3(Pup3), Î²6(Pre7), and Î²7(Pre4) show that the presence of Gly1, Thr1, Asp17, Lys33, Ser129, Asp166, and Ser169 is not sufficient to generate activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqATmrU0JPzvrVg90H21EOLACvtfcHk0lhb89nJdVld_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmvVCnt7c%253D&md5=5f4948819bf38d5364c61ffd16167a00</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.20.10976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.20.10976%26sid%3Dliteratum%253Aachs%26aulast%3DGroll%26aufirst%3DM.%26aulast%3DHeinemeyer%26aufirst%3DW.%26aulast%3DJ%25C3%25A4ger%26aufirst%3DS.%26aulast%3DUllrich%26aufirst%3DT.%26aulast%3DBochtler%26aufirst%3DM.%26aulast%3DWolf%26aufirst%3DD.%2BH.%26aulast%3DHuber%26aufirst%3DR.%26atitle%3DThe%2520Catalytic%2520Sites%2520of%252020S%2520Proteasomes%2520and%2520Their%2520Role%2520in%2520Subunit%2520Maturation%253A%2520A%2520Mutational%2520and%2520Crystallographic%2520Study%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26issue%3D20%26spage%3D10976%26epage%3D10983%26doi%3D10.1073%2Fpnas.96.20.10976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmony, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.-B.</span></span> <span> </span><span class="NLM_article-title">A FRET-Based Approach for Identification of Proteasome Catalytic Subunit Composition</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">196</span>â <span class="NLM_lpage">200</span>, <span class="refDoi">Â DOI: 10.1039/C3MB70471H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1039%2FC3MB70471H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=24301521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvF2kt7fN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=196-200&issue=2&author=J.+E.+Parkauthor=Y.+Wuauthor=K.+C.+Carmonyauthor=Z.+Millerauthor=L.+K.+Sharmaauthor=D.-M.+Leeauthor=D.-Y.+Kimauthor=W.+Leeauthor=K.-B.+Kim&title=A+FRET-Based+Approach+for+Identification+of+Proteasome+Catalytic+Subunit+Composition&doi=10.1039%2FC3MB70471H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A FRET-based approach for identification of proteasome catalytic subunit composition</span></div><div class="casAuthors">Park, Ji Eun; Wu, Ying; Carmony, Kimberly Cornish; Miller, Zachary; Sharma, Lalit Kumar; Lee, Do-Min; Kim, Doo-Young; Lee, Wooin; Kim, Kyung-Bo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">196-200</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-2051</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Mammalian cells have two main types of proteasomes, the constitutive proteasome and the immunoproteasome, each contg. a distinct set of three catalytic subunits.  Recently, addnl. proteasome subtypes contg. a non-std. mixt. of catalytic subunits have gained increasing attention, esp. due to their presence in cancer settings.  However, practical methods for identifying proteasome subtypes have been lacking.  Here, we report the development of the first fluorescence resonance energy transfer (FRET)-based strategy that can be utilized to identify different proteasome subtypes present within cells.  We have developed FRET donor- and acceptor-probes that are based on previously reported peptide epoxyketones and selectively target individual proteasome catalytic subunits.  Using the purified proteasome and cancer cell lysates, we demonstrate the feasibility of a FRET-based approach for detg. the catalytic subunit compn. of individual 20S proteasome subtypes.  Ultimately, this approach may be utilized to study the functions of individual proteasome subtypes in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhgLKcZOP5H7Vg90H21EOLACvtfcHk0lhc0yp2lxD6Ww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvF2kt7fN&md5=c0fc15b0a6dac620b689ab5b26d3e38c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1039%2FC3MB70471H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC3MB70471H%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BE.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DCarmony%26aufirst%3DK.%2BC.%26aulast%3DMiller%26aufirst%3DZ.%26aulast%3DSharma%26aufirst%3DL.%2BK.%26aulast%3DLee%26aufirst%3DD.-M.%26aulast%3DKim%26aufirst%3DD.-Y.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DK.-B.%26atitle%3DA%2520FRET-Based%2520Approach%2520for%2520Identification%2520of%2520Proteasome%2520Catalytic%2520Subunit%2520Composition%26jtitle%3DMol.%2520BioSyst.%26date%3D2014%26volume%3D10%26issue%3D2%26spage%3D196%26epage%3D200%26doi%3D10.1039%2FC3MB70471H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Bruin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, B.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florea, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span> <span> </span><span class="NLM_article-title">Proteasome Subunit Selective Activity-Based Probes Report on Proteasome Core Particle Composition in a Native Polyacrylamide Gel Electrophoresis Fluorescence-Resonance Energy Transfer Assay</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>138</i></span> (<span class="NLM_issue">31</span>),  <span class="NLM_fpage">9874</span>â <span class="NLM_lpage">9880</span>, <span class="refDoi">Â DOI: 10.1021/jacs.6b04207</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.6b04207" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFyitLrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=9874-9880&issue=31&author=G.+de%0ABruinauthor=B.-T.+Xinauthor=B.+I.+Floreaauthor=H.+S.+Overkleeft&title=Proteasome+Subunit+Selective+Activity-Based+Probes+Report+on+Proteasome+Core+Particle+Composition+in+a+Native+Polyacrylamide+Gel+Electrophoresis+Fluorescence-Resonance+Energy+Transfer+Assay&doi=10.1021%2Fjacs.6b04207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome Subunit Selective Activity-Based Probes Report on Proteasome Core Particle Composition in a Native Polyacrylamide Gel Electrophoresis Fluorescence-Resonance Energy Transfer Assay</span></div><div class="casAuthors">de Bruin, Gerjan; Xin, Bo-Tao; Florea, Bogdan I.; Overkleeft, Herman S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">9874-9880</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Most mammalian tissues contain a single proteasome species: constitutive proteasomes.  Tissues able to express, next to the constitutive proteasome catalytic activities (Î²1c, Î²2c, Î²5c), the three homologous activities, Î²1i, Î²2i and Î²5i, may contain numerous distinct proteasome particles: immunoproteasomes (composed of Î²1i, Î²2i and Î²5i) and mixed proteasomes contg. a mix of these activities.  This work describes the development of new subunit-selective activity-based probes and their use in an activity-based protein profiling assay that allows the detection of various proteasome particles.  Tissue exts. are treated with subunit-specific probes bearing distinct fluorophores and subunit-specific inhibitors.  The samples are resolved by native PAGE, after which fluorescence-resonance energy transfer (FRET) reports on the nature of proteasomes present.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLNYVRgN-5w7Vg90H21EOLACvtfcHk0lhc0yp2lxD6Ww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFyitLrI&md5=4d9a6aa332499943d9a3952ce9b9cef5</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjacs.6b04207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.6b04207%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBruin%26aufirst%3DG.%26aulast%3DXin%26aufirst%3DB.-T.%26aulast%3DFlorea%26aufirst%3DB.%2BI.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26atitle%3DProteasome%2520Subunit%2520Selective%2520Activity-Based%2520Probes%2520Report%2520on%2520Proteasome%2520Core%2520Particle%2520Composition%2520in%2520a%2520Native%2520Polyacrylamide%2520Gel%2520Electrophoresis%2520Fluorescence-Resonance%2520Energy%2520Transfer%2520Assay%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2016%26volume%3D138%26issue%3D31%26spage%3D9874%26epage%3D9880%26doi%3D10.1021%2Fjacs.6b04207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cornish
Carmony, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.-B.</span></span> <span> </span><span class="NLM_article-title">Elucidating the Catalytic Subunit Composition of Distinct Proteasome Subtypes: A Crosslinking Approach Employing Bifunctional Activity-Based Probes</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">284</span>â <span class="NLM_lpage">292</span>, <span class="refDoi">Â DOI: 10.1002/cbic.201402491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1002%2Fcbic.201402491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=25477005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVaksbnI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=284-292&issue=2&author=K.+Cornish%0ACarmonyauthor=L.+K.+Sharmaauthor=D.-M.+Leeauthor=J.+E.+Parkauthor=W.+Leeauthor=K.-B.+Kim&title=Elucidating+the+Catalytic+Subunit+Composition+of+Distinct+Proteasome+Subtypes%3A+A+Crosslinking+Approach+Employing+Bifunctional+Activity-Based+Probes&doi=10.1002%2Fcbic.201402491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Elucidating the Catalytic Subunit Composition of Distinct Proteasome Subtypes: A Crosslinking Approach Employing Bifunctional Activity-Based Probes</span></div><div class="casAuthors">Cornish Carmony, Kimberly; Sharma, Lalit Kumar; Lee, Do-Min; Park, Ji Eun; Lee, Wooin; Kim, Kyung-Bo</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">284-292</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">In addn. to two well-recognized proteasome subtypes-constitutive proteasomes and immunoproteasomes-mounting evidence also suggests the existence of intermediate proteasome subtypes contg. unconventional mixts. of catalytic subunits.  Although they appear to play unique biol. roles, the lack of practical methods for detecting distinct proteasome subtypes has limited functional investigations.  Here, we report the development of activity-based probes that crosslink two catalytic subunits within intact proteasome complexes.  Identification of the crosslinked subunit pairs provides direct evidence of the catalytic subunit compn. of proteasomes.  Using these probes, we found that U266 multiple myeloma cells contain intermediate proteasomes comprising both Î²1i and Î²2, but not Î²1 and Î²2i, consistent with previous findings with other cell types.  Our bifunctional probes can be utilized in functional investigations of distinct proteasome subtypes in various biol. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkAqXgBr4VX7Vg90H21EOLACvtfcHk0lgYycazZG4t_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVaksbnI&md5=639cbfaeb83cf6e3811b696af9971c1b</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201402491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201402491%26sid%3Dliteratum%253Aachs%26aulast%3DCornish%2BCarmony%26aufirst%3DK.%26aulast%3DSharma%26aufirst%3DL.%2BK.%26aulast%3DLee%26aufirst%3DD.-M.%26aulast%3DPark%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DK.-B.%26atitle%3DElucidating%2520the%2520Catalytic%2520Subunit%2520Composition%2520of%2520Distinct%2520Proteasome%2520Subtypes%253A%2520A%2520Crosslinking%2520Approach%2520Employing%2520Bifunctional%2520Activity-Based%2520Probes%26jtitle%3DChemBioChem%26date%3D2015%26volume%3D16%26issue%3D2%26spage%3D284%26epage%3D292%26doi%3D10.1002%2Fcbic.201402491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zerfas, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trader, D. J.</span></span> <span> </span><span class="NLM_article-title">Monitoring the Immunoproteasome in Live Cells Using an Activity-Based PeptideâPeptoid Hybrid Probe</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">5252</span>â <span class="NLM_lpage">5260</span>, <span class="refDoi">Â DOI: 10.1021/jacs.8b12873</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b12873" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVSmsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=5252-5260&issue=13&author=B.+L.+Zerfasauthor=D.+J.+Trader&title=Monitoring+the+Immunoproteasome+in+Live+Cells+Using+an+Activity-Based+Peptide%E2%80%93Peptoid+Hybrid+Probe&doi=10.1021%2Fjacs.8b12873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Monitoring the immunoproteasome in live cells using an activity-based peptide-peptoid hybrid probe</span></div><div class="casAuthors">Zerfas, Breanna L.; Trader, Darci J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5252-5260</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Activity-based probes have greatly improved our understanding of the intrinsic roles and expression levels of various proteins within cells.  To be useful in live cells, probes must be cell permeable and provide a read-out that can be measured without disrupting the cells or the activity of the target.  Unfortunately, probes for the various forms of the proteasome that can be utilized in intact cells are limited; com. available probes are most effectively used with purified protein or cell lysate.  The proteasome, both the 26S and various isoforms of the 20S CP, is an important target with reported roles in cancer, autoimmune disorders, and neurodegenerative diseases.  Here, we present the development of a selective probe for the immunoproteasome, a specialized isoform of the 20S proteasome, that becomes expressed in cells that encounter an inflammatory signal.  Using a one-bead, one-compd. library of small peptides, we discovered a trimer sequence efficiently cleaved by the immunoproteasome with significant selectivity over the std. proteasome.  Upon conjugating this sequence to rhodamine 110 and a peptoid, we generated a probe with a considerable improvement in sensitivity compared to that of current aminomethylcoumarin-based proteasome probes.  Importantly, our probe was capable of labeling immunoproteasome-expressing cells while maintaining its selectivity over other cellular proteases in live cell cultures.  We anticipate this probe to find wide utility for those that wish to study the immunoproteasome's activity in a variety of cell lines and to be used as a reporter to discover small mols. that can perturb the activity of this proteasome isoform.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGottEI8PGqCE7Vg90H21EOLACvtfcHk0lgYycazZG4t_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVSmsLo%253D&md5=a475e510aaccc86edb1ca80e21eb7d5c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b12873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b12873%26sid%3Dliteratum%253Aachs%26aulast%3DZerfas%26aufirst%3DB.%2BL.%26aulast%3DTrader%26aufirst%3DD.%2BJ.%26atitle%3DMonitoring%2520the%2520Immunoproteasome%2520in%2520Live%2520Cells%2520Using%2520an%2520Activity-Based%2520Peptide%25E2%2580%2593Peptoid%2520Hybrid%2520Probe%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D141%26issue%3D13%26spage%3D5252%26epage%3D5260%26doi%3D10.1021%2Fjacs.8b12873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henninot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuss, J. M.</span></span> <span> </span><span class="NLM_article-title">The Current State of Peptide Drug Discovery: Back to the Future?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1382</span>â <span class="NLM_lpage">1414</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00318</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00318" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1ansLbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1382-1414&issue=4&author=A.+Henninotauthor=J.+C.+Collinsauthor=J.+M.+Nuss&title=The+Current+State+of+Peptide+Drug+Discovery%3A+Back+to+the+Future%3F&doi=10.1021%2Facs.jmedchem.7b00318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">The Current State of Peptide Drug Discovery: Back to the Future?</span></div><div class="casAuthors">Henninot, Antoine; Collins, James C.; Nuss, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1382-1414</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Over the last decade, peptide drug discovery has experienced a revival of interest and scientific momentum, as the pharmaceutical industry has come to appreciate the role that peptide therapeutics can play in addressing unmet medical needs, and how this class of compds. can be an excellent complement or even preferable alternative to small mol. and biol. therapeutics.  In this perspective we give a concise description of the recent progress in peptide drug discovery in a holistic manner, highlighting enabling technol. advances affecting nearly every aspect of this field: from lead discovery, to synthesis and optimization, to peptide drug delivery.  An emphasis is placed on describing research efforts to overcome the inherent weaknesses of peptide drugs, in particular their poor pharmacokinetic properties, and how these efforts have been crit. to the discovery, design and subsequent development of novel therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosOkeBHqLwj7Vg90H21EOLACvtfcHk0lgYycazZG4t_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1ansLbM&md5=825f15ed57fceaa1226f57be696c639e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00318%26sid%3Dliteratum%253Aachs%26aulast%3DHenninot%26aufirst%3DA.%26aulast%3DCollins%26aufirst%3DJ.%2BC.%26aulast%3DNuss%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520Current%2520State%2520of%2520Peptide%2520Drug%2520Discovery%253A%2520Back%2520to%2520the%2520Future%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D4%26spage%3D1382%26epage%3D1414%26doi%3D10.1021%2Facs.jmedchem.7b00318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fosgerau, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, T.</span></span> <span> </span><span class="NLM_article-title">Peptide Therapeutics: Current Status and Future Directions</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">122</span>â <span class="NLM_lpage">128</span>, <span class="refDoi">Â DOI: 10.1016/j.drudis.2014.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.drudis.2014.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=25450771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsl2ksLnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=122-128&issue=1&author=K.+Fosgerauauthor=T.+Hoffmann&title=Peptide+Therapeutics%3A+Current+Status+and+Future+Directions&doi=10.1016%2Fj.drudis.2014.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide therapeutics: current status and future directions</span></div><div class="casAuthors">Fosgerau, Keld; Hoffmann, Torsten</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">122-128</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Peptides are recognized for being highly selective and efficacious and, at the same time, relatively safe and well tolerated.  Consequently, there is an increased interest in peptides in pharmaceutical research and development (R&D), and approx. 140 peptide therapeutics are currently being evaluated in clin. trials.  Given that the low-hanging fruits in the form of obvious peptide targets have already been picked, it has now become necessary to explore new routes beyond traditional peptide design.  Examples of such approaches are multifunctional and cell penetrating peptides, as well as peptide drug conjugates.  Here, we discuss the current status, strengths, and weaknesses of peptides as medicines and the emerging new opportunities in peptide drug design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmhpp8GnJ6JLVg90H21EOLACvtfcHk0lg3m-XYCg4eNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsl2ksLnM&md5=f6b74aaa4e3fdb317b091b0450f3618a</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DFosgerau%26aufirst%3DK.%26aulast%3DHoffmann%26aufirst%3DT.%26atitle%3DPeptide%2520Therapeutics%253A%2520Current%2520Status%2520and%2520Future%2520Directions%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26issue%3D1%26spage%3D122%26epage%3D128%26doi%3D10.1016%2Fj.drudis.2014.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span> <span> </span><span class="NLM_article-title">Proteasome Dysregulation in Human Cancer: Implications for Clinical Therapies</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">703</span>â <span class="NLM_lpage">716</span>, <span class="refDoi">Â DOI: 10.1007/s10555-017-9704-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1007%2Fs10555-017-9704-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=29039081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1KgsLnE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2017&pages=703-716&issue=4&author=Y.+Chenauthor=Y.+Zhangauthor=X.+Guo&title=Proteasome+Dysregulation+in+Human+Cancer%3A+Implications+for+Clinical+Therapies&doi=10.1007%2Fs10555-017-9704-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome dysregulation in human cancer: implications for clinical therapies</span></div><div class="casAuthors">Chen, Yulin; Zhang, Yanan; Guo, Xing</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">703-716</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Cancer cells show heightened dependency on the proteasome for their survival, growth, and spread.  Proteasome dysregulation is therefore commonly selected in favor of the development of many types of cancer.  The vast abnormalities in a cancer cell, on top of the complexity of the proteasome itself, have enabled a plethora of mechanisms gearing the proteasome to the oncogenic process.  Here, we use selected examples to highlight some general mechanisms underlying proteasome dysregulation in cancer, including copy no. variations, transcriptional control, epigenetic regulation, and post-translational modifications.  Research in this field has greatly advanced our understanding of proteasome regulation and will shed new light on proteasome-based combination therapies for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGPLufCMjdrLVg90H21EOLACvtfcHk0lg3m-XYCg4eNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1KgsLnE&md5=5666e31291740ebd904f5da56b5a13a1</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs10555-017-9704-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-017-9704-y%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DX.%26atitle%3DProteasome%2520Dysregulation%2520in%2520Human%2520Cancer%253A%2520Implications%2520for%2520Clinical%2520Therapies%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2017%26volume%3D36%26issue%3D4%26spage%3D703%26epage%3D716%26doi%3D10.1007%2Fs10555-017-9704-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Almond, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, G. M.</span></span> <span> </span><span class="NLM_article-title">The Proteasome: A Novel Target for Cancer Chemotherapy</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">433</span>â <span class="NLM_lpage">443</span>, <span class="refDoi">Â DOI: 10.1038/sj.leu.2402417</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fsj.leu.2402417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=11960320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvFGnur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2002&pages=433-443&issue=4&author=J.+B.+Almondauthor=G.+M.+Cohen&title=The+Proteasome%3A+A+Novel+Target+for+Cancer+Chemotherapy&doi=10.1038%2Fsj.leu.2402417"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome: A novel target for cancer chemotherapy</span></div><div class="casAuthors">Almond, J. B.; Cohen, G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">433-443</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The ubiquitin-proteasome system is an important regulator of cell growth and apoptosis.  The potential of specific proteasome inhibitors to act as novel anti-cancer agents is currently under intensive investigation.  Several proteasome inhibitors exert anti-tumor activity in vivo and potently induce apoptosis in tumor cells in vitro, including those resistant to conventional chemotherapeutic agents.  By inhibiting NF-ÎºB transcriptional activity, proteasome inhibitors may also prevent angiogenesis and metastasis in vivo and further increase the sensitivity of cancer cells to apoptosis.  Proteasome inhibitors also exhibit some level of selective cytotoxicity to cancer cells by preferentially inducing apoptosis in proliferating or transformed cells or by overcoming deficiencies in growth-inhibitory or proapoptotic mols.  High expression of oncogene products like c-Myc also makes cancer cells more susceptible to proteasome inhibitor-induced apoptosis.  The induction of apoptosis by proteasome inhibitors varies between cell types but often occurs following an initial accumulation of short-lived proteins such as p53, p27, pro-apoptotic Bcl-2 family members or activation of the stress kinase JNK.  These initial events often result in a perturbation of mitochondria with concomitant release of cytochrome c and activation of the Apaf-1 contg. apoptosome complex.  This results in activation of the apical caspase-9 followed by activation of effector caspases-3 and -7, which are responsible for the biochem. and morphol. changes assocd. with apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohX4u2GEzGOLVg90H21EOLACvtfcHk0lg3m-XYCg4eNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvFGnur8%253D&md5=1ebb4d9573591c2076bf56f5c75547e8</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2402417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2402417%26sid%3Dliteratum%253Aachs%26aulast%3DAlmond%26aufirst%3DJ.%2BB.%26aulast%3DCohen%26aufirst%3DG.%2BM.%26atitle%3DThe%2520Proteasome%253A%2520A%2520Novel%2520Target%2520for%2520Cancer%2520Chemotherapy%26jtitle%3DLeukemia%26date%3D2002%26volume%3D16%26issue%3D4%26spage%3D433%26epage%3D443%26doi%3D10.1038%2Fsj.leu.2402417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freije, J. M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraile, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LÃ³pez-OtÃ­n, C.</span></span> <span> </span><span class="NLM_article-title">Protease Addiction and Synthetic Lethality in Cancer</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">25</span>, <span class="refDoi">Â DOI: 10.3389/fonc.2011.00025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.3389%2Ffonc.2011.00025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=22655236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BC38notFWgsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=25&author=J.+M.+P.+Freijeauthor=J.+M.+Fraileauthor=C.+L%C3%B3pez-Ot%C3%ADn&title=Protease+Addiction+and+Synthetic+Lethality+in+Cancer&doi=10.3389%2Ffonc.2011.00025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Protease addiction and synthetic lethality in cancer</span></div><div class="casAuthors">Freije Jose M P; Fraile Julia M; Lopez-Otin Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">25</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The "oncogene addiction" concept refers to the dependence of cancer cells on the function of the oncogenes responsible for their transformed phenotype, while the term "non-oncogene addiction" has been introduced to define the exacerbated necessity of the normal function of non-mutated genes.  In this Perspective, we focus on the importance of proteolytic enzymes to maintain the viability of cancer cells and hypothesize that most, if not all, tumors present "addiction" to a number of proteolytic activities, which in turn may represent valuable targets of anti-cancer therapies, even without being mutated or over-expressed by the malignant cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQGOjJJch7csyCEBeYuoi7AfW6udTcc2eatlRp8F7niC7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38notFWgsQ%253D%253D&md5=c7638722f1588919cde3972f6ae4b48f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2011.00025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2011.00025%26sid%3Dliteratum%253Aachs%26aulast%3DFreije%26aufirst%3DJ.%2BM.%2BP.%26aulast%3DFraile%26aufirst%3DJ.%2BM.%26aulast%3DL%25C3%25B3pez-Ot%25C3%25ADn%26aufirst%3DC.%26atitle%3DProtease%2520Addiction%2520and%2520Synthetic%2520Lethality%2520in%2520Cancer%26jtitle%3DFront.%2520Oncol.%26date%3D2011%26volume%3D1%26spage%3D25%26doi%3D10.3389%2Ffonc.2011.00025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunsucker, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorhees, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, R. Z.</span></span> <span> </span><span class="NLM_article-title">Targeted Inhibition of the Immunoproteasome Is a Potent Strategy against Models of Multiple Myeloma That Overcomes Resistance to Conventional Drugs and Nonspecific Proteasome Inhibitors</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">4667</span>â <span class="NLM_lpage">4676</span>, <span class="refDoi">Â DOI: 10.1182/blood-2008-07-171637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1182%2Fblood-2008-07-171637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=19050304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvVyqurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=4667-4676&issue=19&author=D.+J.+Kuhnauthor=S.+A.+Hunsuckerauthor=Q.+Chenauthor=P.+M.+Voorheesauthor=M.+Orlowskiauthor=R.+Z.+Orlowski&title=Targeted+Inhibition+of+the+Immunoproteasome+Is+a+Potent+Strategy+against+Models+of+Multiple+Myeloma+That+Overcomes+Resistance+to+Conventional+Drugs+and+Nonspecific+Proteasome+Inhibitors&doi=10.1182%2Fblood-2008-07-171637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors</span></div><div class="casAuthors">Kuhn, Deborah J.; Hunsucker, Sally A.; Chen, Qing; Voorhees, Peter M.; Orlowski, Marian; Orlowski, Robert Z.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4667-4676</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Proteasome inhibition is a validated strategy for therapy of multiple myeloma, but this disease remains challenging as relapses are common, and often assocd. with increasing chemoresistance.  Moreover, nonspecific proteasome inhibitors such as bortezomib can induce peripheral neuropathy and other toxicities that may compromise the ability to deliver therapy at full doses, thereby decreasing efficacy.  One novel approach may be to target the immunoproteasome, a proteasomal variant found predominantly in cells of hematopoietic origin that differs from the constitutive proteasome found in most other cell types.  Using purified prepns. of constitutive and immunoproteasomes, we screened a rationally designed series of peptidyl-aldehydes and identified several with relative specificity for the immunoproteasome.  The most potent immunoproteasome-specific inhibitor, IPSI-001, preferentially targeted the Î²1i subunit of the immunoproteasome in vitro and in cellulo in a dose-dependent manner.  This agent induced accumulation of ubiquitin-protein conjugates, proapoptotic proteins, and activated caspase-mediated apoptosis.  IPSI-001 potently inhibited proliferation in myeloma patient samples and other hematol. malignancies.  Importantly, IPSI-001 was able to overcome conventional and novel drug resistance, including resistance to bortezomib.  These findings provide a rationale for the translation of IPSIs to the clinic, where they may provide antimyeloma activity with greater specificity and less toxicity than current inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyFUysXTzcsrVg90H21EOLACvtfcHk0ljYH3w1N-UnOw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvVyqurk%253D&md5=6753f40ae6057eeadbbde2f6650828fc</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-07-171637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-07-171637%26sid%3Dliteratum%253Aachs%26aulast%3DKuhn%26aufirst%3DD.%2BJ.%26aulast%3DHunsucker%26aufirst%3DS.%2BA.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DVoorhees%26aufirst%3DP.%2BM.%26aulast%3DOrlowski%26aufirst%3DM.%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26atitle%3DTargeted%2520Inhibition%2520of%2520the%2520Immunoproteasome%2520Is%2520a%2520Potent%2520Strategy%2520against%2520Models%2520of%2520Multiple%2520Myeloma%2520That%2520Overcomes%2520Resistance%2520to%2520Conventional%2520Drugs%2520and%2520Nonspecific%2520Proteasome%2520Inhibitors%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26issue%3D19%26spage%3D4667%26epage%3D4676%26doi%3D10.1182%2Fblood-2008-07-171637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wehenkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ban, J.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, Y.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmony, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">A Selective Inhibitor of the Immunoproteasome Subunit LMP2 Induces Apoptosis in PC-3 Cells and Suppresses Tumour Growth in Nude Mice</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>107</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">53</span>â <span class="NLM_lpage">62</span>, <span class="refDoi">Â DOI: 10.1038/bjc.2012.243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fbjc.2012.243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=22677907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC38Xptl2isbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2012&pages=53-62&issue=1&author=M.+Wehenkelauthor=J.-O.+Banauthor=Y.-K.+Hoauthor=K.+C.+Carmonyauthor=J.+T.+Hongauthor=K.+B.+Kim&title=A+Selective+Inhibitor+of+the+Immunoproteasome+Subunit+LMP2+Induces+Apoptosis+in+PC-3+Cells+and+Suppresses+Tumour+Growth+in+Nude+Mice&doi=10.1038%2Fbjc.2012.243"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice</span></div><div class="casAuthors">Wehenkel, M.; Ban, J.-O.; Ho, Y.-K.; Carmony, K. C.; Hong, J. T.; Kim, K. B.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-62</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Although the proteasome is a validated anticancer target, the clin. application of its inhibitors has been limited because of inherent systemic toxicity.  To broaden clin. utility of proteasome inhibitors as anticancer agents, it is crit. to develop strategies to selectively target proteasomes in cancer cells.  The immunoproteasome is an alternative form of the constitutive proteasome that is expressed at high levels in cancer tissues, but not in most normal cells in the body.  Methods: To validate the immunoproteasome as a chemotherapeutic target, an immunoproteasome catalytic subunit LMP2-targeting inhibitor and siRNA were used.  The sensitivity of PC-3 prostate cancer cells to these reagents was investigated using viability assays.  Further, a xenograft model of prostate cancer was studied to test the in vivo effects of LMP2 inhibition.  Results: A small mol. inhibitor of the immunoproteasome subunit LMP2, UK-101, induced apoptosis of PC-3 cells and resulted in significant inhibition (â¼50-60%) of tumor growth in vivo.  Interestingly, UK-101 did not block degrdn. of IÎºBÎ± in PC-3 cells treated with TNF-Î±, suggesting that its mode of action may be different from that of general proteasome inhibitors, such as bortezomib, which block IÎºBÎ± degrdn.  Conclusion: These results strongly suggest that the immunoproteasome has important roles in cancer cell growth and thus provide a rationale for targeting the immunoproteasome in the treatment of prostate cancer.  British Journal of Cancer (2012) 107, 53-62. doi:10.1038/bjc.2012.243 www.bjcancer.com published online 7 June 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrLJQKXNlNKrVg90H21EOLACvtfcHk0ljYH3w1N-UnOw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xptl2isbk%253D&md5=59390ce6295216a78e584049754b2c03</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2012.243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2012.243%26sid%3Dliteratum%253Aachs%26aulast%3DWehenkel%26aufirst%3DM.%26aulast%3DBan%26aufirst%3DJ.-O.%26aulast%3DHo%26aufirst%3DY.-K.%26aulast%3DCarmony%26aufirst%3DK.%2BC.%26aulast%3DHong%26aufirst%3DJ.%2BT.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DA%2520Selective%2520Inhibitor%2520of%2520the%2520Immunoproteasome%2520Subunit%2520LMP2%2520Induces%2520Apoptosis%2520in%2520PC-3%2520Cells%2520and%2520Suppresses%2520Tumour%2520Growth%2520in%2520Nude%2520Mice%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2012%26volume%3D107%26issue%3D1%26spage%3D53%26epage%3D62%26doi%3D10.1038%2Fbjc.2012.243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mlecnik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bindea, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirilovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angell, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obenauf, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Church, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maby, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasaturo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredriksen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speicher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pages, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valge-Archer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galon, J.</span></span> <span> </span><span class="NLM_article-title">The Tumor Microenvironment and Immunoscore Are Critical Determinants of Dissemination to Distant Metastasis</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">327</span>),  <span class="NLM_fpage">327ra26</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.aad6352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1126%2Fscitranslmed.aad6352" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=26912905" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=327ra26&issue=327&author=B.+Mlecnikauthor=G.+Bindeaauthor=A.+Kirilovskyauthor=H.+K.+Angellauthor=A.+C.+Obenaufauthor=M.+Tosoliniauthor=S.+E.+Churchauthor=P.+Mabyauthor=A.+Vasaturoauthor=M.+Angelovaauthor=T.+Fredriksenauthor=S.+Maugerauthor=M.+Waldnerauthor=A.+Bergerauthor=M.+Speicherauthor=F.+Pagesauthor=V.+Valge-Archerauthor=J.+Galon&title=The+Tumor+Microenvironment+and+Immunoscore+Are+Critical+Determinants+of+Dissemination+to+Distant+Metastasis&doi=10.1126%2Fscitranslmed.aad6352"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aad6352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aad6352%26sid%3Dliteratum%253Aachs%26aulast%3DMlecnik%26aufirst%3DB.%26aulast%3DBindea%26aufirst%3DG.%26aulast%3DKirilovsky%26aufirst%3DA.%26aulast%3DAngell%26aufirst%3DH.%2BK.%26aulast%3DObenauf%26aufirst%3DA.%2BC.%26aulast%3DTosolini%26aufirst%3DM.%26aulast%3DChurch%26aufirst%3DS.%2BE.%26aulast%3DMaby%26aufirst%3DP.%26aulast%3DVasaturo%26aufirst%3DA.%26aulast%3DAngelova%26aufirst%3DM.%26aulast%3DFredriksen%26aufirst%3DT.%26aulast%3DMauger%26aufirst%3DS.%26aulast%3DWaldner%26aufirst%3DM.%26aulast%3DBerger%26aufirst%3DA.%26aulast%3DSpeicher%26aufirst%3DM.%26aulast%3DPages%26aufirst%3DF.%26aulast%3DValge-Archer%26aufirst%3DV.%26aulast%3DGalon%26aufirst%3DJ.%26atitle%3DThe%2520Tumor%2520Microenvironment%2520and%2520Immunoscore%2520Are%2520Critical%2520Determinants%2520of%2520Dissemination%2520to%2520Distant%2520Metastasis%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2016%26volume%3D8%26issue%3D327%26spage%3D327ra26%26doi%3D10.1126%2Fscitranslmed.aad6352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heo, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span> <span> </span><span class="NLM_article-title">Expression of Immunoproteasome Subunit LMP7 in Breast Cancer and Its Association with Immune-Related Markers</span>. <i>Cancer Res. Treat. Off. J. Korean Cancer Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">80</span>â <span class="NLM_lpage">89</span>, <span class="refDoi">Â DOI: 10.4143/crt.2017.500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.4143%2Fcrt.2017.500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=29510614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BC1Mrot1yhsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2019&pages=80-89&issue=1&author=M.+Leeauthor=I.+H.+Songauthor=S.-H.+Heoauthor=Y.-A.+Kimauthor=I.+A.+Parkauthor=W.+S.+Bangauthor=H.+S.+Parkauthor=G.+Gongauthor=H.+J.+Lee&title=Expression+of+Immunoproteasome+Subunit+LMP7+in+Breast+Cancer+and+Its+Association+with+Immune-Related+Markers&doi=10.4143%2Fcrt.2017.500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of Immunoproteasome Subunit LMP7 in Breast Cancer and Its Association with Immune-Related Markers</span></div><div class="casAuthors">Lee Miseon; Song In Hye; Heo Sun-Hee; Kim Young-Ae; Park In Ah; Bang Won Seon; Park Hye Seon; Gong Gyungyub; Lee Hee Jin; Heo Sun-Hee; Kim Young-Ae; Bang Won Seon; Park Hye Seon</div><div class="citationInfo"><span class="NLM_cas:title">Cancer research and treatment : official journal of Korean Cancer Association</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80-89</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  In the presence of interferon, proteasome subunits are replaced by their inducible counterparts to form an immunoproteasome (IP) plays a key role in generation of antigenic peptides presented by MHC class I molecules, leading to elicitation of a T cell-mediated immune response.  Although the roles of IP in other cancers, and inflammatory diseases have been extensively studied, its significance in breast cancer is unclear.  Materials and Methods:  We investigated the expression of LMP7, an IP subunit, and its relationship with immune system components in two breast cancer cohorts.  RESULTS:  In 668 consecutive breast cancer cohort, 40% of tumors showed high level of LMP7 expression, and tumors with high expression of LMP7 had more tumor-infiltrating lymphocytes (TILs) in each subtype of breast cancer.  In another cohort of 681 triple-negative breast cancer patients cohort, the expression of LMP7 in tumor cells was significantly correlated with the amount of TILs and the expression of interferon-associated molecules (MxA [p < 0.001] and PKR [p < 0.001]), endoplasmic reticulum stress-associated molecules (PERK [p=0.012], p-eIF2a [p=0.001], and XBP1 [p < 0.001]), and damage-associated molecular patterns (HMGN1 [p < 0.001] and HMGB1 [p < 0.001]).  Patients with higher LMP7 expression had better disease-free survival outcomes than those with no or low expression in the positive lymph node metastasis group (p=0.041).  CONCLUSION:  Close association between the TIL levels and LMP7 expression in breast cancer indicates that better antigen presentation through greater LMP7 expression might be associated with more TILs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_FuCjjUju10h5eUSa2oe_fW6udTcc2eaTERWo9QJ-j7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mrot1yhsw%253D%253D&md5=06caad90faf567c04c36a9faab4366c5</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.4143%2Fcrt.2017.500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4143%252Fcrt.2017.500%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%26aulast%3DSong%26aufirst%3DI.%2BH.%26aulast%3DHeo%26aufirst%3DS.-H.%26aulast%3DKim%26aufirst%3DY.-A.%26aulast%3DPark%26aufirst%3DI.%2BA.%26aulast%3DBang%26aufirst%3DW.%2BS.%26aulast%3DPark%26aufirst%3DH.%2BS.%26aulast%3DGong%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26atitle%3DExpression%2520of%2520Immunoproteasome%2520Subunit%2520LMP7%2520in%2520Breast%2520Cancer%2520and%2520Its%2520Association%2520with%2520Immune-Related%2520Markers%26jtitle%3DCancer%2520Res.%2520Treat.%2520Off.%2520J.%2520Korean%2520Cancer%2520Assoc.%26date%3D2019%26volume%3D51%26issue%3D1%26spage%3D80%26epage%3D89%26doi%3D10.4143%2Fcrt.2017.500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koerner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition and Deficiency of the Immunoproteasome Subunit LMP7 Suppress the Development and Progression of Colorectal Carcinoma in Mice</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">31</span>),  <span class="NLM_fpage">50873</span>â <span class="NLM_lpage">50888</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.15141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.18632%2Foncotarget.15141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=28881611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BC1cbls1Onug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=50873-50888&issue=31&author=J.+Koernerauthor=T.+Brunnerauthor=M.+Groettrup&title=Inhibition+and+Deficiency+of+the+Immunoproteasome+Subunit+LMP7+Suppress+the+Development+and+Progression+of+Colorectal+Carcinoma+in+Mice&doi=10.18632%2Foncotarget.15141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition and deficiency of the immunoproteasome subunit LMP7 suppress the development and progression of colorectal carcinoma in mice</span></div><div class="casAuthors">Koerner Julia; Groettrup Marcus; Koerner Julia; Brunner Thomas; Groettrup Marcus; Brunner Thomas; Groettrup Marcus</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">50873-50888</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">New treatment options and drug targets for colorectal carcinoma are a pressing medical need.  Inflammation and pro-inflammatory cytokines produced by Th1 and Th17 cells like IL-6, TNF, IL-17 and IL-23 promote the development and growth of colorectal cancer (CRC).  The immunoproteasome is a proteasome subtype highly expressed in immune cells but also in the intestine.  Since the immunoproteasome promotes Th1 and Th17 differentiation and pro-inflammatory cytokine production, we investigated here whether deficiency or inhibition of the immunoproteasome subunit LMP7 would interfere with CRC development and exacerbation in preventive and therapeutic mouse models.  Treatment with the LMP7 inhibitor ONX 0914 blocked tumor initiation and progression in either chemically-induced (AOM/DSS) or transgenic mouse models (Apc(Min/+)) of colon carcinogenesis.  ONX 0914 treatment strongly reduced tumor numbers and CRC-associated loss of body weight while the survival rates were significantly enhanced.  Moreover, genetic LMP7 deficiency markedly reduced the tumor burden in AOM/DSS induced wild type and Apc(Min/+) mice.  In conclusion, we show that the immunoproteasome is involved in CRC development and progression and we identify LMP7 as a new potential drug target for the treatment of CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR4ra5hF3i41sjl5L8hwNX0fW6udTcc2eaTERWo9QJ-j7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbls1Onug%253D%253D&md5=957c97b288946ec6953a305f0b743e8f</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.15141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.15141%26sid%3Dliteratum%253Aachs%26aulast%3DKoerner%26aufirst%3DJ.%26aulast%3DBrunner%26aufirst%3DT.%26aulast%3DGroettrup%26aufirst%3DM.%26atitle%3DInhibition%2520and%2520Deficiency%2520of%2520the%2520Immunoproteasome%2520Subunit%2520LMP7%2520Suppress%2520the%2520Development%2520and%2520Progression%2520of%2520Colorectal%2520Carcinoma%2520in%2520Mice%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D31%26spage%3D50873%26epage%3D50888%26doi%3D10.18632%2Foncotarget.15141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frisan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitsky, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masucci, M. G.</span></span> <span> </span><span class="NLM_article-title">Variations in Proteasome Subunit Composition and Enzymatic Activity in B-Lymphoma Lines and Normal B Cells</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>88</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">881</span>â <span class="NLM_lpage">888</span>, <span class="refDoi">Â DOI: 10.1002/1097-0215(20001215)88:6<881::AID-IJC7>3.0.CO;2-D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1002%2F1097-0215%2820001215%2988%3A6%3C881%3A%3AAID-IJC7%3E3.0.CO%3B2-D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=11093809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovVGht7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2000&pages=881-888&issue=6&author=T.+Frisanauthor=V.+Levitskyauthor=M.+G.+Masucci&title=Variations+in+Proteasome+Subunit+Composition+and+Enzymatic+Activity+in+B-Lymphoma+Lines+and+Normal+B+Cells&doi=10.1002%2F1097-0215%2820001215%2988%3A6%3C881%3A%3AAID-IJC7%3E3.0.CO%3B2-D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Variations in proteasome subunit composition and enzymatic activity in B-lymphoma lines and normal B cells</span></div><div class="casAuthors">Frisan, Teresa; Levitsky, Victor; Masucci, Maria G.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">881-888</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">We investigated the expression of interferon gamma (IFN-Î³)-regulated subunits and the enzymic activity of proteasomes purified from tumor-derived and normal B lymphocytes representing different stages of B-cell activation/differentiation.  The catalytic Î² subunits (Lmp2 and Lmp7) and the regulatory subunits (PA28Î± and PA28Î²) were expressed at equally high levels in Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCLs), freshly isolated B-chronic lymphocytic leukemia (B-CLL) cells and normal CD23- B lymphocytes.  Lmp2 and Lmp7 were selectively down-regulated in germinal center cell-derived Burkitt's lymphoma (BL) and Hodgkin's lymphoma (HD) cell lines.  There was a direct correlation between the expression of Lmp2/7 and the chymotrypsin and trypsin-like activities in proteasomes purified from LCLs, BLs and CLL cells, whereas 5 HD cell lines expressing B or T-cell markers exhibited a variable pattern of subunit expression and enzymic activity.  Poor hydrolysis of the fluorogenic substrates by proteasomes from BL cells correlated with a distinct pattern of cleavage of a ref. 50mer peptide, prodn. of different sets of degrdn. products and significantly reduced recovery of a known cytotoxic T-lymphocyte (CTL) target epitope.  The enzymic activity of proteasomes from normal CD23- "resting" B lymphocytes resembled that of BL cells in spite of high Lmp2/7 expression.  This pattern was not reversed by treatment with the B-cell mitogen, lipopolysaccharide (LPS).  The results suggest that different stages of B-cell activation/differentiation are assocd. with distinct profiles of IFN-Î³-regulated subunit compn. and enzymic activity of the proteasome.  This may have important implications for the anal. and manipulation of tumor-specific immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGwFbnkq8wvLVg90H21EOLACvtfcHk0lhNbTFQIV2XZA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovVGht7Y%253D&md5=47dc9992bd69e33e2da06bc8af2cd31c</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1002%2F1097-0215%2820001215%2988%3A6%3C881%3A%3AAID-IJC7%3E3.0.CO%3B2-D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1097-0215%252820001215%252988%253A6%253C881%253A%253AAID-IJC7%253E3.0.CO%253B2-D%26sid%3Dliteratum%253Aachs%26aulast%3DFrisan%26aufirst%3DT.%26aulast%3DLevitsky%26aufirst%3DV.%26aulast%3DMasucci%26aufirst%3DM.%2BG.%26atitle%3DVariations%2520in%2520Proteasome%2520Subunit%2520Composition%2520and%2520Enzymatic%2520Activity%2520in%2520B-Lymphoma%2520Lines%2520and%2520Normal%2520B%2520Cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2000%26volume%3D88%26issue%3D6%26spage%3D881%26epage%3D888%26doi%3D10.1002%2F1097-0215%2820001215%2988%3A6%3C881%3A%3AAID-IJC7%3E3.0.CO%3B2-D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ebstein, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kloetzel, P.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KrÃ¼ger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, U.</span></span> <span> </span><span class="NLM_article-title">Emerging Roles of Immunoproteasomes beyond MHC Class I Antigen Processing</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">2543</span>â <span class="NLM_lpage">2558</span>, <span class="refDoi">Â DOI: 10.1007/s00018-012-0938-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1007%2Fs00018-012-0938-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=22382925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVansbbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=2543-2558&issue=15&author=F.+Ebsteinauthor=P.-M.+Kloetzelauthor=E.+Kr%C3%BCgerauthor=U.+Seifert&title=Emerging+Roles+of+Immunoproteasomes+beyond+MHC+Class+I+Antigen+Processing&doi=10.1007%2Fs00018-012-0938-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging roles of immunoproteasomes beyond MHC class I antigen processing</span></div><div class="casAuthors">Ebstein, Frederic; Kloetzel, Peter-Michael; Krueger, Elke; Seifert, Ulrike</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2543-2558</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">A review.  The proteasome is a multi-catalytic protein complex whose primary function is the degrdn. of abnormal or foreign proteins.  Upon exposure of cells to interferons (IFNs), the Î²1i/LMP2, Î²2i/MECL-1, and Î²5i/LMP7 subunits are induced and incorporated into newly synthesized immunoproteasomes (IP), which are thought to function solely as crit. players in the optimization of the CD8+ T-cell response.  However, the observation that IP are present in several non-immune tissues under normal conditions and/or following pathol. events militates against the view that its role is limited to MHC class I presentation.  In support of this concept, the recent use of genetic models deficient for Î²1i/LMP2, Î²2i/MECL-1, or Î²5i/LMP7 has uncovered unanticipated functions for IP in innate immunity and non-immune processes.  Herein, we review recent data in an attempt to clarify the role of IP beyond MHC class I epitope presentation with emphasis on its involvement in the regulation of protein homeostasis, cell proliferation, and cytokine gene expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNZw6RsOpMoLVg90H21EOLACvtfcHk0lhNbTFQIV2XZA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVansbbJ&md5=6f1603c2657b5fea21a5e7e3ad19cdf5</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1007%2Fs00018-012-0938-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-012-0938-0%26sid%3Dliteratum%253Aachs%26aulast%3DEbstein%26aufirst%3DF.%26aulast%3DKloetzel%26aufirst%3DP.-M.%26aulast%3DKr%25C3%25BCger%26aufirst%3DE.%26aulast%3DSeifert%26aufirst%3DU.%26atitle%3DEmerging%2520Roles%2520of%2520Immunoproteasomes%2520beyond%2520MHC%2520Class%2520I%2520Antigen%2520Processing%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2012%26volume%3D69%26issue%3D15%26spage%3D2543%26epage%3D2558%26doi%3D10.1007%2Fs00018-012-0938-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barton, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rangwala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deepe, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monaco, J. J.</span></span> <span> </span><span class="NLM_article-title">Regulation of Immunoproteasome Subunit Expression In Vivo Following Pathogenic Fungal Infection</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>169</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">3046</span>â <span class="NLM_lpage">3052</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.169.6.3046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.4049%2Fjimmunol.169.6.3046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=12218120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD38XntFahtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2002&pages=3046-3052&issue=6&author=L.+F.+Bartonauthor=M.+Cruzauthor=R.+Rangwalaauthor=G.+S.+Deepeauthor=J.+J.+Monaco&title=Regulation+of+Immunoproteasome+Subunit+Expression+In+Vivo+Following+Pathogenic+Fungal+Infection&doi=10.4049%2Fjimmunol.169.6.3046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of immunoproteasome subunit expression in vivo following pathogenic fungal infection</span></div><div class="casAuthors">Barton, Lance F.; Cruz, Miguel; Rangwala, Reshma; Deepe, George S., Jr.; Monaco, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3046-3052</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The proteasome catalytic Î² subunits LMP2, LMP7, and MECL-1 and two proteasome activator proteins, PA28 Î± and Î², are induced following exposure to IFN-Î³ in vitro.  Induction of these immunosubunits and the PA28 Î±/Î² hetero-oligomer alters proteasome catalytic functions and specificity and enhances prodn. of certain MHC class I epitopes.  We sought to det. whether and to what extent proteasome subunit compn. is regulated in vivo and to elucidate the mechanisms of such regulation.  We analyzed basal expression levels of these inducible genes in normal, IFN-Î³-deficient, and Stat-1-deficient mice.  Mice of all three genotypes display constitutive expression of the immunosubunits and PA28, demonstrating that basal expression in vivo is independent of endogenous IFN-Î³ prodn.  However, basal expression levels are reduced in Stat-1-/- mice, demonstrating a role for Stat-1 independent of IFN-Î³ signaling.  To demonstrate that IFN-Î³ can induce these genes in vivo, mice were infected with Histoplasma capsulatum.  Elevated expression of these genes followed the same time course as IFN-Î³ expression in infected mice.  IFN-Î³-deficient mice did not display elevated protein expression following infection, suggesting that other inflammatory cytokines produced in infected mice are unable to influence proteasome expression.  Cytokines other than IFN-Î³ also failed to influence proteasome gene expression in vitro in cell lines that had no basal expression of LMP2, LMP7, or MECL-1.  Thus, both in vitro and in vivo data demonstrate that IFN-Î³ is essential for up-regulation, but not constitutive expression, of immunoproteasome subunits in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEbd92vE7SFLVg90H21EOLACvtfcHk0lhNbTFQIV2XZA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntFahtbg%253D&md5=b8fbef6b077d36d233fac5b382c19328</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.169.6.3046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.169.6.3046%26sid%3Dliteratum%253Aachs%26aulast%3DBarton%26aufirst%3DL.%2BF.%26aulast%3DCruz%26aufirst%3DM.%26aulast%3DRangwala%26aufirst%3DR.%26aulast%3DDeepe%26aufirst%3DG.%2BS.%26aulast%3DMonaco%26aufirst%3DJ.%2BJ.%26atitle%3DRegulation%2520of%2520Immunoproteasome%2520Subunit%2520Expression%2520In%2520Vivo%2520Following%2520Pathogenic%2520Fungal%2520Infection%26jtitle%3DJ.%2520Immunol.%26date%3D2002%26volume%3D169%26issue%3D6%26spage%3D3046%26epage%3D3052%26doi%3D10.4049%2Fjimmunol.169.6.3046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seliger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeurer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrone, S.</span></span> <span> </span><span class="NLM_article-title">Antigen-Processing Machinery Breakdown and Tumor Growth</span>. <i>Immunol. Today</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">455</span>â <span class="NLM_lpage">464</span>, <span class="refDoi">Â DOI: 10.1016/S0167-5699(00)01692-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2FS0167-5699%2800%2901692-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10953098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtVCmsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2000&pages=455-464&issue=9&author=B.+Seligerauthor=M.+J.+Maeurerauthor=S.+Ferrone&title=Antigen-Processing+Machinery+Breakdown+and+Tumor+Growth&doi=10.1016%2FS0167-5699%2800%2901692-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Antigen-processing machinery breakdown and tumor growth</span></div><div class="casAuthors">Seliger, B.; Maeurer, M. J.; Ferrone, S.</div><div class="citationInfo"><span class="NLM_cas:title">Immunology Today</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">455-464</span>CODEN:
                <span class="NLM_cas:coden">IMTOD8</span>;
        ISSN:<span class="NLM_cas:issn">0167-4919</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 96 refs.  Defects in the major histocompatibility complex (MHC) class I antigen-processing machinery (APM) have been described in tumors of different histol.  Murine data suggest that defects in the MHC class II APM might also be assocd. with malignant transformation of human cells.  This article describes the pathophysiol. of the MHC class I and II APM, reviews APM abnormalities in tumor cells and discusses their role in the escape of tumor cells from in vitro recognition by T cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0G2-lKQUf2bVg90H21EOLACvtfcHk0lhNbTFQIV2XZA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtVCmsr0%253D&md5=37a986d69d3b6d49850c56d6429d1b40</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2FS0167-5699%2800%2901692-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0167-5699%252800%252901692-3%26sid%3Dliteratum%253Aachs%26aulast%3DSeliger%26aufirst%3DB.%26aulast%3DMaeurer%26aufirst%3DM.%2BJ.%26aulast%3DFerrone%26aufirst%3DS.%26atitle%3DAntigen-Processing%2520Machinery%2520Breakdown%2520and%2520Tumor%2520Growth%26jtitle%3DImmunol.%2520Today%26date%3D2000%26volume%3D21%26issue%3D9%26spage%3D455%26epage%3D464%26doi%3D10.1016%2FS0167-5699%2800%2901692-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cenci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezghrani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerruti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelouard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masciarelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattioli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasqualetto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruffato, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagliavacca, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitia, R.</span></span> <span> </span><span class="NLM_article-title">Progressively Impaired Proteasomal Capacity during Terminal Plasma Cell Differentiation</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1104</span>â <span class="NLM_lpage">1113</span>, <span class="refDoi">Â DOI: 10.1038/sj.emboj.7601009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fsj.emboj.7601009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=16498407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD28XitVyisrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=1104-1113&issue=5&author=S.+Cenciauthor=A.+Mezghraniauthor=P.+Cascioauthor=G.+Bianchiauthor=F.+Cerrutiauthor=A.+Fraauthor=H.+Lelouardauthor=S.+Masciarelliauthor=L.+Mattioliauthor=L.+Olivaauthor=A.+Orsiauthor=E.+Pasqualettoauthor=P.+Pierreauthor=E.+Ruffatoauthor=L.+Tagliavaccaauthor=R.+Sitia&title=Progressively+Impaired+Proteasomal+Capacity+during+Terminal+Plasma+Cell+Differentiation&doi=10.1038%2Fsj.emboj.7601009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Progressively impaired proteasomal capacity during terminal plasma cell differentiation</span></div><div class="casAuthors">Cenci, Simone; Mezghrani, Alexandre; Cascio, Paolo; Bianchi, Giada; Cerruti, Fulvia; Fra, Anna; Lelouard, Hugues; Masciarelli, Silvia; Mattioli, Laura; Oliva, Laura; Orsi, Andrea; Pasqualetto, Elena; Pierre, Philippe; Ruffato, Elena; Tagliavacca, Luigina; Sitia, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1104-1113</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">After few days of intense Ig secretion, most plasma cells undergo apoptosis, thus ending the humoral immune response.  The authors asked whether intrinsic factors link plasma cell lifespan to Ig secretion.  Here the authors show that in the late phases of plasmacytic differentiation, when antibody prodn. becomes maximal, proteasomal activity decreases.  The excessive load for the reduced proteolytic capacity correlates with accumulation of polyubiquitinated proteins, stabilization of endogenous proteasomal substrates (including Xbp1s, IÎºBÎ±, and Bax), onset of apoptosis, and sensitization to proteasome inhibitors (PI).  These events can be reproduced by expressing Ig-Î¼ chain in nonlymphoid cells.  The authors' results suggest that a developmental program links plasma cell death to protein prodn., and help explaining the peculiar sensitivity of normal and malignant plasma cells to PI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriiTN9EGlsB7Vg90H21EOLACvtfcHk0lgJXemfa2F53g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitVyisrc%253D&md5=73c65465fd831fb4560d67e9740c6b21</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7601009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7601009%26sid%3Dliteratum%253Aachs%26aulast%3DCenci%26aufirst%3DS.%26aulast%3DMezghrani%26aufirst%3DA.%26aulast%3DCascio%26aufirst%3DP.%26aulast%3DBianchi%26aufirst%3DG.%26aulast%3DCerruti%26aufirst%3DF.%26aulast%3DFra%26aufirst%3DA.%26aulast%3DLelouard%26aufirst%3DH.%26aulast%3DMasciarelli%26aufirst%3DS.%26aulast%3DMattioli%26aufirst%3DL.%26aulast%3DOliva%26aufirst%3DL.%26aulast%3DOrsi%26aufirst%3DA.%26aulast%3DPasqualetto%26aufirst%3DE.%26aulast%3DPierre%26aufirst%3DP.%26aulast%3DRuffato%26aufirst%3DE.%26aulast%3DTagliavacca%26aufirst%3DL.%26aulast%3DSitia%26aufirst%3DR.%26atitle%3DProgressively%2520Impaired%2520Proteasomal%2520Capacity%2520during%2520Terminal%2520Plasma%2520Cell%2520Differentiation%26jtitle%3DEMBO%2520J.%26date%3D2006%26volume%3D25%26issue%3D5%26spage%3D1104%26epage%3D1113%26doi%3D10.1038%2Fsj.emboj.7601009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakkis, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, G.</span></span> <span> </span><span class="NLM_article-title">B Cells, Antibodies, and More</span>. <i>Clin. J. Am. Soc. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">137</span>â <span class="NLM_lpage">154</span>, <span class="refDoi">Â DOI: 10.2215/CJN.09430915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.2215%2FCJN.09430915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=26700440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC28XntFWjsLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=137-154&issue=1&author=W.+Hoffmanauthor=F.+G.+Lakkisauthor=G.+Chalasani&title=B+Cells%2C+Antibodies%2C+and+More&doi=10.2215%2FCJN.09430915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">B Cells, antibodies, and more</span></div><div class="casAuthors">Hoffman, William; Lakkis, Fadi G.; Chalasani, Geetha</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">137-154</span>CODEN:
                <span class="NLM_cas:coden">CJASC7</span>;
        ISSN:<span class="NLM_cas:issn">1555-9041</span>.
    
            (<span class="NLM_cas:orgname">American Society of Nephrology</span>)
        </div><div class="casAbstract">B cells play a central role in the immunopathogenesis of glomerulonephritides and transplant rejection.  B cells secrete antibodies that contribute to tissue injury via multiple mechanisms.  In addn., B cells contribute to disease pathogenesis in autoimmunity and alloimmunity by presenting antigens as well as providing costimulation and cytokines to T cells.  B cells also play an immunomodulatory role in regulating the immune response by secreting cytokines that inhibit disease onset and/or progression.  B cell-targeted approaches for treating immune diseases of the kidney and other organs have gained significant momentum.  However, much remains to be understood about B-cell biol. in order to det. the timing, duration, and context of optimal therapeutic response to B cell-targeted approaches.  In this review, we discuss the multifaceted roles of B cells as enhancers and regulators of immunity with relevance to kidney disease and transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0W5E5D9x6FbVg90H21EOLACvtfcHk0lgJXemfa2F53g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntFWjsLg%253D&md5=71b5c946dea4849cd1386104add29d58</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.2215%2FCJN.09430915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2215%252FCJN.09430915%26sid%3Dliteratum%253Aachs%26aulast%3DHoffman%26aufirst%3DW.%26aulast%3DLakkis%26aufirst%3DF.%2BG.%26aulast%3DChalasani%26aufirst%3DG.%26atitle%3DB%2520Cells%252C%2520Antibodies%252C%2520and%2520More%26jtitle%3DClin.%2520J.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2016%26volume%3D11%26issue%3D1%26spage%3D137%26epage%3D154%26doi%3D10.2215%2FCJN.09430915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pengo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerruti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasqualetto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezghrani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calbi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palladini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cenci, S.</span></span> <span> </span><span class="NLM_article-title">The Proteasome Load versus Capacity Balance Determines Apoptotic Sensitivity of Multiple Myeloma Cells to Proteasome Inhibition</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3040</span>â <span class="NLM_lpage">3049</span>, <span class="refDoi">Â DOI: 10.1182/blood-2008-08-172734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1182%2Fblood-2008-08-172734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=19164601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFWntrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=3040-3049&issue=13&author=G.+Bianchiauthor=L.+Olivaauthor=P.+Cascioauthor=N.+Pengoauthor=F.+Fontanaauthor=F.+Cerrutiauthor=A.+Orsiauthor=E.+Pasqualettoauthor=A.+Mezghraniauthor=V.+Calbiauthor=G.+Palladiniauthor=N.+Giulianiauthor=K.+Andersonauthor=R.+Sitiaauthor=S.+Cenci&title=The+Proteasome+Load+versus+Capacity+Balance+Determines+Apoptotic+Sensitivity+of+Multiple+Myeloma+Cells+to+Proteasome+Inhibition&doi=10.1182%2Fblood-2008-08-172734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition</span></div><div class="casAuthors">Bianchi, Giada; Oliva, Laura; Cascio, Paolo; Pengo, Niccolo; Fontana, Francesca; Cerruti, Fulvia; Orsi, Andrea; Pasqualetto, Elena; Mezghrani, Alexandre; Calbi, Valeria; Palladini, Giovanni; Giuliani, Nicola; Anderson, Kenneth C.; Sitia, Roberto; Cenci, Simone</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3040-3049</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Proteasome inhibitors (PIs) are effective against multiple myeloma (MM), but the mechanisms of action and bases of individual susceptibility remain unclear.  Recent work linked PI sensitivity to protein synthesis and proteasome activity, raising the question whether different levels of proteasome expression and workload underlie PI sensitivity in MM cells (MMCs).  Exploiting human MM lines characterized by differential PI sensitivity, we report that highly sensitive MMCs express lower proteasome levels and higher proteasomal workload than relatively PI-resistant MMCs, resulting in the accumulation of polyubiquitinated proteins at the expense of free ubiquitin (proteasome stress).  Manipulating proteasome expression or workload alters apoptotic sensitivity to PI, demonstrating a cause-effect relationship between proteasome stress and apoptotic responses in MMCs.  Intracellular immunostaining in primary, patient-derived MMCs reveals that polyubiquitinated proteins hallmark neoplastic plasma cells, in pos. correlation with Ig content, both intra- and interpatient.  Moreover, overall proteasome activity of primary MMCs inversely correlates with apoptotic sensitivity to PI.  Altogether, our data indicate that the balance between proteasome workload and degradative capacity represents a crit. determinant of apoptotic sensitivity of MMCs to PI, potentially providing a framework for identifying indicators of responsiveness and designing novel combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojZB8ZrWDyLbVg90H21EOLACvtfcHk0livi_oPX0oaMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFWntrs%253D&md5=dd9f98f07f06ba2d312a54228d96ceef</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-08-172734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-08-172734%26sid%3Dliteratum%253Aachs%26aulast%3DBianchi%26aufirst%3DG.%26aulast%3DOliva%26aufirst%3DL.%26aulast%3DCascio%26aufirst%3DP.%26aulast%3DPengo%26aufirst%3DN.%26aulast%3DFontana%26aufirst%3DF.%26aulast%3DCerruti%26aufirst%3DF.%26aulast%3DOrsi%26aufirst%3DA.%26aulast%3DPasqualetto%26aufirst%3DE.%26aulast%3DMezghrani%26aufirst%3DA.%26aulast%3DCalbi%26aufirst%3DV.%26aulast%3DPalladini%26aufirst%3DG.%26aulast%3DGiuliani%26aufirst%3DN.%26aulast%3DAnderson%26aufirst%3DK.%26aulast%3DSitia%26aufirst%3DR.%26aulast%3DCenci%26aufirst%3DS.%26atitle%3DThe%2520Proteasome%2520Load%2520versus%2520Capacity%2520Balance%2520Determines%2520Apoptotic%2520Sensitivity%2520of%2520Multiple%2520Myeloma%2520Cells%2520to%2520Proteasome%2520Inhibition%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26issue%3D13%26spage%3D3040%26epage%3D3049%26doi%3D10.1182%2Fblood-2008-08-172734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frezza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanwar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, Q. P.</span></span> <span> </span><span class="NLM_article-title">Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">239</span>â <span class="NLM_lpage">253</span>, <span class="refDoi">Â DOI: 10.2174/156800911794519752</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.2174%2F156800911794519752" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=21247388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjt1agtbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=239-253&issue=3&author=D.+Chenauthor=M.+Frezzaauthor=S.+Schmittauthor=J.+Kanwarauthor=Q.+P.+Dou&title=Bortezomib+as+the+First+Proteasome+Inhibitor+Anticancer+Drug%3A+Current+Status+and+Future+Perspectives&doi=10.2174%2F156800911794519752"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives</span></div><div class="casAuthors">Chen, D.; Frezza, M.; Schmitt, S.; Kanwar, J.; Dou, Q. P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-253</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Targeting the ubiquitin-proteasome pathway has emerged as a rational approach in the treatment of human cancer.  Based on pos. preclin. and clin. studies, bortezomib was subsequently approved for the clin. use as a front-line treatment for newly diagnosed multiple myeloma patients and for the treatment of relapsed/refractory multiple myeloma and mantle cell lymphoma, for which this drug has become the staple of treatment.  The approval of bortezomib by the US Food and Drug Administration (FDA) represented a significant milestone as the first proteasome inhibitor to be implemented in the treatment of malignant disease.  Bortezomib has shown a pos. clin. benefit either alone or as a part of combination therapy to induce chemo-/radio-sensitization or overcome drug resistance.  One of the major mechanisms of bortezomib assocd. with its anticancer activity is through upregulation of NOXA, which is a proapoptotic protein, and NOXA may interact with the anti-apoptotic proteins of Bcl-2 subfamily Bcl-XL and Bcl-2, and result in apoptotic cell death in malignant cells.  Another important mechanism of bortezomib is through suppression of the NF-ÎºB signaling pathway resulting in the down-regulation of its anti-apoptotic target genes.  Although the majority of success achieved with bortezomib has been in hematol. malignancies, its effect toward solid tumors has been less than encouraging.  Addnl., the widespread clin. use of bortezomib continues to be hampered by the appearance of dose-limiting toxicities, drug-resistance and interference by some natural compds.  These findings could help guide physicians in refining the clin. use of bortezomib, and encourage basic scientists to generate next generation proteasome inhibitors that broaden the spectrum of efficacy and produce a more durable clin. response in cancer patients.  Other desirable applications for the use of proteasome inhibitors include the development of inhibitors against specific E3 ligases, which act at an early step in the ubiquitin-proteasome pathway, and the discovery of less toxic and novel proteasome inhibitors from natural products and traditional medicines, which may provide more viable drug candidates for cancer chemoprevention and the treatment of cancer patients in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP4QCk3nP8BLVg90H21EOLACvtfcHk0livi_oPX0oaMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjt1agtbs%253D&md5=15becbceb98ec3e244fc066315815dd2</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.2174%2F156800911794519752&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156800911794519752%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DD.%26aulast%3DFrezza%26aufirst%3DM.%26aulast%3DSchmitt%26aufirst%3DS.%26aulast%3DKanwar%26aufirst%3DJ.%26aulast%3DDou%26aufirst%3DQ.%2BP.%26atitle%3DBortezomib%2520as%2520the%2520First%2520Proteasome%2520Inhibitor%2520Anticancer%2520Drug%253A%2520Current%2520Status%2520and%2520Future%2520Perspectives%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2011%26volume%3D11%26issue%3D3%26spage%3D239%26epage%3D253%26doi%3D10.2174%2F156800911794519752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kane, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bross, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">VelcadeÂ®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">508</span>â <span class="NLM_lpage">513</span>, <span class="refDoi">Â DOI: 10.1634/theoncologist.8-6-508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1634%2Ftheoncologist.8-6-508" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=14657528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BD3srnslGhtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=508-513&issue=6&author=R.+C.+Kaneauthor=P.+F.+Brossauthor=A.+T.+Farrellauthor=R.+Pazdur&title=Velcade%C2%AE%3A+U.S.+FDA+Approval+for+the+Treatment+of+Multiple+Myeloma+Progressing+on+Prior+Therapy&doi=10.1634%2Ftheoncologist.8-6-508"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy</span></div><div class="casAuthors">Kane Robert C; Bross Peter F; Farrell Ann T; Pazdur Richard</div><div class="citationInfo"><span class="NLM_cas:title">The oncologist</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">508-13</span>
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    </div><div class="casAbstract">Bortezomib (formerly PS-341), a promising new drug for the treatment of multiple myeloma, recently received accelerated approval from the U.S.  Food and Drug Administration (FDA) for the therapy of patients with progressive myeloma after previous treatment.  Two phase II studies of bortezomib used the same schedule of twice-weekly i.v. dosing for the first 2 weeks of each 3-week cycle.  In a randomized study of 54 patients, two doses were compared (1.0 and 1.3 mg/m2) and objective responses occurred at both dose levels (23% versus 35%), including one complete response in each arm.  In the other phase II study, 202 heavily pretreated patients (median of six prior therapies) all received the same schedule at 1.3 mg/m2.  Of 188 evaluable patients, complete responses occurred in five (3%) and partial responses occurred in 47 (25%).  The median duration of response was 365 days.  The most clinically relevant adverse events were asthenic conditions, nausea, vomiting, diarrhea, thrombocytopenia, and a peripheral neuropathy that often was painful.  This report highlights the FDA analysis supporting the accelerated approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTS_wiRSzN1ZNy3lHz94U-GfW6udTcc2eaunaie0x2yIbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3srnslGhtQ%253D%253D&md5=e5420a8677aa046abed3f232889d194c</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.8-6-508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.8-6-508%26sid%3Dliteratum%253Aachs%26aulast%3DKane%26aufirst%3DR.%2BC.%26aulast%3DBross%26aufirst%3DP.%2BF.%26aulast%3DFarrell%26aufirst%3DA.%2BT.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DVelcade%25C2%25AE%253A%2520U.S.%2520FDA%2520Approval%2520for%2520the%2520Treatment%2520of%2520Multiple%2520Myeloma%2520Progressing%2520on%2520Prior%2520Therapy%26jtitle%3DOncologist%26date%3D2003%26volume%3D8%26issue%3D6%26spage%3D508%26epage%3D513%26doi%3D10.1634%2Ftheoncologist.8-6-508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manyak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altamirano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borad, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frantzen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neeser, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjak-Shie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vescio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berenson, J.</span></span> <span> </span><span class="NLM_article-title">The Proteasome Inhibitor PS-341 Markedly Enhances Sensitivity of Multiple Myeloma Tumor Cells to Chemotherapeutic Agents</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1136</span>â <span class="NLM_lpage">1144</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=12631619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvFKitbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=1136-1144&issue=3&author=M.+H.+Maauthor=H.+H.+Yangauthor=K.+Parkerauthor=S.+Manyakauthor=J.+M.+Friedmanauthor=C.+Altamiranoauthor=Z.+Wuauthor=M.+J.+Boradauthor=M.+Frantzenauthor=E.+Roussosauthor=J.+Neeserauthor=A.+Mikaliauthor=J.+Adamsauthor=N.+Sjak-Shieauthor=R.+Vescioauthor=J.+Berenson&title=The+Proteasome+Inhibitor+PS-341+Markedly+Enhances+Sensitivity+of+Multiple+Myeloma+Tumor+Cells+to+Chemotherapeutic+Agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">The Proteasome Inhibitor PS-341 Markedly Enhances Sensitivity of Multiple Myeloma Tumor Cells to Chemotherapeutic Agents</span></div><div class="casAuthors">Ma, Mark H.; Yang, Hank H.; Parker, Kimberly; Manyak, Steven; Friedman, Jeffrey M.; Altamirano, Cibby; Wu, Zhi-qun; Borad, Mitesh J.; Frantzen, Malka; Roussos, Evanthia; Neeser, Jason; Mikail, Amy; Adams, Julian; Sjak-Shie, Nelida; Vescio, Robert A.; Berenson, James R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1136-1144</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Increased nuclear factor ÎºB (NF-ÎºB) activity is assocd. with increased tumor cell survival in multiple myeloma.  The function of NF-ÎºB is inhibited through binding to its inhibitor, IÎºB.  Release of activated NF-B follows proteasome-mediated degrdn. of IB resulting from phosphorylation of the inhibitor and, finally, conjugation with ubiquitin.  We report that myeloma cells have enhanced IÎºBÎ± phosphorylation and increased NF-ÎºB activity compared with normal hematopoietic cells.  The proteasome inhibitor PS-341 blocked nuclear translocation of NF-ÎºB, blocked NF-ÎºB DNA binding, and demonstrated consistent antitumor activity against chemoresistant and chemosensitive myeloma cells.  The sensitivity of chemoresistant myeloma cells to chemotherapeutic agents was markedly increased (100,000-1,000,000-fold) when combined with a noncytotoxic dose of PS-341 without affecting normal hematopoietic cells.  Similar effects were obsd. using a dominant neg. super-repressor for IÎºBÎ±.  Thus, these results suggest that inhibition of NF-ÎºB with PS-341 may overcome chemoresistance and allow doses of chemotherapeutic agents to be markedly reduced with antitumor effects without significant toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIyqYjYivBfrVg90H21EOLACvtfcHk0ljw6Id8ZyYs8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvFKitbo%253D&md5=4c8ec85cedfe85c29a297d687091b5cf</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DM.%2BH.%26aulast%3DYang%26aufirst%3DH.%2BH.%26aulast%3DParker%26aufirst%3DK.%26aulast%3DManyak%26aufirst%3DS.%26aulast%3DFriedman%26aufirst%3DJ.%2BM.%26aulast%3DAltamirano%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DBorad%26aufirst%3DM.%2BJ.%26aulast%3DFrantzen%26aufirst%3DM.%26aulast%3DRoussos%26aufirst%3DE.%26aulast%3DNeeser%26aufirst%3DJ.%26aulast%3DMikali%26aufirst%3DA.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DSjak-Shie%26aufirst%3DN.%26aulast%3DVescio%26aufirst%3DR.%26aulast%3DBerenson%26aufirst%3DJ.%26atitle%3DThe%2520Proteasome%2520Inhibitor%2520PS-341%2520Markedly%2520Enhances%2520Sensitivity%2520of%2520Multiple%2520Myeloma%2520Tumor%2520Cells%2520to%2520Chemotherapeutic%2520Agents%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2003%26volume%3D9%26issue%3D3%26spage%3D1136%26epage%3D1144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">An, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagosklonny, M. V.</span></span> <span> </span><span class="NLM_article-title">Protease Inhibitor-Induced Apoptosis: Accumulation of Wt P53, P21WAF1/CIP1, and Induction of Apoptosis Are Independent Markers of Proteasome Inhibition</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1276</span>â <span class="NLM_lpage">1283</span>, <span class="refDoi">Â DOI: 10.1038/sj.leu.2401812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fsj.leu.2401812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10914553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD3cXls1Oitbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2000&pages=1276-1283&issue=7&author=W.+G.+Anauthor=S.+G.+Hwangauthor=J.+B.+Trepelauthor=M.+V.+Blagosklonny&title=Protease+Inhibitor-Induced+Apoptosis%3A+Accumulation+of+Wt+P53%2C+P21WAF1%2FCIP1%2C+and+Induction+of+Apoptosis+Are+Independent+Markers+of+Proteasome+Inhibition&doi=10.1038%2Fsj.leu.2401812"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Protease inhibitor-induced apoptosis: Accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition</span></div><div class="casAuthors">An, W. G.; Hwang, S. -G.; Trepel, J. B.; Blagosklonny, M. V.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1276-1283</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibitors of proteases are currently emerging as a potential anti-cancer modality.  Nonselective protease inhibitors are cytotoxic to leukemia and cancer cell lines and we found that this cytotoxicity is correlated with their potency as inhibitors of the proteasome but not as inhibitors of calpain and cathepsin.  Highly selective inhibitors of the proteasome were more cytotoxic and fast-acting than less selective inhibitors (PS341Â»ALLNÂ»ALLM).  Induction of wt p53 correlated with inhibition of the proteasome and antiproliferative effect in MCF-7, a breast cancer cell line, which was resistant to apoptosis caused by proteasome inhibitors.  In contrast, inhibitors of the proteasome induced apoptosis in four leukemia cell lines lacking wt p53.  The order of sensitivity of leukemia cells was: Jurkat>HL60âªU937Â»K562.  The highly selective proteasome inhibitor PS-341 induced cell death with an IC50 as low as 5 nM in apoptosis-prone leukemia cells.  Cell death was preceded by p21WAF1/CIP1 accumulation, an alternative marker of proteasome inhibition, and by cleavage of PARP and Rb proteins and nuclear fragmentation.  Inhibition of caspases abrogated PARP cleavage and nuclear fragmentation and delayed, but did not completely prevent cell death caused by PS-341.  Re-introduction of wt p53 into p53-null PC3 prostate carcinoma cells did not increase their sensitivity to proteasome inhibitors.  Likewise, comparison of parental and p21-deficient cells demonstrated that p21WAF1/CIP1 was dispensable for proteasome inhibitor-induced cytotoxicity.  We conclude that accumulation of wt p53 and induction of apoptosis are independent markers of proteasome inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1tvPyuwzZzLVg90H21EOLACvtfcHk0ljw6Id8ZyYs8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXls1Oitbg%253D&md5=be2c8a1811cef52258092b592d405ac8</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2401812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2401812%26sid%3Dliteratum%253Aachs%26aulast%3DAn%26aufirst%3DW.%2BG.%26aulast%3DHwang%26aufirst%3DS.%2BG.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26aulast%3DBlagosklonny%26aufirst%3DM.%2BV.%26atitle%3DProtease%2520Inhibitor-Induced%2520Apoptosis%253A%2520Accumulation%2520of%2520Wt%2520P53%252C%2520P21WAF1%252FCIP1%252C%2520and%2520Induction%2520of%2520Apoptosis%2520Are%2520Independent%2520Markers%2520of%2520Proteasome%2520Inhibition%26jtitle%3DLeukemia%26date%3D2000%26volume%3D14%26issue%3D7%26spage%3D1276%26epage%3D1283%26doi%3D10.1038%2Fsj.leu.2401812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonneveld, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irwin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmauer, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harousseau, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Yehuda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldschmidt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reece, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San-Miguel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blade, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boccadoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavenagh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boral, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esseltine, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenkein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span> <span> </span><span class="NLM_article-title">Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">2487</span>â <span class="NLM_lpage">2498</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa043445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1056%2FNEJMoa043445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=15958804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlaksLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=2487-2498&issue=24&author=P.+G.+Richardsonauthor=P.+Sonneveldauthor=M.+W.+Schusterauthor=D.+Irwinauthor=E.+A.+Stadtmauerauthor=T.+Faconauthor=J.-L.+Harousseauauthor=D.+Ben-Yehudaauthor=S.+Lonialauthor=H.+Goldschmidtauthor=D.+Reeceauthor=J.+San-Miguelauthor=J.+Bladeauthor=M.+Boccadoroauthor=J.+Cavenaghauthor=W.+Daltonauthor=A.+Boralauthor=D.+Esseltineauthor=J.+Porterauthor=D.+Schenkeinauthor=K.+Anderson&title=Bortezomib+or+High-Dose+Dexamethasone+for+Relapsed+Multiple+Myeloma&doi=10.1056%2FNEJMoa043445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Bortezomib or high-dose dexamethasone for relapsed multiple myeloma</span></div><div class="casAuthors">Richardson, Paul G.; Sonneveld, Pieter; Schuster, Michael W.; Irwin, David; Stadtmauer, Edward A.; Facon, Thierry; Harousseau, Jean-Luc; Ben-Yehuda, Dina; Lonial, Sagar; Goldschmidt, Hartmut; Reece, Donna; San-Miguel, Jesus F.; Blade, Joan; Boccadoro, Mario; Cavenaugh, Jamie; Dalton, William S.; Boral, Anthony L.; Esseltine, Dixie L.; Porter, Jane B.; Schenkein, David; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2487-2498</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">This study compared bortezomib with high-dose dexamethasone in patients with re- lapsed multiple myeloma who had received one to three previous therapies.  We randomly assigned 669 patients with relapsed myeloma to receive either an i.v. bolus of bortezomib (1.3 mg per square meter of body-surface area) on days 1, 4, 8, and 11 for eight three-week cycles, followed by treatment on days 1, 8, 15, and 22 for three five-week cycles, or high-dose dexamethasone (40 mg orally) on days 1 through 4, 9 through 12, and 17 through' 20 for four five-week cycles, followed by treatment on days 1 through 4 for five four-week cycles.  Patients who were assigned to receive dexamethasone were permitted to cross over to receive bortezomib in a companion study after disease progression.  Patients treated with bortezomib had higher response rates, a longer time to progression (the primary end point), and a longer survival than patients treated with dexamethasone.  The combined complete and partial response rates were 38 % for bortezomib and 18 % for dexamethasone (P < 0.001), and the complete response rates were 6 % and less than 1 %, resp. (P < 0.001).  Median times to progression in the bortezomib and dexamethasone groups were 6.22 mo (189 days) and 3.49 mo (106 days), resp. (hazard ratio, 0.55; P < 0.001).  The one-year survival rate was 80 % among patients taking bortezomib and 66 % among patients taking dexamethasone (P = 0.003), and the hazard ratio for overall survival with bortezomib was 0.57 (P = 0.001).  Grade 3 or 4 adverse events were reported in 75 % of patients treated with bortezomib and in 60 % of those treated with dexamethasone.  Bortezomib is superior to high-dose dexamethasone for the treatment of patients with multiple myeloma who have had a relapse after one to three previous therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlMw95MftsqLVg90H21EOLACvtfcHk0ljw6Id8ZyYs8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlaksLc%253D&md5=d277c662178e725f9f88aa6a7e1187f2</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa043445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa043445%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DSonneveld%26aufirst%3DP.%26aulast%3DSchuster%26aufirst%3DM.%2BW.%26aulast%3DIrwin%26aufirst%3DD.%26aulast%3DStadtmauer%26aufirst%3DE.%2BA.%26aulast%3DFacon%26aufirst%3DT.%26aulast%3DHarousseau%26aufirst%3DJ.-L.%26aulast%3DBen-Yehuda%26aufirst%3DD.%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DGoldschmidt%26aufirst%3DH.%26aulast%3DReece%26aufirst%3DD.%26aulast%3DSan-Miguel%26aufirst%3DJ.%26aulast%3DBlade%26aufirst%3DJ.%26aulast%3DBoccadoro%26aufirst%3DM.%26aulast%3DCavenagh%26aufirst%3DJ.%26aulast%3DDalton%26aufirst%3DW.%26aulast%3DBoral%26aufirst%3DA.%26aulast%3DEsseltine%26aufirst%3DD.%26aulast%3DPorter%26aufirst%3DJ.%26aulast%3DSchenkein%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DK.%26atitle%3DBortezomib%2520or%2520High-Dose%2520Dexamethasone%2520for%2520Relapsed%2520Multiple%2520Myeloma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26issue%3D24%26spage%3D2487%26epage%3D2498%26doi%3D10.1056%2FNEJMoa043445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lichter, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danaee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickard, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tayber, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavenagh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BladÃ©, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FaÃ§on, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niesvizky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonneveld, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Velde, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esseltine, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepicchio, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span> <span> </span><span class="NLM_article-title">Sequence Analysis of Î²-Subunit Genes of the 20S Proteasome in Patients with Relapsed Multiple Myeloma Treated with Bortezomib or Dexamethasone</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>120</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">4513</span>â <span class="NLM_lpage">4516</span>, <span class="refDoi">Â DOI: 10.1182/blood-2012-05-426924</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1182%2Fblood-2012-05-426924" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=23018640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVWgtb%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2012&pages=4513-4516&issue=23&author=D.+I.+Lichterauthor=H.+Danaeeauthor=M.+D.+Pickardauthor=O.+Tayberauthor=M.+Sintchakauthor=H.+Shiauthor=P.+G.+Richardsonauthor=J.+Cavenaghauthor=J.+Blad%C3%A9author=T.+Fa%C3%A7onauthor=R.+Niesvizkyauthor=M.+Alsinaauthor=W.+Daltonauthor=P.+Sonneveldauthor=S.+Lonialauthor=H.+van+de+Veldeauthor=D.+Ricciauthor=D.+Esseltineauthor=W.+Trepicchioauthor=G.+Mulliganauthor=K.+Anderson&title=Sequence+Analysis+of+%CE%B2-Subunit+Genes+of+the+20S+Proteasome+in+Patients+with+Relapsed+Multiple+Myeloma+Treated+with+Bortezomib+or+Dexamethasone&doi=10.1182%2Fblood-2012-05-426924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Sequence analysis of Î²-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone</span></div><div class="casAuthors">Lichter, David I.; Danaee, Hadi; Pickard, Michael D.; Tayber, Olga; Sintchak, Michael; Shi, Hongliang; Richardson, Paul G.; Cavenagh, Jamie; Blade, Joan; Facon, Thierry; Niesvizky, Ruben; Alsina, Melissa; Dalton, William; Sonneveld, Pieter; Lonial, Sagar; van de Velde, Helgi; Ricci, Deborah; Esseltine, Dixie-Lee; Trepicchio, William L.; Mulligan, George; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4513-4516</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Variations within proteasome Î² (PSMB) genes, which encode the Î² subunits of the 20S proteasome, may affect proteasome function, assembly, and/or binding of proteasome inhibitors.  To investigate the potential assocn. between PSMB gene variants and treatment-emergent resistance to bortezomib and/or long-term outcomes, in the present study, PSMB gene sequence variation was characterized in tumor DNA samples from patients who participated in the phase 3 Assessment of Proteasome Inhibition for Extending Remissions (APEX) study of bortezomib vs. high-dose dexamethasone for treatment of relapsed multiple myeloma.  Twelve new PSMB variants were identified.  No assocns. were found between PSMB single nucleotide polymorphism genotype frequency and clin. response to bortezomib or dexamethasone treatment or between PSMB single nucleotide polymorphism allelic frequency and pooled overall survival or time to progression.  Although specific PSMB5 variants have been identified previously in preclin. models of bortezomib resistance, these variants were not detected in patient tumor samples collected after clin. relapse from bortezomib, which suggests that alternative mechanisms underlie bortezomib insensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX89b8LFEdJrVg90H21EOLACvtfcHk0ljvUt2MYJ8oKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVWgtb%252FJ&md5=a2b26bfdf114d54db88202a929c4734f</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1182%2Fblood-2012-05-426924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2012-05-426924%26sid%3Dliteratum%253Aachs%26aulast%3DLichter%26aufirst%3DD.%2BI.%26aulast%3DDanaee%26aufirst%3DH.%26aulast%3DPickard%26aufirst%3DM.%2BD.%26aulast%3DTayber%26aufirst%3DO.%26aulast%3DSintchak%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DCavenagh%26aufirst%3DJ.%26aulast%3DBlad%25C3%25A9%26aufirst%3DJ.%26aulast%3DFa%25C3%25A7on%26aufirst%3DT.%26aulast%3DNiesvizky%26aufirst%3DR.%26aulast%3DAlsina%26aufirst%3DM.%26aulast%3DDalton%26aufirst%3DW.%26aulast%3DSonneveld%26aufirst%3DP.%26aulast%3DLonial%26aufirst%3DS.%26aulast%3Dvan%2Bde%2BVelde%26aufirst%3DH.%26aulast%3DRicci%26aufirst%3DD.%26aulast%3DEsseltine%26aufirst%3DD.%26aulast%3DTrepicchio%26aufirst%3DW.%26aulast%3DMulligan%26aufirst%3DG.%26aulast%3DAnderson%26aufirst%3DK.%26atitle%3DSequence%2520Analysis%2520of%2520%25CE%25B2-Subunit%2520Genes%2520of%2520the%252020S%2520Proteasome%2520in%2520Patients%2520with%2520Relapsed%2520Multiple%2520Myeloma%2520Treated%2520with%2520Bortezomib%2520or%2520Dexamethasone%26jtitle%3DBlood%26date%3D2012%26volume%3D120%26issue%3D23%26spage%3D4513%26epage%3D4516%26doi%3D10.1182%2Fblood-2012-05-426924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LÃ¼, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Different Mutants of PSMB5 Confer Varying Bortezomib Resistance in T Lymphoblastic Lymphoma/Leukemia Cells Derived from the Jurkat Cell Line</span>. <i>Exp. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">831</span>â <span class="NLM_lpage">837</span>, <span class="refDoi">Â DOI: 10.1016/j.exphem.2009.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.exphem.2009.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=19426847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFSjtb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=831-837&issue=7&author=S.+L%C3%BCauthor=J.+Yangauthor=Z.+Chenauthor=S.+Gongauthor=H.+Zhouauthor=X.+Xuauthor=J.+Wang&title=Different+Mutants+of+PSMB5+Confer+Varying+Bortezomib+Resistance+in+T+Lymphoblastic+Lymphoma%2FLeukemia+Cells+Derived+from+the+Jurkat+Cell+Line&doi=10.1016%2Fj.exphem.2009.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line</span></div><div class="casAuthors">Lue, Shuqing; Yang, Jianmin; Chen, Zhilong; Gong, Shenglan; Zhou, Hong; Xu, Xiaoqian; Wang, Jianmin</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Hematology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">831-837</span>CODEN:
                <span class="NLM_cas:coden">EXHMA6</span>;
        ISSN:<span class="NLM_cas:issn">0301-472X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Objective: To investigate the relationship between bortezomib resistance and mutations in the proteasome Î²5 subunit (PSMB5) gene.  Materials and Methods: Various bortezomib-resistant lymphoblastic lymphoma/leukemia lines were established by repeated cycles of bortezomib selection.  Mutations were detected by sequencing the complementary DNA of the PSMB5 gene.  Mutated clones were selected by limited diln. and cultured without bortezomib.  MRNA expression levels of PSMB5 in these mutated clones were measured by quant. reverse transcription polymerase chain reaction.  The degree of resistance was detd. by cytotoxicity at various bortezomib concns.  The chymotrypsin-like activities were assayed by measuring the release of the fluorescent 7-amido-4-methylcoumarin from the substrate N-succinyl-Leu-Leu-Val-Tyr - 7-amido-4-methylcoumarin.  Results: In addn. to the previously reported PSMB5 G322A mutant (Ala49Thr), a C323T mutant (Ala49Val), and G322A, C326T conjoined mutant (Ala49Thr and Ala50Val) were selected and clones contg. these mutations (JurkatB-G322A, JurkatB-C323T, and JurkatB-G322A/C326T) were obtained.  After being cultured without bortezomib for >2 mo, no significant difference in PSMB5 mRNA levels was detected between these JurkatB cells and parental Jurkat cells.  JurkatB-G322A, JurkatB-C323T, and JurkatB-G322A/C326T clones displayed 22.0-fold, 39.4-fold, and 66.7-fold resistance, resp., to bortezomib compared to Jurkat cells.  There were no significant differences between the chymotrypsin-like activities of these mutants and Jurkat cells.  The inhibitory effect of bortezomib on chymotrypsin-like activity was the weakest in JurkatB-G322A/C326T cells, and the strongest in JurkatB-G322A cells, with JurkatB-C323T cells falling in between.  Conclusion: Mutations of the PSMB5 gene resulting in substitutions of Ala49 and Ala50 of PSMB5 protein can confer varying bortezomib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbRv5fdeYb57Vg90H21EOLACvtfcHk0ljvUt2MYJ8oKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFSjtb4%253D&md5=35b9303e3b0393f867a67a197c688c10</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.exphem.2009.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exphem.2009.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25BC%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DGong%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DDifferent%2520Mutants%2520of%2520PSMB5%2520Confer%2520Varying%2520Bortezomib%2520Resistance%2520in%2520T%2520Lymphoblastic%2520Lymphoma%252FLeukemia%2520Cells%2520Derived%2520from%2520the%2520Jurkat%2520Cell%2520Line%26jtitle%3DExp.%2520Hematol.%26date%3D2009%26volume%3D37%26issue%3D7%26spage%3D831%26epage%3D837%26doi%3D10.1016%2Fj.exphem.2009.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oerlemans, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franke, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaraf, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Zantwijk, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffer, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debipersad, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vojtekova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Heijden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ylstra, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaspers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dijkmans, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheper, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, G.</span></span> <span> </span><span class="NLM_article-title">Molecular Basis of Bortezomib Resistance: Proteasome Subunit Beta5 (PSMB5) Gene Mutation and Overexpression of PSMB5 Protein</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>112</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2489</span>â <span class="NLM_lpage">2499</span>, <span class="refDoi">Â DOI: 10.1182/blood-2007-08-104950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1182%2Fblood-2007-08-104950" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=18565852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFCru7zO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2008&pages=2489-2499&issue=6&author=R.+Oerlemansauthor=N.+E.+Frankeauthor=Y.+G.+Assarafauthor=J.+Cloosauthor=I.+van+Zantwijkauthor=C.+R.+Berkersauthor=G.+L.+Schefferauthor=K.+Debipersadauthor=K.+Vojtekovaauthor=C.+Lemosauthor=J.+van+der%0AHeijdenauthor=B.+Ylstraauthor=G.+Petersauthor=G.+Kaspersauthor=B.+Dijkmansauthor=R.+Scheperauthor=G.+Jansen&title=Molecular+Basis+of+Bortezomib+Resistance%3A+Proteasome+Subunit+Beta5+%28PSMB5%29+Gene+Mutation+and+Overexpression+of+PSMB5+Protein&doi=10.1182%2Fblood-2007-08-104950"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis of bortezomib resistance: proteasome subunit Î²5 (PSMB5) gene mutation and overexpression of PSMB5 protein</span></div><div class="casAuthors">Oerlemans, Ruud; Franke, Niels E.; Assaraf, Yehuda G.; Cloos, Jacqueline; van Zantwijk, Ina; Berkers, Celia R.; Scheffer, George L.; Debipersad, Kabir; Vojtekova, Katharina; Lemos, Clara; van der Heijden, Joost W.; Ylstra, Bauke; Peters, Godefridus J.; Kaspers, Gertjan L.; Dijkmans, Ben A. C.; Scheper, Rik J.; Jansen, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2489-2499</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The proteasome inhibitor bortezomib is a novel anticancer drug that has shown promise in the treatment of refractory multiple myeloma.  However, its clin. efficacy has been hampered by the emergence of drug-resistance phenomena, the mol. basis of which remains elusive.  Toward this end, we here developed high levels (45- to 129-fold) of acquired resistance to bortezomib in human myelomonocytic THP1 cells by exposure to stepwise increasing (2.5-200 nM) concns. of bortezomib.  Study of the mol. mechanism of bortezomib resistance in these cells revealed (1) an Ala49Thr mutation residing in a highly conserved bortezomib-binding pocket in the proteasome Î²5-subunit (PSMB5) protein, (2) a dramatic overexpression (up to 60-fold) of PSMB5 protein but not of other proteasome subunits including PSMB6, PSMB7, and PSMA7, (3) high levels of cross-resistance to Î²5 subunit-targeted cytotoxic peptides 4A6, MG132, MG262, and ALLN, but not to a broad spectrum of chemotherapeutic drugs, (4) no marked changes in chymotrypsin-like proteasome activity, and (5) restoration of bortezomib sensitivity in bortezomib-resistant cells by siRNA-mediated silencing of PSMB5 gene expression.  Collectively, these findings establish a novel mechanism of bortezomib resistance assocd. with the selective overexpression of a mutant PSMB5 protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtSyGb53RI9rVg90H21EOLACvtfcHk0ljvUt2MYJ8oKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFCru7zO&md5=48981ee986f506ff7c36107cfd606d43</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-08-104950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-08-104950%26sid%3Dliteratum%253Aachs%26aulast%3DOerlemans%26aufirst%3DR.%26aulast%3DFranke%26aufirst%3DN.%2BE.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3DCloos%26aufirst%3DJ.%26aulast%3Dvan%2BZantwijk%26aufirst%3DI.%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3DScheffer%26aufirst%3DG.%2BL.%26aulast%3DDebipersad%26aufirst%3DK.%26aulast%3DVojtekova%26aufirst%3DK.%26aulast%3DLemos%26aufirst%3DC.%26aulast%3Dvan%2Bder%2BHeijden%26aufirst%3DJ.%26aulast%3DYlstra%26aufirst%3DB.%26aulast%3DPeters%26aufirst%3DG.%26aulast%3DKaspers%26aufirst%3DG.%26aulast%3DDijkmans%26aufirst%3DB.%26aulast%3DScheper%26aufirst%3DR.%26aulast%3DJansen%26aufirst%3DG.%26atitle%3DMolecular%2520Basis%2520of%2520Bortezomib%2520Resistance%253A%2520Proteasome%2520Subunit%2520Beta5%2520%2528PSMB5%2529%2520Gene%2520Mutation%2520and%2520Overexpression%2520of%2520PSMB5%2520Protein%26jtitle%3DBlood%26date%3D2008%26volume%3D112%26issue%3D6%26spage%3D2489%26epage%3D2499%26doi%3D10.1182%2Fblood-2007-08-104950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reece, D. E.</span></span> <span> </span><span class="NLM_article-title">Carfilzomib in Multiple Myeloma: Gold, Silver, or Bronze?</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>120</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2776</span>â <span class="NLM_lpage">2777</span>, <span class="refDoi">Â DOI: 10.1182/blood-2012-08-446534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1182%2Fblood-2012-08-446534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=23043023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFaksLnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2012&pages=2776-2777&issue=14&author=D.+E.+Reece&title=Carfilzomib+in+Multiple+Myeloma%3A+Gold%2C+Silver%2C+or+Bronze%3F&doi=10.1182%2Fblood-2012-08-446534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Carfilzomib in multiple myeloma: gold, silver, or bronze?</span></div><div class="casAuthors">Reece, Donna E.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2776-2777</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  In this issue of Blood, Siegel and colleagues report that the next-generation proteasome inhibitor carfilzomib, when administered as a single agent, can produce meaningful disease control in heavily pretreated patients with relapsed/refractory multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS7nBQyV3bI7Vg90H21EOLACvtfcHk0liitLzCqtL_qg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFaksLnM&md5=cb0f5c40fdb7b12609b4c1c60dbaf8e5</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1182%2Fblood-2012-08-446534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2012-08-446534%26sid%3Dliteratum%253Aachs%26aulast%3DReece%26aufirst%3DD.%2BE.%26atitle%3DCarfilzomib%2520in%2520Multiple%2520Myeloma%253A%2520Gold%252C%2520Silver%252C%2520or%2520Bronze%253F%26jtitle%3DBlood%26date%3D2012%26volume%3D120%26issue%3D14%26spage%3D2776%26epage%3D2777%26doi%3D10.1182%2Fblood-2012-08-446534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parlati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aujay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitsky, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorens, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Micklem, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruurs, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylvain, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M.</span></span> <span> </span><span class="NLM_article-title">Carfilzomib Can Induce Tumor Cell Death through Selective Inhibition of the Chymotrypsin-like Activity of the Proteasome</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">3439</span>â <span class="NLM_lpage">3447</span>, <span class="refDoi">Â DOI: 10.1182/blood-2009-05-223677</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1182%2Fblood-2009-05-223677" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=19671918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlensb7L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=3439-3447&issue=16&author=F.+Parlatiauthor=S.+J.+Leeauthor=M.+Aujayauthor=E.+Suzukiauthor=K.+Levitskyauthor=J.+B.+Lorensauthor=D.+R.+Micklemauthor=P.+Ruursauthor=C.+Sylvainauthor=Y.+Luauthor=K.+Shenkauthor=M.+Bennett&title=Carfilzomib+Can+Induce+Tumor+Cell+Death+through+Selective+Inhibition+of+the+Chymotrypsin-like+Activity+of+the+Proteasome&doi=10.1182%2Fblood-2009-05-223677"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome</span></div><div class="casAuthors">Parlati, Francesco; Lee, Susan J.; Aujay, Monette; Suzuki, Erika; Levitsky, Konstantin; Lorens, James B.; Micklem, David R.; Ruurs, Paulina; Sylvain, Catherine; Lu, Yan; Shenk, Kevin D.; Bennett, Mark K.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3439-3447</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Carfilzomib is a proteasome inhibitor in clin. development that primarily targets the chymotrypsin-like (CT-L) subunits in both the constitutive proteasome (c20S) and the immunoproteasome (i20S).  To investigate the impact of inhibiting the CT-L activity with carfilzomib, we set out to quantitate the levels of CT-L subunits Î²5 from the c20S and LMP7 from the i20S in normal and malignant hematopoietic cells.  We found that the i20S is a major form of the proteasome expressed in cells of hematopoietic origin, including multiple myeloma (MM) CD138+ tumor cells.  Although specific inhibition of either LMP7 or Î²5 alone was insufficient to produce an antitumor response, inhibition of all proteasome subunits was cytotoxic to both hematol. tumor cells and peripheral blood mononuclear cells.  However, selective inhibition of both Î²5 and LMP7 was sufficient to induce an antitumor effect in MM, non-Hodgkin lymphoma, and leukemia cells while minimizing the toxicity toward nontransformed cells.  In MM tumor cells, CT-L inhibition alone was sufficient to induce proapoptotic sequelae, including proteasome substrate accumulation, Noxa and caspase 3/7 induction, and phospho-eIF2Î± suppression.  These data support a hypothesis that hematol. tumor cells are uniquely sensitive to CT-L inhibition and provide a mechanistic understanding of the clin. safety profile and antitumor activity of proteasome inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqao7Quh7ueurVg90H21EOLACvtfcHk0liitLzCqtL_qg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlensb7L&md5=8f430741ad461693fc89907fff97f731</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-05-223677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-05-223677%26sid%3Dliteratum%253Aachs%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DAujay%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DE.%26aulast%3DLevitsky%26aufirst%3DK.%26aulast%3DLorens%26aufirst%3DJ.%2BB.%26aulast%3DMicklem%26aufirst%3DD.%2BR.%26aulast%3DRuurs%26aufirst%3DP.%26aulast%3DSylvain%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DShenk%26aufirst%3DK.%26aulast%3DBennett%26aufirst%3DM.%26atitle%3DCarfilzomib%2520Can%2520Induce%2520Tumor%2520Cell%2520Death%2520through%2520Selective%2520Inhibition%2520of%2520the%2520Chymotrypsin-like%2520Activity%2520of%2520the%2520Proteasome%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26issue%3D16%26spage%3D3439%26epage%3D3447%26doi%3D10.1182%2Fblood-2009-05-223677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niewerth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Meerloo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaraf, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickx, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderl, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zweegman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaspers, G. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloos, J.</span></span> <span> </span><span class="NLM_article-title">Anti-Leukemic Activity and Mechanisms Underlying Resistance to the Novel Immunoproteasome Inhibitor PR-924</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>89</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">43</span>â <span class="NLM_lpage">51</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2014.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.bcp.2014.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=24552657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjsF2htLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2014&pages=43-51&issue=1&author=D.+Niewerthauthor=J.+van+Meerlooauthor=G.+Jansenauthor=Y.+G.+Assarafauthor=T.+C.+Hendrickxauthor=C.+J.+Kirkauthor=J.+L.+Anderlauthor=S.+Zweegmanauthor=G.+J.+L.+Kaspersauthor=J.+Cloos&title=Anti-Leukemic+Activity+and+Mechanisms+Underlying+Resistance+to+the+Novel+Immunoproteasome+Inhibitor+PR-924&doi=10.1016%2Fj.bcp.2014.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924</span></div><div class="casAuthors">Niewerth, Denise; van Meerloo, Johan; Jansen, Gerrit; Assaraf, Yehuda G.; Hendrickx, Tessa C.; Kirk, Christopher J.; Anderl, Janet L.; Zweegman, Sonja; Kaspers, Gertjan J. L.; Cloos, Jacqueline</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-51</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">PR-924 is a novel prototypic immunoproteasome inhibitor bearing markedly enhanced specificity for the Î²5i immunoproteasome subunit, compared to the classical proteasome inhibitor bortezomib.  Here, we assessed the growth inhibitory potential of PR-924 in three human hematol. malignancy cell lines (CCRF-CEM, THP1, and 8226) and their bortezomib-resistant sublines.  Parental cells displayed equal sensitivity to PR-924 (IC50: 1.5-2.8 Î¼M), whereas their bortezomib-resistant tumor lines displayed a 10-12 fold cross-resistance to PR-924.  However, PR-924 cross-resistance factors for bortezomib-resistant sublines were markedly lower compared to the resistance factors to bortezomib.  Proteasome inhibition expts. confirmed that PR-924 specifically inhibited Î²5i activity, even far below concns. that exerted anti-proliferative activity.  We further detd. whether PR-924 activity might be compromised by acquisition of drug resistance phenomena.  Indeed, CEM cells rendered stepwise resistant to 20 Î¼M PR-924 (CEM/PR20) displayed 13-fold PR-924-resistance and 10-fold cross-resistance to bortezomib.  CEM/PR20 cells were devoid of mutations in the PSMB8 gene (encoding Î²5i), but acquired Met45Ile mutation in the PSMB5 gene (encoding constitutive Î²5), consistent with Î²5 mutations obsd. in bortezomib-resistant cells.  Furthermore, compared to parental CEM cells, CEM/PR20 cells exhibited 2.5-fold upregulation of constitutive proteasome subunit expression, whereas immunoproteasome subunit expression was 2-fold decreased.  In conclusion, PR-924 displayed potent anti-leukemic activity including toward bortezomib-resistant leukemia cells.  Despite the specificity of PR-924 to the Î²5i immunoproteasome subunit, its anti-leukemic effect required concns. that blocked both Î²5 and Î²5i subunits.  This is underscored by the emergence of mutations in PSMB5 rather than in PSMB8.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs3uUbQ67XibVg90H21EOLACvtfcHk0liitLzCqtL_qg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjsF2htLk%253D&md5=4bb4db2af8ae1a1676d7e126b49c2b26</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2014.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2014.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DNiewerth%26aufirst%3DD.%26aulast%3Dvan%2BMeerloo%26aufirst%3DJ.%26aulast%3DJansen%26aufirst%3DG.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3DHendrickx%26aufirst%3DT.%2BC.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DAnderl%26aufirst%3DJ.%2BL.%26aulast%3DZweegman%26aufirst%3DS.%26aulast%3DKaspers%26aufirst%3DG.%2BJ.%2BL.%26aulast%3DCloos%26aufirst%3DJ.%26atitle%3DAnti-Leukemic%2520Activity%2520and%2520Mechanisms%2520Underlying%2520Resistance%2520to%2520the%2520Novel%2520Immunoproteasome%2520Inhibitor%2520PR-924%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2014%26volume%3D89%26issue%3D1%26spage%3D43%26epage%3D51%26doi%3D10.1016%2Fj.bcp.2014.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aujay, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hark, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raje, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">PR-924, a Selective Inhibitor of the Immunoproteasome Subunit LMP-7, Blocks Multiple Myeloma Cell Growth Both in Vitro and in Vivo</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>152</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">155</span>â <span class="NLM_lpage">163</span>, <span class="refDoi">Â DOI: 10.1111/j.1365-2141.2010.08491.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1111%2Fj.1365-2141.2010.08491.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=21114484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVGjtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2011&pages=155-163&issue=2&author=A.+V.+Singhauthor=M.+Bandiauthor=M.+A.+Aujayauthor=C.+J.+Kirkauthor=D.+E.+Harkauthor=N.+Rajeauthor=D.+Chauhanauthor=K.+C.+Anderson&title=PR-924%2C+a+Selective+Inhibitor+of+the+Immunoproteasome+Subunit+LMP-7%2C+Blocks+Multiple+Myeloma+Cell+Growth+Both+in+Vitro+and+in+Vivo&doi=10.1111%2Fj.1365-2141.2010.08491.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo</span></div><div class="casAuthors">Singh, Ajita V.; Bandi, Madhavi; Aujay, Monette A.; Kirk, Christopher J.; Hark, David E.; Raje, Noopur; Chauhan, Dharminder; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">155-163</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">PR-924 is an LMP-7-selective tripeptide epoxyketone proteasome inhibitor that covalently modifies proteasomal N-terminal threonine active sites.  In the present study, we show that PR-924 inhibits growth and triggers apoptosis in multiple myeloma (MM) cell lines and primary patient MM cells, without significantly affecting normal peripheral blood mononuclear cells.  PR-924-induced apoptosis in MM cells is assocd. with activation of caspase-3, caspase-8, caspase-9, BID, PARP and cytochrome-c release.  In vivo administration of PR-924 inhibits tumor growth in human plasmacytoma xenografts.  Results from SCID-hu model show a significant redn. in the shIL-6R levels in mice treated with PR-924 vs. vehicle-control.  PR-924 treatment was well tolerated as evidenced by the lack of wt. loss.  Importantly, treatment of tumor-bearing mice with PR-924, but not vehicle alone, prolonged survival.  Our preclin. findings therefore validate immunoproteasome LMP-7 subunit as a novel therapeutic target in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU0KS8376dorVg90H21EOLACvtfcHk0lji-VleCe0MHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVGjtrs%253D&md5=c33893786317e38b96c2fe6817925e85</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2010.08491.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2010.08491.x%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DA.%2BV.%26aulast%3DBandi%26aufirst%3DM.%26aulast%3DAujay%26aufirst%3DM.%2BA.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DHark%26aufirst%3DD.%2BE.%26aulast%3DRaje%26aufirst%3DN.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DPR-924%252C%2520a%2520Selective%2520Inhibitor%2520of%2520the%2520Immunoproteasome%2520Subunit%2520LMP-7%252C%2520Blocks%2520Multiple%2520Myeloma%2520Cell%2520Growth%2520Both%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2011%26volume%3D152%26issue%3D2%26spage%3D155%26epage%3D163%26doi%3D10.1111%2Fj.1365-2141.2010.08491.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bo Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the Immunoproteasome: Current Status and Future Directions</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">4140</span>â <span class="NLM_lpage">4151</span>, <span class="refDoi">Â DOI: 10.2174/1381612811319220018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.2174%2F1381612811319220018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=23181576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslyrtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=4140-4151&issue=22&author=Z.+Millerauthor=L.+Aoauthor=K.+Bo+Kimauthor=W.+Lee&title=Inhibitors+of+the+Immunoproteasome%3A+Current+Status+and+Future+Directions&doi=10.2174%2F1381612811319220018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of the immunoproteasome: current status and future directions</span></div><div class="casAuthors">Miller, Zachary; Ao, Lin; Kim, Kyung Bo; Lee, Wooin</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4140-4151</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The ubiquitin-proteasome system (UPS) plays a vital role in maintaining protein homeostasis and regulating numerous cellular processes.  The proteasome, a multi-protease complex, is the key component of the UPS and has been validated as a therapeutic target by the FDA's approval of bortezomib and carfilzomib.  These proteasome inhibitor drugs have substantially improved outcomes in patients with hematol. malignancies and are currently being investigated for other types of cancer as well as several other diseases.  These approved proteasome inhibitors target the catalytic activity of both the constitutive proteasome and the immunoproteasome indiscriminately, and their inhibitory effects on the constitutive proteasome in normal cells are believed to contribute to unwanted side effects.  In addn., selective immunoproteasome inhibition has been proposed to have unique effects on other diseases, including those involving aberrant immune function.  Initially recognized for its role in the adaptive immune response, the immunoproteasome is often upregulated in disease states such as inflammatory diseases and cancer, suggesting functions beyond antigen presentation.  In an effort to explore the immunoproteasome as a potential therapeutic target in these diseases, the development of immunoproteasome-specific inhibitors has become the focus of recent studies.  Owing to considerable efforts by both academic and industry groups, immunoproteasome-selective inhibitors have now been identified and tested against several disease models.  These inhibitors also provide a valuable set of chem. tools for investigating the biol. function of the immunoproteasome.  In this review, we will focus on the recent efforts towards the development of immunoproteasome-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiaZ1chVK_KrVg90H21EOLACvtfcHk0lji-VleCe0MHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslyrtrc%253D&md5=597fa7cdfee60647d64bad55a2bb0672</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.2174%2F1381612811319220018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612811319220018%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DZ.%26aulast%3DAo%26aufirst%3DL.%26aulast%3DBo%2BKim%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DW.%26atitle%3DInhibitors%2520of%2520the%2520Immunoproteasome%253A%2520Current%2520Status%2520and%2520Future%2520Directions%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2013%26volume%3D19%26issue%3D22%26spage%3D4140%26epage%3D4151%26doi%3D10.2174%2F1381612811319220018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Proteasome Inhibition by the Natural Products Epoxomicin and Dihydroeponemycin: Insights into Specificity and Potency</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">3335</span>â <span class="NLM_lpage">3340</span>, <span class="refDoi">Â DOI: 10.1016/S0960-894X(99)00612-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2FS0960-894X%2899%2900612-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10612595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADyaK1MXotFSrsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1999&pages=3335-3340&issue=23&author=K.+B.+Kimauthor=J.+Myungauthor=N.+Sinauthor=C.+M.+Crews&title=Proteasome+Inhibition+by+the+Natural+Products+Epoxomicin+and+Dihydroeponemycin%3A+Insights+into+Specificity+and+Potency&doi=10.1016%2FS0960-894X%2899%2900612-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency</span></div><div class="casAuthors">Kim, Kyung Bo; Myung, Jayhyuk; Sin, Ny; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3335-3340</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">While two structurally related epoxyketone-contg. antitumor natural products, epoxomicin and eponemycin, share the proteasome as a common intracellular target, they differ in their antiproliferative activity, proteasome subunit binding specificity, and rates of proteasome inhibition.  As a first step towards understanding such differences and developing novel proteasome subunit-specific inhibitors, the authors report here the synthesis and characterization of epoxomicin/dihydroeponemycin chimerae.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdGLgLcWtf2bVg90H21EOLACvtfcHk0lj53gYuvvBjzg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXotFSrsLw%253D&md5=22d279a74a2c4051ee980f2f844be12b</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2899%2900612-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252899%252900612-5%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DMyung%26aufirst%3DJ.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DProteasome%2520Inhibition%2520by%2520the%2520Natural%2520Products%2520Epoxomicin%2520and%2520Dihydroeponemycin%253A%2520Insights%2520into%2520Specificity%2520and%2520Potency%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1999%26volume%3D9%26issue%3D23%26spage%3D3335%26epage%3D3340%26doi%3D10.1016%2FS0960-894X%2899%2900612-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargagna-Mohan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehenkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.-B.</span></span> <span> </span><span class="NLM_article-title">LMP2-Specific Inhibitors: Chemical Genetic Tools for Proteasome Biology</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">419</span>â <span class="NLM_lpage">430</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2007.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.chembiol.2007.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=17462577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkslaitbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=419-430&issue=4&author=Y.+K.+Hoauthor=P.+Bargagna-Mohanauthor=M.+Wehenkelauthor=R.+Mohanauthor=K.-B.+Kim&title=LMP2-Specific+Inhibitors%3A+Chemical+Genetic+Tools+for+Proteasome+Biology&doi=10.1016%2Fj.chembiol.2007.03.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">LMP2-Specific Inhibitors: Chemical Genetic Tools for Proteasome Biology</span></div><div class="casAuthors">Ho, Yik Khuan; Bargagna-Mohan, Paola; Wehenkel, Marie; Mohan, Royce; Kim, Kyung-Bo</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">419-430</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The immunoproteasome, having been linked to neurodegenerative diseases and hematol. cancers, has been shown to play an important role in MHC class I antigen presentation.  However, its other pathophysiol. functions are still not very well understood.  This can be attributed mainly to a lack of appropriate mol. probes that can selectively modulate the immunoproteasome catalytic subunits.  Herein, the authors report the development of mol. probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome.  The authors show that these compds. irreversibly modify the LMP2 subunit with high specificity.  Importantly, LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of malignant tumors that highly express LMP2.  Thus, the development of the immunoproteasome catalytic subunit LMP2-specific inhibitors may not only hold great potential as a therapeutic agent for certain diseases but can also provide a valuable chem. genetic probe to investigate immunoproteasome biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDvEUufIJ3K7Vg90H21EOLACvtfcHk0lj53gYuvvBjzg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkslaitbY%253D&md5=d12fa5065f6bdd4aee8ad12491a1c072</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2007.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2007.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DY.%2BK.%26aulast%3DBargagna-Mohan%26aufirst%3DP.%26aulast%3DWehenkel%26aufirst%3DM.%26aulast%3DMohan%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DK.-B.%26atitle%3DLMP2-Specific%2520Inhibitors%253A%2520Chemical%2520Genetic%2520Tools%2520for%2520Proteasome%2520Biology%26jtitle%3DChem.%2520Biol.%26date%3D2007%26volume%3D14%26issue%3D4%26spage%3D419%26epage%3D430%26doi%3D10.1016%2Fj.chembiol.2007.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul Hameed, M. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehenkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzyka, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, C.-G.</span></span> <span> </span><span class="NLM_article-title">Molecular Basis of the Selectivity of the Immunoproteasome Catalytic Subunit LMP2-Specific Inhibitor Revealed by Molecular Modeling and Dynamics Simulations</span>. <i>J. Phys. Chem. B</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">38</span>),  <span class="NLM_fpage">12333</span>â <span class="NLM_lpage">12339</span>, <span class="refDoi">Â DOI: 10.1021/jp1058098</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp1058098" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFSlsrvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2010&pages=12333-12339&issue=38&author=B.+Leiauthor=M.+D.+M.+Abdul+Hameedauthor=A.+Hamzaauthor=M.+Wehenkelauthor=J.+L.+Muzykaauthor=X.-J.+Yaoauthor=K.-B.+Kimauthor=C.-G.+Zhan&title=Molecular+Basis+of+the+Selectivity+of+the+Immunoproteasome+Catalytic+Subunit+LMP2-Specific+Inhibitor+Revealed+by+Molecular+Modeling+and+Dynamics+Simulations&doi=10.1021%2Fjp1058098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Basis of the Selectivity of the Immunoproteasome Catalytic Subunit LMP2-Specific Inhibitor Revealed by Molecular Modeling and Dynamics Simulations</span></div><div class="casAuthors">Lei, Beilei; Abdul Hameed, Mohamed Diwan M.; Hamza, Adel; Wehenkel, Marie; Muzyka, Jennifer L.; Yao, Xiao-Jun; Kim, Kyung-Bo; Zhan, Chang-Guo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry B</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">12333-12339</span>CODEN:
                <span class="NLM_cas:coden">JPCBFK</span>;
        ISSN:<span class="NLM_cas:issn">1520-6106</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Given that immunoproteasome inhibitors are currently being developed for a variety of potent therapeutic purposes, the unique specificity of an Î±',Î²'-epoxyketone peptide (UK101) toward the LMP2 subunit of the immunoproteasome (analogous to Î²5 subunit of the constitutive proteasome) has been investigated in this study for the first time by employing homol. modeling, mol. docking, mol. dynamics simulation, and mol. mechanics Poisson-Boltzmann surface area (MM-PBSA) binding free energy calcns.  On the basis of the simulated binding structures, the calcd. binding free energies are in qual. agreement with the corresponding exptl. data, and the selectivity of UK101 is explained reasonably.  The obsd. selectivity of UK101 for the LMP2 subunit is rationalized by the requirement for both a linear hydrocarbon chain at the N terminus and a bulky group at the C terminus of the inhibitor, because the LMP2 subunit has a much more favorable hydrophobic pocket interacting with the linear hydrocarbon chain, and the bulky group at the C terminus has a steric clash with the Tyr 169 in Î²5 subunit.  Finally, our results help to clarify why UK101 is specific to the LMP2 subunit of immunoproteasome, and this investigation should be valuable for rational design of more potent LMP2-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIzcYhY1bQYLVg90H21EOLACvtfcHk0lj53gYuvvBjzg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFSlsrvE&md5=a0cdc03651c648729405d1a9a6f5c12e</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fjp1058098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp1058098%26sid%3Dliteratum%253Aachs%26aulast%3DLei%26aufirst%3DB.%26aulast%3DAbdul%2BHameed%26aufirst%3DM.%2BD.%2BM.%26aulast%3DHamza%26aufirst%3DA.%26aulast%3DWehenkel%26aufirst%3DM.%26aulast%3DMuzyka%26aufirst%3DJ.%2BL.%26aulast%3DYao%26aufirst%3DX.-J.%26aulast%3DKim%26aufirst%3DK.-B.%26aulast%3DZhan%26aufirst%3DC.-G.%26atitle%3DMolecular%2520Basis%2520of%2520the%2520Selectivity%2520of%2520the%2520Immunoproteasome%2520Catalytic%2520Subunit%2520LMP2-Specific%2520Inhibitor%2520Revealed%2520by%2520Molecular%2520Modeling%2520and%2520Dynamics%2520Simulations%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D2010%26volume%3D114%26issue%3D38%26spage%3D12333%26epage%3D12339%26doi%3D10.1021%2Fjp1058098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wehenkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ban, J.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, Y.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmony, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">A Selective Inhibitor of the Immunoproteasome Subunit LMP2 Induces Apoptosis in PC-3 Cells and Suppresses Tumour Growth in Nude Mice</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>107</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">53</span>â <span class="NLM_lpage">62</span>, <span class="refDoi">Â DOI: 10.1038/bjc.2012.243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fbjc.2012.243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=22677907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC38Xptl2isbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2012&pages=53-62&issue=1&author=M.+Wehenkelauthor=J.-O.+Banauthor=Y.-K.+Hoauthor=K.+C.+Carmonyauthor=J.+T.+Hongauthor=K.+B.+Kim&title=A+Selective+Inhibitor+of+the+Immunoproteasome+Subunit+LMP2+Induces+Apoptosis+in+PC-3+Cells+and+Suppresses+Tumour+Growth+in+Nude+Mice&doi=10.1038%2Fbjc.2012.243"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice</span></div><div class="casAuthors">Wehenkel, M.; Ban, J.-O.; Ho, Y.-K.; Carmony, K. C.; Hong, J. T.; Kim, K. B.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-62</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Although the proteasome is a validated anticancer target, the clin. application of its inhibitors has been limited because of inherent systemic toxicity.  To broaden clin. utility of proteasome inhibitors as anticancer agents, it is crit. to develop strategies to selectively target proteasomes in cancer cells.  The immunoproteasome is an alternative form of the constitutive proteasome that is expressed at high levels in cancer tissues, but not in most normal cells in the body.  Methods: To validate the immunoproteasome as a chemotherapeutic target, an immunoproteasome catalytic subunit LMP2-targeting inhibitor and siRNA were used.  The sensitivity of PC-3 prostate cancer cells to these reagents was investigated using viability assays.  Further, a xenograft model of prostate cancer was studied to test the in vivo effects of LMP2 inhibition.  Results: A small mol. inhibitor of the immunoproteasome subunit LMP2, UK-101, induced apoptosis of PC-3 cells and resulted in significant inhibition (â¼50-60%) of tumor growth in vivo.  Interestingly, UK-101 did not block degrdn. of IÎºBÎ± in PC-3 cells treated with TNF-Î±, suggesting that its mode of action may be different from that of general proteasome inhibitors, such as bortezomib, which block IÎºBÎ± degrdn.  Conclusion: These results strongly suggest that the immunoproteasome has important roles in cancer cell growth and thus provide a rationale for targeting the immunoproteasome in the treatment of prostate cancer.  British Journal of Cancer (2012) 107, 53-62. doi:10.1038/bjc.2012.243 www.bjcancer.com published online 7 June 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrLJQKXNlNKrVg90H21EOLACvtfcHk0liI61A-LB8jtA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xptl2isbk%253D&md5=59390ce6295216a78e584049754b2c03</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2012.243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2012.243%26sid%3Dliteratum%253Aachs%26aulast%3DWehenkel%26aufirst%3DM.%26aulast%3DBan%26aufirst%3DJ.-O.%26aulast%3DHo%26aufirst%3DY.-K.%26aulast%3DCarmony%26aufirst%3DK.%2BC.%26aulast%3DHong%26aufirst%3DJ.%2BT.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DA%2520Selective%2520Inhibitor%2520of%2520the%2520Immunoproteasome%2520Subunit%2520LMP2%2520Induces%2520Apoptosis%2520in%2520PC-3%2520Cells%2520and%2520Suppresses%2520Tumour%2520Growth%2520in%2520Nude%2520Mice%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2012%26volume%3D107%26issue%3D1%26spage%3D53%26epage%3D62%26doi%3D10.1038%2Fbjc.2012.243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esdar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friese-Hamim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musil, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohdich, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanelli, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span> <span> </span><span class="NLM_article-title">Abstract LB-054: Discovery and Profiling of M3258, a Potent and Selective LMP7 Inhibitor Demonstrating High Efficacy in Multiple Myeloma Models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">LB-054</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.AM2019-LB-054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1158%2F1538-7445.AM2019-LB-054" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=LB-054&author=M.+Kleinauthor=M.+Buschauthor=C.+Esdarauthor=M.+Friese-Hamimauthor=M.+Krierauthor=D.+Musilauthor=F.+Rohdichauthor=M.+Sandersonauthor=G.+Walterauthor=O.+Schadtauthor=U.+Zanelliauthor=J.+Ma&title=Abstract+LB-054%3A+Discovery+and+Profiling+of+M3258%2C+a+Potent+and+Selective+LMP7+Inhibitor+Demonstrating+High+Efficacy+in+Multiple+Myeloma+Models&doi=10.1158%2F1538-7445.AM2019-LB-054"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-LB-054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-LB-054%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%26aufirst%3DM.%26aulast%3DBusch%26aufirst%3DM.%26aulast%3DEsdar%26aufirst%3DC.%26aulast%3DFriese-Hamim%26aufirst%3DM.%26aulast%3DKrier%26aufirst%3DM.%26aulast%3DMusil%26aufirst%3DD.%26aulast%3DRohdich%26aufirst%3DF.%26aulast%3DSanderson%26aufirst%3DM.%26aulast%3DWalter%26aufirst%3DG.%26aulast%3DSchadt%26aufirst%3DO.%26aulast%3DZanelli%26aufirst%3DU.%26aulast%3DMa%26aufirst%3DJ.%26atitle%3DAbstract%2520LB-054%253A%2520Discovery%2520and%2520Profiling%2520of%2520M3258%252C%2520a%2520Potent%2520and%2520Selective%2520LMP7%2520Inhibitor%2520Demonstrating%2520High%2520Efficacy%2520in%2520Multiple%2520Myeloma%2520Models%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3DLB-054%26doi%3D10.1158%2F1538-7445.AM2019-LB-054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esdar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friese-Hamim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musil, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohdich, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sloot, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanelli, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, M.</span></span> <span> </span><span class="NLM_article-title">Abstract DDT02â01: First-Time Disclosure of M3258: A Selective Inhibitor of the Immunoproteasome Subunit LMP7 with Potential for Improved Therapeutic Utility in Multiple Myeloma Compared to Pan-Proteasome Inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">DDT02-01</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.AM2019-DDT02-01</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1158%2F1538-7445.AM2019-DDT02-01" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=DDT02-01&author=M.+Sandersonauthor=M.+Buschauthor=C.+Esdarauthor=M.+Friese-Hamimauthor=M.+Krierauthor=J.+Maauthor=D.+Musilauthor=F.+Rohdichauthor=W.+Slootauthor=G.+Walterauthor=U.+Zanelliauthor=O.+Schadtauthor=M.+Klein&title=Abstract+DDT02%E2%80%9301%3A+First-Time+Disclosure+of+M3258%3A+A+Selective+Inhibitor+of+the+Immunoproteasome+Subunit+LMP7+with+Potential+for+Improved+Therapeutic+Utility+in+Multiple+Myeloma+Compared+to+Pan-Proteasome+Inhibitors&doi=10.1158%2F1538-7445.AM2019-DDT02-01"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-DDT02-01&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-DDT02-01%26sid%3Dliteratum%253Aachs%26aulast%3DSanderson%26aufirst%3DM.%26aulast%3DBusch%26aufirst%3DM.%26aulast%3DEsdar%26aufirst%3DC.%26aulast%3DFriese-Hamim%26aufirst%3DM.%26aulast%3DKrier%26aufirst%3DM.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DMusil%26aufirst%3DD.%26aulast%3DRohdich%26aufirst%3DF.%26aulast%3DSloot%26aufirst%3DW.%26aulast%3DWalter%26aufirst%3DG.%26aulast%3DZanelli%26aufirst%3DU.%26aulast%3DSchadt%26aufirst%3DO.%26aulast%3DKlein%26aufirst%3DM.%26atitle%3DAbstract%2520DDT02%25E2%2580%259301%253A%2520First-Time%2520Disclosure%2520of%2520M3258%253A%2520A%2520Selective%2520Inhibitor%2520of%2520the%2520Immunoproteasome%2520Subunit%2520LMP7%2520with%2520Potential%2520for%2520Improved%2520Therapeutic%2520Utility%2520in%2520Multiple%2520Myeloma%2520Compared%2520to%2520Pan-Proteasome%2520Inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3DDDT02-01%26doi%3D10.1158%2F1538-7445.AM2019-DDT02-01" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Downey-Kopyscinski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daily, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florea, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisselev, A. F.</span></span> <span> </span><span class="NLM_article-title">An Inhibitor of Proteasome B2 Sites Sensitizes Myeloma Cells to Immunoproteasome Inhibitors</span>. <i>Blood Adv.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">2443</span>â <span class="NLM_lpage">2451</span>, <span class="refDoi">Â DOI: 10.1182/bloodadvances.2018016360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1182%2Fbloodadvances.2018016360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=30266819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFWhtL7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2018&pages=2443-2451&issue=19&author=S.+Downey-Kopyscinskiauthor=E.+W.+Dailyauthor=M.+Gautierauthor=A.+Bhattauthor=B.+I.+Floreaauthor=C.+S.+Mitsiadesauthor=P.+G.+Richardsonauthor=C.+Driessenauthor=H.+S.+Overkleeftauthor=A.+F.+Kisselev&title=An+Inhibitor+of+Proteasome+B2+Sites+Sensitizes+Myeloma+Cells+to+Immunoproteasome+Inhibitors&doi=10.1182%2Fbloodadvances.2018016360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">An inhibitor of proteasome Î²2 sites sensitizes myeloma cells to immunoproteasome inhibitors</span></div><div class="casAuthors">Downey-Kopyscinski, Sondra; Daily, Ellen W.; Gautier, Marc; Bhatt, Ananta; Florea, Bogdan I.; Mitsiades, Constantine S.; Richardson, Paul G.; Driessen, Christoph; Overkleeft, Herman S.; Kisselev, Alexei F.</div><div class="citationInfo"><span class="NLM_cas:title">Blood Advances</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2443-2451</span>CODEN:
                <span class="NLM_cas:coden">BALDBA</span>;
        ISSN:<span class="NLM_cas:issn">2473-9537</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Proteasome inhibitors bortezomib, carfilzomib and ixazomib (approved by the US Food and Drug Administration [FDA]) induce remissions in patients with multiple myeloma (MM), but most patients eventually become resistant.  MM and other hematol. malignancies express ubiquitous constitutive proteasomes and lymphoid tissue-specific immunoproteasomes; immunoproteasome expression is increased in resistant patients.  Immunoproteasomes contain 3 distinct pairs of active sites, Î²5i, Î²1i, and Î²2i, which are different from their constitutive Î²5c, Î²1c, and Î²2c counterparts.  Bortezomib and carfilzomib block Î²5c and Î²5i sites.  We report here that pharmacol. relevant concns. of Î²5i-specific inhibitor ONX-0914 show cytotoxicity in MM cell lines similar to that of carfilzomib and bortezomib.  In addn., increasing immunoproteasome expression by interferon-Î³ increases sensitivity to ONX-0914 but not to carfilzomib.  LU-102, an inhibitor of Î²2 sites, dramatically sensitizes MM cell lines and primary cells to ONX-0914.  ONX-0914 synergizes with all FDA-approved proteasome inhibitors in MM in vitro and in vivo.  Thus, immunoproteasome inhibitors, currently in clin. trials for the treatment of autoimmune diseases, should also be considered for the treatment of MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwFqWlmqq7yrVg90H21EOLACvtfcHk0ljB7mjKPftpRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFWhtL7O&md5=cf4301160cd5251989f7cde1ecff4a89</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1182%2Fbloodadvances.2018016360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fbloodadvances.2018016360%26sid%3Dliteratum%253Aachs%26aulast%3DDowney-Kopyscinski%26aufirst%3DS.%26aulast%3DDaily%26aufirst%3DE.%2BW.%26aulast%3DGautier%26aufirst%3DM.%26aulast%3DBhatt%26aufirst%3DA.%26aulast%3DFlorea%26aufirst%3DB.%2BI.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DDriessen%26aufirst%3DC.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26atitle%3DAn%2520Inhibitor%2520of%2520Proteasome%2520B2%2520Sites%2520Sensitizes%2520Myeloma%2520Cells%2520to%2520Immunoproteasome%2520Inhibitors%26jtitle%3DBlood%2520Adv.%26date%3D2018%26volume%3D2%26issue%3D19%26spage%3D2443%26epage%3D2451%26doi%3D10.1182%2Fbloodadvances.2018016360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, H. W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderl, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moebius, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMinn, D. L.</span></span> <span> </span><span class="NLM_article-title">Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 <i>S</i>, 3 <i>R</i>)- <i>N</i> -((<i>S</i>)-3-(Cyclopent-1-En-1-Yl)-1-((<i>R</i>)-2-Methyloxiran-2-Yl)-1-Oxopropan-2-Yl)-3-Hydroxy-3-(4-Methoxyphenyl)-2-((<i>S</i>)-2-(2-Morpholinoacetamido)Propanamido)Propenamide)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">11127</span>â <span class="NLM_lpage">11143</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b01201</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01201" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVKltLfF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=11127-11143&issue=24&author=H.+W.+B.+Johnsonauthor=E.+Loweauthor=J.+L.+Anderlauthor=A.+Fanauthor=T.+Muchamuelauthor=S.+Bowersauthor=D.+C.+Moebiusauthor=C.+Kirkauthor=D.+L.+McMinn&title=Required+Immunoproteasome+Subunit+Inhibition+Profile+for+Anti-Inflammatory+Efficacy+and+Clinical+Candidate+KZR-616+%28%282+S%2C+3+R%29-+N+-%28%28S%29-3-%28Cyclopent-1-En-1-Yl%29-1-%28%28R%29-2-Methyloxiran-2-Yl%29-1-Oxopropan-2-Yl%29-3-Hydroxy-3-%284-Methoxyphenyl%29-2-%28%28S%29-2-%282-Morpholinoacetamido%29Propanamido%29Propenamide%29&doi=10.1021%2Facs.jmedchem.8b01201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2S,3R)-N-((S)-3-(Cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenamide)</span></div><div class="casAuthors">Johnson, Henry W. B.; Lowe, Eric; Anderl, Janet L.; Fan, Andrea; Muchamuel, Tony; Bowers, Simeon; Moebius, David C.; Kirk, Christopher; McMinn, Dustin L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11127-11143</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selective immunoproteasome inhibition is a promising approach for treating autoimmune disorders, but optimal proteolytic active site subunit inhibition profiles remain unknown.  We reveal here our design of peptide epoxyketone-based selective low mol. mass polypeptide-7 (LMP7) and multicatalytic endopeptidase complex subunit-1 (MECL-1) subunit inhibitors.  Utilizing these and our previously disclosed low mol. mass polypeptide-2 (LMP2) inhibitor, we demonstrate a requirement of dual LMP7/LMP2 or LMP7/MECL-1 subunit inhibition profiles for potent cytokine expression inhibition and in vivo efficacy in an inflammatory disease model.  These and addnl. findings toward optimized soly. led the design and selection of KZR-616 disclosed here and presently in clin. trials for treatment of rheumatic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNq1pg3kpVXrVg90H21EOLACvtfcHk0ljB7mjKPftpRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVKltLfF&md5=70170b636fbb858edda5f571af45ca7f</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01201%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DH.%2BW.%2BB.%26aulast%3DLowe%26aufirst%3DE.%26aulast%3DAnderl%26aufirst%3DJ.%2BL.%26aulast%3DFan%26aufirst%3DA.%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DBowers%26aufirst%3DS.%26aulast%3DMoebius%26aufirst%3DD.%2BC.%26aulast%3DKirk%26aufirst%3DC.%26aulast%3DMcMinn%26aufirst%3DD.%2BL.%26atitle%3DRequired%2520Immunoproteasome%2520Subunit%2520Inhibition%2520Profile%2520for%2520Anti-Inflammatory%2520Efficacy%2520and%2520Clinical%2520Candidate%2520KZR-616%2520%2528%25282%2520S%252C%25203%2520R%2529-%2520N%2520-%2528%2528S%2529-3-%2528Cyclopent-1-En-1-Yl%2529-1-%2528%2528R%2529-2-Methyloxiran-2-Yl%2529-1-Oxopropan-2-Yl%2529-3-Hydroxy-3-%25284-Methoxyphenyl%2529-2-%2528%2528S%2529-2-%25282-Morpholinoacetamido%2529Propanamido%2529Propenamide%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D24%26spage%3D11127%26epage%3D11143%26doi%3D10.1021%2Facs.jmedchem.8b01201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Firestein, G. S.</span></span> <span> </span><span class="NLM_article-title">The Disease Formerly Known as Rheumatoid Arthritis</span>. <i>Arthritis Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">114</span>, <span class="refDoi">Â DOI: 10.1186/ar4593</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1186%2Far4593" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=25167330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252Fls1SqtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=114&issue=3&author=G.+S.+Firestein&title=The+Disease+Formerly+Known+as+Rheumatoid+Arthritis&doi=10.1186%2Far4593"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">The disease formerly known as rheumatoid arthritis</span></div><div class="casAuthors">Firestein Gary S</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis research & therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">114</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Rheumatoid arthritis is a complex disease where predetermined and stochastic factors conspire to confer disease susceptibility.  In light of the diverse responses to targeted therapies, rheumatoid arthritis might represent a final common clinical phenotype that reflects many pathogenic pathways.  Therefore, it might be appropriate to begin thinking about rheumatoid arthritis as a syndrome rather than a disease.  Use of genetics, epigenetics, microbiomics,and other unbiased technologies will probably permit stratification of patients based on mechanisms of disease rather than by clinical phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcruvwZJ_w7gWRJ3OJdH_qfW6udTcc2eZTZ70Bbi3I_rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252Fls1SqtQ%253D%253D&md5=55e32e410846b2185c1d928fea511f66</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1186%2Far4593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Far4593%26sid%3Dliteratum%253Aachs%26aulast%3DFirestein%26aufirst%3DG.%2BS.%26atitle%3DThe%2520Disease%2520Formerly%2520Known%2520as%2520Rheumatoid%2520Arthritis%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2014%26volume%3D16%26issue%3D3%26spage%3D114%26doi%3D10.1186%2Far4593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Catrina, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ytterberg, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynisdottir, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MalmstrÃ¶m, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klareskog, L.</span></span> <span> </span><span class="NLM_article-title">Lungs, Joints and Immunity against Citrullinated Proteins in Rheumatoid Arthritis</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">645</span>â <span class="NLM_lpage">653</span>, <span class="refDoi">Â DOI: 10.1038/nrrheum.2014.115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fnrrheum.2014.115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=25072264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1GksLrF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=645-653&issue=11&author=A.+I.+Catrinaauthor=A.+J.+Ytterbergauthor=G.+Reynisdottirauthor=V.+Malmstr%C3%B6mauthor=L.+Klareskog&title=Lungs%2C+Joints+and+Immunity+against+Citrullinated+Proteins+in+Rheumatoid+Arthritis&doi=10.1038%2Fnrrheum.2014.115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Lungs, joints and immunity against citrullinated proteins in rheumatoid arthritis</span></div><div class="casAuthors">Catrina, Anca I.; Ytterberg, A. Jimmy; Reynisdottir, Gudrun; Malmstroem, Vivianne; Klareskog, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Rheumatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">645-653</span>CODEN:
                <span class="NLM_cas:coden">NRRACB</span>;
        ISSN:<span class="NLM_cas:issn">1759-4790</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Rheumatoid arthritis (RA) is a prototype for a criterion-defined inflammatory disease, for which the etiol. and initial mol. pathogenesis has been elusive for a long time.  We describe in this Review how studies on the interplay between specific immunity, alongside genetic and environmental predisposing factors, provide new tools to understand the mol. basis of distinct subsets of the disease.  A particular emphasis is on the possibility that pathogenic immune reactions might be initiated at other sites than the joints, and that the lungs could harbor such sites.  New data strengthen this concept, showing that local immunity towards citrullinated proteins and accompanying inflammation might be present in the lungs early during disease development.  This progress makes RA an interesting case for the future development of therapies that might be directed against disease-inducing immunity even before inflammation and destruction of joints has begun.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbs3opo4mVm7Vg90H21EOLACvtfcHk0lgRls0P81EqpA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1GksLrF&md5=5034084a9f9a6163e6c2db19db69f2f1</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2014.115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2014.115%26sid%3Dliteratum%253Aachs%26aulast%3DCatrina%26aufirst%3DA.%2BI.%26aulast%3DYtterberg%26aufirst%3DA.%2BJ.%26aulast%3DReynisdottir%26aufirst%3DG.%26aulast%3DMalmstr%25C3%25B6m%26aufirst%3DV.%26aulast%3DKlareskog%26aufirst%3DL.%26atitle%3DLungs%252C%2520Joints%2520and%2520Immunity%2520against%2520Citrullinated%2520Proteins%2520in%2520Rheumatoid%2520Arthritis%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2014%26volume%3D10%26issue%3D11%26spage%3D645%26epage%3D653%26doi%3D10.1038%2Fnrrheum.2014.115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Catrina, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshua, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klareskog, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MalmstrÃ¶m, V.</span></span> <span> </span><span class="NLM_article-title">Mechanisms Involved in Triggering Rheumatoid Arthritis</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>269</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">162</span>â <span class="NLM_lpage">174</span>, <span class="refDoi">Â DOI: 10.1111/imr.12379</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1111%2Fimr.12379" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=26683152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVeqtrzN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=2016&pages=162-174&issue=1&author=A.+I.+Catrinaauthor=V.+Joshuaauthor=L.+Klareskogauthor=V.+Malmstr%C3%B6m&title=Mechanisms+Involved+in+Triggering+Rheumatoid+Arthritis&doi=10.1111%2Fimr.12379"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms involved in triggering rheumatoid arthritis</span></div><div class="casAuthors">Catrina, Anca I.; Joshua, Vijay; Klareskog, Lars; Malmstroem, Vivianne</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">162-174</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Rheumatoid arthritis (RA) is a chronic inflammatory syndrome with a strong autoimmune component.  The autoantigens in RA are neither tissue nor organ-specific, but comprise a broad collection of post-translational modified proteins, such as citrullinated proteins.  These modifications are likely to be triggered by innate stimuli.  In genetically susceptible hosts, they can lead to a more substantiated secondary autoimmune reaction targeting the joints and pptg. the clin. onset of RA.  Both innate and adaptive mechanisms will then closely interplay to promote chronic joint inflammation in the several absence of appropriate treatment.  This scenario, is shared with other autoimmune diseases where potentially pathogenic immune responses are present already before disease onset.  Better understanding of these processes will allow both earlier diagnosis of RA and identification of those healthy individuals that are at risk of developing disease, opening possibilities for disease prevention.  In this review, we discuss the iterative processes of innate and adaptive immunity responsible for the (longitudinal) development of immune reactions that may contribute to the development of RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfWw33Fo2zLLVg90H21EOLACvtfcHk0lgRls0P81EqpA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVeqtrzN&md5=9dfcd32551a9119e1476b922f121cee4</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1111%2Fimr.12379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fimr.12379%26sid%3Dliteratum%253Aachs%26aulast%3DCatrina%26aufirst%3DA.%2BI.%26aulast%3DJoshua%26aufirst%3DV.%26aulast%3DKlareskog%26aufirst%3DL.%26aulast%3DMalmstr%25C3%25B6m%26aufirst%3DV.%26atitle%3DMechanisms%2520Involved%2520in%2520Triggering%2520Rheumatoid%2520Arthritis%26jtitle%3DImmunol.%2520Rev.%26date%3D2016%26volume%3D269%26issue%3D1%26spage%3D162%26epage%3D174%26doi%3D10.1111%2Fimr.12379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Firestein, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I. B.</span></span> <span> </span><span class="NLM_article-title">Immunopathogenesis of Rheumatoid Arthritis</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">183</span>â <span class="NLM_lpage">196</span>, <span class="refDoi">Â DOI: 10.1016/j.immuni.2017.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.immuni.2017.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=28228278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtlerur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2017&pages=183-196&issue=2&author=G.+S.+Firesteinauthor=I.+B.+McInnes&title=Immunopathogenesis+of+Rheumatoid+Arthritis&doi=10.1016%2Fj.immuni.2017.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Immunopathogenesis of Rheumatoid Arthritis</span></div><div class="casAuthors">Firestein, Gary S.; McInnes, Iain B.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">183-196</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Rheumatoid arthritis (RA) is the most common inflammatory arthropathy.  The majority of evidence, derived from genetics, tissue analyses, models, and clin. studies, points to an immune-mediated etiol. assocd. with stromal tissue dysregulation that together propagate chronic inflammation and articular destruction.  A pre-RA phase lasting months to years may be characterized by the presence of circulating autoantibodies, increasing concn. and range of inflammatory cytokines and chemokines, and altered metab.  Clin. disease onset comprises synovitis and systemic comorbidities affecting the vasculature, metab., and bone.  Targeted immune therapeutics and aggressive treatment strategies have substantially improved clin. outcomes and informed pathogenetic understanding, but no cure as yet exists.  Herein we review recent data that support intriguing models of disease pathogenesis.  They allude to the possibility of restoration of immunol. homeostasis and thus a state of tolerance assocd. with drug-free remission.  This target represents a bold vision for the future of RA therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCIKsD764_-bVg90H21EOLACvtfcHk0liknXxtv8-MZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtlerur8%253D&md5=dc7e6fe1fb3a5c9470718f1b2699f9e0</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2017.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2017.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DFirestein%26aufirst%3DG.%2BS.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26atitle%3DImmunopathogenesis%2520of%2520Rheumatoid%2520Arthritis%26jtitle%3DImmunity%26date%3D2017%26volume%3D46%26issue%3D2%26spage%3D183%26epage%3D196%26doi%3D10.1016%2Fj.immuni.2017.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weyand, C. M.</span></span> <span> </span><span class="NLM_article-title">The Influence of HLA-DRB1 Genes on Disease Severity in Rheumatoid Arthritis</span>. <i>Ann. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>117</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">801</span>, <span class="refDoi">Â DOI: 10.7326/0003-4819-117-10-801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.7326%2F0003-4819-117-10-801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1416553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADyaK3s%252Fjs12htQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=1992&pages=801&issue=10&author=C.+M.+Weyand&title=The+Influence+of+HLA-DRB1+Genes+on+Disease+Severity+in+Rheumatoid+Arthritis&doi=10.7326%2F0003-4819-117-10-801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis</span></div><div class="casAuthors">Weyand C M; Hicok K C; Conn D L; Goronzy J J</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">801-6</span>
        ISSN:<span class="NLM_cas:issn">0003-4819</span>.
    </div><div class="casAbstract">OBJECTIVE:  To explore the role of HLA-DRB1 genes in determining disease severity in rheumatoid arthritis.  DESIGN:  Case series of patients with seropositive rheumatoid arthritis.  SETTING:  The outpatient clinic of the Division of Rheumatology, Mayo Clinic.  PATIENTS:  One hundred and two patients with seropositive, erosive rheumatoid arthritis and a minimum disease duration of 3 years.  MEASUREMENTS:  Patients were genotyped for both HLA-DRB1 alleles and were categorized according to the expression of one or two disease-linked HLA-DRB1 alleles.  Identification of HLA-DRB1 alleles was done by the polymerase chain reaction and subsequent oligonucleotide hybridization.  Homozygosity for allelic variants was confirmed by sequence analysis.  Immunogenetically defined patient subgroups were retrospectively evaluated for joint destruction and patterns of disease manifestation, including rheumatoid organ disease.  RESULTS:  Of 102 patients, 98 (96%) expressed the disease-linked sequence polymorphism.  Forty-seven patients (46%) carried a double dose of the relevant sequence stretch: Twenty-eight patients expressed HLA-DRB1*04 variants on both alleles, and 19 combined an HLA-DRB*04 variant with HLA-DRB1*0101 or DRB1*1402.  Nodular disease was present in 100% of patients typed as HLA-DRB1*04/04 and in 59% of patients typed as HLA-DRB1*04 and who had inherited only a single dose of the disease-linked sequence polymorphism (P < 0.0001).  Major organ systems were involved in 61% and 11% of these two patient groups, respectively (P < 0.0001); and joint surgery was required in 61% and 25% (P < 0.002), respectively.  Patients typed as HLA-DR*04/01 had intermediate clinical courses.  CONCLUSION:  Genotyping patients with rheumatoid arthritis for both HLA-DRB1 alleles identifies clinical subsets with distinct profiles of disease manifestations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS65dOdFeMH0xLDWw4HIq2sfW6udTcc2eZ0HUhUrj4j-rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s%252Fjs12htQ%253D%253D&md5=f6014e58e6e74c45590557d54260e0c5</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-117-10-801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-117-10-801%26sid%3Dliteratum%253Aachs%26aulast%3DWeyand%26aufirst%3DC.%2BM.%26atitle%3DThe%2520Influence%2520of%2520HLA-DRB1%2520Genes%2520on%2520Disease%2520Severity%2520in%2520Rheumatoid%2520Arthritis%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D1992%26volume%3D117%26issue%3D10%26spage%3D801%26doi%3D10.7326%2F0003-4819-117-10-801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scally, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nel, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijeyewickrema, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckle, S. B.G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van
Heemst, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCluskey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toes, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Gruta, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcell, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossjohn, J.</span></span> <span> </span><span class="NLM_article-title">A Molecular Basis for the Association of the HLA-DRB1 Locus, Citrullination, and Rheumatoid Arthritis</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>210</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2569</span>â <span class="NLM_lpage">2582</span>, <span class="refDoi">Â DOI: 10.1084/jem.20131241</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1084%2Fjem.20131241" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=24190431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKjsbfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2013&pages=2569-2582&issue=12&author=S.+W.+Scallyauthor=J.+Petersenauthor=S.+C.+Lawauthor=N.+L.+Dudekauthor=H.+J.+Nelauthor=K.+L.+Lohauthor=L.+C.+Wijeyewickremaauthor=S.+B.G.+Eckleauthor=J.+van%0AHeemstauthor=R.+N.+Pikeauthor=J.+McCluskeyauthor=R.+E.+Toesauthor=N.+L.+La+Grutaauthor=A.+W.+Purcellauthor=H.+H.+Reidauthor=R.+Thomasauthor=J.+Rossjohn&title=A+Molecular+Basis+for+the+Association+of+the+HLA-DRB1+Locus%2C+Citrullination%2C+and+Rheumatoid+Arthritis&doi=10.1084%2Fjem.20131241"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis</span></div><div class="casAuthors">Scally, Stephen W.; Petersen, Jan; Law, Soi Cheng; Dudek, Nadine L.; Nel, Hendrik J.; Loh, Khai Lee; Wijeyewickrema, Lakshmi C.; Eckle, Sidonia B. G.; van Heemst, Jurgen; Pike, Robert N.; McCluskey, James; Toes, Rene E.; La Gruta, Nicole L.; Purcell, Anthony W.; Reid, Hugh H.; Thomas, Ranjeny; Rossjohn, Jamie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2569-2582</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Rheumatoid arthritis (RA) is strongly assocd. with the human leukocyte antigen (HLA)-DRB1 locus that possesses the shared susceptibility epitope (SE) and the citrullination of self-antigens.  We show how citrullinated aggrecan and vimentin epitopes bind to HLA-DRB1*04:01/04.  Citrulline was accommodated within the electropos. P4 pocket of HLA-DRB1*04:01/04, whereas the electroneg. P4 pocket of the RA-resistant HLA-DRB1*04:02 allomorph interacted with arginine or citrulline-contg. epitopes.  Peptide elution studies revealed P4 arginine-contg. peptides from HLA-DRB1*04:02, but not from HLA-DRB1*04:01/04.  Citrullination altered protease susceptibility of vimentin, thereby generating self-epitopes that are presented to T cells in HLA-DRB1*04:01+ individuals.  Using HLA-II tetramers, we obsd. citrullinated vimentin- and aggrecan-specific CD4+ T cells in the peripheral blood of HLA-DRB1*04:01+ RA-affected and healthy individuals.  In RA patients, autoreactive T cell nos. correlated with disease activity and were deficient in regulatory T cells relative to healthy individuals.  These findings reshape our understanding of the assocn. between citrullination, the HLA-DRB1 locus, and T cell autoreactivity in RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaneyo6yni2rVg90H21EOLACvtfcHk0liknXxtv8-MZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKjsbfN&md5=a4b53a2a1ca25c49c00265a776b3f048</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1084%2Fjem.20131241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20131241%26sid%3Dliteratum%253Aachs%26aulast%3DScally%26aufirst%3DS.%2BW.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DLaw%26aufirst%3DS.%2BC.%26aulast%3DDudek%26aufirst%3DN.%2BL.%26aulast%3DNel%26aufirst%3DH.%2BJ.%26aulast%3DLoh%26aufirst%3DK.%2BL.%26aulast%3DWijeyewickrema%26aufirst%3DL.%2BC.%26aulast%3DEckle%26aufirst%3DS.%2BB.G.%26aulast%3Dvan%2BHeemst%26aufirst%3DJ.%26aulast%3DPike%26aufirst%3DR.%2BN.%26aulast%3DMcCluskey%26aufirst%3DJ.%26aulast%3DToes%26aufirst%3DR.%2BE.%26aulast%3DLa%2BGruta%26aufirst%3DN.%2BL.%26aulast%3DPurcell%26aufirst%3DA.%2BW.%26aulast%3DReid%26aufirst%3DH.%2BH.%26aulast%3DThomas%26aufirst%3DR.%26aulast%3DRossjohn%26aufirst%3DJ.%26atitle%3DA%2520Molecular%2520Basis%2520for%2520the%2520Association%2520of%2520the%2520HLA-DRB1%2520Locus%252C%2520Citrullination%252C%2520and%2520Rheumatoid%2520Arthritis%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2013%26volume%3D210%26issue%3D12%26spage%3D2569%26epage%3D2582%26doi%3D10.1084%2Fjem.20131241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Semerano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minichiello, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bessis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boissier, M.-C.</span></span> <span> </span><span class="NLM_article-title">Novel Immunotherapeutic Avenues for Rheumatoid Arthritis</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">214</span>â <span class="NLM_lpage">229</span>, <span class="refDoi">Â DOI: 10.1016/j.molmed.2016.01.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.molmed.2016.01.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=26875450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFSku7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=214-229&issue=3&author=L.+Semeranoauthor=E.+Minichielloauthor=N.+Bessisauthor=M.-C.+Boissier&title=Novel+Immunotherapeutic+Avenues+for+Rheumatoid+Arthritis&doi=10.1016%2Fj.molmed.2016.01.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Immunotherapeutic Avenues for Rheumatoid Arthritis</span></div><div class="casAuthors">Semerano, Luca; Minichiello, Emeline; Bessis, Natacha; Boissier, Marie-Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">214-229</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Rheumatoid arthritis (RA) is the most common inflammatory rheumatic disease.  It leads to irreversible joint damage, phys. handicap, and reduced life expectancy.  The past two decades have seen considerable therapeutic advances with the development of biol. treatments to block proinflammatory cytokines or modulate lymphocyte function, followed by the development of small mols. to target intracellular signaling.  Nevertheless, only a minority of patients can achieve disease remission, esp. long term, warranting further investigation into newer therapeutic options.  Targeting single proinflammatory pathways may not be sufficient, as suggested by variable results with T helper (Th)-17-related cytokine blockade.  Multilevel information from 'omics' techniques along with data from mechanistic studies might facilitate the identification of pivotal checkpoints in RA disease pathogenesis and the subsequent development of new effective treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaylgOPcQjrbVg90H21EOLACvtfcHk0likULEoL3GZew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFSku7k%253D&md5=57c882580d93a5c290184995061a41df</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2016.01.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2016.01.005%26sid%3Dliteratum%253Aachs%26aulast%3DSemerano%26aufirst%3DL.%26aulast%3DMinichiello%26aufirst%3DE.%26aulast%3DBessis%26aufirst%3DN.%26aulast%3DBoissier%26aufirst%3DM.-C.%26atitle%3DNovel%2520Immunotherapeutic%2520Avenues%2520for%2520Rheumatoid%2520Arthritis%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2016%26volume%3D22%26issue%3D3%26spage%3D214%26epage%3D229%26doi%3D10.1016%2Fj.molmed.2016.01.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hallermalm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivoltini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiessling, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitskaya, J.</span></span> <span> </span><span class="NLM_article-title">Tumor Necrosis Factor-Î± Induces Coordinated Changes in Major Histocompatibility Class I Presentation Pathway, Resulting in Increased Stability of Class I Complexes at the Cell Surface</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>98</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1108</span>â <span class="NLM_lpage">1115</span>, <span class="refDoi">Â DOI: 10.1182/blood.V98.4.1108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1182%2Fblood.V98.4.1108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=11493458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmtFeisbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=1108-1115&issue=4&author=K.+Hallermalmauthor=K.+Sekiauthor=C.+Weiauthor=C.+Castelliauthor=L.+Rivoltiniauthor=R.+Kiesslingauthor=J.+Levitskaya&title=Tumor+Necrosis+Factor-%CE%B1+Induces+Coordinated+Changes+in+Major+Histocompatibility+Class+I+Presentation+Pathway%2C+Resulting+in+Increased+Stability+of+Class+I+Complexes+at+the+Cell+Surface&doi=10.1182%2Fblood.V98.4.1108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor necrosis factor-Î± induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface</span></div><div class="casAuthors">Hallermalm, Kristian; Seki, Katzutake; Wei, Chenhong; Castelli, Chiara; Rivoltini, Licia; Kiessling, Rolf; Levitskaya, Jelena</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1108-1115</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">It is demonstrated that similar to interferon Î³ (IFN-Î³), tumor necrosis factor-Î± (TNF-Î±) induces coordinated changes at different steps of the major histocompatibility complex (MHC) class I processing and presentation pathway in nonprofessional antigen-presenting cells (APCs).  TNF-Î± up-regulates the expression of 3 catalytic immunoproteasome subunits-LMP2, LMP7, and MECL-1-the immunomodulatory proteasome activator PA28Î±, the TAP1/TAP2 heterodimer, and the total pool of MHC class I heavy chain.  It was also found that in TNF-Î±-treated cells, MHC class I mols. reconstitute more rapidly and have an increased av. half-life at the cell surface.  Biochem. changes induced by TNF-Î± in the MHC class I pathway were translated into increased sensitivity of TNF-Î±-treated targets to lysis by CD8+ cytotoxic T cells, demonstrating improved presentation of at least certain endogenously processed MHC class I-restricted peptide epitopes.  Significantly, it was demonstrated that the effects of TNF-Î± obsd. in this exptl. system were not mediated through the induction of IFN-Î³.  It appears to be likely that TNF-Î±-mediated effects on MHC class I processing and presentation do not involve any intermediate messengers.  Collectively, these data demonstrate the existence of yet another biol. activity exerted by TNF-Î±, namely its capacity to act as a coordinated multi-step modulator of the MHC class I pathway of antigen processing and presentation.  These results suggest that TNF-Î± may be useful when a concerted up-regulation of the MHC class I presentation machinery is required but cannot be achieved by IFN-Î³.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNs_fYNnbk67Vg90H21EOLACvtfcHk0likULEoL3GZew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmtFeisbo%253D&md5=d7ed804b083677777a5f9c3635d8e2fa</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1182%2Fblood.V98.4.1108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V98.4.1108%26sid%3Dliteratum%253Aachs%26aulast%3DHallermalm%26aufirst%3DK.%26aulast%3DSeki%26aufirst%3DK.%26aulast%3DWei%26aufirst%3DC.%26aulast%3DCastelli%26aufirst%3DC.%26aulast%3DRivoltini%26aufirst%3DL.%26aulast%3DKiessling%26aufirst%3DR.%26aulast%3DLevitskaya%26aufirst%3DJ.%26atitle%3DTumor%2520Necrosis%2520Factor-%25CE%25B1%2520Induces%2520Coordinated%2520Changes%2520in%2520Major%2520Histocompatibility%2520Class%2520I%2520Presentation%2520Pathway%252C%2520Resulting%2520in%2520Increased%2520Stability%2520of%2520Class%2520I%2520Complexes%2520at%2520the%2520Cell%2520Surface%26jtitle%3DBlood%26date%3D2001%26volume%3D98%26issue%3D4%26spage%3D1108%26epage%3D1115%26doi%3D10.1182%2Fblood.V98.4.1108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qureshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perera, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenschat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Splitter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, S. N.</span></span> <span> </span><span class="NLM_article-title">The Proteasome as a Lipopolysaccharide-Binding Protein in Macrophages: Differential Effects of Proteasome Inhibition on Lipopolysaccharide-Induced Signaling Events</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>171</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1515</span>â <span class="NLM_lpage">1525</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.171.3.1515</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.4049%2Fjimmunol.171.3.1515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=12874245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlsFyltbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2003&pages=1515-1525&issue=3&author=N.+Qureshiauthor=P.-Y.+Pereraauthor=J.+Shenauthor=G.+Zhangauthor=A.+Lenschatauthor=G.+Splitterauthor=D.+C.+Morrisonauthor=S.+N.+Vogel&title=The+Proteasome+as+a+Lipopolysaccharide-Binding+Protein+in+Macrophages%3A+Differential+Effects+of+Proteasome+Inhibition+on+Lipopolysaccharide-Induced+Signaling+Events&doi=10.4049%2Fjimmunol.171.3.1515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">The Proteasome as a Lipopolysaccharide-Binding Protein in Macrophages: Differential Effects of Proteasome Inhibition on Lipopolysaccharide-Induced Signaling Events</span></div><div class="casAuthors">Qureshi, Nilofer; Perera, Pin-Yu; Shen, Jing; Zhang, Guochi; Lenschat, Arnd; Splitter, Gary; Morrison, David C.; Vogel, Stefanie N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1515-1525</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The authors have developed a novel LPS probe using a highly purified and homogeneous prepn. of [3H] Escherichia coli LPS from the deep rough mutant, which contains a covalently linked, photoactivable 4-p-(azidosalicylamido)-butylamine group.  This cross-linker was used to identify the LPS-binding proteins in membranes of the murine-macrophage-like cell line RAW 264.7.  The Î±-subunit (PSMA1 C2, 29.5 kDa) and the Î²-subunit (PSMB4 N3, 24.36 kDa) of the 20S proteasome complex were identified as LPS-binding proteins.  This is the first report demonstrating LPS binding to enzymes such as the proteasome subunits.  Functionally, LPS enhanced the chymotrypsin-like activity of the proteasome to degrade synthetic peptides in vitro and, conversely, the proteasome inhibitor lactacystin completely blocked the LPS-induced proteasome's chymotrypsin activity as well as macrophage TNF-Î± secretion and the expression of multiple inflammatory mediator genes.  Lactacystin also completely blocked the LPS-induced expression of Toll-like receptor 2 mRNA.  In addn., lactacystin dysregulated mitogen-activated protein kinase phosphorylation in LPS-stimulated macrophages, but failed to inhibit IL-1 receptor-assocd. kinase-1 activity.  Importantly, lactacystin also prevented LPS-induced shock in mice.  These data strongly suggest that the proteasome complex regulates the LPS-induced signal transduction and that it may be an important therapeutic target in Gram-neg. sepsis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoICoGVmBiUsrVg90H21EOLACvtfcHk0ljTx_Jvybwtug"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlsFyltbY%253D&md5=a36e0928159357968b2201b606d6ee3e</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.171.3.1515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.171.3.1515%26sid%3Dliteratum%253Aachs%26aulast%3DQureshi%26aufirst%3DN.%26aulast%3DPerera%26aufirst%3DP.-Y.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DLenschat%26aufirst%3DA.%26aulast%3DSplitter%26aufirst%3DG.%26aulast%3DMorrison%26aufirst%3DD.%2BC.%26aulast%3DVogel%26aufirst%3DS.%2BN.%26atitle%3DThe%2520Proteasome%2520as%2520a%2520Lipopolysaccharide-Binding%2520Protein%2520in%2520Macrophages%253A%2520Differential%2520Effects%2520of%2520Proteasome%2520Inhibition%2520on%2520Lipopolysaccharide-Induced%2520Signaling%2520Events%26jtitle%3DJ.%2520Immunol.%26date%3D2003%26volume%3D171%26issue%3D3%26spage%3D1515%26epage%3D1525%26doi%3D10.4049%2Fjimmunol.171.3.1515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aujay, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalim, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylvain, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ring, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shields, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shwonek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parlati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span> <span> </span><span class="NLM_article-title">A Selective Inhibitor of the Immunoproteasome Subunit LMP7 Blocks Cytokine Production and Attenuates Progression of Experimental Arthritis</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">781</span>â <span class="NLM_lpage">787</span>, <span class="refDoi">Â DOI: 10.1038/nm.1978</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fnm.1978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=19525961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1ShtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=781-787&issue=7&author=T.+Muchamuelauthor=M.+Baslerauthor=M.+A.+Aujayauthor=E.+Suzukiauthor=K.+W.+Kalimauthor=C.+Lauerauthor=C.+Sylvainauthor=E.+R.+Ringauthor=J.+Shieldsauthor=J.+Jiangauthor=P.+Shwonekauthor=F.+Parlatiauthor=S.+Demoauthor=M.+Bennettauthor=C.+Kirkauthor=M.+Groettrup&title=A+Selective+Inhibitor+of+the+Immunoproteasome+Subunit+LMP7+Blocks+Cytokine+Production+and+Attenuates+Progression+of+Experimental+Arthritis&doi=10.1038%2Fnm.1978"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis</span></div><div class="casAuthors">Muchamuel, Tony; Basler, Michael; Aujay, Monette A.; Suzuki, Erika; Kalim, Khalid W.; Lauer, Christoph; Sylvain, Catherine; Ring, Eileen R.; Shields, Jamie; Jiang, Jing; Shwonek, Peter; Parlati, Francesco; Demo, Susan D.; Bennett, Mark K.; Kirk, Christopher J.; Groettrup, Marcus</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">781-787</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The immunoproteasome, a distinct class of proteasome found predominantly in monocytes and lymphocytes, is known to shape the antigenic repertoire presented on class I major histocompatibility complexes (MHC-I).  However, a specific role for the immunoproteasome in regulating other facets of immune responses has not been established.  The authors describe here the characterization of PR-957, a selective inhibitor of low-mol. mass polypeptide-7 (LMP7, encoded by Psmb8), the chymotrypsin-like subunit of the immunoproteasome.  PR-957 blocked presentation of LMP7-specific, MHC-I-restricted antigens in vitro and in vivo.  Selective inhibition of LMP7 by PR-957 blocked prodn. of interleukin-23 (IL-23) by activated monocytes and interferon-Î³ and IL-2 by T cells.  In mouse models of rheumatoid arthritis, PR-957 treatment reversed signs of disease and resulted in redns. in cellular infiltration, cytokine prodn. and autoantibody levels.  These studies reveal a unique role for LMP7 in controlling pathogenic immune responses and provide a therapeutic rationale for targeting LMP7 in autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJsuXHN4oyBbVg90H21EOLACvtfcHk0ljTx_Jvybwtug"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1ShtLs%253D&md5=3961ba1ec6786d0318bfa2b64e5e7cfa</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fnm.1978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.1978%26sid%3Dliteratum%253Aachs%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DBasler%26aufirst%3DM.%26aulast%3DAujay%26aufirst%3DM.%2BA.%26aulast%3DSuzuki%26aufirst%3DE.%26aulast%3DKalim%26aufirst%3DK.%2BW.%26aulast%3DLauer%26aufirst%3DC.%26aulast%3DSylvain%26aufirst%3DC.%26aulast%3DRing%26aufirst%3DE.%2BR.%26aulast%3DShields%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DShwonek%26aufirst%3DP.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DDemo%26aufirst%3DS.%26aulast%3DBennett%26aufirst%3DM.%26aulast%3DKirk%26aufirst%3DC.%26aulast%3DGroettrup%26aufirst%3DM.%26atitle%3DA%2520Selective%2520Inhibitor%2520of%2520the%2520Immunoproteasome%2520Subunit%2520LMP7%2520Blocks%2520Cytokine%2520Production%2520and%2520Attenuates%2520Progression%2520of%2520Experimental%2520Arthritis%26jtitle%3DNat.%2520Med.%26date%3D2009%26volume%3D15%26issue%3D7%26spage%3D781%26epage%3D787%26doi%3D10.1038%2Fnm.1978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mishto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellavista, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligorio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Textoris-Taube, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâAlfonso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ListÃ¬, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacmias, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cellini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimaldi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenoglio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposito, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli-Boneschi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galimberti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foschini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kloetzel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceschi, C.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasome LMP2 60HH Variant Alters MBP Epitope Generation and Reduces the Risk to Develop Multiple Sclerosis in Italian Female Population</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">e9287</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0009287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1371%2Fjournal.pone.0009287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=20174631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BC3c7itlKqtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=e9287&issue=2&author=M.+Mishtoauthor=E.+Bellavistaauthor=C.+Ligorioauthor=K.+Textoris-Taubeauthor=A.+Santoroauthor=M.+Giordanoauthor=S.+D%E2%80%99Alfonsoauthor=F.+List%C3%ACauthor=B.+Nacmiasauthor=E.+Celliniauthor=M.+Leoneauthor=L.+Grimaldiauthor=C.+Fenoglioauthor=F.+Espositoauthor=F.+Martinelli-Boneschiauthor=D.+Galimbertiauthor=E.+Scarpiniauthor=U.+Seifertauthor=M.+Amatoauthor=C.+Carusoauthor=M.+Foschiniauthor=P.+Kloetzelauthor=C.+Franceschi&title=Immunoproteasome+LMP2+60HH+Variant+Alters+MBP+Epitope+Generation+and+Reduces+the+Risk+to+Develop+Multiple+Sclerosis+in+Italian+Female+Population&doi=10.1371%2Fjournal.pone.0009287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoproteasome LMP2 60HH variant alters MBP epitope generation and reduces the risk to develop multiple sclerosis in Italian female population</span></div><div class="casAuthors">Mishto Michele; Bellavista Elena; Ligorio Claudia; Textoris-Taube Kathrin; Santoro Aurelia; Giordano Mara; D'Alfonso Sandra; Listi Florinda; Nacmias Benedetta; Cellini Elena; Leone Maurizio; Grimaldi Luigi M E; Fenoglio Chiara; Esposito Federica; Martinelli-Boneschi Filippo; Galimberti Daniela; Scarpini Elio; Seifert Ulrike; Amato Maria Pia; Caruso Calogero; Foschini Maria P; Kloetzel Peter M; Franceschi Claudio</div><div class="citationInfo"><span class="NLM_cas:title">PloS one</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e9287</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Albeit several studies pointed out the pivotal role that CD4+T cells have in Multiple Sclerosis, the CD8+ T cells involvement in the pathology is still in its early phases of investigation.  Proteasome degradation is the key step in the production of MHC class I-restricted epitopes and therefore its activity could be an important element in the activation and regulation of autoreactive CD8+ T cells in Multiple Sclerosis.  METHODOLOGY/PRINCIPAL FINDINGS:  Immunoproteasomes and PA28-alphabeta regulator are present in MS affected brain area and accumulated in plaques.  They are expressed in cell types supposed to be involved in MS development such as neurons, endothelial cells, oligodendrocytes, macrophages/macroglia and lymphocytes.  Furthermore, in a genetic study on 1262 Italian MS cases and 845 controls we observed that HLA-A*02+ female subjects carrying the immunoproteasome LMP2 codon 60HH variant have a reduced risk to develop MS.  Accordingly, immunoproteasomes carrying the LMP2 60H allele produce in vitro a lower amount of the HLA-A*0201 restricted immunodominant epitope MBP(111-119).  CONCLUSION/SIGNIFICANCE:  The immunoproteasome LMP2 60HH variant reduces the risk to develop MS amongst Italian HLA-A*02+ females.  We propose that such an effect is mediated by the altered proteasome-dependent production of a specific MBP epitope presented on the MHC class I.  Our observations thereby support the hypothesis of an involvement of immunoproteasome in the MS pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRqeMCB9jJ7CkPI-fCgwosgfW6udTcc2eblOGuK8Cy9arntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7itlKqtw%253D%253D&md5=6cd094e954c051702c322c26392e22ac</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0009287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0009287%26sid%3Dliteratum%253Aachs%26aulast%3DMishto%26aufirst%3DM.%26aulast%3DBellavista%26aufirst%3DE.%26aulast%3DLigorio%26aufirst%3DC.%26aulast%3DTextoris-Taube%26aufirst%3DK.%26aulast%3DSantoro%26aufirst%3DA.%26aulast%3DGiordano%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Alfonso%26aufirst%3DS.%26aulast%3DList%25C3%25AC%26aufirst%3DF.%26aulast%3DNacmias%26aufirst%3DB.%26aulast%3DCellini%26aufirst%3DE.%26aulast%3DLeone%26aufirst%3DM.%26aulast%3DGrimaldi%26aufirst%3DL.%26aulast%3DFenoglio%26aufirst%3DC.%26aulast%3DEsposito%26aufirst%3DF.%26aulast%3DMartinelli-Boneschi%26aufirst%3DF.%26aulast%3DGalimberti%26aufirst%3DD.%26aulast%3DScarpini%26aufirst%3DE.%26aulast%3DSeifert%26aufirst%3DU.%26aulast%3DAmato%26aufirst%3DM.%26aulast%3DCaruso%26aufirst%3DC.%26aulast%3DFoschini%26aufirst%3DM.%26aulast%3DKloetzel%26aufirst%3DP.%26aulast%3DFranceschi%26aufirst%3DC.%26atitle%3DImmunoproteasome%2520LMP2%252060HH%2520Variant%2520Alters%2520MBP%2520Epitope%2520Generation%2520and%2520Reduces%2520the%2520Risk%2520to%2520Develop%2520Multiple%2520Sclerosis%2520in%2520Italian%2520Female%2520Population%26jtitle%3DPLoS%2520One%26date%3D2010%26volume%3D5%26issue%3D2%26spage%3De9287%26doi%3D10.1371%2Fjournal.pone.0009287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bizzozero, O. A.</span></span> <span> </span><span class="NLM_article-title">Decreased Activity of the 20S Proteasome in the Brain White Matter and Gray Matter of Patients with Multiple Sclerosis</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>117</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">143</span>â <span class="NLM_lpage">153</span>, <span class="refDoi">Â DOI: 10.1111/j.1471-4159.2011.07182.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1111%2Fj.1471-4159.2011.07182.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=21235577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFalsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=143-153&issue=1&author=J.+Zhengauthor=O.+A.+Bizzozero&title=Decreased+Activity+of+the+20S+Proteasome+in+the+Brain+White+Matter+and+Gray+Matter+of+Patients+with+Multiple+Sclerosis&doi=10.1111%2Fj.1471-4159.2011.07182.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Decreased activity of the 20S proteasome in the brain white matter and gray matter of patients with multiple sclerosis</span></div><div class="casAuthors">Zheng, Jianzheng; Bizzozero, Oscar A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">143-153</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Carbonylated (oxidized) proteins are known to accumulate in the cerebral white matter (WM) and gray matter (GM) of patients with multiple sclerosis (MS).  Although oxidative stress is necessary for carbonyl generation, it is the failure of the degrdn. systems that ultimately leads to the buildup of carbonylated proteins within tissues.  In this study, we measured the activity of the 20S proteasome and other proteolytic systems in the cerebral WM and GM of 13 MS patients and 13 controls.  We report that the activities of the 3 peptidases of the 20S proteasome (i.e. chymotrypsin-like, caspase-like and trypsin-like) in both MS-WM and MS-GM are greatly reduced.  Interestingly, neither the amt. of proteasome nor the levels of the catalytic subunits (Î²1, Î²2, and Î²5) are diminished in this disease.  Proteins contg. Lys-48 poly-ubiquitin also accumulate in MS tissues, indicating failure of the 26S proteasome as well.  Levels of the regulatory caps 11S Î± and 19S are also lower in MS than in controls, suggesting that the activity of the more complex proteasomes may be reduced further.  Finally, the activities of other proteases that might also remove oxidized proteins (calpain, cathepsin B, mitochondrial LonP) are not lessened in MS.  Together, these studies suggest that direct inactivation of proteolytic centers in the 20S particle and/or the presence of specific inhibitors is the underlying cause of proteasomal dysfunction in MS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCkGx4gyYzg7Vg90H21EOLACvtfcHk0ljACl5ZYhuLRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFalsbY%253D&md5=356908c0754d91ad183f78b4815dd974</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2011.07182.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2011.07182.x%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DBizzozero%26aufirst%3DO.%2BA.%26atitle%3DDecreased%2520Activity%2520of%2520the%252020S%2520Proteasome%2520in%2520the%2520Brain%2520White%2520Matter%2520and%2520Gray%2520Matter%2520of%2520Patients%2520with%2520Multiple%2520Sclerosis%26jtitle%3DJ.%2520Neurochem.%26date%3D2011%26volume%3D117%26issue%3D1%26spage%3D143%26epage%3D153%26doi%3D10.1111%2Fj.1471-4159.2011.07182.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Constantinescu, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farooqi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâBrien, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gran, B.</span></span> <span> </span><span class="NLM_article-title">Experimental Autoimmune Encephalomyelitis (EAE) as a Model for Multiple Sclerosis (MS)</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>164</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1079</span>â <span class="NLM_lpage">1106</span>, <span class="refDoi">Â DOI: 10.1111/j.1476-5381.2011.01302.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1111%2Fj.1476-5381.2011.01302.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=21371012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlShtrjK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2011&pages=1079-1106&issue=4&author=C.+S.+Constantinescuauthor=N.+Farooqiauthor=K.+O%E2%80%99Brienauthor=B.+Gran&title=Experimental+Autoimmune+Encephalomyelitis+%28EAE%29+as+a+Model+for+Multiple+Sclerosis+%28MS%29&doi=10.1111%2Fj.1476-5381.2011.01302.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)</span></div><div class="casAuthors">Constantinescu, Cris S.; Farooqi, Nasr; O'Brien, Kate; Gran, Bruno</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1079-1106</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Exptl. autoimmune encephalomyelitis (EAE) is the most commonly used exptl. model for the human inflammatory demyelinating disease, multiple sclerosis (MS).  EAE is a complex condition in which the interaction between a variety of immunopathol. and neuropathol. mechanisms leads to an approxn. of the key pathol. features of MS: inflammation, demyelination, axonal loss and gliosis.  The counter-regulatory mechanisms of resoln. of inflammation and remyelination also occur in EAE, which, therefore can also serve as a model for these processes.  Moreover, EAE is often used as a model of cell-mediated organ-specific autoimmune conditions in general.  EAE has a complex neuropharmacol., and many of the drugs that are in current or imminent use in MS have been developed, tested or validated on the basis of EAE studies.  There is great heterogeneity in the susceptibility to the induction, the method of induction and the response to various immunol. or neuropharmacol. interventions, many of which are reviewed here.  This makes EAE a very versatile system to use in translational neuro- and immunopharmacol., but the model needs to be tailored to the scientific question being asked.  While creating difficulties and underscoring the inherent weaknesses of this model of MS in straightforward translation from EAE to the human disease, this variability also creates an opportunity to explore multiple facets of the immune and neural mechanisms of immune-mediated neuroinflammation and demyelination as well as intrinsic protective mechanisms.  This allows the eventual development and preclin. testing of a wide range of potential therapeutic interventions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNSPtAegOyxbVg90H21EOLACvtfcHk0lgyTlQNouyuGg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlShtrjK&md5=3ded21438fbedc8ce73c659424fdf5de</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01302.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01302.x%26sid%3Dliteratum%253Aachs%26aulast%3DConstantinescu%26aufirst%3DC.%2BS.%26aulast%3DFarooqi%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DK.%26aulast%3DGran%26aufirst%3DB.%26atitle%3DExperimental%2520Autoimmune%2520Encephalomyelitis%2520%2528EAE%2529%2520as%2520a%2520Model%2520for%2520Multiple%2520Sclerosis%2520%2528MS%2529%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D164%26issue%3D4%26spage%3D1079%26epage%3D1106%26doi%3D10.1111%2Fj.1476-5381.2011.01302.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moll, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the Immunoproteasome Ameliorates Experimental Autoimmune Encephalomyelitis</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">226</span>â <span class="NLM_lpage">238</span>, <span class="refDoi">Â DOI: 10.1002/emmm.201303543</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1002%2Femmm.201303543" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=24399752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWkur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=226-238&issue=2&author=M.+Baslerauthor=S.+Mundtauthor=T.+Muchamuelauthor=C.+Mollauthor=J.+Jiangauthor=M.+Groettrupauthor=C.+J.+Kirk&title=Inhibition+of+the+Immunoproteasome+Ameliorates+Experimental+Autoimmune+Encephalomyelitis&doi=10.1002%2Femmm.201303543"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis</span></div><div class="casAuthors">Basler, Michael; Mundt, Sarah; Muchamuel, Tony; Moll, Carlo; Jiang, Jing; Groettrup, Marcus; Kirk, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">226-238</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Multiple sclerosis (MS) is a chronic demyelinating immune mediated disease of the central nervous system.  The immunoproteasome is a distinct class of proteasomes found predominantly in monocytes and lymphocytes.  Recently, we demonstrated a novel function of immunoproteasomes in cytokine prodn. and T cell differentiation.  In this study, we investigated the therapeutic efficacy of an inhibitor of the immunoproteasome (ONX 0914) in two different mouse models of MS.  ONX 0914 attenuated disease progression after active and passive induction of exptl. autoimmune encephalomyelitis (EAE), both in MOG35-55 and PLP139-151-induced EAE.  Isolation of lymphocytes from the brain or spinal cord revealed a strong redn. of cytokine-producing CD4+ cells in ONX 0914 treated mice.  Addnl., ONX 0914 treatment prevented disease exacerbation in a relapsing-remitting model.  An anal. of draining lymph nodes after induction of EAE revealed that the differentiation to Th17 or Th1 cells was strongly impaired in ONX 0914 treated mice.  These results implicate the immunoproteasome in the development of EAE and suggest that immunoproteasome inhibitors are promising drugs for the treatment of MS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7NZVATJbqxLVg90H21EOLACvtfcHk0lgyTlQNouyuGg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWkur4%253D&md5=b092b6f79d66e9bcc23c4477cce19a67</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1002%2Femmm.201303543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.201303543%26sid%3Dliteratum%253Aachs%26aulast%3DBasler%26aufirst%3DM.%26aulast%3DMundt%26aufirst%3DS.%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DMoll%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DGroettrup%26aufirst%3DM.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26atitle%3DInhibition%2520of%2520the%2520Immunoproteasome%2520Ameliorates%2520Experimental%2520Autoimmune%2520Encephalomyelitis%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2014%26volume%3D6%26issue%3D2%26spage%3D226%26epage%3D238%26doi%3D10.1002%2Femmm.201303543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsokos, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, K. E.</span></span> <span> </span><span class="NLM_article-title">New Insights into the Immunopathogenesis of Systemic Lupus Erythematosus</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">716</span>â <span class="NLM_lpage">730</span>, <span class="refDoi">Â DOI: 10.1038/nrrheum.2016.186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fnrrheum.2016.186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=27872476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFGgsbfF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=716-730&issue=12&author=G.+C.+Tsokosauthor=M.+S.+Loauthor=P.+C.+Reisauthor=K.+E.+Sullivan&title=New+Insights+into+the+Immunopathogenesis+of+Systemic+Lupus+Erythematosus&doi=10.1038%2Fnrrheum.2016.186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into the immunopathogenesis of systemic lupus erythematosus</span></div><div class="casAuthors">Tsokos, George C.; Lo, Mindy S.; Reis, Patricia Costa; Sullivan, Kathleen E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Rheumatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">716-730</span>CODEN:
                <span class="NLM_cas:coden">NRRACB</span>;
        ISSN:<span class="NLM_cas:issn">1759-4790</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The etiol. of systemic lupus erythematosus (SLE) is multifactorial, and includes contributions from the environment, stochastic factors, and genetic susceptibility.  Great gains have been made in understanding SLE through the use of genetic variant identification, mouse models, gene expression studies, and epigenetic analyses.  Collectively, these studies support the concept that defective clearance of immune complexes and biol. waste (such as apoptotic cells), neutrophil extracellular traps, nucleic acid sensing, lymphocyte signalling, and interferon prodn. pathways are all central to loss of tolerance and tissue damage.  Increased understanding of the pathogenesis of SLE is driving a renewed interest in targeted therapy, and researchers are now on the verge of developing targeted immunotherapy directed at treating either specific organ system involvement or specific subsets of patients with SLE.  Accordingly, this Review places these insights within the context of our current understanding of the pathogenesis of SLE and highlights pathways that are ripe for therapeutic targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzf0_wLOx_aLVg90H21EOLACvtfcHk0lgyTlQNouyuGg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFGgsbfF&md5=58b91fc499fbcd3628cd67c400798d00</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2016.186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2016.186%26sid%3Dliteratum%253Aachs%26aulast%3DTsokos%26aufirst%3DG.%2BC.%26aulast%3DLo%26aufirst%3DM.%2BS.%26aulast%3DReis%26aufirst%3DP.%2BC.%26aulast%3DSullivan%26aufirst%3DK.%2BE.%26atitle%3DNew%2520Insights%2520into%2520the%2520Immunopathogenesis%2520of%2520Systemic%2520Lupus%2520Erythematosus%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2016%26volume%3D12%26issue%3D12%26spage%3D716%26epage%3D730%26doi%3D10.1038%2Fnrrheum.2016.186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">AlarcÃ³n-Segovia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AlarcÃ³n-Riquelme, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardiel, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caeiro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pons-Estel, B. A.</span></span> <span> </span><span class="NLM_article-title">Familial Aggregation of Systemic Lupus Erythematosus, Rheumatoid Arthritis, and Other Autoimmune Diseases in 1,177 Lupus Patients from the GLADEL Cohort</span>. <i>Arthritis Rheum.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1138</span>â <span class="NLM_lpage">1147</span>, <span class="refDoi">Â DOI: 10.1002/art.20999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1002%2Fart.20999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=15818688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BD2M7ptlWnsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2005&pages=1138-1147&issue=4&author=D.+Alarc%C3%B3n-Segoviaauthor=M.+E.+Alarc%C3%B3n-Riquelmeauthor=M.+H.+Cardielauthor=F.+Caeiroauthor=L.+Massardoauthor=A.+R.+Villaauthor=B.+A.+Pons-Estel&title=Familial+Aggregation+of+Systemic+Lupus+Erythematosus%2C+Rheumatoid+Arthritis%2C+and+Other+Autoimmune+Diseases+in+1%2C177+Lupus+Patients+from+the+GLADEL+Cohort&doi=10.1002%2Fart.20999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort</span></div><div class="casAuthors">Alarcon-Segovia Donato; Alarcon-Riquelme Marta E; Cardiel Mario H; Caeiro Francisco; Massardo Loreto; Villa Antonio R; Pons-Estel Bernardo A</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis and rheumatism</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1138-47</span>
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    </div><div class="casAbstract">OBJECTIVE:  To determine whether there is familial aggregation of systemic lupus erythematosus (SLE) and/or other autoimmune diseases in SLE patients and to identify clinical differences between patients with and those without familial autoimmunity.  METHODS:  We interviewed members of the Grupo Latinoamericano de Estudio del Lupus Eritematoso (GLADEL) inception cohort of 1,214 SLE patients to ascertain whether they had relatives with SLE and/or other autoimmune diseases.  Identified relatives were studied.  Familial aggregation was tested using reported highest and intermediate population prevalence data for SLE, rheumatoid arthritis (RA), or all autoimmune diseases, and studies were performed to identify the genetic model applicable for SLE.  RESULTS:  We identified 116 first-, second-, or third-degree relatives with SLE, 79 with RA, 23 with autoimmune thyroiditis, 3 with scleroderma, 1 with polymyositis, and 16 with other autoimmune diseases, related to 166 of the 1,177 SLE patients in the GLADEL cohort who agreed to participate.  Forty-two SLE patients had 2 or more relatives with an autoimmune disease.  We found a lambda(sibling) of 5.8 and 29.0 for SLE and of 3.2-5.3 for RA, when comparing with their reported high or intermediate population prevalence, respectively.  We also found familial aggregation for autoimmune disease in general (lambda(sibling) = 1.5) and determined that for SLE, a polygenic additive genetic model, rather than a multiplicative one, is applicable.  CONCLUSION:  In SLE there is familial aggregation of SLE, RA, and autoimmune disease in general.  A polygenic additive model applies for SLE.  American Indian-white Mestizo SLE patients and those with higher socioeconomic level were more likely to have familial autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSroVkpgDFNoGyYR5VtavbzfW6udTcc2ebIW47XkU5VObntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7ptlWnsA%253D%253D&md5=d37934a9cef4ff883e07dcda67fd9487</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1002%2Fart.20999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.20999%26sid%3Dliteratum%253Aachs%26aulast%3DAlarc%25C3%25B3n-Segovia%26aufirst%3DD.%26aulast%3DAlarc%25C3%25B3n-Riquelme%26aufirst%3DM.%2BE.%26aulast%3DCardiel%26aufirst%3DM.%2BH.%26aulast%3DCaeiro%26aufirst%3DF.%26aulast%3DMassardo%26aufirst%3DL.%26aulast%3DVilla%26aufirst%3DA.%2BR.%26aulast%3DPons-Estel%26aufirst%3DB.%2BA.%26atitle%3DFamilial%2520Aggregation%2520of%2520Systemic%2520Lupus%2520Erythematosus%252C%2520Rheumatoid%2520Arthritis%252C%2520and%2520Other%2520Autoimmune%2520Diseases%2520in%25201%252C177%2520Lupus%2520Patients%2520from%2520the%2520GLADEL%2520Cohort%26jtitle%3DArthritis%2520Rheum.%26date%3D2005%26volume%3D52%26issue%3D4%26spage%3D1138%26epage%3D1147%26doi%3D10.1002%2Fart.20999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">Genetic Susceptibility to SLE: Recent Progress from GWAS</span>. <i>J. Autoimmun.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">25</span>â <span class="NLM_lpage">33</span>, <span class="refDoi">Â DOI: 10.1016/j.jaut.2013.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.jaut.2013.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=23395425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Khtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=25-33&author=Y.+Cuiauthor=Y.+Shengauthor=X.+Zhang&title=Genetic+Susceptibility+to+SLE%3A+Recent+Progress+from+GWAS&doi=10.1016%2Fj.jaut.2013.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic susceptibility to SLE: Recent progress from GWAS</span></div><div class="casAuthors">Cui, Yong; Sheng, Yujun; Zhang, Xuejun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Autoimmunity</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">25-33</span>CODEN:
                <span class="NLM_cas:coden">JOAUEP</span>;
        ISSN:<span class="NLM_cas:issn">0896-8411</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Systemic lupus erythematosus (SLE) is a prototype autoimmune disease with a strong genetic component, characterized by hyperactive T and B cells, autoantibody prodn., immune complex deposition and multi-organ damage.  It affects predominantly women of child-bearing age and has population differences in both disease prevalence and severity.  Genetic factors are known to play key roles in the disease through the use of assocn. and family studies.  Previously, SLE susceptibility genes were mainly revealed through linkage anal. and candidate gene studies.  Since 2008, our understanding of the genetic basis of SLE has been rapidly advanced through genome-wide assocn. studies (GWASs).  More than 40 robust susceptibility loci have been identified and conformed to be assocd. with SLE using this technique.  Most of these assocd. genes productions participate in important pathways involved in the pathogenesis of SLE, such as immune complex processing, toll-like receptor signaling, type I interferon prodn., and so on.  A no. of susceptibility loci with unknown functions in the pathogenesis of SLE have also been identified, indicating that addnl. mol. mechanisms contribute to the risk of developing SLE.  It is noteworthy that susceptibility loci of SLE are shared by other immune-related diseases.  Thus, common mol. pathways may be involved in the pathogenesis of these diseases.  In this review, we summarize the key loci, achieving genome-wide significance, which have been shown to predispose to SLE.  Anal. of relevant mol. pathways suggests new etiol. clues to SLE development.  These genetic loci may help building the foundation for genetic diagnosis and personalized treatment for patients with SLE in the near future.  However, substantial addnl. studies, including functional and gene-targeted studies, are required to confirm the causality of the genetic variants and their biol. relevance in SLE development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfMjUpspSKirVg90H21EOLACvtfcHk0lhjtQ1zmZGxEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Khtrs%253D&md5=87d587e3dde2ed3bffa0eed22426d546</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.jaut.2013.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaut.2013.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DGenetic%2520Susceptibility%2520to%2520SLE%253A%2520Recent%2520Progress%2520from%2520GWAS%26jtitle%3DJ.%2520Autoimmun.%26date%3D2013%26volume%3D41%26spage%3D25%26epage%3D33%26doi%3D10.1016%2Fj.jaut.2013.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span> <span> </span><span class="NLM_article-title">IFNÎ± Inducible Models of Murine SLE</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">306</span>, <span class="refDoi">Â DOI: 10.3389/fimmu.2013.00306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.3389%2Ffimmu.2013.00306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=24106491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BC2cfltlWmsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=306&author=A.+Davidsonauthor=Z.+Liu&title=IFN%CE%B1+Inducible+Models+of+Murine+SLE&doi=10.3389%2Ffimmu.2013.00306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">IFNÎ± Inducible Models of Murine SLE</span></div><div class="casAuthors">Liu Zheng; Davidson Anne</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">306</span>
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    </div><div class="casAbstract">The role of type I interferons (IFNs) in SLE pathogenesis has been a subject of intense investigation in the last decade.  The strong link between type I IFNs and SLE was initially provided by ex vivo studies showing that exposure of peripheral blood mononuclear cells to immune complexes from SLE patients elicits a signature of IFN inducible genes and was then further highlighted by human genetic studies.  The mechanisms by which type I IFNs, especially IFN alpha (IFNÎ±), modulate the immune system and exacerbate SLE have been largely elucidated through studies in mouse lupus models.  In this review, we discuss the characteristics of several such models in which disease is accelerated by ectopically expressed IFNÎ±.  We also summarize several studies which tested therapeutic interventions in these models and discuss the advantages and disadvantages of using IFNÎ± accelerated models to study experimental treatments for lupus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0YQxum6hoa669lAbTj9rGfW6udTcc2ebIW47XkU5VObntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfltlWmsQ%253D%253D&md5=71900c110682f12925125e6d40dbef26</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2013.00306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2013.00306%26sid%3Dliteratum%253Aachs%26aulast%3DDavidson%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DZ.%26atitle%3DIFN%25CE%25B1%2520Inducible%2520Models%2520of%2520Murine%2520SLE%26jtitle%3DFront.%2520Immunol.%26date%3D2013%26volume%3D4%26spage%3D306%26doi%3D10.3389%2Ffimmu.2013.00306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ledford, H.</span></span> <span> </span><span class="NLM_article-title">After Half-Centuryâs Wait, Approval Paves Path for New Lupus Drugs</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">400</span>, <span class="refDoi">Â DOI: 10.1038/nm0411-400a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fnm0411-400a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=21475219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksVCqs7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=400&issue=4&author=H.+Ledford&title=After+Half-Century%E2%80%99s+Wait%2C+Approval+Paves+Path+for+New+Lupus+Drugs&doi=10.1038%2Fnm0411-400a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Pooled trials drowning in conflict-of-interest oversights</span></div><div class="casAuthors">Ledford, Heidi</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">400-401</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTpW99kq1e27Vg90H21EOLACvtfcHk0lhjtQ1zmZGxEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksVCqs7k%253D&md5=a9939df17ee82e5d0781cdade3ead335</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1038%2Fnm0411-400a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0411-400a%26sid%3Dliteratum%253Aachs%26aulast%3DLedford%26aufirst%3DH.%26atitle%3DAfter%2520Half-Century%25E2%2580%2599s%2520Wait%252C%2520Approval%2520Paves%2520Path%2520for%2520New%2520Lupus%2520Drugs%26jtitle%3DNat.%2520Med.%26date%3D2011%26volume%3D17%26issue%3D4%26spage%3D400%26doi%3D10.1038%2Fnm0411-400a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernatsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boivin, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginzler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladman, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urowitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isenberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dooley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nived, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturfelt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinsson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alarcon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senecal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zummer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ensworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pope, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edworthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Gabalawy, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Pierre, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey-Goldman, R.</span></span> <span> </span><span class="NLM_article-title">Mortality in Systemic Lupus Erythematosus</span>. <i>Arthritis Rheum.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2550</span>â <span class="NLM_lpage">2557</span>, <span class="refDoi">Â DOI: 10.1002/art.21955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1002%2Fart.21955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=16868977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BD28rgvFOrtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2006&pages=2550-2557&issue=8&author=S.+Bernatskyauthor=J.-F.+Boivinauthor=L.+Josephauthor=S.+Manziauthor=E.+Ginzlerauthor=D.+D.+Gladmanauthor=M.+Urowitzauthor=P.+R.+Fortinauthor=M.+Petriauthor=S.+Barrauthor=C.+Gordonauthor=S.+Baeauthor=D.+Isenbergauthor=A.+Zomaauthor=C.+Aranowauthor=M.+Dooleyauthor=O.+Nivedauthor=G.+Sturfeltauthor=K.+Steinssonauthor=G.+Alarconauthor=J.+Senecalauthor=M.+Zummerauthor=J.+Hanlyauthor=S.+Ensworthauthor=J.+Popeauthor=S.+Edworthyauthor=A.+Rahmanauthor=J.+Sibleyauthor=H.+El-Gabalawyauthor=T.+McCarthyauthor=Y.+St.+Pierreauthor=A.+Clarkeauthor=R.+Ramsey-Goldman&title=Mortality+in+Systemic+Lupus+Erythematosus&doi=10.1002%2Fart.21955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Mortality in systemic lupus erythematosus</span></div><div class="casAuthors">Bernatsky S; Boivin J-F; Joseph L; Manzi S; Ginzler E; Gladman D D; Urowitz M; Fortin P R; Petri M; Barr S; Gordon C; Bae S-C; Isenberg D; Zoma A; Aranow C; Dooley M-A; Nived O; Sturfelt G; Steinsson K; Alarcon G; Senecal J-L; Zummer M; Hanly J; Ensworth S; Pope J; Edworthy S; Rahman A; Sibley J; El-Gabalawy H; McCarthy T; St Pierre Y; Clarke A; Ramsey-Goldman R</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis and rheumatism</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2550-7</span>
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    </div><div class="casAbstract">OBJECTIVE:  To examine mortality rates in the largest systemic lupus erythematosus (SLE) cohort ever assembled.  METHODS:  Our sample was a multisite international SLE cohort (23 centers, 9,547 patients).  Deaths were ascertained by vital statistics registry linkage.  Standardized mortality ratio (SMR; ratio of deaths observed to deaths expected) estimates were calculated for all deaths and by cause.  The effects of sex, age, SLE duration, race, and calendar-year periods were determined.  RESULTS:  The overall SMR was 2.4 (95% confidence interval 2.3-2.5).  Particularly high mortality was seen for circulatory disease, infections, renal disease, non-Hodgkin's lymphoma, and lung cancer.  The highest SMR estimates were seen in patient groups characterized by female sex, younger age, SLE duration <1 year, or black/African American race.  There was a dramatic decrease in total SMR estimates across calendar-year periods, which was demonstrable for specific causes including death due to infections and death due to renal disorders.  However, the SMR due to circulatory diseases tended to increase slightly from the 1970s to the year 2001.  CONCLUSION:  Our data from a very large multicenter international cohort emphasize what has been demonstrated previously in smaller samples.  These results highlight the increased mortality rate in SLE patients compared with the general population, and they suggest particular risk associated with female sex, younger age, shorter SLE duration, and black/African American race.  The risk for certain types of deaths, primarily related to lupus activity (such as renal disease), has decreased over time, while the risk for deaths due to circulatory disease does not appear to have diminished.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbwHSFM5QIVY3yKPtYViAGfW6udTcc2eYX0dIehg2GDrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rgvFOrtw%253D%253D&md5=c2eed8393fc4f4598a46bbbebe8c87d7</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1002%2Fart.21955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.21955%26sid%3Dliteratum%253Aachs%26aulast%3DBernatsky%26aufirst%3DS.%26aulast%3DBoivin%26aufirst%3DJ.-F.%26aulast%3DJoseph%26aufirst%3DL.%26aulast%3DManzi%26aufirst%3DS.%26aulast%3DGinzler%26aufirst%3DE.%26aulast%3DGladman%26aufirst%3DD.%2BD.%26aulast%3DUrowitz%26aufirst%3DM.%26aulast%3DFortin%26aufirst%3DP.%2BR.%26aulast%3DPetri%26aufirst%3DM.%26aulast%3DBarr%26aufirst%3DS.%26aulast%3DGordon%26aufirst%3DC.%26aulast%3DBae%26aufirst%3DS.%26aulast%3DIsenberg%26aufirst%3DD.%26aulast%3DZoma%26aufirst%3DA.%26aulast%3DAranow%26aufirst%3DC.%26aulast%3DDooley%26aufirst%3DM.%26aulast%3DNived%26aufirst%3DO.%26aulast%3DSturfelt%26aufirst%3DG.%26aulast%3DSteinsson%26aufirst%3DK.%26aulast%3DAlarcon%26aufirst%3DG.%26aulast%3DSenecal%26aufirst%3DJ.%26aulast%3DZummer%26aufirst%3DM.%26aulast%3DHanly%26aufirst%3DJ.%26aulast%3DEnsworth%26aufirst%3DS.%26aulast%3DPope%26aufirst%3DJ.%26aulast%3DEdworthy%26aufirst%3DS.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DSibley%26aufirst%3DJ.%26aulast%3DEl-Gabalawy%26aufirst%3DH.%26aulast%3DMcCarthy%26aufirst%3DT.%26aulast%3DSt.%2BPierre%26aufirst%3DY.%26aulast%3DClarke%26aufirst%3DA.%26aulast%3DRamsey-Goldman%26aufirst%3DR.%26atitle%3DMortality%2520in%2520Systemic%2520Lupus%2520Erythematosus%26jtitle%3DArthritis%2520Rheum.%26date%3D2006%26volume%3D54%26issue%3D8%26spage%3D2550%26epage%3D2557%26doi%3D10.1002%2Fart.21955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neubert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maseda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiethe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalden, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manz, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voll, R.</span></span> <span> </span><span class="NLM_article-title">The Proteasome Inhibitor Bortezomib Depletes Plasma Cells and Protects Mice with Lupus-like Disease from Nephritis</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">748</span>â <span class="NLM_lpage">755</span>, <span class="refDoi">Â DOI: 10.1038/nm1763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fnm1763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=18542049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotF2lurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=748-755&issue=7&author=K.+Neubertauthor=S.+Meisterauthor=K.+Moserauthor=F.+Weiselauthor=D.+Masedaauthor=K.+Amannauthor=C.+Wietheauthor=T.+H.+Winklerauthor=J.+R.+Kaldenauthor=R.+A.+Manzauthor=R.+Voll&title=The+Proteasome+Inhibitor+Bortezomib+Depletes+Plasma+Cells+and+Protects+Mice+with+Lupus-like+Disease+from+Nephritis&doi=10.1038%2Fnm1763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis</span></div><div class="casAuthors">Neubert, Kirsten; Meister, Silke; Moser, Katrin; Weisel, Florian; Maseda, Damian; Amann, Kerstin; Wiethe, Carsten; Winkler, Thomas H.; Kalden, Joachim R.; Manz, Rudolf A.; Voll, Reinhard E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">748-755</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bortezomib, a drug useful for the treatment of multiple myeloma, reduces kidney damage in animal models of lupus.  Autoantibody-mediated diseases like myasthenia gravis, autoimmune hemolytic anemia and systemic lupus erythematosus represent a therapeutic challenge.  In particular, long-lived plasma cells producing autoantibodies resist current therapeutic and exptl. approaches.  Recently, we showed that the sensitivity of myeloma cells toward proteasome inhibitors directly correlates with their Ig synthesis rates.  Therefore, we hypothesized that normal plasma cells are also hypersensitive to proteasome inhibition owing to their extremely high amt. of protein biosynthesis.  Here we show that the proteasome inhibitor bortezomib, which is approved for the treatment of multiple myeloma, eliminates both short- and long-lived plasma cells by activation of the terminal unfolded protein response.  Treatment with bortezomib depleted plasma cells producing antibodies to double-stranded DNA, eliminated autoantibody prodn., ameliorated glomerulonephritis and prolonged survival of two mouse strains with lupus-like disease, NZB/W F1 and MRL/lpr mice.  Hence, the elimination of autoreactive plasma cells by proteasome inhibitors might represent a new treatment strategy for antibody-mediated diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZtv5EvAwSRLVg90H21EOLACvtfcHk0lgH6D22eTL1sg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotF2lurw%253D&md5=a53d9cfc5690c95b1454a50b40a0bdb7</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1038%2Fnm1763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1763%26sid%3Dliteratum%253Aachs%26aulast%3DNeubert%26aufirst%3DK.%26aulast%3DMeister%26aufirst%3DS.%26aulast%3DMoser%26aufirst%3DK.%26aulast%3DWeisel%26aufirst%3DF.%26aulast%3DMaseda%26aufirst%3DD.%26aulast%3DAmann%26aufirst%3DK.%26aulast%3DWiethe%26aufirst%3DC.%26aulast%3DWinkler%26aufirst%3DT.%2BH.%26aulast%3DKalden%26aufirst%3DJ.%2BR.%26aulast%3DManz%26aufirst%3DR.%2BA.%26aulast%3DVoll%26aufirst%3DR.%26atitle%3DThe%2520Proteasome%2520Inhibitor%2520Bortezomib%2520Depletes%2520Plasma%2520Cells%2520and%2520Protects%2520Mice%2520with%2520Lupus-like%2520Disease%2520from%2520Nephritis%26jtitle%3DNat.%2520Med.%26date%3D2008%26volume%3D14%26issue%3D7%26spage%3D748%26epage%3D755%26doi%3D10.1038%2Fnm1763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Badros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goloubeva, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalal, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Can, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapoport, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akpek, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenton, R. G.</span></span> <span> </span><span class="NLM_article-title">Neurotoxicity of Bortezomib Therapy in Multiple Myeloma: A Single-Center Experience and Review of the Literature</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>110</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1042</span>â <span class="NLM_lpage">1049</span>, <span class="refDoi">Â DOI: 10.1002/cncr.22921</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1002%2Fcncr.22921" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=17654660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVChs7fP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=1042-1049&issue=5&author=A.+Badrosauthor=O.+Goloubevaauthor=J.+S.+Dalalauthor=I.+Canauthor=J.+Thompsonauthor=A.+P.+Rapoportauthor=M.+Heymanauthor=G.+Akpekauthor=R.+G.+Fenton&title=Neurotoxicity+of+Bortezomib+Therapy+in+Multiple+Myeloma%3A+A+Single-Center+Experience+and+Review+of+the+Literature&doi=10.1002%2Fcncr.22921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature</span></div><div class="casAuthors">Badros, Ashraf; Goloubeva, Olga; Dalal, Jay S.; Can, Ilyas; Thompson, Jennifer; Rapoport, Aaron P.; Heyman, Meyer; Akpek, Gorgon; Fenton, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1042-1049</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">BACKGROUND: Bortezomib is active in heavily pretreated multiple myeloma patients; the dose-limiting toxicity is peripheral neuropathy (PN).  METHODS: The authors retrospectively reviewed the incidence, severity, and risk factors for PN in 78 patients who received bortezomib.  The median age was 57 years (range, 33-80 years), 62% of patients were men, and 37% of patients were African Americans.  Seventeen patients (22%) had diabetes mellitus (DM), and 66 patients (85%) had received thalidomide.  Before bortezomib treatment, 37% of the patients reported subjective, grade 1 or 2 PN.  Patients received bortezomib alone (n - 10 patients) plus dexamethasone (n - 36 patients) and thalidomide (n = 20 patients) or chemotherapy (n = 12 patients).  PN affected 52% of patients, including grade 3 and 4 PN in 15% and 7% resp.  RESULTS: Twelve patients stopped bortezomib because of side effects that included PN (n = 9 patients), diarrhea (n = 2 patients) and cytomegalovirus pneumonia (n = 1 patient); 11 patients had dose redns. because of PN.  Grade 4 PN affected 6 patients (sensory, n = 4 patients; motor/sensory, n - 2 patients).  The onset of grade 4 PN was sudden rather than cumulative.  Factors that were predictive of PN grade were baseline PN (P = .002), prior thalidomide use (P = .03), and the presence of DM (P = .03).  Multiple myeloma responses included complete, near complete, and partial responses in 5% of patients, 10% of patients, and 27% of patients, resp.  Responses were independent of PN and of whether bortezomib was combined with chemotherapy or thalidomide.  Patients remained on therapy longer for a median of 5 cycles (range, 2-36 cycles) when they received bortezomib plus thalidomide vs. 3 cycles (range, 1-19 cycles) for the other combinations.  PN therapy was mostly supportive.  It was noteworthy that 6 of 9 patients with PN who received lenalidomide as salvage therapy after bortezomib had significant improvement in their symptoms.  CONCLUSIONS: The risk of bortezomib-related PN was greater in patients who had PN and DM at baseline.  The authors concluded that an unexpected, symptomatic improvement of PN on lenalidomide is worth further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPiBBwv4BrjLVg90H21EOLACvtfcHk0ljCUqbqIQU_eQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVChs7fP&md5=a6237838ddb35e2984b4b79e84001fd3</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1002%2Fcncr.22921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.22921%26sid%3Dliteratum%253Aachs%26aulast%3DBadros%26aufirst%3DA.%26aulast%3DGoloubeva%26aufirst%3DO.%26aulast%3DDalal%26aufirst%3DJ.%2BS.%26aulast%3DCan%26aufirst%3DI.%26aulast%3DThompson%26aufirst%3DJ.%26aulast%3DRapoport%26aufirst%3DA.%2BP.%26aulast%3DHeyman%26aufirst%3DM.%26aulast%3DAkpek%26aufirst%3DG.%26aulast%3DFenton%26aufirst%3DR.%2BG.%26atitle%3DNeurotoxicity%2520of%2520Bortezomib%2520Therapy%2520in%2520Multiple%2520Myeloma%253A%2520A%2520Single-Center%2520Experience%2520and%2520Review%2520of%2520the%2520Literature%26jtitle%3DCancer%26date%3D2007%26volume%3D110%26issue%3D5%26spage%3D1042%26epage%3D1049%26doi%3D10.1002%2Fcncr.22921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conley, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevarez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Looney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anolik, J.</span></span> <span> </span><span class="NLM_article-title">Novel Proteasome Inhibitors Have a Beneficial Effect in Murine Lupus via the Dual Inhibition of Type I Interferon and Autoantibody Secreting Cells</span>. <i>Arthritis Rheum.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>64</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">493</span>â <span class="NLM_lpage">503</span>, <span class="refDoi">Â DOI: 10.1002/art.33333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1002%2Fart.33333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=21905015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yrurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=493-503&issue=2&author=H.+T.+Ichikawaauthor=T.+Conleyauthor=T.+Muchamuelauthor=J.+Jiangauthor=S.+Leeauthor=T.+Owenauthor=J.+Barnardauthor=S.+Nevarezauthor=B.+I.+Goldmanauthor=C.+J.+Kirkauthor=R.+Looneyauthor=J.+Anolik&title=Novel+Proteasome+Inhibitors+Have+a+Beneficial+Effect+in+Murine+Lupus+via+the+Dual+Inhibition+of+Type+I+Interferon+and+Autoantibody+Secreting+Cells&doi=10.1002%2Fart.33333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells</span></div><div class="casAuthors">Ichikawa, H. Travis; Conley, Thomas; Muchamuel, Tony; Jiang, Jing; Lee, Susan; Owen, Teresa; Barnard, Jennifer; Nevarez, Sarah; Goldman, Bruce I.; Kirk, Christopher J.; Looney, R. John; Anolik, Jennifer H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">493-503</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : To investigate the hypothesis that proteasome inhibition may have potential in the treatment of SLE, by targeting plasmacytoid dendritic cells (PDCs) and plasma cells, both of which are crit. in disease pathogenesis.  Methods : Lupus-prone mice were treated with the nonselective proteasome inhibitors carfilzomib and bortezomib, the immunoproteasome inhibitor ONX 0914, or vehicle control.  Tissue was harvested and analyzed by flow cytometry using std. markers.  Nephritis was monitored by evaluation for proteinuria and by histol. anal. of kidneys.  Serum anti-double-stranded DNA (anti-dsDNA) levels were measured by ELISA (ELISA), and total IgG and dsDNA antibody-secreting cells (ASCs) by enzyme-linked immunospot assay.  Human peripheral blood mononuclear cells or mouse bone marrow cells were incubated with Toll-like receptor (TLR) agonists and proteasome inhibitors, and interferon-Î± (IFNÎ±) levels were measured by ELISA and flow cytometry.  Results : Early treatment of lupus-prone mice with the dual-targeting proteasome inhibitors carfilzomib or bortezomib or the immunoproteasome-specific inhibitor ONX 0914 prevented disease progression, and treatment of mice with established disease dramatically abrogated nephritis.  Treatment had profound effects on plasma cells, with greater redns. in autoreactive than in total IgG ASCs, an effect that became more pronounced with prolonged treatment and was reflected in decreasing serum autoantibody levels.  Notably, proteasome inhibition efficiently suppressed prodn. of IFNÎ± by TLR-activated PDCs in vitro and in vivo, an effect mediated by inhibition of both PDC survival and PDC function.  Conclusion : Inhibition of the immunoproteasome is equally efficacious as dual targeting agents in preventing lupus disease progression by targeting 2 crit. pathways in disease pathogenesis, type I IFN activation and autoantibody prodn. by plasma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgx8A-mW0b_bVg90H21EOLACvtfcHk0ljCUqbqIQU_eQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yrurk%253D&md5=1055201f4931e5c09ae292b07e26c0cc</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1002%2Fart.33333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.33333%26sid%3Dliteratum%253Aachs%26aulast%3DIchikawa%26aufirst%3DH.%2BT.%26aulast%3DConley%26aufirst%3DT.%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DOwen%26aufirst%3DT.%26aulast%3DBarnard%26aufirst%3DJ.%26aulast%3DNevarez%26aufirst%3DS.%26aulast%3DGoldman%26aufirst%3DB.%2BI.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DLooney%26aufirst%3DR.%26aulast%3DAnolik%26aufirst%3DJ.%26atitle%3DNovel%2520Proteasome%2520Inhibitors%2520Have%2520a%2520Beneficial%2520Effect%2520in%2520Murine%2520Lupus%2520via%2520the%2520Dual%2520Inhibition%2520of%2520Type%2520I%2520Interferon%2520and%2520Autoantibody%2520Secreting%2520Cells%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26issue%3D2%26spage%3D493%26epage%3D503%26doi%3D10.1002%2Fart.33333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaStant, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurits, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langrish, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span> <span> </span><span class="NLM_article-title">Co-Inhibition of Immunoproteasome Subunits LMP2 and LMP7 Is Required to Block Autoimmunity</span>. <i>EMBO Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">e46521</span>, <span class="refDoi">Â DOI: 10.15252/embr.201846512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.15252%2Fembr.201846512" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=e46521&issue=12&author=M.+Baslerauthor=M.+M.+Lindstromauthor=J.+J.+LaStantauthor=J.+M.+Bradshawauthor=T.+D.+Owensauthor=C.+Schmidtauthor=E.+Mauritsauthor=C.+Tsuauthor=H.+S.+Overkleeftauthor=C.+J.+Kirkauthor=C.+Langrishauthor=M.+Groettrup&title=Co-Inhibition+of+Immunoproteasome+Subunits+LMP2+and+LMP7+Is+Required+to+Block+Autoimmunity&doi=10.15252%2Fembr.201846512"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.15252%2Fembr.201846512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Fembr.201846512%26sid%3Dliteratum%253Aachs%26aulast%3DBasler%26aufirst%3DM.%26aulast%3DLindstrom%26aufirst%3DM.%2BM.%26aulast%3DLaStant%26aufirst%3DJ.%2BJ.%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DSchmidt%26aufirst%3DC.%26aulast%3DMaurits%26aufirst%3DE.%26aulast%3DTsu%26aufirst%3DC.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DLangrish%26aufirst%3DC.%26aulast%3DGroettrup%26aufirst%3DM.%26atitle%3DCo-Inhibition%2520of%2520Immunoproteasome%2520Subunits%2520LMP2%2520and%2520LMP7%2520Is%2520Required%2520to%2520Block%2520Autoimmunity%26jtitle%3DEMBO%2520Rep.%26date%3D2018%26volume%3D19%26issue%3D12%26spage%3De46521%26doi%3D10.15252%2Fembr.201846512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, H. W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderl, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arastu-Kapur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moebius, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMinn, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">413</span>â <span class="NLM_lpage">417</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.6b00496</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00496" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktVahtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=413-417&issue=4&author=H.+W.+B.+Johnsonauthor=J.+L.+Anderlauthor=E.+K.+Bradleyauthor=J.+Buiauthor=J.+Jonesauthor=S.+Arastu-Kapurauthor=L.+M.+Kellyauthor=E.+Loweauthor=D.+C.+Moebiusauthor=T.+Muchamuelauthor=C.+Kirkauthor=Z.+Wangauthor=D.+McMinn&title=Discovery+of+Highly+Selective+Inhibitors+of+the+Immunoproteasome+Low+Molecular+Mass+Polypeptide+2+%28LMP2%29+Subunit&doi=10.1021%2Facsmedchemlett.6b00496"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit</span></div><div class="casAuthors">Johnson, Henry W. B.; Anderl, Janet L.; Bradley, Erin K.; Bui, John; Jones, Jeffrey; Arastu-Kapur, Shirin; Kelly, Lisa M.; Lowe, Eric; Moebius, David C.; Muchamuel, Tony; Kirk, Christopher; Wang, Zhengping; McMinn, Dustin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">413-417</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Building upon the success of bortezomib (VELCADE) and carfilzomib (KYPROLIS), the design of a next generation of inhibitors targeting specific subunits within the immunoproteasome is of interest for the treatment of autoimmune disease.  There are three catalytic subunits within the immunoproteasome (low mol. mass polypeptide-7, -2, and multicatalytic endopeptidase complex subunit-1; LMP7, LMP2, and MECL-1), and a campaign was undertaken to design a potent and selective LMP2 inhibitor with sufficient properties to allow for sustained inhibition in vivo.  Screening a focused library of epoxyketones revealed a series of potent dipeptides that were optimized to provide the highly selective inhibitor KZR-504 (12).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL-9Mx7yA1VLVg90H21EOLACvtfcHk0ljhUPnTjGquag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktVahtLs%253D&md5=5abf3912c1dbcc6f77d271235c75b17c</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00496%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DH.%2BW.%2BB.%26aulast%3DAnderl%26aufirst%3DJ.%2BL.%26aulast%3DBradley%26aufirst%3DE.%2BK.%26aulast%3DBui%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DJ.%26aulast%3DArastu-Kapur%26aufirst%3DS.%26aulast%3DKelly%26aufirst%3DL.%2BM.%26aulast%3DLowe%26aufirst%3DE.%26aulast%3DMoebius%26aufirst%3DD.%2BC.%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DKirk%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DMcMinn%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520Highly%2520Selective%2520Inhibitors%2520of%2520the%2520Immunoproteasome%2520Low%2520Molecular%2520Mass%2520Polypeptide%25202%2520%2528LMP2%2529%2520Subunit%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D4%26spage%3D413%26epage%3D417%26doi%3D10.1021%2Facsmedchemlett.6b00496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, H. W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderl, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moebius, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMinn, D. L.</span></span> <span> </span><span class="NLM_article-title">Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 <i>S</i>, 3 <i>R</i>)- <i>N</i> -((<i>S</i>)-3-(Cyclopent-1-En-1-Yl)-1-((<i>R</i>)-2-Methyloxiran-2-Yl)-1-Oxopropan-2-Yl)-3-Hydroxy-3-(4-Methoxyphenyl)-2-((<i>S</i>)-2-(2-Morpholinoacetamido)Propanamido)Propenamide</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">11127</span>â <span class="NLM_lpage">11143</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b01201</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01201" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVKltLfF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=11127-11143&issue=24&author=H.+W.+B.+Johnsonauthor=E.+Loweauthor=J.+L.+Anderlauthor=A.+Fanauthor=T.+Muchamuelauthor=S.+Bowersauthor=D.+C.+Moebiusauthor=C.+Kirkauthor=D.+L.+McMinn&title=Required+Immunoproteasome+Subunit+Inhibition+Profile+for+Anti-Inflammatory+Efficacy+and+Clinical+Candidate+KZR-616+%28%282+S%2C+3+R%29-+N+-%28%28S%29-3-%28Cyclopent-1-En-1-Yl%29-1-%28%28R%29-2-Methyloxiran-2-Yl%29-1-Oxopropan-2-Yl%29-3-Hydroxy-3-%284-Methoxyphenyl%29-2-%28%28S%29-2-%282-Morpholinoacetamido%29Propanamido%29Propenamide&doi=10.1021%2Facs.jmedchem.8b01201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2S,3R)-N-((S)-3-(Cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenamide)</span></div><div class="casAuthors">Johnson, Henry W. B.; Lowe, Eric; Anderl, Janet L.; Fan, Andrea; Muchamuel, Tony; Bowers, Simeon; Moebius, David C.; Kirk, Christopher; McMinn, Dustin L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11127-11143</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selective immunoproteasome inhibition is a promising approach for treating autoimmune disorders, but optimal proteolytic active site subunit inhibition profiles remain unknown.  We reveal here our design of peptide epoxyketone-based selective low mol. mass polypeptide-7 (LMP7) and multicatalytic endopeptidase complex subunit-1 (MECL-1) subunit inhibitors.  Utilizing these and our previously disclosed low mol. mass polypeptide-2 (LMP2) inhibitor, we demonstrate a requirement of dual LMP7/LMP2 or LMP7/MECL-1 subunit inhibition profiles for potent cytokine expression inhibition and in vivo efficacy in an inflammatory disease model.  These and addnl. findings toward optimized soly. led the design and selection of KZR-616 disclosed here and presently in clin. trials for treatment of rheumatic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNq1pg3kpVXrVg90H21EOLACvtfcHk0ljhUPnTjGquag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVKltLfF&md5=70170b636fbb858edda5f571af45ca7f</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01201%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DH.%2BW.%2BB.%26aulast%3DLowe%26aufirst%3DE.%26aulast%3DAnderl%26aufirst%3DJ.%2BL.%26aulast%3DFan%26aufirst%3DA.%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DBowers%26aufirst%3DS.%26aulast%3DMoebius%26aufirst%3DD.%2BC.%26aulast%3DKirk%26aufirst%3DC.%26aulast%3DMcMinn%26aufirst%3DD.%2BL.%26atitle%3DRequired%2520Immunoproteasome%2520Subunit%2520Inhibition%2520Profile%2520for%2520Anti-Inflammatory%2520Efficacy%2520and%2520Clinical%2520Candidate%2520KZR-616%2520%2528%25282%2520S%252C%25203%2520R%2529-%2520N%2520-%2528%2528S%2529-3-%2528Cyclopent-1-En-1-Yl%2529-1-%2528%2528R%2529-2-Methyloxiran-2-Yl%2529-1-Oxopropan-2-Yl%2529-3-Hydroxy-3-%25284-Methoxyphenyl%2529-2-%2528%2528S%2529-2-%25282-Morpholinoacetamido%2529Propanamido%2529Propenamide%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D24%26spage%3D11127%26epage%3D11143%26doi%3D10.1021%2Facs.jmedchem.8b01201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span> </span><span class="NLM_article-title">A Study of KZR-616 in Patients With Systemic
Lupus Erythematosus
With and Without Nephritis</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT03393013" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03393013</a> (accessed June 20, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study+of+KZR-616+in+Patients+With+Systemic%0ALupus+Erythematosus%0AWith+and+Without+Nephritis.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03393013+%28accessed+June+20%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520Study%2520of%2520KZR-616%2520in%2520Patients%2520With%2520Systemic%250ALupus%2520Erythematosus%250AWith%2520and%2520Without%2520Nephritis" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ladi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stivala, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durk, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huestis, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaesse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidenschenk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, M.</span></span> <span> </span><span class="NLM_article-title">Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">7032</span>â <span class="NLM_lpage">7041</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b00509</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00509" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlamsbnO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7032-7041&issue=15&author=E.+Ladiauthor=C.+Everettauthor=C.+E.+Stivalaauthor=B.+E.+Danielsauthor=M.+R.+Durkauthor=S.+F.+Harrisauthor=M.+P.+Huestisauthor=H.+E.+Purkeyauthor=S.+T.+Stabenauthor=M.+Augustinauthor=M.+Blaesseauthor=S.+Steinbacherauthor=C.+Eidenschenkauthor=R.+Pappuauthor=M.+Siu&title=Design+and+Evaluation+of+Highly+Selective+Human+Immunoproteasome+Inhibitors+Reveal+a+Compensatory+Process+That+Preserves+Immune+Cell+Viability&doi=10.1021%2Facs.jmedchem.9b00509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability</span></div><div class="casAuthors">Ladi, Ena; Everett, Christine; Stivala, Craig E.; Daniels, Blake E.; Durk, Matthew R.; Harris, Seth F.; Huestis, Malcolm P.; Purkey, Hans E.; Staben, Steven T.; Augustin, Martin; Blaesse, Michael; Steinbacher, Stefan; Eidenschenk, Celine; Pappu, Rajita; Siu, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7032-7041</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pan-proteasome inhibitor bortezomib demonstrated clin. efficacy in off-label trials of Systemic Lupus Erythematosus.  One potential mechanism of this clin. benefit is from the depletion of pathogenic immune cells (plasmablasts and plasmacytoid dendritic cells).  However, bortezomib is cytotoxic against non-immune cells which limits its use for autoimmune diseases.  An attractive alternative is to selectively inhibit the immune cell-specific immunoproteasome to deplete pathogenic immune cells and spare non-hematopoietic cells.  Here we disclose the development of highly subunit-selective immunoproteasome inhibitors using insights obtained from the first bona fide human immunoproteasome co-crystal structures.  Evaluation of these inhibitors revealed that immunoproteasome-specific inhibition does not lead to immune cell death as anticipated and that targeting viability requires inhibition of both immuno- and constitutive proteasomes.  CRISPR/Cas9-mediated knock-out expts. confirmed upregulation of the constitutive proteasome upon disruption of the immunoproteasome, protecting cells from death.  Thus, immunoproteasome inhibition alone is not a suitable approach to deplete immune cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBtaasYDyZZ7Vg90H21EOLACvtfcHk0ljhUPnTjGquag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlamsbnO&md5=21b810621134c447794d5fb88337dbd2</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00509%26sid%3Dliteratum%253Aachs%26aulast%3DLadi%26aufirst%3DE.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DStivala%26aufirst%3DC.%2BE.%26aulast%3DDaniels%26aufirst%3DB.%2BE.%26aulast%3DDurk%26aufirst%3DM.%2BR.%26aulast%3DHarris%26aufirst%3DS.%2BF.%26aulast%3DHuestis%26aufirst%3DM.%2BP.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DAugustin%26aufirst%3DM.%26aulast%3DBlaesse%26aufirst%3DM.%26aulast%3DSteinbacher%26aufirst%3DS.%26aulast%3DEidenschenk%26aufirst%3DC.%26aulast%3DPappu%26aufirst%3DR.%26aulast%3DSiu%26aufirst%3DM.%26atitle%3DDesign%2520and%2520Evaluation%2520of%2520Highly%2520Selective%2520Human%2520Immunoproteasome%2520Inhibitors%2520Reveal%2520a%2520Compensatory%2520Process%2520That%2520Preserves%2520Immune%2520Cell%2520Viability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D15%26spage%3D7032%26epage%3D7041%26doi%3D10.1021%2Facs.jmedchem.9b00509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, S. M.</span>; <span class="NLM_string-name">Neidhart, W.</span>; <span class="NLM_string-name">Plancher, J.-M.</span>; <span class="NLM_string-name">Schulz-Gasch, T.</span></span> <span> </span><span class="NLM_article-title">Substituted Triazole Boronic Acid Compounds</span>. <span class="NLM_patent">EP2925765A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=S.+M.+Lynch&author=W.+Neidhart&author=J.-M.+Plancher&author=T.+Schulz-Gasch&title=Substituted+Triazole+Boronic+Acid+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DS.%2BM.%26atitle%3DSubstituted%2520Triazole%2520Boronic%2520Acid%2520Compounds%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harjutsalo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SjÃ¶berg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuomilehto, J.</span></span> <span> </span><span class="NLM_article-title">Time Trends in the Incidence of Type 1 Diabetes in Finnish Children: A Cohort Study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>371</i></span> (<span class="NLM_issue">9626</span>),  <span class="NLM_fpage">1777</span>â <span class="NLM_lpage">1782</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(08)60765-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2FS0140-6736%2808%2960765-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=18502302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BD1czjvFKmtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2008&pages=1777-1782&issue=9626&author=V.+Harjutsaloauthor=L.+Sj%C3%B6bergauthor=J.+Tuomilehto&title=Time+Trends+in+the+Incidence+of+Type+1+Diabetes+in+Finnish+Children%3A+A+Cohort+Study&doi=10.1016%2FS0140-6736%2808%2960765-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study</span></div><div class="casAuthors">Harjutsalo Valma; Sjoberg Lena; Tuomilehto Jaakko</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">9626</span>),
    <span class="NLM_cas:pages">1777-82</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Finland has the highest incidence of type 1 diabetes worldwide, reaching 40 per 100,000 people per year in the 1990s.  Our aim was to assess the temporal trend in type 1 diabetes incidence since 2000 in Finnish children aged younger than 15 years and to predict the number of cases of type 1 diabetes in the future.  METHODS:  Children with newly diagnosed type 1 diabetes in Finland who were listed on the National Public Health Institute diabetes register, Central Drug Register, and Hospital Discharge Register in 1980-2005 were included in a cohort study.  We excluded patients with type 2 diabetes and diabetes occurring secondary to other conditions, such as steroid use, Down's syndrome, and congenital malformations of pancreas.  FINDINGS:  10,737 children-5816 boys and 4921 girls-were diagnosed with type 1 diabetes before 15 years of age during 1980-2005.  The average age-standardised incidence was 42.9 per 100,000 per year (95% CI 42.6-44.3) during this period, increasing from 31.4 per 100,000 per year in 1980 to 64.2 per 100,000 per year in 2005.  The age-specific rates per 100,000 per year were 31.0, 50.5, and 50.6 at ages 0-4 years, 5-9 years, and 10-14-years, respectively.  We noted a significant non-linear component to the time trend (p<0.0003).  In children aged 0-4 years, the increase was largest, at 4.7% more affected every year.  The overall boy-to-girl ratio of incidence was 1.1; at the age of 13 years, it was 1.7 (1.4-2.0).  The predicted cumulative number of new cases with type 1 diabetes before 15 years of age between 2006 and 2020 was about 10 800.  INTERPRETATION:  The incidence of type 1 diabetes in Finnish children is increasing even faster than before.  The number of new cases diagnosed at or before 14 years of age will double in the next 15 years and the age of onset will be younger (0-4 years).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQy9T5zwrdRZu3MPKNEWB5RfW6udTcc2eaNx2144QbF9Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czjvFKmtQ%253D%253D&md5=c17ff8ede34255155db2d1fd6f8e22d0</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2808%2960765-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252808%252960765-5%26sid%3Dliteratum%253Aachs%26aulast%3DHarjutsalo%26aufirst%3DV.%26aulast%3DSj%25C3%25B6berg%26aufirst%3DL.%26aulast%3DTuomilehto%26aufirst%3DJ.%26atitle%3DTime%2520Trends%2520in%2520the%2520Incidence%2520of%2520Type%25201%2520Diabetes%2520in%2520Finnish%2520Children%253A%2520A%2520Cohort%2520Study%26jtitle%3DLancet%26date%3D2008%26volume%3D371%26issue%3D9626%26spage%3D1777%26epage%3D1782%26doi%3D10.1016%2FS0140-6736%2808%2960765-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, R. D.</span></span> <span> </span><span class="NLM_article-title">Predicting Adult-Onset Autoimmune Diabetes</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">330</span>â <span class="NLM_lpage">331</span>, <span class="refDoi">Â DOI: 10.2337/db09-1620</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.2337%2Fdb09-1620" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=20103711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvVyrur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2010&pages=330-331&issue=2&author=R.+D.+Leslie&title=Predicting+Adult-Onset+Autoimmune+Diabetes&doi=10.2337%2Fdb09-1620"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting adult-onset autoimmune diabetes: clarity from complexity</span></div><div class="casAuthors">Leslie, R. David</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">330-331</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">A review of findings by V. Lundgren et al. (ibid.) that presence of autoantibodies to glutamic acid decarboxylase predicts development of autoimmune diabetes in adult humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBsX99XvCTM7Vg90H21EOLACvtfcHk0liIYX5nL8Zb9w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvVyrur8%253D&md5=a1b6e9f64d45501825e99199b7ea1e96</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.2337%2Fdb09-1620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb09-1620%26sid%3Dliteratum%253Aachs%26aulast%3DLeslie%26aufirst%3DR.%2BD.%26atitle%3DPredicting%2520Adult-Onset%2520Autoimmune%2520Diabetes%26jtitle%3DDiabetes%26date%3D2010%26volume%3D59%26issue%3D2%26spage%3D330%26epage%3D331%26doi%3D10.2337%2Fdb09-1620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenbarth, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, A. W.</span></span> <span> </span><span class="NLM_article-title">Type 1 Diabetes</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>383</i></span> (<span class="NLM_issue">9911</span>),  <span class="NLM_fpage">69</span>â <span class="NLM_lpage">82</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(13)60591-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2FS0140-6736%2813%2960591-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=23890997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BC3sfksFaqtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2014&pages=69-82&issue=9911&author=M.+A.+Atkinsonauthor=G.+S.+Eisenbarthauthor=A.+W.+Michels&title=Type+1+Diabetes&doi=10.1016%2FS0140-6736%2813%2960591-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Type 1 diabetes</span></div><div class="casAuthors">Atkinson Mark A; Eisenbarth George S; Michels Aaron W</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue">9911</span>),
    <span class="NLM_cas:pages">69-82</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Over the past decade, knowledge of the pathogenesis and natural history of type 1 diabetes has grown substantially, particularly with regard to disease prediction and heterogeneity, pancreatic pathology, and epidemiology.  Technological improvements in insulin pumps and continuous glucose monitors help patients with type 1 diabetes manage the challenge of lifelong insulin administration.  Agents that show promise for averting debilitating disease-associated complications have also been identified.  However, despite broad organisational, intellectual, and fiscal investments, no means for preventing or curing type 1 diabetes exists, and, globally, the quality of diabetes management remains uneven.  This Seminar discusses current progress in epidemiology, pathology, diagnosis, and treatment of type 1 diabetes, and prospects for an improved future for individuals with this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgANOcimHnecuCWE5mhx1RfW6udTcc2eaNx2144QbF9Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfksFaqtw%253D%253D&md5=09e0deffd2247e7ea14627ffd147dee8</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2813%2960591-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252813%252960591-7%26sid%3Dliteratum%253Aachs%26aulast%3DAtkinson%26aufirst%3DM.%2BA.%26aulast%3DEisenbarth%26aufirst%3DG.%2BS.%26aulast%3DMichels%26aufirst%3DA.%2BW.%26atitle%3DType%25201%2520Diabetes%26jtitle%3DLancet%26date%3D2014%26volume%3D383%26issue%3D9911%26spage%3D69%26epage%3D82%26doi%3D10.1016%2FS0140-6736%2813%2960591-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brorsson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tue Hansen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergholdt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pociot, F.</span></span> <span> </span><span class="NLM_article-title">The Type 1 Diabetes - HLA Susceptibility Interactome - Identification of HLA Genotype-Specific Disease Genes for Type 1 Diabetes</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">e9576</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0009576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1371%2Fjournal.pone.0009576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=20221424" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=e9576&issue=3&author=C.+Brorssonauthor=N.+Tue+Hansenauthor=R.+Bergholdtauthor=S.+Brunakauthor=F.+Pociot&title=The+Type+1+Diabetes+-+HLA+Susceptibility+Interactome+-+Identification+of+HLA+Genotype-Specific+Disease+Genes+for+Type+1+Diabetes&doi=10.1371%2Fjournal.pone.0009576"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0009576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0009576%26sid%3Dliteratum%253Aachs%26aulast%3DBrorsson%26aufirst%3DC.%26aulast%3DTue%2BHansen%26aufirst%3DN.%26aulast%3DBergholdt%26aufirst%3DR.%26aulast%3DBrunak%26aufirst%3DS.%26aulast%3DPociot%26aufirst%3DF.%26atitle%3DThe%2520Type%25201%2520Diabetes%2520-%2520HLA%2520Susceptibility%2520Interactome%2520-%2520Identification%2520of%2520HLA%2520Genotype-Specific%2520Disease%2520Genes%2520for%2520Type%25201%2520Diabetes%26jtitle%3DPLoS%2520One%26date%3D2010%26volume%3D5%26issue%3D3%26spage%3De9576%26doi%3D10.1371%2Fjournal.pone.0009576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noble, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdes, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varney, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moonsamy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fear, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavant, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Concannon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mychaleckyj, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlich, H.</span></span> <span> </span><span class="NLM_article-title">HLA Class I and Genetic Susceptibility to Type 1 Diabetes: Results from the Type 1 Diabetes Genetics Consortium</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2972</span>â <span class="NLM_lpage">2979</span>, <span class="refDoi">Â DOI: 10.2337/db10-0699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.2337%2Fdb10-0699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=20798335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsV2nsb3P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2010&pages=2972-2979&issue=11&author=J.+A.+Nobleauthor=A.+M.+Valdesauthor=M.+D.+Varneyauthor=J.+A.+Carlsonauthor=P.+Moonsamyauthor=A.+L.+Fearauthor=J.+A.+Laneauthor=E.+Lavantauthor=R.+Rappnerauthor=A.+Loueyauthor=P.+Concannonauthor=J.+Mychaleckyjauthor=H.+Erlich&title=HLA+Class+I+and+Genetic+Susceptibility+to+Type+1+Diabetes%3A+Results+from+the+Type+1+Diabetes+Genetics+Consortium&doi=10.2337%2Fdb10-0699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">HLA class I and genetic susceptibility to type 1 diabetes: results from the type 1 diabetes genetics consortium</span></div><div class="casAuthors">Noble, Janelle A.; Valdes, Ana Maria; Varney, Michael D.; Carlson, Joyce A.; Moonsamy, Priscilla; Fear, Anna Lisa; Lane, Julie A.; Lavant, Eva; Rappner, Rebecca; Louey, Anthony; Concannon, Patrick; Mychaleckyj, Josyf C.; Erlich, Henry A.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2972-2979</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">We report here genotyping data and type 1 diabetes assocn. analyses for HLA class I loci (A, B, and C) on 1,753 multiplex pedigrees from the Type 1 Diabetes Genetics Consortium (T1DGC), a large international collaborative study.  Complete eight-locus HLA genotyping data were generated.  Expected patient class I (HLA-A, -B, and -C) allele frequencies were calcd., based on linkage disequil. (LD) patterns with obsd. HLA class II DRB1-DQA1-DQB1 haplotype frequencies.  Expected frequencies were compared to obsd. allele frequencies in patients.  Significant type 1 diabetes assocns. were obsd. at all class I HLA loci.  After accounting for LD with HLA class II, the most significantly type 1 diabetes-assocd. alleles were B*5701 (odds ratio 0.19; P = 4 Ã 10-11) and B*3906 (10.31; P = 4 Ã 10-10).  Other significantly type 1 diabetes-assocd. alleles included A*2402, A*0201, B*1801, and C*0501 (predisposing) and A*1101, A*3201, A*6601, B*0702, B*4403, B*3502, C*1601, and C*0401 (protective).  Some alleles, notably B*3906, appear to modulate the risk of all DRB1-DQA1-DQB1 haplotypes on which they reside, suggesting a class I effect that is independent of class II.  Other class I type 1 diabetes assocns. appear to be specific to individual class II haplotypes.  Some apparent assocns. (e.g., C*1601) could be attributed to strong LD to another class I susceptibility locus (B*4403).  These data indicate that HLA class I alleles, in addn. to and independently from HLA class II alleles, are assocd. with type 1 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1KvYg-D1Sl7Vg90H21EOLACvtfcHk0lgNoC3SbT8-KQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsV2nsb3P&md5=85ed308ca1b23e522f49f6e89c44c4e8</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.2337%2Fdb10-0699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb10-0699%26sid%3Dliteratum%253Aachs%26aulast%3DNoble%26aufirst%3DJ.%2BA.%26aulast%3DValdes%26aufirst%3DA.%2BM.%26aulast%3DVarney%26aufirst%3DM.%2BD.%26aulast%3DCarlson%26aufirst%3DJ.%2BA.%26aulast%3DMoonsamy%26aufirst%3DP.%26aulast%3DFear%26aufirst%3DA.%2BL.%26aulast%3DLane%26aufirst%3DJ.%2BA.%26aulast%3DLavant%26aufirst%3DE.%26aulast%3DRappner%26aufirst%3DR.%26aulast%3DLouey%26aufirst%3DA.%26aulast%3DConcannon%26aufirst%3DP.%26aulast%3DMychaleckyj%26aufirst%3DJ.%26aulast%3DErlich%26aufirst%3DH.%26atitle%3DHLA%2520Class%2520I%2520and%2520Genetic%2520Susceptibility%2520to%2520Type%25201%2520Diabetes%253A%2520Results%2520from%2520the%2520Type%25201%2520Diabetes%2520Genetics%2520Consortium%26jtitle%3DDiabetes%26date%3D2010%26volume%3D59%26issue%3D11%26spage%3D2972%26epage%3D2979%26doi%3D10.2337%2Fdb10-0699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, D. A.</span></span> <span> </span><span class="NLM_article-title">Autoimmune Markers in Diabetes</span>. <i>Clin. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">168</span>â <span class="NLM_lpage">175</span>, <span class="refDoi">Â DOI: 10.1373/clinchem.2010.148205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1373%2Fclinchem.2010.148205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=21127152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3MXislajurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2011&pages=168-175&issue=2&author=W.+E.+Winterauthor=D.+A.+Schatz&title=Autoimmune+Markers+in+Diabetes&doi=10.1373%2Fclinchem.2010.148205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Autoimmune markers in diabetes</span></div><div class="casAuthors">Winter, William E.; Schatz, Desmond A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Chemistry (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">168-175</span>CODEN:
                <span class="NLM_cas:coden">CLCHAU</span>;
        ISSN:<span class="NLM_cas:issn">0009-9147</span>.
    
            (<span class="NLM_cas:orgname">American Association for Clinical Chemistry</span>)
        </div><div class="casAbstract">A review.  BACKGROUND: Type 1 diabetes (T1DM) results from cell-mediated autoimmune destruction of the Î² cells of the islets of Langerhans.  Autoantibodies directed against the islets are useful clin. tools that allow the recognition and confirmation of Î²-cell autoimmunity.  CONTENT: In this review we define the term "islet autoantibody," describe the pathogenesis of autoantibody generation, and explain the uses of islet autoantibodies in clin. medicine and in research studies that concern the interruption or prevention of T1DM.  We also discuss the biol. of islet autoantibodies and their rates of appearance at the time of onset of T1DM and their appearance before the development of T1DM.  SUMMARY: The presence of islet autoantibodies in persons with diabetes confirms an autoimmune etiol.  In nondiabetic individuals, islet autoantibodies are strong predictors of the later development of T1DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGxqY9V4OXeLVg90H21EOLACvtfcHk0lgNoC3SbT8-KQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXislajurc%253D&md5=17af37daeaa33ce068c44a60ff2a1cc0</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1373%2Fclinchem.2010.148205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1373%252Fclinchem.2010.148205%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DW.%2BE.%26aulast%3DSchatz%26aufirst%3DD.%2BA.%26atitle%3DAutoimmune%2520Markers%2520in%2520Diabetes%26jtitle%3DClin.%2520Chem.%26date%3D2011%26volume%3D57%26issue%3D2%26spage%3D168%26epage%3D175%26doi%3D10.1373%2Fclinchem.2010.148205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Juvenile Diabetes Research Foundation Continuous
Glucose Monitoring
Study Group</span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamborlane, W. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckingham, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chase, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiallo-Scharer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliam, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laffel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauras, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâGrady, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruedy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tansey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsalikian, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinzimer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolpert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wysocki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, D.</span></span> <span> </span><span class="NLM_article-title">Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>359</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">1464</span>â <span class="NLM_lpage">1476</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa0805017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1056%2FNEJMoa0805017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=18779236" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2008&pages=1464-1476&issue=14&author=Juvenile+Diabetes+Research+Foundation+Continuous%0AGlucose+Monitoring%0AStudy+Groupauthor=W.+V.+Tamborlaneauthor=R.+W.+Beckauthor=B.+W.+Bodeauthor=B.+Buckinghamauthor=H.+P.+Chaseauthor=R.+Clemonsauthor=R.+Fiallo-Scharerauthor=L.+A.+Foxauthor=L.+K.+Gilliamauthor=I.+Hirschauthor=E.+Huangauthor=C.+Kollmanauthor=A.+Kowalskiauthor=J.+Laffelauthor=J.+Leeauthor=N.+Maurasauthor=M.+O%E2%80%99Gradyauthor=K.+Ruedyauthor=M.+Tanseyauthor=E.+Tsalikianauthor=S.+Weinzimerauthor=D.+Wilsonauthor=H.+Wolpertauthor=T.+Wysockiauthor=D.+Xing&title=Continuous+Glucose+Monitoring+and+Intensive+Treatment+of+Type+1+Diabetes&doi=10.1056%2FNEJMoa0805017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0805017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0805017%26sid%3Dliteratum%253Aachs%26aulast%3D%26aulast%3DTamborlane%26aufirst%3DW.%2BV.%26aulast%3DBeck%26aufirst%3DR.%2BW.%26aulast%3DBode%26aufirst%3DB.%2BW.%26aulast%3DBuckingham%26aufirst%3DB.%26aulast%3DChase%26aufirst%3DH.%2BP.%26aulast%3DClemons%26aufirst%3DR.%26aulast%3DFiallo-Scharer%26aufirst%3DR.%26aulast%3DFox%26aufirst%3DL.%2BA.%26aulast%3DGilliam%26aufirst%3DL.%2BK.%26aulast%3DHirsch%26aufirst%3DI.%26aulast%3DHuang%26aufirst%3DE.%26aulast%3DKollman%26aufirst%3DC.%26aulast%3DKowalski%26aufirst%3DA.%26aulast%3DLaffel%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DMauras%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Grady%26aufirst%3DM.%26aulast%3DRuedy%26aufirst%3DK.%26aulast%3DTansey%26aufirst%3DM.%26aulast%3DTsalikian%26aufirst%3DE.%26aulast%3DWeinzimer%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DD.%26aulast%3DWolpert%26aufirst%3DH.%26aulast%3DWysocki%26aufirst%3DT.%26aulast%3DXing%26aufirst%3DD.%26atitle%3DContinuous%2520Glucose%2520Monitoring%2520and%2520Intensive%2520Treatment%2520of%2520Type%25201%2520Diabetes%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D359%26issue%3D14%26spage%3D1464%26epage%3D1476%26doi%3D10.1056%2FNEJMoa0805017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergenstal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamborlane, W. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buse, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dailey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peoples, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsh, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span> <span> </span><span class="NLM_article-title">Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">311</span>â <span class="NLM_lpage">320</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1002853</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1056%2FNEJMoa1002853" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=20587585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptFajtLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=311-320&issue=4&author=R.+M.+Bergenstalauthor=W.+V.+Tamborlaneauthor=A.+Ahmannauthor=J.+B.+Buseauthor=G.+Daileyauthor=S.+N.+Davisauthor=C.+Joyceauthor=T.+Peoplesauthor=B.+A.+Perkinsauthor=J.+B.+Welshauthor=S.+Williauthor=M.+Wood&title=Effectiveness+of+Sensor-Augmented+Insulin-Pump+Therapy+in+Type+1+Diabetes&doi=10.1056%2FNEJMoa1002853"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes</span></div><div class="casAuthors">Bergenstal, Richard M.; Tamborlane, William V.; Ahmann, Andrew; Buse, John B.; Dailey, George; Davis, Stephen N.; Joyce, Carol; Peoples, Tim; Perkins, Bruce A.; Welsh, John B.; Willi, Steven M.; Wood, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">311-320</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Recently developed technologies for the treatment of type 1 diabetes mellitus include a variety of pumps and pumps with glucose sensors.  METHODS: In this 1-yr, multicenter, randomized, controlled trial, we compared the efficacy of sensor-augmented pump therapy (pump therapy) with that of a regimen of multiple daily insulin injections (injection therapy) in 485 patients (329 adults and 156 children) with inadequately controlled type 1 diabetes.  Patients received recombinant insulin analogs and were supervised by expert clin. teams.  The primary end point was the change from the baseline glycated Hb level.  RESULTS: At 1 yr, the baseline mean glycated Hb level (8.3% in the two study groups) had decreased to 7.5% in the pump-therapy group, as compared with 8.1% in the injection-therapy group (P < 0.001).  The proportion of patients who reached the glycated Hb target ( < 7%) was greater in the pump-therapy group than in the injection-therapy group.  The rate of severe hypoglycemia in the pump-therapy group (13.31 cases per 100 person-years) did not differ significantly from that in the injection-therapy group (13.48 per 100 person-years, P = 0.58).  There was no significant wt. gain in either group.  CONCLUSIONS: In both adults and children with inadequately controlled type 1 diabetes, sensor-augmented pump therapy resulted in significant improvement in glycated Hb levels, as compared with injection therapy.  A significantly greater proportion of both adults and children in the pump-therapy group than in the injection-therapy group reached the target glycated Hb level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpashlH1Eh19LVg90H21EOLACvtfcHk0lh5CJDu2_AccQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptFajtLw%253D&md5=ae39e3228636b53dfdbc259459097c3a</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002853%26sid%3Dliteratum%253Aachs%26aulast%3DBergenstal%26aufirst%3DR.%2BM.%26aulast%3DTamborlane%26aufirst%3DW.%2BV.%26aulast%3DAhmann%26aufirst%3DA.%26aulast%3DBuse%26aufirst%3DJ.%2BB.%26aulast%3DDailey%26aufirst%3DG.%26aulast%3DDavis%26aufirst%3DS.%2BN.%26aulast%3DJoyce%26aufirst%3DC.%26aulast%3DPeoples%26aufirst%3DT.%26aulast%3DPerkins%26aufirst%3DB.%2BA.%26aulast%3DWelsh%26aufirst%3DJ.%2BB.%26aulast%3DWilli%26aufirst%3DS.%26aulast%3DWood%26aufirst%3DM.%26atitle%3DEffectiveness%2520of%2520Sensor-Augmented%2520Insulin-Pump%2520Therapy%2520in%2520Type%25201%2520Diabetes%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26issue%3D4%26spage%3D311%26epage%3D320%26doi%3D10.1056%2FNEJMoa1002853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergenstal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinzimer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckingham, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamborlane, W. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, F. R.</span></span> <span> </span><span class="NLM_article-title">Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>316</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1407</span>, <span class="refDoi">Â DOI: 10.1001/jama.2016.11708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1001%2Fjama.2016.11708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=27629148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BC2svgsFWrsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2016&pages=1407&issue=13&author=R.+M.+Bergenstalauthor=S.+Gargauthor=S.+A.+Weinzimerauthor=B.+A.+Buckinghamauthor=B.+W.+Bodeauthor=W.+V.+Tamborlaneauthor=F.+R.+Kaufman&title=Safety+of+a+Hybrid+Closed-Loop+Insulin+Delivery+System+in+Patients+With+Type+1+Diabetes&doi=10.1001%2Fjama.2016.11708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes</span></div><div class="casAuthors">Bergenstal Richard M; Garg Satish; Weinzimer Stuart A; Tamborlane William V; Buckingham Bruce A; Bode Bruce W; Kaufman Francine R</div><div class="citationInfo"><span class="NLM_cas:title">JAMA</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1407-1408</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ91Ck_h9aCvdbHMBt0mMIXfW6udTcc2eap-0PHj-fSdbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svgsFWrsQ%253D%253D&md5=7f6c1e7117ea124854dee9b2baa80271</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1001%2Fjama.2016.11708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2016.11708%26sid%3Dliteratum%253Aachs%26aulast%3DBergenstal%26aufirst%3DR.%2BM.%26aulast%3DGarg%26aufirst%3DS.%26aulast%3DWeinzimer%26aufirst%3DS.%2BA.%26aulast%3DBuckingham%26aufirst%3DB.%2BA.%26aulast%3DBode%26aufirst%3DB.%2BW.%26aulast%3DTamborlane%26aufirst%3DW.%2BV.%26aulast%3DKaufman%26aufirst%3DF.%2BR.%26atitle%3DSafety%2520of%2520a%2520Hybrid%2520Closed-Loop%2520Insulin%2520Delivery%2520System%2520in%2520Patients%2520With%2520Type%25201%2520Diabetes%26jtitle%3DJAMA%26date%3D2016%26volume%3D316%26issue%3D13%26spage%3D1407%26doi%3D10.1001%2Fjama.2016.11708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, D. M.</span></span> <span> </span><span class="NLM_article-title">Long-Term Complications of Diabetes Mellitus</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>328</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">1676</span>â <span class="NLM_lpage">1685</span>, <span class="refDoi">Â DOI: 10.1056/NEJM199306103282306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1056%2FNEJM199306103282306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=8487827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADyaK3s3lsVGgsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=328&publication_year=1993&pages=1676-1685&issue=23&author=D.+M.+Nathan&title=Long-Term+Complications+of+Diabetes+Mellitus&doi=10.1056%2FNEJM199306103282306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term complications of diabetes mellitus</span></div><div class="casAuthors">Nathan D M</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">328</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">1676-85</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQeI2Wva4wSrWlSCSgBhwJFfW6udTcc2eap-0PHj-fSdbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s3lsVGgsA%253D%253D&md5=2a29d58d4dec1bf483f668b439055709</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1056%2FNEJM199306103282306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199306103282306%26sid%3Dliteratum%253Aachs%26aulast%3DNathan%26aufirst%3DD.%2BM.%26atitle%3DLong-Term%2520Complications%2520of%2520Diabetes%2520Mellitus%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1993%26volume%3D328%26issue%3D23%26spage%3D1676%26epage%3D1685%26doi%3D10.1056%2FNEJM199306103282306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foulis, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farquharson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardman, R.</span></span> <span> </span><span class="NLM_article-title">Aberrant Expression of Class II Major Histocompatibility Complex Molecules by B Cells and Hyperexpression of Class I Major Histocompatibility Complex Molecules by Insulin Containing Islets in Type 1 (Insulin-Dependent) Diabetes Mellitus</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">333</span>â <span class="NLM_lpage">343</span>, <span class="refDoi">Â DOI: 10.1007/BF00299027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1007%2FBF00299027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=3301484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADyaL2s3nslSisg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1987&pages=333-343&issue=5&author=A.+K.+Foulisauthor=M.+A.+Farquharsonauthor=R.+Hardman&title=Aberrant+Expression+of+Class+II+Major+Histocompatibility+Complex+Molecules+by+B+Cells+and+Hyperexpression+of+Class+I+Major+Histocompatibility+Complex+Molecules+by+Insulin+Containing+Islets+in+Type+1+%28Insulin-Dependent%29+Diabetes+Mellitus&doi=10.1007%2FBF00299027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Aberrant expression of class II major histocompatibility complex molecules by B cells and hyperexpression of class I major histocompatibility complex molecules by insulin containing islets in type 1 (insulin-dependent) diabetes mellitus</span></div><div class="casAuthors">Foulis A K; Farquharson M A; Hardman R</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">333-43</span>
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    </div><div class="casAbstract">Twenty-three patients with recent onset Type 1 (insulin-dependent) diabetes in whom residual insulin secreting B cells were present and 12 patients with disease of more prolonged duration (maximum 9 years), 8 of whom had residual B cells, were studied.  Aberrant expression of Class II major histocompatibility complex molecules was demonstrated immunohistochemically on insulin secreting B cells in 21 out of 23 patients with recent onset disease and 6 of the patients with more prolonged disease.  No such expression was seen on glucagon secreting A cells or somatostatin secreting D cells.  Islets where there was marked hyperexpression of Class I major histocompatibility complex molecules on islet endocrine cells were seen in all cases in which residual B cells were present.  Ninety-two per cent of insulin containing islets but only 1% of insulin deficient islets exhibited this phenomenon (p less than 0.001, Chi-squared test).  There was evidence to suggest that both these abnormalities of major histocompatibility complex expression preceded insulitis within a given islet.  They also appeared to be unique to Type 1 diabetes, being absent in pancreases of patients with Type 2 (non-insulin-dependent) diabetes, chronic pancreatitis, cystic fibrosis, graft-versus-host disease and Coxsackie B viral pancreatitis.  The development of autoimmunity to B cells in Type 1 diabetes may be a "multistep" process in which abnormalities of major histocompatibility complex expression on islet endocrine cells are crucial events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSSZHEhX5gIXUH3Rlp_k91zfW6udTcc2ebs11IIFy_xhrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2s3nslSisg%253D%253D&md5=841f370771c5eeddcc3e375d6365396e</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1007%2FBF00299027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00299027%26sid%3Dliteratum%253Aachs%26aulast%3DFoulis%26aufirst%3DA.%2BK.%26aulast%3DFarquharson%26aufirst%3DM.%2BA.%26aulast%3DHardman%26aufirst%3DR.%26atitle%3DAberrant%2520Expression%2520of%2520Class%2520II%2520Major%2520Histocompatibility%2520Complex%2520Molecules%2520by%2520B%2520Cells%2520and%2520Hyperexpression%2520of%2520Class%2520I%2520Major%2520Histocompatibility%2520Complex%2520Molecules%2520by%2520Insulin%2520Containing%2520Islets%2520in%2520Type%25201%2520%2528Insulin-Dependent%2529%2520Diabetes%2520Mellitus%26jtitle%3DDiabetologia%26date%3D1987%26volume%3D30%26issue%3D5%26spage%3D333%26epage%3D343%26doi%3D10.1007%2FBF00299027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bottazzo, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNally, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKay, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swift, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamble, D. R.</span></span> <span> </span><span class="NLM_article-title">In Situ Characterization of Autoimmune Phenomena and Expression of HLA Molecules in the Pancreas in Diabetic Insulitis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>313</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">353</span>â <span class="NLM_lpage">360</span>, <span class="refDoi">Â DOI: 10.1056/NEJM198508083130604</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1056%2FNEJM198508083130604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=3159965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADyaL2M3ktVCqsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=1985&pages=353-360&issue=6&author=G.+F.+Bottazzoauthor=B.+M.+Deanauthor=J.+M.+McNallyauthor=E.+H.+MacKayauthor=P.+G.+Swiftauthor=D.+R.+Gamble&title=In+Situ+Characterization+of+Autoimmune+Phenomena+and+Expression+of+HLA+Molecules+in+the+Pancreas+in+Diabetic+Insulitis&doi=10.1056%2FNEJM198508083130604"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis</span></div><div class="casAuthors">Bottazzo G F; Dean B M; McNally J M; MacKay E H; Swift P G; Gamble D R</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">313</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">353-60</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">After the death of a 12-year old girl with newly discovered insulin-dependent diabetes mellitus, we used monoclonal antibodies in an effort to identify the cells invading the pancreas.  The majority of infiltrating lymphocytes were of the T cytotoxic/suppressor phenotype, but other T-cell subpopulations were present.  Some of the T cells were "activated" (positive for HLA-DR antigen, and the interleukin-2 receptor).  Immunocytes bearing IgG were scattered in the gland, and complement-fixing IgG antibodies were deposited in some islets.  Increased expression of Class I (HLA-A, B, and C) molecules was observed in the affected islet cells, and in damaged islets showing scant lymphocytic infiltration, some beta cells (still producing insulin), but not glucagon or somatostatin cells, were HLA-DR positive.  The capillary endothelium was markedly dilated and strongly HLA-DR positive.  These findings may contribute to an understanding of the sequence of events leading to the destruction of beta cells in classic Type I diabetes mellitus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTHZ86wpEiL0yCEBeYuoi7AfW6udTcc2ebs11IIFy_xhrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2M3ktVCqsQ%253D%253D&md5=2bf422c4fcabc121ef52fb4c684898e2</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1056%2FNEJM198508083130604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM198508083130604%26sid%3Dliteratum%253Aachs%26aulast%3DBottazzo%26aufirst%3DG.%2BF.%26aulast%3DDean%26aufirst%3DB.%2BM.%26aulast%3DMcNally%26aufirst%3DJ.%2BM.%26aulast%3DMacKay%26aufirst%3DE.%2BH.%26aulast%3DSwift%26aufirst%3DP.%2BG.%26aulast%3DGamble%26aufirst%3DD.%2BR.%26atitle%3DIn%2520Situ%2520Characterization%2520of%2520Autoimmune%2520Phenomena%2520and%2520Expression%2520of%2520HLA%2520Molecules%2520in%2520the%2520Pancreas%2520in%2520Diabetic%2520Insulitis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1985%26volume%3D313%26issue%3D6%26spage%3D353%26epage%3D360%26doi%3D10.1056%2FNEJM198508083130604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pujol-Borrell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doshi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottazzo, G. F.</span></span> <span> </span><span class="NLM_article-title">Differential Expression and Regulation of MHC Products in the Endocrine and Exocrine Cells of the Human Pancreas</span>. <i>Clin. Exp. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">128</span>â <span class="NLM_lpage">139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=3098471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADyaL2s%252FnvV2ksw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1986&pages=128-139&issue=1&author=R.+Pujol-Borrellauthor=I.+Toddauthor=M.+Doshiauthor=D.+Grayauthor=M.+Feldmannauthor=G.+F.+Bottazzo&title=Differential+Expression+and+Regulation+of+MHC+Products+in+the+Endocrine+and+Exocrine+Cells+of+the+Human+Pancreas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Differential expression and regulation of MHC products in the endocrine and exocrine cells of the human pancreas</span></div><div class="casAuthors">Pujol-Borrell R; Todd I; Doshi M; Gray D; Feldmann M; Bottazzo G F</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and experimental immunology</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-39</span>
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    </div><div class="casAbstract">Inappropriate expression of HLA Class II (D/DR) molecules has been detected in the target cells of most autoimmune diseases including Type I (insulin-dependent) diabetes.  The possibility that this phenomenon is due to the action of lymphocytes or some of their products has been investigated by analysing in vitro the modulation of HLA products in Beta cells.  Monolayer cultures from 25 human pancreatic glands were supplemented with alpha-interferon (IFN), beta-IFN or gamma-IFN, interleukin 2 (IL-2) and supernatants from activated lymphocytes.  In addition, lectins and a variety of other hormones, biological products and chemicals were tested.  Major histocompatibility complex (MHC) expression was assessed by double immunofluorescence technique using monoclonal antibodies to non-polymorphic determinants of Class I and Class II molecules and the pancreatic cells were identified by antibodies to islet hormones and other cytoplasmic antigens. gamma-IFN and lectins produced a parallel enhancement of HLA-A,B,C expression in islet, exocrine/ductal cells and fibroblasts.  HLA-D/DR was inducible in all pancreatic cell types, except endocrine islet cells which did not produce Class II molecules in response to any of the stimuli including supernatants from activated lymphocytes.  Exocrine/ductal cells from glands of patients with chronic pancreatitis spontaneously expressed Class II products, but islet cells were devoid of any detectable D/DR.  These data are consistent with recent observations which have indicated that in the 'diabetic' pancreas inappropriate Class II expression in the Beta cells occurs independently of the presence of lymphocytes infiltrating the islets, and make it necessary to postulate that other factors are responsible for the Class II induction in Beta cells in human Type I diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLAwTKyoIkO5otVjB3IRIyfW6udTcc2eZuV445XeOdj7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2s%252FnvV2ksw%253D%253D&md5=c23b5691b1ca79e81eb7041acf427883</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPujol-Borrell%26aufirst%3DR.%26aulast%3DTodd%26aufirst%3DI.%26aulast%3DDoshi%26aufirst%3DM.%26aulast%3DGray%26aufirst%3DD.%26aulast%3DFeldmann%26aufirst%3DM.%26aulast%3DBottazzo%26aufirst%3DG.%2BF.%26atitle%3DDifferential%2520Expression%2520and%2520Regulation%2520of%2520MHC%2520Products%2520in%2520the%2520Endocrine%2520and%2520Exocrine%2520Cells%2520of%2520the%2520Human%2520Pancreas%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D1986%26volume%3D65%26issue%3D1%26spage%3D128%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Calvo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerling, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaddis, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeissler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leete, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogvold, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahl-JÃ¸rgensen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Herrath, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugliese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, N. G.</span></span> <span> </span><span class="NLM_article-title">Islet Cell Hyperexpression of HLA Class I Antigens: A Defining Feature in Type 1 Diabetes</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2448</span>â <span class="NLM_lpage">2458</span>, <span class="refDoi">Â DOI: 10.1007/s00125-016-4067-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1007%2Fs00125-016-4067-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=27506584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtleqsLbK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2448-2458&issue=11&author=S.+J.+Richardsonauthor=T.+Rodriguez-Calvoauthor=I.+C.+Gerlingauthor=C.+E.+Mathewsauthor=J.+S.+Kaddisauthor=M.+A.+Russellauthor=M.+Zeisslerauthor=P.+Leeteauthor=L.+Krogvoldauthor=K.+Dahl-J%C3%B8rgensenauthor=M.+von+Herrathauthor=A.+Puglieseauthor=M.+A.+Atkinsonauthor=N.+G.+Morgan&title=Islet+Cell+Hyperexpression+of+HLA+Class+I+Antigens%3A+A+Defining+Feature+in+Type+1+Diabetes&doi=10.1007%2Fs00125-016-4067-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes</span></div><div class="casAuthors">Richardson, Sarah J.; Rodriguez-Calvo, Teresa; Gerling, Ivan C.; Mathews, Clayton E.; Kaddis, John S.; Russell, Mark A.; Zeissler, Marie; Leete, Pia; Krogvold, Lars; Dahl-Joergensen, Knut; von Herrath, Matthias; Pugliese, Alberto; Atkinson, Mark A.; Morgan, Noel G.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2448-2458</span>CODEN:
                <span class="NLM_cas:coden">DBTGAJ</span>;
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Aims/hypothesis: Human pancreatic beta cells may be complicit in their own demise in type 1 diabetes, but how this occurs remains unclear.  One potentially contributing factor is hyperexpression of HLA class I antigens.  This was first described approx. 30 years ago, but has never been fully characterised and was recently challenged as artifactual.  Therefore, we investigated HLA class I expression at the protein and RNA levels in pancreases from three cohorts of patients with type 1 diabetes.  The principal aims were to consider whether HLA class I hyperexpression is artifactual and, if not, to det. the factors driving it.  Methods: Pancreas samples from type 1 diabetes patients with residual insulin-contg. islets (n = 26) from the Network for Pancreatic Organ donors with Diabetes (nPOD), Diabetes Virus Detection study (DiViD) and UK recent-onset type 1 diabetes collections were immunostained for HLA class I isoforms, signal transducer and activator of transcription 1 (STAT1), NLR family CARD domain contg. 5 (NLRC5) and islet hormones.  RNA was extd. from islets isolated by laser-capture microdissection from nPOD and DiViD samples and analyzed using gene-expression arrays.  Results: Hyperexpression of HLA class I was obsd. in the insulin-contg. islets of type 1 diabetes patients from all three tissue collections, and was confirmed at both the RNA and protein levels.  The expression of Î²2-microglobulin (a second component required for the generation of functional HLA class I complexes) was also elevated.  Both 'classical' HLA class I isoforms (i.e. HLA-ABC) as well as a 'non-classical' HLA mol., HLA-F, were hyperexpressed in insulin-contg. islets.  This hyperexpression did not correlate with detectable upregulation of the transcriptional regulator NLRC5.  However, it was strongly assocd. with increased STAT1 expression in all three cohorts.  Islet hyperexpression of HLA class I mols. occurred in the insulin-contg. islets of patients with recent-onset type 1 diabetes and was also detectable in many patients with disease duration of up to 11 years, declining thereafter.  Conclusions/interpretation: Islet cell HLA class I hyperexpression is not an artifact, but is a hallmark in the immunopathogenesis of type 1 diabetes.  The response is closely assocd. with elevated expression of STAT1 and, together, these occur uniquely in patients with type 1 diabetes, thereby contributing to their selective susceptibility to autoimmune-mediated destruction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVeRphwEO_-LVg90H21EOLACvtfcHk0liMlEPcgHB1bg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtleqsLbK&md5=cc5d7964a3a4607d447cc35d91e7cdb8</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1007%2Fs00125-016-4067-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-016-4067-4%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DS.%2BJ.%26aulast%3DRodriguez-Calvo%26aufirst%3DT.%26aulast%3DGerling%26aufirst%3DI.%2BC.%26aulast%3DMathews%26aufirst%3DC.%2BE.%26aulast%3DKaddis%26aufirst%3DJ.%2BS.%26aulast%3DRussell%26aufirst%3DM.%2BA.%26aulast%3DZeissler%26aufirst%3DM.%26aulast%3DLeete%26aufirst%3DP.%26aulast%3DKrogvold%26aufirst%3DL.%26aulast%3DDahl-J%25C3%25B8rgensen%26aufirst%3DK.%26aulast%3Dvon%2BHerrath%26aufirst%3DM.%26aulast%3DPugliese%26aufirst%3DA.%26aulast%3DAtkinson%26aufirst%3DM.%2BA.%26aulast%3DMorgan%26aufirst%3DN.%2BG.%26atitle%3DIslet%2520Cell%2520Hyperexpression%2520of%2520HLA%2520Class%2520I%2520Antigens%253A%2520A%2520Defining%2520Feature%2520in%2520Type%25201%2520Diabetes%26jtitle%3DDiabetologia%26date%3D2016%26volume%3D59%26issue%3D11%26spage%3D2448%26epage%3D2458%26doi%3D10.1007%2Fs00125-016-4067-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foulis, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farquharson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meager, A.</span></span> <span> </span><span class="NLM_article-title">Immunoreactive Alpha-Interferon in Insulin-Secreting Beta Cells in Type 1 Diabetes Mellitus</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>330</i></span> (<span class="NLM_issue">8573</span>),  <span class="NLM_fpage">1423</span>â <span class="NLM_lpage">1427</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(87)91128-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2FS0140-6736%2887%2991128-7" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=1987&pages=1423-1427&issue=8573&author=A.+K.+Foulisauthor=M.+A.+Farquharsonauthor=A.+Meager&title=Immunoreactive+Alpha-Interferon+in+Insulin-Secreting+Beta+Cells+in+Type+1+Diabetes+Mellitus&doi=10.1016%2FS0140-6736%2887%2991128-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2887%2991128-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252887%252991128-7%26sid%3Dliteratum%253Aachs%26aulast%3DFoulis%26aufirst%3DA.%2BK.%26aulast%3DFarquharson%26aufirst%3DM.%2BA.%26aulast%3DMeager%26aufirst%3DA.%26atitle%3DImmunoreactive%2520Alpha-Interferon%2520in%2520Insulin-Secreting%2520Beta%2520Cells%2520in%2520Type%25201%2520Diabetes%2520Mellitus%26jtitle%3DLancet%26date%3D1987%26volume%3D330%26issue%3D8573%26spage%3D1423%26epage%3D1427%26doi%3D10.1016%2FS0140-6736%2887%2991128-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mishto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellavista, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolzing, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligorio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacmias, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spazzafumo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiappelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licastro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorbi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pession, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grune, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceschi, C.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasome and LMP2 Polymorphism in Aged and Alzheimerâs Disease Brains</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">54</span>â <span class="NLM_lpage">66</span>, <span class="refDoi">Â DOI: 10.1016/j.neurobiolaging.2004.12.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.neurobiolaging.2004.12.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=16298241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1egsr3E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=54-66&issue=1&author=M.+Mishtoauthor=E.+Bellavistaauthor=A.+Santoroauthor=A.+Stolzingauthor=C.+Ligorioauthor=B.+Nacmiasauthor=L.+Spazzafumoauthor=M.+Chiappelliauthor=F.+Licastroauthor=S.+Sorbiauthor=A.+Pessionauthor=T.+Ohmauthor=T.+Gruneauthor=C.+Franceschi&title=Immunoproteasome+and+LMP2+Polymorphism+in+Aged+and+Alzheimer%E2%80%99s+Disease+Brains&doi=10.1016%2Fj.neurobiolaging.2004.12.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains</span></div><div class="casAuthors">Mishto, Michele; Bellavista, Elena; Santoro, Aurelia; Stolzing, Alexandra; Ligorio, Claudia; Nacmias, Benedetta; Spazzafumo, Liana; Chiappelli, Martina; Licastro, Federico; Sorbi, Sandro; Pession, Annalisa; Ohm, Thomas; Grune, Tilman; Franceschi, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-66</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In this study, we investigated the presence and role of immunoproteasome and its LMP2 subunit polymorphism at codon 60 in Alzheimer's disease (AD).  Immunoproteasome was present in brain areas such as hippocampus and cerebellum and localized in neurons, astrocytes and endothelial cells.  A higher expression of immunoproteasome was found in brain of AD patients than in brain of non-demented elderly, being its expression in young brain negligible or absent.  Furthermore, AD affected regions showed a partial decrease in proteasome trypsin-like activity.  The study of LMP2 polymorphism (R/H) showed that it does not influence LMP2 expression (neither the mRNA nor mature protein) in brain tissue.  However, control brain areas of AD patients carrying the RR genotype showed an increased proteasome activity in comparison with RH carriers.  To test whether this effect of the genotype might be related to AD onset we performed a genetic study, which allowed us to exclude an assocn. of LMP2 codon 60 polymorphism with AD onset, despite its influence on the proteasome activity in human brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBR5TJqY4-frVg90H21EOLACvtfcHk0lieOChDGtWDTQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1egsr3E&md5=cb7aeff396023f3fcfd6664e775b2c06</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2004.12.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2004.12.004%26sid%3Dliteratum%253Aachs%26aulast%3DMishto%26aufirst%3DM.%26aulast%3DBellavista%26aufirst%3DE.%26aulast%3DSantoro%26aufirst%3DA.%26aulast%3DStolzing%26aufirst%3DA.%26aulast%3DLigorio%26aufirst%3DC.%26aulast%3DNacmias%26aufirst%3DB.%26aulast%3DSpazzafumo%26aufirst%3DL.%26aulast%3DChiappelli%26aufirst%3DM.%26aulast%3DLicastro%26aufirst%3DF.%26aulast%3DSorbi%26aufirst%3DS.%26aulast%3DPession%26aufirst%3DA.%26aulast%3DOhm%26aufirst%3DT.%26aulast%3DGrune%26aufirst%3DT.%26aulast%3DFranceschi%26aufirst%3DC.%26atitle%3DImmunoproteasome%2520and%2520LMP2%2520Polymorphism%2520in%2520Aged%2520and%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Brains%26jtitle%3DNeurobiol.%2520Aging%26date%3D2006%26volume%3D27%26issue%3D1%26spage%3D54%26epage%3D66%26doi%3D10.1016%2Fj.neurobiolaging.2004.12.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DÃ­az-HernÃ¡ndez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HernÃ¡ndez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MartÃ­n-Aparicio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GÃ³mez-Ramos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MorÃ¡n, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">CastaÃ±o, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, J. J.</span></span> <span> </span><span class="NLM_article-title">Neuronal Induction of the Immunoproteasome in Huntingtonâs Disease</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">37</span>),  <span class="NLM_fpage">11653</span>â <span class="NLM_lpage">11661</span>, <span class="refDoi">Â DOI: 10.1523/JNEUROSCI.23-37-11653.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1523%2FJNEUROSCI.23-37-11653.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=14684867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFyntA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=11653-11661&issue=37&author=M.+D%C3%ADaz-Hern%C3%A1ndezauthor=F.+Hern%C3%A1ndezauthor=E.+Mart%C3%ADn-Aparicioauthor=P.+G%C3%B3mez-Ramosauthor=M.+A.+Mor%C3%A1nauthor=J.+G.+Casta%C3%B1oauthor=I.+Ferrerauthor=J.+Avilaauthor=J.+J.+Lucas&title=Neuronal+Induction+of+the+Immunoproteasome+in+Huntington%E2%80%99s+Disease&doi=10.1523%2FJNEUROSCI.23-37-11653.2003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Neuronal induction of the immunoproteasome in Huntington's disease</span></div><div class="casAuthors">Diaz-hernandez, Miguel; Hernandez, Felix; Martin-aparicio, Ester; Gomez-ramos, Pilar; Moran, Maria A.; Castano, Jose G.; Ferrer, Isidro; Avila, Jesus; Lucas, Jose J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">11653-11661</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Huntington's disease (HD) inclusions are stained with anti-ubiquitin and anti-proteasome antibodies.  This, together with proteasome activity studies on transfected cells, suggest that an impairment of the ubiquitin-proteasome system (UPS) may be key in HD pathogenesis.  To test whether proteasome activity is impaired in vivo, we performed enzymic assays for the three peptidase activities of the proteasome in brain exts. from the HD94 conditional mouse model of HD.  We found no inhibition of any of the activities, suggesting that if UPS impairment happens in vivo, it is not at the level of the proteasome catalytic core.  Intriguingly, the chymotrypsin- and trypsin-like activities increased selectively in the affected and aggregate-contg. regions: cortex and striatum.  Western blot anal. revealed no difference in total proteasome content whereas an increase in the interferon-inducible subunits of the immunoproteasome, LMP2 and LMP7, was obsd.  These subunits confer to the proteasome catalytic properties that are optimal for MHC-I peptide presentation.  Immunohistochem. in control mouse brain revealed LMP2 and LMP7 mainly in neurons.  Accordingly, their increase in HD94 mice predominantly took place in neurons, and 5% of the ubiquitin-pos. cortical aggregates were also LMP2-pos.  Ultrastructural anal. of neurons with high level of immunoproteasome subunits revealed signs of neurodegeneration like nuclear indentation or fragmentation and dark cell appearance.  The neuronal induction of LMP2 and LMP7 and the assocd. signs of neurodegeneration were also found in HD postmortem brains.  Our results indicate that LMP2 and LMP7 participate in normal neuronal physiol. and suggest a role in HD neurodegeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUuKczRgYbE7Vg90H21EOLACvtfcHk0lieOChDGtWDTQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFyntA%253D%253D&md5=b862bc3c6d5b8e4f1c0ea213878d8da3</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.23-37-11653.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.23-37-11653.2003%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25ADaz-Hern%25C3%25A1ndez%26aufirst%3DM.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DF.%26aulast%3DMart%25C3%25ADn-Aparicio%26aufirst%3DE.%26aulast%3DG%25C3%25B3mez-Ramos%26aufirst%3DP.%26aulast%3DMor%25C3%25A1n%26aufirst%3DM.%2BA.%26aulast%3DCasta%25C3%25B1o%26aufirst%3DJ.%2BG.%26aulast%3DFerrer%26aufirst%3DI.%26aulast%3DAvila%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DJ.%2BJ.%26atitle%3DNeuronal%2520Induction%2520of%2520the%2520Immunoproteasome%2520in%2520Huntington%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Neurosci.%26date%3D2003%26volume%3D23%26issue%3D37%26spage%3D11653%26epage%3D11661%26doi%3D10.1523%2FJNEUROSCI.23-37-11653.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheroni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peviani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debiasi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendotti, C.</span></span> <span> </span><span class="NLM_article-title">Accumulation of Human SOD1 and Ubiquitinated Deposits in the Spinal Cord of SOD1G93A Mice during Motor Neuron Disease Progression Correlates with a Decrease of Proteasome</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">509</span>â <span class="NLM_lpage">522</span>, <span class="refDoi">Â DOI: 10.1016/j.nbd.2004.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.nbd.2004.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=15755678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhvFyns7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=509-522&issue=3&author=C.+Cheroniauthor=M.+Pevianiauthor=P.+Cascioauthor=S.+Debiasiauthor=C.+Montiauthor=C.+Bendotti&title=Accumulation+of+Human+SOD1+and+Ubiquitinated+Deposits+in+the+Spinal+Cord+of+SOD1G93A+Mice+during+Motor+Neuron+Disease+Progression+Correlates+with+a+Decrease+of+Proteasome&doi=10.1016%2Fj.nbd.2004.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Accumulation of human SOD1 and ubiquitinated deposits in the spinal cord of SOD1G93A mice during motor neuron disease progression correlates with a decrease of proteasome</span></div><div class="casAuthors">Cheroni, C.; Peviani, M.; Cascio, P.; DeBiasi, S.; Monti, C.; Bendotti, C.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">509-522</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Mutations in SOD1 cause selective motor neuron degeneration in familial amyotrophic lateral sclerosis patients and transgenic mice overexpressing the mutant enzyme.  Formation and accumulation of ubiquitinated aggregates in motor neurons are thought to be involved in the toxic gain of function of mutant SOD1.  The present study shows that the accumulation of sol. and detergent-insol. mutant SOD1 in spinal cord of symptomatic SOD1G93A transgenic mice is due to impaired degrdn. of mutant SOD1 rather than to increased transcript levels.  This effect was accompanied by a decrease of constitutive proteasome levels and a concomitant increase of immunoproteasome in the spinal cord homogenate which resulted in overall unchanged proteasome activity.  A decrease of constitutive proteasome occurred in the motor neurons of SOD1G93A mice at the presymptomatic stage and became remarkable with the progression of the disease.  This provides further evidence for an involvement of proteasome impairment in the toxicity of mutant SOD1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5IdE87NeAPrVg90H21EOLACvtfcHk0lgNJZRr5XoKUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhvFyns7s%253D&md5=f96f6999700cd639253f8b875eb33068</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2004.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2004.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DCheroni%26aufirst%3DC.%26aulast%3DPeviani%26aufirst%3DM.%26aulast%3DCascio%26aufirst%3DP.%26aulast%3DDebiasi%26aufirst%3DS.%26aulast%3DMonti%26aufirst%3DC.%26aulast%3DBendotti%26aufirst%3DC.%26atitle%3DAccumulation%2520of%2520Human%2520SOD1%2520and%2520Ubiquitinated%2520Deposits%2520in%2520the%2520Spinal%2520Cord%2520of%2520SOD1G93A%2520Mice%2520during%2520Motor%2520Neuron%2520Disease%2520Progression%2520Correlates%2520with%2520a%2520Decrease%2520of%2520Proteasome%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2005%26volume%3D18%26issue%3D3%26spage%3D509%26epage%3D522%26doi%3D10.1016%2Fj.nbd.2004.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pintado, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GavilÃ¡n, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GavilÃ¡n, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GarcÃ­a-Cuervo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GutiÃ©rrez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitorica, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">CastaÃ±o, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RÃ­os, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruano, D.</span></span> <span> </span><span class="NLM_article-title">Lipopolysaccharide-Induced Neuroinflammation Leads to the Accumulation of Ubiquitinated Proteins and Increases Susceptibility to Neurodegeneration Induced by Proteasome Inhibition in Rat Hippocampus</span>. <i>J. Neuroinflammation</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">87</span>, <span class="refDoi">Â DOI: 10.1186/1742-2094-9-87</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1186%2F1742-2094-9-87" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=22559833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsVChsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=87&issue=1&author=C.+Pintadoauthor=M.+P.+Gavil%C3%A1nauthor=E.+Gavil%C3%A1nauthor=L.+Garc%C3%ADa-Cuervoauthor=A.+Guti%C3%A9rrezauthor=J.+Vitoricaauthor=A.+Casta%C3%B1oauthor=R.+M.+R%C3%ADosauthor=D.+Ruano&title=Lipopolysaccharide-Induced+Neuroinflammation+Leads+to+the+Accumulation+of+Ubiquitinated+Proteins+and+Increases+Susceptibility+to+Neurodegeneration+Induced+by+Proteasome+Inhibition+in+Rat+Hippocampus&doi=10.1186%2F1742-2094-9-87"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Lipopolysaccharide-induced neuroinflammation leads to the accumulation of ubiquitinated proteins and increases susceptibility to neurodegeneration induced by proteasome inhibition in rat hippocampus</span></div><div class="casAuthors">Pintado, Cristina; Gavilan, Maria P.; Gavilan, Elena; Garcia-Cuervo, Luisa; Gutierrez, Antonia; Vitorica, Javier; Castano, Angelica; Rios, Rosa M.; Ruano, Diego</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroinflammation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">87</span>CODEN:
                <span class="NLM_cas:coden">JNOEB3</span>;
        ISSN:<span class="NLM_cas:issn">1742-2094</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Neuroinflammation and protein accumulation are characteristic hallmarks of both normal aging and age-related neurodegenerative diseases.  However, the relationship between these factors in neurodegenerative processes is poorly understood.  We have previously shown that proteasome inhibition produced higher neurodegeneration in aged than in young rats, suggesting that other addnl. age-related events could be involved in neurodegeneration.  We evaluated the role of lipopolysaccharide (LPS)-induced neuroinflammation as a potential synergic risk factor for hippocampal neurodegeneration induced by proteasome inhibition.  Methods: Young male Wistar rats were injected with 1 Î¼L of saline or LPS (5 mg/mL) into the hippocampus to evaluate the effect of LPS-induced neuroinflammation on protein homeostasis.  The synergic effect of LPS and proteasome inhibition was analyzed in young rats that first received 1 Î¼L of LPS and 24 h later 1 Î¼L (5 mg/mL) of the proteasome inhibitor lactacystin.  Animals were sacrificed at different times post-injection and hippocampi isolated and processed for gene expression anal. by real-time polymerase chain reaction; protein expression anal. by western blots; proteasome activity by fluorescence spectroscopy; immunofluorescence anal. by confocal microscopy; and degeneration assay by Fluoro-Jade B staining.  Results: LPS injection produced the accumulation of ubiquitinated proteins in hippocampal neurons, increased expression of the E2 ubiquitin-conjugating enzyme UB2L6, decreased proteasome activity and increased immunoproteasome content.  However, LPS injection was not sufficient to produce neurodegeneration.  The combination of neuroinflammation and proteasome inhibition leads to higher neuronal accumulation of ubiquitinated proteins, predominant expression of pro-apoptotic markers and increased neurodegeneration, when compared with LPS or lactacystin (LT) injection alone.  Conclusions: Our results identify neuroinflammation as a risk factor that increases susceptibility to neurodegeneration induced by proteasome inhibition.  These results highlight the modulation of neuroinflammation as a mechanism for neuronal protection that could be relevant in situations where both factors are present, such as aging and neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1-VCUFdZox7Vg90H21EOLACvtfcHk0lgNJZRr5XoKUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsVChsw%253D%253D&md5=4d3af7ab4628c7a1af1a4c9dd6411ac8</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1186%2F1742-2094-9-87&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-2094-9-87%26sid%3Dliteratum%253Aachs%26aulast%3DPintado%26aufirst%3DC.%26aulast%3DGavil%25C3%25A1n%26aufirst%3DM.%2BP.%26aulast%3DGavil%25C3%25A1n%26aufirst%3DE.%26aulast%3DGarc%25C3%25ADa-Cuervo%26aufirst%3DL.%26aulast%3DGuti%25C3%25A9rrez%26aufirst%3DA.%26aulast%3DVitorica%26aufirst%3DJ.%26aulast%3DCasta%25C3%25B1o%26aufirst%3DA.%26aulast%3DR%25C3%25ADos%26aufirst%3DR.%2BM.%26aulast%3DRuano%26aufirst%3DD.%26atitle%3DLipopolysaccharide-Induced%2520Neuroinflammation%2520Leads%2520to%2520the%2520Accumulation%2520of%2520Ubiquitinated%2520Proteins%2520and%2520Increases%2520Susceptibility%2520to%2520Neurodegeneration%2520Induced%2520by%2520Proteasome%2520Inhibition%2520in%2520Rat%2520Hippocampus%26jtitle%3DJ.%2520Neuroinflammation%26date%3D2012%26volume%3D9%26issue%3D1%26spage%3D87%26doi%3D10.1186%2F1742-2094-9-87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alzheimerâs Association</span></span> <span> </span><span class="NLM_article-title">2017 Alzheimerâs Disease Facts and Figures</span>. <i>Alzheimer's Dementia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">325</span>â <span class="NLM_lpage">373</span>, <span class="refDoi">Â DOI: 10.1016/j.jalz.2017.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.jalz.2017.02.001" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=325-373&issue=4&author=+Alzheimer%E2%80%99s+Association&title=2017+Alzheimer%E2%80%99s+Disease+Facts+and+Figures&doi=10.1016%2Fj.jalz.2017.02.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.jalz.2017.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jalz.2017.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DAlzheimer%25E2%2580%2599s%2BAssociation%26atitle%3D2017%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Facts%2520and%2520Figures%26jtitle%3DAlzheimer%2527s%2520Dementia%26date%3D2017%26volume%3D13%26issue%3D4%26spage%3D325%26epage%3D373%26doi%3D10.1016%2Fj.jalz.2017.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nijholt, D. a. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Graaf, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Haastert, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoozemans, J. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheper, W.</span></span> <span> </span><span class="NLM_article-title">Endoplasmic Reticulum Stress Activates Autophagy but Not the Proteasome in Neuronal Cells: Implications for Alzheimerâs Disease</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1071</span>â <span class="NLM_lpage">1081</span>, <span class="refDoi">Â DOI: 10.1038/cdd.2010.176</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1038%2Fcdd.2010.176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=21252911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvFCrurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=1071-1081&issue=6&author=D.+a.+T.+Nijholtauthor=T.+R.+de+Graafauthor=E.+S.+van+Haastertauthor=A.+O.+Oliveiraauthor=C.+R.+Berkersauthor=R.+Zwartauthor=H.+Ovaaauthor=F.+Baasauthor=J.+J.+M.+Hoozemansauthor=W.+Scheper&title=Endoplasmic+Reticulum+Stress+Activates+Autophagy+but+Not+the+Proteasome+in+Neuronal+Cells%3A+Implications+for+Alzheimer%E2%80%99s+Disease&doi=10.1038%2Fcdd.2010.176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Endoplasmic reticulum stress activates autophagy but not the proteasome in neuronal cells: implications for Alzheimer's disease</span></div><div class="casAuthors">Nijholt, D. A. T.; de Graaf, T. R.; van Haastert, E. S.; Oliveira, A. Osorio; Berkers, C. R.; Zwart, R.; Ovaa, H.; Baas, F.; Hoozemans, J. J. M.; Scheper, W.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1071-1081</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein folding stress in the endoplasmic reticulum (ER) may lead to activation of the unfolded protein response (UPR), aimed to restore cellular homeostasis via transcriptional and post-transcriptional mechanisms.  ER stress is also reported to activate the ER overload response (EOR), which activates transcription via NF-ÎºB.  We previously demonstrated that UPR activation is an early event in pre-tangle neurons in Alzheimer's disease (AD) brain.  Misfolded and unfolded proteins are degraded via the ubiquitin proteasome system (UPS) or autophagy.  UPR activation is found in AD neurons displaying both early UPS pathol. and autophagic pathol.  Here we investigate whether activation of the UPR and/or EOR is employed to enhance the proteolytic capacity of neuronal cells.  Expression of the immunoproteasome subunits Î²2i and Î²5i is increased in AD brain.  However, expression of the proteasome subunits is not increased by the UPR or EOR.  UPR activation does not relocalize the proteasome or increase overall proteasome activity.  Therefore proteasomal degrdn. is not increased by ER stress.  In contrast, UPR activation enhances autophagy and LC3 levels are increased in neurons displaying UPR activation in AD brain.  Our data suggest that autophagy is the major degradational pathway following UPR activation in neuronal cells and indicate a connection between UPR activation and autophagic pathol. in AD brain.  Cell Death and Differentiation (2011) 18, 1071-1081; doi:10.1038/cdd.2010.176; published online 21 Jan. 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTEqki0ep4NLVg90H21EOLACvtfcHk0lgUIdttk2xBzg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvFCrurw%253D&md5=48b285e857833fc14871b5ccd170a0ed</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2010.176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2010.176%26sid%3Dliteratum%253Aachs%26aulast%3DNijholt%26aufirst%3DD.%2Ba.%2BT.%26aulast%3Dde%2BGraaf%26aufirst%3DT.%2BR.%26aulast%3Dvan%2BHaastert%26aufirst%3DE.%2BS.%26aulast%3DOliveira%26aufirst%3DA.%2BO.%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3DZwart%26aufirst%3DR.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DBaas%26aufirst%3DF.%26aulast%3DHoozemans%26aufirst%3DJ.%2BJ.%2BM.%26aulast%3DScheper%26aufirst%3DW.%26atitle%3DEndoplasmic%2520Reticulum%2520Stress%2520Activates%2520Autophagy%2520but%2520Not%2520the%2520Proteasome%2520in%2520Neuronal%2520Cells%253A%2520Implications%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2011%26volume%3D18%26issue%3D6%26spage%3D1071%26epage%3D1081%26doi%3D10.1038%2Fcdd.2010.176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekavali</span></span> <span> </span><span class="NLM_article-title">A Review on Alzheimerâs Disease Pathophysiology and Its Management: An Update</span>. <i>Pharmacol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">195</span>â <span class="NLM_lpage">203</span>, <span class="refDoi">Â DOI: 10.1016/j.pharep.2014.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.pharep.2014.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=25712639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmt1Shu7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=195-203&issue=2&author=A.+Kumarauthor=A.+Singhauthor=+Ekavali&title=A+Review+on+Alzheimer%E2%80%99s+Disease+Pathophysiology+and+Its+Management%3A+An+Update&doi=10.1016%2Fj.pharep.2014.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">A review on Alzheimer's disease pathophysiology and its management: an update</span></div><div class="casAuthors">Kumar, Anil; Singh, Arti; Ekavali</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-203</span>CODEN:
                <span class="NLM_cas:coden">PRHEDU</span>;
        ISSN:<span class="NLM_cas:issn">2299-5684</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Alzheimer's disease acknowledged as progressive multifarious neurodegenerative disorder, is the leading cause of dementia in late adult life.  Pathol. it is characterized by intracellular neurofibrillary tangles and extracellular amyloidal protein deposits contributing to senile plaques.  Over the last two decades, advances in the field of pathogenesis have inspired the researchers for the investigation of novel pharmacol. therapeutics centered more towards the pathophysiol. events of the disease.  Currently available treatments i.e. acetylcholinesterase inhibitors (rivastigmine, galantamine, donepezil) and N-Me d-aspartate receptor antagonist (memantine) contribute minimal impact on the disease and target late aspects of the disease.  These drugs decelerate the progression of the disease, provide symptomatic relief but fail to achieve a definite cure.  While the neuropathol. features of Alzheimer's disease are recognized but the intricacies of the mechanism have not been clearly defined.  This lack of understanding regarding the pathogenic process may be the likely reason for the non-availability of effective treatment which can prevent onset and progression of the disease.  Owing to the important progress in the field of pathophysiol. in the last couple of years, new therapeutic targets are available that should render the underlying disease process to be tackled directly.  In this review, authors will discusses the different aspects of pathophysiol. mechanisms behind Alzheimer's disease and its management through conventional drug therapy, including modern investigational therapeutic strategies, recently completed and ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb19P5Zhq4u7Vg90H21EOLACvtfcHk0lgUIdttk2xBzg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmt1Shu7o%253D&md5=34c2453a693877d1c787687bf978b775</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.pharep.2014.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharep.2014.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DEkavali%26atitle%3DA%2520Review%2520on%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Pathophysiology%2520and%2520Its%2520Management%253A%2520An%2520Update%26jtitle%3DPharmacol.%2520Rep.%26date%3D2015%26volume%3D67%26issue%3D2%26spage%3D195%26epage%3D203%26doi%3D10.1016%2Fj.pharep.2014.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamphuis, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dooves, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kooijman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimayuga Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hol, E.</span></span> <span> </span><span class="NLM_article-title">Reactive Glia Show Increased Immunoproteasome Activity in Alzheimerâs Disease</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">1415</span>â <span class="NLM_lpage">1431</span>, <span class="refDoi">Â DOI: 10.1093/brain/awt083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1093%2Fbrain%2Fawt083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=23604491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BC3srmvFaisg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2013&pages=1415-1431&author=M.+Orreauthor=W.+Kamphuisauthor=S.+Doovesauthor=L.+Kooijmanauthor=E.+T.+Chanauthor=C.+J.+Kirkauthor=V.+Dimayuga+Smithauthor=S.+Kootauthor=C.+Mamberauthor=A.+H.+Jansenauthor=H.+Ovaaauthor=E.+Hol&title=Reactive+Glia+Show+Increased+Immunoproteasome+Activity+in+Alzheimer%E2%80%99s+Disease&doi=10.1093%2Fbrain%2Fawt083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive glia show increased immunoproteasome activity in Alzheimer's disease</span></div><div class="casAuthors">Orre Marie; Kamphuis Willem; Dooves Stephanie; Kooijman Lieneke; Chan Elena T; Kirk Christopher J; Dimayuga Smith Vanessa; Koot Sanne; Mamber Carlyn; Jansen Anne H; Ovaa Huib; Hol Elly M</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">Pt 5</span>),
    <span class="NLM_cas:pages">1415-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The proteasome is the major protein degradation system within the cell, comprised of different proteolytic subunits; amyloid-Î² is thought to impair its activity in Alzheimer's disease.  Neuroinflammation is a prominent hallmark of Alzheimer's disease, which may implicate an activation of the immunoproteasome, a specific proteasome variant induced by immune signalling that holds slightly different proteolytic properties than the constitutive proteasome.  Using a novel cell-permeable proteasome activity probe, we found that amyloid-Î² enhances proteasome activity in glial and neuronal cultures.  Additionally, using a subunit-specific proteasome activity assay we showed that in the cortex of the APPswePS1dE9 plaque pathology mouse model, immunoproteasome activities were strongly increased together with increased messenger RNA and protein expression in reactive glia surrounding plaques.  Importantly, this elevated activity was confirmed in human post-mortem tissue from donors with Alzheimer's disease.  These findings are in contrast with earlier studies, which reported impairment of proteasome activity in human Alzheimer's disease tissue and mouse models.  Targeting the increased immunoproteasome activity with a specific inhibitor resulted in a decreased expression of inflammatory markers in ex vivo microglia.  This may serve as a potential novel approach to modulate sustained neuroinflammation and glial dysfunction associated with Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRtUv1o7ovLKYYPsCkJIw00fW6udTcc2ebErqxCp1NhB7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srmvFaisg%253D%253D&md5=8ae273c3ca26fd107d41a141afa4e0ef</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawt083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawt083%26sid%3Dliteratum%253Aachs%26aulast%3DOrre%26aufirst%3DM.%26aulast%3DKamphuis%26aufirst%3DW.%26aulast%3DDooves%26aufirst%3DS.%26aulast%3DKooijman%26aufirst%3DL.%26aulast%3DChan%26aufirst%3DE.%2BT.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DDimayuga%2BSmith%26aufirst%3DV.%26aulast%3DKoot%26aufirst%3DS.%26aulast%3DMamber%26aufirst%3DC.%26aulast%3DJansen%26aufirst%3DA.%2BH.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DHol%26aufirst%3DE.%26atitle%3DReactive%2520Glia%2520Show%2520Increased%2520Immunoproteasome%2520Activity%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DBrain%26date%3D2013%26volume%3D136%26spage%3D1415%26epage%3D1431%26doi%3D10.1093%2Fbrain%2Fawt083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilling, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schormann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kloetzel, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppner, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KrÃ¼ger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prokop, S.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasome Deficiency Alters Microglial Cytokine Response and Improves Cognitive Deficits in Alzheimerâs Disease-like APPPS1Mice</span>. <i>Acta Neuropathol. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">52</span>, <span class="refDoi">Â DOI: 10.1186/s40478-017-0453-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1186%2Fs40478-017-0453-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=28646899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvF2qt7vI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=52&issue=1&author=L.+K.+Wagnerauthor=K.+E.+Gillingauthor=E.+Schormannauthor=P.+M.+Kloetzelauthor=F.+L.+Heppnerauthor=E.+Kr%C3%BCgerauthor=S.+Prokop&title=Immunoproteasome+Deficiency+Alters+Microglial+Cytokine+Response+and+Improves+Cognitive+Deficits+in+Alzheimer%E2%80%99s+Disease-like+APPPS1Mice&doi=10.1186%2Fs40478-017-0453-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoproteasome deficiency alters microglial cytokine response and improves cognitive deficits in Alzheimer's disease-like APPPS1 mice</span></div><div class="casAuthors">Wagner, Lisa K.; Gilling, Kate E.; Schormann, Eileen; Kloetzel, Peter M.; Heppner, Frank L.; Krueger, Elke; Prokop, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Acta Neuropathologica Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">52/1-52/16</span>CODEN:
                <span class="NLM_cas:coden">ANCCC9</span>;
        ISSN:<span class="NLM_cas:issn">2051-5960</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The immunoproteasome (iP) represents a specialized type of proteasomes, which plays an important role in the clearance of oxidant-damaged proteins under inflammatory and pathol. conditions detg. the outcome of various diseases.  In Alzheimer's disease (AD)-like APPPS1 mice AÎ²-deposition is paralleled by iP upregulation,most likely mediated through type I interferon induction.  To define the impact of increased iP expression we crossed APPPS1 mice with mice deficient in the iP subunit LMP7 resulting in impaired iP function.  While LMP7 deficient APPPS1 mice showed no major change in cerebral AÎ²-pathol., we obsd. an altered cytokine response in microglia isolated from LMP7 deficient APPPS1 mice compared to LMP7 expressing APPPS1 control mice.  The altered microglial cytokine profile upon iP deficiency in the presence of extracellular AÎ²-pathol. was assocd. with an improvement of AÎ²-assocd. cognitive deficits typically present in APPPS1 mice.  Our findings suggest a role for iP in the regulation of the innate immune response towards extracellular AÎ²-pathol. and indicate that inhibition of iP function can modulate the cognitive phenotype upon overexpression of AÎ².</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9-Es2yxPY3LVg90H21EOLACvtfcHk0ljKRbKMxcqhkQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvF2qt7vI&md5=4de0d34ef2bf87269cf1c26d6ec11052</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1186%2Fs40478-017-0453-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40478-017-0453-5%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DL.%2BK.%26aulast%3DGilling%26aufirst%3DK.%2BE.%26aulast%3DSchormann%26aufirst%3DE.%26aulast%3DKloetzel%26aufirst%3DP.%2BM.%26aulast%3DHeppner%26aufirst%3DF.%2BL.%26aulast%3DKr%25C3%25BCger%26aufirst%3DE.%26aulast%3DProkop%26aufirst%3DS.%26atitle%3DImmunoproteasome%2520Deficiency%2520Alters%2520Microglial%2520Cytokine%2520Response%2520and%2520Improves%2520Cognitive%2520Deficits%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease-like%2520APPPS1Mice%26jtitle%3DActa%2520Neuropathol.%2520Commun.%26date%3D2017%26volume%3D5%26issue%3D1%26spage%3D52%26doi%3D10.1186%2Fs40478-017-0453-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blurton-Jones, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFerla, F. M.</span></span> <span> </span><span class="NLM_article-title">AÎ² Inhibits the Proteasome and Enhances Amyloid and Tau Accumulation</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1607</span>â <span class="NLM_lpage">1618</span>, <span class="refDoi">Â DOI: 10.1016/j.neurobiolaging.2007.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2Fj.neurobiolaging.2007.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=17544172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFCksLzN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=1607-1618&issue=11&author=B.+P.+Tsengauthor=K.+N.+Greenauthor=J.+L.+Chanauthor=M.+Blurton-Jonesauthor=F.+M.+LaFerla&title=A%CE%B2+Inhibits+the+Proteasome+and+Enhances+Amyloid+and+Tau+Accumulation&doi=10.1016%2Fj.neurobiolaging.2007.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">AÎ² inhibits the proteasome and enhances amyloid and tau accumulation</span></div><div class="casAuthors">Tseng, Bertrand P.; Green, Kim N.; Chan, Julie L.; Blurton-Jones, Mathew; LaFerla, Frank M.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1607-1618</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The accumulation of misfolded protein aggregates is a common feature of numerous neurodegenerative disorders including Alzheimer disease (AD).  Here, we examd. the effects of different assembly states of amyloid beta (AÎ²) on proteasome function.  We find that AÎ² oligomers, but not monomers, inhibit the proteasome in vitro.  In young 3xTg-AD mice, we obsd. impaired proteasome activity that correlates with the detection of intraneuronal AÎ² oligomers.  Blocking proteasome function in pre-pathol. 3xTg-AD mice with specific inhibitors causes a marked increase in AÎ² and tau accumulation, highlighting the adverse consequences of impaired proteasome activity for AD.  Lastly, we show that AÎ² immunotherapy in the 3xTg-AD mice reduces AÎ² oligomers and reverses the deficits in proteasome activity.  Taken together, our results indicate that AÎ² oligomers impair proteasome activity, contributing to the age-related pathol. accumulation of AÎ² and tau.  These findings provide further evidence that the proteasome represents a viable target for therapeutic intervention in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpttqgvGJaDL7Vg90H21EOLACvtfcHk0ljKRbKMxcqhkQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFCksLzN&md5=a89d83f96442fad61c84cb9b3d9b6df8</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2007.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2007.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DTseng%26aufirst%3DB.%2BP.%26aulast%3DGreen%26aufirst%3DK.%2BN.%26aulast%3DChan%26aufirst%3DJ.%2BL.%26aulast%3DBlurton-Jones%26aufirst%3DM.%26aulast%3DLaFerla%26aufirst%3DF.%2BM.%26atitle%3DA%25CE%25B2%2520Inhibits%2520the%2520Proteasome%2520and%2520Enhances%2520Amyloid%2520and%2520Tau%2520Accumulation%26jtitle%3DNeurobiol.%2520Aging%26date%3D2008%26volume%3D29%26issue%3D11%26spage%3D1607%26epage%3D1618%26doi%3D10.1016%2Fj.neurobiolaging.2007.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dasgupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahallati, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tashima, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferro, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricker, L. D.</span></span> <span> </span><span class="NLM_article-title">Reduced Levels of Proteasome Products in a Mouse Striatal Cell Model of Huntingtonâs Disease</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">e0145333</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0145333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1371%2Fjournal.pone.0145333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=26691307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BC28Xms1arsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0145333&issue=12&author=S.+Dasguptaauthor=M.+A.+Fishmanauthor=H.+Mahallatiauthor=L.+M.+Castroauthor=A.+K.+Tashimaauthor=E.+S.+Ferroauthor=L.+D.+Fricker&title=Reduced+Levels+of+Proteasome+Products+in+a+Mouse+Striatal+Cell+Model+of+Huntington%E2%80%99s+Disease&doi=10.1371%2Fjournal.pone.0145333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Reduced levels of proteasome products in a mouse striatal cell model of Huntington's disease</span></div><div class="casAuthors">Dasgupta, Sayani; Fishman, Michael A.; Mahallati, Hana; Castro, Leandro M.; Tashima, Alexandre K.; Ferro, Emer S.; Fricker, Lloyd D.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e0145333/1-e0145333/20</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Huntington's disease is the result of a long polyglutamine tract in the gene encoding huntingtin protein, which in turn causes a large no. of cellular changes and ultimately results in neurodegeneration of striatal neurons.  Although many theories have been proposed, the precise mechanism by which the polyglutamine expansion causes cellular changes is not certain.  Some evidence supports the hypothesis that the long polyglutamine tract inhibits the proteasome, a multiprotein complex involved in protein degrdn.  However, other studies report normal proteasome function in cells expressing long polyglutamine tracts.  The controversy may be due to the methods used to examine proteasome activity in each of the previous studies.  In the present study, we measured proteasome function by examg. levels of endogenous peptides that are products of proteasome cleavage.  Peptide levels were compared among mouse striatal cell lines expressing either 7 glutamines (STHdhQ7/Q7) or 111 glutamines in the huntingtin protein, either heterozygous (STHdhQ7/Q111) or homozygous (STHdhQ111/Q111).  Both of the cell lines expressing huntingtin with 111 glutamines showed a large redn. in nearly all of the peptides detected in the cells, relative to levels of these peptides in cells homozygous for 7 glutamines.  Treatment of STHdhQ7/Q7 cells with proteasome inhibitors epoxomicin or bortezomib also caused a large redn. in most of these peptides, suggesting that they are products of proteasome-mediated cleavage of cellular proteins.  Taken together, these results support the hypothesis that proteasome function is impaired by the expression of huntingtin protein contg. long polyglutamine tracts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0Zm6uS3iyBLVg90H21EOLACvtfcHk0ljKRbKMxcqhkQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xms1arsr0%253D&md5=31dae2383c38a024d901fd37dfc969e8</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0145333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0145333%26sid%3Dliteratum%253Aachs%26aulast%3DDasgupta%26aufirst%3DS.%26aulast%3DFishman%26aufirst%3DM.%2BA.%26aulast%3DMahallati%26aufirst%3DH.%26aulast%3DCastro%26aufirst%3DL.%2BM.%26aulast%3DTashima%26aufirst%3DA.%2BK.%26aulast%3DFerro%26aufirst%3DE.%2BS.%26aulast%3DFricker%26aufirst%3DL.%2BD.%26atitle%3DReduced%2520Levels%2520of%2520Proteasome%2520Products%2520in%2520a%2520Mouse%2520Striatal%2520Cell%2520Model%2520of%2520Huntington%25E2%2580%2599s%2520Disease%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26issue%3D12%26spage%3De0145333%26doi%3D10.1371%2Fjournal.pone.0145333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DÃ­az-HernÃ¡ndez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MartÃ­n-Aparicio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HernÃ¡ndez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, J. J.</span></span> <span> </span><span class="NLM_article-title">Enhaced Induction of the Immunoproteasome by Interferon Gamma in Neurons Expressing Mutant Huntingtin</span>. <i>Neurotoxic. Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">463</span>â <span class="NLM_lpage">468</span>, <span class="refDoi">Â DOI: 10.1007/BF03033282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1007%2FBF03033282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=15658001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A280%3ADC%252BD2M%252FjtVyrsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=463-468&issue=6&author=M.+D%C3%ADaz-Hern%C3%A1ndezauthor=E.+Mart%C3%ADn-Aparicioauthor=J.+Avilaauthor=F.+Hern%C3%A1ndezauthor=J.+J.+Lucas&title=Enhaced+Induction+of+the+Immunoproteasome+by+Interferon+Gamma+in+Neurons+Expressing+Mutant+Huntingtin&doi=10.1007%2FBF03033282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced induction of the immunoproteasome by interferon gamma in neurons expressing mutant Huntingtin</span></div><div class="casAuthors">Diaz-Hernandez Miguel; Martin-Aparicio Ester; Avila Jesus; Hernandez Felix; Lucas Jose J</div><div class="citationInfo"><span class="NLM_cas:title">Neurotoxicity research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">463-8</span>
        ISSN:<span class="NLM_cas:issn">1029-8428</span>.
    </div><div class="casAbstract">Huntington disease (HD) inclusions are stained with anti-ubiquitin and anti-proteasome antibodies.  This, together with proteasome activity studies on transfected cell, suggested that alterations in the ubiquitin-proteasome system (UPS) might contribute to HD pathogenesis.  In previous work we reported that in a conditional mouse model of Huntington's disease (HD94 mice), the chymiotrypsin- and trypsin-"like" activities of the proteasome are increased selectivity in the affected and aggregate-containing brain regions: striatum, and cortex.  Moreover, in these areas a neuronal increase in the interferon-inducible subunits of the immunoproteasome LMP2 and LPM7 was observed.  In order to test if the expression of N-terminal mutant huntingtin (htt) by itself is sufficient to induce the change in proteasome catalytic activities as well as in LMP2 subunit expression, we performed activities of the proteasome and western blot experiments in striatal cultured neurons from HD94 mice free of glial contamination.  We found no changes in any of the activities in these cells.  Furthermore, western blot analysis performed with specific antibody against LMP2 subunits, revealed no difference in levels of this subunit in striatal neurons from HD94 compared to control cultures were treated with interferon-gamma (IFN-gamma) during 72 hours, a clear increase in LMP2 levels was observed in control neuronal cultures.  Interestingly, this increase was much more pronounced (95% higher) in HD94 striatal cultures.  These results indicate that although expression of mutant htt is not sufficient to induce the changes in proteasome catalytic core observed in HD, it synergizes the changes induced by IFN-gamma.  Furthermore, immunocytochemical studies revealed that HD94 striatal neuron expressing high levels of LMP2 subunit showed a pre-apoptotic appearance.  These results suggest that the correlation between neuronal induction of the immunoproteasome and neurodegeneration found in HD brains is secondary to inflammatory processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfl0yIS-3DfoHWj6b1v8uTfW6udTcc2eYWj0QFoCDGB7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M%252FjtVyrsg%253D%253D&md5=ce24f9933f7fedcee1d94e602cf8894a</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1007%2FBF03033282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF03033282%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25ADaz-Hern%25C3%25A1ndez%26aufirst%3DM.%26aulast%3DMart%25C3%25ADn-Aparicio%26aufirst%3DE.%26aulast%3DAvila%26aufirst%3DJ.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DF.%26aulast%3DLucas%26aufirst%3DJ.%2BJ.%26atitle%3DEnhaced%2520Induction%2520of%2520the%2520Immunoproteasome%2520by%2520Interferon%2520Gamma%2520in%2520Neurons%2520Expressing%2520Mutant%2520Huntingtin%26jtitle%3DNeurotoxic.%2520Res.%26date%3D2004%26volume%3D6%26issue%3D6%26spage%3D463%26epage%3D468%26doi%3D10.1007%2FBF03033282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheroni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tortarolo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veglianese, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Biasi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccarello, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynard, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dantuma, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendotti, C.</span></span> <span> </span><span class="NLM_article-title">Functional Alterations of the Ubiquitin-Proteasome System in Motor Neurons of a Mouse Model of Familial Amyotrophic Lateral Sclerosis</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">82</span>â <span class="NLM_lpage">96</span>, <span class="refDoi">Â DOI: 10.1093/hmg/ddn319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1093%2Fhmg%2Fddn319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=18826962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsV2lurrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=82-96&issue=1&author=C.+Cheroniauthor=M.+Marinoauthor=M.+Tortaroloauthor=P.+Veglianeseauthor=S.+De+Biasiauthor=E.+Fontanaauthor=L.+V.+Zuccarelloauthor=C.+J.+Maynardauthor=N.+P.+Dantumaauthor=C.+Bendotti&title=Functional+Alterations+of+the+Ubiquitin-Proteasome+System+in+Motor+Neurons+of+a+Mouse+Model+of+Familial+Amyotrophic+Lateral+Sclerosis&doi=10.1093%2Fhmg%2Fddn319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Functional alterations of the ubiquitin-proteasome system in motor neurons of a mouse model of familial amyotrophic lateral sclerosis</span></div><div class="casAuthors">Cheroni, Cristina; Marino, Marianna; Tortarolo, Massimo; Veglianese, Pietro; De Biasi, Silvia; Fontana, Elena; Zuccarello, Laura Vitellaro; Maynard, Christa J.; Dantuma, Nico P.; Bendotti, Caterina</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">82-96</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">In familial and sporadic amyotrophic lateral sclerosis (ALS) and in rodent models of the disease, alterations in the ubiquitin-proteasome system (UPS) may be responsible for the accumulation of potentially harmful ubiquitinated proteins, leading to motor neuron death.  In the spinal cord of transgenic mice expressing the familial ALS superoxide dismutase 1 (SOD1) gene mutation G93A (SOD1G93A), we found a decrease in constitutive proteasome subunits during disease progression, as assessed by real-time PCR and immunohistochem.  In parallel, an increased immunoproteasome expression was obsd., which correlated with a local inflammatory response due to glial activation.  These findings support the existence of proteasome modifications in ALS vulnerable tissues.  To functionally investigate the UPS in ALS motor neurons in vivo, we crossed SOD1G93A mice with transgenic mice that express a fluorescently tagged reporter substrate of the UPS.  In double-transgenic UbG76V-GFP /SOD1G93A mice an increase in UbG76V-GFP reporter, indicative of UPS impairment, was detectable in a few spinal motor neurons and not in reactive astrocytes or microglia, at symptomatic stage but not before symptoms onset.  The levels of reporter transcript were unaltered, suggesting that the accumulation of UbG76V-GFP was due to deficient reporter degrdn.  In some motor neurons the increase of UbG76V-GFP was accompanied by the accumulation of ubiquitin and phosphorylated neurofilaments, both markers of ALS pathol.  These data suggest that UPS impairment occurs in motor neurons of mutant SOD1-linked ALS mice and may play a role in the disease progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm-JWqfmORsbVg90H21EOLACvtfcHk0li2OXzLs1t23w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsV2lurrL&md5=ac070204ef2793217df6b1828053a428</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddn319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddn319%26sid%3Dliteratum%253Aachs%26aulast%3DCheroni%26aufirst%3DC.%26aulast%3DMarino%26aufirst%3DM.%26aulast%3DTortarolo%26aufirst%3DM.%26aulast%3DVeglianese%26aufirst%3DP.%26aulast%3DDe%2BBiasi%26aufirst%3DS.%26aulast%3DFontana%26aufirst%3DE.%26aulast%3DZuccarello%26aufirst%3DL.%2BV.%26aulast%3DMaynard%26aufirst%3DC.%2BJ.%26aulast%3DDantuma%26aufirst%3DN.%2BP.%26aulast%3DBendotti%26aufirst%3DC.%26atitle%3DFunctional%2520Alterations%2520of%2520the%2520Ubiquitin-Proteasome%2520System%2520in%2520Motor%2520Neurons%2520of%2520a%2520Mouse%2520Model%2520of%2520Familial%2520Amyotrophic%2520Lateral%2520Sclerosis%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2009%26volume%3D18%26issue%3D1%26spage%3D82%26epage%3D96%26doi%3D10.1093%2Fhmg%2Fddn319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahtoniemi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsteins, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keksa-Goldsteine, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanninen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salminen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koistinaho, J.</span></span> <span> </span><span class="NLM_article-title">Pyrrolidine Dithiocarbamate Inhibits Induction of Immunoproteasome and Decreases Survival in a Rat Model of Amyotrophic Lateral Sclerosis</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>71</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">30</span>â <span class="NLM_lpage">37</span>, <span class="refDoi">Â DOI: 10.1124/mol.106.028415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1124%2Fmol.106.028415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=17008387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1GktA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2007&pages=30-37&issue=1&author=T.+Ahtoniemiauthor=G.+Goldsteinsauthor=V.+Keksa-Goldsteineauthor=T.+Malmauthor=K.+Kanninenauthor=A.+Salminenauthor=J.+Koistinaho&title=Pyrrolidine+Dithiocarbamate+Inhibits+Induction+of+Immunoproteasome+and+Decreases+Survival+in+a+Rat+Model+of+Amyotrophic+Lateral+Sclerosis&doi=10.1124%2Fmol.106.028415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrrolidine dithiocarbamate inhibits induction of immunoproteasome and decreases survival in a rat model of amyotrophic lateral sclerosis</span></div><div class="casAuthors">Ahtoniemi, Toni; Goldsteins, Gundars; Keksa-Goldsteine, Velta; Malm, Tarja; Kanninen, Katja; Salminen, Antero; Koistinaho, Jari</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-37</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Pyrrolidine dithiocarbamate (PDTC), an inhibitor of nuclear transcription factor Îº-B (NF-ÎºB) and an antioxidant, has beneficial effects in animal models of various diseases, including arthritis, brain ischemia, spinal cord injury, Alzheimer's disease, and Duchenne muscular dystrophy.  Because inflammation and oxidative damage are also hallmarks of amyotrophic lateral sclerosis (ALS), we studied the effect of oral PDTC treatment on G93A-superoxide dismutase 1 (SOD1) transgenic (TG) rat model of human ALS and obsd. that PDTC treatment significantly decreases the survival.  PDTC treatment evoked the end stage of the disease at 121Â±21 days, whereas untreated TG animals reached the end stage at 141Â±13 days (p < 0.01).  The DNA binding activity of NF-ÎºB was not altered in G93A-SOD1 TG rats by PDTC treatment.  The copper concn. in the spinal cord was increased after PDTC treatment both in G93A-SOD1 TG and wild-type rats, suggesting that increased copper may enhance the neurotoxicity of mutant SOD1.  The amt. of ubiquitinated proteins were significantly higher and proteasomal activity was decreased in the spinal cords of PDTC-treated TG rats compared with other groups, suggesting that PDTC treatment decreases proteasome function.  Immunoblotting and immunocytochem. showed that the level of immunoproteasome but not constitutive proteasome was increased in glia of G93A-SOD1 TG rats along with disease development.  PDTC treatment completely blocked the induction of immunoproteasome expression without affecting constitutive proteasome.  These results suggest that PDTC acts as an immunoproteasome inhibitor in mutant SOD1 rats and that immunoproteasome may help the nervous system to cope with deleterious effects of SOD1-G93A mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDufLbSaKmK7Vg90H21EOLACvtfcHk0li2OXzLs1t23w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1GktA%253D%253D&md5=e20bfe3e7e735ddb9df9aa6ae3509347</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1124%2Fmol.106.028415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.106.028415%26sid%3Dliteratum%253Aachs%26aulast%3DAhtoniemi%26aufirst%3DT.%26aulast%3DGoldsteins%26aufirst%3DG.%26aulast%3DKeksa-Goldsteine%26aufirst%3DV.%26aulast%3DMalm%26aufirst%3DT.%26aulast%3DKanninen%26aufirst%3DK.%26aulast%3DSalminen%26aufirst%3DA.%26aulast%3DKoistinaho%26aufirst%3DJ.%26atitle%3DPyrrolidine%2520Dithiocarbamate%2520Inhibits%2520Induction%2520of%2520Immunoproteasome%2520and%2520Decreases%2520Survival%2520in%2520a%2520Rat%2520Model%2520of%2520Amyotrophic%2520Lateral%2520Sclerosis%26jtitle%3DMol.%2520Pharmacol.%26date%3D2007%26volume%3D71%26issue%3D1%26spage%3D30%26epage%3D37%26doi%3D10.1124%2Fmol.106.028415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desrosiers, R. C.</span></span> <span> </span><span class="NLM_article-title">Viral Persistence: HIVâs Strategies of Immune System Evasion</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">499</span>â <span class="NLM_lpage">518</span>, <span class="refDoi">Â DOI: 10.1146/annurev.med.53.082901.104053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1146%2Fannurev.med.53.082901.104053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=11818487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD38Xitl2mt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2002&pages=499-518&issue=1&author=W.+E.+Johnsonauthor=R.+C.+Desrosiers&title=Viral+Persistence%3A+HIV%E2%80%99s+Strategies+of+Immune+System+Evasion&doi=10.1146%2Fannurev.med.53.082901.104053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Viral Persistence: HIV's strategies of immune system evasion</span></div><div class="casAuthors">Johnson, Welkin E.; Desrosiers, Ronald C.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">499-518</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  In contrast to most animal viruses, infection with the human and simian immunodeficiency viruses results in prolonged, continuous viral replication in the infected host.  Remarkably, viral persistence is not thwarted by the presence of apparently vigorous, virus-specific immune responses.  Several factors are thought to contribute to persistent viral replication, most notably the destruction of virus-specific T helper cells, the emergence of antigenic escape variants, and the expression of an envelope complex that structurally minimizes antibody access to conserved epitopes.  Not as well understood, though potentially important, is the ability of at least one viral encoded protein (Nef) to prevent presentation of viral antigens in the context of major histocompatibility complex.  The future success of antiviral therapies and vaccination strategies may depend largely on understanding how and to what degree each of these factors (and presumably others) contributes to immune evasion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobcjc-d9AagrVg90H21EOLACvtfcHk0li2OXzLs1t23w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xitl2mt7c%253D&md5=0bdd07b0423098e52c8d154cce5be92b</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1146%2Fannurev.med.53.082901.104053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.med.53.082901.104053%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DW.%2BE.%26aulast%3DDesrosiers%26aufirst%3DR.%2BC.%26atitle%3DViral%2520Persistence%253A%2520HIV%25E2%2580%2599s%2520Strategies%2520of%2520Immune%2520System%2520Evasion%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2002%26volume%3D53%26issue%3D1%26spage%3D499%26epage%3D518%26doi%3D10.1146%2Fannurev.med.53.082901.104053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arora, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredericksen, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, J. V.</span></span> <span> </span><span class="NLM_article-title">Nef: Agent of Cell Subversion</span>. <i>Microbes Infect.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">189</span>â <span class="NLM_lpage">199</span>, <span class="refDoi">Â DOI: 10.1016/S1286-4579(01)01527-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2FS1286-4579%2801%2901527-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=11880052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD38XhslWguro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2002&pages=189-199&issue=2&author=V.+K.+Aroraauthor=B.+L.+Fredericksenauthor=J.+V.+Garcia&title=Nef%3A+Agent+of+Cell+Subversion&doi=10.1016%2FS1286-4579%2801%2901527-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Nef: agent of cell subversion</span></div><div class="casAuthors">Arora, Vivek K.; Fredericksen, Brenda L.; Garcia, J. Victor</div><div class="citationInfo"><span class="NLM_cas:title">Microbes and Infection</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">189-199</span>CODEN:
                <span class="NLM_cas:coden">MCINFS</span>;
        ISSN:<span class="NLM_cas:issn">1286-4579</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">A review.  Primate lentiviruses encode a small protein designated Nef that has been shown to be a major determinant of virus pathogenicity.  Nef regulates multiple host factors in order to optimize the cellular environment for virus replication.  The mechanisms by which this small protein modulates distinct host cell properties provide intriguing insight into the intricate interaction between virus and host.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgKXFZoc2_xbVg90H21EOLACvtfcHk0lgIOD62_eP98Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhslWguro%253D&md5=d49e2de63907bc285cbb94437bb40cff</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2FS1286-4579%2801%2901527-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1286-4579%252801%252901527-1%26sid%3Dliteratum%253Aachs%26aulast%3DArora%26aufirst%3DV.%2BK.%26aulast%3DFredericksen%26aufirst%3DB.%2BL.%26aulast%3DGarcia%26aufirst%3DJ.%2BV.%26atitle%3DNef%253A%2520Agent%2520of%2520Cell%2520Subversion%26jtitle%3DMicrobes%2520Infect.%26date%3D2002%26volume%3D4%26issue%3D2%26spage%3D189%26epage%3D199%26doi%3D10.1016%2FS1286-4579%2801%2901527-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishido, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, J. U.</span></span> <span> </span><span class="NLM_article-title">Downregulation of Major Histocompatibility Complex Class I Molecules by Kaposiâs Sarcoma-Associated Herpesvirus K3 and K5 Proteins</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">5300</span>â <span class="NLM_lpage">5309</span>, <span class="refDoi">Â DOI: 10.1128/JVI.74.11.5300-5309.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1128%2FJVI.74.11.5300-5309.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10799607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjsVKns7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2000&pages=5300-5309&issue=11&author=S.+Ishidoauthor=C.+Wangauthor=B.-S.+Leeauthor=G.+B.+Cohenauthor=J.+U.+Jung&title=Downregulation+of+Major+Histocompatibility+Complex+Class+I+Molecules+by+Kaposi%E2%80%99s+Sarcoma-Associated+Herpesvirus+K3+and+K5+Proteins&doi=10.1128%2FJVI.74.11.5300-5309.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins</span></div><div class="casAuthors">Ishido, Satoshi; Wang, Chunyang; Lee, Bok-Soo; Cohen, George B.; Jung, J. U.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5300-5309</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The T-cell-mediated immune response plays a central role in the defense against intracellular pathogens.  To avoid this immune response, viruses have evolved elaborate mechanisms that target and modulate many different aspects of the host's immune system.  A target common to many of these viruses is the major histocompatibility complex (MHC) class I mols.  Kaposi's sarcoma-assocd. herpesvirus (KSHV) encodes K3 and K5 zinc finger membrane proteins which remove MHC class I mols. from the cell surface.  K3 and K5 exhibit 40% amino acid identity to each other and localize primarily near the plasma membrane.  While K3 and K5 dramatically downregulated class I mols., they displayed different specificities in downregulation of HLA allotypes.  K5 significantly downregulated HLA-A and -B and downregulated HLA-C only weakly, but not HLA-E, whereas K3 downregulated all four HLA allotypes.  This selective downregulation of HLA allotypes by K5 was partly due to differences in amino acid sequences in their transmembrane regions.  Biochem. analyses demonstrated that while K3 and K5 did not affect expression and intracellular transport of class I mols., their expression induced rapid endocytosis of the mols.  These results demonstrate that KSHV has evolved a novel immune evasion mechanism by harboring similar but distinct genes, K3 and K5, which target MHC class I mols. in different ways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3lJ48LzDuV7Vg90H21EOLACvtfcHk0lgIOD62_eP98Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjsVKns7o%253D&md5=f9b5a3f99a0468212958730b848b8fe4</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1128%2FJVI.74.11.5300-5309.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.74.11.5300-5309.2000%26sid%3Dliteratum%253Aachs%26aulast%3DIshido%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DB.-S.%26aulast%3DCohen%26aufirst%3DG.%2BB.%26aulast%3DJung%26aufirst%3DJ.%2BU.%26atitle%3DDownregulation%2520of%2520Major%2520Histocompatibility%2520Complex%2520Class%2520I%2520Molecules%2520by%2520Kaposi%25E2%2580%2599s%2520Sarcoma-Associated%2520Herpesvirus%2520K3%2520and%2520K5%2520Proteins%26jtitle%3DJ.%2520Virol.%26date%3D2000%26volume%3D74%26issue%3D11%26spage%3D5300%26epage%3D5309%26doi%3D10.1128%2FJVI.74.11.5300-5309.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coscoy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganem, D.</span></span> <span> </span><span class="NLM_article-title">Kaposiâs Sarcoma-Associated Herpesvirus Encodes Two Proteins That Block Cell Surface Display of MHC Class I Chains by Enhancing Their Endocytosis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>97</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">8051</span>â <span class="NLM_lpage">8056</span>, <span class="refDoi">Â DOI: 10.1073/pnas.140129797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1073%2Fpnas.140129797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10859362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkvFCmsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=8051-8056&issue=14&author=L.+Coscoyauthor=D.+Ganem&title=Kaposi%E2%80%99s+Sarcoma-Associated+Herpesvirus+Encodes+Two+Proteins+That+Block+Cell+Surface+Display+of+MHC+Class+I+Chains+by+Enhancing+Their+Endocytosis&doi=10.1073%2Fpnas.140129797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis</span></div><div class="casAuthors">Coscoy, Laurent; Ganem, Don</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">8051-8056</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Down-regulation of the cell surface display of class I MHC proteins is an important mechanism of immune evasion by human and animal viruses.  Herpesviruses in particular encode a variety of proteins that function to lower MHC I display by several mechanisms.  These include binding and retention of MHC I chains in the endoplasmic reticulum, dislocation of class I chains from the ER, inhibition of the peptide transporter (TAP) involved in antigen presentation, and shunting of newly assembled chains to lysosomes.  Kaposi's sarcoma (KS)-assocd. herpesvirus (KSHV) is a human herpesvirus strongly linked to the development of KS and to certain AIDS-assocd. lymphoproliferative disorders.  Here the authors show that KSHV encodes 2 distinctive gene products that function to dramatically reduce cell surface MHC I expression.  These viral proteins are localized predominantly to the ER.  However, unlike previously described MHC I inhibitors, they do not interfere with the synthesis, translocation, or assembly of class I chains, nor do they retain them in the ER.  Rather, they act to enhance endocytosis of MHC I from the cell surface; internalized class I chains are delivered to endolysosomal vesicles, where they undergo degrdn.  These KSHV proteins define a mechanism of class I down-regulation distinct from the mechanisms of other herpesviruses and are likely to contribute importantly to immune evasion during viral infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdQbe-2HOQQLVg90H21EOLACvtfcHk0lhN_Ljk7XIAzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkvFCmsrc%253D&md5=1a794c029769a193d0b83aa8cee210ff</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1073%2Fpnas.140129797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.140129797%26sid%3Dliteratum%253Aachs%26aulast%3DCoscoy%26aufirst%3DL.%26aulast%3DGanem%26aufirst%3DD.%26atitle%3DKaposi%25E2%2580%2599s%2520Sarcoma-Associated%2520Herpesvirus%2520Encodes%2520Two%2520Proteins%2520That%2520Block%2520Cell%2520Surface%2520Display%2520of%2520MHC%2520Class%2520I%2520Chains%2520by%2520Enhancing%2520Their%2520Endocytosis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2000%26volume%3D97%26issue%3D14%26spage%3D8051%26epage%3D8056%26doi%3D10.1073%2Fpnas.140129797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tortorella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gewurz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schust, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploegh, H. L.</span></span> <span> </span><span class="NLM_article-title">Viral Subversion of the Immune System</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">861</span>â <span class="NLM_lpage">926</span>, <span class="refDoi">Â DOI: 10.1146/annurev.immunol.18.1.861</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1146%2Fannurev.immunol.18.1.861" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10837078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjs1Gmt78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2000&pages=861-926&issue=1&author=D.+Tortorellaauthor=B.+E.+Gewurzauthor=M.+H.+Furmanauthor=D.+J.+Schustauthor=H.+L.+Ploegh&title=Viral+Subversion+of+the+Immune+System&doi=10.1146%2Fannurev.immunol.18.1.861"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Viral subversion of the immune system</span></div><div class="casAuthors">Tortorella, Domenico; Gewurz, Benjamin E.; Furman, Margo H.; Schust, Danny J.; Ploegh, Hidde L.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">861-926</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review, with 418 refs., describing the diverse array of pathways and mol. targets that are used by viruses to elude immune detection and destruction.  These include targeting of pathways for major histocompatibility complex-restricted antigen presentation, apoptosis, cytokine-mediated signaling, and humoral immune responses.  The continuous interactions between host and pathogens during their coevolution have shaped the immune system, but also the counter measures used by pathogens.  Further study of their interactions should improve the authors' ability to manipulate and exploit the various pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKostmJ51-27Vg90H21EOLACvtfcHk0lhN_Ljk7XIAzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjs1Gmt78%253D&md5=5c88fc8e2f439d29024c7b1e041c37ca</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.18.1.861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.18.1.861%26sid%3Dliteratum%253Aachs%26aulast%3DTortorella%26aufirst%3DD.%26aulast%3DGewurz%26aufirst%3DB.%2BE.%26aulast%3DFurman%26aufirst%3DM.%2BH.%26aulast%3DSchust%26aufirst%3DD.%2BJ.%26aulast%3DPloegh%26aufirst%3DH.%2BL.%26atitle%3DViral%2520Subversion%2520of%2520the%2520Immune%2520System%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2000%26volume%3D18%26issue%3D1%26spage%3D861%26epage%3D926%26doi%3D10.1146%2Fannurev.immunol.18.1.861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tortorella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploegh, H. L.</span></span> <span> </span><span class="NLM_article-title">The Human Cytomegalovirus US10 Gene Product Delays Trafficking of Major Histocompatibility Complex Class I Molecules</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">11753</span>â <span class="NLM_lpage">11756</span>, <span class="refDoi">Â DOI: 10.1128/JVI.76.22.11753-11756.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1128%2FJVI.76.22.11753-11756.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=12388737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD38XoslKjtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2002&pages=11753-11756&issue=22&author=M.+H.+Furmanauthor=N.+Deyauthor=D.+Tortorellaauthor=H.+L.+Ploegh&title=The+Human+Cytomegalovirus+US10+Gene+Product+Delays+Trafficking+of+Major+Histocompatibility+Complex+Class+I+Molecules&doi=10.1128%2FJVI.76.22.11753-11756.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">The human cytomegalovirus US10 gene product delays trafficking of major histocompatibility complex class I molecules</span></div><div class="casAuthors">Furman, Margo H.; Dey, Neelendu; Tortorella, Domenico; Ploegh, Hidde L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">11753-11756</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Human cytomegalovirus (HCMV) US10 encodes a glycoprotein that binds to major histocompatibility complex (MHC) class I heavy chains.  While expression of US10 delays the normal trafficking of MHC class I mols. out of the endoplasmic reticulum, US10 does not obviously facilitate or inhibit the action of two other HCMV-encoded MHC class I binding proteins, US2 and US11.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh3EaY3wmaELVg90H21EOLACvtfcHk0lhN_Ljk7XIAzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XoslKjtLg%253D&md5=a2d4e5a578897e30435bd9653ea25c7a</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1128%2FJVI.76.22.11753-11756.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.76.22.11753-11756.2002%26sid%3Dliteratum%253Aachs%26aulast%3DFurman%26aufirst%3DM.%2BH.%26aulast%3DDey%26aufirst%3DN.%26aulast%3DTortorella%26aufirst%3DD.%26aulast%3DPloegh%26aufirst%3DH.%2BL.%26atitle%3DThe%2520Human%2520Cytomegalovirus%2520US10%2520Gene%2520Product%2520Delays%2520Trafficking%2520of%2520Major%2520Histocompatibility%2520Complex%2520Class%2520I%2520Molecules%26jtitle%3DJ.%2520Virol.%26date%3D2002%26volume%3D76%26issue%3D22%26spage%3D11753%26epage%3D11756%26doi%3D10.1128%2FJVI.76.22.11753-11756.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, E. W.</span></span> <span> </span><span class="NLM_article-title">The MHC Class I Antigen Presentation Pathway: Strategies for Viral Immune Evasion</span>. <i>Immunology</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>110</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">163</span>â <span class="NLM_lpage">169</span>, <span class="refDoi">Â DOI: 10.1046/j.1365-2567.2003.01738.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1046%2Fj.1365-2567.2003.01738.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=14511229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotFSmtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2003&pages=163-169&issue=2&author=E.+W.+Hewitt&title=The+MHC+Class+I+Antigen+Presentation+Pathway%3A+Strategies+for+Viral+Immune+Evasion&doi=10.1046%2Fj.1365-2567.2003.01738.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">The MHC class I antigen presentation pathway: Strategies for viral immune evasion</span></div><div class="casAuthors">Hewitt, Eric W.</div><div class="citationInfo"><span class="NLM_cas:title">Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-169</span>CODEN:
                <span class="NLM_cas:coden">IMMUAM</span>;
        ISSN:<span class="NLM_cas:issn">0019-2805</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Presumably because of the selective pressure exerted by the immune system, many viruses have evolved proteins that interfere with antigen presentation by major histocompatibility complex (MHC) class I mols.  These viruses utilize a whole variety of ingenious strategies to inhibit the MHC class I pathway.  Viral proteins have been characterized that exploit bottlenecks in the MHC class I pathway, such as peptide translocation by the transporter assocd. with antigen processing.  Alternatively, viral proteins can cause the degrdn. or mislocalization of MHC class I mols.  This is often achieved by the subversion of the host cell's own protein degrdn. and trafficking pathways.  As a consequence elucidation of how these viral proteins act to subvert host cell function will continue to give important insights not only into virus-host interactions but also the function and mechanism of cellular pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjcMhRExiK2rVg90H21EOLACvtfcHk0lisEekd-dOg-w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFSmtbk%253D&md5=c669b243791ce0c2a3e6e6dad5665c12</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2567.2003.01738.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2567.2003.01738.x%26sid%3Dliteratum%253Aachs%26aulast%3DHewitt%26aufirst%3DE.%2BW.%26atitle%3DThe%2520MHC%2520Class%2520I%2520Antigen%2520Presentation%2520Pathway%253A%2520Strategies%2520for%2520Viral%2520Immune%2520Evasion%26jtitle%3DImmunology%26date%3D2003%26volume%3D110%26issue%3D2%26spage%3D163%26epage%3D169%26doi%3D10.1046%2Fj.1365-2567.2003.01738.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Apcher, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heink, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zantopf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kloetzel, P.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, H.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KrÃ¼ger, E.</span></span> <span> </span><span class="NLM_article-title">Human Immunodeficiency Virus-1 Tat Protein Interacts with Distinct Proteasomal Î± and Î² Subunits</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>553</i></span> (<span class="NLM_issue">1â2</span>),  <span class="NLM_fpage">200</span>â <span class="NLM_lpage">204</span>, <span class="refDoi">Â DOI: 10.1016/S0014-5793(03)01025-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=10.1016%2FS0014-5793%2803%2901025-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=14550573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvFWhtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=553&publication_year=2003&pages=200-204&issue=1%E2%80%932&author=G.+S.+Apcherauthor=S.+Heinkauthor=D.+Zantopfauthor=P.-M.+Kloetzelauthor=H.-P.+Schmidauthor=R.+J.+Mayerauthor=E.+Kr%C3%BCger&title=Human+Immunodeficiency+Virus-1+Tat+Protein+Interacts+with+Distinct+Proteasomal+%CE%B1+and+%CE%B2+Subunits&doi=10.1016%2FS0014-5793%2803%2901025-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Human immunodeficiency virus-1 Tat protein interacts with distinct proteasomal Î± and Î² subunits</span></div><div class="casAuthors">Apcher, G. Sebastien; Heink, Sylvia; Zantopf, Daniela; Kloetzel, Peter-M.; Schmid, Hans-P.; Mayer, R. John; Kruger, Elke</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">553</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">200-204</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The human immunodeficiency virus-1 (HIV-1) Tat protein was previously reported to compete the assocn. of PA28 regulator with the Î± rings of the 20S proteasome and to inhibit its peptidase activity.  However, the distinct interaction sites within the proteasome complex remained to be detd.  Here the authors show that HIV-1 Tat binds to Î±4 and Î±7, six Î² subunits of the constitutive 20S proteasome and the interferon-Î³-inducible subunits Î²2i and Î²5i.  A Tat-proteasome interaction can also be demonstrated in vivo and leads to inhibition of proteasomal activity.  This indicates that Tat can modulate or interfere with cellular proteasome function by specific interaction with distinct proteasomal subunits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOWMBmk7NxXbVg90H21EOLACvtfcHk0lisEekd-dOg-w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvFWhtrc%253D&md5=f17e506eec7b159b3f1979ac535a9e19</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2FS0014-5793%2803%2901025-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-5793%252803%252901025-1%26sid%3Dliteratum%253Aachs%26aulast%3DApcher%26aufirst%3DG.%2BS.%26aulast%3DHeink%26aufirst%3DS.%26aulast%3DZantopf%26aufirst%3DD.%26aulast%3DKloetzel%26aufirst%3DP.-M.%26aulast%3DSchmid%26aufirst%3DH.-P.%26aulast%3DMayer%26aufirst%3DR.%2BJ.%26aulast%3DKr%25C3%25BCger%26aufirst%3DE.%26atitle%3DHuman%2520Immunodeficiency%2520Virus-1%2520Tat%2520Protein%2520Interacts%2520with%2520Distinct%2520Proteasomal%2520%25CE%25B1%2520and%2520%25CE%25B2%2520Subunits%26jtitle%3DFEBS%2520Lett.%26date%3D2003%26volume%3D553%26issue%3D1%25E2%2580%25932%26spage%3D200%26epage%3D204%26doi%3D10.1016%2FS0014-5793%2803%2901025-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01226&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01226%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-5" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01226" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799822f5f253cee","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
